(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 1 August 2002 (01.08.2002)

PCT

(10) International Publication Number WO 02/059377 A2

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/US02/02242

(22) International Filing Date: 24 January 2002 (24.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/263,965	24 January 2001 (24.01.2001)	US
60/265,928	2 February 2001 (02.02.2001)	US
09/829,472	9 April 2001 (09.04.2001)	US
60/282,698	9 April 2001 (09.04.2001)	US
60/288,590	4 May 2001 (04.05.2001)	US
60/294,443	29 May 2001 (29.05.2001)	US

- (71) Applicant: EOS BIOTECHNOLOGY, INC. [US/US]; 225A Gateway Boulevard, South San Francisco, CA 94080-7019 (US).
- (72) Inventors: MACK, David, H.; 2076 Monterey Avenue, Menlo Park, CA 94025 (US). GISH, Kurt, C.; 40 Perego Terrace #2, San Francisco, CA 94131 (US). AFAR, Daniel; 435 Visitacion Avenue, Brisbane, CA 94005 (US).

- (74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



059377

(54) Title: METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.

METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

5

10

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to USSN 60/263,965, filed January 24, 2001; USSN 60/265,928, filed February 2, 2001; USSN 09/829,472 filed April 9, 2001; USSN 60/282,698, filed April 9, 2001; USSN 60/288,590, filed May 4, 2001; and USSN 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in breast cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of breast cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit breast cancer.

20

25

15

BACKGROUND OF THE INVENTION

Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of female cancer death in North America and northern Europe, with lung cancer being the leading cause. Lifetime incidence of the disease in the United States is one-in-eight, with a 1-in-29 lifetime risk of dying from breast cancer. Early detection of breast cancer, using mammography, clinical breast examination, and self breast examination, has dramatically improved the treatment of the disease, although sensitivity is still major concern, as mammographic sensitivity has been estimated at only 60%–90%. Treatment of breast cancer consists largely of surgical lumpectomy or mastectomy, radiation therapy, anti-

hormone therapy, and/or chemotherapy. Although many breast cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons et al., 2000, Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart, 2000, Ann. Oncol. 11:647-663), including genetic predispostion markers BRCA-1 and BRCA-2 (Robson, 2000, J. Clin. Oncol. 18:113sup-118sup).

5

10

15

20

25

30

Imaging of breast cancer for diagnosis has been problematic and limited. In addition, dissemination of tumor cells (metastases) to locoregional lymph nodes is an important prognostic factor; five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of breast cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998).

The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monclonal antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer (Ross and Fletcher, 1998, Stem Cells 16:413-428). Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgekin's lymphoma (Maloney et al., 1997, Blood 90:2188-2195; Leget and Czuczman, 1998, Curr. Opin. Oncol. 10:548-551).

Other potential immunotherapeutic targets have been identified for breast cancer. One such target is polymorphic epithelial mucin (MUC1). MUC1 is a transmembrane

protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in breast cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target (Gilewski et al., 2000, Clin. Cancer Res. 6:1693-1701; Scholl et al., 2000, J. Immunother. 23:570-580). The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3 (Bon et al., 1997, Clin. Chem. 43:585-593). However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease. Many other genes have been reported to be overexpressed in breast cancer, such as EGFR (Sainsbury et al., 1987, Lancet 1(8547):1398-1402), c-erbB3 (Naidu et al., 1988, Br. J. Cancer 78:1385-1390), FGFR2 (Penault-Llorca et al., 1991, Int. J. Cancer 61:170-176), PKW (Preiherr et al., 2000, Anticancer Res. 20:2255-2264), MTA1 (Nawa et al., 2000, J. Cell Biochem. 79:202-212), breast cancer associated gene 1 (Kurt et al., 2000, Breast Cancer Res. Treat. 59:41-48). Although monoclonal antibodies to the protein products of some of these overexpressed genes have been reported (for review, see Green et al., 2000, Cancer Treat. Rev. 26:269-286), none are currently approved for breast cancer therapy in the US.

5

10

15

20

25

30

Disclosures of certain genes and ESTs described as being expressed in breast cancer are found in international patent applications WO-99/33869, WO-97/25426, WO-97/02280 and WO-00/55173, WO-98/45328 and WO-00/22130. Similarly, genes and ESTs described as being expressed in breast cancer are disclosed in US Patent Nos. 5,759,776 and 5,693,522. The utility of such genes is described in each of these publications, and their disclosures are incorporated herein in their entirety.

While industry and academia have identified novel sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in breast and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of breast cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer.

SUMMARY OF THE INVENTION

The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in breast cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate breast cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

5

10

15

20

25

In one aspect, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the present invention provides a method of determining the level of a breast cancer associated transcript in a cell from a patient.

In one embodiment, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-25.

In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface.

In one embodiment, the patient is undergoing a therapeutic regimen to treat breast cancer. In another embodiment, the patient is suspected of having metastatic breast cancer.

In one embodiment, the patient is a human.

In one embodiment, the breast cancer associated transcript is mRNA.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

5

10

15

20

25

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of breast cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a breast cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic breast cancer. In a further embodiment, the patient has a drug resistant form of breast cancer.

In one embodiment, the method further comprises the step of: (iii) comparing the level of the breast cancer-associated transcript to a level of the breast cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

Additionally, provided herein is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-25.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid.

In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

5

10

15

20

25

30

In one aspect, the present invention provides a method of detecting a breast cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to breast cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-25.

In another aspect, the present invention provides a method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.

In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation of a breast cancer-associated cell to treat breast cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having breast cancer

or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.

5

10

15

20

25

30

In one embodiment, the control is a mammal with breast cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.

In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-25 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.

In another aspect, the present invention provides a method for treating a mammal having breast cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having breast cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a breast cancer. In one embodiment, a gene is selected from Tables 1-25. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of

expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.

5

10

15

20

25

30

Also provided is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the breast cancer modulatory protein, or an animal lacking the breast cancer modulatory protein, for example as a result of a gene knockout.

Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-25, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.

Furthermore, a method of diagnosing a disorder associated with breast cancer is provided. The method comprises determining the expression of a gene of Tables 1-25, preferably a gene of Table 25, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with breast cancer.

In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in breast cancer.

In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a breast cancer modulating protein (breast cancer modulatory protein) or a fragment thereof and an antibody which binds to said breast cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a breast cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said breast cancer modulatory protein or fragment thereof. The method further includes determining the binding of said breast cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits breast cancer.

Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a breast cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

5

10

15

20

30

Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a breast cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-25, more preferably of Table 25, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a breast cancer modulating protein, preferably selected from the nucleic acids of Tables 1-25, and a pharmaceutically acceptable carrier.

Also provided are methods of neutralizing the effect of a breast cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

In another aspect of the invention, a method of treating an individual for breast cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a breast cancer modulating protein. In another embodiment, the method comprises administering to a patient having breast cancer an antibody to a breast cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for breast cancer (PC), including metastatic breast cancer, as well as methods for screening for compositions which modulate breast cancer. Also provided are methods for treating breast cancer.

Tables 1-24B provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in breast cancer

samples. Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, and 22 list those genes that are up-regulated in breast cancer cells. Table 14 lists those genes that are highly upregulated in breast cancer cells. Table 1, 2, 3, 15, and 23 list genes that are down-regulated in breast cancer cells and Table 16, lists genes that are highly down-regulated in breast cancer genes. The Tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

Definitions

5

10

15

20

25

The term "breast cancer protein" or "breast cancer polynucleotide" or "breast cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-25 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "breast cancer polypeptide" and a "breast cancer polynucleotide," include both naturally occurring or recombinant forms.

A "full length" breast cancer protein or nucleic acid refers to a breast cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type breast cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

5

10

15

20

25

30

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a breast cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention *in vivo*. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (*see, e.g.*, NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to

be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

5

10

15

20

25

30

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms,

which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

5

10

15

20

25

30

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a

nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

5

10

15

20

25

30

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells *in vivo*, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (*see*, *e.g.*, the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means

removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

5

10

15

20

25

30

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino

acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

5

10

15

20

25

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that 30

often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β -sheet and α -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

5

10

15

20

25

30

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805

(1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and 5 linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; 10 Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 15 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs 20 are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T_m) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T_m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is

25

30

relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

5

10

15

20

25

30

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ³²P, fluorescent dyes, electron-dense reagents, enzymes (*e.g.*, as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, *e.g.*, by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the breast cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including

radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

5

10

15

20

25

30

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes,

chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed

or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a

promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

5

10

15

20

25

30

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times

background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis *et al.* (1990) *PCR Protocols, A Guide to Methods and Applications*, Academic Press, Inc. N.Y.).

5

10

15

20

25

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, *et al.*

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a breast cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the breast cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease breast cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact

inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis *in vivo*; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. "Functional effects" include *in vitro*, *in vivo*, and *ex vivo* activities.

5

10

15

20

25

30

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a breast cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the breast cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on breast cancer can also be performed using breast cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for breast cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β-gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of breast cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using *in vitro* and *in vivo* assays of breast cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block

activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of breast cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate breast cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of breast cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the breast cancer protein *in vitro*, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of breast cancer can also be identified by incubating breast cancer cells with the test compound and determining increases or decreases in the expression of 1 or more breast cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more breast cancer proteins, such as breast cancer proteins encoded by the sequences set out in Tables 1-25.

Samples or assays comprising breast cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a breast cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics *in vitro* or *in vivo*, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or

immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3rd ed. 1994).

5

10

15

20

25

30

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor.

"Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3rd ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'₂, a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The F(ab)'₂

may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'₂ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (*see*, *e.g.*, Kohler & Milstein, *Nature* 256:495-497 (1975); Kozbor *et al.*, *Immunology Today* 4:72 (1983); Cole *et al.*, pp. 77-96 in *Monoclonal Antibodies and Cancer Therapy* (1985); Coligan, *Current Protocols in Immunology* (1991); Harlow & Lane, *Antibodies, A Laboratory Manual* (1988); and Goding, *Monoclonal Antibodies: Principles and Practice* (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (*see*, *e.g.*, McCafferty *et al.*, *Nature* 348:552-554 (1990); Marks *et al.*, *Biotechnology* 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, *e.g.*, an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

Identification of breast cancer-associated sequences

5

10

15

20

25

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal breast or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the breast, or breast cancer tissue or metastatic breast cancerous tissue can be compared with tissue samples of breast and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different breast cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in breast cancer versus non-breast cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate breast cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of breast cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the breast cancer expression profile. This may be done by making biochips comprising sets of the important breast cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the breast cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the breast cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the breast cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in breast cancer, herein termed "breast cancer sequences." As outlined below, breast cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in breast cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the breast cancer sequences are from humans; however, as will be appreciated by those in the art, breast cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other breast cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Breast cancer sequences from other organisms may be obtained using the techniques outlined below.

5

10

15

20

25

30

Breast cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, breast cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the breast cancer sequences can be generated.

A breast cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying breast cancer-associated sequences, the breast cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing breast cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of breast cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art

for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal breast, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the breast cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, breast cancer sequences are those that are upregulated in breast cancer; that is, the expression of these genes is higher in the breast cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). U.S. Patent Application N. 09/687,576, with the same assignee as the present application,

In another preferred embodiment, breast cancer sequences are those that are down-regulated in the breast cancer; that is, the expression of these genes is lower in breast cancer tissue as compared to non-cancerous tissue (*see, e.g.*, Tables 1,2, 3, 15, 16 etc...). "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

further discloses related sequences, compositions, and methods of diagnosis and treatment of

breast cancer is hereby expressly incorporated by reference.

5

10

15

20

25

Informatics

5

10

15

20

25

30

The ability to identify genes that are over or under expressed in breast cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with breast cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing breast cancer, i.e., the identification of breast cancer-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring,

gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using high-speed computers is utilized.

5

10

15

20

25

30

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount et al., Bioinformatics (2001); Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999); Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et

al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995).

5

10

15

20

25

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for breast cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

5

10

15

20

25

30

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the

assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Characteristics of breast cancer-associated proteins

5

10

15

20

25

30

Breast cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the breast cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular

Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

5

10

15

20

25

30

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al., Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al., Proteins 28:405-420 (1997); Bateman et al., Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al., Nuc. Acids Res. 26:320-322-(1998)).

In another embodiment, the breast cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described

for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

5

10

15

20

25

30

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor,

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include

cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Breast cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins *in situ*. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the breast cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Breast cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, *e.g.*, for blood, plasma, serum, or stool tests.

Use of breast cancer nucleic acids

5

10

15

20

25

30

As described above, breast cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the breast cancer

sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

5

10

15

20

25

30

The breast cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-25, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the breast cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, *et al.*, *supra*. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the breast cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire breast cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant breast cancer nucleic acid can be further-used as a probe to identify and isolate other breast cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant breast cancer nucleic acids and proteins.

The breast cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the breast cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications.

Alternatively, the breast cancer nucleic acids that include coding regions of breast cancer proteins can be put into expression vectors for the expression of breast cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to breast cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are

made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the breast cancer nucleic acids, *i.e.* the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

5

10

15

20

25

30

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of electrostatic,

hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

5

10

15

20

25

In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silicabased materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize

sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

5

10

15

20

25

30

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (*see* 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChipTM technology.

Often, amplification-based assays are performed to measure the expression level of breast cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a breast cancer-associated nucleic acid

sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of breast cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al., Science 241:1077 (1988), and Barringer et al., Gene 89:117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

Expression of breast cancer proteins from nucleic acids

5

10

15

20

25

30

In a preferred embodiment, breast cancer nucleic acids, e.g., encoding breast cancer proteins are used to make a variety of expression vectors to express breast cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these

expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the breast cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

5

10

15

20

25

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the breast cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, *supra*).

5

10

15

20

25

30

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The breast cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a breast cancer protein, under the appropriate conditions to induce or cause expression of the breast cancer protein. Conditions appropriate for breast cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Saccharomyces cerevisiae* and other yeasts, *E. coli, Bacillus subtilis*, Sf9 cells, C129 cells, 293 cells, *Neurospora*, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the breast cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include

retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (*see*, *e.g.*, Fernandez & Hoeffler, *supra*). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.

Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, breast cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the breast cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which

render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others (e.g., Fernandez & Hoeffler, *supra*). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

5

15

20

25

30

In one embodiment, breast cancer proteins are produced in insect cells.

Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, breast cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The breast cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the breast cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the breast cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the breast cancer protein is a breast cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the breast cancer protein is purified or isolated after expression. Breast cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the breast cancer protein may be purified using a standard anti-breast cancer protein antibody column. Ultrafiltration

and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, *Protein Purification* (1982). The degree of purification necessary will vary depending on the use of the breast cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the breast cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

Variants of breast cancer proteins

5

10

15

20

25

30

In one embodiment, the breast cancer proteins are derivative or variant breast cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative breast cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the breast cancer peptide.

Also included within one embodiment of breast cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the breast cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant breast cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the breast cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to

optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed breast cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of breast cancer protein activities.

5

10

15

20

25

30

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the breast cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the breast cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the breast cancer protein is altered. For example, glycosylation sites may be altered or removed.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue

having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

5

10

15

20

25

Covalent modifications of breast cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a breast cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a breast cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking breast cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-breast cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, *Proteins: Structure and Molecular Properties*, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the breast cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence breast cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence breast cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express breast cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to breast cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence breast cancer polypeptide (for O-linked glycosylation sites). The breast cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the breast cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

5

10

15

20

25

30

Another means of increasing the number of carbohydrate moieties on the breast cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, *CRC Crit. Rev. Biochem.*, pp. 259-306 (1981).

Removal of carbohydrate moieties present on the breast cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of breast cancer comprises linking the breast cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Breast cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a breast cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a breast cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the breast cancer polypeptide. The presence of such epitope-tagged forms of a breast cancer polypeptide can be detected using

5

10

15

20

25

30

an antibody against the tag polypeptide. Also, provision of the epitope tag enables the breast cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a breast cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field *et al., Mol. Cell. Biol.* 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan *et al., Molecular and Cellular Biology* 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (*Paborsky et al., Protein Engineering* 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (*Hopp et al., BioTechnology* 6:1204-1210 (1988)); the KT3 epitope peptide (Martin *et al., Science* 255:192-194 (1992)); tubulin epitope peptide (Skinner *et al., J. Biol. Chem.* 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth *et al., Proc. Natl. Acad. Sci. USA* 87:6393-6397 (1990)).

Also included are other breast cancer proteins of the breast cancer family, and breast cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related breast cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the breast cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, *supra*).

Antibodies to breast cancer proteins

In a preferred embodiment, when the breast cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the breast cancer protein

should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller breast cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, *supra*; and Harlow & Lane, *supra*). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, *Nature* 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-25 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene

glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

5

10

15

20

25

30

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-25 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to breast cancer protein are capable of reducing or eliminating a biological function of a breast cancer protein, as is described below. That is, the addition of anti-breast cancer protein antibodies (either polyclonal or preferably monoclonal) to breast cancer tissue (or cells containing breast cancer) may reduce or eliminate the breast cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the breast cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs,Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include

5

10

15

20

25

30

human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a nonhuman species.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, *J. Mol. Biol.* 227:381 (1991); Marks *et al.*, *J. Mol. Biol.* 222:581 (1991)). The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, p. 77 (1985) and Boerner *et al.*, *J. Immunol.* 147(1):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all

respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, *Bio/Technology* 10:779-783 (1992); Lonberg *et al.*, *Nature* 368:856-859 (1994); Morrison, *Nature* 368:812-13 (1994); Fishwild *et al.*, *Nature Biotechnology* 14:845-51 (1996); Neuberger, *Nature Biotechnology* 14:826 (1996); Lonberg & Huszar, *Intern. Rev. Immunol.* 13:65-93 (1995).

5

10

15

20

25

30

By immunotherapy is meant treatment of breast cancer with an antibody raised against breast cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the breast cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted breast cancer protein.

In another preferred embodiment, the breast cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the breast cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane breast cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the breast cancer protein. The antibody is also an antagonist of the breast cancer protein. Further, the antibody prevents activation of the transmembrane breast cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the breast cancer

protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF- α , TNF- β , IL-1, INF- γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, breast cancer is treated by administering to a patient antibodies directed against the transmembrane breast cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the breast cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the breast cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with breast cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to breast cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with breast cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against breast cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane breast cancer proteins not only serves to increase the local concentration of therapeutic moiety in the breast cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

In another preferred embodiment, the breast cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the breast cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

5

10

15

20

25

30

The breast cancer antibodies of the invention specifically bind to breast cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a K_d of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better. Selectivity of binding is also important.

Detection of breast cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the breast cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing breast cancer) and in breast cancer tissue (and in some cases, for varying severities of breast cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can

5

10

15

20

25

qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus breast cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the breast cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to breast cancer genes, i.e., those identified as being important in a breast cancer phenotype, can be evaluated in a breast cancer diagnostic test.

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in

a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

5

10

15

20

25

30

In a preferred embodiment nucleic acids encoding the breast cancer protein are detected. Although DNA or RNA encoding the breast cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a breast cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a breast cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, breast cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of breast cancer.

Detection of these proteins in putative breast cancer tissue allows for detection or diagnosis

of breast cancer. In one embodiment, antibodies are used to detect breast cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the breast cancer protein is detected, e.g., by immunoblotting with antibodies raised against the breast cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

5

10

15

20

25

30

In another preferred method, antibodies to the breast cancer protein find use in *in situ* imaging techniques, e.g., in histology (e.g., *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the breast cancer protein(s). Following washing to remove nonspecific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the breast cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of breast cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing breast cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of breast cancer proteins.

Antibodies can be used to detect a breast cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous breast cancer protein.

In a preferred embodiment, *in situ* hybridization of labeled breast cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including

breast cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to breast cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, breast cancer probes may be attached to biochips for the detection and quantification of breast cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

Assays for therapeutic compounds

5

10

15

20

25

30

In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, *et al.*, *Science* 279:84-8 (1998); Heid, *Genome Res* 6:986-94, 1996).

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified breast cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the breast cancer phenotype or an identified physiological function of a breast cancer protein. As above, this can be done on an individual gene level or

by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, *supra*.

5

10

15

20

25

Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in breast cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the breast cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing breast cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in breast cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in breast cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the breast cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more breast cancer-associated sequences, e.g., a polynucleotide sequence set out inTable 17. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate breast cancer, modulate breast cancer proteins, bind to a breast cancer protein, or interfere with the binding of a breast cancer protein and an antibody or other binding partner.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the breast cancer phenotype or the expression of a breast cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a breast cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a breast cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

In one aspect, a modulator will neutralize the effect of a breast cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a breast cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

5

10

15

20

25

30

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop *et al.*, *J. Med. Chem.* 37(9):1233-1251 (1994)).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent No. 5,010,175, Furka, *Pept. Prot. Res.* 37:487-493 (1991), Houghton *et al.*, *Nature*, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as

hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

5

10

15

20

25

Devices for the preparation of combinatorial libraries are commercially available (*see, e.g.,* 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis,

MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of breast cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

5

10

15

20

25

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, *e.g.*, cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially

preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, *e.g.*, substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

5

10

15

20

25

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of breast cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an *in vitro* transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

5

10

15

20

25

30

In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to,

temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

5

10

15

20

25

30

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, *etc.* which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, *etc.*, may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the breast cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, *e.g.*, for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a breast cancer expression pattern leading to a normal expression pattern, or to modulate a single breast cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically

modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated breast cancer tissue reveals genes that are not expressed in normal tissue or breast cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for breast cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated breast cancer tissue sample.

5

10

15

20

25

30

Thus, in one embodiment, a test compound is administered to a population of breast cancer cells, that have an associated breast cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., breast cancer tissue may be screened for agents that modulate, e.g., induce or suppress the breast cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on breast cancer activity. By defining such a signature for the breast cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of

either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins" or a "breast cancer modulatory protein". The breast cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the breast cancer modulatory protein is a fragment. In a preferred embodiment, the breast cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Table 25. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Table 25. In another embodiment, the sequences are sequence variants as further described herein.

5

10

15

20

25

Preferably, the breast cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine.

In one embodiment the breast cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the breast cancer protein is conjugated to BSA.

Measurements of breast cancer polypeptide activity, or of breast cancer or the breast cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the breast cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of breast cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second

messengers such as cGMP. In the assays of the invention, mammalian breast cancer polypeptide is typically used, e.g., mouse, preferably human.

5

10

15

20

25

Assays to identify compounds with modulating activity can be performed *in vitro*. For example, a breast cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the breast cancer polypeptide levels are determined *in vitro* by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the breast cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the breast cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins." The breast cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate

differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the breast cancer proteins can be used in the assays.

5

10

15

20

25

30

Thus, in a preferred embodiment, the methods comprise combining a breast cancer protein and a candidate compound, and determining the binding of the compound to the breast cancer protein. Preferred embodiments utilize the human breast cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative breast cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the breast cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflonTM, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving

areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the breast cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the breast cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

5

10

15

20

25

30

The determination of the binding of the test modulating compound to the breast cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the breast cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., ¹²⁵I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a breast cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput

screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the breast cancer protein and thus is capable of binding to, and potentially modulating, the activity of the breast cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

5

10

15

20

25

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the breast cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the breast cancer protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the breast cancer proteins. In this embodiment, the methods comprise combining a breast cancer protein and a competitor in a first sample. A second sample comprises a test compound, a breast cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the breast cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the breast cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native breast cancer protein, but cannot bind to modified breast cancer proteins. The structure of the breast cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a

breast cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

5

10

15

20

25

30

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a breast cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising breast cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a breast cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate breast cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the breast cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting breast cancer cell division is provided. The method comprises administration of a breast cancer inhibitor. In another embodiment, a method of inhibiting breast cancer is provided. The method comprises administration of a breast cancer inhibitor. In a further embodiment, methods of treating cells or individuals with breast cancer are provided. The method comprises administration of a breast cancer inhibitor.

In one embodiment, a breast cancer inhibitor is an antibody as discussed above. In another embodiment, the breast cancer inhibitor is an antisense molecule.

5

10

15

20

25

30

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of breast cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, *Culture of Animal Cells a Manual of Basic Technique* (3rd ed., 1994), herein incorporated by reference. *See also*, the methods section of Garkavtsev *et al.* (1996), *supra*, herein incorporated by reference.

Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a

higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (³H)-thymidine at saturation density can be used to measure density limitation of growth. *See* Freshney (1994), *supra*. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (³H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a breast cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (³H)-thymidine is determined autoradiographically. *See*, Freshney (1994), *supra*.

Growth factor or serum dependence

5

10

15

20

25

30

Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), *supra*. Also, *see*, Unkless *et al.*, *J. Biol. Chem.* 249:4295-4305 (1974); Strickland & Beers, *J. Biol. Chem.* 251:5694-5702 (1976); Whur *et al.*, *Br. J. Cancer* 42:305-

312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

Invasiveness into Matrigel

5

10

15

20

25

30

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate breast cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with ¹²⁵I and counting the radioactivity on the distal side of the filter or bottom of the dish. *See, e.g.*, Freshney (1984), *supra*.

Tumor growth in vivo

Effects of breast cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the breast cancer gene is disrupted or in which a breast cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous breast cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous breast cancer gene with a mutated version of the breast cancer gene, or by mutating the endogenous breast cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice

that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (*see, e.g.*, Giovanella *et al.*, *J. Natl. Cancer Inst.* 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (*see, e.g.*, Bradley *et al.*, *Br. J. Cancer* 38:263 (1978); Selby *et al.*, *Br. J. Cancer* 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10⁶ cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a breast cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

Polynucleotide modulators of breast cancer

5

10

15

20

25

30

Antisense Polynucleotides

In certain embodiments, the activity of a breast cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, *i.e.*, a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a breast cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other

sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the breast cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized *in vitro*. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for breast cancer molecules. A preferred antisense molecule is for a breast cancer sequences in Tables 1-25, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (*Cancer Res.* 48:2659 (1988 and van der Krol *et al.* (*BioTechniques* 6:958 (1988)).

Ribozymes

5

10

15

20

25

30

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of breast cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (*see, e.g.,* Castanotto *et al., Adv. in Pharmacology* 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel *et al.*, *Nucl. Acids Res.* 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (*see, e.g.*,

WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205: 121-126 (1994)).

5

10

15

20

25

Polynucleotide modulators of breast cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of breast cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating breast cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-breast cancer antibody that reduces or eliminates the biological activity of an endogenous breast cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a breast cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g. when the breast cancer sequence is down-regulated in breast cancer, such state may be reversed by increasing the amount of breast cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous breast cancer gene or administering a gene encoding the breast cancer sequence, using known gene-therapy techniques, e.g.. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g. as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g. when the breast cancer

sequence is up-regulated in breast cancer, the activity of the endogenous breast cancer gene is decreased, e.g. by the administration of a breast cancer antisense nucleic acid.

In one embodiment, the breast cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to breast cancer proteins. Similarly, the breast cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify breast cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a breast cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The breast cancer antibodies may be coupled to standard affinity chromatography columns and used to purify breast cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the breast cancer protein.

Methods of identifying variant breast cancer-associated sequences

5

10

15

20

25

30

Without being bound by theory, expression of various breast cancer sequences is correlated with breast cancer. Accordingly, disorders based on mutant or variant breast cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant breast cancer genes, e.g., determining all or part of the sequence of at least one endogenous breast cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the breast cancer genotype of an individual, e.g., determining all or part of the sequence of at least one breast cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced breast cancer gene to a known breast cancer gene, i.e., a wild-type gene.

The sequence of all or part of the breast cancer gene can then be compared to the sequence of a known breast cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the breast cancer gene of

the patient and the known breast cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the breast cancer genes are used as probes to determine the number of copies of the breast cancer gene in the genome.

In another preferred embodiment, the breast cancer genes are used as probes to determine the chromosomal localization of the breast cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the breast cancer gene locus.

10

15

20

25

30

5

Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a breast cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for breast cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in breast cancer is hereby expressly incorporated by reference.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the breast cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the breast cancer proteins and modulators may be directly applied as a solution or spray.

5

10

15

20

25

The pharmaceutical compositions of the present invention comprise a breast cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that breast cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, *etc.*) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

The compositions for administration will commonly comprise a breast cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., *Remington's Pharmaceutical Science* (15th ed., 1980) and Goodman & Gillman, *The Pharmacologial Basis of Therapeutics* (Hardman *et al.*,eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of breast cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

5

10

15

20

25

30

It will be appreciated that the present breast cancer protein-modulating compounds can be administered alone or in combination with additional breast cancer modulating compounds or with other therapeutic agent, *e.g.*, other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, *e.g.*, polynucleotides comprising nucleic acid sequences set forth in Tables 1-25, such as antisense polynucleotides or ribozymes, will be introduced into cells, *in vitro* or *in vivo*. The present invention provides methods, reagents, vectors, and cells useful for expression of breast cancer-associated polypeptides and nucleic acids using *in vitro* (cell-free), *ex vivo* or *in vivo* (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use

of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al., eds., Current Protocols (supplemented through 1999), and Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989.

5

10

15

20

25

30

In a preferred embodiment, breast cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, breast cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the breast cancer coding regions) can be administered in a gene therapy application. These breast cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

Breast cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, A. et al., J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, (1991); Alonso et al., Vaccine 12:299-306 (1994); Jones et al., Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875 (1990); Hu et al., Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tam, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tam, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al., Nature 320:535 (1986); Hu et al., Nature 320:537 (1986); Kieny, et al., AIDS Bio/Technology 4:790 (1986); Top et al., J. Infect. Dis. 124:148 (1971); Chanda et al., Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al., J. Immunol. Methods. 192:25 (1996); Eldridge et al., Sem. Hematol. 30:16 (1993); Falo et al., Nature Med. 7:649 (1995)), adjuvants (Warren et al., Annu. Rev. Immunol. 4:369 (1986);

Gupta et al., Vaccine 11:293 (1993)), liposomes (Reddy et al., J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al., Science 259:1745 (1993); Robinson et al., Vaccine 11:957 (1993); Shiver et al., In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al., Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

5

10

15

20

25

30

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bortadella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff *et. al.*, *Science* 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (*see, e.g.*, U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of

vaccinia virus, e.g., as a vector to express nucleotide sequences that encode breast cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al., Mol Med Today 6:66-71 (2000); Shedlock et al., J Leukoc Biol 68:793-806 (2000); Hipp et al., In Vivo 14:571-85 (2000)).

5

10

15

20

25

30

Methods for the use of genes as DNA vaccines are well known, and include placing a breast cancer gene or portion of a breast cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a breast cancer patient. The breast cancer gene used for DNA vaccines can encode full-length breast cancer proteins, but more preferably encodes portions of the breast cancer proteins including peptides derived from the breast cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a breast cancer gene. For example, breast cancer-associated genes or sequence encoding subfragments of a breast cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the breast cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another preferred embodiment breast cancer genes find use in generating animal models of breast cancer. When the breast cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed

to the breast cancer gene will also diminish or repress expression of the gene. Animal models of breast cancer find use in screening for modulators of a breast cancer-associated sequence or modulators of breast cancer. Similarly, transgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the breast cancer protein. When desired, tissue-specific expression or knockout of the breast cancer protein may be necessary.

It is also possible that the breast cancer protein is overexpressed in breast cancer. As such, transgenic animals can be generated that overexpress the breast cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of breast cancer and are additionally useful in screening for modulators to treat breast cancer.

15

20

10

5

Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, breast cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative breast cancer polypeptides or polynucleotides, small molecules inhibitors of breast cancer-associated sequences *etc*. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions

(i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the

like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of breast cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a breast cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing breast cancer-associated activity. Optionally, the kit contains biologically active breast cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

15 EXAMPLES

5

10

20

25

30

Example 1: Tissue Preparation, Labeling Chips, and Fingerprints

Purifying total RNA from tissue sample using TRIzol Reagent

The sample weight is first estimated. The tissue samples are homogenized in 1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polytron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization.

Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared

homogenate is then transferred to a new tube(s). Samples may be frozen and stored at -60 to -70°C for at least one month or else continue with the purification.

The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogenization mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp. for 2-3 minutes and next centrifuged at 6500 rpm in a Sorvall superspeed for 30 min. at 4oC.

5

10

15

25

The next process is RNA Precipitation. The aqueous phase is transferred to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp. for 10 minutes an centrifuged at 6500 rpm in Sorvall for 20 min. at 4°C.

The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing . They are next centrifuged at $<8000\,$ rpm ($<7500\,$ x g) for 5 minutes at 4° C.

The RNA wash is decanted. The pellet is carefully transferred to an

Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes. Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H₂0. The absorbance is then measured.

The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen's RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA.

The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-treated water, 2 x Binding

Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature.

The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A⁺ mRNA has been found.

Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute.

Next, the spin column is transferred to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein.

5

10

15

20

25

Then, the spin column is transferred to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low.

The absorbance is next read to determine the yield, using diluted Elution Buffer as the blank.

Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The 80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H₂0 at 1 ug/ul concentration.

Alternatively the RNA may be purified using other methods (e.g., Qiagen's RNeasy kit).

No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 rpm). If yield is low, reapply the flowthrough to the column and centrifuge again.

Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at >10,000 rpm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 rpm. The flowthrough is discarded. and the column membrane dried by centrifuging for 2 min at maximum speed. The column is transferred to a new 1.5-ml collection tube. 30-50 ul of RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 rpm and the elution step repeated.

The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol.

15

20

25

30

5

10

First Strand cDNA Synthesis

The first strand can be make using using Gibco's "SuperScript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of polyA+ mRNA1. For total RNA, 2 ul of SuperScript RT is used; for polyA+ mRNA, 1 ul of SuperScript RT is used. The final volume of first strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1st Strand Buffer, 2 ul of 0.1M DTT, and 1 ul of 10mM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the SuperScript RT followed by incubation at 37°C for 1 hour.

Second Strand Synthesis

For the second strand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H₂0; 30 ul 5X 2nd Strand Buffer; 3 ul 10mM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10 U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2

hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA.

Cleaning up cDNA

The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then transferred to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is transferred to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100% ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80% ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water.

15

20

25

30

10

5

In vitro Transcription (IVT) and labeling with biotin

In vitro Transcription (IVT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDNA into a thin-wall PCR tube. Make NTP labeling mix by combining 2 ul T7 10xATP (75 mM) (Ambion); 2 ul T7 10xGTP (75 mM) (Ambion); 1.5 ul T7 10xCTP (75 mM) (Ambion); 3.75 ul 10 mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul 10x T7 transcription buffer (Ambion); and 2 ul 10x T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RNA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen's RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step.

Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment

RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final conc.); 50 pM 948-b control oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with 1xMES hyb buffer.

The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to IVT): The following mixture is prepared:

15 IVT antisense RNA; 4 μg: μl
Random Hexamers (1 μg/μl): 4 μl
H₂O: μl
14 μl

5

10

Incubate the above 14 µl mixture at 70°C for 10 min.; then put on ice.

The Reverse transcription procedure uses the following mixture:

0.1 M DTT: 3 μl
50X dNTP mix: 0.6 μl
H₂O: 2.4 μl
Cy3 or Cy5 dUTP (1mM): 3 μl
25 SS RT II (BRL): 1 μl

The above solution is added to the hybridization reaction and incubated for 30 min., 42° C. Then, 1 μ l SSII is added and incubated for another hour before being placed on ice.

The 50X dNTP mix contains 25mM of cold dATP, dCTP, and dGTP, 10mM of dTTP and is made by adding 25 μ l each of 100mM dATP, dCTP, and dGTP; 10 μ l of 100mM dTTP to 15 μ l H₂O.]

RNA degradation is performed as follows. Add 86 μ l H₂O, 1.5 μ l 1M NaOH/2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 μ l TE/sample spin at 7000 g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500 μ l buffer PB and proceed using Qiagen protocol. For DNAse digestion, add 1 ul of 1/100 dilution of DNAse/30 ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95°C to denature the DNAse.

10

15

5

Sample preparation

For sample preparation, add Cot-1 DNA, 10 μl; 50X dNTPs, 1 μl; 20X SSC, 2.3 μl; Na pyro phosphate, 7.5 μl; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μl H₂0. Add 0.38 μl 10% SDS. Heat 95°C, 2 min and slow cool at room temp. for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H₂O; 1X SSC: 5 min., 12.5 ml 20X SSC in 250ml H₂O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H₂O. Dry slides and scan at appropriate PMT's and channels.

TABLE 1: Figure 1 from BRCA 001 US

Table 1 shows genes, (incorporated in their entirety here and throughout the application where primekeys are provided), downregulated in tumor tissue compared to normal breast tissue.

10		
	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title
15	R1:	Ratio of normal breast tissue to tumor

				\$	
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
20	100472	D90084	Hs.1023	pyruvate dehydrogenase (lipoamide) alpha	5
_ `		T51986		hemoglobin, gamma G	10
		M55405		gb:Homo sapiens mucin (MUC-3) mRNA, part	5
		BE142019	Hs.222056	Homo sapiens cDNA FLJ11572 fis, clone HE	10
		X52078		transcription factor 3 (E2A immunoglobul	5
25		BE259039		Ewing sarcoma breakpoint region 1	5
		X16841		neural cell adhesion molecule 1	5
		A03758		NM_000477*:Homo sapiens albumin (ALB), m	10
		L27065		gb:Human neurofibromatosis 2 (NF2) mRNA,	5
		M60832	Hs.249239	collagen, type VIII, alpha 2	5
30		BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	10
	101125	AJ250562	Hs.82749	transmembrane 4 superfamily member 2	5
		M90424	Hs.2099	lipocalin 1 (protein migrating faster th	5
	101184	NM_001674	Hs.460	activating transcription factor 3	10
	101336	NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10
35	101367	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	101447	M21305		gb:Human alpha satellite and satellite 3	10
		N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10
		M27826		endogenous retroviral protease	10
4.0		AV650262	Hs.75765	GRO2 oncogene	5
40		M74447	Hs.502	transporter 2, ATP-binding cassette, sub	10
		U22961		gb:Human mRNA clone with similarity to L	10
		NM_001504		G protein-coupled receptor 9	5
		U48251	Hs.75871	protein kinase C binding protein 1	10
4 =		U89337		tenascin XB	10
45		U60115	Hs.239069	four and a half LIM domains 1	5
		AA313538		gb:EST185419 Colon carcinoma (HCC) cell	10
		NM_006744	Hs.76461	retinol-binding protein 4, interstitial	10 10
		AA829286		serum amyloid A1	5
50		X98085	Hs.54433	tenascin R (restrictin, janusin) gb:zn26d06.r1 Stratagene neuroepithelium	10
30		AA081995		gb;zm78c07.r1 Stratagene neuroepithelium	5
		AA126129	Ha 226204	Homo sapiens, clone MGC:16638, mRNA, com	10
		AA137107	Hs.8719	hypothetical protein MGC1136	5
		AA326216 AB041036	Hs.57771	kallikrein 11 (KLK11; TLSP; PRSS20; hipp	5
55		R50727	Hs.336970		10
55		AA422123	HS.330310	gb;zv26h12.r1 Soares_NhHMPu_S1 Homo sapi	5
		AL353957	He 28/181	hypothetical protein DKFZp434P0531	10
		F06638	Hs.12440	Homo sapiens clone 24734 mRNA sequence	10
		AA426189	113.12770	gb:zw11e09.r1 Soares_NhHMPu_S1 Homo sapi	5
60		N73185	Hs.94285	EST	10
30		N91071	Hs.109650		10
		N99542	Hs.572	orosomucoid 1	5
	104532	Al498763		hypothetical protein FLJ12748	10
	104002	100, 00			

		R24024	Hs.158101	Homo sapiens cDNA FLJ14673 fis, clone NT	5
		Y11312		phosphoinositide-3-kinase, class 2, beta	5
		AW969769	Hs.105201 Hs.190380		5 10
5		AA009764 AA017245	Hs.32794	ESTS	10
5	104711	AA019300		ESTs, Moderately similar to I54374 gene	10
		AI039243	Hs.278585		5
		Al298208	Hs.28805	ESTs	10
	105036	AA130390	Hs.25549	hypothetical protein FLJ20898	10
10		R61532	Hs.87016	hypothetical protein FLJ22938	5
		AW970043	Hs.238039	hypothetical protein FLJ11090	5
		AA221036	11 400440	gb:zr03f12.r1 Stratagene NT2 neuronal pr	10
		AA421973	HS.169119	ESTs, Weakly similar to T25731 hypotheti	5 5
15		BE242857 N79885	Hs.27021 Hs.6382	hypothetical protein FLJ11159 ESTs, Highly similar to T00391 hypotheti	10
13		AL359624	Hs.11387	KIAA1453 protein	5
		AI803651	Hs.191608		10
		AW976171		hypothetical protein FLJ22233	5
		A1085846	Hs.25522	KIAA1808 protein	10
20	106379	AL042069	Hs.119021	DKFZP434N061 protein	10
	106451	AW235928	Hs.313182	ESTs	10
		AA135688	Hs.10083	Homo sapiens, clone IMAGE:4139786, mRNA,	10
		AA906434	Hs.3776	zinc finger protein 216	5
25		AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,	10
25		AI458623	Un 00520	gb:tk04g09.x1 NCI_CGAP_Lu24 Homo sapiens	5 5
		Al983730 Al347578	Hs.26530	serum deprivation response (phosphatidyl hypothetical protein MGC2605	5
		AF128847		indolethylamine N-methyltransferase	5
		AJ223811	Hs.30127	hypothetical protein	5
30		Al446183	Hs.9572	ESTs, Highly similar to CYA5_HUMAN ADENY	5
		AB006532	Hs.31442	RecQ protein-like 4	10
	107148	A1005036	Hs.334305	GS1999full	10
		AF127026	Hs.5394	myosin IA	10
25		AB020672		KIAA0865 protein	10
35		AI905985	Hs.111805		10
		U51704		ESTs, Moderately similar to ALU8_HUMAN A	5 5
		W26652 W28516	Hs.6163 Hs.19210	PTEN induced putative kinase 1 hypothetical protein MGC11308	10
		AL042425		hypthetical protein PRO2389	10
40		AI092790		hypothetical protein FLJ14529	5
. •		W38002		Empirically selected from AFFX single pr	10
	107683	N53167	Hs.47623	ESTs	10
	107711	W96141	Hs.220687		10
4 ~		AA017462	Hs.269244		10
45		BE621721		hypothetical protein FLJ12387 similar to	10
		AA025060	Hs.61246	ESTs	10 10
		BE271708	Hs.95110 Hs.191637	ESTs, Weakly similar to A55943 1-phospha	5
		AA025836 AL049176	Hs.82223	chordin-like	10
50		AA043675	Hs.62633	ESTs	10
20		AA093668	Hs.28578	muscleblind (Drosophila)-like	5
		AA012881	Hs.72531	hypothetical protein FLJ11838	10
	108238	AA059473	Hs.66783	EST	10
	108257	AA677927	Hs.144269		5
55		AA070500		gb:zm70h03.s1 Stratagene neuroepithelium	5
	108351	AA071193	11- 07700	gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10
		NM_006770	Hs.67726	macrophage receptor with collagenous str gb:zm86a01.s1 Stratagene ovarian cancer	5 10
	108392	AA075124 AA079079		gb:zm97c09.s1 Stratagene colon HT29 (937	10
60	100441	AA085383		gb:zn13g03.s1 Stratagene hNT neuron (937	10
UU	108497	AA074897		gb:zm85a05.r1 Stratagene ovarian cancer	10
		AA934589	Hs.49696	ESTs	5
	108662	AF117646		Cas-Br-M (murine) ectropic retroviral tr	5
	108706	AA121820	Hs.74569	KIAA0842 protein	10
65	108738	AA126583	Hs.158725		10
	108827	Al273692	Hs.110470		10 10
	109123	Al028376	Hs.73232	ESTs	10

	109389	AA101325	Hs.86154	hypothetical protein FLJ12457	10
		F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	5
		R40604		ESTs, Weakly similar to MCAT_HUMAN MITOC	10
_		AI094674	Hs.30524	ring finger protein 24	10
5		H46749	Hs.31540	ESTs	10
		W22165	Hs.22586	ESTs	5
		AW294162		UDP-N-acetyl-alpha-D-galactosamine:polyp	10
		H51276	Hs.13526	hypothetical protein FLJ12688	10 5
10		H52576	LI- 407000	gb:yt85e08.r1 Soares_pineal_gland_N3HPG	5 5
10		H72639 H60593	Hs.167608 Hs.124990		10
	110000	AL044174		patched (Drosophila) homolog	10
		AI753316	Hs.26034	ESTs	5
		N66616		H.sapiens mRNA for subtelomeric repeat s	5
15		Al798376	113.10023	gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
1.5		AJ224864	Hs.9688	leukocyte membrane antigen	5
		AA641636	Hs.37477	ESTs, Weakly similar to T46908 hypotheti	5
		R00144	Hs.189771		10
		Al168511	7101100111	gb:ow90h09.s1 Soares_fetal_liver_spleen_	10
20		R16733	Hs.20499	ESTs	10
		R26065		gb:yh39d03.s1 Soares placenta Nb2HP Homo	5
		AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
	111995	R42333	Hs.302292	ESTs	10
	112071	AL117490	Hs.47225	Ras-associated protein Rap1	10
25	112204	NM_006668	Hs.25121	cytochrome P450, subfamily 46 (cholester	10
	112258	R51889	Hs.24990	ESTs	5
	112490	R31094	Hs.24378	ESTs	10
		R77302		gb:yi75h08.s1 Soares placenta Nb2HP Homo	10
20		BE618629	Hs.268809		5
30		T98628	Hs.191290		5
		AI057205	Hs.14584		5
		AA581428	Hs.5021	EST	10
		T16837	Hs.4241	ESTs	5 10
35		T51588	Un 2017EE	gb:yb27e06.s1 Stratagene fetal spleen (9	5
33		T54659 AA743563	Hs.10305	Homo sapiens cDNA FLJ11465 fis, clone HE ESTs	5
		AW207424	Hs.332594		10
		N92359		ESTs, Moderately similar to A48752 B-cel	10
		R16763	Hs.268679		5
40		AA913635		Homo sapiens cDNA FLJ20812 fis, clone AD	10
		R06874		ESTs, Moderately similar to ALU1_HUMAN A	5
		Al791905	Hs.95549	hypothetical protein	10
		Al244311	Hs.26912	ESTs	10
	113807	W07586	Hs.8045	ESTs	3
45	113958	W86195		gb:zh54e05.s1 Soares_fetal_liver_spleen_	· 10
	114211	Z39319	Hs.27347	EST	10
		AB018263		tumor necrosis factor receptor superfami	5
		AA745978	Hs.28273	ESTs	5
50		AA020736	11 007040	gb:ze63b11.s1 Soares retina N2b4HR Homo	5
50		AA034378	Hs.267319	endogenous retroviral protease	5
		AA065096		gb:zm50a02.s1 Stratagene fibroblast (937	5 5
		AA081507	11- 07200	gb:zn05b10.r1 Stratagene hNT neuron (937	5 5
		AA234826	Hs.87386	EST ESTs	5
55		AA234462 AK000725	Hs.87350 Hs.50579	hypothetical protein FLJ20718	3
55		AF173081		Vertebrate LIN7 homolog 1, Tax interacti	5
		AB020649	Hs.74569	KIAA0842 protein	5
		AA398841	Hs.39850	hypothetical protein FLJ20517	10
		Al478427	Hs.43125	esophageal cancer related gene 4 protein	10
60		AL133916		hypothetical protein FLJ20093	10
		AA463902	Hs.13522	ESTs, Weakly similar to I38022 hypotheti	5
		AW968703	Hs.30085	hypothetical protein FLJ23186	5
		AW410377	Hs.41502	hypothetical protein FLJ21276	5
	116527	AW194253	Hs.68607	ESTs	10
65		BE314852		Homo sapiens clone 23763 unknown mRNA, p	5
		F10528	Hs.70001	ESTs, Moderately similar to JC6169 nucle	5
	117058	AW801806		gb:IL5-UM0070-110400-062-g07 UM0070 Homo	5

	117151	A1803656	Hs.42373	ESTs	5
	117226	N20468		gb:yx39b10.s1 Soares melanocyte 2NbHM Ho	10
	117323	AI472863	Hs.43387	ESTs	5
		N34417	Hs.44584		3
5		N26627	Hs.82364		5
		N40551		Homo sapiens Ets-1 binding protein (E1B)	10 10
		N49285 AW263476	Hs.182391 Hs.44268	myelin gene expression factor 2	10
		BE222341	Hs.279472		5
10		N53145	113.210712	gb:yv55f09.s1 Soares fetal liver spleen	3
10		AW955696	Hs.90960	ESTs	10
		Al078236	Hs.49688		5
	118664	N70907	Hs.230619		10
		AL122040		Homo sapiens mRNA; cDNA DKFZp434G1972 (f	3
15		AA993527		hypothetical protein FLJ23403	5
		Al160570		pregnancy specific beta-1-glycoprotein 6	3
		AF142419	Hs.15020		5 5
		AA514422 AK002001	Hs.221849 Hs.51305		10
20		T77892	HS.5 1505	gb:yd20f04.s1 Soares fetal liver spleen	5
20		T81824	Hs.90949	EST	5
		W38051	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Empirically selected from AFFX single pr	10
		AL049798	Hs.80552	dermatopontin	3
		AF086332	Hs.58314	ESTs	10
25		AF088061	Hs.159690		5
		AF086429	Hs.58429		5
		AW803308	Hs.62954		5
		U34249	Hs.33/461	Human putative zinc finger protein (ZNFB	5 10
30		AL042725 AW136934	Hs.97162	gb:DKFZp434B1822_r1 434 (synonym: htes3) ESTs	5
50		AA907743	Hs.142373		5
		AA401695	Hs.97334		5
		AA405763		Homo sapiens cDNA FLJ20470 fis, clone KA	5
		AA421452		ESTs, Weakly similar to KIAA0926 protein	5
35		AK000229	Hs.98017		10
	122441	AA447555	Hs.99116		10
		AA458945	Hs.95898	ESTs	10
		AW135093		ESTs, Highly similar to G100_HUMAN 110 K	5
40		AA609122		Homo sapiens mRNA; cDNA DKFZp434D2472 (f	5 5
40		AI024595 AA621529	Hs.97508	a disintegrin and metalloproteinase doma gb:af47a02.s1 Soares_total_fetus_Nb2HF8_	10
		H62570		gb:yr44a01.r1 Soares fetal liver spleen	5
		H83465		gb:ys91a11.s1 Soares retina N2b5HR Homo	5
		AK001527	Hs.163953	hypothetical protein FLJ10665	5
45	125099	NM_014312		cortic al thymocyte receptor (X. laevis	10
		T98199	Hs.48403		10
		BE299567		ESTs, Moderately similar to ALU8_HUMAN A	5
		NM_002666	Hs.103253	· ·	10
50		BE256206	Hs.17775		5 10
50		AA485421 NM_002250	Hs.270503 Hs.10082	ESTs, Weakly similar to ALU7_HUMAN ALU S potassium intermediate/small conductance	10
		R44214	Hs.101189	•	5
		C16161		hypothetical protein PRO2543	5
		AA193106		chromosome 11 open reading frame 23	10
55		H39537	Hs.75309		10
		AW150717	Hs.296176	STAT induced STAT inhibitor 3	10
		N62889		Homo sapiens cDNA FLJ12965 fis, clone NT	10
		AA443323		BPOZ protein	5
60		AA056483		Human Chromosome 16 BAC clone CIT987SK-A	5 10
60		NM_013403	Hs.108665	zinedin SH3-domain protein 5 (ponsin)	5
		AL117472 Al146494		ESTs, Weakly similar to IRX2_HUMAN IROQU	3
		U40714		tyrosyl-tRNA synthetase	5
		AA530892		dual specificity phosphatase 1	5
65	129285	BE617015	Hs.11006	ESTs, Moderately similar to T17372 plasm	10
	129346	AF110141	Hs.288908	WAS protein family, member 2	10
		NM_003877	Hs.110776	STAT induced STAT inhibitor-2	5

		X06828 AW245805		von Willebrand factor claudin 5 (transmembrane protein deleted	5 10
		W37944	Hs.4007	Sarcolemmal-associated protein	5
	129441	BE061069		KIAA0467 protein	10
5	129516	AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
		BE222078	Hs.113069		10
		BE622468	Hs.11924		5
		Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	5
10		AK001676	Hs.12457	hypothetical protein FLJ10814	10
10		AK000956 Al338993	Hs.13209 Hs.134535	hypothetical protein FLJ10094	5 5
		AJ251760		guanine nucleotide binding protein (G pr	5
		NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	5
		NM_001158		amine oxidase, copper containing 2 (reti	5
15		M62402		insulin-like growth factor binding prote	10
	130089	AA452006	Hs.333199		5
	130162	W80711		Homo sapiens mRNA for KIAA1727 protein,	5
		D88435		cyclin G associated kinase	10
20		Al241084	Hs.154353	nonselective sodium potassium/proton exc	5
20		AA435746	U= 002400	gb:zt79e03.s1 Soares_testis_NHT Homo sap	5 10
		V00517 NM_001928		hemoglobin, gamma G D component of complement (adipsin)	10
		X72308		small inducible cytokine A7 (monocyte ch	5
		BE222978	Hs.15760	MYG1 protein	10
25		AW390834	Hs.75874	pregnancy-associated plasma protein A	5
		BE270472		HSPC015 protein	10
	130589	AL110226	Hs.16441	DKFZP434H204 protein	10
		Al652143		hypothetical protein FLJ13111	5
20		A1769067		ESTs, Weakly similar to T28770 hypotheti	3
30		AA993269	Hs.17872	Homo sapiens, clone IMAGE:3875012, mRNA	10 10
		NM_006691	Hs.17917	extracellular link domain-containing 1	5
		AA232075 AF263462	Hs.18259 Hs.18376	XPA binding protein 1; putative ATP(GTP) KIAA1319 protein	10
		N41322	Hs.18441	ESTs	5
35		M81349	Hs.1955	serum amyloid A4, constitutive	10
		BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
	131184	AB040935	Hs.23954	cerebral cell adhesion molecule	10
		AA360419		inositol(myo)-1(or 4)-monophosphatase 1	10
40		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
40		AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
		AK000393 AF110908	Hs.25817	BTB (POZ) domain containing 2	5 5
		H83294		TNF receptor-associated factor 3 Wnt inhibitory factor-1	5
		BE394648	Hs.27414	hypothetical protein	5
45		AW966881	Hs.41639	programmed cell death 2	10
		BE559681	Hs.30736	KIAA0124 protein	5
	131753	AA829286	Hs.332053	serum amyloid A1	10
		AA443966	Hs.31595	ESTs	10
50		H69342	Hs.26320	TRABID protein	10
50		AA021258 BE244961	Hs.32753	ESTs FE65-LIKE 2	5 5
		AJ000263		keratin, hair, basic, 6 (monilethrix)	10
	131888	AW294659	Hs.34054	Homo sapiens cDNA: FLJ22488 fis, clone H	5
		AJ003112	Hs.34780	doublecortex; lissencephaly, X-linked (d	5
55	131949	AK000010	Hs.258798		10
	132115	H81604	Hs.178471		5
	132177	X80818	Hs.178078		5
	132296	AA467752	Hs.195161		5
60	132426	AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
60	132477	S68874	Hs.170917 Hs.5476		5 10
	132706	Al291496 NM_006283		Homo sapiens, clone IMAGE:3530123, mRNA, transforming, acidic coiled-coil contain	10
	132898	W28548	Hs.224829		10
	132905	NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
65	132953	BE175645		LBP protein 32	5
	133116	BE563966	Hs.6529	ESTs, Weakly similar to I78885 serine/th	5
	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10

	133139	AF052138	Hs.6580	Homo sapiens cDNA: FLJ23227 fis, clone C	5
		AA668224	Hs.6634	Homo sapiens cDNA: FLJ22547 fis, clone H	5
	133268	AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	5
_	133272	NM_002776	Hs.69423	kallikrein 10 (KLK10) (PRSSL1) (nes1)	5
5	133379	AA207059		gb:zq80h09.s1 Stratagene hNT neuron (937	5
	133407	AF017987	Hs.7306	secreted frizzled-related protein 1	5
	133552	H21497	Hs.7471	BBP-like protein 1	5
	133702		Hs.75652	glutathione S-transferase M5	5
10		H26904	Hs.75736	apolipoprotein D	5
10	133731			hemoglobin, alpha 2	10
		T85626	Hs.76239	hypothetical protein FLJ20608	5
		AF072441	Hs.7840	calcineurin binding protein 1	10
		D86062		ES1 (zebrafish) protein, human homolog o	10
15		Al372588	Hs.8022	TU3A protein	10
15		AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	10
		BE243319	Hs.79672	KIAA0652 gene product	5 10
		AW905827	Hs.81454	ketohexokinase (fructokinase)	5
		BE549343	Hs.82208	acyl-Coenzyme A dehydrogenase, very long	5
20		AF207664	Hs.8230	a disintegrin-like and metalloprotease (5
20	134449		Hs.83450	laminin, alpha 3 (nicein (150kD), kalini	10
		AI190413	Hs.8373	ESTs	10
		M64936 NM 002757	Un 250070	gb:Homo sapiens retinoic acid-inducible	10
				mitogen-activated protein kinase kinase CD8 antigen, alpha polypeptide (p32)	10
25		M26315	Hs.85258 Hs.85951	• • • • • • • • • • • • • • • • • • • •	5
23		BE244323		exportin, tRNA (nuclear export receptor	5
		U73394		killer cell immunoglobulin-like receptor dynein, axonemal, light polypeptide 4	5
,		AL008583 D10216	Hs.89394	POU domain, class 1, transcription facto	5
		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10
30		T29618	Hs.89640	TEK tyrosine kinase, endothelial (venous	10
50	134912		Hs.261457		5
		NM_003394	Hs.91985	wingless-type MMTV integration site fami	10
		H22570		hypothetical protein FLJ20093	5
		AA302517	Hs.92732	KIAA1444 protein	5
35		X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10
~~		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	10
		U76456		tissue inhibitor of metalloproteinase 4	5
		AB002361	Hs.96633	KIAA0363 protein	5
		U83171	Hs.97203	small inducible cytokine subfamily A (Cy	5
40		AA416829	Hs.191597		5
		AA905406	Hs.9905	ESTs, Weakly similar to unnamed protein	3
	135417	X55019	Hs.99975	cholinergic receptor, nicotinic, delta p	10
	101367	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	5 ·
	128870	H39537	Hs.75309	eukaryotic translation elongation factor	5
45	129381	AW245805		claudin 5 (transmembrane protein deleted	5
	130085	M62402	Hs.274313	insulin-like growth factor binding prote	5
	130689	NM_006691	Hs.17917	extracellular link domain-containing 1	10
	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	3
	133407	AF017987	Hs.7306	secreted frizzled-related protein 1	5
50		N71725	Hs.272572	hemoglobin, alpha 2	5
		AF207664	Hs.8230	a disintegrin-like and metalloprotease (5
		X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5
<i></i>		AK001852	Hs.274151		5
55		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
		AW377752	Hs.83341	AXL receptor tyrosine kinase	5
		BE208364	Hs.29283	ESTs, Weakly similar to LKHU proteoglycan link	5
		AA563892		solute carrier family 4 (anion exchanger), memb	10
60	449820	U85642	Hs.138506		5
60		RC_H15814_s		Human apM1 mRNA for GS3109 (novel adipose specific colla	3
		YEL024w/RIP1		EST - YEL024w/RIP1	5

TABLE 1A

Table 1 A shows the accession numbers for those pkeys lacking unigeneID's for Table 1. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	Λ
1	u

5

Pkey:	

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15

	Pkey	CAT Number	Accessions
20	108446 108497	112224_1 110079_2	AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 AA074897 AA113914 AA064871 AA079329 AA071309 AA084710 AA129030 AA075042 AA074794 AA071453 AA078803 AA148628 AA122204 AA074159 AA126185 AA079117 AA127089 AA070912 AA079280 AA131372 AA078833 AA071087 AA076131 AA071047 AA079401 AA083070 AA102076 AA115163 AA074198 AA134725 AA113889 AA121103 AA075041 AA065148 AA071310 AA101144 AA079659 AA078931 AA079209 AA070928 AA068994 AA069817 AA076187 AA069053
25			AA131489 AA071308 AA063317 AA070556 AA071430 AA076056 AA0776584 AA070053 AA126283 AA126078 AA053056 AA071308 AA063317 AA0705684 AA079208 AA074583 AA071308 AA079622 AA076622 AA065051 AA079143 AA071100 AA079434 AA148748 AA079230 AA085188 AA074485 AA070580 AA076151 AA083166 AA085118 AA079450 AA085044 AA120938 AA079200 AA100188 AA08472 AA122355 AA129031 AA085362 AA069220 AA070940 AA075968 AA074563 AA084027 AA115929
30	124215 117058 110455 111168	1597154_1 1219924_1 46874_1 38585_1	H62570 H59063 AW801806 H90434 BE086530 H52576 AF085971 H52172 AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384
35			AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
40	111498 104340 103747 134496 Al684569 A	411008_1 46289_10 117944_1 46501_1	Al168511 Al022712 AA700366 R07371 R07324 AA426189 F15201 AA081995 AA101099 M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311
45	103750 105239	118365_1 34624_1	Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514 AA126129 AA126033 AA082561 AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904
50	120379	34624_3	C16859 AL042725 BE063316 AW975610 AA457591 BE062092 Al655202 AA714296 Al267264 Al075321 AA223286 AA071122 AA227849 AA216700 Al696002 AA101867 AA099426 AA135997 AL041698 T02815 T51824 AA207189 T59230 T51868 AA663341 BE165757 AW818104 AW392886 AA584918 AA099408 AW856396 AW861859 AA053045
55	114624 106851 108392 100545 100654	111686_1 322947_1 113549_1 22955_11 tigr_HT2969	AA081507 AA070071 AA070840 AA084362 AI458623 AA639708 AA485409 R22065 AA485570 AA075124 AA075208 M55405 AW752552 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495
60	100702 102208	tigr_HT3413 6735_9	X51363 X51364 X51365 L27065 U22961 AA203623 AA503337 AI174733 AI192802 C06092 AA035357 AI190619 AI199244 AI828450 AA602296 AI378195 AI209170 AI186653 AI127795 AI183846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 AI745413 AI685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101

N70806 Al141254 Al383191 Al401237 Al080709 Al093400 W84549 T90806 R00012 W01413 AA630557 Al378348 Al559265 AA877103 W84464 AA625146 R68379 AI133207 AI132980 AI133214 AI064826 AI061615 AI133473 AI174852 AI133404 AI133272 V00494 M12523 M12523 AI207526 AI133120 AI064802 AI174993 AI114729 AI061645 AI064716 AI064959 H77388 T85706 AF075298 AI110799 D17107 NM_000477 AF190168 R50724 AI248416 AI207432 AI133684 AI133345 AI174710 5 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 AI444620 T52290 D16931 T40012 T48403 T58926 T69195 AI133061 T50850 AI400677 AI091136 AA334608 T57411 Z20979 10 N56507 T87485 AI133622 AA343370 T40075 T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AI114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 15 H71080 T73217 AA343950 AI174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 Al065049 T84512 T55918 Al207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 20 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289 AA046980 AI823482 AI114536 AA860651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 25 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 30 T28321 T55864 genbank_AA621529 123941 AA621529 118049 genbank_N53145 N53145 AA313538 U88895 U88902 102800 14782_20 AA422123_i_atAA422123_i 35 104106 genbank_R26065 R26065 111738 T51588 113149 genbank_T51588 113958 genbank_W86195 W86195 genbank_AA070500 genbank_AA071193 108335 AA070500 40 AA071193 108351 108441 genbank_AA079079 AA079079 genbank_H83465 124276 H83465 entrez_M21305 101447 M21305 117226 genbank_N20468 N20468 45 AA207059,AA207241 133379 genbank_AA207059 119366 genbank T77892 T77892 NOT_FOUND_entrez_W38051 W38051 119528 112588 genbank_R77302 R77302 114449 genbank_AA020736 AA020736 50 114576 genbank_AA065096 AA065096 W38002_s_at W38002_s 107459 AA435746 130339 genbank_AA435746

TABLE 2: Figure 2 from BRCA 001 US

Table 2 shows genes downregulated in tumor tissue compared to normal breast tissue. 5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

Pkey: ExAccn: UnigenelD: Unigene Title: R1: 10

15	Pkey	ExAccn	UnigenelD	Unigene Tittle	R1
	100499	T51986	Hs.283108	hemoglobin, gamma G	10
	100549	BE142019	Hs.222056	Homo sapiens cDNA FLJ11572 fis, clone HE	10
	100654	A03758		NM_000477*:Homo sapiens albumin (ALB), m	10
20	100971	BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	10
		NM_001674	Hs.460	activating transcription factor 3	10
		NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
25		M21305		gb:Human alpha satellite and satellite 3	10
25		N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10
		M27826	Hs.267319	endogenous retroviral protease	10
		M74447	Hs.502	transporter 2, ATP-binding cassette, sub-famil	10
		U22961	11a 75074	gb:Human mRNA clone with similarity to L	10
30		U48251	Hs.75871	protein kinase C binding protein 1	10 10
30		AA313538 NM_006744	Hs.76461	gb:EST185419 Colon carcinoma (HCC) cell retinol-binding protein 4, interstitial	10
		AA829286	Hs.332053		10
		AA029200 AA081995	H8.332033	serum amyloid A1 gb:zn26d06.r1 Stratagene neuroepithelium	10
		AA137107	Hs.326391	Homo sapiens, clone MGC:16638, mRNA, com	10
35		R50727	Hs.336970	ESTs	10
55		AL353957	Hs.284181	hypothetical protein DKFZp434P0531	10
		F06638	Hs.12440	Homo sapiens clone 24734 mRNA sequence	10
		N73185	Hs.94285	EST	10
		N91071	Hs.109650	ESTs	10
40		AI498763	Hs.203013	hypothetical protein FLJ12748	10
		AA009764	Hs.190380	ESTs	10
	104711	AA017245	Hs.32794	ESTs	10
	104731	AA019300	Hs.125070	ESTs, Moderately similar to I54374 gene	10
	105005	A1298208	Hs.28805	ESTs	10
45	105036	AA130390	Hs.25549	hypothetical protein FLJ20898	10
	105239	AA221036		gb:zr03f12.r1 Stratagene NT2 neuronal pr	10
	106052	N79885	Hs.6382	ESTs, Highly similar to T00391 hypotheti	10
	106181	A1803651	Hs.191608	ESTs	10
~ 0		AI085846	Hs.25522	KIAA1808 protein	10
50		AL042069	Hs.119021	DKFZP434N061 protein	10
		AW235928	Hs.313182	ESTs	10
		AA135688	Hs.10083	Homo sapiens, clone IMAGE:4139786, mRNA,	10
		AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,	10
<i>5 </i>		AB006532	Hs.31442	RecQ protein-like 4	10
55		AI005036	Hs.334305	GS1999full	10
		AF127026	Hs.5394	myosin IA	10
		AB020672	Hs.175411	KIAA0865 protein ESTs	10 10
		AI905985 W28516	Hs.111805 Hs.19210	hypothetical protein MGC11308	10
60		AL042425	Hs.283976	hypthetical protein PRO2389	10
UU		BE271708	Hs.95110	ESTs, Weakly similar to A55943 1-phospha	10
		AA071193	110.00110	gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10
		F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	10
		AW294162	Hs.301062	UDP-N-acetyl-alpha-D-galactosamine:polyp	10
65		AL044174	Hs.159526	patched (Drosophila) homolog	5
55	, ,,,,,,			Farmer /- sasking) Housided	-

		Al798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
		R16733	Hs.20499	ESTs	10
		AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
	114484	AA034378	Hs.267319	endogenous retroviral protease	10
5	125284	NM_002666	Hs.103253	perilipin	10
	128850	AA193106	Hs.180817	chromosome 11 open reading frame 23	5
	128903	AW150717	Hs.296176	STAT induced STAT inhibitor 3	10
	129346	AF110141	Hs.288908	WAS protein family, member 2	10
		AW245805	Hs.110903	claudin 5 (transmembrane protein deleted	10
10		AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
		BE222078	Hs.113069	ESTs	10
		M62402	Hs.274313	insulin-like growth factor binding prote	10
		D88435	Hs.153227	cyclin G associated kinase	10
		V00517	Hs.283108	hemoglobin, gamma G	10
15		NM_001928	Hs.155597	D component of complement (adipsin)	10
13		BE270472	Hs.279900	HSPC015 protein	10
		AL110226	Hs.16441	DKFZP434H204 protein	10
		AA993269		Homo sapiens, clone IMAGE:3875012, mRNA	10
			Hs.17872 Hs.17917	extracellular link domain-containing 1	10
20		NM_006691			10
20		AA046747	Hs.17917 Hs.18376	extracellular link domain-containing 1 KIAA1319 protein	10
		N70196			10
		M81349	Hs.1955	serum amyloid A4, constitutive	10
		BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
25		AB040935	Hs.23954	cerebral cell adhesion molecule	
25		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
		AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
		AW966881	Hs.41639	programmed cell death 2	10
		AA829286	Hs.332053	serum amyloid A1	10
20		H69342	Hs.26320	TRABID protein	10
30		AJ000263	Hs.278658	keratin, hair, basic, 6 (monilethrix)	10
		AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
		AI291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
		W28548	Hs.224829	ESTs	10
o. =		NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
35	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10
	133407	AF017987	Hs.7306	secreted frizzled-related protein 1	10
	133719	H26904	Hs.75736	apolipoprotein D	10
	134007	AF072441	Hs.7840	calcineurin binding protein 1	10
	134055	D86062	Hs.182423	ES1 (zebrafish) protein, human homolog o	10
40	134111	Al372588	Hs.8022	TU3A protein	5
	134117	AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	5
	134177	BE243319	Hs.79672	KIAA0652 gene product	10
	134369	AF207664	Hs.8230	a disintegrin-like and metalloprotease (10
	134496	M64936		gb:Homo sapiens retinoic acid-inducible	10
45	134510	NM 002757	Hs.250870	mitogen-activated protein kinase kinase	10
		M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	5
		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	5
		NM_003394	Hs.91985	wingless-type MMTV integration site fami	10
		X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10
50		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
50		AA563892	Hs.306000	solute carrier family 4 (anion exchanger), memb	10
	740074	スプリウラウス	110.000000	coluct during a (amon exonaliger), memb	

TABLE 2A

Table 2A shows the accession numbers for those pkeys lacking unigeneID's for Table 2. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	

Unique Eos probeset identifier number

Pkey: CAT number: Accession:

Gene cluster number Genbank accession numbers

1	5	

5

15	Pkey	CAT number	r Accessions
20	111168	38585_1	Al798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 Al267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 Al829309 AW991957 N66951 AA527374 H66215 AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
25	103747 134496	117944_1 46501_1	AA081995 AA101099 M64936 AI025512 AI382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 AI269283 T40311 AI684569 AA257011 AI079277 AI241318 BE327710 AW975215 AW896268 AA884990 BE327514
30	105239	34624_1	AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16859
	100654	tigr_HT2969	A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365
35	102208	6735_9	U22961 AA203623 AA503337 Al174733 Al192802 C06092 AA035357 Al190619 Al199244 Al828450 AA602296 Al378195 Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al685092 Al093426 Al623873 Al074570 N50096 AA047486 N25060 AA327614 Al042512 Al383957 AA156873 Al333101 N70806 Al141254 Al383191 Al401237 Al080709 Al093400 W84549 T90806 R00012 W01413 AA630557 Al378348 Al559265 AA877103 W84464 AA625146 R68379 Al133207 Al132980 Al133214 Al064826 Al061615 Al133473 Al174852 Al133404
40			Al133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al133648 Al133345 Al174710 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al1144498 Al114759 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772
45			Al174748 Al1 14663 Al133 164 Al132999 Al133 160 Al04922 Al04979 Al13306 AS34347 T69291 AA23399 139772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T74820 AF075316 Al110818 T40121 T57381 Al114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106
50			R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 Al065049 T84512 T55918 Al207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 Al114676 Al064778 AA035710 W52763 Al114786 T83564 AA341859 T81684 T55769 Al114710 T51776 AA343213 Al114714 T58102 Al110809 R28984 Al174854 AA305675
55			AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289 AA046980 Al823482 Al114536 AA860651 AW242644 R07469 AW300438 Al133416 AW271670 Al991363 T78943 Al823481
60			AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 Al114860 T62093 T61797 Al522333 T73322 H92981 T56018 T61811 T57232 Al336158

> T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

102800

108351

5

101447

TABLE 3: Figure 3 from BRCA 001 US

Table 3 shows genes downregulated in tumor tissue compared to normal breast tissue.

	5	,	

	Pkey: ExAccn:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number
10	UnigenelD: Unigene Title:	Unigene number Unigene gene title

Ratio of normal breast tissue to tumor

15					
13	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	101336	NM 006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10.0
	102208	U22961		gb:Human mRNA clone with similarity to L	10.0
20	102990	AA829286	Hs.332053	serum amyloid A1	10.0
	111168	AI798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10.0
	111803	AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10.0
	130085	M62402	Hs.274313	insulin-like growth factor binding prote	10.0
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10.0
25	131543	AW966881	Hs.41639	programmed cell death 2	10.0
	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10.0
	134758	NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10.0

TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigeneID's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:	

5

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

1	5	Pkey	CAT	number	Accessions
---	---	------	-----	--------	------------

20	111168 38585_1	Al798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 Al267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 Al829309 AW991957 N66951 AA527374 H66215
		AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
25	1022086735_9	U22961 AA203623 AA503337 Al174733 Al192802 C06092 AA035357 Al190619 Al199244 Al828450 AA602296 Al378195
25		Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al685092 Al093426 Al623873 Al074570 N50096 AA047486 N25060 AA327614 Al042512 Al383957 AA156873 Al333101 N70806 Al141254
		AI383191 AI401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464
		AA625146 R68379 AI133207 AI132980 AI133214 Al064826 AI061615 AI133473 AI174852 AI133404 AI133272 V00494 M12523 M12523 AI207526 AI133120 AI064802 AI174993 AI114729 AI061645 AI064716 AI064959 H77388 T85706 AF075298 AI110799
30		D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710 Al133290 Al133304 Al174948
		AI207484 AI110717 AF074624 AI114515 AF063516 AI110642 AI114559 AI114498 AI114759 AI207568 AI064960 AI174753
		Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999
		Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403
35		T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075
		T69671 T53849 T74820 AF075316 AI110818 T40121 T57381 AI114468 AA332728 T51362 AI114589 R06691 AI110629 AF063503 AI140543 AA334661 AA332720 AA343262 T73513 T86549 AI114840 T57284 T39981 T61407 T72757 T51749
		T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753
40		T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805
40		Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874
		AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676
		AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102
45		AI110809 R28984 AI174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 AI114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976
43		R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693
		Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354
		AI114720 AI433289 AA046980 AI823482 AI114536 AA860651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AI174774
50	•	T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111
20	•	AA025050 T73330 W52657 T71984 T69118 W92684 Al114860 T62093 T61797 Al522333 T73322 H92981 T56018 T61811
	•	T57232 Al336158 T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809
		T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290
55		Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412
		T64300 T28321 T55864

TABLE 4: Figure 4 from BRCA 001 US

5 Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number
EXAccn: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title
R1: Ratio of tumor to normal breast tissue

15	Pkey	ExAccn	UnigenelD	Unigene Title	R1
,	100112	NM_001269	0He 9/7/6	chromosome condensation 1	2.3
		X02308	Hs.82962	thymidylate synthetase	2.9
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodiesterase 1	1.9
20	100146	BE185499		KIAA0020 gene product	1.9
20		D13666		osteoblast specific factor 2 (fasciclin I-like) (periostin)	7.5
		H60720			9.2
		W44671	Hs.124	gene predicted from cDNA with a complete coding sequence	1.6
				annexin A2	2.0
25		D38521		KIAA0077 protein	1.5
	100271	BE160081	Hs.256290	S100 calcium-binding protein A11 (calgizzarin)	13.5
			Hs.154797	KIAA0090 protein	5.1
	100323	D50920	Hs.23106	KIAA0130 gene product	1.9
	100335	AW247529	Hs.6793	platelet-activating factor acetylhydrolase, isoform lb, gamma subunit (29kD)	2.7
30	100364	NM_00434	1Hs.154868	carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase	2.0
				KIAA0175 gene product	2.6
		D84145	Hs.39913	novel RGD-containing protein	3.2
		AW954324		phosphatidylinositol glycan, class C	1.5
2.5		D86978		KIAA0225 protein	2.0 2.9
35		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein A/B	2.9 1.9
			5Hs.74316	desmoplakin (DPI, DPII)	5.7
		L05424	HS.169610	CD44 antigen (homing function and Indian blood group system)	9.0
		L05424 L05424	HS. 169610	CD44 antigen (homing function and Indian blood group system) CD44 antigen (homing function and Indian blood group system)	7.6
40					53.2
40		AW502935		PTK2 protein tyrosine kinase 2 ribosomal protein L24	1.8
		AA383256		estrogen receptor 1	1.6
	100090	AA303230	He 101356	general transcription factor IIH, polypeptide 2 (44kD subunit)	5.9
	100703	A A R 3 G A 7 7	He 207030	cathepsin B	1.7
45	100000	RE245294	Hs 180789	S164 protein	1.7
73	100032	ΔE002225	Hs 180686	ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)	1.5
	100343	AA157634	Hs.79172	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5	6.3
		AK000405		ubiquitin-like 4	11.4
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5 reductase)	1.6
50		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)	8.2
-		J05614	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:Human proliferating cell nuclear antigen (PCNA) gene, promoter region.	5.0
		N99692	Hs.75227	Empirically selected from AFFX single probeset	2.6
	101093	L06419	Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome ty	pe VI)1.4
	101161	NM_00626	2Hs.37044	peripherin	16.9
55	101186	AA020956	Hs.179881	core-binding factor, beta subunit	2.0
	101216	AA284166	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	1.8
	101228	AA333387	Hs.82916	chaperonin containing TCP1, subunit 6A (zeta 1)	1.7
	101247	AA132666		glycogen synthase kinase 3 beta	1.9
	101249	L18964	Hs.1904	protein kinase C, iota	1.5
60	101332	J04088		topoisomerase (DNA) II alpha (170kD)	5.2
	101332	J04088		topoisomerase (DNA) II alpha (170kD)	3.4
	101352	Al494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxidase assembly protein	6.3
	101396	BE267931	Hs.78996	proliferating cell nuclear antigen	4.2
~~	101445	M21259	011-4040	gb:Human Alu repeats in the region 5' to the small nuclear rib	1.9 1.6
65	101470	NM_00054	0HS. 1846	tumor protein p53 (Lì-Fraumeni syndrome)	1.0

	101478	NM_0028901	He 758	RAS p21 protein activator (GTPase activating protein) 1	2.5
				The protein delicated (of the decidency protein) and the protein and the prote	
			Hs.76768	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I	5.5
	101540	J04977 I	Hs.84981	X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoin	ing 2.1
	101573	AW248421 I	Hs 250758	proteasome (prosome, macropain) 26S subunit, ATPase, 3	1.6
5					5.7
5		NM_012151		coagulation factor VIII-associated (intronic transcript)	
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G protein), beta polypeptide 2	1.8
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6
		BE391804		guanylate binding protein 1, interferon-inducible, 67kD	2.4
				guarrylate binding protein, interferon-inducible, 07 kb	
	101702	AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform	1.3
10	101734	M74099 I	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacement protein)	2.1
		M80244	He 19/601	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	5.0
	101767	M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4
	101782	AA306495	Hs.1869	phosphoglucomutase 1	5.2
		AW409747		stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)	8.6
15					8.9
15				S100 calcium-binding protein A7 (psoriasin 1)	
	101810	NM_000318	Hs.180612	peroxisomal membrane protein 3 (35kD, Zellweger syndrome)	3.2
				nuclear autoantigenic sperm protein (histone-binding)	1.6
					31.3
				glycoprotein hormones, alpha polypeptide	
	101920	AF182645 I	Hs.8024	IK cytokine, down-regulator of HLA II	1.8
20	101973	U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T	1) 2.4
		AI904232	He 75222	prohibitin	8.4
	102009	BE245149		protein tyrosine kinase 9	1.3
	102036	BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevisiae, homolog)	2.0
				interleukin enhancer binding factor 2, 45kD	1.6
25					
25	102083	T35901	Hs.75117	interleukin enhancer binding factor 2, 4	1.3
	102107	BE258602	Hs.182366	heat shock protein 75	1.4
		NM_001809		centromere protein A (17kD)	1.8
				•	
	102165	BE313280	HS.159627	death associated protein 3	4.6
	102198	AW950852	Hs.74598	polymerase (DNA directed), delta 2, regulatory subunit (50kD)	4.3
30	102217	AA829978	Hs 301613	JTV1 gene	6.7
-0					4.3
			Hs.65436	lysosomal	
	102234	AW163390	Hs.278554	heterochromatin-like protein 1	1.9
	102260	AL039104	Hs.159557	karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	4.4
		AA306342		protein kinase C-like 2	2.7
25					
33	102330	BE298063	Hs.77254	chromobox homolog 1 (Drosophila HP1 beta)	1.5
	102339	BE378432	Hs.95577	cyclin-dependent kinase 4	2.3
			Hs.87539	aldehyde dehydrogenase 3 family, member B2	2.0
				baculoviral IAP repeat-containing 2	3.2
	102369	U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	2.0
40	102374	U33635	Hs 90572	PTK7 protein tyrosine kinase 7	6.2
.0					1.5
		AA296874		deoxyguanosine kinase	
	102455	U48705	Hs.75562	discoidin domain receptor family, member 1	6.9
	102465	NM_001359	Hs.81548	2,4-dienoyl CoA reductase 1, mitochondrial	1.8
			Hs.61828	amyloid beta precursor protein-binding protein 1, 59kD	1.5
15				anyold beta precursor protein protein (1, 50kb	3.3
45		AL080116		origin recognition complex, subunit 3 (yeast homolog)-like	
	102494	Al188137	Hs.75193	COP9 homolog	2.1
	102501	AF217197	Hs 74562	siah binding protein 1; FBP interacting repressor; pyrimidine tract binding splicing	3.2
	102501	BE350044	He 192550	solute carrier family 1 (neutral amino acid transporter), member 5	2.8
	102532	AF040253		suppressor of Ty (S.cerevisiae) 5 homolog	5.7
50	102564	U59423	Hs.79067	MAD (mothers against decapentaplegic, Drosophila) homolog 1	2.3
				RAB31, member RAS oncogene family	5.3
	102500	1100000	11-450020	ODD (for the seal continue for both and better the seal of the sea	2.1
				CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1	
	102581	AU077228	Hs.77256	enhancer of zeste (Drosophila) homolog 2	1.6
	102582	U61232	Hs 32675	tubulin-specific chaperone e	2.1
55	102002				1.8
33				COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5	
	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8
	102627	AI 021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3
				karyopherin (importin) bela 2	1.8
		BE262989		putative protein	2.3
60		NM_007019		ubiquitin carrier protein E2-C	4.3
		U96132	He 171290	hydroxyacyl-Coenzyme A dehydrogenase, type II	6.0
		BE540274		forkhead box M1	4.2
	102704	AU077058	Hs.54089	BRCA1 associated RING domain 1	1.9
			Hs.50002	small inducible cytokine subfamily A (Cys-Cys), member 19	2.3
65				nth (E.coli endonuclease III)-like 1	1.2
65	102/50	AB014460	115.00 190		
	102801	BE252241	Hs.38041	pyridoxal (pyridoxine, vitamin B6) kinase	6.4
	102812	U90549	Hs.236774	high-mobility group (nonhistone chromosomal) protein 17-like 3	1.6

	40000-	D=044=00 11 04=0	1 1 1 TOP4 11 10 (bullet	F.C.
		BE244588 Hs.6456	chaperonin containing TCP1, subunit 2 (beta)	5.6
		AA262170 Hs.80917	adaptor-related protein complex 3, sigma 1 subunit	2.0
	102844		5 WW domain-containing protein 1	1.3
_	102868	X02419 Hs.77274	plasminogen activator, urokinase	4.4
5	102925	BE440142 Hs.2943	signal recognition particle 19kD	1.9
	102935	BE561850 Hs.80506	small nuclear ribonucleoprotein polypeptide A'	2.4
	102968	AU076611 Hs 154672	2 methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclol	ovdrolase2.7
	102983	BE387202 Hs 118638	non-metastatic cells 1, protein (NM23A) expressed in	3.1
		U95742 Hs.2707	G1 to S phase transition 1	5.2
10	102303	113.2707 113.2707	O Ho S phase dansition 1 multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase	1.6
10				2.5
			3 CDC28 protein kinase 1	
			matrix metalloproteinase 11 (MMP11; stromelysin 3)	4.5
		AU077231 Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatosis 1)	3.1
	103089	D31152 Hs.179729	oollagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	2.4
15	103177	BE244377 Hs.48876	farnesyl-diphosphate farnesyltransferase 1	3.5
	103178	AA205475 Hs.275869	5 ribosomal protein S18	9.9
		NM_001777Hs.82685		1.3
		X69636 Hs.33473	Homo sapiens, clone IMAGE:3448306, mRNA, partial cds	2.0
		NM_006825Hs.74368	transmembrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment	1.6
20			protein phosphatase 4 (formerly X), catalytic subunit	2.5
20		AA401039 Hs.2903		2.2
		NM_004766Hs.75724	coatomer protein complex, subunit beta 2 (beta prime)	
		NM_004939Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1	6.3
		X72755 Hs.77367	monokine induced by gamma interferon	8.8
	103223	BE275607 Hs.1708	chaperonin containing TCP1, subunit 3 (gamma)	3.0
25	103232	X75962 Hs.129780	tumor necrosis factor receptor superfamily, member 4	1.8
	103238	Al369285 Hs.75189	death-associated protein	5.6
		NM_001545Hs.9078	immature colon carcinoma transcript 1	1.9
		Al803447 Hs.77496	small nuclear ribonucleoprotein polypeptide G	2.5
		X89059	gb:H.sapiens mRNA for unknown protein expressed in macrophage	1.6
30			3 coated vesicle membrane protein	1.8
50		V04452 Lie 11426	5 pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase)	2.3
			by pyroline-o-carpoylate synthetase (glutariate garinia-semialderiyde synthetase)	4.0
		X94563	gb:H.sapiens dbi/acbp gene exon 1 & 2.	
		BE564090 Hs.20716		1.3
			myeloid/lymphoid or mixed-lineage leukemia 3	5.6
35	103505	AL031224 Hs.33102	transcription factor AP-2 beta (activating enhancer-binding protein 2 beta)	5.1
	103547	Al376722 Hs.18006	2 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)	9.7
		NM_006218Hs.85701	phosphoinositide-3-kinase, catalytic, alpha polypeptide	2.0
		NM_000346Hs.2316	SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal)	1 <i>.</i> 3
			polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	2.0
40			2 membrane component, chromosome 11, surface marker 1	2.3
-10			growth factor receptor-bound protein 2	1.3
				1.8
	100749	AL135301 Hs.8768	hypothetical protein FLJ10849	1.3
			Homo sapiens mRNA; cDNA DKFZp586l2022 (from clone DKFZp586l2022)	
4.5			2 hypothetical 43.2 Kd protein	7.5
45		H26531 Hs.7367	Homo sapiens BTB domain protein (BDPL) mRNA, partial cds	1.2
		AA080912	gb:zn04d03.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone 5' similar	1.5
	103813	AI042582 Hs.18127	CGI-120 protein	1.5
	103855	W02363 Hs.30226	7 hypothetical protein FLJ10330	1.5
	103886	AK001278 Hs.10573	7 hypothetical protein FLJ10416 similar to constitutive photomorphogenic protein 1	6.5
50		NM_002407Hs.97644		2.9
		AA251242 Hs.10323		1.4
	104174	AA478984 Hs.6451	PRO0659 protein	5.6
	104174	AB002343 Hs.98938	protocadherin alpha 9	1.6
	104227	A1751070 He 10106	GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2	5.4
55	104270	PE270700 Ha.10100	5 polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	6.3
55				1.6
	104370	AA324597 Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	
	104423	R83113 Hs.1432	protein kinase C substrate 80K-H	5.2
	104482	AB037762 Hs.44268	myelin gene expression factor 2	1.2
	104532	A1498763 Hs.20301	hypothetical protein FLJ12748	2.1
60	104563	AL117403 Hs.30618	9 DKFZP434F1735 protein	1.2
	104667	Al239923 Hs.30098	ESTs	1.3
			olfactory receptor, family 2, subfamily I, member 6	2.3
	104804	Al858702 Hs.31803	ESTs, Weakly similar to N-WASP [H.sapiens]	1.3
	104806	AB023175 Hs.22982	KIAA0958 protein	2.3
65	104000	AW052006 Hs.8551	PRP4/STK/WD splicing factor	10.9
03		Al250789 Hs.32478	ESTs	5.6
	104040	ΛΔΩΛ1276 He 15/172	9 3-phosphoinositide dependent protein kinase-1	12.3
	104004	MUTICIO 113.10472	o prospromodituo dependent protein mindee 1	, 2.0

	104867	AA278898	Hs.225979	hypothetical protein similar to small G proteins, especially RAP-2A	2.0
	104871	T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (from clone DKFZp564O2364)	1.3
	104896	AW015318	Hs.23165	ESTs	17.7
	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5.0
5	104916	AW958157	Hs.155489	NS1-associated protein 1	1.7
		AA026880		prolactin receptor	1.4
	104930	AF043467	Hs.32893	neurexophilin 2	2.2
		NM_015310		KIAA0942 protein	5.0
		Y12059		bromodomain-containing 4	1.4
10		AL136877		SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	2.4
		AL136877		SMC4 (structural maintenance of chromoso	2.3
		Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010317E24 gene, clone IMAGE:3502019, mRNA, partial	cds 7.2
			Hs.321062		1.3
		AI499930		mitochondrial GTP binding protein	3.5
15		BE379584		dolichyl-diphosphooligosaccharide-protein glycosyltransferase	5.5
10		AF098158		chromosome 20 open reading frame 1	3.3
		AI050715		E2F transcription factor 5, p130-binding	2.2
		AA127818	110.2001	gb:zl12a02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:501674 3'	6.8
		AA907305	Hs 36475	ESTs	2.5
20		AB037716		KIAA1295 protein	2.2
20				speckle-type POZ protein	3.8
		AA151342		CGI-147 protein	9.5
		AA147884		Homo sapiens cDNA FLJ14388 fis, clone HEMBA1002716	5.6
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
25		Z78407	Hs.27023	vesicle transport-related protein	2.2
25		BE387350		KIAA1160 protein	1.6
		AW975433		ESTs	6.3
				nudix (nucleoside diphosphate linked moiety X)-type motif 5	2.1
	105121	ΔΔ16/1687	He 177576	mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isoenzyme A	2.7
30				hypothetical protein NUF2R	1.9
50				S164 protein	1.7
		AA191512		Homo sapiens cDNA FLJ11309 fis, clone PLACE1010076	4.8
		AA071276		KIAA0859 protein	1.9
		AA263143		RAD51-interacting protein	2.8
35		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	1.9
55		AA700122		sentrin-specific protease	8.0
				KIAA0779 protein	1.8
		NM_01601		CGI-68 protein	8.2
				hypothetical protein FLJ21918	5.0
40	105373	AW887701	Hs.32356	hypothetical protein FLJ20628	2.5
				hypothetical protein FLJ10326	2.2
				membrane protein CH1	2.3
	105393	AF167570	Hs.256583	interleukin enhancer binding factor 3, 90kD	5.4
	105399	BE386877	Hs.334811	Npw38-binding protein NpwBP	1.6
45		AF198620		RNA binding motif protein 8A	1.6
	105445	AA252395		gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:685026 3', mRNA sequence	e. 5.0
	105507	BE268348	Hs.226318	CCR4-NOT transcription complex, subunit 7	1.6
	105529	AA113449	Hs.32471	hypothetical protein FLJ20364	1.3
	105530	AB023179	Hs.9059	KIAA0962 protein	3.4
50	105547	AA262640	Hs.27445	unknown	9.3
	105564	BE616694	Hs.288042	hypothetical protein FLJ14299	1.4
	105596	AA579535	Hs.18490	hypothetical protein FLJ20452	10.9
	105597	AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9
	105608	AI808201	Hs.287863	hypothetical protein FLJ12475	1.7
55	105610	AA280072	Hs.99872	fetal Alzheimer antigen	1.4
	105617	AK000892	Hs.4069	glucocorticoid modulatory element binding protein 1	1.7
	105620	AW302245	Hs.181390	casein kinase 1, gamma 2	5.5
				hypothetical protein FLJ20059	9.4
	105697	AW499988	Hs.27801	zinc finger protein 278	2.0
60	105708	R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264)	1.7
	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short	2.6
		AW151952		hypothetical protein FLJ20739	1.5
		AI123118	Hs.15159	chemokine-like factor, alternatively spliced	1.3
	105771	Al267720	Hs.153221	synovial sarcoma, translocated to X chromosome	1.6
65				transcriptional unit N143	2.2
				E3 ubiquitin ligase SMURF2	1.3
	105856	AI262106	Hs.12653	ESTs	2.4

	105858	AF151066	Hs.281428	/	2.9
	105875	AK001708	Hs.32271		1.4
	105930	AF016371	Hs.9880		5.2
	106000	AW194426	Hs.20726		1.7
5	106011	AW081202	Hs.12284	1 totalo captorio, dictio tita to minococoto, tita in il portuni anti	2.8
	106017	AA477956	Hs.26268		1.4
	106073	AL157441	Hs.17834		1.4
	106078	AA130158	Hs.19977	ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	1.6
	106094	AA533491		hypothetical protein FLJ14681	6.8
10	106140	AB006624	Hs.14912		1.6
	106271	AA251393	Hs.289052	Homo sapiens, Similar to RIKEN cDNA 5430429M05 gene, clone MGC:13155, mRNA, complete cd	ls 10.8
	106288	AB037742	Hs.24336	KIAA1321 protein	1.3
		Y10043	Hs.19114	high-mobility group (nonhistone chromosomal) protein 4	3.6
		AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen alpha 1(VII) chain precursor [H.sapiens]	5.4
15		AK001404			5.7
		AW390282		transmembrane 7 superfamily member 2	6.3
		AB040916		KIAA1483 protein	6.5
		AW748420		Homo sapiens cDNA: FLJ21487 fis, clone COL05419	2.2
		AF119256		zìnc finger protein 278	2.7
20				Homo sapiens cDNA: FLJ23038 fis, clone LNG02039	2.3
		AA454036		ESTs	1.6
		AA243837			1.6
		AK000933			2.4
		AA458882		fibulin 1	7.9
25		NM_003595			7.7
23		AL049951	He 22370	tyrooy, protein democratic -	1.8
	106660	AV657117	He 184164		1.3
	100003	DE61/1902	He 18/352	hypothetical protein FLJ12549	4.5
					1.3
30		BE388094		The control of the co	1.6
30	100723	AE174407			5.7
		AW959893		Doi E tolatoa evarian tiller pretein ille	16.2
				centrin, EF-hand protein, 3 (CDC31 yeast homolog)	1.5
		BE564871		ocham, Zr. mana protom, a (az az r.) anarmanag,	2.2
35	100840	AB037744		TAIL OF TOO PLOCOTE	1.3
33				nypoutous pretent	16.8
		N49809		Fronto depictor diato in a tomo for to, in a a figure of	1.5
		W79171	Hs.9567	out of history	2.2
				danonipaon lactor bita taa	3.3
40					6.8
40		AK000511		hypothologic protonic print pr	6.6
		BE156256		hypothotical protein	4.8
		AL043152		100 to Eco gono product	6.0
	106978	AW631480	Hs.8688	4010	1.3
4 ~				njpourousur protestri zozer z.	1.8
45		AF264750		myototanymphota of mixed imedge touriering e	
		AW385224			1.7
		AK000733			2.5
		AK000512		Manage Protest and a second	1.7
		AV661958		Cross protein	4.6
50		AV661958		Cito i protein	3.3
		AK001455		20th cytharama annual region game 2	2.0
	107151	AW378065	Hs.8687		6.3
		AW391927		·	33.5
		BE122762	Hs.25338		5.2
55	107197	W15477	Hs.64639	Sueria bana Santana tanàna harana	6.1
	107221	AW888411	Hs.81915		17.4
	107243	BE219716	Hs.34727		7.4
		AW263124			1.8
	107263	D60341	Hs.21198		6.6
60		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.5
		N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL HYPOTHETICAL 63.5 KD PROTEIN ZK353.1 IN	2.5
		N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	1.7
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2
		T63174	Hs.193700		2.0
65	107354	NM 00629	9Hs.96448	zinc finger protein 193	5.0
	107392	AW299900	Hs.267632	TATA element modulatory factor 1	1.2
	107481	AA307703	Hs.279766	kinesin family member 4A	1.6

					3.0	
	107554	AA001386	Hs.59844		1.3	
	107681	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION		
_	107772	AA018587	Hs.303055	Loto, trodity diffici to file file in the contract of the cont	2.1	
5				homeonic to and district and the second seco	8.4	
	107901		Hs.335952	Notalii 42	2.5	
	107901		Hs.335952	1141411114	1.6	
				ig caperiarim, receptor =:	2.2	
	107974	AW956103	Hs.61712		6.7	
10	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	1.5	
	108230	AA054224	Hs.59847	2010	1.3	
				1 Box only protein o	7.1	
		N31256	Hs.161623	2010	2.5	
			Hs.339659		3.5	
15				Tionie explores and the control in a second	3.4	
			Hs.182685	2010	1.6	
		AW022410		20.0	1.7	
		BE546947		Holling box o re	9.8	
•		AB029000		Title trot i protoni	7.2	
20				in pourous protein i Euros is	1.3	
		Al089575		progeotorone membrane amaning present	2.7	
				5.0 In 50.00 to protein	1.8	
			Hs.178904	20.0	1.5	
~~		H06720		Ondooding diplica	2.1	
25		Al801235		2010	5.3	
	108894	AK001431	Hs.5105		4.0	
	108955	AA149754	Hs.195155	1 total baptorio attanto abia transporte y otomi il 1 (2112) il militari y otto protesto alla	5.6	
				Hollies Box (expresses in the sens)	1.6	
20			Hs.23467	mypouloudal protein r to room	6.2 1.7	
30			Hs.72134	1004 protein	1.7	
		AA156542	Hs.72127			5.3
		AA157811	11 70545	gb:zo35d07.s1 Stratagene colon (937204) Homo sapiens cDNA clone 3' similar to contains Alu report	2.9	5.5
		AA164293			2.5 1.6	
25			Hs.52184	Trypodiodod proton i Zozo a to	3.2	
35				n) posiosos protos i i es ro-	1.7	
				nypourousur protein r asaaris .	2.6	
			Hs.59757	Zino migor protein zo i	2.9	
					2.0	
40		BE566742			5.3	
40		NM_016603	Hs.189998	potential fraction protein order in all and protein	5.7	
	109220	A11077281	He 170285	20.0	5.3	
		N99673	Hs.3585	nadioopoini 2 i iii (or iii)	1.4	
	100270	A A 3 7 5 7 5 2	He 82719		2.9	
45			Hs.86276		1.3	
73			Hs.115099	om in (mapper type) time image. Present	2.9	
	100041	A1 096858	Hs 184245		1.5	
		H83603	Hs.40408	homeo box C9	2.2	
		N30531	Hs.42215		3.0	
50		Al160029			1.9	
-			Hs.189915		1.8	
				KIAA1143 protein	3.7	
		NM_01531		KIAA0942 protein	3.2	
	109478	AW074143	Hs.87134		2.0	
55		L40027	Hs.118890		2.1	
		F02614	Hs.27319		1.4	
	109825	R71264	Hs.16798		1.3	
		H11938	Hs.21907	histone acetyltransferase	2.0	
	110056	AA503041	Hs.279009	matrix Gla protein	2.5	
60	110085	AA603840	Hs.29956	KIAA0460 protein	1.7	
		T07353	Hs.7948	ESTs	2.9	
	110129	R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	1.7	
	110154	NM_01452	1Hs.17667	SH3-domain binding protein 4	4.2	
	110240	Al668594	Hs.176588		4.2	
65	110242	N41744		a a v a a fragative	1.3	
		H28428	Hs.32406		2.2	
	440040	DEGEROOR	Un 44006	hypothetical protein Et 112080	21	

		Al288666	Hs.16621	DKFZP434I116 protein	6.2
		H55748		gb:yq94a01.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:203400 3'	6.1
		H55915		hypothetical protein FLJ11016	6.1
5		H57330 AK001160	Hs.37430	EST	6.3 1.3
5		T97586	Hs.18090	hypothetical protein FLJ10298 ESTs	1.8
		AB007902		KIAA0442 protein	1.6
		AW190338		hypothetical protein MGC11256	7.6
		AL138077		hypothetical protein FLJ12707	2.5
10		BE044245		hypothetical protein MGC2963	9.3
		AK000322		hypothetical protein FLJ20315	5.5
		BE000831		Homo sapiens cDNA FLJ11812 fis, clone HEMBA1006364	2.1
				dpy-30-like protein	1.5
15		T25829	Hs.24048	FK506 binding protein precursor	6.6
13		AA767373 R33261	Hs.6614	ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal [H.sapiens]	3.4
		N31598	Hs.12727	hypothetical protein FLJ21610	1.7
		AI740792			1.7
		BE612992		hypothetical protein FLJ10607 similar to glucosamine-phosphate N-acetyltransferase	4.7
20		AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3' similar to contains element	2.3
	110885	BE384447	Hs.16034	hypothetical protein MGC13186	3.5
		AL117430		DKFZP434D156 protein	2.2
		BE092285		hypothetical protein FLJ13187	2.6
25		H04360	Hs.24283	ESTs, Moderately similar to reduced expression in cancer [H.sapiens]	1.9
23		NM_005864		signal transduction protein (SH3 containing)	6.7 2.0
		AK002180 AK001980		DKFZP564O123 protein ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2	1.3
		AW613287			
		N63823		ESTs, Moderately similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	3.6
30		AB037807		hypothetical protein	2.1
		N46180		Homo sapiens cDNA FLJ13289 fis, clone OVARC1001170	2.3
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	3.7
		AL050166		Homo sapiens mRNA; cDNA DKFZp586D1122 (from clone DKFZp586D1122)	7.5
25		AK000136		asporin (LRR class 1)	7.1
35				Homo sapiens cDNA FLJ20738 fis, clone HEP08257	6.7 3.3
		Al815486 N67603		Homo sapiens cDNA FLJ20738 fis, clone HE ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.sapiens]	3.6
		AW139408			1.5
				KIAA1361 protein	2.6
40				KIAA1866 protein	4.6
	111239	N90956	Hs.17230	hypothetical protein FLJ22087	7.9
		AA778711		eukaryotic translation initiation factor 1A	6.9
				KIAA1265 protein	5.0
45			Hs.34504		3.8 1.2
43		T99755	Hs.334728	LIS1-interacting protein NUDE1, rat homolog	5.1
		H58589		Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
			Hs.94631	brefeldin A-inhibited guanine nucleotide-exchange protein 1	2.8
				HSCARG protein	2.2
50		AK000987	Hs.169111	oxidation resistance 1	2.1
				sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase)	5.1
	111392	W46342		Homo sapiens, clone IMAGE:3659680, mRNA, partial cds	8.4
		R02354	Hs.15999		2.7
55		Al051194 W90638	Hs.227978 Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN ZUOTIN RELATED FACTOR-1 (M-PHASE	6.5 1.4
55		R10720	Hs.20670	EST SIMULATED FACTOR-1 (NA-FILAGE	1.6
	111627	R52656	Hs.21691	ESTs	1.6
		AB037834		Homo saplens mRNA for KIAA1413 protein, partial cds	2.4
	111937	BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016)	10.6
60	111944	AW083791	Hs.21263	suppressor of potassium transport defect 3	6.6
		NM_015310		KIAA0942 protein	5.1
	112134		Hs.7413	ESTs; calsyntenin-2	2.8
		AB029000	HS.70823	KIAA1077 protein	14.6
65	112388	NM 016249	1093 PS.3U	Homo sapiens, clone IMAGE:3638994, mRNA, partial cds	9.0
05	112400	AW007287	Hs 28538	A kinase (PRKA) anchor protein 11 Homo sapiens cDNA: FLJ21086 fis, clone CAS03272	1.4 1.4
		Al742756		ESTs	3.2
	, ,				J

	112513	R68425	Hs.13809		2.0	
	112752	AK001635	Hs.14838		1.8	
		AK000004	Hs.5013	Homo sapiens mRNA for FLJ00004 protein, partial cds	6.6	
_	112923	T10258	Hs.5037	EST	1.5	
5	112936	AW970826	Hs.6185	KIAA1557 protein	3.2	
	112958	R61388	Hs.6724	ESTs	6.0	
	112966	Z44718	Hs.102548	glucocorticoid receptor DNA binding factor 1	6.4	
	112978	AK000272			1.2	
	112995	AA737033	Hs.7155		5.6	
10		BE276112		zinc finger protein 259	2.0	
		Al571940		ESTs	1.9	
		AW965190			2.4	
			Hs.270862		1.3	
		T57317			1.7	
15		T63857		gb:yc16e01.s1 Stratagene lung (937210) Homo sapiens cDNA clone 3', mRNA sequence	2.8	
			Hs.11449		1.3	
			Hs.11774		3.2	
			Hs.179808		1.2	
		Al467908			5.9	
20		H59588	Hs.15233		2.0	
_0			Hs.142442	——————————————————————————————————————	3.6	
					1.3	
		T97307	113.100170		4.4	
			Hs.184411	3-1,	1.3	
25		AW499665		SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member s		
45			Hs.10590		13.4	
		AL359588		hypothetical protein DKFZp762B226	1.7	
					1.3	
		W44735	Hs.9286		3.3	
30		BE207480			3.1	
50					3.2	
		H13325 AW378212			2.3	
					11.3	
		T26483	Hs.6059		2.7	
35		W57902	Hs.90744	(1	6.1	
33		AL079314				
		AW959486			6.6	
		AW953484			1.9	
		W87544	Hs.268828		1.2	
40		AI539519			5.4	
40				.,,,	9.4	
		AB029551		a	1.8	
				fucose-1-phosphate guanylyltransferase	1.5	
	114226	AB028968	Hs.7989	KIAA1045 protein	1.8	
4 =				Homo sapiens, Similar to zinc finger protein 136 (clone pHZ-20), clone MGC:10647, mRNA, complete the complete sapiens of the c		2.3
45		AL117518			1.4	
				KIAA0306 protein	15.8	
	114292	AI815395	Hs.184641	fatty acid desaturase 2	1.9	
	114309	AA332453	Hs.20824	CGI-85 protein	2.4	
					1.8	
50	114407	BE539976			1.2	
	114455	H37908	Hs.271616	ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE	5.5	
	114463	AL120247	Hs.40109	KIAA0872 protein	5.2	
				Homo sapiens, Similar to RIKEN cDNA 1110012M11 gene, clone IMAGE:3688605, mRNA, partial	cds1.2	
	114471	AA028074	Hs.104613	RP42 homolog	1.8	
55	114480	BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-Teachtylgalactosaminyltransferase 6 (GalNAc-Teachtylgalactosami	3) 13.4	
	114671	AA766268	Hs.266273	hypothetical protein FLJ13346	1.9	
	114698	AA476966	Hs.110857		3.5	
	114730	Al373544	Hs.331328	intermediate filament protein syncoilin	3.8	
	114767	AI859865	Hs.154443	minichromosome maintenance deficient (S. cerevisiae) 4	1.6	
60	114774	AV656017	Hs.184325	CGI-76 protein	3.1	
	114798	AA159181	Hs.54900	serologically defined colon cancer antigen 1	3.5	
	114860	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.3	
		AA236177		KIAA0887 protein	7.1	
	114896	BE539101	Hs.5324	hypothetical protein	1.3	
65	114911	AA236672		gb:zt29f02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:723771 3', mRNA se	equence.	1.5
	114930	AA237022	Hs.188717	ESTs	2.0	
	114938	AA242834	Hs.58384	ESTs	2.9	

		A1733881		BMP-R1B	2.3
		AF102546		dachshund (Drosophila) homolog	1.3
				toll-like receptor 9	1.6
~				Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076	11.8
5				LIM protein (similar to rat protein kina	1.5 1.5
		A1670847		hypothetical protein	2.8
		Al634549 AW183695			2.5
				hypothetical protein FLJ10116	1.5
10		BE251328			1.3
	115242	Al368236	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	1.4
				hypothetical protein FLJ11301	1.5
	115285	AW972872	Hs.293736	ESTs	2.4
				hypothetical protein FLJ10461	6.2
15		Al215069		ESTs	6.6
		AA314349		tumor antigen SLP-8p	7.4 1.4
	115471	AK001376	Hs.59346	hypothetical protein FLJ10514	4.0
				ESTs, Moderately similar to I54374 gene NF2 protein [H.sapiens]	16.3
20		AW247593 Y14443	Hs.88219	eukaryotic translation initiation factor 4E binding protein 1 zinc finger protein 200	5.0
20		AJ275986		transcription factor (SMIF gene)	2.5
		AI540842		ESTs	6.1
				HSPC039 protein	2.9
			Hs.67896	7-60 protein	5.3
25	115646	N36110	Hs.305971	solute carrier family 2 (facilitated glucose transporter), member 10	4.7
		BE093589		hypothetical protein FLJ23468	10.6
				Homo sapiens, clone MGC:16063, mRNA, complete cds	12.7
		Al138785		ESTs	2.0 3.0
20		AA953006		ESTs	1.7
30		AA625132		hypothetical protein FLJ21615 cadherin, EGF LAG seven-pass G-type receptor 3, flamingo (Drosophila) homolog	6.8
		AF231023 BE395161		proteasome (prosome, macropain) subunit, beta type, 2	1.7
		Al950339		ESTs	2.6
		NM_015434		DKFZP434B168 protein	2.1
35		AI732742		ESTs	2.1
		Al675217		ESTs	1.3
				hypothetical protein MGC5370	4.4
		AW062629		KIAA0867 protein	7.2 1.2
40		N55669		mitochondrial ribosomal protein L13	5.5
40		AI867451 AB037753		hypothetical protein FLJ20739 KIAA1332 protein	9.8
		BE275469		Down syndrome critical region gene 5	1.4
	116011	AL359053	Hs.57664	Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2005735	2.4
	116108	AA770688	Hs.28777	H2A histone family, member L	1.8
45		BE243834		CGI-04 protein	1.4
		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypothetical protein KIAA0684 [H.sapiens]	1.2
		AW821113	Hs.72402	ESTs	2.1
	116238			DIAMED COOKING A C	47
	440040	AV66U/1/	Hs.47144	DKFZP586N0819 protein	1.7 1.7
50		AF265555	Hs.250646	baculoviral IAP repeat-containing 6	1.7
50	116262	AF265555 Al936442	Hs.250646 Hs.59838	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808	1.7 1.7
50	116262 116298	AF265555 AI936442 AI955411	Hs.250646 Hs.59838 Hs.94109	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133	1.7
50	116262 116298 116318	AF265555 AI936442 AI955411 AF097645	Hs.250646 Hs.59838 Hs.94109 Hs.58570	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1: RNA helicase HDB/DICE1	1.7 1.7 1.9
	116262 116298 116318 116325 116336	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133	1.7 1.7 1.9 4.9 1.4 1.9
50 55	116262 116298 116318 116325 116336 116339	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8	1.7 1.7 1.9 4.9 1.4 1.9
	116262 116298 116318 116325 116336 116339 116350	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor)	1.7 1.7 1.9 4.9 1.4 1.9 1.5
	116262 116298 116318 116325 116336 116339 116350 116358	AF265555 Al936442 Al955411 AF097645 Al472106 AL133033 AK000290 AA497129 Al149586	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD	1.7 1.7 1.9 4.9 1.4 1.9 1.5 1.9
	116262 116298 116318 116325 116336 116339 116350 116358	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.46765	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs	1.7 1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1
55	116262 116298 116318 116325 116336 116339 116350 116358 116365	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI49586 N50174 N90466	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.46765 Hs.71109	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein	1.7 1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1
	116262 116298 116318 116325 116336 116350 116358 116365 116368	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.46765 Hs.71109 Hs.12484	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence	1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6
55	116262 116298 116318 116325 116336 116350 116358 116368 116368 116417 116436	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664 AA161411	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.46765 Hs.71109 Hs.12484 Hs.58668	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence chromosome 21 open reading frame 57	1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6 7.4
55	116262 116298 116318 116325 116336 116350 116358 116368 116417 116446	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664 AA4161411 AF218313	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.46765 Hs.71109 Hs.12484 Hs.58668 Hs.236828	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence chromosome 21 open reading frame 57 putative helicase RUVBL	1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6 7.4
55	116262 116298 116318 116325 116339 116350 116358 116368 116477 116470	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664 AA161411 AF218313 AI272141 AI272141	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.46765 Hs.71109 Hs.12484 Hs.58668 Hs.236828 Hs.83484 Hs.83484	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence chromosome 21 open reading frame 57 putative helicase RUVBL SRY (sex determining region Y)-box 4 SRY (sex determining region Y)-box 4	1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6 7.4 2.1 1.5
55	116262 116298 116318 116325 116336 116350 116358 116368 116417 116470 116470 116470	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664 AA161411 AF218313 AI272141 AI272141 AA312572	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.46765 Hs.71109 Hs.12484 Hs.58668 Hs.236828 Hs.83484 Hs.83484 Hs.8241	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence chromosome 21 open reading frame 57 putative helicase RUVBL SRY (sex determining region Y)-box 4 SRY (sex determining region Y)-box 4 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)	1.7 1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6 7.4 2.1 1.5 2.1
55 60	116262 116298 116318 116325 116336 116350 116358 116365 116368 116417 116470 116470 116575 116637	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664 AA161411 AF218313 AI272141 AI272141 AA312572 AK001043	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.71109 Hs.12484 Hs.58668 Hs.236828 Hs.83484 Hs.83484 Hs.83484 Hs.8241 Hs.92033	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence chromosome 21 open reading frame 57 putative helicase RUVBL SRY (sex determining region Y)-box 4 SRY (sex determining region Y)-box 4 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) integrin-linked kinase-associated serine/threonine phosphatase 2C	1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6 7.4 2.1 1.5 2.1
55 60	116262 116298 116318 116325 116336 116350 116358 116365 116368 116417 116470 116470 116575 116637	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664 AA161411 AF218313 AI272141 AI272141 AA312572	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.71109 Hs.12484 Hs.58668 Hs.236828 Hs.83484 Hs.83484 Hs.83484 Hs.8241 Hs.92033	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence chromosome 21 open reading frame 57 putative helicase RUVBL SRY (sex determining region Y)-box 4 SRY (sex determining region Y)-box 4 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)	1.7 1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6 7.4 2.1 1.5 2.1
55 60	116262 116298 116318 116325 116336 116350 116358 116365 116368 116417 116470 116470 116575 116637	AF265555 AI936442 AI955411 AF097645 AI472106 AL133033 AK000290 AA497129 AI149586 N50174 N90466 AW499664 AA161411 AF218313 AI272141 AI272141 AA312572 AK001043	Hs.250646 Hs.59838 Hs.94109 Hs.58570 Hs.49303 Hs.4084 Hs.44033 Hs.184771 Hs.38125 Hs.71109 Hs.12484 Hs.58668 Hs.236828 Hs.83484 Hs.83484 Hs.83484 Hs.8241 Hs.92033	baculoviral IAP repeat-containing 6 hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1 Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631 KIAA1025 protein dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transcription factor) interferon-induced protein 75, 52kD ESTs KIAA1229 protein Human clone 23826 mRNA sequence chromosome 21 open reading frame 57 putative helicase RUVBL SRY (sex determining region Y)-box 4 SRY (sex determining region Y)-box 4 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) integrin-linked kinase-associated serine/threonine phosphatase 2C	1.7 1.9 4.9 1.4 1.9 1.5 1.9 6.1 1.6 7.4 2.1 1.5 2.1 1.5 2.1

	116700	Al800202	Hs.317589	hypothetical protein MGC10765	1.4	
		AW074819			3.4	
				ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	2.9	
		AW068115		biglycan	8.3	
5	116926	H73608	Hs.290830		1.7	
	117034	U72209		YY1-associated factor 2	3.4	
	117132	Al393666	Hs.42315	p10-binding protein	5.2	
		N21032		gb:yx46f06.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:264803 3', mRNA se	equence.	5.5
	117276	N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HEMBB1001208	1.5	
10		AK001701	Hs.183779	Homo sapiens cDNA FLJ10590 fis, clone NT2RP2004392, weakly similar to MNN4 PROTEIN	2.0	
			Hs.42502	ESTs	2.0	
				ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J	2.1	
		AF150275		ESTs	2.7	
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic acid transporters), member 6	1.4	
15		AF123050		diubiquitin	3.4	
		N34895	Hs.44648	·	3.4	
		BE294925			3.0	
		AA121673		zinc finger protein 281	1.9	
				chromosome 11 open reading frame 24	1.8	
20				butyrate-induced transcript 1	5.7	
20	117001	BEEVUEZE	He 332038	hypothetical protein MGC5370	5.9	
				hypothetical protein FLJ13912	1.7	
		Y10518		hypothetical protein FLJ20048	1.7	
				KIAA1785 protein	5.4	
25					5.2	
23	118078		Hs.47790		2.6	
		AA453902			2.5	
				cytochrome c oxidase subunit VIc	4.1	1
	118472	AL157545	HS.421/9	bromodomain and PHD finger containing, 3	1.2	
30				rapa-2 (rapa gene)	1.5	
30		N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HEMBA1006595	7.4	
		AI949952		ESTs	2.5	
			Hs.293287		1.2	
				ESTs, Moderately similar to ZN91_HUMAN ZINC FINGER PROTEIN 91 [H.sapiens]	2.1	
35			HS.50187	KIAA1287 protein	5.2	
33		AA199686		gb:zq75g09.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone IMAGE:647488 5'		
		N92293	HS.206832	ESTS, Moderately similar to ALUS_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	2.6	
				ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	J.0	
				bladder cancer overexpressed protein	4.8	
40		W24781		KIAA1710 protein	1.7	
40		AW453069		activity-dependent neuroprotective protein	2.2	
		AW453069		activity-dependent neuroprotective prote	1.6	
		BE539706		ESIS	1.4	
		N57568	Hs.48028	EST	25.1	
4 =	119298	NM_00124	1Hs.155478	cyclin T2	1.6	
45	119338	Al417240		ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	1.3	
		T65004	Hs.163561		8.4	
				nucleolar protein NOP5/NOP58	6.7	
			Hs.170042		2.4	
			Hs.55513	ESTs	2.1	
50		W37933		Empirically selected from AFFX single probeset	1.9	
				Homo sapiens mRNA; cDNA DKFZp667I103 (from clone DKFZp667I103)	3.7	
	119602	AW675298	Hs.233694	hypothetical protein FLJ11350	3.0	
	119676	AA243837	Hs.57787	ESTs	1.4	
	119682	W61019	Hs.57811	ESTs	1.2	
55	119774	AB032977	Hs.6298	KIAA1151 protein	1.8	
	119780	NM_01662	5Hs.191381	hypothetical protein	3.1	
	119789	BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum comeum tryptic enzyme)	9.2	
	119805	AJ223810	Hs.43213	ESTs, Weakly similar to IEFS_HUMAN TRANSFORMATION-SENSITIVE PROTEIN IEF SSP	3.6	
		AA130970		hypothetical protein FLJ11101	2.5	
60	119863	AA081218	Hs.58608	Homo sapiens cDNA FLJ14206 fis, clone NT2RP3003157	2.7	
	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	2.6	
		AA703129		ESTs	2.7	
		W57554		lymphoid nuclear protein (LAF-4) mRNA	1.2	
		H26735		Homo sapiens clone PP1498 unknown mRNA	45.7	
65				uncharacterized bone marrow protein BM033	1.2	
55				fibroblast growth factor 12B	38.9	
		AW131940			9.6	

	12027/	AA177051		gb:nc02a02.s1 NCI_CGAP_Pr3 Homo sapiens cDNA clone IMAGE:194 similar to contains Alu	4.6
				guillozadoza i folición di circino applició de por cantona o DNA ciono 21 mDNA acquisono	2.0
		AA190577		gb:zp52g02.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 3', mRNA sequence	
	120296	AW995911	Hs.299883°	hypothetical protein FLJ23399	1.8
	120297	AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	15.2
5		AA195517			5.5
-					6.4
		AA195651			
	120327	AK000292	Hs.278732	hypothetical protein FLJ20285	16.1
	120336	N85785	Hs.181165	eukaryotic translation elongation factor 1 alpha 1	2.9
				hypothetical protein DKFZp434I143	5.7
10				· · · · · · · · · · · · · · · · · · ·	4.5
IU		AA210722			
	120349	AW969481		hypothetical protein	16.8
	120352	R06859	Hs.193172	ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	5.0
				putative purinergic receptor	28.1
					12.4
1 ~		AA219305			
15		AA228026			4.0
	120383	AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolog 1	9.7
				hypothetical protein DKFZp434D0127	32.6
		AA232874			3.1
	120300	AM232014	115.104243	EOTS MANAGEMENT DE LA SELECTION DE LA SELECTIO	
•	120389	AW967985	Hs.3255/2	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	121./
20	120396	AA134006	Hs.79306	eukaryotic translation initiation factor 4E	12.5
	120404	AB023230	Hs.96427	KIAA 1013 protein	7.2
				Homo sapiens mRNA; cDNA DKFZp586F1323 (from clone DKFZp586F1323)	11.4
					1.9
		AA236453	HS.18978	Homo sapiens cDNA: FLJ22822 fis, clone KAIA3968	
	120472	Al950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	19.4
25	120473	AA251973	Hs.269988	ESTs	5.4
_		AA253170			10.4
			113.30773	gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:682387 3', mRNA sequer	
		AA256837			0.4
	120509	BE047718	Hs.96545	ESTs	9.4
	120520	AA258601	Hs.161731	EST	2.4
30		BE350244			2.5
J 0				Homo sapiens, clone IMAGE:3613029, mRNA, partial cds	5.2
	120551	AA2/9100	115.111407	TOTIO SAPIGIO, GOTTE INTO TOUCH, INTO TOUCH, PARISA VILVE OF OUT AND A TION	14.4
	120570	AA280679	Hs.2/1445	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	
	120582	BE244830	Hs.284228	ZNF135-like protein	10.2
	120590	AW372799	Hs.125790	leucine-rich repeat-containing 2	2.1
35				N-acetylglucosamine-phosphate mutase	7.5
55					2.5
		AW965339			
	120624	AW407987	Hs.173518	M-phase phosphoprotein homolog	52.0
	120639	AA286942		gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:701505 3' similar to contains	Alu2.4
			Hs 140309	Homo sapiens, clone IMAGE:3677194, mRNA, partial cds	5.0
40		AW063659			2.2
1 0					2.2
				6.2 kd protein	
	120669	BE536739	Hs.109909	ESTs	1.9
		AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone 3' similar to contains PTR7.t1 PTR7	46.8
		AI821539	He 07240	ESTs	2.5
15					5.9
45		AW449855			
	120718	AA292747	Hs.97296	ESTs	2.9
	120750	Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B cell growth factor [H.saplens]	7.0
	120774	AI608909	Hs.193985	FSTs	7.8
					6.8
50		AA346385	HS.30002	5-15-containing protein 5-15-5LbZ, NIAA 1040 protein	
50		AA346495		gb:EST52657 Fetal heart II Homo sapiens cDNA 3' end similar to EST containing O family repeat,	4.4
	120938	AA386260	Hs.104632	EST	4.4
	120977	AA398155	Hs 97600	ESTs	4.4
					5.6
		BE262951		ESTS	
		Al219896			1.2
55	121011	AA398360	Hs.97608	EST	3.1
	121026	Al439713	Hs.165295	ESTs	3.5
	121020	Δ Δ 3 0 9 7 2 4	He 1867/0	ESTs, Highly similar to 137550 mismatch repair protein MSH2 [H.sapiens]	5.4
	121133	AA363307	HS.9/032	ESTs	3.7
	121176	AL121523	Hs.97774	ESTs	1.7
60		Al002110		ESTs, Weakly similar to dJ667H12.2.1 [H.sapiens]	2.9
-		AA403008			1.9
				Home capions aDNA EL 113393 fin along DLACE4004034	
		AW956981		Homo sapiens cDNA FLJ13383 fis, clone PLACE1001024	3.5
	121408	AA406137	Hs.98019	EST	6.0
	121439	AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	7.4
65	121450	AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, complete cds	6.9
00	404450	AW971063	He 202882	FSTe	1.8
	121402	WAAA1 1000	110.202002	color cald induced 4.6	
	121455	H58306	HS.75765	retinoic acid induced 14	10.5

	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.4
	121496	AA442224	Hs.97900		14.4
	121505	AA494172	Hs.194417	ESTs	13.1
	121508	AA402515	Hs.97887	ESTs	28.0
5	121513	AA416653	Hs.181510	ESTs	6.2
	121514	AA412112		gb:zt69b02.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:727563 3', mRNA sequence	e. 2.6
			Hs.98142	EST	7.4
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:730150 3' similar to contains	s2.8
			Hs.98096	EST	3.5
10		AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	6.1
-0		AD001528	Hs 89718	spermine synthase	3.9
			Hs.98247		2.2
,			Hs.126065		4.2
	121622	AAA24537	He 178072	Homo sapiens mRNA; cDNA DKFZp434B1023 (from clone DKFZp434B1023)	7.8
15	121000	A A A 19160	He 86043	Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	2.0
13			Hs.110286		4.7
		U55184		hypothetical protein FLJ11585	12.7
					8.1
				Homo sapiens cDNA FLJ11953 fis, clone HEMBB1000883	1.8
20		A1949597			4.0
20			Hs.180744		7.1
			Hs.97514		
				hypothetical protein NUF2R	19.5
				KIAA1196 protein	7.9
0.5			Hs.161008		1.7
25				hypothetical protein FLJ22501	6.6
		Al810774			10.5
			Hs.98434		5.8
			Hs.218289		3.8
•				ESTs, Highly similar to KIAA1048 protein [H.sapiens]	5.0
30				serine/threonine kinase 23	2.7
		AA446628		cartilage linking protein 1	2.3
			Hs.293044		2.9
			Hs.98459		5.0
~ -		AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:773499 3'	7.2
35				ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]	2.5
			Hs.98611	EST	2.3
				hypothetical protein FLJ14904	3.4
	121985	A1862570	Hs.299214	Homo sapiens, clone IMAGE:2822295, mRNA, partial cds	11.4
	121995	AA210863	Hs.3532	nemo-like kinase	3.8
40	121999	AA430211	Hs.98668	EST	6.4
	122009	AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone ADKA01804	2.2
	122013	AA431085	Hs.98706	ESTs	6.5
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION	13.1
	122050	Al453076	Hs.166109	ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2	9.1
45	122060	AA431738	Hs.98750	EST	13.1
	122114	AW161023	Hs.104921	ESTs	1.5
	122188	AA398838		gb:zt80d01.r1 Soares_testis_NHT Homo sapiens cDNA clone 5', mRNA sequence	3.3
	122204	AA435936	Hs.98842	EST	5.6
	122246	AA329550	Hs.29417	HCF-binding transcription factor Zhangfei	5.1
50	122257	AA436819	Hs.98899	ESTs	5.6
	122302	AA441801	Hs.104947	ESTs	5.8
	122341	AW601969	Hs.99010	hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1	2.0
	122356	AA443794	Hs.98390	ESTs	7.3
	122369	AA443985	Hs.303222	ESTs	12.2
55	122371	AA868555	Hs.178222	ESTs	5.0
•••	122372	AA446008	Hs.336677	EST	7.6
	122378	AB032948	Hs.21356	hypothetical protein DKFZp762K2015	2.5
			Hs.303223		2.8
	122412	AA446869	Hs.119316	ESTs	7.3
60		AA446918		EST	1.9
50	122418	AA446966	Hs.99090	ESTs, Moderately similar to similar to KIAA0766 [H.sapiens]	6.8
	122410	AW505139	Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244)	2.6
	122440	AA447603	Hs 99123	EST	1.8
	122440	AA447626	Hs 99127	EST	3.5
65	122440	A1266150	Hs.104980		1.5
00	122450	AW418788	Hs 99148	ESTs, Weakly similar to S43569 R01H10.6 protein - Caenorhabditis elegans [C.elegans]	9.7
			Hs.99152		4.8

	122490	AA448349	Hs.238151	EST	6.1	
	122492	AA448417	Hs.104990	ESTs	5.4	
	122502	AA204969	Hs.234863	ESTs Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492 ESTs adaptor-related protein complex 1, sigma 2 subunit ESTs	1.3	
	122510	AA449232	Hs.99195	ESTs	11.2	
5	122530	AW959741	Hs.40368	adaptor-related protein complex 1, sigma 2 subunit	10.1	
	122547	AA779725	Hs.164589	ESTs	2.5	
		AA194055		ESTs	1.9	
		AA452578		ESTs	9.5	
		AA452601			11.0	
10	122586	AK001910	Hs 99303	Homo sapiens cDNA FLJ11048 fis, clone PLACE1004516	3.4	
10	122500	AB040893	He 6968	KIAA1460 protein	2.0	
	122507	AI028173	He 00320	ESTs	1.7	
		AL355841		hypothetical protein FLJ23588	4.4	
		AA411925		EQTe	4.6	
15		AA411925 AA453518		EOTo	61.5	
13					10.7	
		AA453630			107.3	
		AA453638			121.4	
				serine/threonine kinase 33	31.1	
20	122018	AA453641	11 444000	gb:zx48e06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	5.6	
20	122622	AA453987	HS.144802	ES18	8.5	
	122717	AA456859	Hs.1/8358	ESIS	10.4	
	122762	Al376875	Hs.105119	ESIS	81.8	
	122829	AW204530	Hs.99500	ESTS		
~ -	122834	AA461492	Hs.99545	Homo sapiens cDNA FLJ10658 fis, clone N12RP2006052	3.6	
25	122836	AA460581	Hs.290996	ESTs	4.5	
	122837	AA461509	Hs.293565	EST's EST's EST's EST's Homo sapiens cDNA FLJ10658 fis, clone NT2RP2006052 EST's EST's, Weakly similar to putative p150 [H.sapiens] EST's NIMA (never in mitosis gene a)-related kinase 6 Src-like-adapter	2.7	
	122838	AA460584	Hs.334386	ESTs	75.3	
	122854	AA600235	Hs.9625	NIMA (never in mitosis gene a)-related kinase 6	7.7	
	122856	AI929374	Hs.75367	Src-like-adapter	5.8	
30	122861	AA335721	Hs.119394	ESTs	1.3	
	122866	BE539656	Hs.283705	ESTs	4.1	
	122868	AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinase)	5.3	
	122870	AW576312	Hs.318722	Homo sapiens cDNA: FLJ21766 fis, clone COLF7179	9.9	
	122872	AW081394	Hs.97103	ESTs	5.3	
35	122879	AA769410	Hs.128654	ESTs	13.9	
	122907	AA470074	Hs.169896	ESTs	11.5	
	122916	AA470140	Hs.229170	Src-like-adapter ESTs ESTs Janus kinase 2 (a protein tyrosine kinase) Homo sapiens cDNA: FLJ21766 fis, clone COLF7179 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	1.7	
	122981	AA478951	Hs.105629	ESTs	5.0	
	123013	AW968324	Hs.17384	ESTs	15.4	
40	123016	AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HEMBB1000709	2.8	
	123034	AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7	
	123072	Al382600	Hs.104308	ESTs, Weakly similar to KIAA1395 protein [H.sapiens]	8.8	
	123082	AA485360	Hs.105661	ESTs	3.9	
	123088	Al343652	Hs.105667	ESTs	3.8	
45	123110	AA486256	Hs.193510	EST	7.4	
	123114	BE304942	Hs.265848	myomegalin	2.8	
		T52027	Hs.271795	ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]	2.4	
	123132	AI061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MAMMA1002434	15.6	
	123136	AW451999	Hs.194024	ESTs	5.1	
50	123149	Al734179	Hs.105676	ESTs	23.8	
	122152	A\M601773	Hs 270259	FSTs	5.2	
	123258	AA490929	Hs.105274	FSTs, Weakly similar to RMS1, HUMAN REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 [H.s	sapiens]	9.3
	123315	AA496369	***************************************	gb:zv37d10.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755827 3' similar t	o4.1	
	123369	AA504757	Hs.105738	ESTs	6.9	
55		AA731404			3.6	
55		AW450922			3.7	
		AA599042			7.4	
	123470	AW303285	Hs 303632	Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene simila	r to 3.5	
				zinc finger protein 14 (KOX 6)	5.2	
60				Homo sapiens, clone IMAGE:4098694, mRNA, partial cds	1.7	
JU		N95059	Hs.55098	ESTs	1.6	
	123402	REN10070	He 334803	Homo sapiens cDNA FLJ14680 fis, clone NT2RP2004242, weakly similar to	2.4	
	123400	7/V/38U388	He 155546	KIAA1080 protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2	2.2	
	100615	AA609170	113.100040	gb:af12a12.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	7.8	
65	122610	AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens cDNA clone, mRNA sequence	2.8	
05		AA609364		gb:zu71d09.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:743441 3' similar to contai	ns Alu.	1.7
			Hs.105187	/ kinesin protein 9 gene	5.7	

	123735	NM_01324	1Hs.95231	FH1/FH2 domain-containing protein	10.0	
		AA609891			5.2	
				Huntingtin interacting protein E	30.6	
_	123804	AA620464	Hs.261915	EST, Weakly similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	2.1	
5		AA620586		gb:ae60g05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone IMAGE:951320 3'	2.7	
	123951	AB012922	Hs.173043	metastasis-associated 1-like 1	6.2	
	123983	AJ272267	Hs.146178	choline dehydrogenase .	4.4	
	124001	L42542	Hs.75447	ralA binding protein 1	7.0	
		AI147155			8.1	
10	124070	AI950314	Hs.154762	HIV-1 rev binding protein 2	3.7	
	124074	H05635	Hs.294030	topoisomerase-related function protein 4-2	1.2	
	124178	BE463721	Hs.97101	putative G protein-coupled receptor	3.1	
	124203	AA372796	Hs.269339	ESTs, Weakly similar to AF161356 1 HSPC093 [H.sapiens]	5.7	
	124352	AA640891	Hs.102406	ESTs	3.1	
15		D87454	Hs.192966	KIAA0265 protein	3.5	
	124385	Al267847		gb:aq49a10.x1 Stanley Frontal NB pool 2 Homo sapiens cDNA clone similar to contains	57.1	
		AA317338	Hs.7535	COBW-like protein	2.8	
				NY-REN-18 antigen	7.1	
		N34059		gb:yv28h09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3' similar to contains A	lu 3.3	
20		H13540	Hs.82202	ribosomal protein L17	2.9	
				Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a	7.8	
		R10084		kinesin heavy chain member 2	2.6	
		N53935		gb:yv59d09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3', mRNA sequence	7.9	
		H79433	Hs.268997		7.8	
25		AA669097			3.3	
		N71076		ESTs, Weakly similar to neuronal thread protein AD7c-NTP [H.sapiens]	4.5	
				FLVCR protein	3.2	
				Homo sapiens cDNA FLJ13533 fis, clone PLACE1006371	5.8	
				hypothetical protein	9.3	
30				sorting nexin 17	3.5	
-		N92593	Hs.313054		6.1	
		AW297702			8.3	
		R48170	Hs.78436		5.6	
			Hs 119878	ESTs, Weakly similar to M3K9_HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE	7.9	
35		R09166	Hs.191148		5.7	
<i></i>		R22952	Hs.268685		11.3	
				Homo sapiens mRNA for KIAA1771 protein, partial cds	9.0	
		AW368528			8.1	
		R41772	Hs.100878		4.9	
40		R41933		ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	2.8	
				Homo sapiens cDNA: FLJ22726 fis, clone HSI15005	5.1	
				Homo sapiens EST from clone 35214, full insert	4.2	
				hypothetical protein FLJ22604	14.2	
		R47948	Hs.188732		7.9	
45				Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	6.6	
7,2		AA501669			2.3	
		AW975868			2.7	
		R63652	Hs.137190		2.3	
			Hs.101477		23.9	
50				bromodomain-containing 1	2.0	
50		AF135422			4.4	
				hypothetical protein FLJ22242	2.7	
			Hs.101883		5.7	
		H37941 AW296713			32.4	
55		AI076343		ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY !!! [H.sapiens]	22.8	
55		R99978		ESTs, Moderately similar to B34087 hypothetical protein [H.sapiens]	6.1	
			Hs.431	murine leukemia viral (bmi-1) oncogene homolog	1.9	
		T40841	Hs.98681	ESTs	4.5	
		T59338		ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	4.9	
60					5.0	
UU		T79815	Hs.279793			
		T79956	Hs.100588		135.3	
		T81310	Hs.100592		5.4	
		A1472068	HS.200230	KIAA1856 protein	5.6	
65	125113	T96595	HS.3022/0	ESTs, Weakly similar to ALUF_HUMAN !!!! ALU CLASS F WARNING ENTRY !!! [H.sapiens]	1.8	
65		T97341	LI= 040707	gb:ye57e05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121856 3' simil		9.6
		Al222382	HS.24U/0/	Human DNA sequence from clone RP1-12G14 on chromosome 6q24.1-25.2. Contains the 5' end of Empirically selected from AFEX single probeset.	or the gene	1.5

	125161	W44657	Hs.144232	EST	10.7
	125249	AA630863	Hs.131375	ESTs, Moderately similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY !!! [H.sapiens]	1.3
				timeless (Drosophila) homolog	9.4
	125279	AW401809	Hs.4779	KIAA1150 protein	1.5
5	125280	Al123705	Hs.106932	ESTs	8.0
	125298	AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone HEP01068	1.5
	125660	AW292171	Hs.23978	scaffold attachment factor B	5.9
	125827	NM_003403	3Hs.97496	YY1 transcription factor	1.2
	125891	U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.4
10	126005	AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (survivin)	14.3
				vacuolar proton pump delta polypeptide	2.4
				a disintegrin and metalloproteinase domain 10	9.1
	127050	AW411066	Hs.274351	CGI-89 protein	17.0
				Homo sapiens cDNA FLJ12789 fis, clone NT2RP2001947	12.8
15		AW293012			7.3
		D87466		KIAA0276 protein	3.1
		D87466		KIAA0276 protein	1.3
	128522	BE173977	Hs.10098	putative nucleolar RNA helicase	9.4
20			Hs.101047	transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)	1.5
20		R39234		ESTs, Weakly similar to IDN4-GGTR14 [H.sapiens]	2.8
		U31875		short-chain alcohol dehydrogenase family member	12.1
	128599	NM_015366	6Hs.102336	Rho GTPase activating protein 8	2.3
				GIOT-3 for gonadotropin inducible transcription repressor-3	1.3
25				zinc finger protein	7.1
25				hypothetical protein ASH1	1.3 3.2
				DKFZP434A043 protein	2.0
				CGI-47 protein	1.4
				coatomer protein complex, subunit epsilon	1.3
30	128656	AA458542	HS. 10326	coatomer protein complex, subunit epsilo	2.4
30	128658	BE397354	HS.324830	diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 Homo sapiens, Similar to RIKEN cDNA 1700010L19 gene, clone MGC:16214, mRNA, complete c	
					7.7
		W27939		hypothetical protein MGC5576 nuclear receptor coactivator 3	3.8
		Y15221	H5.220811	small inducible cytokine subfamily B (Cys-X-Cys), member 11	1.6
35		T85231		tubulin, beta 5	7.6
33				hypothetical protein FLJ10702	5.5
35				ESTs, Moderately similar to I38022 hypothetical protein [H.sapiens]	2.7
				RP42 homolog	2.8
				proteasome (prosome, macropain) subunit, alpha type, 4	4.4
40				actin related protein 2/3 complex, subunit 4 (20 kD)	2.2
-10				PDZ-binding kinase; T-cell originated protein kinase	2.8
				thymidine kinase 1, soluble	5.3
		N71826		small nuclear ribonucleoprotein polypeptide F	53.9
			5Hs 105927	stem cell growth factor; lymphocyte secreted C-type lectin	13.3
45				RD RNA-binding protein	2.6
				nuclear prelamin A recognition factor	2.2
				valosin-containing protein	5.9
	128835	AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924)	1.6
				hypothetical protein FLJ13855	2.2
50				hypothetical protein FLJ13855	1.9
	128868	AA419008	Hs.106730	chromosome 22 open reading frame 3	3.0
	128868	AA419008	Hs.106730	chromosome 22 open reading frame 3	2.2
	128871	AF189723	Hs.106778	ATPase, Ca++ transporting, type 2C, member 1	1.5
		F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, complete cds	13.3
55		R57988	Hs.10706	epithelial protein lost in neoplasm beta	4.7
	128920	AA622037		programmed cell death 5	1.4
	128925	R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	1.9
	128946	Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	7.2
	128949	AA009647	Hs.8850	a disintegrin and metalloproteinase domain 12 (meltrin alpha) (ADAM-12)	2.4
60	128958	AW139032	Hs.107376	hypothetical protein DKFZp434N035	1.3
	128959	Al580127		hypothetical protein FLJ11200	10.9
	128965	AW150697	Hs.107418	ESTs	1.4
	128970	Al375672	Hs.165028	ESTS	1.3
	128975	BE560779	Hs.284233	NICE-5 protein	14.0
65			Hs.281434	Homo sapiens cDNA FLJ14028 fis, clone HEMBA1003838	1.6
		AI816224	Hs.107747	DKFZP566C243 protein	1.9
	129019	A1950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	2.9

	129021	A1 044675 H	ls 173081	KIAA0530 protein	3.8
				KIAA0530 protein	2.5
	129032	R80088 H	ls.108104	ubiquitin-conjugating enzyme E2L 3	3.4
	129076	AW296806 H	ls.326234	ESTs, Highly similar to T46422 hypothetical protein DKFZp434M2023.1 [H.sapiens]	5.0
5		Al351010 H			2.1
		AA744610 H			17.1
				thrombospondin 2	2.7 20.9
				WW Domain-Containing Gene	3.0
10				zinc finger protein 22 (KOX 15) ATP-binding cassette, sub-family C (CFTR/MRP), member 5	5.8
10				hypothetical protein MGC2747	5.9
				KIAA0050 gene product	6.3
				hypothetical protein PRO2577	1.8
		AA286914 H			2.1
15				latexin protein	3.2
				KIAA1415 protein	5.8
	129207			osteoglycin (osteoinductive factor, mimecan)	8.0
		U40714 H	ls.239307	tyrosyl-tRNA synthetase	2.9
••	129229	AF013758 H	ls.109643	polyadenylate binding protein-interacting protein 1	3.2
20		AA252468 H		DKFZp434J1813 protein	2.6
		Al961727 F	ds.109804	H1 histone family, member X	7.3 9.6
				ESTs, Weakly similar to S13495 pregnancy zone protein [H.sapiens]	1.2
		Al051967 F AA287239 F		Homo sapiens cDNA FLJ11311 fis, clone PLACE1010102	5.1
25				F-box only protein 9	4.6
23	129340	RE61/102 F	15.11030 1e 270860	melanoma-associated antigen recognised by cytotoxic T lymphocytes	7.6
		U30246 F	ls 110736	solute carrier family 12 (sodium/potassium/chloride transporters), member 2	6.7
		BE220806 F	ds.184697	Homo sapiens clone 23785 mRNA sequence	8.6
		Al686379 F			1.4
30	129372	NM_016039F	Hs.110803	CGI-99 protein	2.0
	129403	AF149785 H	Hs.111126	pituitary tumor-transforming 1 interacting protein	7.4
		AI267700 H			5.0
		AI267700 H			2.5
25				hypothetical protein FLJ20647	10.2 8.0
35				ADP-ribosylation factor-like 7	3.2
		AW974265 F			6.7
		AA188185 H			3.6
		AA188185 H		hypothetical protein AL110115	7.1
40				membrane-associated nucleic acid binding protein	2.5
70		AA769221 H			3.2
	129559				7.5
		AA317841 H		hypothetical protein MGC2752	6.8
		Al923097 H			2.0
45				progestin induced protein	1.6
			∃s.11506		6.8
	129588			postmeiotic segregation increased 2-like 9	1.4
				HSPC055 protein	7.3
50	129594	AW403724 F	Hs.36989	coagulation factor VII (serum prothrombin conversion accelerator)	9.0 1.6
50				REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta	2.2
			Hs.1174	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	1.4
		U38945 H AK000398 H	Hs.1174 Hs.11747	cyclin-dependent kinase inhibitor 2A (me hypothetical protein FLJ20391	3.8
		AD000092 H		calreticulin	3.3
55				KIAA0440 protein	13.4
55		U03749		gb:Human chromogranin A (CHGA) gene, promoter an	14.1
	129689	AW748482 H	Hs.77873	B7 homolog 3	2.6
	129702	Al304966 H	Hs.12035	ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]	7.4
	129720	AA156214 H	Hs.12152	APMCF1 protein	2.0
60	129721	NM_001415h	Hs.211539	eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD)	1.7
				fatty acid desaturase 1	8.3
		AK001676 H		hypothetical protein FLJ10814	1.8 5.4
	129779	AA394090 I	HS.12460	Homo sapiens clone 23870 mRNA sequence	5.4 1.7
C F		AF052112		lysosomal	1.7
65		BE565817		KIAA0931 protein hypothetical protein FLJ21657	3.1
		NM_006590		SnRNP assembly defective 1 homolog	1.8
	123040	. 111,_0000001		Children accountry deligative i fronteleg	

	129861	AL049999	Hs.85963	DKFZP564M182 protein	2.2
	129864	Al393237	Hs.129914	runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene)	1.7
	129869			hypothetical protein similar to mouse Dnajl1	2.7
	129922	AF042379		gamma-tubulin complex protein 2	4.5
5	129945	BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8
		AA412195		ESTs	2.5
				dynamin 1-like	1.8
		U09848		zinc finger protein 36 (KOX 18)	1.3
	129989	AB015856		activating transcription factor 6	4.0
10				nucleolar phosphoprotein Nopp34	1.6
		AA287325		ESTs	4.0
		S73265	Hs.1473	gastrin-releasing peptide	1.8
		AL046962		forkhead box O3A	2.8
		AL135561		hypothetical protein FLJ21047	2.3
15		X53002		integrin, beta 5	2.3
				splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated)	3.0
				splicing factor proline/glutamine rich (2.1
		L76937		Werner syndrome	1.8
				tubulin, gamma 1	6.1
20		NM_003358	3Hs 23703		
		D80001		KIAA0179 protein	1.3
		R85367			2.0
				MyoD family inhibitor	3.2
				synovial sarcoma, translocated to X chromosome	5.4
25		D81983		GAS2-related on chromosome 22	4.8
45				NIMA (never in mitosis gene a)-related kinase 2	1.4
				tumor suppressing subtransferable candidate 3	2.6
					6.3
		Z19084		amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 3 MUF1 protein	6.2
30					2.4
30				nuclear receptor interacting protein 1	3.4
				putative methyltransferase	8.5
				bromodomain adjacent to zinc finger domain, 2A	1.4
		AL135301		hypothetical protein FLJ10849	
25			Hs.5011	RNA binding motif protein 9	3.3 1.8
35		N89487		KIAA0005 gene product	
				hypothetical protein MGC2840 similar to a putative glucosyltransferase	3.4
				hypothetical protein MGC3017	2.3
				BCL2-interacting killer (apoptosis-inducing)	2.7
40				NS1-associated protein 1	1.8
40		U63630		protein kinase, DNA-activated, catalytic polypeptide	2.3
		BE513202		PPAR binding protein	3.9
		D90041		N-acetyltransferase 1 (arylamine N-acetyltransferase)	33.6
		D90041		N-acetyltransferase 1 (arylamine N-acety	4.6
4 =				adducin 1 (alpha)	2.7
45				H2B histone family, member B	5.0
		U49844		ataxia telangiectasia and Rad3 related	4.3
		L38951		karyopherin (importin) beta 1	1.6
				KIAA0618 gene product	16.1
	130511	L32137	Hs.1584	cartilage oligomeric matrix protein (pseudoachondroplasia, epiphyseal dysplasia 1, multiple)	6.1
50	130511	L32137	Hs.1584	cartilage oligomeric matrix protein (pse	5.3
	130526	AW876523		hypothetical protein FLJ12910	2.1
	130542	U64675	Hs.179825	RAN binding protein 2-like 1	7.8
	130544	AA321238	Hs.4310	eukaryotic translation initiation factor 1A	1.5
	130553	AF062649	Hs.252587	pituitary tumor-transforming 1	14.4
55	130556	Al907018	Hs.15977	Empirically selected from AFFX single probeset	4.7
	130567	AA383092	Hs.1608	replication protein A3 (14kD)	7.9
	130568	AA232119	Hs.16085	putative G-protein coupled receptor	3.3
	130574	AF083208	Hs.16178	apoptosis antagonizing transcription factor	1.2
		AB007891		KIAA0431 protein	5.6
60		AL042210		hypothetical protein DKFZp762N2316; KIAA1803 protein	1.4
		AA609738		ESTs	1.5
		AI354355	Hs.16697	down-regulator of transcription 1, TBP-binding (negative cofactor 2)	1.3
		M90516	Hs.1674	glutamine-fructose-6-phosphate transaminase 1	12.1
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	2.4
65		AA383439		Spir-1 protein	15.9
55		BE246961		Homo sapiens ubiquitin protein ligase (UBE3B) mRNA, partial cds	13.9
		AL048842			1.5

	130675	AA442233	Hs.17731	hypothetical protein FLJ12892	5.4
	130692	AA652501	Hs.13561	hypothetical protein MGC4692	5.0
	130693	R68537	Hs.17962	ESTs	2.0
_	130712	AJ271881	Hs.279762	bromodomain-containing 7	1.8
5	130714	A1348274	Hs.18212	DNA segment on chromosome X (unique) 9879 expressed sequence	2.0
	130730	AB007920	Hs.18586	KIAA0451 gene product	3.7
	130744	H59696	Hs.18747	POP7 (processing of precursor, S. cerevisiae) homolog	3.1
	130751	AF052105	Hs.18879	chromosome 12 open reading frame	1.4
	130757	AL036067	Hs.18925	protein x 0001	5.7
10	130768	AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1), member 1	5.1
	130789	AK000355	Hs.8899	sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 5	5.2
		AB018298	Hs.19822	SEC24 (S. cerevisiae) related gene family, member D	1.5
	130836	J05068	Hs.2012	transcobalamin I (vitamin B12 binding protein, R binder family)	15.7
				Homo sapiens cDNA FLJ20848 fis, clone ADKA01732	2.8
15	130843	AA447492		ESTs, Weakly similar to AF164793 1 protein x 013 [H.sapiens]	1.5
		U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.4
	130855	AJ243706	Hs.143323	putative DNA/chromatin binding motif	1.7
		NM_016578		HBV pX associated protein-8	1.9
20		NM_003410		zinc finger protein 7 (KOX 4, clone HF.16)	1.4
20		BE514434		kinesin-like 2	2.1
		AL120837		high-glucose-regulated protein 8	2.4
				sphingosine-1-phosphate lyase 1	1.7
		BE409769		DnaJ (Hsp40) homolog, subfamily A, member 2	1.8
0.5		N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture antigen) binding protein	2.3
25		BE382657		signal transducer and activator of transcription 1, 91kD	5.4
		N39842	Hs.301444		2.2
		BE398091		desmoplakin (DPI, DPII)	1.8
		T97401	Hs.21929	ESTs	1.6
20		AV658308		thyroid hormone receptor interactor 3	1.6 1.2
30		A1879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP), gamma	1.6
		Al826288		hypothetical protein MGC2628	7.4
		AA321649		small inducible cytokine subfamily B (Cys-X-Cys), member 10	3.0
		AA321649		small inducible cytokine subfamily B (Cy	1.7
35		H23230	Hs.22481	ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]	5.1
33		AA194422		myosin VI	2.5
		AA194422		myosin VI	7.1
		N53344	Hs.22607	ESTs dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (2.0
		AA749230		dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotralisterase 1 (1.9
40		AA749230		COX15 (yeast) homolog, cytochrome c oxidase assembly protein	7.0
40		NM_00654		nuclear receptor coactivator 2	1.9
		BE280074		cyclin B1	5.8
		AW138839		ESTs	2.0
		AA885699		CGI-26 protein	7.0
45		H62087	Hs.31659	thyroid hormone receptor-associated protein, 95-kD subunit	7.5
73		N47468	Hs.59757	zinc finger protein 281	2.9
		D89053		fatty-acid-Coenzyme A ligase, long-chain 3	3.5
		AW383256			2.8
		AL080080		thioredoxin domain-containing	2.8
50				fatty acid amide hydrolase	5.6
-	131281	AA251716	Hs.25227	ESTs	5.7
	131283	X80038		Homo sapiens clone F19374 APO E-C2 gene cluster	1.3
				CGI-76 protein	5.0
				splicing factor (CC1.3)	1.8
55	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6
	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6
	131375	AW293165	Hs.143134	ESTs	5.4
	131390	BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.3
	131410	BE259110	Hs.279836	HSPC166 protein	2.2
60	131412	NM_01224	7Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human selenium donor protein	2.0
		AL046302		hypothetical protein FLJ21908	1.4
	131458	BE297567	Hs.27047	hypothetical protein FLJ20392	1.7
	131475	AA992841	Hs.27263	KIAA1458 protein	2.0
	131501	AV661958	Hs.8207	GK001 protein	2.6
65	131501	AV661958	Hs.8207	GK001 protein	1.6
	131511	AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fis, clone COL02535	2.0
	131528	AU076408	Hs.28309	UDP-qlucose dehydrogenase	1.6

	131532	BE268278	He 28393	hypothetical protein MGC2592	7.4
		AW966881		programmed cell death 2	2.2
				programmed cell death 9 (PDCD9)	2.1
	121544	AL355715	NS.20000	Programmed cell deall 3 (PDOD3)	1.7
5		MM_003512	MS.20777	H2A histone family, member L	5.1
3	131564	193500	HS.28792	Homo sapiens cDNA FLJ11041 fis, clone PLACE1004405	
	131564			Homo sapiens cDNA FLJ11041 fis, clone PL	1.8
				nucleoporin 50kD	5.0
		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (from clone DKFZp761C029); partial cds	1.8
	131622			Homo sapiens cDNA FLJ11436 fis, clone HEMBA1001213	1.3
10	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	2.2
	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	1.9
	131643	AW410601	Hs.30026	HSPC182 protein	2.9
	131653	AW960597	Hs.30164	ESTs	1.3
		Al218918		KIAA0854 protein	2.8
15	131669		Hs.3041	uracil-DNA glycosylase 2	2.8
		BE559681		KIAA0124 protein	5.6
		AA642831		putative DNA binding protein	2.9
		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransferase	3.4
		AK001641		inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein	3.8
20		X76732	Hs.3164	nucleobindin 2	2,9
20				nucleobindin 2	2.8
		X76732	Hs.3164		3.4
		AI878932		topoisomerase (DNA) I	25.5
				KIAA0948 protein	5.5
0.5				DKFZP586J0119 protein	
25			Hs.196275	KIAA0240 protein	2.4
		AW966127			7.9
		BE501849		high-mobility group 20B	1.4
			Hs.301449	adenovirus 5 E1A binding protein	4.1
	131817	U20536	Hs.3280	caspase 6, apoptosis-related cysteine protease	4.2
30	131824	U28838	Hs.32935	TATA box binding protein (TBP)-associated factor, RNA polymerase III, GTF3B subunit 2	3.5
	131850	Al251317	Hs.33184	ESTs	5.1
	131878	AA083764	Hs.6101	hypothetical protein MGC3178	5.8
	131885	BE502341	Hs.3402	ESTs	13.7
	131885	BE502341	Hs.3402	ESTs	2.4
35		W17064	Hs.332848	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, membe	r1 3.2
				Homo sapiens, clone MGC:15961, mRNA, complete cds	8.7
				Homo sapiens, clone MGC:15961, mRNA, com	2.0
				Homo sapiens cDNA: FLJ22993 fis, clone KAT11914	5.5
		AA179298		stomatin-like 2	11.3
40	131013	A14/207/4/0	He 185073	degenerative spermatocyte (homolog Drosophila; lipid desaturase)	1.7
70		AA025976			5.2
	131910	AAU23310	115.54505 Lia 402400	anaphase promoting complex subunit 11 (yeast APC11 homolog)	2.7
	131920	AF 10 1040	HS. 103 100	Homo sapiens cDNA FLJ11472 fis, clone HEMBA1001711	5.3
		BE541211			2.3
15		BE252983		ubiquitin specific protease 1	1.5
45		AA355113		x 001 protein	2.3
				hypothetical protein FLJ20039	2.3 1.4
		W79283	Hs.35962	ESTs	
				hypothetical protein MDS025	3.5
- 0		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II	6.5
50		AA503020		hypothetical protein FLJ22418	2.4
	131991	AF053306	Hs.36708	budding uninhibited by benzimidazoles 1 (yeast homolog), beta	2.1
	132019	H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, partial cds	3.2
	132031	AF193844	Hs.3758	COP9 complex subunit 7a	5.8
	132062	BE266155	Hs.3832	clathrin-associated protein AP47	1.5
55		NM_002267		karyopherin alpha 3 (importin alpha 4)	3.7
	132103	BE171921	Hs.3991	ESTs	1.4
		AV646076		ESTs	5.8
		AW960474		ESTs	1.7
		AA857025		kinesin-like 1	3.3
60		NM_004460		fibroblast activation protein, alpha	14.7
50	132192	AA206153	Hs.4209	mitochondrial ribosomal protein L37	5.5
		R42432	Hs.4212	ESTs	4.4
		NM_00478			2.2
		BE206939		E2F transcription factor 6	2.2
65		AV658411		KIAA1681 protein	7.8
UJ				· · · · · · · · · · · · · · · · · · ·	1.5
	102240	AB018324	110.42070 Up 1/11000	KIAA0781 protein Homo sapiens cDNA: FLJ21550 fis, clone COL06258	1.3
	132232	MI0000U4	115.141209	FIGHIU SAPICHS CDIVA: FLUZ 1000 HS, GIONE COLUGADO	1.0

	122266	A A 204000	Un 42200	hundhatiaal aratain El 119900	5.7
		AA301228		•••	4.2
		AA227710		DKFZP586L151 protein hypothetical protein FLJ13089	2.1
				solute carrier family 2 (facilitated glucose transporter), member 10	1.5
5		AB023191	He 4/131	KIAA0974 protein	10.0
5		NM_015986		cytokine receptor-like molecule 9	1.9
		AW405882			9.2
			Hs.44856	hypothetical protein FLJ12116	2.0
				heterogeneous nuclear ribonucleoprotein D-like	6.5
10		AW572805		ESTs	3.8
10		AF155582		core1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase	1.5
		Al279892		sorting nexin 14	12.5
		AA312135		HSPCO34 protein	28.3
		AL135094		hypothetical protein FLJ14495	1.9
15		AA100012		hypothetical protein FLJ12085	1.9
				mitochondrial ribosomal protein S14	6.1
	132456	AB011084	Hs.48924	KIAA0512 gene product; ALEX2	1.7
	132465	AW169847	Hs.49169	KIAA1634 protein	8.6
	132470	Al224456	Hs.4934	H.sapiens polyA site DNA	5.2
20	132484	X16660	Hs.119007	RAB4, member RAS oncogene family	1.4
	132518	AW885606	Hs.5064	ESTs	6.1
	132528	T78736	Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	3.3
	132530	AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. cerevisiae)-like 1	2.0
		AA454132		mitochondrial ribosomal protein L16	2.9
25	132534	BE388673	Hs.5086	hypothetical protein MGC10433	2.2
		BE568452		protein regulator of cytokinesis 1	7.3
		AW674699		suppressor of G2 allele of SKP1, S. cerevisiae, homolog of	1.7
		AW631437		TH1 drosophila homolog	7.1
•		AK001484		CGI-45 protein	2.2
30		AA345547		hypothetical protein FLJ13287	. 2.2
		H12751	Hs.5327	PRO1914 protein	6.8
				hypothetical protein PRO1855	14.0
25		Al796870		DNA segment on chromosome X (unique) 9928 expressed sequence	11.4 1.9
		U51127	Hs.54434	hypothetical protein MGC1715	2.6
35		AB018319		KIAA0776 protein	2.0
				collagen, type VIII, alpha 2 Homo sapiens cDNA FLJ12961 fis, clone NT2RP2005645	1.5
		F11875	Hs.5534	Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro)	3.0
		NM_004600 Al142265		geranylgeranyl diphosphate synthase 1	2.4
40				hypothetical protein MGC4840	12.4
70		AA010233		glutamyl-prolyl-tRNA synthetase	14.6
		AA125985		thymosin, beta, identified in neuroblastoma cells	2.7
		Y10275	Hs.56407		3.0
				KIAA0493 protein	2.3
45				GDP dissociation inhibitor 2	1.8
10		AI026701		KIAA0310 gene product	3.7
		U07418	Hs.57301	muti. (E. coli) homolog 1 (colon cancer, nonpolyposis type 2)	1.8
		AB007944		KIAA0475 gene product	5.9
	132813	BE313625	Hs.57435	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	8.7
50				sex comb on midleg homolog 1	6.4
				tousled-like kinase 2	3.6
	132821	AJ251595	Hs.169610	CD44 antigen (homing function and Indian blood group system)	2.8
	132833	U78525	Hs.57783	eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)	14.6
	132842	NM_016154	Hs.279771	Homo sapiens clone PP1596 unknown mRNA	1.6
55		F12200	Hs.5811	chromosome 21 open reading frame 59	2.5
	132851	U09716	Hs.287912	lectin, mannose-binding, 1	1.4
	132863	BE268048	Hs.236494	RAB10, member RAS oncogene family	4.2
				ESTs, Moderately similar to AF116721 89 PRO2168 [H.sapiens]	2.8
		AW007683		KIAA1266 protein	2.0
60		NM_004850		Rho-associated, coiled-coil containing protein kinase 2	1.6
		BE267143		U2(RNU2) small nuclear RNA auxillary factor 1 (non-standard symbol)	1.4
		AW503667		ring finger protein 15	5.4
	132902	A1936442	Hs.59838	hypothetical protein FLJ10808	6.1
65				Homo sapiens cDNA FLJ11095 fis, clone PLACE1005374	7.1 2.8
65	132913	W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PLACE1009921 Homo sapiens mRNA for KIAA1724 protein, partial cds	6.1
	132940	T79136		hypothetical protein FLJ13222	10.3
	132941	Al817165	Hs.6120	וואַסטוופווסמו סוטופוודו בס וסגבב	10.0

				Annual Control of the	4.0
	132942	AA554458	Hs.197751	KIAA0666 protein	1.8
	132952	A1658580	Hs.61426	Homo sapiens mesenchymal stem cell protein DSC96 mRNA, partial cds	2.2
		AA576635		CGI-48 protein	4.9
					2.7
_				Homo sapiens cDNA FLJ11392 fis, clone HEMBA1000575	
5	132973	AA035446	Hs.323277	ESTs	5.3
	132977	AA093322	Hs.301404	RNA binding motif protein 3	3.2
		AA040696		ESTs	1.3
					3.0
				clone HQ0310 PRO0310p1	
	133012	AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	10.3
10	133015	AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T	7) 2.1
		AI439688	Hs.6289	hypothetical protein FLJ20886	1.3
					6.0
		A1065016		Homo sapiens clone FLB3344 PRO0845 mRNA, complete cds	
	133062	AW500374	Hs.64056	PRO0149 protein	5.3
	133069	BE247441	Hs.6430	protein with polyglutamine repeat; calcium (ca2+) homeostasis endoplasmic reticulum protein	4.9
15		AK001628		KIAA0483 protein	3.5
13					13.1
		AA808177		ESTs	
	133134	AF198620	Hs.65648	RNA binding motif protein 8A	1.3
	133145	H94227	Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA, partial cds	2.2
		Z11695		mitogen-activated protein kinase 1	1.3
20				hypothetical protein MGC2745	17.1
20					
	133175	AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-rich protein MP4 - mouse [M.musculus]	1.8
	133177	X97795	Hs.66718	RAD54 (S.cerevisiae)-like	4.9
	133197	A1275243	Hs 180201	hypothetical protein FLJ20671	3.1
		AI801777	Hs.6774	ESTs	4.4
25	100200	AINOCATOO	115.0774		1.7
25				Homo sapiens, Similar to bromodomain-containing 4, clone IMAGE:3542455, mRNA, partial cds	
	133228	A1492924	Hs.6831	golgi phosphoprotein 1	6.0
1: 1: 1: 1: 30 1: 1: 1:	133240	AK001489	Hs.242894	ADP-ribosylation factor-like 1	1.5
				Homo sapiens, clone IMAGE:3544662, mRNA, partial cds	1.4
					5.6
20	133200	AI160873	MS.09233	zinc finger protein	
30				ESTs, Weakly similar to FXD2_HUMAN FORKHEAD BOX PROTEIN D2 [H.sapiens]	1.9
	133285	M76477	Hs.289082	GM2 ganglioside activator protein	4.7
		BE297855		NRAS-related gene	5.0
		AA102670		gamma-aminobutyric acid (GABA) A receptor, pi	2.7
					9.3
25		T79526		integral type I protein	
35	133327	AL390127	Hs.7104	Kruppel-like factor 13	4.4
	133347	BE257758	Hs 71475	acid cluster protein 33	1.8
		Al016521	Hs.71816	v-akt murine thymoma viral oncogene homolog 1	5.5
				V-axt mainte unimonia vitat officogene nomolog 1	2.7
		AA292811		non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase)	
	133367	AF231919	Hs.18759	KIAA0539 gene product	1.7
40	133370	AF245505	Hs.72157	DKFZP564I1922 protein	1.8
		BE313555		KIAA1224 protein	1.7
					1.3
		AI950382		phosphatidylserine receptor	
	133391	AW103364	Hs.727	inhibin, beta A (activin A, activin AB alpha polypeptide)	16.1
	133394	AA305127	Hs.237225	hypothetical protein HT023	12.2
45		AL031591		phosphotidylinositol transfer protein, beta	10.4
-13	400450	NEW OOOTE	011-074200	protein kinase, interferon-inducible double stranded RNA dependent	1.2
	133453	A1659306	Hs.73826	protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)	1.7
	133500	AW964804	Hs.74280	hypothetical protein FLJ22237	11.1
	133529	W45623	Hs.74571	ADP-ribosylation factor 1	2.8
50		AL037159		proteasome (prosome, macropain) 26S subunit, non-ATPase, 2	2.9
50					2.5
				damage-specific DNA binding protein 1 (127kD)	
	133578	AU077050	Hs.75066	translin	1.5
	133579	X75346	Hs.75074	mitogen-activated protein kinase-activated protein kinase 2	2.1
			Hs.75087	Fas-activated serine/threonine kinase	1.3
EE	100002				2.2
55				nuclear phosphoprotein similar to S. cerevisiae PWP1	
	133595	AA393273	Hs.75133	transcription factor 6-like 1 (mitochondrial transcription factor 1-like)	1.5
	133599	NM_00288	5Hs.75151	RAP1, GTPase activating protein 1	5.7
	133621	NM_00489	3Hs 75258	H2A histone family, member Y	25.5
	100021	MINITORNO	7He 75200		15.8
C O		NM_00204		glycyl-tRNA synthetase	
60		NM_00040		exostoses (multiple) 2	3.3
	133649	U25849	Hs.75393	acid phosphatase 1, soluble	1.6
		AV661185		mitochondrial ribosomal protein L19	4.1
			Hs.75737	pericentriolar material 1	1.5
	133720	L27841			
	133722	AW969976	Hs.2/9009	matrix Gla protein	6.3
65	133751	AW402048	. Hs.334787	Homo sapiens, Similar to likely ortholog of yeast ARV1, clone IMAGE:3506392, mRNA	3.9
	133757	T52946	Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.7
	122760	BE271766	Hs 181357	laminin receptor 1 (67kD, ribosomal protein SA)	1.8
	100100				

					1.5
	133780	AA557660	Hs.76152	decorin	3.5
	133784	BE622743	Hs.301064	arfaptin 1	6.8
_			Hs.76244	spermidine synthase	2.6
5	133797	AL133921	Hs.76272	retinoblastoma-binding protein 2	1.4
	133822	D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin B)	8.0
	133842	AW797468	Hs.285013	putative human HLA class II associated protein I	13.5
	133845	AA147026	Hs.76704	ESTs	2.2
	133850	W29092	Hs.7678	cellular retinoic acid-binding protein 1	1.8
10					2.0
133784 BE622743 Hs.301064 arfaptin 1 133797 Al.133921 Hs.76244 133820 D50525 Hs.699 133842 AW797468 Hs.28501 133845 AA147026 Hs.76704 EST 133859 U866782 Hs.176704 EST 133868 AB011195 Hs.767801 133869 U866782 Hs.17661 133867 AW340125 Hs.76899 133886 AB011195 Hs.77691 133887 AW340125 Hs.76980 133881 U30872 Hs.378901 133891 U30872 Hs.378901 133922 U30825 Hs.378901 133924 D86326 Hs.325948 vesicle docking protein protein for protein for splicing factor, arginine/serine-rich 9 133924 D86326 Hs.325948 vesicle docking protein p115 133929 NM_006306Hs.211602 133939 Alray Hs.77207 adaptor-related protein complex 3, mu 2 subunit splicing factor 3, subunit 3, 60KD 133939 Alray NM_003590Hs.78946 134010 AB016092 Hs.37913 13410 U41060 Hs.79136 13410 U41060 Hs.79136 13410 NM_003590Hs.78946 13410 NM_000280Hs.79943 13420 BE59598 Hs.178943 13420 RF07483 Hs.7993 134219 NM_00042Hs.80260 Hs.881360 134320 AB02903 Hs.81849 13424 AB029023 Hs.179946 134324 AB029023 Hs.817994 134331 NM_004922Hs.83080 Hs.81800 134329 NS0368 Hs.81800 134329 NS0368 Hs.81800 134329 NS0368 Hs.81800 134337 NW36259 Hs.81840 13437 AW33449 Hs.822855 134377 AW3349 Hs.82285 134379 AW3347 Hs.822865 134		2.8			
					6.7
					2.5
					3.0
15	133922	1130825			1.4
13					5.4
					4.9
					3.7
					12.1
20					9.7
20		X81769			
		A1908165	HS.169946	GATA-binding protein 3 (1-ceil receptor gene activator)	
0.5					
25					
• •					
30	134200	BE559598	Hs.197803		
	134206	AF107463	Hs.79968		
	134208	NM_000288	3Hs.79993	peroxisomal biogenesis factor 7	
	134219	NM_000402	2Hs.80206	glucose-6-phosphate dehydrogenase	
25	134234	BE300078	Hs.80449	Homo sapiens, clone IMAGE:3535294, mRNA, partial cds	2.8
35	134275	AI878910	Hs.3688	cisplatin resistance-associated overexpressed protein	1.8
	134292	Al906291	Hs.81234	immunoglobulin superfamily, member 3	2.0
35	134301	AW502505	Hs.81360	Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly similar to HSU90909	
	134305	U61397	Hs.81424	ubiquitin-like 1 (sentrin)	
	134324	AB029023	Hs.179946	KIAA1100 protein	
40	134326	AW903838	Hs.81800	chondroitin sulfate proteoglycan 2 (versican)	
	134329	N92036	Hs.81848		
	134337	NM_004922	2Hs.81964	SEC24 (S. cerevisiae) related gene family, member C	
	134348	AW291946	Hs.82065	interleukin 6 signal transducer (gp130, oncostatin M receptor)	13.0
	134367	AA339449	Hs.82285	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase,	8.8
45	134376	X06560	Hs.82396		1.5
			Hs.323193	hypothetical protein MGC3222	8.1
				Homo sapiens, Similar to tumor differentially expressed 1, clone IMAGE:3639252, mRNA, partial contents of the	ds 2.6
					ne activator) lependent regulator of chromatin lependent regulator lependent regulator lependent regulator of chromatin lependent regulator lepende
					1.7
50					2.6
• •					1.3
	134421	ALI077196	Hs 82985	collagen type V alpha 2	
55					
55	134446	ΔΔ112036			
	13///7	M58603		nuclear factor of kanna light polypertide gene enhancer in B-cells 1 (p105)	
	134410	NIM ODEOO		Empirically selected from AFEV single probeset	
60					
JU					
	104490	MYVZ4UZ/3	He 8///20		
	104010	MM420410	He 272267		
				activated RNA polymerase II transcription cofactor 4	
65	134520	BE091005 AW411479	1 13.7 400 1 He 8/10	FK506-binding protein 4 (59kD)	
65	134329	BE244323	He SEGE4	exportin, tRNA (nuclear export receptor for tRNAs)	5.5
	1345//	DEZ44323	1 15.0090 I	CGG triplet repeat binding protein 1	5.8
	134562	AA927177	115.0004	000 triblet reheat purgitid biotein 1	0.0

	134612	AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.2
	134624	AF035119	Hs.8700	deleted in liver cancer 1	2.0
				chloride channel 3	2.3
_	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	1.4
5		AA256106		ESTs	72.9
		BE391929		transmembrane protein 4	8.5 6.0
			Hs.88251	arylsulfatase A	4.3
	134692	NM_003474	HS.8850	a disintegrin and metalloproteinase domain 12 (meltrin alpha)	2.3
10		BE161887		anaphase-promoting complex subunit 10	6.7
10		Y14768 AA852985	Hs.890	lysosomal chromobox homolog 5 (Drosophila HP1 alpha)	2.3
				F-box only protein 6	2.9
				ring finger protein 22	6.6
				CD2 antigen (p50), sheep red blood cell receptor	2.3
15		AW630803		lamin B1	6.2
				integral membrane protein 1	1.9
	134806	AD001528	Hs.89718	spermine synthase	1.8
	134834	AW451370	Hs.8991	adaptor-related protein complex 1, gamma 2 subunit	1.4
• •		Al701162		hypothetical protein MGC11138	1.4
20		BE268326		5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	5.6
		D26488		KIAA0007 protein	2.8 1.7
		AI879195		15 kDa selenoprotein	1.7
		AA532963		Homo sapiens cDNA FLJ13100 fis, clone NT2RP3002255	2.1
25		AW885909 AW401361		PRO1073 protein protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	1.3
25				phosphoserine aminotransferase	2.1
		R50333		Leman coiled-coil protein	2.3
				KIAA1414 protein	1.6
		NM_000408		glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	3.9
30				hypothetical protein FLJ12619	6.2
		AW503733		KIAA1488 protein	2.0
		AB036063		p53-inducible ribonucleotide reductase small subunit 2 homolog	1.3
	135095	AF027219	Hs.9443	zinc finger protein 202	7.1
~ ~				zinc finger protein 36 (KOX 18)	3.2
35		Al093155		JM27 protein	2.5 1.4
				px19-like protein	5.0
		AA477514		translin-associated factor X ESTs, Highly similar to C10_HUMAN PUTATIVE C10 PROTEIN [H.sapiens]	6.1
		N26427	Hs.9634 Hs.96560		4.6
40		T78802 BE463721		putative G protein-coupled receptor	5.6
-1 0		Al028767			3.5
	135257	AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]	1.2
		A1088775		geranylgeranyl diphosphate synthase 1	2.6
		AA448460			5.3
45		AA150320		protein kinase Njmu-R1	9.1
	135295	A1090838	Hs.98006	ESTs	2.4
			Hs.98368	ESTs, Weakly similar to KIAA0822 protein [H.sapiens]	13.3
		A1652069		ribosome binding protein 1 (dog 180kD homolog)	2.6
50	135354	AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE proteins)	8.3 1.5
50				Homo sapiens cDNA FLJ10174 fis, clone HEMBA1003959	4.9
		U05237		fetal Alzheimer antigen androgen receptor; testicular feminization; spinal and bulbar	2.0
		X78592 R50333	Hs.99915	Leman coiled-coil protein	2.6
		AB037835	Hs.92186	KIAA1414 protein	1.4
55		NM_00040		glycerol-3-phosphate dehydrogenase 2 (mi	1.6
33				hypothetical protein FLJ12619	1.4
		AW503733		KIAA1488 protein	1.8
	135083	AB036063	Hs.94262	p53-inducible ribonucleotide reductase s	2.5
		AF027219		zinc finger protein 202	1.5
60	135096	AA081258		zinc finger protein 36 (KOX 18)	2.1
	135153	Al093155	Hs.95420	JM27 protein	4.4
				px19-like protein	14.9
		AA477514		translin-associated factor X	1.3
<u> </u>	135207	N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7
65	135214	T78802	Hs.96560	hypothetical protein FLJ11656	6.1 2.7
		BE463721		putative G protein-coupled receptor	12.2

	135257	AW291023 Hs.9	97255	ESTs, Weakly similar to A46010 X-linked	7.6
				gorariji gorariji dipriooprimto oj rimoo v	1.8
		AA448460 Hs.1			4.1
_		AA150320 Hs.9		proton in the contract of the	1.2
5				2010	4.8
				2010, 170mm, 10 1 mm 10 mm	5.8 12.3
				inpoconio sinding protein i (and incine in	5.7
					7.9
10					1.9
10					13.9
				HIV TAT specific factor 1	5.3
				HER2 receptor tyrosine kinase (c-erb-b2,	2.2
				HSPC070 protein	1.4
15	303686	AK000714 Hs.1	109441		5.2
				Tomo dapiene diene ini relicione, in in reeq	2.3
		AA808229 Hs.1		2010	2.8
		NM_007057Hs.4		ETT TO INCOME.	2.0 5.5
20				tabo or, and additional transfer and transfe	1.4
20		N24236 Hs.1	10919 170662	Coigi apparatao protoni i	1.3
					2.9
					1.6
		AF292100 Hs.1			1.8
25	407827	BE278431 Hs.4	40323	BUB3 (budding uninhibited by benzimidazo	1.6
		AL034548 Hs.4		SRY (sex determining region Y)-box 22	6.1
				t trat rionada tarring	5.6
				Loto, Would billian to Youdan Hypothesis	2.6
20		AB000115 Hs.7		hypothotical protein, expressed in sette	2.4 1.5
30		Al267592 Hs.7		of the proton times .	4.2
		AW304454 Hs.7 AA381133 Hs.8			23.6
				mgn modility group (normistens ememess	5.8
				cathepsin K (pycnodysostosis)	1.3
35		NM_006910Hs.8		retinoblastoma-binding protein 6	1.6
-				alpha thalassemia/mental retardation syn	2.3
	420802	U22376 Hs.1	1334	v-myb avian myeloblastosis viral oncogen	1.6
		AA463798 Hs.1			3.5
40				Totalolo dola roprecensio preteni	4.9
40				histone deacetylase 3	3.1 1.9
				peptidylprolyl isomerase C (cyclophilin	2.4
	422052	AA302744 Hs.1	104518	putative heme-binding protein	4.1
	422000	AF165883 Hs.2	208220	pulative herie-billulity protein	7.0
45		W67883 Hs.1	137476	paternally expressed 10 (PEG10; KIAA105	4.9
				zinc finger protein 217	3.4
	425284	AF155568 Hs.1	155489	NS1-associated protein 1	2.1
	426372	BE304680 Hs.1	169531	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	7.5
~ ^	428049	AW183765 Hs.1	182238	GW128 protein	1.7
50				splicing factor, arginine/serine-rich 11	2.4 3.8
		AB001636 Hs.5		DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	5.6
		AK001333 Hs.6		Homo sapiens hepatocellular carcinoma-as Homo sapiens clone 23736 mRNA sequence	2.0
		F13386 Hs.7 AF167572 Hs.1		skb1 (S. pombe) homolog	7.5
55	445560	AA151520 Hs 3	334822	hypothetical protein MGC4485	2.2
55			17409	cysteine-rich protein 1 (intestinal)	2.8
		BE620592 Hs.7		ESTs, Weakly similar to S16506 hypotheti	1.7
		NM 003677Hs.2	22393	density-regulated protein	5.9
	449687	W68520 Hs.3	331328	intermediate filament protein syncoilin	5.6
60	450701	H39960 Hs.2	288467	Homo sapiens cDNA FLJ12280 fis, clone MA	1.4
			184771	nuclear factor I/C (CCAAT-binding transc	4.7
	452461	N78223 Hs.1	708106	transcription factor	2.9 12.1
				Homo sapiens cDNA FLJ20845 fis, clone AD DKFZP586G1722 protein	4.7
65		AF077036 Hs.3 BE541906 Hs.8		Homo sapiens, clone MGC:2492, mRNA, comp	1.3
05	100833	AF135168 Hs.	108802	N-ethylmaleimide-sensitive factor	3.2
		U50360		gb:Human calcium, calmodulin-dependent p	6.2

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	7	7.9
	103549		Hs.78793	protein kinase C, zeta	2	2.0
	104331	AB040450	Hs.279862	cdk inhibitor p21 binding protein	5	5.3
	110018	AW579842	Hs.104557	hypothetical protein FLJ10697		2.0
5	115008	AK001827	Hs.87889	helicase-moi		5.7
	119075	M10905	Hs.287820	fibronectin 1		1,3
	119615	AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant		2.9
	125006	BE065136	Hs.145696	splicing factor (CC1.3)		.7
	127609	X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture		2.4
10	129209	R62676	Hs.17820	Rho-associated, coiled-coil containing p		5.2
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg		1.5
	130182	BE267033	Hs.192853			11.0
	130365	W56119	Hs.155103	eukaryotic translation initiation factor		3.3
	131135	NM_016569	9Hs.267182	TBX3-iso protein		1.3
15	131853	Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		3.2
	131881	AW361018	Hs.3383	upstream regulatory element binding prot		14.3
	132726	N52298	Hs.55608	hypothetical protein MGC955		3.0
	135193	X95525	Hs.96103	TATA box binding protein (TBP)-associate		2.7
		H19886		gb:yn57a05.r1 Soares adult brain N2b5H		2.3
20	416040	AW819158	Hs.289044	Homo sapiens cDNA FLJ12048 fis. clone HE	7	7.4

TABLE 4A

Table 4A shows the accession numbers for those pkeys lacking unigeneID's for Table 4. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

CAT number Accessions

5

10

15

55

60

123658 genbank_AA609364

123811 genbank_AA620586

120274 genbank_AA177051 113196 genbank_T57317

120504 genbank_AA256837

120639 genbank_AA286942

NOT_FOUND_entrez_W38150

125115 genbank_T97341

118737 382979_1

125147

AA609364

AA620586

AA177051

AA256837

AA286942

T57317

AA199686 N73861

W38150

Pkey

123615 30686 -15 AA609170 123619 371681_1 AA602964 AA609200 20 101445 1650_-5 M21259 124385 656394 1 AI267847 N27351 124417 1642364_1 N34059 N46979 N53935 N53950 124482 1657509_1 102481 31281_-28 U50360 25 103349 11052 -2 X89059 110856 19346_14 AA992380 N33063 N21418 H79958 R21911 H79957 109699_1 AA080912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA113892 103797 AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW974305 120280 160212_1 AA190577 AA181657 30 113248 328626_1 T63857 AW971220 AA493469 T63699 AJ950087 N70208 R97040 N36809 AJ308119 AW967677 N35320 AJ251473 H59397 AW971573 R97278 W01059 AW967671 120472 44573_2 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 35 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 40 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 129019 44573_2 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 45 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AJ819225 AW205862 AJ683338 AJ858509 AW276905 AJ633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 120695 9683_3 50 AA970201 Al633384 AA425910 Al017004 Al241295 AA402816 AA291468 AA398838 AA435847 122188 275673 1 AA416568 AA442889 AA417233 AA442223 121581 283769_1 122618 305217 1 AA453641 AA454061 AA157811 AA836869 109026 150431_1

		genbank_AA34		AA346495
		genbank_T973		T97307 001275 J03483 J03915 Al214509 AW245744 AL046455 AA318960 Al741505 AA843875 Al829382 Al560122
	129000	23162_1		55958 A 684005 D53170 AA854091 A 025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441
5				Al969102 AA405741 Al091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 Al148432
5				A782478 AA910064 Al220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054
				132275 A1584185 C05724 AA789023 A1686818 D54392 A1022485 AA431410 AA854232 W39212 W15214 AA894441
				1167381 AW245389 AA319430 AA335156 Al042646 AA327030 AA725170 T27943 AA889304 AA976699 Al687001
				1865540 AA772107 C06286 AA319661 AA405992
10	101045	entrez_J05614		000040 AA772107 000200 AA013001 AA400392
10		genbank	N21032	
			H55748	
		genbank		
		entrez_X94563		
1.5		genbank	AA127818	NATION .
15		NOT_FOUND_	-	W37933
		genbank	AA252395	
		genbank	AA412112	
	121558	genbank	AA412497	
	121911	genbank	AA427950	
20	123315	714071_1	AA496369	√ A496646
	114911	genbank	AA236672	
	409487	1134778_1	H19886 AV	402806 T10231

TABLE 5: Figure 5 from BRCA 001 US

Table 5 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

10

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal breast tissue

Pkey: ExAccn: UnigenelD: Unigene Title: R1:

15	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	100114	X02308	Hs.82962	thymidylate synthetase	2.9
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
	100154	H60720	Hs.81892	KIAA0101 gene product	9.2
	100335	AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.7
20	100666	L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7
	100667	L05424	Hs.169610	CD44 antigen (homing function and Indian	9
	100668	L05424	Hs.169610	CD44 antigen (homing function and Indian	7.6
	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
~ -		AK000405		ubiquitin-like 4	11.4
25	101031		Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.2
	101045			gb:Human proliferating cell nuclear anti	5
	101332		Hs.156346	topoisomerase (DNA) II alpha (170kD)	3.4
		A1494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	6.3
20		NM_012151		coagulation factor VIII-associated (intr	5.7
30		AF064853		guanine nucleotide binding protein (5.6 14.4
		M81057 AA586894	Hs.180884	carboxypeptidase B1 (tissue) S100 calcium-binding protein A7 (psorias	8.9
		NM 000318		peroxisomal membrane protein 3 (35kD, Ze	3.2
		AJ904232	Hs.75323	prohibitin	8.4
35		BE258602		heat shock protein 75	1.4
55		BE313280		death associated protein 3	4.6
		AW950852		polymerase (DNA directed), delta 2, regu	4.3
		AA829978		JTV1 gene	6.7
		U24389	Hs.65436	lysosomal	4.3
40	102302	AA306342	Hs.69171	protein kinase C-like 2	2.7
	102348	U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2
	102374	U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2
		U48705	Hs.75562	discoidin domain receptor family, member	6.9
4.~		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3
45		AL037672		extracellular matrix protein 1	5.8
		NM_007019		ubiquitin carrier protein E2-C	4.3
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6
		AU077058		BRCA1 associated RING domain 1	1.9
50		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3 6.4
30	102801	BE252241 BE244588		pyridoxal (pyridoxine, vitamin B6) kinas chaperonin containing TCP1, subunit 2 (b	5.6
		NM_005940		matrix metalloproteinase 11 (MMP11; stro	4.5
		AU077231		cyclin D1 (PRAD1: parathyroid adenomatos	3.1
		AA205475		ribosomal protein S18	9.9
55		X72755	Hs.77367	monokine induced by gamma interferon	8.8
55		Al369285	Hs.75189	death-associated protein	5.6
		Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7
		BE270465	Hs.78793	protein kinase C, zeta	7.9
		AK001278		hypothetical protein FLJ10416 similar to	6.5
60	104325	BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.3
		AW052006	Hs.8551	PRP4/STK/WD splicing factor	10.9
		A1250789	Hs.32478	ESTs	5.6
		AA041276		3-phosphoinositide dependent protein kin	12.3
	104867	AA278898	Hs.225979	hypothetical protein similar to small G	2

	104896	AW015318	Hs.23165	ESTs	17.7
		AW408164		transcription factor 19 (SC1)	5
		AW958157		NS1-associated protein 1	1.7
	104919	AA026880	Hs.25252	prolactin receptor	1.4
5	104974	Y12059	Hs.278675	bromodomain-containing 4	1.4
	104978	Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	7.2
	105012	AF098158	Hs.9329	chromosome 20 open reading frame 1	3.3
	105039	AA907305	Hs.36475	ESTs	2.5
	105079	AA151342	Hs.12677	CGI-147 protein	9.5
10		H58589	Hs.35156		2.2
		AF167570		interleukin enhancer binding factor 3, 9	5.4
		AA262640		unknown	9.3
		BE616694		hypothetical protein FLJ14299	1.4
1.5		AA985190		hypothetical protein FLJ20059	9.4
15		AW151952		hypothetical protein FLJ20739	1.5
		AF151066		hypothetical protein	2.9 5.2
		AF016371		peptidyl prolyl isomerase H (cyclophilin	6.8
		AA533491		hypothetical protein FLJ14681	5.7
20		AK001404 AW390282		cyclin B2 transmembrane 7 superfamily member 2	6.3
20		AA458882		fibulin 1	7.9
		NM_003595		tyrosylprotein sulfotransferase 2	7.7
		BE614802		hypothetical protein FLJ12549	4.5
		AW959893		hypothetical protein FLJ23293 similar to	16.2
25		AB037744		KIAA1323 protein	2.2
		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA	, 16.8
		BE156256		hypothetical protein	6.6
		AF264750		myeloid/lymphoid or mixed-lineage leukem	1.8
	107197	W15477	Hs.64639	glioma pathogenesis-related protein	6.1
30	107859	AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.4
	107901	L42612	Hs.335952	keratin 6B	2.5
	107922	BE153855	Hs.61460	lg superfamily receptor LNIR	2.2
		AW956103		pyruvate dehydrogenase kinase, isoenzyme	6.7
2 ~		AF129535		F-box only protein 5	7.1
35		BE546947		homeo box C10	9.8
		AB029000		KIAA1077 protein	7.2
		AK001431		hypothetical protein FLJ10569	4 1.4
		AA156542		ESTs ESTs	2.9
40		AA164293 AA375752		Homo sapiens mRNA; cDNA DKFZp586F182.	
40		NM_015310		KIAA0942 protein	3.2
		Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTO	
		AI288666	Hs.16621	DKFZP4341116 protein	6.2
		H55748		gb:yq94a01.s1 Soares fetal liver spleen	6.1
45		AW190338	Hs.28029	hypothetical protein MGC11256	7.6
		BE044245		hypothetical protein MGC2963	9.3
	110856	AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sap	2.3
	110958	NM_005864	4Hs.24587	signal transduction protein (SH3 contain	6.7
	111125	N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	
50		AK000136		asporin (LRR class 1)	7.1
		N90956	Hs.17230	hypothetical protein FLJ22087	7.9
	111285	AA778711		eukaryotic translation initiation factor	6.9
		W46342	Hs.325081	Homo sapiens, clone IMAGE:3659680, mRNA	, 8.4 (fr. 40.0
<i></i>	111937		Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016	14.6
55	112244	AB029000	Hs.70823	KIAA1077 protein ESTs, Moderately similar to 2115357A TYK	5.6
	112995	AA737033 BE266947	Hs.7155 Hs.10590	zinc finger protein 313	13.4
		Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3
	113791	BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1
60	113811 113834	T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3
00	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7
	113870	AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1
	113923	AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.9
	114275	AW515443	Hs.306117	KIAA0306 protein	15.8
65	114895	AA236177	Hs.76591	KIAA0887 protein	7.1
	114965	AI733881	Hs.72472	BMP-R1B	2.3
	115061	AI751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8

	115278	AK002163	Hs.301724	hypothetical protein FLJ11301	1.5
		BE545072		hypothetical protein FLJ10461	6.2
	115652	BE093589	Hs.38178	hypothetical protein FLJ23468	10.6
		AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.8
5		A1867451	Hs.46679	hypothetical protein FLJ20739	5.5
		AB037753	Hs.62767	KIAA1332 protein	9.8
		AL359053	Hs.57664	Homo sapiens mRNA full length insert cDN Human clone 23826 mRNA sequence	2.4 7.4
		AW499664 Al272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1
10		AK001043	Hs.92033	integrin-linked kinase-associated serine	2.7
10		Al393666	Hs.42315	p10-binding protein	5.2
			Hs.260622	butyrate-induced transcript 1	5.7
		Al949952	Hs.49397	ESTs	7.4
	119075	M10905	Hs.287820	fibronectin 1	5.7
15		BE539706	Hs.285363	ESTs	1.4
		T65004	Hs.163561	ESTs	8.4
		AL117554	Hs.119908	nucleolar protein NOP5/NOP58	6.7 9.2
		BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum com Homo sapiens clone PP1498 unknown mRNA	
20		H26735 AA131376	Hs.91668 Hs.326401	fibroblast growth factor 12B	38.9
20		AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	
		AA195651	Hs.104106	ESTs	6.4
		AK000292	Hs.278732	hypothetical protein FLJ20285	16.1
	120349	AW969481	Hs.55189	hypothetical protein	16.8
25		AF000545	Hs.296433	putative purinergic receptor	28.1
		AA219305	Hs.104196	EST	12.4
		AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolo hypothetical protein DKFZp434D0127	9.7 32.6
		AW969665 AW967985		ESTs, Moderately similar to ALU7_HUMAN A	
30		AA134006		eukaryotic translation initiation factor	12.5
50		AW966893		Homo sapiens mRNA; cDNA DKFZp586F132	
		Al950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapi	en 19.4
	120484	AA253170	Hs.96473	EST	10.4
o =		AA280679		ESTs, Weakly similar to ALU1_HUMAN ALU	
35		BE244830	Hs.284228	ZNF135-like protein	10.2
		AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	7.5 52
		AW407987	HS.173518	M-phase phosphoprotein homolog gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapie	
		AA976503 AW449855	He 96557	Homo sapiens cDNA FLJ12727 fis, clone NT	5.9
40		Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7
••		A1608909	Hs.193985	ESTs	7.8
		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	6.8
		AA346495		gb:EST52657 Fetal heart II Homo sapiens	4.4
45		BE262951	Hs.99052	ESTs	5.6
45		AA398721	Hs.186749	ESTs, Highly similar to I37550 mismatch	5.4
		AA406137 AA494172	Hs.98019 Hs.194417	EST ESTs	6 13.1
		AA402515	Hs.97887	ESTs	28
		AA416653	Hs.181510	ESTs	6.2
50		AA412477	Hs.98142	EST	7.4
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sap	2.8
		AA421537		Homo sapiens mRNA; cDNA DKFZp434B102	3 (f 7.8
		AA398784		ESTS	7.1
55	121748	BE536911	Hs.234545 Hs.158654	hypothetical protein NUF2R	19.5 7.9
33		AB033022 AW340797		KIAA1196 protein ESTs	5.8
	121839	AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein	5
	121882	AA426376	Hs.98459	ESTs	5
	121911	AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.2
60	121999	AA430211	Hs.98668	EST	6.4
	122013	AA431085	Hs.98706	ESTs	6.5
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU	
	122356	AA443794 AA868555	Hs.98390	ESTs ESTs	7.3 5
65	122377	AA446008	Hs.178222 Hs.336677	EST	7.6
05		AW418788		ESTs, Weakly similar to S43569 R01H10.6	9.7
	122490	AA448349	Hs.238151	EST	6.1
		-			

	122492	AA448417 Hs.10	4990	ESTs	5.4
	122510	AA449232 Hs.99		ESTs	11.2
		AW959741 Hs.40		adaptor-related protein complex 1, sigma	10.1
~		AA452601 Hs.99		EST	11
5		AA453518 Hs.98		ESTs	61.5
		AA453630 Hs.99		EST	10.7 107.3
		AA453638 Hs.16 AA453641		ESTs gb:zx48e06.s1 Soares_testis_NHT Homo sap	
		AA453987 Hs.14		ESTs	5.6
10		AA456859 Hs.17		ESTs	8.5
		AW204530 Hs.99		ESTs	81.8
		AA460584 Hs.33		ESTs	75.3
	122856	Al929374 Hs.75	367	Src-like-adapter	5.8
	122868	AF005216 Hs.11	5541	Janus kinase 2 (a protein tyrosine kinas	5.3
15		AA470074 Hs.16		ESTs	11.5
		AW338067 Hs.32		Homo sapiens cDNA FLJ11946 fis, clone HE	
		AL359571 Hs.44		ninein (GSK3B interacting protein)	8.7
		AW451999 Hs.19		ESTS	5.1
20		AW601773 Hs.27		ESTs	5.2 3.6
20		AA731404 Hs.10 AA599042 Hs.11		ESTs EST	7.4
		BE019072 Hs.33		Homo sapiens cDNA FLJ14680 fis, clone NT	
		AA609170	71002	gb:af12a12.s1 Soares_testis_NHT Homo sap	7.8
		NM_013241Hs.95		FH1/FH2 domain-containing protein	10
25		AA609955 Hs.23		Huntingtin interacting protein E	30.6
	124006	AI147155 Hs.27	70016	ESTs	8.1
	124385	Al267847		gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
		AA532519 Hs.12		Human DNA sequence from clone 989H11 on	
20		AW297702 Hs.10		ESTs	8.3
30		AA381661 Hs.11		ESTs, Weakly similar to M3K9_HUMAN MITO	
		R22952 Hs.26		ESTS	11.3 9
		AA374756 Hs.93 AW368528 Hs.10		Homo sapiens mRNA for KIAA1771 protein, ESTs	8.1
		R43543 Hs.10		Homo sapiens cDNA: FLJ22726 fis, clone H	5.1
35		R46068 Hs.28		hypothetical protein FLJ22604	14.2
		R47948 Hs.18		ESTs	7.9
		AA418160 Hs.86	6043	Homo sapiens cDNA FLJ13558 fis, clone PL	6.6
	124860	R65763 Hs.10)1477	EST	23.9
40	124903	AW296713 Hs.22		ESTs	32.4
40		AI076343 Hs.17		ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8
		R99978 Hs.26		ESTs, Moderately similar to B34087 hypot	6.1
		T79956 Hs.10		EST	135.3
		T81310 Hs.10		ESTs	5.4 5.6
45	125101	Al472068 Hs.28	00230	KIAA1856 protein gb:ye57e05.s1 Soares fetal liver spleen	9.6
73			06932	ESTs	8
		AW966158 Hs.58		Homo sapiens cDNA FLJ12789 fis, clone NT	12.8
	128528		51699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8
		AA975486 Hs.10	3441		7.1
50	128691	W27939 Hs.10	03834	hypothetical protein MGC5576	7.7
		BE302796 Hs.10		thymidine kinase 1, soluble	5.3
				small nuclear ribonucleoprotein polypept	-53.9
	128797	NM_002975Hs.10		stem cell growth factor; lymphocyte secr	13.3
55		AA419008 Hs.10		chromosome 22 open reading frame 3 Homo sapiens, clone MGC:16362, mRNA, cor	3 m 13.3
55	128891		92457 97318	kynurenine 3-monooxygenase (kynurenine 3	7.2
		BE560779 Hs.28		NICE-5 protein	14
)7747	DKFZP566C243 protein	1.9
		Al950087	T1	ab:wg05c02.x1 NCI_CGAP_Kid12 Homo sapi	
60		AW296806 Hs.32		ESTs, Highly similar to T46422 hypotheti	5
		AA744610 Hs.19		palladin	17.1
	129096	AA463189 Hs.28	38906	WW Domain-Containing Gene	20.9
	129198		09315	KIAA1415 protein	5.8
~~		BE614192 Hs.27		melanoma-associated antigen recognised b	7.6
65			10736	solute carrier family 12 (sodium/potassi	6.7
		NM_016039Hs.11		CGI-99 protein	2 5
	129404	Al267700 Hs.31	17584	ESTs	5

	120400	A A 40040E	11- 000042		67
		AA188185 W01296		spindlin	6.7 7.5
		H14718	Hs.11360 Hs.11506	hypothetical protein FLJ14784 Human clone 23589 mRNA sequence	6.8
		AK000398	Hs.11747	hypothetical protein FLJ20391	3.8
5		AD000092		caireticulin	3.3
•		U03749	110.10100	gb:Human chromogranin A (CHGA) gene, pro	
		AW748482	Hs.77873	B7 homolog 3	2.6
		Al304966	Hs.12035	ESTs, Weakly similar to 138022 hypotheti	7.4
		AA156214		APMCF1 protein	2
10	130010	AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	1.6
	130097	AL046962	Hs.14845	forkhead box O3A	2.8
		AA311426		tubulin, gamma 1	6.1
		NM_003358		ESTs, Moderately similar to CEGT_HUMAN C	
1 -		X79201	Hs.153221	synovial sarcoma, translocated to X chro	5.4
15		NM_013449		bromodomain adjacent to zinc finger doma	8.5
		W56119	Hs.155103	eukaryotic translation initiation factor	11
		BE513202	Hs.15589	PPAR binding protein	3.9
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6 2.7
20		AL121438 BE208491	Hs.183706 Hs.295112	adducin 1 (alpha)	16.1
20		L32137	Hs.1584	KIAA0618 gene product cartilage oligomeric matrix protein (pse	6.1
		U64675	Hs.179825	RAN binding protein 2-like 1	7.8
		AF062649	Hs.252587	pituitary tumor-transforming 1	14.4
		AI907018	Hs.15977	Empirically selected from AFFX single pr	4.7
25		AA383092	Hs.1608	replication protein A3 (14kD)	7.9
		AF083208	Hs.16178	apoptosis antagonizing transcription fac	1.2
	130617	M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1
	130667	BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9
•		R68537	Hs.17962	ESTs	2
30		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	3.1
		AL036067	Hs.18925	protein x 0001	5.7
		BE514434		kinesin-like 2	2.1
		BE382657		signal transducer and activator of trans	5.4 7.4
35		AA321649		small inducible cytokine subfamily B (Cy myosin VI	7.4 5.1
33		AA194422 AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7
		NM_016569		TBX3-iso protein	3.3
		BE280074		cyclin B1	5.8
		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.5
40		AL080080	Hs.24766	thioredoxin domain-containing	2.8
	131283	X80038	Hs.339713	Homo sapiens clone F19374 APO E-C2 gene	1.3
	131569	AL389951	Hs.271623	nucleoporin 50kD	5
		AW410601		HSPC182 protein	2.9
15		AA642831		putative DNA binding protein	2.9
45		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4
		X76732	Hs.3164	nucleobindin 2 Homo sapiens cDNA FLJ14656 fis, clone NT	2.9 7.9
		AW966127 BE502341	Hs.3402	ESTs	13.7
		AA099014		Homo sapiens, clone MGC:15961, mRNA, co	
50			Hs.3439	stomatin-like 2	11.3
• •			Hs.35086	ubiquitin specific protease 1	2.3
		BE567100		hypothetical protein MDS025	3.5
		NM_004460		fibroblast activation protein, alpha	14.7
		NM_004782		synaptosomal-associated protein, 29kD	7.8
55		AA227710	Hs.43658	DKFZP586L151 protein	10
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2
		AB023191	Hs.44131	KIAA0974 protein	2
		AW067708		heterogeneous nuclear ribonucleoprotein	12.5
60		AW572805		ESTs	28.3
60		AA312135		HSPCO34 protein	6.1
		AA100012 AW169847		hypothetical protein FLJ12085 KIAA1634 protein	8.6 6.1
		AA454132		mitochondrial ribosomal protein L16	7.1
		AW631437		TH1 drosophila homolog	14
65		Al796870	Hs.54277	DNA segment on chromosome X (unique) 992	
		NM_004600		Sjogren syndrome antigen A2 (60kD, ribon	3.7
		N52298	Hs.55608	hypothetical protein MGC955	14.3
				•	

	132731	AI189075	Hs.301872	hypothetical protein MGC4840	5.9
		AA010233			6.4
			Hs.295901	KIAA0493 protein	14.6
			Hs.5716		2.5
5			Hs.5737		4.2
	132833	U78525	Hs.57783		6.1
	132842	NM_016154	Hs.279771	Homo sapiens clone PP1596 unknown mRNA	
		U09716	Hs.287912	lectin, mannose-binding, 1	6.1
1.0		BE267143		U2(RNU2) small nuclear RNA auxillary fac	2.7
10		Al817165	Hs.6120	hypothetical protein FLJ13222	2.1
		AA034365		Homo sapiens cDNA FLJ11392 fis, clone HE	
			Hs.62016	ESTS	1.3 17.1
		AA112748 Al439688	Hs.279905	clone HQ0310 PRO0310p1 hypothetical protein FLJ20886	4.4
15	133177		Hs.6289 Hs.66718		4.4
13		Al801777	Hs.6774	ESTs	5.5
		Al567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA	
		Al160873	Hs.69233	zinc finger protein	16.1
		AW956781		ESTs, Weakly similar to FXD2_HUMAN FORK	
20		M76477	Hs.289082	GM2 ganglioside activator protein	10.4
		Al950382	Hs.72660	phosphatidylserine receptor	5.7
	133391	AW103364	Hs.727	inhibin, beta A (activin A, activin AB a	25.5
	133540	AL037159	Hs.74619	proteasome (prosome, macropain) 26S subu	1.7
	133594	AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	2.6
25		NM_004893		H2A histone family, member Y	13.5
	133720		Hs.75737	pericentriolar material 1	6.7
		BE271766		laminin receptor 1 (67kD, ribosomal prot	5.4
			Hs.301064	arfaptin 1	12.1
20		M34338	Hs.76244	spermidine synthase	9.7 1.3
30		AL133921	Hs.76272	retinoblastoma-binding protein 2 peptidylprolyl isomerase B (cyclophilin	9.7
		D50525 W29092	Hs.699 Hs.7678	cellular retinoic acid-binding protein 1	4.2
		AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5
		U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1
35		D86326	Hs.325948	vesicle docking protein p115	1.8
20		X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	10.4
		AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6
	133997	Al824113	Hs.78281	regulator of G-protein signalling 12	13
	134234	BE300078	Hs.80449	Homo sapiens, clone IMAGE:3535294, mRNA	
40		AW291946		interleukin 6 signal transducer (gp130,	6.7
		X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46	5.5
		AW362124		hypothetical protein MGC3222	5.8
		AW067903		collagen, type XI, alpha 1	72.9
45		AU077196		collagen, type V, alpha 2 Empirically selected from AFFX single pr	6.7 6.2
43		NM_005000 AK001571		hypothetical protein FLJ10709	1.4
		AW411479		FK506-binding protein 4 (59kD)	2.8
		AW630803		lamin B1	6.1
		BE002798		integral membrane protein 1	1.2
50		AD001528		spermine synthase	2.6
		Al701162	Hs.90207	hypothetical protein MGC11138	9.1
		D26488	Hs.90315	KIAA0007 protein	13.3
	134971	Al097346	Hs.286049	phosphoserine aminotransferase	2
		BE250865	Hs.279529	px19-like protein	14.9
55		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	
	135245	AI028767	Hs.262603	ESTS	12.2
		AW291023		ESTs, Weakly similar to A46010 X-linked	7.6
	135307	A1743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.8
60		A1652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3 5.7
60		AA456454	Hs.183418 Hs.99915	cell division cycle 2-like 1 (PITSLRE pr androgen receptor (dihydrotestosterone r	13.9
	130400	X78592 AW057736		HER2 receptor tyrosine kinase (c	5.3
	317781		7Hs 42650	ZW10 interactor	2.8
			Hs.78979	Golgi apparatus protein 1	5.5
65		BE041451	Hs.177507	hypothetical protein	2.9
05	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.3
		W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7

	425182	AF041259	. Hs.155040	zinc finger protein 217	2.3
	446999	AA151520	Hs.334822	hypothetical protein MGC4485	7.5
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.6
	452461	N78223	Hs.108106	transcription factor	4.7
5	453157	AF077036	He 31989	DKFZP586G1722 protein	12.1

TABLE 5A

Table 5A shows the accession numbers for those pkeys lacking unigeneID's for Table 5. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:	Unique Eos probeset identifier number
	CAT number:	Gene cluster number
	Accession:	Genhank accession numbers

5

15	Pkey	CAT number	Accessions
13	rkey	CAT Humber	Accessions
20	123615 124385 110856 120472	3068615 656394_1 19346_14 44573_2	AA609170 AI267847 N27351 AA992380 N33063 N21418 H79958 R21911 H79957 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586
25			AW150329 Al653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005
30	129019	44573_2	A4950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512
35			Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005
40	122618 125115	305217_1 genbank_T973	120695 9683_3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 AI241295 AA402816 AA291468 AA453641 AA454061
45	120809 129680	genbank_AA3 23162_1	46495 AA346495 U03749 NM_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122 AI858999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432 AI038109 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054 AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214
50	101045 110501	entrez_J05614 genbank_H55	AA894441 AI803081 AI167381 AW245389 AA319430 AA335156 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AI865540 AA772107 C06286 AA319661 AA405992 4 J05614
55	121558 121911	genbank_AA4 genbank_AA4	:12497 AA412497

TABLE 6: Figure 6 from BRCA 001 US

Table 6 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

Pkey: ExAccn:

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number

UnigenelD: 10

Unigene Title: R1:

Unigene number
Unigene gene title
Ratio of tumor to normal breast tissue

15	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias	8.9
	102455	U48705	Hs.75562	discoidin domain receptor family, member	6.9
20	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8
	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	2.6
	105746	AW151952	Hs.46679	hypothetical protein FLJ20739	1.5
	106373	AW503807	Hs.21907	histone acetyltransferase	1.8
	110240	A1668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.2
25	119260	AK001724	Hs.102950	coat protein gamma-cop	3.2
	120206	H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7
	120253	AA131376	Hs.326401	fibroblast growth factor 12B	38.9
	120297	AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2
	120624	AW407987	Hs.173518	M-phase phosphoprotein homolog	52
30	120695	AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	6.8
		AA402515		ESTs	28
		AA453518		ESTs	61.5
~ ~	122616	AA453638	Hs.161873		107.3
35		AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1
		AW204530		ESTs	81.8
		AA460584			75.3
		AA609955	Hs.234961	Huntingtin interacting protein E	30.6
40		Al267847		gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
40		R65763	Hs.101477		23.9
		Al076343		ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8
	125051		Hs.100588		135.3
		N71826		small nuclear ribonucleoprotein polypept	53.9
4 =				WW Domain-Containing Gene	20.9
45				melanoma-associated antigen recognised b	7.6
		AW748482		B7 homolog 3	2.6
				KIAA0618 gene product	16.1
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1
50		AA321649		small inducible cytokine subfamily B (Cy	7.4
50		AW410601		HSPC182 protein	2.9 2.7
		AF151048			2. <i>1</i> 14.7
f		NM_004460		fibroblast activation protein, alpha ESTs	28.3
	132370	AW572805	HS.40040	clone HQ0310 PRO0310p1	17.1
55				hypothetical protein FLJ20886	4.4
55		AJ439688	Hs.6289 Hs.69233	zinc finger protein	16.1
		Al160873		inhibin, beta A (activin A, activin AB a	25.5
		AW103364 Al690916	Hs.178137		1.2
		NM 000402		glucose-6-phosphate dehydrogenase	1.9
60		AW067903		collagen, type XI, alpha 1	72.9
00		AW411479		FK506-binding protein 4 (59kD)	2.8
		R50333	Hs.92186	Leman coiled-coil protein	2.6
		BE250865			14.9
		BE041451		•	2.9

TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigeneID's for Table 6. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

	\sim	
ı		

5

Pkey: CAT number: Unique Eos probeset identifier number

Gene cluster number

Genbank accession numbers Accession:

15

13		Pkey	CAT number	Accessions
20	124385 120695	656394_1 9683_3	Al267847 N27351 AA976503 Al917802 AA953664 AA404613 AA428771 BE280542 AW194691 Al927301 Al740458 Al796100 Al935603	
	122618	305217_1	AW052210 AA970201 Al633384 AA425910 Al017004 Al241295 AA402816 AA291468 AA453641 AA454061	

TABLE 7: Figure 7 from BRCA 001-1 US

Table 7 shows genes upregulated in tumor tissue compared to normal breast tissue. Open reading frames in the sequences have been characterized as having a signal sequence (SS), a transmembrane domain (TM) or other.

10	Pkev:	Unique Eos probeset identifier number
	ExAcon:	Exemplar Accession number, Genbank accession number
	UnigeneID:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal breast tissue
15	ORF struct info:	Structural characterization of open reading frame for the sequence of the o

15	ORF str	ruct info: Struc	ctural characte	rization of open reading frame for the sequence of t	he gene	
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1	ORF struct info
	100113	NM_001269	Hs.84746	chromosome condensation 1	2.3	TM
20	100114	X02308	Hs.82962	thymidylate synthetase	2.9	other
	100131	D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	1.9	other
	100146	BE185499	Hs.2471	KIAA0020 gene product	1.9	TM
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.6	other
	100154	H60720	Hs.81892	KIAA0101 gene product	9.2	other
25	100163	W44671	Hs.124	gene predicted from cDNA with a complete	1.6	other
	100220	AW015534	Hs.217493	annexin A2	2	other
	100265	D38521	Hs.112396	KIAA0077 protein	1.5	other
		BE160081	Hs.256290	S100 calcium-binding protein A11 (calgiz	13.5	other
	100275	BE242802	Hs.154797	KIAA0090 protein	5.1	other
30		D50920	Hs.23106	KIAA0130 gene product	1.9	TM
	100335	AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.7	other
		NM_004341	Hs.154868	carbamoyl-phosphate synthetase 2, aspart	2	other
		NM_014791	Hs.184339	KIAA0175 gene product	2.6	other
~ ~		D84145	Hs.39913	novel RGD-containing protein	3.2	other
35		AW954324	Hs.75790	phosphatidylinositol glycan, class C	1.5	other
		D86978	Hs.84790	KIAA0225 protein	2	other
		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein	2.9	other
		NM_004415	Hs.74316	desmoplakin (DPI, DPII)	1.9	other
40		L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7	other
40		L05424	Hs.169610	CD44 antigen (homing function and Indian	9	?
		L05424	Hs.169610	CD44 antigen (homing function and Indian	7.7	other
		AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2	other
		AF078847	Hs.191356	general transcription factor IIH, polype	6	other ?
15		BE245294	Hs.180789	S164 protein	1.7	•
45		AF002225	Hs.180686	ubiquitin protein ligase E3A (human papi	1.5 6.3	other
		AA157634	Hs.79172	solute carrier family 25 (mitochondrial		other
		AK000405	Hs.76480	ubiquitin-like 4	11.4	? other
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5	1.6 8.4	other other
50		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	5	?
50		J05614	Un 75007	gb:Human proliferating cell nuclear anti	2.6	other
		N99692	Hs.75227 Hs.75093	Empirically selected from AFFX single pr	1.4	?
		L06419	Hs.179881	procollagen-lysine, 2-oxoglutarate 5-dio	2	TM
		AA020956		core-binding factor, beta subunit cyclin-dependent kinase inhibitor 3 (CDK	1.8	other
55		AA284166 AA333387	Hs.84113 Hs.82916	chaperonin containing TCP1, subunit 6A (1.7	TM
23			Hs.78802	glycogen synthase kinase 3 beta	1.9	other
	101247	AA132666	Hs.1904	protein kinase C, iota	1.5	other
		L18964 J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5.3	other
		AJ494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	4.2	other
60		BE267931	Hs.78996	proliferating cell nuclear antigen	1.9	TM
OO		M21259	. 13.1 0330	gb:Human Alu repeats in the region 5' to	1.6	TM
		NM_000546	Hs.1846	tumor protein p53 (Li-Fraumeni syndrome)	2.5	other
		NM_002890	Hs.758	RAS p21 protein activator (GTPase activa	5.5	other
	1014/0	, ,4141_002030	1 13.1 00	14 10 pz i protoni doniator (011 doo donia	2.0	·

	4044			n n n o de la	0.4	- 11
		M24486	Hs.76768	procollagen-proline, 2-oxoglutarate 4-di	2.1	other
		J04977	Hs.84981	X-ray repair complementing defective rep	1.6	other
		AW248421	Hs.250758	proteasome (prosome, macropain) 26S subu	5.7	other
_	101580	NM_012151	Hs.83363	coagulation factor VIII-associated (intr	1.8	other
5	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6	?
	101621	BE391804	Hs.62661	guanylate binding protein 1, interferon-	2.4	other
	101702	AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), reg	1.3	other
	101734	M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacem	2.1	?
		M80244	Hs.184601	solute carrier family 7 (cationic amino	5	TM
10		M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4	SS,
10		AA306495	Hs.1869	phosphoglucomutase 1	5.2	other
		AW409747	Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/H	8.6	other
					8.9	SS,TM
		AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias		
1.5		NM_000318	Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	3.2	TM
15		AA176374	Hs.243886	nuclear autoantigenic sperm protein (his	1.6	other
		AA441787	Hs.119689	glycoprotein hormones, alpha polypeptide	31.3	?
	101920	AF182645	Hs.8024	IK cytokine, down-regulator of HLA II	1.8	other
		U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.4	other
	102009	BE245149	Hs.82643	protein tyrosine kinase 9	1.3	other
20	102036	BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevi	2	?
	102083	T35901	Hs.75117	interleukin enhancer binding factor 2, 4	1.6	other
	102107	BE258602	Hs.182366	heat shock protein 75	1.4	other
		NM_001809	Hs.1594	centromere protein A (17kD)	1.8	other
		BE313280	Hs.159627	death associated protein 3	4.6	?
25		AW950852	Hs.74598	polymerase (DNA directed), delta 2, regu	4.4	?
2,5		AA829978	Hs.301613	JTV1 gene	6.7	other
		U24389		lysosomal	4.4	TM
			Hs.65436	•	1.9	TM
		AW163390	Hs.278554	heterochromatin-like protein 1		other
20		AL039104	Hs.159557	karyopherin alpha 2 (RAG cohort 1, impor	4.4	
30		AA306342	Hs.69171	protein kinase C-like 2	2.7	?
		BE298063	Hs.77254	chromobox homolog 1 (Drosophila HP1 beta	1.5	other
	102339	BE378432	Hs.95577	cyclin-dependent kinase 4	2.3	TM
	102348	U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2	TM
	102349	AU077055	Hs.289107	baculoviral IAP repeat-containing 2	3.2	other
35	102369	U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	2	other
	102374	U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2	other
		AA296874	Hs.77494	deoxyguanosine kinase	1.5	TM
		U48705	Hs.75562	discoidin domain receptor family, member	7	other
		NM_001359	Hs.81548	2,4-dienoyl CoA reductase 1, mitochondri	1.8	SS,
40		U50939	Hs.61828	amyloid beta precursor protein-binding p	1.5	?
1 0		AL080116	Hs.74420	origin recognition complex, subunit 3 (y	3.3	other
				COP9 homolog	2.1	other
		AI188137	Hs.75193		3.2	other
		AF217197	Hs.74562	siah binding protein 1; FBP interacting		
4 =		BE250944	Hs.183556	solute carrier family 1 (neutral amino a	2.8	?
45		AF040253	Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolo	5.7	?
	102564	U59423	Hs.79067	MAD (mothers against decapentaplegic, Dr	2.3	other
	102568	W81489	Hs.223025	RAB31, member RAS oncogene family	5.3	other
	102580	U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	2.1	other
	102581	AU077228	Hs.77256	enhancer of zeste (Drosophila) homolog 2	1.6	?
50	102582	U61232	Hs.32675	tubulin-specific chaperone e	2.1	other
	102617	AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Ara	1.8	other
		AL037672	Hs.81071	extracellular matrix protein 1	5.8	other
		AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3	other
		NM_002270	Hs.168075	karyopherin (importin) beta 2	1.8	TM
55		BE262989	Hs.12045	putative protein	2.3	other
55		NM_007019	Hs.93002	ubiquitin carrier protein E2-C	4.4	?
				hydroxyacyl-Coenzyme A dehydrogenase, ty	6	?
		U96132	Hs.171280		4.2	other
		BE540274	Hs.239	forkhead box M1		
~		AU077058	Hs.54089	BRCA1 associated RING domain 1	1.9	other
60		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3	SS,TM
		AB014460	Hs.66196	nth (E.coli endonuclease III)-like 1	1.2	TM
		BE252241	Hs.38041	pyridoxal (pyridoxine, vitamin B6) kinas	6.5	other
	102812	U90549	Hs.236774	high-mobility group (nonhistone chromoso	1.6	other
		BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	5.6	TM
65	102844	AV653790	Hs.324275	WW domain-containing protein 1	1.3	TM
	102868	X02419	Hs.77274	plasminogen activator, urokinase	4.4	other
	102925	BE440142	Hs.2943	signal recognition particle 19kD	1.9	other

		BE561850	Hs.80506	small nuclear ribonucleoprotein polypept	2.4	?
		AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase	2.7	other
	102983	BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A)	3.1	other
_	102985	U95742	Hs.2707	G1 to S phase transition 1	5.2	?
5	103023	AW500470	Hs.117950	multifunctional polypeptide similar to S	1.6	other
	103038	AA926960	Hs.334883	CDC28 protein kinase 1	2.5	TM
	103060	NM 005940	Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.5	other
		AU077231	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatos	3.1	other
		D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	2.4	other
10		BE244377	Hs.48876	farnesyl-diphosphate farnesyltransferase	3.5	other
10		AA205475	Hs.275865	ribosomal protein S18	9.9	?
			Hs.82685	CD47 antigen (Rh-related antigen, integr	1.3	other
		NM_001777		Homo sapiens, clone IMAGE:3448306, mRNA,	2	other
		X69636	Hs.334731			
15		NM_006825	Hs.74368	transmembrane protein (63kD), endoplasmi	1.6	other
15		AA401039	Hs.2903	protein phosphatase 4 (formerly X), cata	2.5	other
		NM_004766	Hs.75724	coatomer protein complex, subunit beta 2	2.2	TM
	103194	NM_004939	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	6.3	TM
	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8	TM
	103223	BE275607	Hs.1708	chaperonin containing TCP1, subunit 3 (g	3	other
20	103232	X75962	Hs.129780	tumor necrosis factor receptor superfami	1.8	other
	103238	A1369285	Hs.75189	death-associated protein	5.6	TM
		NM_001545	Hs.9078	immature colon carcinoma transcript 1	1.9	?
		AI803447	Hs.77496	small nuclear ribonucleoprotein polypept	2.5	other
		X89059	110.77 100	gb:H.sapiens mRNA for unknown protein ex	1.6	other
25		AL036166	Hs.323378	coated vesicle membrane protein	1.8	other
23			Hs.114366	pyrroline-5-carboxylate synthetase (glut	2.3	other
		X94453	П5.114300	gb:H.sapiens dbi/acbp gene exon 1 & 2.	4	TM
		X94563	11- 00740		1.3	other
		BE564090	Hs.20716	translocase of inner mitochondrial membr		?
20		AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	5.7	
30		AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.1	other
	103547	AI376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7	?
	103588	NM_006218	Hs.85701	phosphoinositide-3-kinase, catalytic, al	2	other
	103613	NM_000346	Hs.2316	SRY (sex determining region Y)-box 9 (ca	1.3	?
	103621	BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	2	other
35	103622	AA609685	Hs.278672	membrane component, chromosome 11, surfa	2.3	TM
		AI878883	Hs.296381	growth factor receptor-bound protein 2	1.3	other
		AI015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022 (f	1.3	other
		AA094752	Hs.169992	hypothetical 43.2 Kd protein	7.6	?
		H26531	Hs.7367	Homo sapiens BTB domain protein (BDPL) m	1.3	SS,TM
40			113.7307	gb:zn04d03.r1 Stratagene hNT neuron (937	1.6	other
40		AA080912	Lla 404074		1.6	other
		Al042582	Hs.181271	CGI-120 protein	1.6	other
		W02363	Hs.302267	hypothetical protein FLJ10330		
		AK001278	Hs.105737	hypothetical protein FLJ10416 similar to	6.6	TM
4 ~		NM_002407	Hs.97644	mammaglobin 2	2.9	other
45	104079	AA251242	Hs.103238	ESTs	1.4	other
	104174	AA478984	Hs.6451	PRO0659 protein	5.6	TM
	104227	AB002343	Hs.98938	protocadherin alpha 9	1.6	other
	104275	Al751970	Hs.101067	GCN5 (general control of amino-acid synt	5.4	other
	104325	BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.4	other
50	104370	AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.6	other
		R83113	Hs.1432	protein kinase C substrate 80K-H	5.2	other
		AB037762	Hs.44268	myelin gene expression factor 2	1.2	other
		A1239923	Hs.30098	ESTs	1.4	other
		AI694413	Hs.332649	olfactory receptor, family 2, subfamily	2.4	other
55				ESTs, Weakly similar to N-WASP [H.sapien	1.4	other
55		AI858702	Hs.31803		2.4	other
		AB023175	Hs.22982	KIAA0958 protein		
		AW052006	Hs.8551	PRP4/STK/WD splicing factor	10.9	other
		AI250789	Hs.32478	ESTs	5.7	other
		AA041276	Hs.154729	3-phosphoinositide dependent protein kin	12.3	?
60		AA278898	Hs.225979	hypothetical protein similar to small G	2.1	other
	104871	T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (f	1.4	other
	104896	AW015318	Hs.23165	ESTs	17.7	other
	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5.1	TM
		AW958157	Hs.155489	NS1-associated protein 1	1.8	other
65		AA026880	Hs.25252	prolactin receptor	1.5	other
		AF043467	Hs.32893	neurexophilin 2	2.3	other
		NM_015310	Hs.6763	KIAA0942 protein	5.1	other
	1070.0	0 ,00 ,0	. 10.0.00	· ··· - · · · · · · · · · · · · · · · ·		

	10/07/	V42050	Un 270675	bromodomain containing A	1.5	other
		Y12059	Hs.278675	bromodomain-containing 4 SMC4 (structural maintenance of chromoso	2.4	other
		AL136877 Al199268	Hs.50758 Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	7.3	other
		AA937934	Hs.321062	ESTs	1.3	other
5		AI499930	Hs.334885	mitochondrial GTP binding protein	3.6	?
,		BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protei	5.6	other
		AF098158	Hs.9329	chromosome 20 open reading frame 1	3.4	other
		AI050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2	other
		AB037716	Hs.26204	KIAA1295 protein	2.2	other
10		BE242899	Hs.129951	speckle-type POZ protein	3.9	?
10		AA151342	Hs.12677	CGI-147 protein	9.5	TM
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	5.7	other
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
		Z78407	Hs.27023	vesicle transport-related protein	2.2	other
15		BE387350	Hs.33122	KIAA1160 protein	1.6	other
10		AW975433	Hs.36288	ESTs	6.4	?
		AA045648	Hs.301957	nudix (nucleoside diphosphate linked moi	2.2	other
		AA164687	Hs.177576	mannosyl (alpha-1,3-)-glycoprotein beta-	2.8	other
		AW976357	Hs.234545	hypothetical protein NUF2R	2	other
20		BE245294	Hs.180789	S164 protein	1.7	other
	105186	AA191512	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.9	SS,TM
	105254	AA071276	Hs.19469	KIAA0859 protein	2	TM
	105281	AA263143	Hs.24596	RAD51-interacting protein	2.9	?
	105288	N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.9	TM
25	105302	AA700122	Hs.3355	sentrin-specific protease	8.2	?
	105331	AW270037	Hs.179507	KIAA0779 protein	1.8	SS,
	105359	NM_016015	Hs.8054	CGI-68 protein	8.4	other
		BE264645	Hs.282093	hypothetical protein FLJ21918	5.1	other
• •		AW887701	Hs.32356	hypothetical protein FLJ20628	2.6	other
30		BE242803	Hs.262823	hypothetical protein FLJ10326	2.2	TM
		AW592146	Hs.108636	membrane protein CH1	2.3	SS,TM
		AF167570	Hs.256583	interleukin enhancer binding factor 3, 9	5.5	SS,
		BE386877	Hs.334811	Npw38-binding protein NpwBP	1.6	other
25		AF198620	Hs.65648	RNA binding motif protein 8A	1.6	other
35		AA252395	11 000040	gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens	5.1	?
		BE268348	Hs.226318	CCR4-NOT transcription complex, subunit	1.6 1.3	other other
		AA113449	Hs.32471	hypothetical protein FLJ20364	3.5	other
		AB023179	Hs.9059	KIAA0962 protein unknown	9.3	other
40		AA262640 BE616694	Hs.27445 Hs.288042	hypothetical protein FLJ14299	1.4	other
40		AA579535	Hs.18490	hypothetical protein FLJ20452	10.9	TM
		AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9	TM
		Al808201	Hs.287863	hypothetical protein FLJ12475	1.7	?
		AA280072	Hs.99872	fetal Alzheimer antigen	1.4	other
45		AK000892	Hs.4069	glucocorticoid modulatory element bindin	1.7	TM
10		AW302245	Hs.181390	casein kinase 1, gamma 2	5.6	other
		AA985190	Hs.246875	hypothetical protein FLJ20059	9.4	other
		AW499988	Hs.27801	zinc finger protein 278	2	TM
		R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (f	1.7	other
50		BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	2.7	other
		AW151952	Hs.46679	hypothetical protein FLJ20739	1.5	?
	105759	Al123118	Hs.15159	chemokine-like factor, alternatively spl	1.3	other
		AI267720	Hs.153221	synovial sarcoma, translocated to X chro	1.6	other
	105820	AA741336	Hs.152108	transcriptional unit N143	2.2	other
55	105826	AA478756	Hs.194477	E3 ubiquitin ligase SMURF2	1.3	other
	105856	Al262106	Hs.12653	ESTs	2.4	other
	105858	AF151066	Hs.281428	hypothetical protein	2.9	other
	105875	AK001708	Hs.32271	hypothetical protein FLJ10846	1.4	other
		AF016371	Hs.9880	peptidyl prolyl isomerase H (cyclophilin	5.3	other
60		AW194426	Hs.20726	ESTs	1.7	other
		AW081202	Hs.12284	Homo sapiens, clone IMAGE:2989556, mRNA,	2.8	other
		AA477956	Hs.26268	ESTS	1.4	other
		AL157441	Hs.17834	downstream neighbor of SON ESTs, Moderately similar to ALU8_HUMAN A	1.4	other ?
65		AA130158	Hs.19977	hypothetical protein FLJ14681	1.6 6.9	r other
65		AA533491	Hs.23317	KIAA0286 protein	1.6	other
		AB006624	Hs.14912	Homo sapiens, Similar to RIKEN cDNA 5430	10.8	?
	1002/1	AA251393	Hs.289052	Home sapiens, clinica to Mixer obtan 0400		•

	106288	AB037742	Hs.24336	KIAA1321 protein	1.3	other
		Y10043	Hs.19114	high-mobility group (nonhistone chromoso	3.7	other
		AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen	5.5	SS,
		AK001404	Hs.194698	cyclin B2	5.8	other
5		AW390282	Hs.31130	transmembrane 7 superfamily member 2	6.4	other
_		AB040916	Hs.24106	KIAA1483 protein	6.6	other
		AW748420	Hs.6236	Homo sapiens cDNA: FLJ21487 fis, clone C	2.2	TM
	106457	AF119256	Hs.27801	zinc finger protein 278	2.7	other
	106470	D63078	Hs.186180	Homo sapiens cDNA: FLJ23038 fis, clone L	2.3	other
10		AA243837	Hs.57787	ESTs	1.6	other
	106589	AK000933	Hs.28661	Homo sapiens cDNA FLJ10071 fis, clone HE	2.4	?
	106610	AA458882	Hs.79732	fibulin 1	8	SS,
	106624	NM_003595	Hs.26350	tyrosylprotein sulfotransferase 2	7.8	other
	106650	AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp564O0122 (f	1.8	other
15	106669	AV657117	Hs.184164	ESTs, Moderately similar to S65657 alpha	1.3	TM
	106713	BE614802	Hs.184352	hypothetical protein FLJ12549	4.6	other
	106717	AA600357	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	1.3	other
	106723	BE388094	Hs.21857	ESTs	1.6	SS,
• •	106795	AF174487	Hs.293753	Bcl-2-related ovarian killer protein-lik	5.7	other
20	106829	AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2	TM
	106831	BE564871	Hs.29463	centrin, EF-hand protein, 3 (CDC31 yeast	1.5	other
		AB037744	Hs.34892	KIAA1323 protein	2.2	other
		AF151031	Hs.300631	hypothetical protein	1.3	other
0.5		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA,	16.8	other
25		W79171	Hs.9567	GL002 protein	1.5	TM
		AA861271	Hs.222024	transcription factor BMAL2	2.2	other
		AK001838	Hs.296323	serum/glucocorticoid regulated kinase	3.4	other
		AK000511	Hs.6294	hypothetical protein DKFZp434L1435 simil	6.8	?
20		BE156256	Hs.11923	hypothetical protein	6.7	other
30		AW631480	Hs.8688	ESTs	6.1	SS, other
		AA146872	Hs.300700	hypothetical protein FLJ20727 myeloid/lymphoid or mixed-lineage leukem	1.3 1.8	other
		AF264750	Hs.288971		1.7	other
		AW385224	Hs.35198	ectonucleotide pyrophosphatase/phosphodi	2.5	other
35		AK000733	Hs.23900	GTPase activating protein	1.7	other
33		AK000512 AV661958	Hs.69388 Hs.8207	hypothetical protein FLJ20505 GK001 protein	4.7	other
		AK001455	Hs.5198	Down syndrome critical region gene 2	2	other
		AW378065	Hs.8687	ESTs	6.4	TM
		AW391927	Hs.7946	KIAA1288 protein	33.5	other
40		BE122762	Hs.25338	ESTs	5.2	?
		W15477	Hs.64639	glioma pathogenesis-related protein	6.1	other
		AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (17.4	other
		BE219716	Hs.34727	ESTs, Moderately similar to 138759 zinc	7.4	?
		AW263124	Hs.315111	nuclear receptor co-repressor/HDAC3 comp	1.8	other
45	107263	D60341	Hs.21198	translocase of outer mitochondrial membr	6.7	other
	107265	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.5	other
	107299	BE277457	Hs.30661	hypothetical protein MGC4606	3,2	TM
	107316	T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586l0324 (f	2	TM
	107354	NM_006299	Hs.96448	zinc finger protein 193	5	?
50	107392	AW299900	Hs.267632	TATA element modulatory factor 1	1.2	other
		AA307703	Hs.279766	kinesin family member 4A	1.6	other
		BE515065	Hs.296585	nucleolar protein (KKE/D repeat)	3	TM
		AA001386	Hs.59844	ESTS	1.4	other
~ ~		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.3	SS,TM
55		AA018587	Hs.303055	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.2	?
		AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.4	TM
		L42612	Hs.335952	keratin 6B Ig superfamily receptor LNIR	2.5 2.3	other other
		BE153855	Hs.61460		6.8	other
60		AW956103	Hs.61712	pyruvate dehydrogenase kinase, isoenzyme SWI/SNF related, matrix associated, acti	1.6	other
00		AL121031 AA054224	Hs.159971 Hs.59847	ESTs	1.3	other
		AF129535	Hs.272027	F-box only protein 5	7.2	?
		N31256	Hs.161623	ESTs	2.6	other
		AA083069	Hs.339659	ESTs	3.6	other
65		BE300380	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	3.5	other
00		AA101809	Hs.182685	ESTs	1.7	other
		AW022410	Hs.69507	ESTs	1.8	SS,TM

	108647	BE546947	Hs.44276	homeo box C10	9.8	other
		AB029000	Hs.70823	KIAA1077 protein	7.3	other
		AI089575	Hs.9071	progesterone membrane binding protein	2.8	?
	108828	AK001693	Hs.273344	DKFZP564O0463 protein	1.9	other
5	108859	AL121500	Hs.178904	ESTs	1.6	TM
		H06720	Hs.111680	endosulfine alpha	2.2	other
		Al801235	Hs.48480	ESTs	5.4	other
		AK001431	Hs.5105	hypothetical protein FLJ10569	4.1	TM
10		AA149754	Hs.195155	Homo sapiens amino acid transport system	5.7 1.7	? other
10		AA151708	Hs.171980	homeo box (expressed in ES cells) 1 hypothetical protein FLJ10633	6.3	other
		AA152178 AB028987	Hs.23467 Hs.72134	KIAA1064 protein	1.7	other
		AA156542	Hs.72127	ESTs	1.5	other
		AA157811	110.12.12.1	gb:zo35d07.s1 Stratagene colon (937204)	5.4	other
15		AA164293	Hs.72545	ESTs	3	other
		AW608930	Hs.52184	hypothetical protein FLJ20618	1.6	SS,
	109112	AW419196	Hs.257924	hypothetical protein FLJ13782	3.3	TM
	109124	AK000684	Hs.183887	hypothetical protein FLJ22104	1.7	other
• •		AJ132592	Hs.59757	zinc finger protein 281	2.7	other
20		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3 .	TM
		BE566742	Hs.58169	highly expressed in cancer, rich in leuc	2.1	other
		NM_016603	Hs.82035	potential nuclear protein C5ORF5; GAP-li	5.4	other
		AW958181	Hs.189998	ESTs nucleoporin 214kD (CAIN)	5.8 5.3	other other
25		AU077281 N99673	Hs.170285 Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.4	other
23		AA375752	Hs.82719	Homo sapiens mRNA; cDNA DKFZp586F1822 (f	3	other
		AF153201	Hs.86276	C2H2 (Kruppel-type) zinc finger protein	1.3	other
		AA213506	Hs.115099	EST	3	?
		AL096858	Hs.184245	KIAA0929 protein Msx2 interacting nuclea	1.5	other
30		H83603	Hs.40408	homeo box C9	2.2	SS,
	109426	N30531	Hs.42215	protein phosphatase 1, regulatory subuni	3.1	TM
	109429	A1160029	Hs.61438	ESTs	2	?
		AA232103	Hs.189915	ESTs	1.8	other
25		AB032969	Hs.173042	KIAA1143 protein	3.8	other
35		NM_015310	Hs.6763	KIAA0942 protein	3.3	other
		AW074143	Hs.87134	ESTs glycogen synthase kinase 3 alpha	2 2.1	TM other
		L40027 F02614	Hs.118890 Hs.27319	ESTs	1.4	other
		R71264	Hs.16798	ESTs	1.3	other
40		H11938	Hs.21907	histone acetyltransferase	2	other
.0		AA503041	Hs.279009	matrix Gla protein	2.5	other
		AA603840	Hs.29956	KIAA0460 protein	1.7	other
	110110	T07353	Hs.7948	ESTs	2.9	other
	110129	R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU S	1.7	SS,
45	110154	NM_014521	Hs.17667	SH3-domain binding protein 4	4.3	other
		A1668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.3	?
		N41744	Hs.19978	CGI-30 protein	1.3	other
		H28428	Hs.32406	ESTs, Weakly similar to I38022 hypotheti	2.2 2.1	other other
50		BE256986	Hs.11896	hypothetical protein FLJ12089 gb:yq94a01.s1 Soares fetal liver spleen	6.1	?
50		H55748 H55915	Hs.210859	hypothetical protein FLJ11016	6.1	тM
		H57330	Hs.37430	EST	6.4	other
		AK001160	Hs.5999	hypothetical protein FLJ10298	1.3	?
		T97586	Hs.18090	ESTs	1.8	other
55		AB007902	Hs.32168	KIAA0442 protein	1.6	TM
		AW190338	Hs.28029	hypothetical protein MGC11256	7.8	other
		AL138077	Hs.16157	hypothetical protein FLJ12707	2.5	other
		BE044245	Hs.30011	hypothetical protein MGC2963	9.3	?
60		AK000322	Hs.18457	hypothetical protein FLJ20315	5.5	SS,
60		BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 fis, clone HE	2.1 1.5	TM TM
		A1089660	Hs.323401 Hs.24048	dpy-30-like protein FK506 binding protein precursor	6.7	TM
		T25829 AA767373	Hs.24046 Hs.35669	ESTs, Moderately similar to ALU1_HUMAN A	5.7	other
		R33261	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	3.4	other
65		N31598	Hs.12727	hypothetical protein FLJ21610	1.7	TM
		Al740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	1.7	other
		BE612992	Hs.27931	hypothetical protein FLJ10607 similar to	4.7	other

	110056	AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sap	2.3	other
		BE384447	Hs.16034	hypothetical protein MGC13186	3.5	?
		AL117430	Hs.6880	DKFZP434D156 protein	2.2	ż
		BE092285	Hs.29724	hypothetical protein FLJ13187	2.6	SS,
5		H04360	Hs.24283	ESTs, Moderately similar to reduced expr	1.9	TM
		NM 005864	Hs.24587	signal transduction protein (SH3 contain	6.7	other
		AK002180	Hs.11449	DKFZP564O123 protein	2	other
		AK001980	Hs.24284	ADP-ribosyltransferase (NAD+; poly(ADP-r	1.3	other
		AW613287	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	1.8	?
10		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	3.7	other
	111132	AB037807	Hs.83293	hypothetical protein	2.1	TM
	111164	N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	2.3	other
	111172	R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7	other
	111174	AL050166	Hs.26295	Homo sapiens mRNA; cDNA DKFZp586D1122 (f	7.5	other
15	111179	AK000136	Hs.10760	asporin (LRR class 1)	7.1	other
		AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.8	other
		N67603	Hs.272130	ESTs, Weakly similar to S65824 reverse t	3.6	SS,
		AW139408	Hs.152940	ESTs	1.5	other
20		AB037782	Hs.15119	KIAA1361 protein	2.6	other
20		AA852773	Hs.334838	KIAA1866 protein	4.7	other
		N90956	Hs.17230	hypothetical protein FLJ22087	7.9	?
		AA778711	Hs.4310	eukaryotic translation initiation factor	7 5	other other
		AB033091	Hs.74313	KIAA1265 protein ESTs	3.8	other
25		Al523913 T99755	Hs.34504 Hs.334728	ESTs	1.2	TM
2,5		AA837396	Hs.263925	LIS1-interacting protein NUDE1, rat homo	5.1	other
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
		Al478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	2.8	?
		N94606	Hs.288969	HSCARG protein	2.2	other
30		AK000987	Hs.169111	oxidation resistance 1	2.1	other
		R02354	Hs.15999	ESTs	2.7	TM
		Al051194	Hs.227978	EST	6.6	other
		W90638	Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN Z	1.4	other
		R10720	Hs.20670	EST	1.6	?
35	111627	R52656	Hs.21691	ESTs	1.6	other
	111870	AB037834	Hs.18685	Homo sapiens mRNA for KIAA1413 protein,	2.4	other
	111937	BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (fr	10.6	other
		AW083791	Hs.21263	suppressor of potassium transport defect	6.6	TM
40		NM_015310	Hs.6763	KIAA0942 protein	5.1	other
40		R41823	Hs.7413	ESTs; calsyntenin-2	2.8	other
		AB029000	Hs.70823	KIAA1077 protein	14.6 9	other other
		R46071	Hs.301693	Homo sapiens, clone IMAGE:3638994, mRNA,	1.4	other
		NM_016248	Hs.232076 Hs.28538	A kinase (PRKA) anchor protein 11	1.4	TM
45		AW007287 AI742756	Hs.26079	Homo sapiens cDNA: FLJ21086 fis, clone C ESTs	3.2	other
73		R68425	Hs.13809	hypothetical protein FLJ10648	2	TM
		AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	other
		AK000004	Hs.5013	Homo sapiens mRNA for FLJ00004 protein,	6.6	other
		T10258	Hs.5037	EST	1.5	?
50		AW970826	Hs.6185	KIAA1557 protein	3.2	other
		R61388	Hs.6724	ESTs	6.1	other
	112966	Z44718	Hs.102548	glucocorticoid receptor DNA binding fact	6.5	other
	112978	AK000272	Hs.7099	hypothetical protein FLJ20265	1.2	other
		AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYK	5.6	other
55		BE276112	Hs.7165	zinc finger protein 259	2	other
		Al571940	Hs.7549	ESTs	1.9	other
		AW965190	Hs.7560	Homo sapiens mRNA for KIAA1729 protein,	2.4	TM
		T40707	Hs.270862	ESTs	1.3 1.7	SS, other
60		T57317		gb:yb51a03.s1 Stratagene fetal spleen (9	2.8	other
60		T63857	Hs.11449	gb:yc16e01.s1 Stratagene lung (937210) H DKFZP564O123 protein	2.0 1.3	other
		AK002180 AW971049	Hs.11774	protein (peptidyl-prolyl cis/trans isome	3.2	other
*		AA688021	Hs.179808	ESTs	1,2	other
		Al467908	Hs.8882	ESTs	6	other
65		H59588	Hs.15233	ESTs	2	SS,
05		AA813887	Hs.188173	Homo sapiens cDNA FLJ12187 fis, clone MA	1.3	SS,
		T97307		gb:ye53h05.s1 Soares fetal liver spleen	4.4	other
				'		

	440770		outlover to be at the state	4.0	-10	
	113759 AW499665	Hs.9456	SWI/SNF related, matrix associated, acti	1.2	other	
	113777 BE266947	Hs.10590	zinc finger protein 313	13.4	other	
	113783 AL359588	Hs.7041	hypothetical protein DKFZp762B226	1.7	other	
_	113791 Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3	other	
5	113808 W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C	3.3	other	
	113811 BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1	other	
	113817 H13325	Hs.332795	hypothetical protein DKFZp761O17121	3.2	other	
	113826 AW378212	Hs.24809	hypothetical protein FLJ10826	2.3	?	
	113834 T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3	TM	
10	113868 W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7	other	
10	113870 AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1	other	
	113885 AW959486	Hs.21732	ESTs	6.6	other	
				1.9	?	
	113923 AW953484	Hs.3849	hypothetical protein FLJ22041 similar to			
1 5	113989 W87544	Hs.268828	ESTs	1.2	other	
15	114022 Al539519	Hs.120969	Homo sapiens cDNA FLJ11562 fis, clone HE	5.4	other	
	114030 Al825386	Hs.164478	hypothetical protein FLJ21939 similar to	9.4	other	
	114060 AB029551	Hs.7910	RING1 and YY1 binding protein	1.8	other	
	114196 AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	1.5	other	
	114226 AB028968	Hs.7989	KIAA1045 protein	1.8	other	
20	114253 BE149866	Hs.14831	Homo sapiens, Similar to zinc finger pro	2.3	other	
	114262 AL117518	Hs.3686	KIAA0978 protein	1.4	TM	
	114275 AW515443.c	omp	Hs.306117	KIAA0:	306 protein 15.8	other
	114292 Al815395	Hs.184641	fatty acid desaturase 2	1.9	ŤΜ	
	114309 AA332453	Hs.20824	CGI-85 protein	2.4	other	
25	114392 AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-r	1.9	other	
23	114407 BE539976	Hs.103305	Homo sapiens mRNA; cDNA DKFZp434B0425 (f	1.3	TM	
				5.6	other	
	114455 H37908	Hs.271616	ESTs, Weakly similar to ALU8_HUMAN ALU S	5.3	TM	
	114463 AL120247	Hs.40109	KIAA0872 protein			
20	114464 AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110	1.3	other	
30	114471 AA028074	Hs.104613	RP42 homolog	1.9	?	
	114480 BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	13.4	other	
	114671 AA766268	Hs.266273	hypothetical protein FLJ13346	2	other	
	114698 AA476966	Hs.110857	polymerase (RNA) III (DNA directed) poly	3.6	other	
	114730 Al373544	Hs.331328	intermediate filament protein syncoilin	3.9	other	
35	114767 Al859865	Hs.154443	minichromosome maintenance deficient (S.	1.7	other	
	114774 AV656017	Hs.184325	CGI-76 protein	3.2	other	
	114798 AA159181	Hs.54900	serologically defined colon cancer antig	3.6	other	
	114860 AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.4	other	
	114895 AA236177	Hs.76591	KIAA0887 protein	7.2	other	
40		Hs.5324	hypothetical protein	1.3	other	
70	114896 BE539101	115.5524	gb:zt29f02.s1 Soares ovary tumor NbHOT H	1.5	other	
	114911 AA236672	11- 400747	•			
	114930 AA237022	Hs.188717	ESTs	2	SS,	
	114938 AA242834	Hs.58384	ESTs	2.9	other	
4 ~	114965 Al733881	Hs.72472	BMP-R1B	2.3	?	
45	115023 AF102546	Hs.63931	dachshund (Drosophila) homolog	1.3	other	
	115038 AA252360	Hs.87968	toll-like receptor 9	1.6	other	
	115061 Al751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8	other	
	115117 Al670847	Hs.5324	hypothetical protein	1.5	other	
	115206 AW183695	Hs.186572	ESTs	2.5	other	
50	115221 AW365434	Hs.79741	hypothetical protein FLJ10116	1.5	other	
	115239 BE251328	Hs.73291	hypothetical protein FLJ10881	1.3	TM	
	115242 Al368236	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN A	1.4	other	
	115278 AK002163	Hs.301724	hypothetical protein FLJ11301	1.5	other	
		Hs.293736	ESTs	2.4	other	
55	115285 AW972872			6.3	SS,	
55	115291 BE545072	Hs.122579	hypothetical protein FLJ10461			
	115400 Al215069	Hs.89113	ESTs	6.7	?	
	115468 AA314349	Hs.48499	tumor antigen SLP-8p	7.5	?	
	115471 AK001376	Hs.59346	hypothetical protein FLJ10514	1.4	TM	
	115479 AW301608	Hs.278188	ESTs, Moderately similar to I54374 gene	4.1	TM	
60	115496 AW247593	Hs.71819	eukaryotic translation initiation factor	16.3	other	
	115500 Y14443	Hs.88219	zinc finger protein 200	5	other	
	115553 AJ275986	Hs.71414	transcription factor (SMIF gene)	2.5	other	
	115581 Al540842	Hs.61082	ESTs	6.2	other	
	115587 BE081342	Hs.283037	HSPC039 protein	2.9	other	
65	115590 AA399477	Hs.67896	7-60 protein	5.3	TM	
00	115646 N36110	Hs.305971	solute carrier family 2 (facilitated glu	4.8	?	
	115652 BE093589	Hs.38178	hypothetical protein FLJ23468	10.6	other	
	110007 5000000	113.00170	in positional protein i cazatas	. 5.0	QU101	

	448088 4104080		1) 1 1400 40000 "PNA -	40.7	T1.4
	115655 AL048269		Homo sapiens, clone MGC:16063, mRNA, com	12.7	TM
	115663 Al138785	Hs.40507	ESTs	2	other
	115676 AA953006	6 Hs.88143	ESTs	3.1	other
	115690 AA625132	2 Hs.44159	hypothetical protein FLJ21615	1.7	TM
5	115693 AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.9	other
	115715 BE395161	Hs.1390	proteasome (prosome, macropain) subunit,	1.7	other
	115734 AI950339	Hs.40782	ESTs "	2.7	TM
	115811 NM_0154		DKFZP434B168 protein	2.1	other
	115823 AI732742	Hs.87440	ESTs	2.1	other
10	115837 Al675217		ESTs	1.3	other
10		Hs.42761		4.4	other
	115844 Al373062	Hs.332938	hypothetical protein MGC5370		
	115866 AW06262		KIAA0867 protein	7.3	other
	115875 N55669	Hs.333823	mitochondrial ribosomal protein L13	1.2	other
	115941 Al867451	Hs.46679	hypothetical protein FLJ20739	5.5	other
15	115968 AB037753	3 Hs.62767	KIAA1332 protein	9.8	other
	116003 BE275469	Hs.66493	Down syndrome critical region gene 5	1.4	other
	116011 AL359053		Homo sapiens mRNA full length insert cDN	2.4	other
	116108 AA770688		H2A histone family, member L	1.8	other
	116134 BE243834		CGI-04 protein	1.4	other
20	116189 N35719	Hs.44749	ESTs, Moderately similar to T00358 hypot	1.2	other
20				2.1	other
	116195 AW82111		ESTs		
	116238 AV660717		DKFZP586N0819 protein	1.7	other
	116246 AF265555		baculoviral IAP repeat-containing 6	1.7	other
	116262 Al936442	Hs.59838	hypothetical protein FLJ10808	1.8	?
25	116298 Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	1.9	other
	116318 AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DI	5	SS,
	116325 Al472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	1.4	SS,
	116336 AL133033	Hs.4084	KIAA1025 protein	1.9	?
	116339 AK000290		dipeptidyl peptidase 8	1.5	other
30	116350 AA497129		nuclear factor I/C (CCAAT-binding transc	1.9	?
50				1.9	?
	116358 AI149586		interferon-induced protein 75, 52kD	6.1	other
	116365 N50174	Hs.46765	ESTs		
	116368 N90466	Hs.71109	KIAA1229 protein	1.6	?
~ ~	116417 AW49966		Human clone 23826 mRNA sequence	7.4	other
35	116436 AA161411	l Hs.58668	chromosome 21 open reading frame 57	2.1	other
	116462 AF218313	3 Hs.236828	putative helicase RUVBL	1.5	TM
	116470 Al272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1	TM
	116575 AA312572	2 Hs.6241	phosphoinositide-3-kinase, regulatory su	1.5	other
	116637 AK001043	3 Hs.92033	integrin-linked kinase-associated serine	2.7	other
40	116640 X89984	Hs.211563	B-cell CLL/lymphoma 7A	2.3	other
• •	116700 Al800202		hypothetical protein MGC10765	1.4	other
	116705 AW07481		hypothetical protein FLJ14566	3.4	other
			ESTs, Weakly similar to I38022 hypotheti	2.9	other
	116732 AW15222			1.7	TM
15	116926 H73608	Hs.290830	ESTs		
45	117034 U72209	Hs.180324	YY1-associated factor 2	3.4	TM
	117132 Al393666	Hs.42315	p10-binding protein	5.2	?
	117247 N21032		gb:yx46f06.s1 Soares melanocyte 2NbHM Ho	5.5	TM
	117276 N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HE	1.5	TM
	117284 AK00170	1 Hs.183779	Homo sapiens cDNA FLJ10590 fis, clone NT	2	other
50	117367 AI041793	Hs.42502	ESTs	2	other
	117368 Al878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacu	2.1	?
	117382 AF150275		ESTs	2.7	TM
	117412 N32536	Hs.42645	solute carrier family 16 (monocarboxylic	1.4	other
	117557 AF123050		diubiquitin	3.4	TM
55		Hs.44648	ESTs	3.4	?
33	117588 N34895			3	SS,
	117745 BE29492		CGI-12 protein		
	117754 AA12167		zinc finger protein 281	1.9	other
	117879 N54706	Hs.303025	chromosome 11 open reading frame 24	1.8	other
	117904 BE54067	5 Hs.332938	hypothetical protein MGC5370	6	?
60	117911 AL137379	3 Hs.47125	hypothetical protein FLJ13912	1.7	other
	117933 Y10518	Hs.116470	hypothetical protein FLJ20048	1.7	other
	117983 AL110246	6 Hs.47367	KIAA1785 protein	5.4	other
	118078 N54321	Hs.47790	EST	5.2	other
	118301 AA45390		ESTs	2.6	other
65	118429 AA24333	2 Hs.74649	cytochrome c oxidase subunit VIc	2.5	TM
0.5	118472 AL15754		bromodomain and PHD finger containing, 3	4.1	other
	118488 AJ277275		rapa-2 (rapa gene)	1.2	other
	I IUMUU MUAITAT	, 110.00102	Tapa = (Tapa gotto)		20101

		N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HE	1.5	other
		Al949952	Hs.49397	ESTs	7.4	?
		A1458020	Hs.293287	ESTS	2.5 1.2	other TM
5		AA332845 AB033113	Hs.152618 Hs.50187	ESTs, Moderately similar to ZN91_HUMAN Z KIAA1287 protein	2.1	TM
5		AA199686	115.50107	gb:zq75g09.r1 Stratagene hNT neuron (937	5.2	other
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	1.4	other
		Al668709	Hs.240722	ESTs, Moderately similar to ALU8_HUMAN A	3.6	other
	118986	AF148713	Hs.125830	bladder cancer overexpressed protein	4.9	?
10		W24781	Hs.293798	KIAA1710 protein	1.7	TM
		AW453069	Hs.3657	activity-dependent neuroprotective prote	2.2	other
		BE539706	Hs.285363	ESTs	1.4	?
		N57568	Hs.48028	EST	25.1 1.6	other ?
15		NM_001241 Al417240	Hs.155478 Hs.320836	cyclin T2 ESTs, Weakly similar to A47582 B-cell gr	1.3	r other
13		AL117554	Hs.119908	nucleolar protein NOP5/NOP58	6.7	TM
		Al624342	Hs.170042	ESTs	2.4	other
		AI796730	Hs.55513	ESTs	2.1	other
		W37933		Empirically selected from AFFX single pr	1.9	other
20	119601	AK000155	Hs.91684	Homo sapiens mRNA; cDNA DKFZp667l103 (fr	3.7	TM
	119602	AW675298	Hs.233694	hypothetical protein FLJ11350	3	other
		AA243837	Hs.57787	ESTs	1.4	other
		W61019	Hs.57811	ESTs	1.2	?
25		AB032977	Hs.6298	KIAA1151 protein	1.8 3.1	TM other
23		NM_016625 BE393948	Hs.191381 Hs.50915	hypothetical protein kallikrein 5 (KLK5; KLK-L2; stratum corn	9.2	other
		AJ223810	Hs.43213	ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	TM
		AA130970	Hs.58382	hypothetical protein FLJ11101	2.5	?
		AA081218	Hs.58608	Homo sapiens cDNA FLJ14206 fis, clone NT	2.7	TM
30		AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	2.6	other
		AA703129	Hs.58963	ESTs	2.7	other
		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	1.2	other
		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7	other
25		A1924294	Hs.173259	uncharacterized bone marrow protein BM03	1.2	other
35		AW131940	Hs.104030	ESTS	9.6 4.7	other other
		AA177051		gb:nc02a02.s1 NCI_CGAP_Pr3 Homo sapiens gb:zp52g02.s1 Stratagene HeLa cell s3 93	2.1	other
		AA190577 AW995911	Hs.299883	hypothetical protein FLJ23399	1.9	TM
		AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2	other
40		AA195517	Hs.191643	ESTs	5.6	?
		AA195651	Hs.104106	ESTs	6.5	other
	120327	AK000292	Hs.278732	hypothetical protein FLJ20285	16.1	other
		N85785	Hs.181165	eukaryotic translation elongation factor	3	other
4.5		AW450669	Hs.45068	hypothetical protein DKFZp434l143	5.8	other
45		AA210722	Hs.104158	ESTs	4.6	SS,TM
		AW969481 R06859	Hs.55189 Hs.193172	hypothetical protein ESTs, Weakly similar to 138022 hypotheti	16.8 5.1	other other
		AF000545	Hs.296433	putative purinergic receptor	28.1	TM
		AA219305	Hs.104196	EST	12.4	?
50		AA228026	Hs.38774	ESTs	4.1	TM
		AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolo	9.7	TM
		AW969665	Hs.154848	hypothetical protein DKFZp434D0127	32.6	other
		AA232874	Hs.104245	ESTs	3.2	other
~ ~		AW967985	Hs.325572	ESTs, Moderately similar to ALU7_HUMAN A	21.7	other
55		AA134006	Hs.79306	eukaryotic translation initiation factor	12.5 7.3	other other
		AB023230	Hs.96427	KIAA1013 protein Homo sapiens mRNA; cDNA DKFZp586F1323 (f	7.3 11.4	other
		AW966893 AA236453	Hs.26613 Hs.18978	Homo sapiens cDNA: FLJ22822 fis, clone K	1.9	other
		AI950087	113.10370	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien	19.4	other
60		AA251973	Hs.269988	ESTs	5.5	?
-		AA253170	Hs.96473	EST	10.4	?
		AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapi	4	?
		BE047718	Hs.96545	ESTs	9.4	other
<i></i>		AA258601	Hs.161731	EST	2.4	other
65		BE350244	Hs.96547	ESTs	2.5	? other
		AA279160	Hs.111407	Homo sapiens, clone IMAGE:3613029, mRNA, ESTs, Weakly similar to ALU1_HUMAN ALU S	5.3 14.4	?
	1205/0	AA280679	Hs.271445	LOTS, WEARLY SHITHAL TO ALUTE TOWNING ALU S	1777	

		DE044000	11-004000	TAIRAGE III.	40.0	?
		BE244830	Hs.284228	ZNF135-like protein	10.2	?
		AW372799	Hs.125790	leucine-rich repeat-containing 2	2.2 7.6	other
		AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	2.5	other
5		AW965339	Hs.111471	ESTs	52 52	other
5		AW407987 AA286942	Hs.173518	M-phase phosphoprotein homolog gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens	2.4	other
			Un 140200	Homo sapiens, clone IMAGE:3677194, mRNA,	5	other
		AA287095 AW063659	Hs.140309 Hs.191649	ESTs	2.2	other
		AW969638	Hs.112318	6.2 kd protein	2.2	TM
10		BE536739	Hs.109909	ESTs	1.9	TM
10		AA976503	113.103303	gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8	TM
,	_	Al821539	Hs.97249	ESTs	2.5	other
		AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	6	other
		AA292747	Hs.97296	ESTs	2.9	other
15		Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7.1	SS,
10		Al608909	Hs.193985	ESTs	7.9	other
		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	7	TM
		AA346495	110.00002	gb:EST52657 Fetal heart II Homo sapiens	4.5	other
		AA386260	Hs.104632	EST	4.5	?
20		AA398155	Hs.97600	ESTs	4.5	other
~0		BE262951	Hs.99052	ESTs	5.6	other
		Al219896	Hs.97592	ESTs	1.3	other
		AA398360	Hs.97608	EST	3.2	other
		Al439713	Hs.165295	ESTs	3.6	other
25		AA398721	Hs.186749	ESTs, Highly similar to 137550 mismatch	5.5	other
		AA363307	Hs.97032	ESTs	3.8	other
		AL121523	Hs.97774	ESTs	1.7	TM
		Al002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.	2.9	other
		AA403008	Hs.301927	c6.1A	1.9	other
30	121340	AW956981	Hs.97910	Homo sapiens cDNA FLJ13383 fis, clone PL	3.5	other
	121408	AA406137	Hs.98019	EST	6.1	?
	121439	AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell gr	7.5	other
	121450	AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, com	7.1	other
	121452	AW971063	Hs.292882	ESTs	1.8	other
35	121455	H58306	Hs.15165	retinoic acid induced 14	10.5	other
	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.5	TM
	121496	AA442224	Hs.97900	ESTs	14.4	other
		AA494172	Hs.194417	ESTs	13.1	other
4.0		AA402515	Hs.97887	ESTs	28	other
40		AA416653	Hs.181510	ESTs	6.3	other
		AA412112		gb:zt69b02.s1 Soares_testis_NHT Homo sap	2.7	SS,
		AA412477	Hs.98142	EST	7.5	?
		AA412497	11 00000	gb:zt95g12.s1 Soares_testis_NHT Homo sap	2.8	other
15		AA411970	Hs.98096	EST	3.5	? Tha
45		AA416568	11- 00740	gb:zu05c10.s1 Soares_testis_NHT Homo sap	6.2	TM
		AD001528	Hs.89718	spermine synthase	4 2.2	other other
		AA626010	Hs.98247	ESTS	4.3	TM
		AA416931	Hs.126065	ESTs Homo sapiens mRNA; cDNA DKFZp434B1023 (f	7.9	other
50		AA421537	Hs.178072	Homo sapiens cDNA FLJ13558 fis, clone PL	2	other
50		AA418160 AV660305	Hs.86043 Hs.110286	ESTs .	4.7	?
			Hs.154145	hypothetical protein FLJ11585	12.7	other
		U55184 AA419225	Hs.98269	Homo sapiens cDNA FLJ11953 fis, clone HE	8.3	?
		Al949597	Hs.98325	ESTs	1.8	TM
55		AA421041	Hs.180744	ESTs	4.1	TM
55		AA398784	Hs.97514	ESTs	7.1	SS,
		BE536911	Hs.234545	hypothetical protein NUF2R	19.5	other
	121773	AB033022	Hs.158654	KIAA1196 protein	8	other
	121775	AA421773	Hs.161008	ESTs	1.7	other
60		AA292579	Hs.125133	hypothetical protein FLJ22501	6.7	other
	121786	AI810774	Hs.98376	ESTs	10.5	other
	121832	AW340797	Hs.98434	ESTs	5.9	other
		AA328348	Hs.218289	ESTs	3.9	other
	121839	AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein	, 5	other
65	121842	AF027406	Hs.104865	serine/threonine kinase 23	2.7	?
•	121847	AA446628	Hs.2799	cartilage linking protein 1	2.3	other
	121871	AW972668	Hs.293044	ESTs	2.9	TM

	10				_	,,
		AA426376	Hs.98459	ESTs	5	. other
		AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.3	TM
		AA428179	Hs.223405	ESTs, Moderately similar to A46010 X-lin	2.5	other
_		AA428647	Hs.98611	EST	2.3	other
5		AA298760	Hs.180191	hypothetical protein FLJ14904	3.4	other
	121985	Al862570	Hs.299214	Homo sapiens, clone IMAGE:2822295, mRNA,	11.4	other
		AA210863	Hs.3532	nemo-like kinase	3.8	?
	121999	AA430211	Hs.98668	EST	6.5	other
	122009	AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone A	2.2	other
10	122013	AA431085	Hs.98706	ESTs	6.6	other
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU S	13.1	other
	122050	Al453076	Hs.166109	ELAV (embryonic lethal, abnormal vision,	9.1	other
	122060	AA431738	Hs.98750	EST	13.1	?
	122114	AW161023	Hs.104921	ESTs	1.5	other
15	122188	AA398838		gb:zt80d01.r1 Soares_testis_NHT Homo sap	3.4	other
	122204	AA435936	Hs.98842	EST	5.6	other
	122246	AA329550	Hs.29417	HCF-binding transcription factor Zhangfe	5.2	other
	122257	AA436819	Hs.98899	ESTs	5.6	other
	122302	AA441801	Hs.104947	ESTs	5.8	other
20	122341	AW601969	Hs.99010	hypothetical protein FLJ22263 similar to	2	other
		AA443794	Hs.98390	ESTs	7.4	SS,TM
		AA443985	Hs.303222	ESTs	12.2	?
		AA868555	Hs.178222	ESTs	5	?
		AA446008	Hs.336677	EST	7.8	?
25		AB032948	Hs.21356	hypothetical protein DKFZp762K2015	2.5	?
		AA446572	Hs.303223	EST	2.8	TM
		AA446869	Hs.119316	ESTs	7.4	other
		AA446918	Hs.99088	EST	1.9	other
		AA446966	Hs.99090	ESTs. Moderately similar to similar to K	6.9	?
30		AW505139	Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (fr	2.6	other
50		AA447603	Hs.99123	EST	1.8	TM
		AA447626	Hs.99127	EST	3.5	other
		Al266159	Hs.104980	ESTs	1.5	other
		AW418788	Hs.99148	ESTs, Weakly similar to S43569 R01H10.6	9.7	other
35		AA448158	Hs.99152	EST	4.9	other
55		AA448349	Hs.238151	EST	6.2	?
		AA448417	Hs.104990	ESTs	5.5	other
		AA204969	Hs.234863	Homo sapiens cDNA FLJ12082 fis, clone HE	1.3	other
		AA449232	Hs.99195	ESTs	11.2	?
40		AW959741	Hs.40368	adaptor-related protein complex 1, sigma	10.1	other
-10		AA779725	Hs.164589	ESTs	2.5	SS,
		AA194055	Hs.293858	ESTs	1.9	other
		AA452578	Hs.262907	ESTs	9.5	other
		AA452601	Hs.99287	EST	11	?
45		AK001910	Hs.99303	Homo sapiens cDNA FLJ11048 fis, clone PL	3.4	other
73		AB040893	Hs.6968	KIAA1460 protein	2	other
		Al028173	Hs.99329	ESTs	1.7	?
		AL355841	Hs.99330	hypothetical protein FLJ23588	4.4	?
		AA411925	Hs.301960	ESTs	4.7	other
50		AA453518	Hs.98023	ESTs	61.5	other
50		AA453630	Hs.99339	EST	10.7	?
		AA453638	Hs.161873	ESTs	107.3	?
	122010	AI681535	Hs.148135	serine/threonine kinase 33	121.4	other
	100610	AA453641	110.140100	gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1	SS,
55	100000	AA453987	Hs.144802	ESTs	5.6	other
55		AA456859	Hs.178358	ESTs	8.5	SS,
		Al376875	Hs.105119	ESTs	10.4	other
		AW204530	Hs.99500	ESTs	81.8	?
	122023	AA461492	Hs.99545	Homo sapiens cDNA FLJ10658 fis, clone NT	3.7	ż
60		AA460581	Hs.290996	ESTs	4.6	other
UU	122030	AA461509	Hs.293565	ESTs, Weakly similar to putative p150 [H	2.7	TM
	122001	AA460584	Hs.334386	ESTs	75.3	other
	122000	AA600235	Hs.9625	NIMA (never in mitosis gene a)-related k	7.8	other
		Al929374	Hs.75367	Src-like-adapter	5.8	other
65	122000	AA335721	Hs.119394	ESTs	1.3	other
05	122001	BE539656	Hs.283705	ESTs	4.2	other
	122868	AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinas	5.3	other
	122000	000210		annual miner of the branch Arabina annual	-	

	100070	A18/E70040	11- 240700	Hama contana aDNA: El 194766 fin along C	9.9	?
		AW576312	Hs.318722	Homo sapiens cDNA: FLJ21766 fis, clone C	5.3	r other
		AW081394	Hs.97103	ESTS	13.9	other
		AA769410	Hs.128654	ESTs	11.5	other
5		AA470074	Hs.169896	ESTs	1.7	TM
5		AA470140 AA478951	Hs.229170 Hs.105629	EST ESTs	5	other
		AW968324	Hs.17384	ESTs	15.4	other
		AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HE	2.8	other
		AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7	other
10		Al382600	Hs.104308	ESTs, Weakly similar to KIAA1395 protein	8.8	other
10		AA485360	Hs.105661	ESTs	4	?
		Al343652	Hs.105667	ESTs	3.8	other
		AA486256	Hs.193510	EST	7.4	other
		BE304942	Hs.265848	myomegalin	2.8	?
15		T52027	Hs.271795	ESTs, Weakly similar to 138022 hypotheti	2.4	other
10		AI061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MA	15.6	TM
		AW451999	Hs.194024	ESTs	5.2	other
		AI734179	Hs.105676	ESTs	23.8	TM
		AW601773	Hs.270259	ESTs	5.2	other
20		AA490929	Hs.105274	ESTs, Weakly similar to RMS1_HUMAN REGUL	9.3	?
		AA496369		gb:zv37d10.s1 Soares ovary tumor NbHOT H	4.2	TM
		AA504757	Hs.105738	ESTs	7	other
		AA731404	Hs.105510	ESTs	3.7	other
		AW450922	Hs.112478	ESTs	3.8	other
25	123466	AA599042	Hs.112503	EST	7.4	other
	123470	AW303285	Hs.303632	Human DNA sequence from clone RP11-110H4	3.5	other
	123471	AB021644	Hs.197219	zinc finger protein 14 (KOX 6)	5.2	?
	123475	BE439553	Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA,	1.7	other
	123482	N95059	Hs.55098	ESTs	1.6	other
30	123486	BE019072	Hs.334802	Homo sapiens cDNA FLJ14680 fis, clone NT	2.4	other
	123508	AW380388	Hs.155546	KIAA1080 protein; Golgi-associated, gamm	2.2	TM
	123615	AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sap	7.9	other
	123619	AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	2.8	other
~ ~		AA609364		gb:zu71d09.s1 Soares_testis_NHT Homo sap	1.7	?
35		Al269609	Hs.105187	kinesin protein 9 gene	5.7	?
		NM_013241	Hs.95231	FH1/FH2 domain-containing protein	10	other
		AA609891	Hs.112777	EST	5.2	other
		AA609955	Hs.234961	Huntingtin interacting protein E	30.6	TM
40		AA620464	Hs.261915	EST, Weakly similar to S65657 alpha-1C-a	2.1	other
40		AA620586	11- 472042	gb:ae60g05.s1 Stratagene lung carcinoma	2.7	other ?
		AB012922	Hs.173043	metastasis-associated 1-like 1	6.3 4.4	r other
		AJ272267	Hs.146178	choline dehydrogenase ralA binding protein 1	7.1	?
		L42542 Al147155	Hs.75447 Hs.270016	ESTs	8.3	SS,
45		AI147 155 AI950314	Hs.154762	HIV-1 rev binding protein 2	3.8	other
43		H05635	Hs.294030	topoisomerase-related function protein 4	1.2	SS,
		BE463721	Hs.97101	putative G protein-coupled receptor	3.2	?
		AA372796	Hs.269339	ESTs, Weakly similar to AF161356 1 HSPC0	5.7	other
	. —	AA640891	Hs.102406	ESTs	3.1	TM
50		D87454	Hs.192966	KIAA0265 protein	3.5	other
50		AI267847		gb:ag49a10.x1 Stanley Frontal NB pool 2	57.1	?
		AA317338	Hs.7535	COBW-like protein	2.8	other
	124391	AF155099	Hs.279780	NY-REN-18 antigen	7.1	other
		N34059		gb:yv28h09.s1 Soares fetal liver spleen	3.3	other
55		H13540	Hs.82202	ribosomal protein L17	2.9	other
		AA532519	Hs.129043	Human DNA sequence from clone 989H11 on	7.9	other
	124466	R10084	Hs.113319	kinesin heavy chain member 2	2.6	TM
	124482	N53935		gb:yv59d09.s1 Soares fetal liver spleen	7.9	TM
	124498	H79433	Hs.268997	ESTs	7.8	other
60	124515	AA669097	Hs.109370	ESTs	3.3	other
		N71076	Hs.102800	ESTs, Weakly similar to neuronal thread	4.6	?
	124631	NM_014053	Hs.270594	FLVCR protein	3.2	other
		Al765123	Hs.143671	Homo sapiens cDNA FLJ13533 fis, clone PL	5.8	other
<i></i>		AA160474	Hs.75798	hypothetical protein	9.3	other
65		AW968856	Hs.278569	sorting nexin 17	3.5	other
	124649	N92593	Hs.313054	ESTs	6.1 5.6	TM
	124661	R48170	Hs.78436	EphB1	0,0	other

	104600 44004664	Ua 110070	ESTs, Weakly similar to M3K9_HUMAN MITOG	7.9	TM
	124683 AA381661	Hs.119878		7.5 5.7	other
	124712 R09166	Hs.191148	ESTs	11.3	_
	124735 R22952	Hs.268685	ESTs		?
_	124761 AA374756	Hs.93560	Homo sapiens mRNA for KIAA1771 protein,	9	other
5	124768 AW368528	Hs.100855	ESTs	8.3	other
	124775 R41772	Hs.100878	ESTs	4.9	other
	124777 R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.8	other
	124788 R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	5.1	other
	124809 AL355722	Hs.106875	Homo sapiens EST from clone 35214, full	4.2	other
10	124811 R46068	Hs.288912	hypothetical protein FLJ22604	14.2	other
	124812 R47948	Hs.188732	ESTs	7.9	other
	124822 AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	6.6	other
	124825 AA501669	Hs.336693	ESTs	2.3	SS,TM
	124833 AW975868	Hs.294100	ESTs	2.7	SS,TM
15		Hs.137190	ESTs	2.3	other
13	124857 R63652		EST	23.9	?
	124860 R65763	Hs.101477		23.9	: other
	124863 Al382555	Hs.127950	bromodomain-containing 1		
	124876 AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	4.4	SS,
• •	124878 BE397530	Hs.288057	hypothetical protein FLJ22242	2.7	other
20	124902 H37941	Hs.101883	ESTs	5.7	other
	124903 AW296713	Hs.221441	ESTs	32.4	other
	124930 Al076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8	other
	124942 R99978	Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1	other
	124958 AI078645	Hs.431	murine leukemia viral (bmi-1) oncogene h	1.9	other
25	124980 T40841	Hs.98681	ESTs	4.5	?
20	125002 T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU S	4.9	other
	125047 T79815	Hs.279793	ESTs	5	?
		Hs.100588	EST	135.3	?
	125051 T79956			5.4	other
20	125056 T81310	Hs.100592	ESTs		other
30	125101 Al472068	Hs.286236	KIAA1856 protein	5.6	
	125113 T96595	Hs.302270	ESTs, Weakly similar to ALUF_HUMAN !!!!	1.8	other
	125115 T97341		gb:ye57e05.s1 Soares fetal liver spleen	9.6	?
	125125 Al222382	Hs.240767	Human DNA sequence from clone RP1-12G14	1.5	TM
	125147 W38150		Empirically selected from AFFX single pr	1.7	?
35	125161 W44657	Hs.144232	EST	10.7	?
	125249 AA630863	Hs.131375	ESTs, Moderately similar to ALUB_HUMAN!	1.3	other
	125255 AF098162	Hs.118631	timeless (Drosophila) homolog	9.4	other
	125279 AW401809	Hs.4779	KIAA1150 protein	1.5	?
	125280 Al123705	Hs.106932	ESTs	8.1	?
40	125298 AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone H	1.5	other
70	125660 AW292171	Hs.23978	scaffold attachment factor B	5.9	other
		Hs.97496	YY1 transcription factor	1.2	?
	125827 NM_003403		cholinergic receptor, muscarinic 3	6.5	?
	125891 U29589	Hs.7138	has deviced IAD report containing 5 (sur	14.3	; ?
15	126005 AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (sur		
45	126202 AA157632	Hs.272630	vacuolar proton pump delta polypeptide	2.5	SS,
	126695 AA643322	Hs.172028	a disintegrin and metalloproteinase doma	9.1	SS,TM
	127050 AW411066	Hs.274351	CGI-89 protein	17	other
	127274 AW966158	Hs.58582	Homo sapiens cDNA FLJ12789 fis, clone NT	12.8	other
	128355 AW293012	Hs.161623	ESTs	7.4	SS,
50	128493 D87466	Hs.240112	KIAA0276 protein	3.1	TM
	128522 BE173977	Hs.10098	putative nucleolar RNA helicase	9.4	other
	128527 AA504583	Hs.101047	transcription factor 3 (E2A immunoglobul	1.5	other
	128528 R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8	other
	128595 U31875	Hs.272499	short-chain alcohol dehydrogenase family	12.1	TM
55	128599 NM_015366	Hs.102336	Rho GTPase activating protein 8	2.4	?
55	128604 AI879099	Hs.102397	GIOT-3 for gonadotropin inducible transc	1.3	other
	120004 AI07 9099		zinc finger protein	7.2	other
	128608 BE267994	Hs.102419		1.3	other
	128625 AB037841	Hs.102652	hypothetical protein ASH1		
	128629 AL096748	Hs.102708	DKFZP434A043 protein	3.2	other
60	128639 AW582962	Hs.102897	CGI-47 protein	2	TM
	128656 AA458542	Hs.10326	coatomer protein complex, subunit epsilo	1.4	other
	128658 BE397354	Hs.324830	diptheria toxin resistance protein requi	2.5	other
	128670 AA975486	Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	7.1	?
	128691 W27939	Hs.103834	hypothetical protein MGC5576	7.8	?
65	128696 BE081143	Hs.225977	nuclear receptor coactivator 3	3.8	other
	128700 Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	1.6	other
	128714 T85231	Hs.179661	tubulin, beta 5	7.8	other
	·-				

	120717	AV004564	Un 404000	hypothetical protein El 140702	5.5	other
		AK001564 BE147740	Hs.104222 Hs.104558	hypothetical protein FLJ10702 ESTs, Moderately similar to I38022 hypot	2.7	TM
		AF292100			2.8	TM
		AA307211	Hs.104613	RP42 homolog proteasome (prosome, macropain) subunit,	4.5	?
5		Al470163	Hs.251531 Hs.323342	actin related protein 2/3 complex, subun	2.2	other
9		AB027249	Hs.104741	PDZ-binding kinase; T-cell originated pr	2.8	other
		BE302796	Hs.105097	thymidine kinase 1, soluble	5.4	other
		N71826	Hs.105465	small nuclear ribonucleoprotein polypept	53.9	TM
		NM_002975	Hs.105927	stem cell growth factor; lymphocyte secr	13.3	other
10		AW630942	Hs.106061	RD RNA-binding protein	2.6	other
10		AW248431	Hs.256526	nuclear prelamin A recognition factor	2.2	other
		BE281170	Hs.106357	valosin-containing protein	6	other
		AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (f	1.6	SS,
		BE159181	Hs.168232	hypothetical protein FLJ13855	2.3	other
15		AF189723	Hs.106778	ATPase, Ca++ transporting, type 2C, memb	1.5	?
		R57988	Hs.10706	epithelial protein lost in neoplasm beta	4.8	other
		AA622037	Hs.166468	programmed cell death 5	1.4	other
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.9	other
		Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	7.3	?
20		AA009647	Hs.8850	a disintegrin and metalloproteinase doma	2.5	other
		Al580127	Hs.107381	hypothetical protein FLJ11200	1.3	other
	128965	AW150697	Hs.107418	ESTs	1.4	?
	128970	Al375672	Hs.165028	ESTs	1.3	other
	128975	BE560779	Hs.284233	NICE-5 protein	14	other
25	128979	AW271217	Hs.281434	Homo sapiens cDNA FLJ14028 fis, clone HE	1.6	TM
	128995	Al816224	Hs.107747	DKFZP566C243 protein	1.9	other
	-	Al950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien	2.9	other
	129021	AL044675	Hs.173081	KIAA0530 protein	3.8	other
20		R80088	Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4	other
30		AW296806	Hs.326234	ESTs, Highly similar to T46422 hypotheti	5	other
		Al351010	Hs.102267	lysosomal	2.1	other
		AA744610	Hs.194431	palladin	17.1	other
		L12350	Hs.108623	thrombospondin 2	2.7	other
25		AA463189	Hs.288906	WW Domain-Containing Gene	20.9	TM other
35		BE243933	Hs.108642	zinc finger protein 22 (KOX 15)	3 5.8	TM
		AF146074	Hs.108660	ATP-binding cassette, sub-family C (CFTR	6	other
		W93048 AA356620	Hs.250723 Hs.108947	hypothetical protein MGC2747 KIAA0050 gene product	6.4	TM
		AW162916	Hs.241576	hypothetical protein PRO2577	1.8	TM
40		AA286914	Hs.183299	ESTs	2.1	?
70		AA150797	Hs.109276	latexin protein	3.3	SS,TM
		N57532	Hs.109315	KIAA1415 protein	5.9	other
		A1934365	Hs.109439	osteoglycin (osteoinductive factor, mime	8.1	other
		U40714	Hs.239307	tyrosyl-tRNA synthetase	2.9	other
45		AF013758	Hs.109643	polyadenylate binding protein-interactin	3.3	?
		AA252468	Hs.1098	DKFZp434J1813 protein	2.6	SS,TM
		AI961727	Hs.109804	H1 histone family, member X	7.4	other
		W26392	Hs.110080	ESTs, Weakly similar to S13495 pregnancy	9.6	other
		AI051967	Hs.110122	ESTs	1.2	other
50		AA287239	Hs.5518	Homo sapiens cDNA FLJ11311 fis, clone PL	5.2	other
	129340	H75334	Hs.11050	F-box only protein 9	4.7	SS,
	129347	BE614192	Hs.279869	melanoma-associated antigen recognised b	7.7	TM
		U30246	Hs.110736	solute carrier family 12 (sodium/potassi	6.7	TM
	129366	BE220806	Hs.184697	Homo sapiens clone 23785 mRNA sequence	8.6	SS,
55		AI686379	Hs.110796	SAR1 protein	1.4	TM
		NM_016039	Hs.110803	CGI-99 protein	2	other
		AF149785	Hs.111126	pituitary tumor-transforming 1 interacti	7.5	other
		AI267700	Hs.317584	ESTs	5.1	other
60		AA204686	Hs.234149	hypothetical protein FLJ20647	10.2	other
60		AA188185	Hs.289043	spindlin	6.8	other
	129513	AW843633	Hs.306163	hypothetical protein AL110115	7.1	SS,
		AF255303	Hs.112227	membrane-associated nucleic acid binding delta-tubulin	2.5 3.2	other other
		AA769221	Hs.270847 Hs.11360	hypothetical protein FLJ14784	7.5	other
65		W01296 AA317841	Hs.7845	hypothetical protein MGC2752	6.8	other
03		AI923097	Hs.11441	chromosome 1 open reading frame 8	2.1	other
		F08282	Hs.278428	progestin induced protein	1.6	other
	120010		. ,0,2, 0,20	L9-2m		

	129587	H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8	other
		BE408300	Hs.301862	postmeiotic segregation increased 2-like	1.4	TM
	129591	N57423	Hs.179898	HSPC055 protein	7.4	other
_	129594	AW403724	Hs.36989	coagulation factor VII (serum prothrombi	9	?
5	129596	AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic sub	1.6	other
	129628	U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	2.2	other
		AD000092	Hs.16488	calreticulin	3.3	other
		NM_015556	Hs.172180	KIAA0440 protein	13.4	other
1.0		U03749		gb:Human chromogranin A (CHGA) gene, pro	14.1	?
10		AW748482	Hs.77873	B7 homolog 3	2.6	other
		Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	7.5	TM
		AA156214	Hs.12152	APMCF1 protein	2	other
		NM_001415	Hs.211539	eukaryotic translation initiation factor	1.7	TM
15		AK001676	Hs.12457	hypothetical protein FLJ10814	1.8	other
15		AA394090	Hs.12460	Homo sapiens clone 23870 mRNA sequence	5.5 1.7	TM ?
		AF052112 AB023148	Hs.12540	lysosomal KIAA0931 protein	1.2	other
		BE565817	Hs.173373 Hs.26498	hypothetical protein FLJ21657	3.1	other
		NM_006590	Hs.12820	SnRNP assembly defective 1 homolog	1.8	other
20		AL049999	Hs.85963	DKFZP564M182 protein	2.3	other
20		Al393237	Hs.129914	runt-related transcription factor 1 (acu	1.7	SS,
		Al222069	Hs.13015	hypothetical protein similar to mouse Dn	2.8	TM
		BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8	other
		AA412195	Hs.13740	ESTs	2.5	other
25		AW753185	Hs.180628	dynamin 1-like	1.8	?
		U09848	Hs.132390	zinc finger protein 36 (KOX 18)	1.3	other
		AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	1.6	other
		AA287325	Hs.14713	ESTs	4.1	other
		S73265	Hs.1473	gastrin-releasing peptide	1.9	other
30	130097	AL046962	Hs.14845	forkhead box O3A	2.8	other
	130100	AL135561	Hs.14891	hypothetical protein FLJ21047	2.3	other
	130111	X53002	Hs.149846	integrin, beta 5	2.3	other
	130112	AA916785	Hs.180610	splicing factor proline/glutamine rich (3	other
	130128	L76937	Hs.150477	Werner syndrome	1.8	other
35	130135	AA311426	Hs.21635	tubulin, gamma 1	6.1	other
		NM_003358	Hs.23703	ESTs, Moderately similar to CEGT_HUMAN C	1.6	other
		D80001	Hs.152629	KIAA0179 protein	1.3	other
		R85367	Hs.51957	splicing factor, arginine/serine-rich 2,	2	other
40		AL035588	Hs.153203	MyoD family inhibitor	3.2	other
40		X79201	Hs.153221	synovial sarcoma, translocated to X chro	5.4	?
		D81983	Hs.322852	GAS2-related on chromosome 22	4.9 1.4	other other
		NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related k tumor suppressing subtransferable candid	2.6	other
		AA479005 AB011121	Hs.154036 Hs.154248	amyotrophic lateral sclerosis 2 (juvenil	6.3	other
45		Z19084	Hs.172210	MUF1 protein	6.2	other
75		AF127577	Hs.155017	nuclear receptor interacting protein 1	2.4	other
		AJ224442	Hs.155020	putative methyltransferase	3.5	TM
		NM_013449	Hs.277401	bromodomain adjacent to zinc finger doma	8.5	other
		AL135301	Hs.8768	hypothetical protein FLJ10849	1.4	other
50		Al077464	Hs.5011	RNA binding motif protein 9	3.3	?
		N89487	Hs.155291	KIAA0005 gene product	1.8	other
	130399	AW374106	Hs.155356	hypothetical protein MGC2840 similar to	3.4	other
		BE385099	Hs.334727	hypothetical protein MGC3017	2.3	other
	130409	NM_001197	Hs.155419	BCL2-interacting killer (apoptosis-induc	2.7	TM
55	130419	AF037448	Hs.155489	NS1-associated protein 1	1.8	other
		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	2.3	other
	130448	BE513202	Hs.15589	PPAR binding protein	4	TM
	130455	D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6	?
CO		BE245851	Hs.180779	H2B histone family, member B	5	other
60		U49844	Hs.77613	ataxia telangiectasia and Rad3 related	4.4	other
	130498	L38951	Hs.180446	karyopherin (importin) beta 1	1.6	SS,TM
	130503	BE208491	Hs.295112	KIAA0618 gene product cartilage oligomeric matrix protein (pse	16.1 6.1	other other
	130511	L32137 AW876523	Hs.1584 Hs.15929	hypothetical protein FLJ12910	2.1	other
65	130520	AA321238	Hs.4310	eukaryotic translation initiation factor	1.5	other
05	130553	AF062649	Hs.252587	pituitary tumor-transforming 1	14.4	?
	130556	Al907018	Hs.15977	Empirically selected from AFFX single pr	4.8	other
	,,,,,,,,,				-	

	130567	AA383092	Hs.1608	replication protein A3 (14kD)	8	other
		AA232119	Hs.16085	putative G-protein coupled receptor	3.4	other
	130574	AF083208	Hs.16178	apoptosis antagonizing transcription fac	1.2	other
_	130598	AL042210	Hs.16493	hypothetical protein DKFZp762N2316; KIAA	1.4	other
5		AA609738	Hs.16525	ESTs	1.5	TM
		AI354355	Hs.16697	down-regulator of transcription 1, TBP-b	1.3	other
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1	TM
		AA383439	Hs.16758	Spir-1 protein	15.9	other
10		BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9	other
10		AL048842	Hs.194019	attractin	1.5 5.4	other other
		AA442233	Hs.17731	hypothetical protein FLJ12892	5.4	other
		AA652501	Hs.13561	hypothetical protein MGC4692 ESTs	2	other
		R68537 AJ271881	Hs.17962 Hs.279762	bromodomain-containing 7	1.8	TM
15		AI348274	Hs.18212	DNA segment on chromosome X (unique) 987	2	TM
13		AB007920	Hs.18586	KIAA0451 gene product	3.8	?
		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	3.2	?
		AF052105	Hs.18879	chromosome 12 open reading frame	1.4	other
		AL036067	Hs.18925	protein x 0001	5.7	other
20		AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	?
		AK000355	Hs.8899	sirtuin (silent mating type information	1.6	other
		J05068	Hs.2012	transcobalamin I (vitamin B12 binding pr	15.7	SS,
	130841	AL157468	Hs.325825	Homo sapiens cDNA FLJ20848 fis, clone AD	2.8	other
	130843	AA447492	Hs.20183	ESTs, Weakly similar to AF164793 1 prote	1.5	other
25	130844	U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.5	other
	130855	AJ243706	Hs.143323	putative DNA/chromatin binding motif	1.7	other
		NM_016578	Hs.20509	HBV pX associated protein-8	1.9	other
		NM_003416	Hs.2076	zinc finger protein 7 (KOX 4, clone HF.1	1.4	other
20		BE514434	Hs.20830	kinesin-like 2	2.1	TM other
30		AL120837	Hs.20993	high-glucose-regulated protein 8	2.5 1.7	other
		AB033078	Hs.186613	sphingosine-1-phosphate lyase 1 DnaJ (Hsp40) homolog, subfamily A, membe	1.8	other
		BE409769 N79110	Hs.21189 Hs.21276	collagen, type IV, alpha 3 (Goodpasture	2.3	TM
		BE382657	Hs.21486	signal transducer and activator of trans	5.4	other
35		N39842	Hs.301444	KIAA1673	2.2	SS,
55		T97401	Hs.21929	ESTs	1.6	other
		AV658308	Hs.2210	thyroid hormone receptor interactor 3	1.6	?
		Al879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP),	1.2	other
		Al826288	Hs.171637	hypothetical protein MGC2628	1.6	other
40		AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	7.4	?
	131060	AA194422	Hs.22564	myosin VI	5.1	other
	131070	N53344	Hs.22607	ESTs	7.1	other
		AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	2.1	TM
4.5		AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7.1	other
45		NM_006540	Hs.29131	nuclear receptor coactivator 2	1.9	?
		BE280074	Hs.23960	cyclin B1	5.8	? other
		AW138839	Hs.24210	ESTs	2 7.1	TM
		AA885699	Hs.24332	CGI-26 protein thyroid hormone receptor-associated prot	7.1	?
50		H62087 N47468	Hs.31659 Hs.59757	zinc finger protein 281	2.9	other
50		D89053	Hs.268012	fatty-acid-Coenzyme A ligase, long-chain	3.5	other
		AW383256	Hs.24752	spectrin SH3 domain binding protein 1	2.8	?
		AL080080	Hs.24766	thioredoxin domain-containing	2.8	SS,TM
		AL043100	Hs.326190	fatty acid amide hydrolase	5.6	other
55		AA251716	Hs.25227	ESTs	5.8	other
		X80038	Hs.339713	Homo sapiens clone F19374 APO E-C2 gene	1.3	other
	131305	AV656017	Hs.184325	CGI-76 protein	5	?
		AA505691	Hs.145696	splicing factor (CC1.3)	1.8	TM
		AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
60		AW293165	Hs.143134	ESTs	5.4	other
		BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.3	other
		BE259110	Hs.279836	HSPC166 protein	2.2	other 2
		NM_012247	Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human	seien 1.4	∠ other
65		AL046302	Hs.26750	hypothetical protein FLJ21908 hypothetical protein FLJ20392	1.7	other
65	131400	BE297567 AA992841	Hs.27047 Hs.27263	KIAA1458 protein	2	other
		AA992641 AV661958	Hs.8207	GK001 protein	2.6	other
	13 130 1	714001900	110.0201	and protein		

	404844				•	
		AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fis, clone C	2	other
		AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6	TM
	131532	BE268278	Hs.28393	hypothetical protein MGC2592	7.4	other
_	131543	AW966881	Hs.41639	programmed cell death 2	2.2	other
5	131544	AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1	other
	131562	NM_003512	Hs.28777	H2A histone family, member L	1.7	other
		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	5.2	other
		AL389951	Hs.271623	nucleoporin 50kD	5	other
		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (fr	1.8	other
10		R78195	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HE	1.3	other
10		AB037791	Hs.29716	hypothetical protein FLJ10980	2.2	TM
			Hs.30026	HSPC182 protein	3	other
		AW410601		•	1.3	
		AW960597	Hs.30164	ESTs		other
1.5		AI218918	Hs.30209	KIAA0854 protein	2.8	other
15		X52486	Hs.3041	uracil-DNA glycosylase 2	2.8	other
		BE559681	Hs.30736	KIAA0124 protein	5.6	?
		AA642831	Hs.31016	putative DNA binding protein	2.9	?
	131722	D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4	other
	131737	AK001641	Hs.31323	inhibitor of kappa light polypeptide gen	3.9	?
20	131763	A1878932	Hs.317	topoisomerase (DNA) I	3.4	other
	131772	AA382590	Hs.170980	KIAA0948 protein	25.5	other
	131787	D87077	Hs.196275	KIAA0240 protein	2.4	SS,
		AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fis, clone NT	8	TM
		BE501849	Hs.32317	high-mobility group 20B	1.5	other
25		X86098	Hs.301449	adenovirus 5 E1A binding protein	4.2	other
		U20536	Hs.3280	caspase 6, apoptosis-related cysteine pr	4.3	other
		U28838	Hs.32935	TATA box binding protein (TBP)-associate	3.5	other
		Al251317	Hs.33184	ESTs	5.2	TM
					5.9	other
30		AA083764	Hs.6101	hypothetical protein MGC3178	13.7	other
30		BE502341	Hs.3402	ESTS		
		AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	8.7	other
		AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	other
•		AA179298	Hs.3439	stomatin-like 2	11.3	other
2.5		AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	1.7	SS,
35	131916	AA025976	Hs.34569	ESTs	5.2	TM
	131925	AF151048	Hs.183180	anaphase promoting complex subunit 11 (y	2.8	 other
	131929	BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HE	5.4	TM
	131941	BE252983	Hs.35086	ubiquitin specific protease 1	2.4	other
	131950	AA355113	Hs.35380	x 001 protein	1.5	?
40	131962	AK000046	Hs.267448	hypothetical protein FLJ20039	2.3	other
		W79283	Hs.35962	ESTs	1.4	other
		BE567100	Hs.154938	hypothetical protein MDS025	3.5	other
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	6.6	TM
		AA503020	Hs.36563	hypothetical protein FLJ22418	2.4	?
45		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1	2.2	SS,TM
1.5		H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, p	3.3	TM
		BE266155	Hs.3832	clathrin-associated protein AP47	1.5	other
				karyopherin alpha 3 (importin alpha 4)	3.7	other
		NM_002267	Hs.3886 Hs.3991		1.5	other
50		BE171921		ESTs		
30		AV646076	Hs.39959	ESTs	5.8	TM
		AW960474	Hs.40289	ESTs	1.7	other
		AA857025	Hs.8878	kinesin-like 1	3.4	other
		NM_004460	Hs.418	fibroblast activation protein, alpha	14.7	SS,
		R42432	Hs.4212	ESTs	2.2	other
55	132207	BE206939	Hs.42287	E2F transcription factor 6	1.5	other
	132235	AV658411	Hs.42656	KIAA1681 protein	5.7	other
	132252	Al566004	Hs.141269	Homo sapiens cDNA: FLJ21550 fis, clone C	2.1	other
	132266	AA301228	Hs.43299	hypothetical protein FLJ12890	1.5	other
	132273	AA227710	Hs.43658	DKFZP586L151 protein	10	other
60	132276	AA653507	Hs.285711	hypothetical protein FLJ13089	2	other
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2	other
		AB023191	Hs.44131	KIAA0974 protein	2	other
		NM_015986	Hs.7120	cytokine receptor-like molecule 9	6.6	SS,
		AW405882	Hs.44205	cortistatin	3.8	other
65		N37065	Hs.44856	hypothetical protein FLJ12116	1.5	other
0.5		AW572805	Hs.46645	ESTs	28.3	?
		AF155582	Hs.46744	core1 UDP-galactose:N-acetylgalactosamin	1.9	other
	132314	AI 10000Z	1 10.70/ 44	oute i obi -galactoschi acctylgalactosamili	1.0	Jaioi

	132376	Al279892	Hs.46801	sorting nexin 14	2	?
		AA312135	Hs.46967	HSPCO34 protein	6.1	?
		AL135094	Hs.47334	hypothetical protein FLJ14495	1.7	other
	132450	AA100012	Hs.48827	hypothetical protein FLJ12085	8.6	other
5	132452	AW973521	Hs.247324	mitochondrial ribosomal protein S14	5.3	other
	132456	AB011084	Hs.48924	KIAA0512 gene product; ALEX2	1.5	other
	132470	Al224456	Hs.4934	H.sapiens polyA site DNA	2	other
	132484	X16660	Hs.119007	RAB4, member RAS oncogene family	2.9	SS,
10		AW885606	Hs.5064	ESTs	2.2	other
10		AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. c	1.7	other
		AA454132	Hs.5080	mitochondrial ribosomal protein L16	7.2	TM
		BE388673	Hs.5086	hypothetical protein MGC10433	2.2	SS,
		BE568452	Hs.5101	protein regulator of cytokinesis 1	2.2	other
15		AW631437	Hs.5184	TH1 drosophila homolog	14 1.9	? other
15		AK001484	Hs.5298	CGI-45 protein	2.6	TM
		AA345547	Hs.53263	hypothetical protein FLJ13287	2.0	other
		H12751	Hs.5327	PRO1914 protein hypothetical protein PRO1855	3.1	other
		BE262677 Al796870	Hs.283558 Hs.54277	DNA segment on chromosome X (unique) 992	12.4	TM
20		AB018319	Hs.5460	KIAA0776 protein	2.8	SS,
20		AW191962	Hs.249239	collagen, type VIII, alpha 2	3	other
		F11875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT	1.8	other
		NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	3.7	other
		AI142265	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	TM
25		Al189075	Hs.301872	hypothetical protein MGC4840	5.9	other
		AA010233	Hs.55921	glutamyl-prolyl-tRNA synthetase	8.7	other
		AA125985	Hs.56145	thymosin, beta, identified in neuroblast	3.6	other
	132771	Y10275	Hs.56407	phosphoserine phosphatase	2.8	TM
	132773	AA459713	Hs.295901	KIAA0493 protein	14.6	other
30	132784	AI142133	Hs.56845	GDP dissociation inhibitor 2	1.7	other
	132798	AI026701	Hs.5716	KIAA0310 gene product	2.5	other
	132807	U07418	Hs.57301	mutL (E. coli) homolog 1 (colon cancer,	1.4	other
		AB007944	Hs.5737	KIAA0475 gene product	4.3	SS,
25		BE313625	Hs.57435	solute carrier family 11 (proton-coupled	2.8	other
35		Al815189	Hs.57475	sex comb on midleg homolog 1	1.6	other
		N27852	Hs.57553	tousled-like kinase 2	1.4 5.4	other other
		AJ251595	Hs.169610	CD44 antigen (homing function and Indian	5.4 6.1	?
		U78525	Hs.57783	eukaryotic translation initiation factor Homo sapiens clone PP1596 unknown mRNA	7.2	other
40		NM_016154	Hs.279771 Hs.5811	chromosome 21 open reading frame 59	2.9	other
40		F12200 U09716	Hs.287912	lectin, mannose-binding, 1	6.1	other
		AW963217	Hs.203961	ESTs, Moderately similar to AF116721 89	1.8	other
		AW007683	Hs.58598	KIAA1266 protein	2.2	other
		NM_004850	Hs.58617	Rho-associated, coiled-coil containing p	5	TM
45		BE267143	Hs.59271	U2(RNU2) small nuclear RNA auxillary fac	2.7	?
		AW503667	Hs.59545	ring finger protein 15	5.4	?
		Al936442	Hs.59838	hypothetical protein FLJ10808	3.2	other
	132912	AW732760	Hs.167578	Homo sapiens cDNA FLJ11095 fis, clone PL	1.4	other
	132913	W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PL	3	other
50	132940	T79136	Hs.127243	Homo sapiens mRNA for KIAA1724 protein,	10.3	other
		AA554458	Hs.197751	KIAA0666 protein	2.1	SS,
		AI658580	Hs.61426	Homo sapiens mesenchymal stem cell prote	1.3	other
		AA576635	Hs.6153	CGI-48 protein	4.9	other TM
<i></i>		AA034365	Hs.288924	Homo sapiens cDNA FLJ11392 fis, clone HE	3.6 13.1	other
55		AA035446	Hs.323277	ESTs PNA hinding motif protoin 2	1.3	other
		AA093322	Hs.301404	RNA binding motif protein 3 ESTs	2.3	?
		AA040696 AA112748	Hs.62016 Hs.279905	clone HQ0310 PRO0310p1	17.1	other
		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	1.9	other
60		AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	5	TM
UU		AW500374	Hs.64056	PRO0149 protein	6.1	other
		BE247441	Hs.6430	protein with polyglutamine repeat; calci	1.5	TM
		AK001628	Hs.64691	KIAA0483 protein	1.4	other
		AA808177	Hs.65228	ESTs	5.6	other
65		AF198620	Hs.65648	RNA binding motif protein 8A	1.9	other
•	133145	H94227	Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA,	4.8	?
	133152	Z11695	Hs.324473	mitogen-activated protein kinase 1	5	other

		AA431620	Hs.324178	hypothetical protein MGC2745	2.7	other		
		AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	9.3	other		
		X97795	Hs.66718	RAD54 (S.cerevisiae)-like	4.5	TM		
_		A1801777	Hs.6774	ESTs	5.5	TM		
5		AW954569	Hs.296287	Homo sapiens, Similar to bromodomain-con	2.7	other		
		A1492924	Hs.6831	golgi phosphoprotein 1	1.7	? other		
		AI567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA,	1.3	other		
		AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	12.2 1.2	other other		
10		BE297855	Hs.69855	NRAS-related gene	1.7	TM		
10		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	11.1	?		
		T79526	Hs.179516	integral type I protein Kruppel-like factor 13	2.9	other		
		AL390127	Hs.7104 Hs.71475	acid cluster protein 33	2.5	?		
		BE257758	Hs.71816	v-akt murine thymoma viral oncogene homo	1.5	other		
15		Al016521 AA292811	Hs.72050	non-metastatic cells 5, protein expresse	2.1	other		
13		AF231919	Hs.18759	KIAA0539 gene product	1.3	other		
		AF245505	Hs.72157	DKFZP564I1922 protein	2.2	other		
		Al950382	Hs.72660	phosphatidylserine receptor	5.7	TM		
		AW103364	Hs.727	inhibin, beta A (activin A, activin AB a	25.5	other		
20		AA305127	Hs.237225	hypothetical protein HT023	3.3	other		
		AL031591	Hs.7370	phosphotidylinositol transfer protein, b	1.6	other		
		NM_002759	Hs.274382	protein kinase, interferon-inducible dou	4.1	other		
		Al659306	Hs.73826	protein tyrosine phosphatase, non-recept	1.5	other		
		AW964804	Hs.74280	hypothetical protein FLJ22237	6.3	TM		
25		W45623	Hs.74571	ADP-ribosylation factor 1	4	?		
	133543	AU077073	Hs.108327	damage-specific DNA binding protein 1 (1	1.8	?		
		AU077050	Hs.75066	translin	1.5	other		
	133579	X75346	Hs.75074	mitogen-activated protein kinase-activat	3.5	TM		
	133582	BE391579	Hs.75087	Fas-activated serine/threonine kinase	6.8	TM		
30	133594	AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	2.6	TM		
	133595	AA393273	Hs.75133	transcription factor 6-like 1 (mitochond	1.4	other		
	133599	NM_002885	Hs.75151	RAP1, GTPase activating protein 1	8.1	other		
	133621	NM_004893	Hs.75258	H2A histone family, member Y	13.5	other		
0.5		NM_002047	Hs.75280	glycyl-tRNA synthetase	2.2	other		
35		NM_000401	Hs.75334	exostoses (multiple) 2	1.8	other	,	
		U25849	Hs.75393	acid phosphatase 1, soluble	2	other	,	
		AV661185	Hs.75574	mitochondrial ribosomal protein L19	2.8	other		
		L27841	Hs.75737	pericentriolar material 1	6.8 2.5	other other		
40		AW969976	Hs.279009	matrix Gla protein		apiens, Similar to likely ortholog	3.1	ТМ
40		AW402048.co		Hs.334787	1.4	?	J. I	1 141
		T52946	Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	5.4	t other		
		BE271766	Hs.181357 Hs.75929	laminin receptor 1 (67kD, ribosomal prot cadherin 11, type 2, OB-cadherin (osteob	5	other		
		M62194 AA557660	Hs.76152	decorin	3.8	other		
45		AL133921	Hs.76272	retinoblastoma-binding protein 2	3.1	?		
73		D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7	?		
		AW797468	Hs.285013	putative human HLA class II associated p	2.4	other		
		AA147026	Hs.76704	ESTs	2.5	other		
		AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5	other		
50		AW340125	Hs.76989	KIAA0097 gene product	2.5	?		
•		AB012193	Hs.183874	cullin 4A	2.1	other		
		U30825	Hs.77608	splicing factor, arginine/serine-rich 9	2.8	TM		
	133924	D86326	Hs.325948	vesicle docking protein p115	1.8	SS,		
		NM_006306	Hs.211602	SMC1 (structural maintenance of chromoso	2	?		
55	133936	L17128	Hs.77719	gamma-glutamyl carboxylase	2.6	other		
		BE244332	Hs.77770	adaptor-related protein complex 3, mu 2	2.9	other		
		X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	10.4	other		
		Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	1.9	other		
		AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6	SS,		
60		Al824113	Hs.78281	regulator of G-protein signalling 12	13	other		
		AB016092	Hs.197114	RNA binding protein; AT-rich element bin	8.8	other		
		D31764	Hs.278569	sorting nexin 17	1.5	SS,		
		NM_003590	Hs.78946	cullin 3	8.3 2.7	other other		
65		U41060	Hs.79136	LIV-1 protein, estrogen regulated KIAA0255 gene product	4.2	other		
65		NM_014742 H86504	Hs.79305 Hs.173328	protein phosphatase 2, regulatory subuni	1.7	other		
		BE559598	Hs.173320 Hs.197803	KIAA0160 protein	2.6	other		
				to a retachteren.		* * * *		

13420							
134219 NM_000402		134206	AF107463	Hs.79968	splicing factor 30, survival of motor ne	1.3	other
134224 BESJ00078 Hs.80449 Hs.36828 134340 AW502655 Hs.36826 AW502691 Hs.3682 AW502650 Hs.3682 AW502691 Hs.36							other
5 134392 AlisoBozeri His B1234 Immunoglobulin superfamily, member 3 1.3 TM 134305 U81337 Hs 81424 Homo sagines coDNs: FLJ21927 fis, clone H 1.6 TM 10 13428 AW090389 Hs 81800 Hs 17946 For Optoble (Incident) 5.3 7 10 13428 AW090389 Hs 81800 Hs 17946 Hs						10.3	SS,
134301 AW602805	_	134275	A1878910	Hs.3688	cisplatin resistance-associated overexpr		
134306 Usr1397	5						
134324 AB0202023 Ha 179846 Ha 1848 Ha 1840 Table 2 T							
134328 AW903838							
134329 N92038					Alandraitia cultata proteoglycon 2 (yero		
134337 NM, 004922	10						
134348 AW291946	10						
134367 AA39449							
134376 X06560							
134379 AV382124 Hs.322131 hypothetical protein McG3222 5.9 other characteristics of the control						5.5	other
134391 AA417383	15	134379	AW362124			5.9	TM
134395 AA456539				Hs.8254	Homo sapiens, Similar to tumor different		other
134405 AV0657903		134391	AA417383	Hs.82582			
20							
134412 AUD7196	20						
13442 244190	20						
134442							
25 134446 AA112036 Hs.83418							
134470 X54942 Hs.83428 nuclear factor of kappa light polypeptid 6.7 other							
134470 X54942 Hs.83758 CDC28 protein kinase 2 2.4 other 134480 NM_005000 Hs.83916 Empirically selected from AFFX single pr 6.3 ? other 134485 X82153 Hs.83942 cathepsin K (pycnodysostosis) 1.9 other 134488 AW246273 Hs.84131 threonyl-(RNA synthetase 1.8 other 134520 MS414179 Hs.273357 hypothetical protein FLJ10709 1.4 other 134529 AW414179 Hs.848 KfS06-binding protein 4 (59kD) 2.8 ?	25						
134485 NM_005000	20						
134498						6.3	?
134513						1.9	other
134516 AK001571				Hs.84131	threonyl-tRNA synthetase		other
134520 BE091005	30	134513	AA425473	Hs.84429			
134529 AW411479							
34577 BE244323 Hs.85951 exportin, iRNA (nuclear export receptor 1.7 other 134652 AA927177 Hs.86041 CGG triplet repeat blinding protein 1 1.7 TM 134612 AW068223 Hs.171581 ubiquitin C-terminal hydrolase UCH37 2.1 other 134624 AF035119 Hs.8700 deleted in liver cancer 1 1.3 other 134654 AK001741 Hs.8739 hypothetical protein FLJ10879 2.3 other 134666 BE391929 Hs.8752 transmembrane protein 4 4 other 134686 BE391929 Hs.88551 arylsulfatase A 6.2 other 134705 BE161887 Hs.88599 anaphase-promoting complex subunit 10 1.3 SS, 134714 Y14768 Hs.8999 Hs.899232 chromobox homolog 5 (Drosophila HP1 alph 3.2 other 134722 AF129536 Hs.284266 E-box only protein 6 2.5 other 134762 AF129536 Hs.89497 Hs.89476 Lamin B1 6.1 other 134850 AI701162 Hs.90207 Hs.90207 hypothetical protein MGC11138 9.1 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134975 AW0859809 Hs.6975 Hs.90606 15 kDa selenoprotein 2.7 other 134971 Al097346 Hs.91773 Hs.92186 Hs.92291 Hs.90207 Hs.90164 Hs.90207 hypothetical protein MGC11138 9.1 other 134971 Al097346 Hs.99291 Hs.90606 15 kDa selenoprotein 2.7 other 134971 Al097346 Hs.922080 Hs							
35							
134612 AW068223	25						
134624 AF035119	33						
134632 X78520 Hs.174139 chloride channel 3 134654 AK001741 Hs.8739 hypothetical protein FLJ10879 2.3 other 134668 BE391929 Hs.8752 transmembrane protein 4 4 other 134687 U62317 Hs.88251 arylsulfatase A 6.2 other 134705 BE161887 Hs.8879 anaphase-promoting complex subunit 10 134714 Y14768 Hs.890 lysosomal 134712 AF129536 Hs.89232 chromobox homolog 5 (Drosophila HP1 alph 134724 AF129536 Hs.89426 F-box only protein 6 134746 X07871 Hs.89476 CD2 antigen (p50), sheep red blood cell 134790 BE002798 Hs.89497 lamin B1 134791 BE002798 Hs.287850 integral membrane protein 1 134830 AI701162 Hs.90207 hypothetical protein complex 1, gamma 134880 AI879195 Hs.90280 S-aminolimidazole-4-carboxamide ribonucle 134830 AI879195 Hs.90280 S-aminolimidazole-4-carboxamide ribonucle 134925 AW885909 Hs.6975 PRO1073 protein 134975 R50333 Hs.92186 Leman colled-coil protein 135011 AB037835 Hs.9291 KIAA1414 protein 135021 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 135077 AW503733 Hs.92146 KIAA1414 protein 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2 cinc finger protein 202 2 cinc finger protein 202 3 other 4 other 4 other 4 other 5 c. 2 other 5 c. 3 other 5 c. 5							
134654 AK001741 Hs.8739 hypothetical protein FLJ10879							
134666 BE391929							
134687 U62317	40					4	other
134705 BE161887 Hs.88799 anaphase-promoting complex subunit 10 1.3 SS, 134714 Y14768 Hs.890 lysosomal 7.2 ? 134719 AA852985 Hs.89232 chromobox homolog 5 (Drosophila HP1 alph 3.2 other 134722 AF129536 Hs.284226 F-box only protein 6 2.5 other 134746 X07871 Hs.89476 CD2 antigen (p50), sheep red blood cell 5 other 134751 AW630803 Hs.89497 lamin B1 6.1 other 134790 BE002798 Hs.287850 integral membrane protein 1 5.6 TM 134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 13480 Al879195 Hs.90606 15 kDa selenoprotein 2.7 other 134925 AW885909 Hs.6975 PRO1073 protein protein phosphatase 2 (formerly 2A), cat 4.9 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92801 KIAA1414 protein 2.6 TM 135022 NM 000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.173685 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135033 AB036063 Hs.9444 KIAA1488 protein 1.8 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135095 AA081258 Hs.132390 zinc finger protein 202 1.5 TM 135181 BE250865 Hs.279529 px19-like protein 14.9 ?						6.2	other
134714 Y14768 Hs.890 lysosomal 7.2 ? 134719 AA852985 Hs.89232 chromobox homolog 5 (Drosophila HP1 alph 3.2 other 134722 AF129536 Hs.284226 F-box only protein 6 2.5 other 134746 X07871 Hs.89476 CD2 antigen (p50), sheep red blood cell 5 other 134751 AW630803 Hs.89497 lamin B1 6.1 other 134790 BE002798 Hs.287850 integral membrane protein 1 5.6 TM adaptor-related protein complex 1, gamma 5.3 other 134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134880 Al879195 Hs.90606 15 kDa selenoprotein 2.7 other 134925 AW885909 Hs.6975 PRO1073 protein phosphatase 2 (formerly 2A), cat 4.9 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 2.6 TM 135083 AB036063 Hs.94262 pS3-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.279529 px19-like protein 14.9 ?		134692	NM_003474	Hs.8850			
45 134719 AA852985 Hs.89232 chromobox homolog 5 (Drosophila HP1 alph 3.2 other 134722 AF129536 Hs.284226 F-box only protein 6 2.5 other 134746 X07871 Hs.89476 CD2 antigen (p50), sheep red blood cell 5 other 134751 AW630803 Hs.89476 Lamin B1 6.1 other 134790 BE002798 Hs.287850 integral membrane protein 1 5.6 TM 50 134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other 134853 BE268326 Hs.90207 hypothetical protein MGC11138 9.1 other 134880 Al879195 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134925 AW885909 Hs.6975 PRO1073 protein 1.5 other 134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6		134705	BE161887	Hs.88799	anaphase-promoting complex subunit 10		
134722 AF129536							
134746 X07871 Hs.89476 CD2 antigen (p50), sheep red blood cell 5 other 134751 AW630803 Hs.89497 lamin B1 6.1 other 134790 BE002798 Hs.287850 integral membrane protein 1 5.6 TM 5.0 134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other 134850 Al701162 Hs.90207 hypothetical protein MGC11138 9.1 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134880 Al879195 Hs.90606 15 kDa selenoprotein 2.7 other 134925 AW885909 Hs.6975 PRO1073 protein 2.6 TM 134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? hypothetical protein FLJ12619 1.4 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135095 AR03155 Hs.93240 JM27 protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.279529 px19-like protein 14.9 ?	45						
134751 AW630803 Hs.89497 lamin B1 6.1 other 134790 BE002798 Hs.287850 integral membrane protein 1 5.6 TM 134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134838 Al879195 Hs.90806 15 kDa selenoprotein 2.7 other 134925 AW885909 Hs.6975 PRO1073 protein protein protein protein young phosphatase 2 (formerly 2A), cat 4.9 other 134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92186 Leman coiled-coil protein 2.6 TM 135022 NM 000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.4 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135095 AA081258 Hs.132390 jM27 protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.279529 px19-like protein 14.9 ?							
134790 BE002798 Hs.287850 integral membrane protein 1 5.6 TM 134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134825 AW885909 Hs.6975 PRO1073 protein 1.5 other 134925 AW885909 Hs.6975 PRO1073 protein phosphatase 2 (formerly 2A), cat 4.9 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 2.6 TM 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.91783 protein phosphate dehydrogenase 2 (mi 1.6 ? hypothetical protein FLJ12619 1.4 other 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 2504 S181 BE250865 Hs.279529 px19-like protein 14.9 ?							
50 134834 AW451370 Hs.8991 adaptor-related protein complex 1, gamma 5.3 other 134850 Al701162 Hs.90207 hypothetical protein MGC11138 9.1 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134880 Al879195 Hs.90606 15 kDa selenoprotein 2.7 other 134925 AW885909 Hs.6975 PRO1073 protein 1.5 other 134975 AW901361 Hs.91773 protein phosphatase 2 (formerly 2A), cat 4.9 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 60 135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.4 other 135093 AF027219 Hs.9443 zinc finger protein 202 1.5							
134850 AI701162 Hs.90207 hypothetical protein MGC11138 9.1 other 134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other 134880 AI879195 Hs.90606 15 kDa selenoprotein 2.7 other 134925 AW885909 Hs.6975 PRO1073 protein 1.5 other 134971 Al097346 Hs.286049 protein phosphatase 2 (formerly 2A), cat 4.9 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? hypothetical protein FLJ12619 1.4 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.279529 px19-like protein 14.9 ?	50						
134853 BE268326 Hs.90280 5-aminoimidazole-4-carboxamide ribonucle 2.4 other other 134880 Al879195 Hs.6975 PRO1073 protein 1.5 other 134925 AW885909 Hs.6975 PRO1073 protein 1.5 other 134975 R50333 Hs.92186 Hs.286049 phosphoserine aminotransferase 2 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? hypothetical protein FLJ12619 1.4 other 135083 AB036063 Hs.94164 KIAA1488 protein 1.8 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135083 Al093155 Hs.95420 JM27 protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.279529 px19-like protein 14.9 ?	50						
134880 Al879195 Hs.90606 15 kDa selenoprotein 2.7 other 134925 AW885909 Hs.6975 PRO1073 protein 1.5 other 134955 AW8401361 Hs.91773 protein phosphatase 2 (formerly 2A), cat 4.9 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.4 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135086 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.97829 px19-like protein 14.9 ?							
55 134925 AW885909 Hs.6975 AW401361 Hs.91773 PRO1073 protein protein phosphatase 2 (formerly 2A), cat 4.9 other phosphatase 2 (formerly 2A), cat 4.1 other ph							other
55 134955 AW401361 Hs.91773 Hs.286049 Phosphatase 2 (formerly 2A), cat 134971 Al097346 Hs.286049 Phosphoserine aminotransferase 2 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM 000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.4 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135083 AB036063 Hs.94262 ps.316042 protein 202 1.5 TM 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.279529 px19-like protein 14.9 ? 65 135181 BE250865 Hs.279529 Hs.279529 px19-like protein 14.9 ?					PRO1073 protein	1.5	other
134971 Al097346 Hs.286049 phosphoserine aminotransferase 2 other 134975 R50333 Hs.92186 Leman coiled-coil protein 2.6 TM 135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.4 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135181 BE250865 Hs.279529 px19-like protein 14.9 ?	55			Hs.91773			
135011 AB037835 Hs.92991 KIAA1414 protein 1.4 ? 135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.93201 Hs.9414 KIAA1488 protein 1.8 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?		134971	A1097346				
135022 NM_000408 Hs.93201 glycerol-3-phosphate dehydrogenase 2 (mi 1.6 ? 135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.4 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?							
60 135032 AW301984 Hs.173685 hypothetical protein FLJ12619 1.4 other 135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?							
135077 AW503733 Hs.9414 KIAA1488 protein 1.8 other 135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?	CO						
135083 AB036063 Hs.94262 p53-inducible ribonucleotide reductase s 2.5 other 135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?	60						
135095 AF027219 Hs.9443 zinc finger protein 202 1.5 TM 135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?							
135096 AA081258 Hs.132390 zinc finger protein 36 (KOX 18) 2.1 other 65 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?							
65 135153 Al093155 Hs.95420 JM27 protein 4.4 ? 135181 BE250865 Hs.279529 px19-like protein 14.9 ?							
135181 BE250865 Hs.279529 px19-like protein 14.9 ?	65				JM27 protein		
100 111	00	135181	BE250865			14.9	
				Hs.96247	translin-associated factor X	1.3	other

	135207	N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7	other
		T78802	Hs.96560	hypothetical protein FLJ11656	6.2	other
	135243	BE463721	Hs.97101	putative G protein-coupled receptor	2.8	TM
_		Al028767	Hs.262603	ESTs	12.2	TM
5		AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	7.7	TM
		Al088775	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	other
		AA448460	Hs.112017	GE36 gene	4.2 1.2	SS, other
		AA150320	Hs.9800	protein kinase Njmu-R1 ESTs	4.9	other
10		Al090838 Al743770	Hs.98006 Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.9	?
10		Al652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3	TM
		AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.8	?
		AA373452	Hs.167700	Homo sapiens cDNA FLJ10174 fis, clone HE	8.1	other
	-	U05237	Hs.99872	fetal Alzheimer antigen	1.9	other
15	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	13.9	TM
	302256	AA857131	Hs.171595	HIV TAT specific factor 1 *	1.6	other
	302276	AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.3	other
		AW592789	Hs.279474	HSPC070 protein	2.2	TM
20		AK000714	Hs.109441	MSTP033 protein	1.4	SS,
20		R43191	Hs.101248	Homo sapiens clone IMAGE:32553, mRNA seq	5.2 2.3	other ?
		AA808229	Hs.167771	ESTs ZW10 interactor	2.9	?
		NM_007057 Al268997	Hs.42650 Hs.197289	rab3 GTPase-activating protein, non-cata	2.3	other
		AA902256	Hs.78979	Golgi apparatus protein 1	5.6	SS,
25		N24236	Hs.179662	nucleosome assembly protein 1-like 1	1.4	?
220		AF118083	Hs.29494	PRO1912 protein	1.3	other
		BE041451	Hs.177507	hypothetical protein	2.9	SS,
		AF292100	Hs.104613	RP42 homolog	1.6	other
	407827	BE278431	Hs.40323	BUB3 (budding uninhibited by benzimidazo	1.8	other
30		AL034548	Hs.43627	SRY (sex determining region Y)-box 22	1.6	other
		A1580090	Hs.48295	RNA helicase family	6.2	other
		R73727	Hs.101617	ESTs, Weakly similar to T32527 hypotheti	5.7	other
		H19886	11- 75470	gb:yn57a05.r1 Soares adult brain N2b5HB5	2.7 2.6	other ?
35		AB000115	Hs.75470	hypothetical protein, expressed in osteo	2.4	r TM
55		Al267592 AW304454	Hs.75761 Hs.77495	SFRS protein kinase 1 UBX domain-containing 1	2.4	other
		AW819158	Hs.289044	Homo sapiens cDNA FLJ12048 fis, clone	2.3	other
		AA381133	Hs.80684	high-mobility group (nonhistone chromoso	4.2	TM
		R57256	Hs.82037	TATA box binding protein (TBP)-associate	23.6	other
40	418283	S79895	Hs.83942	cathepsin K (pycnodysostosis)	5.8	other
	418467	NM_006910	Hs.85273	retinoblastoma-binding protein 6	1.3	other
		U72937	Hs.96264	alpha thalassemia/mental retardation syn	1.6	?
		U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.3	?
15		AA463798	Hs.102696	MCT-1 protein	1.6 3.5	? other
45		AF172066	Hs.106346	retinoic acid repressible protein	5.5 5	other
		AW891965 AI252640	Hs.279789 Hs.110364	histone deacetylase 3 peptidylprolyl isomerase C (cyclophilin	3.1	TM
		AA302744	Hs.104518	ESTs	1.9	TM
		NM_014320	Hs.111029	putative heme-binding protein	2.4	other
50		AF165883	Hs.298229	prefoldin 2	4.2	?
		W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7.1	?
		AF041259	Hs.155040	zinc finger protein 217	2.3	other
	425284	AF155568	Hs.155489	NS1-associated protein 1	3.5	other
		BE304680	Hs.169531	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.9	?
55		AW183765	Hs.182238	GW128 protein	7.6	?
		AW500533	Hs.11482	splicing factor, arginine/serine-rich 11	1.7 2.4	other other
		AB001636	Hs.5683 Hs.6216	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep Homo sapiens hepatocellular carcinoma-as	3.8	other
		AK001333 F13386	Hs.7888	Homo sapiens clone 23736 mRNA sequence	5.6	other
60		AF167572	Hs.12912	skb1 (S. pombe) homolog	2	TM
00		AA151520	Hs.334822	hypothetical protein MGC4485	7.6	other
		A1017574	Hs.17409	cysteine-rich protein 1 (intestinal)	2.2	other
		BE620592	Hs.71190	ESTs, Weakly similar to S16506 hypotheti	2.9	other
		NM_003677	Hs.22393	density-regulated protein	1.8	other
65		W68520	Hs.331328	intermediate filament protein syncoilin	5.9	other
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.7	other
	450703	AA011202	Hs.184771	nuclear factor I/C (CCAAT-binding transc	1.4	other

	450404 N70000	Un 100106	transariation factor	4.8	?
	452461 N78223	Hs.108106	transcription factor	2.9	other
	452511 BE408178	Hs.285165	Homo sapiens cDNA FLJ20845 fis, clone AD		
	453157 AF077036	Hs.31989	DKFZP586G1722 protein	12.1	SS,TM
	453658 BE541906	Hs.87819	Homo sapiens, clone MGC:2492, mRNA, comp	4.8	other
5	100685 AA328229	Hs.184582	ribosomal protein L24	1.8	TM
	100690 AA383256	Hs.1657	estrogen receptor 1	1.6	other
	100833 AF135168	Hs.108802	N-ethylmaleimide-sensitive factor	1.3	other
	100850 AA836472	Hs.297939	cathepsin B	1.7	?
	101161 NM_006262	Hs.37044	peripherin	16.9	other
10	102481 U50360		gb:Human calcium, calmodulin-dependent p	3.2	other
	102831 AA262170	Hs.80917	adaptor-related protein complex 3, sigma	2	?
	103549 BE270465	Hs.78793	protein kinase C, zeta	8	other
,	103749 AL135301	Hs.8768	hypothetical protein FLJ10849	1.8	other
	104331 AB040450	Hs.279862	cdk inhibitor p21 binding protein	2	?
15	104531 AB040430 104532 Al498763	Hs.203013	hypothetical protein FLJ12748	2.1	other
13			DKFZP434F1735 protein	1.2	other
	104563 AL117403	Hs.306189		7	?
	105032 AA127818	11. 00475	gb:zi12a02.s1 Soares_pregnant_uterus_NbH	2.6	?
	105039 AA907305	Hs.36475	ESTs		other
•	106531 AA454036	Hs.8832	ESTs	1.6	
20	106977 AL043152	Hs.50421	KIAA0203 gene product	4.9	other
	107298 N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	2.5	TM
	108717 AA122393	Hs.70811	hypothetical protein FLJ20516	1.3	other
	110018 AW579842	Hs.104557	hypothetical protein FLJ10697	5.3	TM
	110330 Al288666	Hs.16621	DKFZP434I116 protein	6.3	other
25	111391 NM_003896		sialyltransferase 9 (CMP-NeuAc:lactosylc	5.1	SS,
	111392 W46342	Hs.325081	Homo sapiens, clone IMAGE:3659680, mRNA,	8.4	other
	113554 AW503990	Hs.142442	HP1-BP74	3.7	TM
	113722 AV653556	Hs.184411	albumin	1.3	other
	115008 AK001827	Hs.87889	helicase-moi	2	other
30	115062 AA253314	Hs.154103	LIM protein (similar to rat protein kina	1.5	other
50		Hs.88155	ESTs	2.8	other
	115121 Al634549		butyrate-induced transcript 1	5.8	TM
	117881 AF161470	Hs.260622		5.7	other
	119075 M10905	Hs.287820	fibronectin 1	1.3	other
2.5	119615 AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant	38.9	other
35	120253 AA131376	Hs.326401	fibroblast growth factor 12B		
	125006 BE065136	Hs.145696	splicing factor (CC1.3)	2.9	?
	127609 X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture	1.8	other
	128868 AA419008	Hs.106730	chromosome 22 open reading frame 3	3	other
	128891 F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, com	13.3	other
40	128959 Al580127	Hs.107381	hypothetical protein FLJ11200	10.9	other
	129209 R62676	Hs.17820	Rho-associated, coiled-coil containing p	2.4	other
	129449 Al096988	Hs.111554	ADP-ribosylation factor-like 7	8.2	TM
	129453 AW974265	Hs.111632	Lsm3 protein	3.3	?
	129629 AK000398	Hs.11747	hypothetical protein FLJ20391	3.9	other
45	129917 M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	5.3	TM
1.5	129922 AF042379	Hs.13386	gamma-tubulin complex protein 2	4.6	other
	129989 AB015856	Hs.247433	activating transcription factor 6	4	SS,
	130182 BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo	4.6	other
	130365 W56119	Hs.155103	eukaryotic translation initiation factor	11	other
50		Hs.183706	adducin 1 (alpha)	2.7	other
30	130471 AL121438		RAN binding protein 2-like 1	7.9	other
	130542 U64675	Hs.179825		5.6	TM
	130586 AB007891	Hs.16349	KIAA0431 protein	5.2	other
	130768 AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1		
	130992 BE398091	Hs.74316	desmoplakin (DPI, DPII)	1.8	TM
55	131047 H23230	Hs.22481	ESTs, Moderately similar to A46010 X-lin	1.7	?
	131135 NM_01656	9 Hs.267182	TBX3-iso protein	3.3	TM
	131339 AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
	131760 X76732	Hs.3164	nucleobindin 2	2.9	TM
	131774 BE267158	Hs.169474	DKFZP586J0119 protein	5.6	other
60	131853 Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	1.3	other
	131881 AW361018		upstream regulatory element binding prot	3.2	TM
	131887 W17064	Hs.332848	SWI/SNF related, matrix associated, acti	3.2	other
	132031 AF193844	Hs.3758	COP9 complex subunit 7a	5.9	?
	132192 AA206153	Hs.4209	mitochondrial ribosomal protein L37	2.2	TM
65	132203 NM_00478		synaptosomal-associated protein, 29kD	7.9	?
05	132240 AB018324		KIAA0781 protein	4.3	other
	132348 AW067708	Hs.170311	heterogeneous nuclear ribonucleoprotein	12.5	other
	132370 70007700	, 110,170011	Hororodomona manan mananata		-

	132528	T78736	Hs.50758	SMC4 (structural maintenance of chromoso	7.4	?	
		AW674699	Hs.5169	suppressor of G2 allele of SKP1, S. cere	6.9	other	
		N52298	Hs.55608	hypothetical protein MGC955	14.3	?	
5		BE268048	Hs.236494	RAB10, member RAS oncogene family	10.3	other	
3		AI439688	Hs.6289	hypothetical protein FLJ20886 Homo sapiens clone FLB3344 PRO0845 mRNA,	4.4 1.8	other SS,TM	
		Al065016 Al275243	Hs.6390 Hs.180201	hypothetical protein FLJ20671	1.8	other	
	133240	AK001489	Hs.242894	ADP-ribosylation factor-like 1	1.8	other	
		Al160873	Hs.69233	zinc finger protein	16.1	other	
10		M76477	Hs.289082	GM2 ganglioside activator protein	10.4	SS,	
		BE313555	Hs.7252	KIAA1224 protein	1.5	?	
		AL037159	Hs.74619	proteasome (prosome, macropain) 26S subu	1.7	other	
	133784	BE622743	Hs.301064	arfaptin 1	12.1	other	
		M34338	Hs.76244	spermidine synthase	9.7	other	
15		W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2	SS,	
		U86782	Hs.178761	26S proteasome-associated pad1 homolog	2.2	other	
		U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1	other	
		NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.2	other	
20		AA334551	Hs.82767	sperm specific antigen 2	1.4	other	
20		AF045239	Hs.321576	ring finger protein 22	1.4	other other	
		AD001528	Hs.89718	spermine synthase	2.6 13.3	other	
		D26488 X95525	Hs.90315 Hs.96103	KIAA0007 protein TATA box binding protein (TBP)-associate	3.1	other	
	130 193	AA243007	HS.90103	ESTs	1.6	?	
25		T70541		ESTs	2.5	SS,	
23		X57766		Human stromelysin-3 mRNA	4.5	other	
		S66431		Homo sapiens clone 23592 mRNA sequence	3.1	other	
		AA453483		ESTs	4.6	TM	
		R63925		ESTs	1.4	other	
30		AA173417		ESTs	1.9	other	
		AA280588		ESTs	2.2	other	
		AA504223		ESTs Highly similar to CHROMOSOME	2.4	other	
		AA609996		ESTs Highly similar to Surf-4 protein [M.musculus]	5.5	?	
2 ~		F02907		ESTs	2.3	TM	
35		AA480103		ESTs Weakly similar to !!!! ALU SUBFAMILY J	2.8	TM	
		AA024664		Human NADH:ubiquinone oxidoreductase subunit	6.2	other	
		AA251776		ESTS	2.3	other	
		AA399047		ESTs EST - RC_N34059	2.4 3.3	other other	
40		N34059 U95367		Human GABA-A receptor pi subunit mRNA complet		1.7	TM
70		AA490899		ESTs	3.3	other	• • • • • • • • • • • • • • • • • • • •
		T54762		ESTs	2.9	?	
		Z41963		Homo sapiens HP protein (HP) mRNA complete cds		?	
		AA521186		ESTs	1.6	TM	
45		AA400195		ESTs	1.3	other	
		AA045083		VITAMIN K-DEPENDENT GAMMA-CARBOXYLASI		2.5	other
		AA099589		Homo sapiens mRNA for GDP dissociation inhibitor		1.6	TM
		W85712		ESTs Weakly similar to PROCOLLAGEN ALPHA 2(2.6	TM
		W45728		ESTs Highly similar to HETEROGENEOUS	3.7	other	
50		U61232		Human tubulin-folding cofactor E mRNA complete c		2.1	other
		AA425154		ESTs	5.3	other	
		T39176		ESTs Weakly similar to ZK1058.4 [C.elegans]	2.6	SS,TM	
		AA496000		ESTs	1.9	SS,	
55		W38150		EST - RC_W38150 EST - RC_T96595	1.7 1.8	? TM	
55		T96595 AA227463		ESTs Weakly similar to No definition line found [C.e		1.9	?
		R46025		ESTs	2.8	SS,	•
		AA233177		ESTs	2	other	
		AA338760		ESTs	1.3	?	
60		AA412106		ESTs	6.2	other	
00		L47276		EST - L47276	3.4	other	
		D82307		ESTs Weakly similar to TH1 protein [D.melanogaste	er]	11.4	other
		AA293568		ESTs	1.5	other	
		R37778		ESTs	2.4	other	
65		AA250843		Interferon regulatory factor 5	14.6	?	
		W49521		Human prolyl 4-hydroxylase alpha (II) subunit	6.5	?	
		D80000		Human mRNA for KIAA0178 gene partial cds	2	other	

	R99978	ESTs Weakly similar to line-1 protein ORF2 [H.sapien		?
	AA195036	Human Ro/SSA ribonucleoprotein homolog (RoRet 5		
	Z38501		.4 other	
_	U37547	Human IAP homolog B (MIHB) mRNA complete cds 3		
5	AA479961	ESTs 1	.7 other	
	X57579	Inhibin beta A (activin A activin AB alpha polypeptide)	15.8	?
	AA449071	ESTs	1.3 TM	
	N51855	ESTs Moderately similar to NAD(+) ADP-	l.3 other	
	AA421213	ESTs Weakly similar to F28F8.3 [C.elegans]	3.2 other	
10	AA355201	ESTs 1	I.2 SS,TM	
	N78717	H.sapiens mRNA for translin	1.5 ?	
	N73808	ESTs 5	?	
	U86782	Human 26S proteasome-associated pad1 2	2.2 other	
	AA234817		I.3 other	
15	D13666	Homo sapiens mRNA for osteoblast specific 7	7.5 SS,	
	AA236177		7.1 ?	
	U50648	Protein kinase interferon-inducible double	1.1 ?	
	M28211	Homo sapiens GTP-binding protein (RAB4)	2.9 other	
	AA446949		2.2 other	
20	W03007		1.2 other	
	W61011		I.2 other	
	W87544		l.2 other	
	X02751	Neuroblastoma RAS viral (v-ras) oncogene homolog 1	1.2 ?	
	Z14077		I.2 other	
25	Z38839		1.2 ?	
	AA410894		I.7 other	
	AA504499	ESTs Highly similar to probable chloride channel 3 [H		other
	101007100			- 41

TABLE 7A

Table 7 A shows the accession numbers for those pkeys lacking unigeneID's for Table 7. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

Accession:

Gene cluster number Genbank accession numbers

15

20

Pkey	CAT number	Accession
102481	3128128	U50360

105032 genbank_AA127818 AA127818 409487 1134778_1 H19886 AV

H19886 AW402806 T10231

TABLE 8: Figure 8 from BRCA 001-1 US

5 **Table 8** shows genes upregulated in tumor tissue compared to normal breast tissue. Specifically, one column shows the ratio of expression of the indicated gene in breast tumor tissue compared to other body tissues, and another column shows the ratio of expression of the indicated gene in breast tumor tissue compared to normal breast tissue.

10	Pkey:	Ur	nique Eos probe	eset identifier number					
	ExAccn:		Exemplar Accession number, Genbank accession number						
	Unigene Unigene		nigene number nigene gene title						
15	R1:			normal body tissue					
	R2:		Ratio of tumor to normal breast tissue						
	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2			
20	100075	AF152333	Hs.284160	protocadherin gamma subfamily B, 4	1	3.8			
	100229	AV652249		polymerase (DNA directed), beta	1.7	5.3			
		D38500		postmeiotic segregation increased 2-like	8.0	4.8			
		BE160081		S100 calcium-binding protein A11 (calgiz	3.2	2.3			
0.5		Al907114	Hs.71465	squalene epoxidase	3.3	1.4			
25		X51501	Hs.99949	prolactin-induced protein	11.9	0.4			
		AA019521	Hs.301946		3.8	1.2			
		X77343		transcription factor AP-2 alpha (activat	9.4	9.4			
		X02761		fibronectin 1	3	7.8			
20		AA383256	Hs.1657	estrogen receptor 1	4.4	4.4			
30		U01351	Hs.75772	nuclear receptor subfamily 3, group C, m	1	3.9			
		K01160	11- 050050	NM_002122:Homo sapiens major histocomp	0.8	4 4.1			
		AA382524	Hs.250959 Hs.78944		1.2	12			
		NM_002923 NM_006262		regulator of G-protein signalling 2, 24k	3.1	1.1			
35		L22524	Hs.2256	peripherin matrix metalloproteinase 7 (MMP7; uterin	4.4	0.6			
33		Al186220	Hs.83164	collagen, type XV, alpha 1	3.1	3.4			
		AW468397		S100 calcium-binding protein A8 (calgran	0.9	4.2			
		M21305	110.100000	gb:Human alpha satellite and satellite 3	29.9	0.3			
		AA310162	Hs.169248	cytochrome c	0.8	4.9			
40		M33552	Hs.56729	lysosomal	1	5.9			
		BE561617		H2A histone family, member Z	2.8	4			
		M55998		gb:Human alpha-1 collagen type I gene, 3	3.1	1.7			
	101674	NM_002291	Hs.82124	laminin, beta 1	1.5	4.1			
	101861	AA350659	Hs.83347	angio-associated, migratory cell protein	3.1	1.4			
45	101977	AF112213	Hs.184062	putative Rab5-interacting protein	1.3	6.9			
	102193	AL036335	Hs.313	secreted phosphoprotein 1 (osteopontin,	1.9	4.9			
		AA334592	Hs.79914	lumican	2.2	3.8			
		AF015224	Hs.46452	mammaglobin 1	4.2	0.7			
		NM_003480		Microfibril-associated glycoprotein-2	1.1	4.2			
50		NM_001394		dual specificity phosphatase 4	4.5	0.5			
		U96759		von Hippel-Lindau binding protein 1	1.4	4.2			
		Al379954	Hs.79025	KIAA0096 protein	0.9	3.9			
		BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	1.5	10.9			
		R50032		collagen, type VI, alpha 2	2.2	6.2			
55		AW293542	Hs.75309	eukaryotic translation elongation factor	5.6	5.7			
		X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	3.7 1.3	0.5 4			
		X69089	Hs.79227 Hs.54941	myomesin (M-protein) 2 (165kD)	1.3	3.8			
		D38616		phosphorylase kinase, alpha 2 (liver) tumor necrosis factor receptor superfami	0.8	3.6 4.6			
60		X83492 BE536700	Hs.82359 Hs.4888	seryl-tRNA synthetase	0.8	8			
JU		T34708	Hs.272927		1.1	5.1			
•		Y00815	Hs.75216	protein tyrosine phosphatase, receptor t	3.7	1.2			
	,00	Z14244	Hs.75752	cytochrome c oxidase subunit VIIb	0.9	4.4			
	1000-10	~ 17471	110.10102	of toom only o only on one of the trib					

	103658	NM_000088	Hs.172928	collagen, type I, alpha 1	3.2	3	
		AA084874		gb:zn13e04.r1 Stratagene hNT neuron (937	0.9	10	
	103774	H24185	Hs.92918	hypothetical protein	1.9	15.9	
	103821	AA095971	Hs.198793	Homo sapiens cDNA: FLJ22463 fis, clone H	1.2	3.9	
5	103869	BE439604	Hs.24322	ATPase, H+ transporting, lysosomal (vacu	1.4	3.9	
	103980	AW130242	Hs.293476	hypothetical protein FKSG44	1.6	4.1	
	104054	AK001913	Hs.7100	hypothetical protein	1.5	4.3	
	104115	AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7	7	
	104189	AB040927	Hs.301804	KIAA1494 protein	2	4.6	
10	104230	AB002347	Hs.15303	KIAA0349 protein	0.7	4.5	
	104278	AW583693	Hs.109253	N-terminal acetyltransferase complex ard	3.3	3.3	
	104295	AW365522	Hs.103657	hypothetical protein PRO2219	2.3	4.2	
	104319	AW804296	Hs.9950	Sec61 gamma	3.1	7	
	104425	AF283775	Hs.35380	x 001 protein	4	1.3	
15	104432	X51501	Hs.99949	prolactin-induced protein	3.8	0.6	
	104464	AW966728		methionine adenosyltransferase II, beta	0.8	6.7	
	104479	AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H092	4 (f	1.7	4.8
	104505	W94824		RIKEN cDNA 2010100O12 gene	2	7.5	
	104592	AW630488	Hs.325820	protease, serine, 23	1.9	7.4	
20	104613	AF123303		hypothetical protein	1.1	6.3	
	104636	R82252	Hs.106106	protein kinase (cAMP-dependent, catalyti	1.2	4	
	104782	AW270555	Hs.171774	hypothetical protein	1.4	3.9	
	104792	AA960961	Hs.305953	zinc finger protein 83 (HPF1)	1.5	4.2	
	104848	AA305351	Hs.274369	uncharacterized hypothalamus protein HAR	1.1	4.1	
25	104849	AI279065	Hs.241507	ribosomal protein S6	1.3	4.6	
	104850	AL133035	Hs.8728	hypothetical protein DKFZp434G171	1.2	3.6	
	104852	W70164	Hs.20107	ESTs	0.8	4.2	
	104861	AA058630	Hs.29759	RNA POLYMERASE I AND TRANSCRIPT RE	ELEASE	1.7	5.1
	104873	W03831	Hs.20597	host cell factor homolog	0.8	5.4	
30	104891	W44626	Hs.30627	ESTs	0.7	6.8	
	104920	AW955089	Hs.306083	Novel human gene mapping to chomosome 2	2	1 3.9	
	104926	BE298808	Hs.33363	DKFZP434N093 protein	3.3	3.3	
	104952	AW076098	Hs.74316	desmoplakin (DPI, DPII)	1.2	3.7	
	104963	AB029020	Hs.173694	KIAA1097 protein	1.1	5.5	
35	104977	Al392640	Hs.18272	amino acid transporter system A1	3.2	1.4	
	105030	BE613061	Hs.337772	Homo sapiens, Similar to RIKEN cDNA 0610	1.6	11.4	
	105035	N39760	Hs.8859	Homo sapiens, Similar to RIKEN cDNA 5830	1.5	7.2	
	105068	BE410438	Hs.9006	VAMP (vesicle-associated membrane protei	1.1	3.5	
	105159	AF146277		CD2-associated protein	1.2	10	
40	105178	AA313825	Hs.21941		3.6	8.3	
	105182	BE407961	Hs.18271	golgi phosphoprotein 3	1.7	6.8	
	105274	AI554929	Hs.281866	ATPase, H+ transporting, lysosomal (vacu	1.1	3.7	
	105303	BE243327		chromosome 22 open reading frame 5	1.5	4	
	105413	Al015709		Homo sapiens mRNA; cDNA DKFZp586I2022		1.5	14
45	105426	W20027	Hs.23439	ESTs	4.3	2.9	
	105432	W03516	Hs.76698	stress-associated endoplasmic reticulum	1.5	5	
		AA252372	Hs.12144	KIAA1033 protein	1.2	3.6	
		AL137257	Hs.23458	Homo sapiens cDNA: FLJ23015 fis, clone L	1.7	15.8	
~ 0	105492	A1805717		CGI-43 protein	2	4.8	
50		AL037715	Hs.28785		1.3	3.9	
		AB040884		KIAA1451 protein	2.7	11.4	
		AB024334		tyrosine 3-monooxygenase/tryptophan 5-mo	1.3	6.1	
		BE504200	Hs.30127	hypothetical protein	1.7	4.5	
~ ~		AA788946	Hs.16869	ESTs, Moderately similar to CA1C RAT COL		24.6	
55		BE614149	Hs.20814	CGI-27 protein	1.8	3.6	
		Al559444	Hs.293960		1.9	6.6	
		AA329449		twisted gastrulation	1.5	4.3	
		AI827976	Hs.24391	hypothetical protein FLJ13612	3.8	1.9	
		BE392914	Hs.30503	Homo sapiens cDNA FLJ11344 fis, clone PL	1.7	4	
60		AW028485	Hs.26136	hypothetical protein MGC14156	1.7	7.4	
		AL137728	Hs.12258	Homo sapiens mRNA; cDNA DKFZp434B092		1.2	3.8
		AB033075	Hs.10669	development and differentiation enhancin	1.3	4.6	
		AB030656	Hs.17377	coronin, actin-binding protein, 1C	1.1	5.9	
~~		A1690586	Hs.29403	hypothetical protein FLJ22060	2	4.6	
65	106012	AI240665	Hs.8895	ESTs	4.1	1.2	
	106060	NM_001329		C-terminal binding protein 2	2.6	7 10 7	
	106070	T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	1.4	10.7	

		H62087 AA425414	Hs.31659 Hs.33287	thyroid hormone receptor-associated prot nuclear factor I/B	1.5 5.4	3.6 1.2	
	106255	BE613206	Hs.279607	calpastatin	1.8	4	
-		BE568205	Hs.28827	mitogen-activated protein kinase kinase	5.1	6.1	
5		AK000274		HDCMA18P protein	1.2	5.9	
		AW051564	Hs.28285	patched related protein translocated in	1.8	5.4	
		BE044325		U6 snRNA-associated Sm-like protein	2.3	11.2	
		N88604	Hs.30212	thyroid receptor interacting protein 15	1.2 0.9	3.6 4.4	
10		H09548 AA459480	Hs.5367 Hs.23956	ESTs, Weakly similar to 138022 hypotheti hypothetical protein FLJ20502	1.3	3.6	
10		BE387614	Hs.25797	splicing factor 3b, subunit 4, 49kD	1.6	7.3	
		AA741038	Hs.6670	ESTs	1.7	6.1	
		AA206079	Hs.6693	hypothetical protein FLJ20420	1	5.4	
		AA487416		Homo sapiens cDNA: FLJ23111 fis, clone L	1.6	5.4	
15		BE185536		molecule possessing ankyrin repeats indu	3.3	1.2	
	106887	BE503373		hypothetical protein FLJ13576	1.4	6.3	
	106940	T85594	Hs.339808	hypothetical protein FLJ10120	3.3	1.8	
	106968	AF216751	Hs.26813	CDA14	3	3	
•		BE391904	Hs.12482	glyceronephosphate O-acyltransferase	1.7	7.6	
20		BE147611	Hs.6354	stromal cell derived factor receptor 1	1.2	4.3	
		AI289507		hypothetical protein FLJ23399	1.8	6.5	
		BE172058	Hs.82689	tumor rejection antigen (gp96) 1	1.2	6.9	
		BE267795	Hs.22595	hypothetical protein FLJ10637	1.4	3.5	
25		AA186629	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6 1.8	4.3 4	
23		AA011510 AA027229	Hs.60512	ESTs ESTs, Weakly similar to T16370 hypotheti	1.3	3.5	
		AF109219	Hs.61329	phosphatidylinositol glycan, class N	1.6	3.5	
		AW368993		Homo sapiens clone CDABP0086 mRNA seq		1.8	8.1
		AA291440	Hs.73149	paired box gene 8	1.1	3.5	• • •
30		AA093668	Hs.28578	muscleblind (Drosophila)-like	0.7	5.6	
		Al283611		ESTs, Weakly similar to HMG1_HUMAN HIGH	-1	1.2	5.6
	108186	AW068579	Hs.7780	Homo sapiens mRNA; cDNA DKFZp564A072	(fr	3.1	6.9
		Al879238	Hs.299315	collapsin response mediator protein-5; C	1.5	4.6	
	108297	AA333660	Hs.71331	hypothetical protein MGC5350	1.5	4	
35	108339	AW151340	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU		6.3	4.7
		AA074374	Hs.67639	ESTs	1.3	3.8	
		AF086070	Hs.237519		1_	3.6	
		AA079487		gb:zm97f08.s1 Stratagene colon HT29 (937	1.5	3.6	
40		AA079500	11- 4500	gb:zm96h10.s1 Stratagene colon HT29 (937	1.1	4.3	
40		M23114	Hs.1526	ATP synthese H transporting, cardiac muscl	2	4.9 3.5	
		AA112059	Hs.429	ATP synthase, H+ transporting, mitochond	1.1 1.2	3.6	
		AA058522 AA036725	Hs.185751 Hs.61847	ESTs	1.4	3.6	
		AK001332	Hs.44672	hypothetical protein FLJ10470	1.4	3.5	
45		AA133456		glucocorticoid receptor DNA binding fact	1.2	4	
		BE276891		retinoic acid induced 3	1.3	3.6	
		AA152312	Hs.72047	ESTs	1.1	4.1	
	109072	AI732585	Hs.22394	hypothetical protein FLJ10893	1.2	3.5	
	109097	AA167512		gb:zp10f12.s1 Stratagene fetal retina 93	1.3	5	
50	109160	BE220601		hypothetical protein FLJ13033	4	6.1	
		BE179030	Hs.64239	Human DNA sequence from clone RP5-1174I		1.7	7.4
		AA878923		hypothetical protein FLJ21016	3.8	7.7	
		AA366263	Hs.72531	hypothetical protein FLJ11838	1.9	4	4.0
55		AA173942		Homo sapiens mRNA; cDNA DKFZp564H191		3.7	1.3
55		BE075297	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	4.6	7.4 3.5	
		AW151660	Hs.31444	ESTs Homo sapiens mRNA for KIAA1741 protein,	1.2 3.7	3.3	
		AW001579 NM_014899	Hs.9645	KIAA0878 protein	2.8	3.7	
		N21207	Hs.182999		1.6	3.5	
60		BE242691	Hs.14947	ESTs	3.1	1.2	
00		AI753230	Hs.323562	hypothetical protein DKFZp564K142	1.9	7.5	
		Al681293	Hs.12186	hypothetical protein FLJ22558	2	4	
		AK001566	Hs.23618	hypothetical protein FLJ10704	1.1	3.8	
		BE301871	Hs.4867	mannosyl (alpha-1,3-)-glycoprotein beta-	1	8.2	
65		BE314949	Hs.87128	hypothetical protein FLJ23309	3.3	6.1	
		R27975		ESTs, Moderately similar to S65657 alpha	1.2	5.4	
	111900	AF131784	Hs.25318	Homo sapiens clone 25194 mRNA sequence	3.2	8.0	

	111951 112141	NM_014906 NM_014927 AW137198	Hs.100527 Hs.278682	KIAA1072 protein KIAA0902 protein Phosphatidylglycerophosphate Synthase	1 1 1.4	5.4 3.8 3.5	
5	112610 112971	NM_003655 AW500106 Z42387		ESTs serine/threonine protein kinase MASK transmembrane, prostate androgen induced	1.5 4.6 3.3 3.2	3.6 2 10.5 3	
10	113056 113449 113497	T16971 AF019226 AW160683 AF143321	Hs.8036 Hs.158006 Hs.15572	ESTs, Weakly similar to A43932 mucin 2 p glioblastoma overexpressed hypothetical protein hypothetical protein IMAGE 109914	3.7 4.5 1.2 0.9	10.8 3.7 4.4 3.6	
	113531	AL042936 AK001898 Al075407	Hs.16740	holocytochrome c synthase (cytochrome c hypothetical protein FLJ11036 ESTs, Moderately similar to 154374 gene	1.1 1.2 1.7	3.5 3.9 5.3	
15	113841 113857	NM_014214 W30681 AW243158 BE255499	Hs.5753 Hs.146233 Hs.5297 Hs.3496	inositol(myo)-1(or 4)-monophosphatase 2 Homo sapiens cDNA: FLJ22130 fis, clone H DKFZP564A2416 protein hypothetical protein MGC15749	0.8 1.7 1.2 1.5	6.1 6.2 4.6 4	
20	113936 113987 114132	W17056 AA345519 Al342493	Hs.83623 Hs.9641 Hs.24192	nuclear receptor subfamily 1, group I, m complement component 1, q subcomponent, Homo sapiens cDNA FLJ20767 fis, clone CO	3.8 1.2 0.3	1 4.7 4.3	
25	114213 114636	BE179882 N58309 AA075488	Hs.19575	glutathione peroxidase 3 (plasma) CGI-11 protein gb:zm88d01.s1 Stratagene ovarian cancer	1.1 1.6 1.6	4.3 9.2 3.7	
25	114781 114795	Al929382 T10446 AB037858 AV660012	Hs.95388 Hs.173484	hypothetical protein FLJ20343 ESTs hypothetical protein FLJ10337 hypothetical protein FLJ10788	1.4 1 1.6 1.4	4 4.3 9.2 5.2	
30	115096 115518 115646	Al683069 BE541042 N36110	Hs.175319 Hs.23240 Hs.305971	ESTs Homo sapiens cDNA: FLJ21848 fis, clone H solute carrier family 2 (facilitated glu	3.7 3.2 1.5	1 4.2 3.9 5.9	
35	115802 115994	AW582256 AW410233 AB037836 BE383668		anterior gradient 2 (Xenepus laevis) hom YME1 (S.cerevisiae)-like 1 KIAA1415 protein hypothetical protein FLJ10618	1.3 1.7 1.5 0.9	6.6 9.1 4.3	
55	116046 116274	BE395293 Al129767 Z24854	Hs.94491	hypothetical protein FLJ20297 guanine nucleotide binding protein (G pr ESTs	1.6 3.2 0.8	5.5 2.4 4.7	
40	116429 116461 116470	AI371223 AF191018 AA313607 AI272141 D21262	Hs.279923	Homo sapiens cDNA FLJ11997 fis, clone HE putative nucleotide binding protein, est Homo sapiens cDNA: FLJ22145 fis, clone H SRY (sex determining region Y)-box 4 nucleolar and coiled-body phosphprotein	2.4 5.5 5 8.7 3.2	3.9 5.5 1.3 4.5 6.9	
45	116579 116589 116786	AW888411 Al557212 H25836 N25929	Hs.81915 Hs.17132 Hs.301527	leukemia-associated phosphoprotein p18 (ESTs, Moderately similar to I54374 gene ESTs, Moderately similar to unknown [H.s ADP-ribosylation factor-like 5	3.2 3.1 3.2 7	3 8.3 4.5 5.5	
50	117215 117280 117576 117667	N20066 M18217 AI383467 U59305 AF161470	Hs.133207 Hs.172129 Hs.44597 Hs.44708	PTPRF interacting protein, binding prote Homo sapiens cDNA: FLJ21409 fis, clone C ESTs Ser-Thr protein kinase related to the my butyrate-induced transcript 1	1.2 4.5 1.4 4.3 2.1	6.2 2.4 4.2 0.5 5.7	
55	118336 118475 118493	BE327311 N66845 AL353944 N67343	Hs.47166 Hs.50115	htto21 gb:za46c11.s1 Soares fetal liver spleen Homo sapiens mRNA; cDNA DKFZp761J111: gb:yz50b07.s1 Morton Fetal Cochlea Homo	3.6 4.2	7.7 0.5 3.5 3.8	3.3
60	119159 119307 119355	AF142419 BE048061 BE218319 BE041667	Hs.15020 Hs.37054 Hs.5807 Hs.314544	homolog of mouse quaking QKI (KH domain ephrin-A3 GTPase Rab14 Homo sapiens cervical cancer suppressor-	3.7 3 1.1 1.4	1.5 1.1 5.6 4.3	
00	119771 119940 119943	A1905687 AL050097 BE565849	Hs.2533 Hs.272531 Hs.14158	EST DKFZP586B0319 protein- copine III	3.2 4.3 3.5	1 0.7 1.9	
65	120493 120677	AA235207 AW968080 AF150208 AA350781	Hs.152939	hypothetical protein DKFZp762F2011 Homo sapiens clone 24630 mRNA sequence damage-specific DNA binding protein 1 (1 ESTs	1.5 4 1.6 1.1	3.7 1.4 6.8 3.6	

				191100	4.5		
		BE262956		KIAA0180 protein	1.5	4.1	
		AA416785		•	2.2	5.5	
		AA243499		hypothetical protein FLJ10134	3.4	3.2	•
_		AF169797		adaptor protein containing pH domain, PT	3.9	3.9	
5		AB032948		hypothetical protein DKFZp762K2015	1.4	7.1	
	122946	AI718702		major histocompatibility complex, class	1.4	3.7	
	123155	AF121856		sorting nexin 6	1.2	4.9	
	123158	AF161426		hypothetical protein	2.4	3.6	
	123327	AA421581	Hs.178443		0.9	5.2	
10	123495	W28673	Hs.106747	serine carboxypeptidase 1 precursor prot	1.3	5.1	
	123526	AA608657		gb:ae55d04.s1 Stratagene lung carcinoma	2.1	5.2	
	123533	AA608751		gb:ae56h07.s1 Stratagene lung carcinoma	2.1	9.3	
	123768	AI932318	Hs.188762	ESTs, Moderately similar to H2BL_HUMAN H	1.1	3.6	
	123961	AL050184		DKFZP434B203 protein	1.1	3.5	
15	123999	AF084555	Hs.7351	cyclic AMP phosphoprotein, 19 kD	1.4	3.8	
	124000	BE563957	Hs.74861	activated RNA polymerase II transcriptio	1.9	11.2	
	124038	AB037860	Hs.173933	nuclear factor I/A	1.5	4.4	
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypotheti	14.8	11.5	
	124083	AW195237	Hs.7734	hypothetical protein FLJ22174	1.2	6.2	
20	124148	BE300094	Hs.227751	lectin, galactoside-binding, soluble, 1	2.5	12.7	
	124153	AU077333		erythrocyte membrane protein band 7.2 (s	1	4.1	
	124252	BE613340	Hs.334725	Homo sapiens, Similar to RIKEN cDNA 9430	1.5	8.4	
	124314	AK001552	Hs.215766	GTP-binding protein	1.8	10.2	
	124375	D87454	Hs.192966	KIAA0265 protein	1.1	4.8	
25	124432	N39016	Hs.268869	ESTs, Weakly similar to ALUC_HUMAN !!!!	1.3	4.1	
	124447	N48000		gb:yy98e12.s1 Soares_multiple_sclerosis_	2.7	4.3	
	124539	D54120	Hs.146409	cell division cycle 42 (GTP-binding prot	2.1	5.7	
	124543	AI393320	Hs.104573	ESTs	1	4.1	
	124564	H66409	Hs.108275	ESTs	1.4	4	
30	124574	AL036596	Hs.42322	A kinase (PRKA) anchor protein 2	0.7	4	
	124605	AA749315	Hs.77171	minichromosome maintenance deficient (S.	1.1	3.5	
	124639	H60193	Hs.21143	DKFZP586C1324 protein	1.4	3.6	
	124659	AI680737	Hs.289068	Homo sapiens cDNA FLJ11918 fis, clone HE	1.5	9.9	
	124737	BE270465	Hs.78793	protein kinase C, zeta	0.7	4	
35	124760	AW408586	Hs.91052	ESTs, Moderately similar to ALU5_HUMAN A	0.9	3.6	
	124763	BE410405	Hs.76288	calpain 2, (m/ll) large subunit	1.3	3.9	
	124792	R44357	Hs.48712	hypothetical protein FLJ20736	1.8	4.2	
		R56485		gb:yg93h09.s1 Soares infant brain 1NIB H	1	3.6	
4.0	124940	AF068846		heterogeneous nuclear ribonucleoprotein	3.2	3.4	
40		Al903210		tubulin, beta polypeptide	1	4.4	
		AL023513		seizure related gene 6 (mouse)-like	0.9	5.2	
		T52700	Hs.110044		0.9	3.5	
		AA610577	Hs.187775		1.2	5	^ 7
4.~		BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152		1.5	3.7
45		T83731	Hs.3343	phosphoglycerate dehydrogenase	0.9	6	
		AA973971		gb:oq02h08.s1 NCI_CGAP_Lu5 Homo sapien		1 3.7	
		T91518		gb:ye20f05.s1 Stratagene lung (937210) H	3.2	2.5	
•		AA570056	Hs.122730	ESTs, Moderately similar to KIAA1215 pro	5.3	6.6	
~~		W38419		gb:zc78a07.s1 Pancreatic Islet Homo sapi	0.9	6.1	
50		AA837043	Hs.143669		1.1	4.3	
		AK000669		TRF2-interacting telomeric RAP1 protein	1.1	4.1	
		AL020996		selenoprotein N	1.1	3.8	
		R40815	Hs.12396	ESTs, Weakly similar to 2004399A chromos	1	3.6	
		W67577	Hs.84298	CD74 antigen (invariant polypeptide of m	1.2	7.8	
55		H05635		topoisomerase-related function protein 4	1	4.9	
		AW884980		triple functional domain (PTPRF interact	1.3	4.8	
		BE612888		myosin regulatory light chain	1.1	16.1	
		W27235	Hs.64311	a disintegrin and metalloproteinase doma	1.4	5.3	
60		Z45258		short coiled-coil protein	2.4	8.7	4.0
60		AW630088	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B126		1.8	4.6
		AW504721		high density lipoprotein binding protein	1.9	3.8	
		AW160399	Hs.30376	hypothetical protein	1.4	4.1	
		BE384361		ESTs, Weakly similar to JC5024 UDP-galac	2 1.3	3.7 4.1	
65		AA057593		hypothetical protein FLJ14735		5	
65		AA340277	Hs.10248	Homo sapiens cDNA FLJ20167 fis, clone CO ESTs, Moderately similar to T03094 A-kin	4.3	0.9	
		Al243596	Hs.94830 Hs.150101		1.5	4.7	
	120312	J04182	113.130101	iyoodoinai	1.0	•••	

	400450	V00704	11- 007000	Character May 4	4.0	4.0	
		X02761		fibronectin 1	1.2	4.3	
		T16206		ESTs, Highly similar to LDHH_HUMAN L-LAC		44.4	
		H08379		hypothetical protein DKFZp434N1429	0.6	13.1	
~		NM_005904		MAD (mothers against decapentaplegic, Dr	1.3	4	
5	128546	NM_003478	Hs.101299		1	5.1	
	128574	Al185977		ubiquitin specific protease 18	0.8	4	
	128611	NM_014721	Hs.102471	KIAA0680 gene product	1.3	3.7	
	128652	AA432202	Hs.103147	hypothetical protein FLJ21347	1.4	3.9	
	128653	D87432	Hs.10315	solute carrier family 7 (cationic amino	1.2	3.6	
10	128655	AI246669	Hs.324275	WW domain-containing protein 1	0.8	4.1	
		BE246444		hypothetical protein FLJ20396	3	1.6	
		AK001564		hypothetical protein FLJ10702	2.8	4.8	
		AA476220		CD81 antigen (target of antiproliferativ	1.1	10.6	
		AF026692		secreted frizzled-related protein 4	1	3.8	
15		AA194554		ATPase, H+ transporting, lysosomal (vacu	5.3	5.3	
13		A1638184		Homo sapiens clone 23836 mRNA sequence		5.3	
				•	1	4.5	
		Al917602	Hs.106440				
		AA768242		hypothetical protein	0.8	3.6	
20		D60985			4.6	3.7	
20		Al222020		CocoaCrisp	3	1.5	
		AK000140		••	0.2	3.9	
		AA622037		programmed cell death 5	2.5	15.2	
	128926	AF155096	Hs.107213	hypothetical protein FLJ20585	4	4	
	128930	AA298958	Hs.10724	MDS023 protein	1.2	4.5	
25	128942	AW247536	Hs.10729	hypothetical protein	1.4	5	
	128948	AW953622	Hs.223025	RAB31, member RAS oncogene family	2.3	5.6	
		AB020716		KIAA0909 protein	0.9	3.9	
		AW271217		Homo sapiens cDNA FLJ14028 fis, clone HE	1.5	3.6	
		AA258924		NM_002495*:Homo sapiens NADH dehydroge		0.8	3.8
30		Al770025		hypothetical protein FLJ22059	1.2	5.7	
20		C15105		Homo sapiens cDNA FLJ14368 fis, clone HE		9.9	
		AA371156		DKFZP564M112 protein	2.4	3.8	
		Al634522		KIAA1268 protein	1.2	3.8	
					1.2	5.5	
35		AW504486		sterol regulatory element binding transc			
33		BE543205		DKFZP586A0522 protein	0.5	3.7	
		AB002450		CGI-109 protein	1	5.2	7
		AW881089		Homo sapiens mRNA; cDNA DKFZp566M094		1.5	7
		N23018		C-terminal binding protein 2	2.1	9.7	
4.0		AA335362		Empirically selected from AFFX single pr	0.9	8.6	
40	129234	M18916	Hs.282997	glucosidase, beta; acid (includes glucos	1.1	3.5	
	129238	BE542214	Hs.109697	ESTs	1.1	12.8	
	129239	W57656	Hs.109701	ubiquitin-like 5	3.2	5.1	
	129241	Al878857	Hs.109706	hematological and neurological expressed	1.9	5.7	
	129243	BE169531	Hs.109727	TAK1-binding protein 2; KIAA0733 protein	1.2	6.6	
45		R49920		CGI-131 protein	1.5	3.5	
		AA344367		Empirically selected from multiple AFFX	1	5.4	
		AA250970		poly(A)-binding protein, cytoplasmic 1-l	1.3	4.1	
		AF077200		hypothetical protein	1.6	3.9	
		AA357185		ras homolog gene family, member H	1.8	4.2	
50			Hs.110	putative L-type neutral amino acid trans	1.1	6.1	
50		AB007896					
		AA318224	Hs.296141	with a second protoin 1.96 homolog	2.5	4.8	
		W94197	HS.110105	ribosomal protein L26 homolog	1.6	5.1	
		AF189062	HS.285976	tumor metastasis-suppressor	1.8	6.5	
<i></i>		AW511656	Hs.170177	Meis1 (mouse) homolog	0.9	4	
55		U30246		solute carrier family 12 (sodium/potassi	1.4	9.2	
	129379	BE278964		CGI-111 protein	1	4.8	
	129390	AA318271		hypothetical protein	1	4.1	
	129416	AA016188		hypothetical protein	1.8	10.7	
	129427	AI498631		ferritin, light polypeptide	1.1	4.8	
60		W92931	Hs.250899	heat shock factor binding protein 1	1.8	9.3	
		AL050260	Hs.323817	DKFZP547E1010 protein	1	5	
		NM_004477	Hs.203772	FSHD region gene 1	1.1	4.2	
		AA449789		connective tissue growth factor	1.9	6.8	
		Al631811		STRIN protein	1.1	9.7	
65		AA769221		delta-tubulin	1.1	4.3	
05		R18087		cisplatin resistance related protein CRR	1	4.2	
		AW517695		junctional adhesion molecule 1	2.3	3.5	
	123313	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	. 10,200210	January and Control of the Control o		-	
				100			

	100000	A1M000044	11- 400054	home the tire I meet in DICTACCIACO	0.4	
		AW968941		hypothetical protein DKFZp566I133	2.4	4.4
		AA209534		tetraspan NET-6 protein	3.2	13
		D79338		CCR4-NOT transcription complex, subunit	1.6	4.6
5		AL110212		purine-rich element binding protein B	1.1	5.7
,		AB020335 Al207406	Hs.11866	sel-1 (suppressor of lin-12, C.elegans)- translocase of inner mitochondrial membr	0.9 1.9	4.3 4.8
		AW889132	Hs.11916	ribokinase	0.9	4.0
		U53209	Hs.24937	transformer-2 alpha (htra-2 alpha)	1.3	4.7
		M26939		collagen, type III, alpha 1 (Ehlers-Dani	4.7	3.7
10		U46386	Hs.12102	sorting nexin 3	1.2	3.6
10		AL050272	Hs.12305	DKFZP566B183 protein	1.2	8.9
		BE397454		Homo sapiens clone 24707 mRNA sequence		3.6
		BE218319	Hs.5807	GTPase Rab14	2.9	5.1
		M62839	Hs.1252	apolipoprotein H (beta-2-glycoprotein I)	0.3	5.1
15		AF052112	Hs.12540	lysosomal	1.6	8.8
10		AL080084		CGI-100 protein	0.9	5.3
		AW410233		YME1 (S.cerevisiae)-like 1	1.8	9.9
		NM_014840		KIAA0537 gene product	0.9	3.6
		AA626937		hypothetical protein MGC2594	1.4	9.5
20	129878			30 kDa protein	1.1	6.3
20		AL119499	Hs.13285	neuronal potassium channel alpha subunit	1	3.5
		M30773		protein phosphatase 3 (formerly 2B), reg	2	5.1
		X14008	Hs.234734		0.9	4.9
	129982		113.204704	gb:H.sapiens germline transcript of lg h	1.2	3.6
25		R15917	He 1/2570	Homo sapiens clone 24629 mRNA sequence		1.3
20		BE277024		RNA binding motif protein, X chromosome	1.6	3.8
		X57815.comp	113.140001	Empirically selected from AFFX single pr	1.2	8.2
		M93143	He 262860	plasminogen-like	1.4	7.9
		H97878		zinc finger protein 36 (KOX 18)	1.4	12.3
30		AK001635	Hs.14838	hypothetical protein FLJ10773	0.2	4.6
50		W61005	Hs.14896	DHHC1 protein	1.	4.1
		AA916785		splicing factor proline/glutamine rich (1.2	5.3
		T47294		X-box binding protein 1	3.8	0.8
		NM_005095		zinc finger protein 262	1	4.2
35		BE094848	Hs.15113	homogentisate 1,2-dioxygenase (homogenti	0.5	4
55		R42678		KIAA0564 protein	1	3.7
		M23115	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	0.4	4.4
		BE278370	Hs.15265	heterogeneous nuclear ribonucleoprotein	1.7	7.5
		BE301883		glioblastoma amplified sequence	1	5.6
40		U29463	113.102707	gb:Human cytochrome b561 gen	1.2	4.2
-10		U92014	He 153527	Homo sapiens pTM5 mariner-like transposo	1.3	3.6
		W78907	Hs.15395	similar to arginyl-tRNA synthetase (argi	1.5	4.4
		AB040914		KIAA1481 protein	2.9	7.5
		AW067800		stanniocalcin 2	3.2	0.2
45		AW842182		small inducible cytokine A5 (RANTES)	1.4	10.6
		AW163518		huntingtin interacting protein 2	1.7	11.7
		AA852868		KIAA0171 gene product	1.1	5
		NM_006245		protein phosphatase 2, regulatory subuni	1.4	4.3
		AW362955	Hs.15641	Homo sapiens cDNA FLJ14415 fis, clone HE		7.6
50		R44163	Hs.12457	hypothetical protein FLJ10814	0.9	4.1
•		AB007915		KIAA0446 gene product	1	3.8
		Al598022	Hs.193989	TAR DNA binding protein	1.3	4.7
		AA232119	Hs.16085	putative G-protein coupled receptor	1.2	9.4
		Al652143		hypothetical protein FLJ13111	1	4.1
55		BE242873	Hs.16677	WD repeat domain 15	1.1	3.6
		AL049963		up-regulated by BCG-CWS	0.6	3.8
		AL045128	Hs.1691	glucan (1,4-alpha-), branching enzyme 1	0.9	6.6
		AL042896	Hs.1697	ATPase, H+ transporting, lysosomal (vacu	0.9	3.9
		AW073971	Hs 238954	ESTs, Weakly similar to KiAA1204 protein	0.9	6.9
60		Al557212	Hs.17132	ESTs, Moderately similar to 154374 gene	2.6	3.9
00		AF158555		glutaminase	1.2	13.8
		Al861791	Hs.278479		1.3	4
		Al831962	Hs.17409	cysteine-rich protein 1 (intestinal)	2.5	4
		AL117508		KIAA0737 gene product	1.3	6.2
65		AI928985	Hs.17680	hypothetical protein MGC1314 similar to	1.4	3.9
	130693		Hs.17962	ESTs	3.2	0.8
		NM_014827		KIAA0663 gene product	1.1	4.8
	-			• •		

	130696	AA325308	Hs.18016	Homo sapiens mRNA; cDNA DKFZp586H032	4 (f	1.8
		Z98883	Hs.18079	phosphatidylinositol glycan, class Q	1.1	6.7
	130707	AW190925	Hs.203559	hypothetical protein FLJ12701	1.2	4.1
_	130731	Al932971	Hs.18593	Homo sapiens cDNA: FLJ21449 fis, clone C	1.4	6.9
5		AF072813	Hs.252831	reticulon 3	1.2	11.2
		AA088809	Hs.19525	hypothetical protein FLJ22794	1.8	6.8
		NM_001761	Hs.1973	cyclin F	1.3	4.1
		Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.2	5.9
10		AB037750 AW195747	Hs.21061 Hs.21122	KIAA1329 protein	1 1.3	3.8 7.9
10		BE409769	Hs.21189	hypothetical protein FLJ11830 similar to DnaJ (Hsp40) homolog, subfamily A, membe		3.7
		BE390905	Hs.21198	translocase of outer mitochondrial membr	1.9	4
		H96115	Hs.21293	UDP-N-acteylglucosamine pyrophosphorylas	1.9	10.3
		AB023182		KIAA0965 protein	1.5	6.8
15		AA393071		leucine aminopeptidase	1.4	5.5
	130975	AA099923	Hs.283728	PEST-containing nuclear protein	1.3	3.8
		BE243101	Hs.22391	chromosome 20open reading frame 3	1.9	4.1
		D87436	Hs.166318	•	1.6	3.5
20		AA194422	Hs.22564	myosin VI	4.5	5
20		AL137682	Hs.22937	I-kappa-B-interacting Ras-like protein 2	2	3.7
		BE387561	Hs.22981	DKFZP586M1523 protein	1.6 · 0.9	4.5 3.5
		W27770 BE620886	Hs.75354	ESTs, Weakly similar to T31475 hypotheti GCN1 (general control of amino-acid synt	2.1	4.5
		BE564123	Hs.23060	DKFZP564F0522 protein	1.1	4.6
25		AB033099	Hs.23413	KIAA1273 protein	1.2	4.2
		AW953575		p53-induced protein PIGPC1	4.5	13.5
	131150	X77753	Hs.23582	tumor-associated calcium signal transduc	3.4	0.4
	131156	A1472209	Hs.323117	ESTs	8.0	4.9
• •		AW013807	Hs.182265		3.3	2.4
30		H25094		ESTs, Moderately similar to 138022 hypot	0.6	4
		AW864222	Hs.24083	KIAA0997 protein	1.4	3.8
		AW979155		amino acid transporter 2	1.2	8.5
		AL050107	Hs.24341	transcriptional co-activator with PDZ-bi Homo sapiens cDNA FLJ20738 fis, clone HE	0.7	4.7 8.2
35		Al815486 D89053		fatty-acid-Coenzyme A ligase, long-chain	1.7	3.5
55		AW956868	Hs.24608	DKFZP564D177 protein	1.3	5.4
		AU077158	Hs.24930	tubulin-specific chaperone a	1.6	4.8
		AU077002	Hs.24950	regulator of G-protein signalling 5	1.4	4.4
		Al750575		nuclear factor I/A	3.3	2.2
40	131372	AW293399	Hs.144904	nuclear receptor co-repressor 1	1.6	3.9
	131373	NM_006052	Hs.26146	Down syndrome critical region gene 3	1	11.1
		NM_014810	Hs.92200	KIAA0480 gene product	5	2
		AI452601		nuclear receptor subfamily 2, group F, m	0.9	3.5
45		AW960146		hypothetical protein FLJ12888	1 2	3.5
43		BE270734	Hs.2795	lactate dehydrogenase A	1.5	6.5 10.7
		AB040927 AU076408	Hs.28309	KIAA1494 protein UDP-glucose dehydrogenase	1.3	4.7
		AF157326		TBP-interacting protein	1.3	4.9
		T47364		interferon, alpha-inducible protein 27	1.5	8
50		AA936296		DKFZP586G011 protein	1.8	3.5
	131589	C18825	Hs.29191	epithelial membrane protein 2	1.3	8.2
	131609	D83032	Hs.169984	nuclear protein	2.8	3.9
		BE514605		Homo sapiens cDNA: FLJ22380 fis, clone H	1.3	11.2
<i></i>		H03514	Hs.10130	ESTs	1.3	4.8
55		C19034		Homo sapiens cDNA FLJ14175 fis, clone NT	3.2	9.7
		AF103798 AW160865	Hs.30819	hypothetical protein cytochrome c oxidase subunit VIIa polype	1.3 1.3	5.2 7.8
		AF017986	Hs.30888 Hs.31386	secreted frizzled-related protein 2	10.6	14.7
		AI805664	Hs.31731	peroxiredoxin 5	1.1	3.6
60		AF077036	Hs.31989	DKFZP586G1722 protein	1.6	3.7
	131791			gb:H.sapiens VII-5 gene for immunoglobul	1.1	3.5
		Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		1.2
	131870	NM_014874	Hs.3363	KIAA0214 gene product	0.6	4.2
<i>-</i> -		NM_004642	Hs.3436	deleted in oral cancer (mouse, homolog)	2.4	4.9
65		AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	2.4	6
		AA772603	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	1.7	9.2
	131941	BE252983	Hs.35086	ubiquitin specific protease 1	0.5	5.2

	131947	AI123939	Hs.182997	ESTs	0.7	4.1
	131961	AA129782	Hs.3576	Homo sapiens mRNA full length insert cDN	0.9	4.8
	131964	AW381148	Hs.198365	2,3-bisphosphoglycerate mutase	1.1	6.1
	131974	AF208856		hypothetical protein	1.3	3.9
5		AF119665		pyrophosphatase (inorganic)	3.3	6.9
		AF229181	He 136644	CS box-containing WD protein	0.9	5.2
		AW162336				
			Hs.3709	low molecular mass ubiquinone-binding pr	1.2	3.6
		BE277910	Hs.3833	3'-phosphoadenosine 5'-phosphosulfate sy	3.2	1.8
10		BE379335	Hs.211594			3.6
10	132071	AF217798	Hs.3850	LIS1-interacting protein NUDEL; endoolig	0.7	5.2
	132079	AI701457	Hs.38694	ESTs	2	5.3
	132094	NM 016045	Hs.3945	CGI-107 protein	1.2	4.3
	132116	AW960474	Hs.40289	ESTs	3.1	3.1
		Al752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	1.8	3.7
15		AW961231	Hs.16773	Homo sapiens clone TCCCIA00427 mRNA se		1.2
13						
		AL031709		hypothetical protein CAB56184	1.4	4.2
		AA306325	Hs.4311	SUMO-1 activating enzyme subunit 2	2	10.3
		BE177330	Hs.325093	Homo sapiens cDNA: FLJ21210 fis, clone C	1.2	4.1
	132316	U28831	Hs.44566	KIAA1641 protein	5.9	1.6
20	132358	NM_003542	Hs.46423	H4 histone family, member G	5.8	1.5
	132384	AA312135	Hs.46967	HSPCO34 protein	2.1	9.3
		AA021160	Hs.4750	hypothetical protein DKFZp564K0822	1.3	4.6
		AW361383		metalloprotease 1 (pitrilysin family)	2	4.9
		AW970859	Hs.313503		1.2	
25		BE388673				5
23			Hs.5086	hypothetical protein MGC10433	2	3.9
		BE396290	Hs.5097	synaptogyrin 2	1.4	5.1
		AF065391		zinc finger protein 265	1.2	4
	132575	AV660538		60S ribosomal protein L30 isolog	3	1.7
	132585	AF029750	Hs.179600	TAP binding protein (tapasin)	1.8	4.7
30	132602	AW606927	Hs.5306	hypothetical protein DKFZp586F1122 simil	1.6	4.9
		AA353044	Hs.5321	ARP3 (actin-related protein 3, yeast) ho	1.8	8.1
		NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	4.2	2
		Al264357	Hs.55405		1.1	5.3
				hypothetical protein MGC16212		
25		AK000868	Hs.5570	hypothetical protein FLJ10006	1.4	5.2
35		BE222975	Hs.56205	insulin induced gene 1	1.1	5.8
	132782		Hs.279840	zinc finger protein 222	1.3	3.7
	132793	AB020713	Hs.56966	KIAA0906 protein	2.3	6.3
	132805	AW975748	Hs.5724	sclerostin	0.7	7.7
	132863	BE268048	Hs.236494	RAB10, member RAS oncogene family	1.8	6.2
40	132894	D63209	Hs.5944	solute carrier family 11 (proton-coupled	1.5	20.8
		AA579258	Hs.6083	Homo sapiens cDNA: FLJ21028 fis, clone C	1	3.8
		AW118826	Hs.6093	Homo sapiens cDNA: FLJ22783 fis, clone K	0.7	5.4
		BE263252				
			Hs.6101	hypothetical protein MGC3178	1.6	4.1
15		Al248173		hypothetical protein MGC12936	1	4.2
45		BE539199	Hs.62112	zinc finger protein 207	1.5	4.4
	132990	X77343		transcription factor AP-2 alpha (activat	13.9	8.0
	132998	Y00062	Hs.170121	protein tyrosine phosphatase, receptor t	0.6	4.6
	133002	AW499985	Hs.42915	ARP2 (actin-related protein 2, yeast) ho	1.5	11.1
	133011	NM_006379		sema domain, immunoglobulin domain (Ig),	3.5	1
50		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA		4.5
		AW502761	Hs.30909	KIAA0430 gene product	0.9	5.5
		H12028			4 -	
			HS.6396	jumping translocation breakpoint	1./	5.3
		Al654133	Hs.30212	thyroid receptor interacting protein 15	0.6	4.9
~ ~		AK000708			1.2	3.5
55	133080	AF089816	Hs.6454	chromosome 19 open reading frame 3	1.2	17.5
	133110	AA808177	Hs.65228		0.9	5.1
		AV655783	Hs.661	Empirically selected from AFFX single pr	1.1	4.5
	133175	AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	1.5	4.8
		AF231981			5.5	5.9
60		AA464362	Hs.6748	hypothetical protein PP1665	1.2	3.7
50						
		AB037773	Hs.6762	hypothetical protein	1.6	8.6
		W32474			2.4	4.8
		AL137480	Hs.6834	KIAA1014 protein	1	4.2
<i>-</i> -		AW796524	Hs.68644	Homo sapiens microsomal signal peptidase	1.3	3.9
65		BE617892	Hs.6895	actin related protein 2/3 complex, subun	1.4	5.4
	133271		Hs.283742	H.sapiens mRNA for retrotransposon	3.1	0.7
	133273	N27672	Hs.69469	dendritic cell protein	2.5	6.5

	133287	AW797437	Hs.69771	B-factor, properdin	1.3	4	
	133291	BE297855	Hs.69855	NRAS-related gene	1.4	5	
			Hs.699	peptidylprolyl isomerase B (cyclophilin	2.2	6.8	
~		AJ001388	Hs.69997	zinc finger protein 238	1.5	4.3	
5		AF116666	Hs.70333	hypothetical protein MGC10753	1.4	6.3	
		X04898		apolipoprotein A-II	0.2	3.6	
				H factor 1 (complement)	0.6 1.2	5 4.2	
			Hs.71475 Hs.72157	acid cluster protein 33 DKFZP56411922 protein	3.7	5.8	
10				KIAA0447 gene product	1.4	5.1	
10				hexokinase 2	0.9	6.3	
			Hs.73287	KIAA1235 protein	1.2	3.7	
			Hs.7378	Homo sapiens mRNA; cDNA DKFZp434G227		0.7	4.8
				immunoglobulin lambda-like polypeptide 1	1.1	4.3	
15			Hs.7381	voltage-dependent anion channel 3	0.7	4.2	
	133501	Al962602	Hs.74284	hypothetical protein MGC2714	3.1	5.9	
	133504	NM_004415	Hs.74316	desmoplakin (DPI, DPII)	4.3	11.5	
			Hs.74346	hypothetical protein MGC14353	1.8	19.7	
• •			Hs.74579	KIAA0263 gene product	1.2	5.4	
20				Empirically selected from AFFX single pr	1.4	3.9	
			Hs.225936		0.8	4.9	
	133589		Hs.75104	RNA-binding protein S1, serine-rich doma	2	10.8	
			Hs.75111	protease, serine, 11 (IGF binding)	2.1	4.5	
25				wee1+ (S. pombe) homolog	3.3	1.1	
25			Hs.75249	ADP-ribosylation factor-like 6 interacti	2.3	5.6	
				dihydropyrimidinase-like 2	0.8	13.5	
				popeye protein 3	1 0.5	9.1 5.8	
	133668		Hs.75438	quinoid dihydropteridine reductase	1.1	6.9	
30				mitogen-activated protein kinase 6 zinc finger protein 146	1.8	3.8	
50			Hs.75544	tyrosine 3-monooxygenase/tryptophan 5-mo	1.5	11.1	
				heterogeneous nuclear ribonucleoprotein	2	3.9	
			Hs.75667	synaptophysin	0.6	3.5	
			Hs.75824	KIAA0174 gene product	1.2	7.2	
35			Hs.75847	CREBBP/EP300 inhibitory protein 1	1.5	5	
			Hs.75873	zyxin	1.2	4.8	
			Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	4.1	
	133776	BE268649	Hs.177766	ADP-ribosyltransferase (NAD+; poly (ADP-	2.1	3.8	
	133799	W24087	Hs.76285	DKFZP564B167 protein	1.9	12.6	
40			Hs.76293	thymosin, beta 10	2.6	6.6	
			Hs.76297	G protein-coupled receptor kinase 6	1	4.9	
			Hs.76325	step II splicing factor SLU7	0.5	3.8	
			Hs.7644	H1 histone family, member 2	1.5	4.5	
15			Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B1264		3.7	5.6
45			Hs.76688	carboxylesterase 1 (monocyte/macrophage	0.3	4.4	
			Hs.76704	ESTs	5.5 0.6	2.9	
	133887		Hs.76930	synuclein, alpha (non A4 component of am protein kinase, cAMP-dependent, catalyti	1	4.8 10.2	
			Hs.77271	arginyltransferase 1	0.9	4.8	
50			Hs.7753	calumenin	2.8	10.5	
50			Hs.77542	ESTs	1.8	5.6	
			Hs.7756	proteasome (prosome, macropain) 26S subu		6.6	
	133947		Hs.77810	nuclear factor of activated T-cells, cyt	1.5	3.8	
				v-Ki-ras2 Kirsten rat sarcoma 2 viral on	0.9	4.3	
55	133987	L15409		von Hippel-Lindau syndrome	2.3	4.3	
	133989		Hs.78202	SWI/SNF related, matrix associated, acti	3.3	3.4	
	133990	R48316	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564C1216	6 (f	1.3	5.7
	134029			hypothetical protein hCLA-iso	1	6.5	
			Hs.78683	ubiquitin specific protease 7 (herpes vi	1.7	3.6	
60		AI027881	Hs.7869	lysosomal	1	7.5	
			Hs.78825	matrin 3	1.2	4	
			Hs.79069		2.7	4.8	
		BE513171	Hs.79086	mitochondrial ribosomal protein L3	3.3	2.1	
65	134207	74303A		KIAA0009 gene product	1.3 1.7	3.5	
65	134210		Hs.80019 Hs.80205	programmed cell death 6 pim-2 oncogene	0.8	6.9 5.3	
	134270		Hs.80919	synaptophysin-like protein	1.4	11.4	
	137210	,	. 10.000 10	of repropried more protein			

	134277	NM_004369	Hs.80988	collagen, type VI, alpha 3	2.6	3.5
	134280	NM_000712	Hs.81029	biliverdin reductase A	1.8	5.8
	134288	AI022650	Hs.8117	erbb2-interacting protein ERBIN	1.1	3.6
	134296	R00603	Hs.8128	phosphatidylserine decarboxylase	1.1	5.9
5		NM_001430	Hs.8136	endothelial PAS domain protein 1	0.5	4.8
9		AL037800	Hs.8148	selenoprotein T	1.7	7.9
					0.8	7.6
		D50683	Hs.82028	transforming growth factor, beta recepto		
		X76534	Hs.82226	glycoprotein (transmembrane) nmb	2.2	3.6
10		N22687	Hs.8236	ESTs	1.9	3.6
10	134378	AL035786	Hs.82425	actin related protein 2/3 complex, subun	1.5	8.3
	134382	BE512856	Hs.109051	SH3 domain binding glutamic acid-rich pr	1.1	3.6
	134415	A1750762	Hs.82911	protein tyrosine phosphatase type IVA, m	1.9	4.6
		NM_006416	Hs.82921	solute carrier family 35 (CMP-sialic aci	1.2	7.5
		AU077196	Hs.82985	collagen, type V, alpha 2	6.6	8.7
15		Z23024		Rho GTPase activating protein 1	2	3.9
13					3.5	1.1
		NM_013230		CD24 antigen (small cell lung carcinoma		
		D86981	Hs.84084	amyloid beta precursor protein (cytoplas	1.5	4.4
	134501	W84869		eukaryotic translation initiation factor	1.2	5.7
	134505	AW960673		ATP synthase, H+ transporting, mitochond	1.3	3.9
20	134520	BE091005	Hs.74861	activated RNA polymerase II transcriptio	1.8	4.3
	134528	M23161	Hs.84775	Human transposon-like element mRNA	0.8	5.6
		AI902899	Hs.85155	butyrate response factor 1 (EGF-response	1.4	5
		Al203545		S-phase response (cyclin-related)	0.8	3.9
		NM 016142			1.3	5.7
25		_		steroid dehydrogenase homolog	0.9	3.7
23		AB033017	Hs.8594	KIAA1191 protein		
		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	4	6.8
	134579	AW936928	Hs.85963	DKFZP564M182 protein	2.2	4.3
	134582	AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.6	3.6
	134600	AF078859	Hs.86347	hypothetical protein	2.1	3.5
30		AF265208		SWI/SNF related, matrix associated, acti	1.7	4.2
		AK000606	Hs.8868	golgi SNAP receptor complex member 1	4.4	0.9
		D17530	Hs.89434	drebrin 1	3.1	1.6
					0.5	4.6
		T51986		hemoglobin, gamma G		
25		AA428520	Hs.90061	progesterone binding protein	1.3	3.7
35		J03464		collagen, type I, alpha 2	8.7	17.3
	134865	AA587775	Hs.66295	multi-PDZ-domain-containing protein	1.7	4
	134868	AB020689	Hs.90419	KIAA0882 protein	3.4	0.9
	134874	Al803761	Hs.90458	serine palmitoyltransferase, long chain	1.3	6.9
	134885	AJ002030	Hs.9071	progesterone membrane binding protein	1.4	9.6
40		R51083	Hs.90787	ESTs	1	10.1
		BE089782	Hs.9877	hypothetical protein	1.9	3.9
		AF005043	Hs.91390	poly (ADP-ribose) glycohydrolase	1	4.3
					1.4	10.4
		BE560779		NICE-5 protein		
4 =		AK002085	Hs.92308	Homo sapiens cDNA FLJ11223 fis, clone PL	1.6	4.1
45	135011	AB037835	Hs.92991	KIAA1414 protein	1.2	5.6
	135032	AW301984	Hs.173685	hypothetical protein FLJ12619	1.7	7.6
	135035	AL034344	Hs.284186	forkhead box C1	3.2	0.6
	135051	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	4.2	4.1
		AK001887		protein kinase, AMP-activated, gamma 2 n	1.3	4.8
50		AK000967	Hs.93872	KIAA1682 protein	2	3.7
20		AW503733	Hs.9414	KIAA1488 protein	2.8	3.7
	100077	AB017363	Hs.94234		2.4	4.8
	100002	ADU 17 303		frizzled (Drosophila) homolog 1		
	135107	T97257		ESTs, Moderately similar to I38022 hypot	1.4	5.8
~ ~		AA132813	Hs.69559	KIAA1096 protein	1.8	8.5
55 i	135156	BE563088	Hs.9552	binder of Arl Two	1.2	6.8
	135172	AB028956	Hs.12144	KIAA1033 protein	3.1	1.4
	135181	BE250865	Hs.279529	px19-like protein	1.3	7.5
	135222	AA534009	Hs.183487		1.3	3.8
	135232	AL038812	Hs.96800	ESTs, Moderately similar to ALU7_HUMAN A		3.9
60	100202	AW372569	Hs.9788	hypothetical protein MGC10924 similar to	0.9	8.4
60	100200	V V 3 3 4 U U 4			1	3.8
		AA331901	Hs.184736			
	135291	T83882	Hs.97927	ESTs	1.2	3.5
	135349	AA114212	Hs.9930	serine (or cysteine) proteinase inhibito	2.6	8.9
<i>-</i> -	135357	AI565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	2.5	5.4
65	135398	M16029	Hs.287270	ret proto-oncogene (multiple endocrine n	0.4	7.9
	135399	W79431	Hs.326249	ribosomal protein L22	1.5	4.5
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	1.8

5	302892 302963 303131 303150 310125 312662	AA887146 AA147979 AA233808	Hs.42346 Hs.151945 Hs.103180 Hs.8217 Hs.285005 Hs.286241	Homo sapiens cDNA FLJ12843 fis, clone NT calcineurin-binding protein calsarcin-1 mitochondrial ribosomal protein L43 DC2 protein stromal antigen 2 mitochondrial import receptor Tom22 protein kinase, cAMP-dependent, regulato	3.3 0.9 3 6.2 1.2	3.6 1.6 4.2 17.3 4 6.6 3.5			
10	320591 406779 410691	AA054761 AA412048 AW239226	Hs.169149 Hs.279574 Hs.65450	junctional adhesion molecule 1 karyopherin alpha 1 (importin alpha 5) CGI-39 protein; cell death-regulatory pr reticulon 4	1.3 1.2	4.7 5.6 3.5 13.9			
15	415738 420186 422055	BE539367 NM_015925 NM_014320	Hs.95697 Hs.111029	hypothetical protein FLJ21776 ESTs, Weakly similar to AF220049 1 uncha liver-specific bHLH-Zip transcription fa putative heme-binking protein	2 1.3 1.5 2	5.1 3.9 6.2 11.3			
20	426218 427397 427466	AF119043 AI929685 AA523543	Hs.168005 Hs.177656 Hs.7678	calmodulin 1 (phosphorylase kinase, delt cellular retinoic acid-binding protein 1	1.3 1.1	3.6 2.8 4.7 3.7			
20	427723 428673 430219	Al355260 AW601325 X99209	Hs.279789 Hs.324278 Hs.235887	26S proteasome-associated pad1 homolog histone deacetylase 3 Homo sapiens mRNA; cDNA DKFZp566M063 HMT1 (hnRNP methyltransferase, S. cerevi	1.8	2.5 22 1.1 8.8	5.2		
25	432866 433423 437562	BE395875 BE407127 AB001636	Hs.279609 Hs.8997 Hs.5683	hypothetical protein mitochondrial carrier homolog 2 heat shock 70kD protein 1A DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.1 1.5 1.3 1.6	5.6 6.1 7.6 6.5			-
30	437754 440252 441471	R60366 BE513940 AL042986	Hs.5822 Hs.6101 Hs.7857	junctional adhesion molecule 1 Homo sapiens cDNA: FLJ22120 fis, clone H hypothetical protein MGC3178 erythrocyte membrane protein band	1.3 2 1.1 0.5	3.5 5.7 6.2 3.7			
35	449404 449964 451389	H51066 AW001741 N73222	Hs.279009	hypothetical protein FLJ14495 leptin receptor gene-related protein hypothetical protein FLJ10706 matrix Gla protein	2.5 1.1 1.4 4	4.9 3.6 3.5 11.2			
	452685	Al634651 RC_H15847_s RC_W84712 X14008_rna1_		v-maf musculoaponeurotic fibrosarcoma (a peptidylprolyl isomerase B (cyclophilin B) calumenin lysozyme (renal amyloidosis)	0.8 1.8 3.5 0.9	5.6 4.8 4.6 4.5			
40		RC_H86543_f H07011 RC_AA164586 RC_AA070485		ESTs ESTs; Weakly similar to SAS [H.sapiens] Homo sapiens clone 23967	1.8 1.8 ESTs 3.4	6.6 3.9 6.2 2.6	0.8		
45		RC_H98714_s RC_AA406145 AA458584 AA031548		ESTs SRY (sex determining region Y)-box 4 cell division cycle 42 (GTP-binding protein; 25	1.6 ESTs 3.4 kD)	3.5 4.6 0.4 3.1	3 3.9		
50		X02761 RC_AA487193 R25326 RC_AA393805 RC_AA449333	j	fibronectin 1 secreted frizzled-related protein 4 Homo sapiens mRNA for putative vacuolar ESTs; Weakly similar to (defiine not ESTs	3.6 4.7 0.9 1.1 2.9	15.2 4 5 8.4 4.6	O.C		
55		RC_AA287681 RC_AA490864 RC_C14243_f R21443 RC_AA251902	_s ,	ESTs; Highly similar to heat shock factor ESTs; Highly similar to heat shock factor ESTs Homo saplens lysophospholipase (LPL1)	ESTs 1.4 1.7 1.6 2.2	1.3 5 5 3.7 3.8	4		
60		M21121_s C00038_s Y00503 RC_R27006_f	•	small inducible cytokine A5 (RANTES) ESTs keratin 19 ESTs	0.9 2.8 3.1 1.6	9.9 4.8 1.1 3.7			
65		RC_AA416886 RC_AA460450 RC_AA488433 RC_AA278400 U28831 RC_AA199588	Lf.	ESTs; Weakly similar to predicted using fibroblast growth factor receptor 2 (bacteria-ESTs; Weakly similar to deduced amino acid Human protein immuno-reactive with anti-PTH Homo saplens actin-related protein Arp3 (ARF	Homo sapie 14.4	3.1 3.7 4 ens HRIHFB211 0.6 1.8	5 mRNA; partial cds	1.5	3.6

	AF006082	Homo sapiens actin-related protein Arp2 (ARP2)	1.6	10.9
	RC_H90899	desmoplakin (DPI; DPII)	5.4	5.5	
	RC_W95070	desmoplakin (DPI; DPII)	5	2.6	
_	RC_T90946_f	Human mRNA for KIAA263 gene; comple	te cds	1.1	3.9
5	D87258	protease; serine; 11 (IGF binding)	2.4	3.5	
	AA313414_s	ESTs; Weakly similar to cDNA EST EMBL	::T1157	1.5	5.3
	RC_H73484_s	ESTs; Weakly similar to similar to Yeast	1.3	6.3	
	AFFX-HUMISGF3A/M9	7935_3		2.3	13.5
	AFFX-HUMRGE/M1009	98_5	1.1	7.9	
10	AFFX-M27830_5			0.5	7.4
	AFFX-M27830_5			0.6	5.4
	RC_AA063431_f		ESTs	0.8	4.1
	RC_T63769_f	ferritin; light polypeptide	1.1	3.7	

TABLE 8A

Table 8A shows the accession numbers for those pkeys lacking unigeneID's for Table 8. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15

35

40

45

50

60

Pkey CAT number Accessions

	rney	CAT Humber	Accessions
20	108469 125076 114636	116761_1 190299_1 109698_1	AA079487 AA128547 AA128291 AA079587 AA079600 AA973971 T88817 AA253263 AA075488 AA129081 AA074851 AA082852 AA074732 AA084908 AA084751 AA076042 AA131172 AA085374 AA079519 AA074510 AA113824 AA102437 AA070833 AA070143 AA084693 AA084389 AA076373 AA075492 AA062834 AA084335
			AA078829 AA079344 AA069916 AA079275 AA070914 AA654069 AA081976 AA080957 AA083115 AA070942 AA085296
	123526	genbank_AA6	08657 AA608657
25	123533	genbank_AA6	08751 AA608751
	125090	genbank_T918	518 T91518
	125154	genbank_W38	419 W38419
	118475	genbank_N66	345 N66845
	118505	genbank_N673	343 N67343
30	101046	entrez_K0116	DK01160
	129982	221_267	Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165
			AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X
			Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278

X62107 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004223 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 Al857980 AW368899 Al905833 AW406586 AA482084 Al872299 AA715266 AW404328 Al831674 Al709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113

AW514864 AA4857751
55 108470 genbank_AA079500 AA079500
101447 entrez_M21305 M21305
124447 genbank_N48000 N48000
101624 entrez_M55998 M55998

131791 221_260

X62111 S67984 AJ131056 Z47243 Z47235 AF062268 Z47237 AJ131058 AF062130 AF062282 X62108 AA385989 AA464794 X69861 AW402964 M90808 Z98735 Z98734 Z98736 AF035018 X79161 U00545 AF174046 AF174071 U00552 U96288 AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 S75886 AJ008175 AJ008186 AJ008188 Y08403 H15753 H22208 AA327241 AW405737 H42300 H39677 H26239 H26903

H45128 R86072 AA327565 AI660584 AW361537 AW383759 S71043 H15014 H45570 H42819 H45523 H45134 R72043 H24543 H27636 H27610 T28147 H25496 AW364071 AW364072 H45561 H45556 H42605 Al735017 T47421 R48719 H27570 H44599 Al45958 H42347 H41938 H24993 AA345888 H22339 Al538691 AJ012264 AA664201 Al880450 AA327310 Al991250 AI833028 AW001210 AI956075 H30467 AA326915 H41943 AI749266 AI744441 AA327377 AW512326 AI735170 H01634 5 AI587047 AI571623 AA327486 AA327103 AA327195 AA326973 T28143 R56485 R37248 R59992 124842 217726_1 AA084874 f 103758 AA084874_f_at X57815 L29157 AA367448 AW328098 AW404536 L29156 L29163 H27683 R83195 AA295096 AW327822 H25458 AW404692 130064 221_264 X57819 X57823 AW405604 AW404447 Z34914 AW406542 AA427726 AA604389 AW405606 AW405918 AW405117 AW407182 L03632 AW405058 L03627 AW407470 R72738 L21959 AW375738 X87888 AF124166 AF054638 AJ241406 U09902 AW405284 M12025 AA360219 L03631 L03629 AW327727 AF194810 AF058076 AF194686 AF063774 AF063737 10 AF063755 AF063740 AF063739 AF063738 S73129 L43088 AF063775 L33026 AF060138 AF194813 AF194812 AF194811 AF194809 AF194814 AF194808 AF064505 AF064503 AF063765 AF063757 AF063752 AF063716 AF063736 AF194806 AF058077 AF063747 AF063772 AF063781 AF060137 AF194805 AF060134 AF060132 AF058074 AF063754 AF063764 15 U38589 Z18332 AF060122 AF194807 AF060135 AF064506 AF064504 AF063773 L26540 AF058072 AF060131 AF064500 AF060136 AF064513 AF194683 AF194711 AF058075 AF063717 Z19546 AF194581 X72746 U96393 U09890 X98897 AF194592 M80916 AJ241405 AF194632 AJ388659 AF194625 Z74694 AF194588 AF194601 U09901 U09911 U09892 AJ010336 AJ006162 AJ249377 AJ241414 AA327392 U97248 X72747 Z46850 X95739 AW406701 AJ243109 AF194609 S80758 AF194595 AF194596 L22483 Z70262 D84141 AW405758 AF001788 AF194580 D84143 U76684 AF194593 L03630 20 X87892 X91134 U21249 Z46346 AJ132426 AF103659 AJ233718 AF021038 AJ233727 H24657 U09882 S75627 AA573599 AF047231 AF047232 AF103616 AW404484 Z46848 S76132 AF103663 AF103713 Y17940 AF047216 AF103595 Y17956 AF052799 AF052797 AF052802 AF052798 AF052801 AF052794 AF052796 AF047218 AF052800 AF047217 AF052795 AF032351 AF103701 AF103708 AF103710 AF103706 S62232 AF103645 AF103632 AF103647 AF103644 AF103640 AF103692 AF093581 AF103620 AW405934 Al445389 AW383753 AA360256 AF099676 H21654 H39501 Al820828 H53689 W26785 AW384496 AW407708 AA541663 AA911602 Al821461 AA588300 AA327050 H42717 Al951280 AA421322 Al923193 AA864302 H25133 D87023 J03011 M61771 D87017 AA526865 AA253450 25 130232 18831_2 U29463 U06715 W24970 AA584303 T39581 AA155603 AA305043 AA429426 W05664 AA102382 AA482044 W24487 AA319060 T88946 F10106 AA232161 AA243117 AA158937 AA100864 109097 genbank_AA167512 AA167512

TABLE 9: Figure 9 from BRCA 001-2 US

5 **Table 9** depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey:	Unique Eos probeset identifier number
10	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title

				•
15	Pkey	ExAccn	UnigenelD	UnigeneTitle
		AA383256		estrogen receptor 1
	102211	BE314524	Hs.78776	putative transmembrane protein
• •	103587		Hs.82128	5T4 oncofetal trophoblast glycoprotein
20	104115	AF183810	Hs.26102	opposite strand to trichorhinophalangeal syndrome I
	105038	AW503733	Hs.9414	KIAA1488 protein
	105500	AW602166	Hs.222399	CEGP1 protein
	105990	Al690586	Hs.29403	hypothetical protein FLJ22060
	106155	AA425414	Hs.33287	nuclear factor I/B
25	106373	AW503807	Hs.21907	histone acetyltransferase
	106414	BE568205	Hs.28827	mitogen-activated protein kinase kinase kinase 2
	110009	BE075297	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal
	111900	AF131784	Hs.25318	Homo sapiens clone 25194 mRNA sequence
	114540	Al904232	Hs.75323	prohibitin
30	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone COL03924
	119771	Al905687	Hs.2533	EST
	121723	AA243499	Hs.104800	hypothetical protein FLJ10134
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypothetical protein YGL050w
35	131148	AW953575	Hs.303125	p53-induced protein PIGPC1
	132371	AA235448	Hs.46677	PRO2000 protein
	134169	Al690916	Hs.178137	transducer of ERBB2, 1
	302235	AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112
	452410	AL133619	Hs.29383	Homo sapiens mRNA; cDNA DKFZp434

TABLE 10: Figure 10 from BRCA 001-3 PCT

Table 10 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn: UnigenelD: Unigene Title:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title
	R1:	Ratio of tumor to normal body tissue
	R2:	Ratio of 90th percentile tumor to body
15	R3:	Ratio of 75th percentile body to tumor
	R4:	Ratio of tumor to normal breast tissue

20	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20	100082	AA130080	Hs.4295	proteasome (prosome, macropain) 26S subu	4.2	152	36	12.2
		AA380887		dolichyl-phosphate mannosyltransferase p	9.8	123	13	5
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	13.2	244	19	9.9
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	15.7	1030	66	5
25		H60720	Hs.81892	KIAA0101 gene product	4.1	320	78	10.6
		D14661	Hs.119	Wilms' tumour 1-associating protein	4.7	119	26	3
		AL037228		D123 gene product	5.1	106	21	9.2
		BE242284		adenylate cyclase 7	4.7	47	1	4.3
		D26361	Hs.3104	KIAA0042 gene product	4.7	47	4	0.7
30		AW972300		bone marrow stromal cell antigen 2	3.8	350	93	1.9
-		D29677	Hs.3085	KIAA0054 gene product; Helicase	4.1	64	16	3
		NM 01515		KIAA0071 protein	3.4	77	23	5.9
		NM_00620		platelet-derived growth factor receptor-	4.5	45	4	4
		D38491	Hs.322478	KIAA0117 protein	5.9	59	1	2.6
35		D42084	Hs.82007	KIAA0094 protein	3.5	96	28	1.3
-		BE247550		growth factor receptor-bound protein 7	3.1	306	98	1.5
		AA331881		peroxiredoxin 3	12.8	128	1	11.7
		AW247529		platelet-activating factor acetylhydrola	4.2	187	44	5.4
		AI878927	Hs.79284	mesoderm specific transcript (mouse) hom	4.5	129	29	3.1
40		D80004	Hs.75909	KIAA0182 protein	3.5	78	23	4.8
.0		D86957	Hs.80712	KIAA0202 protein	10.2	102	1	4.8
		D86961	Hs.79299	lipoma HMGIC fusion partner-like 2	4	40	1	3.8
		NM_01473		KIAA0215 gene product	3.2	32	2	2.9
		D86978	Hs.84790	KIAA0225 protein	3.6	36	7	3.2
45		AA013051		topoisomerase (DNA) II binding protein	5.6	76	14	2
		AA347720		KIAA0264 protein	3.5	35	9	3.1
		AF234887		cadherin, EGF LAG seven-pass G-type rece	5.5	145	27	2.2
		D87470	Hs.75400	KIAA0280 protein	3.4	34	1	1.2
		X51501	Hs.99949	prolactin-induced protein	22.7	760	34	1.4
50		AA019521		lysosomal	14.4	144	9	4.7
50		NM_00503		plastin 3 (T isoform)	4.1	259	63	1.9
	100661		Hs.132748	Homo sapiens ribosomal protein L39 mRNA,	3.3	116	36	2.2
		L05424	Hs.169610	CD44 antigen (homing function and Indian	8.5	85	1	3.2
		L05424	Hs.169610	CD44 antigen (homing function and Indian	3	594	201	2.3
55		BE207168		nuclear receptor subfamily 2, group F, m	5	82	17	0.9
55		J05581	Hs.89603	mucin 1, transmembrane	3.5	37	11	2.8
			Hs.191356	general transcription factor IIH, polype	9.7	97	10	7.2
	100821		7,0,70,000	gb:Homo sapiens (clone 104) retinoblasto	3.3	33	1	0.8
		BE563957	Hs 74861	activated RNA polymerase II transcriptio	3.7	477	130	3.1
60		X80821	Hs.27973	KIAA0874 protein	6.3	63	4	5.7
00			Hs.180789	S164 protein	4.7	47	1	4.2
		BE297139		replication protein A2 (32kD)	3.8	115	30	7.1
		K01160		NM_002122:Homo sapiens major histocompat	3.9	390	100	11.1
			Hs.250502	carbonic anhydrase VIII	3.9	39	8	3.6
	10.010	,						

	101084	AW409934	He 75528	nucleolar GTPase	4.1	53	13	4
		AW862258		neuropeptide Y receptor Y1	15.3	153	1	14.1
		NM_00162		aryl hydrocarbon receptor	11.3	113	8	3.9
		L20320	Hs.184298	cyclin-dependent kinase 7 (homolog of Xe	3.1	118	38	2
5		L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	8.2	396	48	0.9
_		AU077288		ADP-ribosylation factor-like 1	4	110	28	10.7
		BE545277		Ts translation elongation factor, mitoch	4.2	50	12	4.4
		BE535511		transmembrane trafficking protein	6.6	135	21	13.1
		BE267931		proliferating cell nuclear antigen	6.4	249	39	22.4
10	101447	M21305		gb:Human alpha satellite and satellite 3	6.5	878	135	8.0
	101448	NM_000424	4Hs.195850	keratin 5 (epidermolysis bullosa simplex	4.8	622	130	0.7
	101470	NM_000546	6Hs.1846	tumor protein p53 (Li-Fraumeni syndrome)	5.1	97	19	9.3
	101478	NM_00289	0Hs.758	RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
4 =		AA053486	Hs.20315	interferon-induced protein with tetratri	11.2	112	8	5.9
15		X16896	Hs.82112	interleukin 1 receptor, type I	3.9	39	2	3.5
		BE391804	Hs.62661	guanylate binding protein 1, interferon-	3.6	36	1	2.6
		M55998		gb:Human alpha-1 collagen type I gene, 3	3.1	2898	923	2.2
		AA436989		H2A histone family, member A	6.9	103	15	8.4
20		M63256	Hs.75124	cerebellar degeneration-related protein	6.4	64	2	4.9
20		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
		S70114	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
		M81057	Hs.180884	carboxypeptidase B1 (tissue)	3.6 9	824 144	227 16	1.4 13
		M83822 M84605	Hs.62354 Hs.957	cell division cycle 4-like putative opioid receptor, neuromedin K (3.3	36	11	2.4
25		AW024390		pre-B-cell leukemia transcription factor	5.4	180	34	15.9
23		M86849	Hs.323733	gap junction protein, beta 2, 26kD (conn	12	120	8	9
		AA446644		GA733-2 antigen; epithelial glycoprotein	3.1	353	116	2.8
		AL049610		transcription elongation factor A (SII)-	7.3	73	1	5.3
		AL036287		calponin 3, acidic	3.8	399	105	3.3
30		BE245149		protein tyrosine kinase 9	4.6	148	32	11.3
		U11313	Hs.75760	sterol carrier protein 2	9.5	95	4	8.8
	102123	NM_00180		centromere protein A (17kD)	4.2	42	7	3.4
	102125	NM_006450	6Hs.288215	sialyltransferase	9.3	93	4	3
	102139	NM_00441	9Hs.2128	dual specificity phosphatase 5	5.4	137	26	2.5
35	102162	AA450274	Hs.1592	CDC16 (cell division cycle 16, S. cerevi	4.6	151	33	2
	102165	BE313280	Hs.159627	death associated protein 3	9.3	93	5	8
		AL036335		secreted phosphoprotein 1 (osteopontin,	45.7	457	1	39.7
		BE314524		putative transmembrane protein	3.9	442	114	1.3
40		NM_00676		LIM domain only 4	4.9	49	1	3.6
40		U27185	Hs.82547	retinoic acid receptor responder (tazaro	3.1	31	1	1.3
		NM_001540		inhibitor of DNA binding 4, dominant neg	3.8	163 45	43 1	0.5 3.6
		AA306342		protein kinase C-like 2	4.5 8.5	2058	243	1.4
		AF015224 U37519	Hs.87539	mammaglobin 1 aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
45		U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	6.7	67	9	6.3
13		AW602154		E74-like factor 2 (ets domain transcript	5.3	53	1	4.8
		BE300330		selenophosphate synthetase 2	3.3	111	34	7.5
		NM_00139		dual specificity phosphatase 4	20.2	202	5	1.3
		NM_00393		kynureninase (L-kynurenine hydrolase)	3.8	38	1	1.5
50		U63830	Hs.146847	TRAF family member-associated NFKB activ	8.2	82	1	6.8
		U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	4.1	41	1	3.3
	102618	AL037672	Hs.81071	extracellular matrix protein 1	10.2	628	62	17.2
	102638	U67319	Hs.9216	caspase 7, apoptosis-related cysteine pr	5	66	13	5.3
		NM_00227		karyopherin (importin) beta 2	6.1	126	21	2.4
55		U71207	Hs.29279	eyes absent (Drosophila) homolog 2	4.5	45	1	2.8
		U79293	Hs.159264	Human clone 23948 mRNA sequence	4.1	41	1	2.4
		U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.4	255	58	1.6
		U90304	Hs.25351	iroquois homeobox protein 5	3.6	142	39	1.6 2.7
60		BE242035	Hs.151461	embryonic ectoderm development	3.5	35 56	1 1	5.3
60		D85390	Hs.5057	carboxypeptidase D clones 23667 and 23775 zinc finger prote	5.6 4.2	56 42	7	3.7
		BE262386 Al815559	Hs.75730	signal recognition particle receptor ('d	3.2	58	18	5
		NM_00227		keratin 15 .	5.8	753	131	0.4
		BE512730		keratin 18	3.1	815	266	1.7
65		AL119505		activating transcription factor 2	3.2	32	4	2.6
-		AU076611		methylene tetrahydrofolate dehydrogenase	5.7	251	44	6.6
		AI910275	Hs.1406	trefoil factor 1 (pS2)	5.6	1346	239	5.4

						040		40
		AW500470			5.8	218	38	13
		NM_002343		lactotransferrin	3.7	1421	388	1.9
	103036	M13509	Hs.83169	· · · · · · · · · · · · · · · · · · ·	3.1	94	30	5.8
_	103038	AA926960	Hs.334883		3.5	332	94	3.1
5	103119	X63629	Hs.2877		4.8	312	65	30.9
	103134		Hs.2839	Norrie disease (pseudoglioma)	5.2	331	64	1.5
	103134	X65724	Hs.2839	Norrie disease (pseudoglioma)	4.9	49	5	3.8
	103171	AW583058	Hs.234726	serine (or cysteine) proteinase inhibito	3.3	1497	458	2.1
	103206	X72755	Hs.77367	monokine induced by gamma interferon	3.5	796	228	3.2
10	103208	AW411340	Hs.31314	retinoblastoma-binding protein 7	5.6	191	34	3.5
	103226		Hs.44313	v-rel avian reticuloendotheliosis viral	4.1	53	13	4.9
		AA206186	Hs.79889	monocyte to macrophage differentiation-a	3.4	34	8	2.3
	103346		Hs.5464	thyroid hormone receptor coactivating pr	3.9	43	11	1
	103352		Hs.78853		9.3	93	8	8.2
15		NM_005982			9.7	97	1	9.3
		AL036166		coated vesicle membrane protein	6.3	98	16	9.1
	103391		Hs.114366	pyrroline-5-carboxylate synthetase (glut	4.3	77	18	7.2
		AW175781		M-phase phosphoprotein 6	4.9	153	31	2.4
			Hs.180139	SMT3 (suppressor of mif two 3, yeast) ho	4.9	261	53	3.7
20	103433		Hs.75216	protein tyrosine phosphatase, receptor t	3.5	564	162	1.7
20		AW408009		alkylglycerone phosphate synthase	3.9	49	13	2.5
		AL133415		vimentin	7.5	136	18	3.4
					7.9	79	2	6.9
		BE270266		5T4 oncofetal trophoblast glycoprotein cadherin 1, type 1, E-cadherin (epitheli	3.3	745	229	1.8
25		BE409838				41	13	2.8
23		AW403814		BCL2-associated athanogene	3.2	73		
		NM_000346		SRY (sex determining region Y)-box 9 (ca	7.3		1	5.2
		NM_000088		collagen, type I, alpha 1	3.8	1612	429	3.1
		NM_003528		H2B histone family, member Q	3.2	32	5	2.8
20		AA314389		ADP-ribosylation factor-like 5	3.2	32	9	2.7
30		AB033112		bromodomain and PHD finger containing, 3	4.9	49	1	4.2
		NM_002407		mammaglobin 2	7.2	498	69	9.3
		AF183810		opposite strand to trichorhinophalangeal	29	290	1	26.8
		H63349	Hs.98806	hypothetical protein	3.7	37	7	2.1
2.5		AW880614		RNA binding motif protein, X chromosome	5.2	52	1	4.3
35	104147	BE081342	Hs.283037	HSPC039 protein	8	84	11	6.3
	104209	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	5.8	58	1	3.2
	104239	AB002367	Hs.21355	doublecortin and CaM kinase-like 1	6.4	64	8	3
	104278	AW583693	Hs.109253	N-terminal acetyltransferase complex ard	4.7	229	49	7.9
	104309	AI337300	Hs.284123	hypothetical protein MGC4604	3.2	32	7	2.4
40	104394	AA129551	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	5.3	144	27	13.1
	104432	X51501	Hs.99949	prolactin-induced protein	6.9	1494	218	1.3
	104558	R56678	Hs.88959	hypothetical protein MGC4816	7.7	77	8	6.9
	104567	AA040620	Hs.5672	hypothetical protein AF140225	3.7	37	5	2.5
	104590	AW373062	Hs.83623	nuclear receptor subfamily 1, group I, m	6.1	493	81	0.7
45		H47610		gb:yp75f03.s1 Soares fetal liver spleen	3.8	38	4	1.2
		AF123303	Hs.24713	hypothetical protein	4.8	231	49	7.3
		H00820	Hs.30977	ESTs, Weakly similar to B34087 hypotheti	3.4	154	46	3
		R82252	Hs.106106	protein kinase (cAMP-dependent, catalyti	5	468	94	4.7
		BE298665		Homo sapiens mRNA; cDNA DKFZp564D016 (fr	3.8	82	22	3.1
50		Al239923	Hs.30098	ESTs	14.9	149	1	6.4
•		BE244072		macrophage erythroblast attacher	6.3	165	26	3.2
	404707	4 4 0 0 7 0 4 7	110120010		3.8	40	11	3.8
		AAU2/31/ AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	7.7	77	1	5.1
		Al139058	Hs.125790	leucine-rich repeat-containing 2	7	70	i	6.5
55		AI250789	Hs.32478	ESTs ESTS	4.7	201	43	4.5
55				ESTs	7.4	74	1	6
		AW015318		prolactin receptor	3.9	280	72	3.3
		AA026880		DKFZP434N093 protein	4.2	135	32	4
		BE298808				162	1	4.2
60		AF072873		frizzled (Drosophila) homolog 6	16.2		1	2.4
60		AI249502	Hs.29669	ESTs	3.8	38		1.9
		Al392640	Hs.18272	amino acid transporter system A1	3.2	522	165 4	2.9
		AA121686		ESTs	3.2	32 157	4	
		Al122691	Hs.13268	ESTs	3.7	157	43	3.6
65		AW503733		KIAA1488 protein	5.5	55	1	5.2 3.9
65		AB037716		KIAA1295 protein	10.3	103 .	1	
		AA148710		lumican	6.6	66	1	5.4
	105088	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	3.1	31	1	2.5

	105091	AA148859	Hs.179909	hypothetical protein FLJ22995	3.2	32	1	3
	105143	Al368836	Hs.24808	ESTs, Weakly similar to I38022 hypotheti	7.3	73	1	3.8
	105154	AA307279	Hs.35947	methyl-CpG binding domain protein 4	4.2	90	22	2.8
		AL133033		KIAA1025 protein	6	60	6	4.6
5				and the second s	3.8		2	3.2
3		AW612147		Homo sapiens C1orf19 mRNA, partial cds		38		
		AA313825		AD036 protein	9.3	436	47	5.8
	105195	AA975096	Hs.19522	hypothetical protein PRO2849	5.7	57	8	5.3
	105200	AA328102	Hs.24641	cytoskeleton associated protein 2	4.5	45	1	3.6
	105248	AW952479	Hs.22826	tropomodulin 3 (ubiquitous)	4.3	43	1	3.9
10		AB039670		ALEX1 protein	8	80	6	7.3
10					3.9	39	6	3.2
		AW997484		KIAA0456 protein				
		AA894638		ESTs	3.5	35	7	2.7
	105288	N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	4.5	45	10	0.5
	105309	AK000796	Hs.4104	hypothetical protein	3.8	93	25	7.5
15		AA234561		ESTs	2.8	131	47	3.9
		AF151073		hypothetical protein	3.9	79	20	6.5
				hypothetical protein EL MORAO				
		AW994032		hypothetical protein FLJ10849	5.1	181	36	15.8
		AW500718		Homo sapiens, clone MGC:16169, mRNA, com	4.1	41	2	3.3
	105400	AF198620	Hs.65648	RNA binding motif protein 8A	6.2	62	6	5.6
20	105426	W20027	Hs.23439	ESTs	3.3	206	63	2.2
_ •		AL137257		Homo sapiens cDNA: FLJ23015 fis, clone L	3.2	466	146	8.4
					16.6	166	8	12.7
		AL117441		hypothetical protein FLJ13033				
		AW602166		CEGP1 protein	25.4	508	20	3
	105508	AA173942	Hs.326416	Homo sapiens mRNA; cDNA DKFZp564H1916 (f	9	117	13	10.6
25	105511	AB037829	Hs.3862	regulator of nonsense transcripts 2; DKF	3.2	32	6	1.5
		AK001269		hypothetical protein FLJ10407	8.3	83	3	1.8
		AB040884		KIAA1451 protein	3.5	73	21	1.6
								2
		BE616694		hypothetical protein FLJ14299	5.8	336	58	
20		AA280072		fetal Alzheimer antigen	3.2	32	1	1
30	105616	R35343	Hs.24968	Human DNA sequence from clone RP1-233G16	4.8	79	17	5.2
	105627	AA281279	Hs.23317	hypothetical protein FLJ14681	4	75	19	1.7
		AA001021		thyroid hormone receptor interactor 8	4.5	45	1	3.7
		AW294631		ESTs	3.6	36	i	0.1
2.5		Al609530	Hs.279789	histone deacetylase 3	6.4	64	8	6
35	105687	NM_014517	7Hs.28423	upstream binding protein 1 (LBP-1a)	4.7	152	33	5.3
	105691	A1680737	Hs.289068	Homo sapiens cDNA FLJ11918 fis, clone HE	5.7	57	8	4.1
	105730	AW377314	Hs.5364	DKFZP564I052 protein	6.9	69	1	4.4
		AA834664		nuclear receptor coactivator 2	3.4	34	1	3.1
		BE246502		sema domain, immunoglobulin domain (Ig),	3	30	10	0.9
40							1	4.4
40			Hs.15159	chemokine-like factor, alternatively spl	5.4	54		
	105772		Hs.221132	ESTs	5.3	67	13	5.3
	105774	AW369278	Hs.23412	hypothetical protein FLJ20160	4.9	49	1	4.5
	105784	W84446	Hs.226434	hypothetical protein MGC4643	3.3	98	30	4.7
	105795	AA878183	Hs.17448	Homo sapiens cDNA FLJ13618 fis, clone PL	3.2	143	46	3.6
45		AF206019		REV1 (yeast homolog)- like	4	40	3	3.2
15		AA788946			4.7	747	158	5.7
				ESTs, Moderately similar to CA1C RAT COL				
		A1559444	Hs.293960	ESTs	3.9	371	94	4.6
		AW802282		pyruvate dehydrogenase phosphatase	3.6	68	19	6
	105840	AA601518	Hs.22209	secreted modular calcium-binding protein	4.8	134	28	3.2
50	105851	Al827976	Hs.24391	hypothetical protein FLJ13612	4.3	772	179	1.7
			Hs.28332	Homo sapiens cDNA: FLJ21560 fis, clone C	4.3	43	1	3.7
		AW021691		GCN5 (general control of amino-acid synt	3.6	36	7	3.1
								2.9
		AK001708		hypothetical protein FLJ10846	3.4	34	8	
~ ~		AK001735		UDP-glucose:glycoprotein glucosyltransfe	3.6	45	13	1.3
55	105906	N25986	Hs.22380	ESTs	3.4	34	1	1.5
	106012	A1240665	Hs.8895	ESTs	21.2	212	6	17.4
	106020	AA043039	Hs.7870	hypothetical protein	3.9	47	12	4.4
		AL122072		heterogeneous nuclear ribonucleoprotein	4.4	174	40	1.6
								4
C O		AW952005		hypothetical protein FLJ12903	4.7	47	1	
60		AA382267	Hs.10653	ESTs	3.4	49	15	4.4
	106055	AA417034		gb:zu04f10.s1 Soares_testis_NHT Homo sap	3.5	53	15	1.2
		BE614474	Hs.289074	F-box only protein 22	3.4	116	35	2.2
		NM_001329		C-terminal binding protein 2	3.6	444	125	4.6
	106070		Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.6	365	103	6.9
65				E74 like feeter 5 (etc. dec. de				1
65		AF115402		E74-like factor 5 (ets domain transcript	26.3	356	14	
		AW379378		protein tyrosine phosphatase, receptor t	3.2	267	83	2.3
	106126	AA576953	Hs.22972	hypothetical protein FLJ13352	3.8	38	1	3.3

	400455	4 4 4 0 5 4 4 4	11. 00007		0.0	402	40	10
		AA425414		nuclear factor I/B	9.9	483	49	1.8
		W37943	Hs.34892	KIAA1323 protein	6.7	94	14	8
		A1244563	Hs.325531	Homo sapiens clone 015h12 My015 protein	3.3	95	29	4.4
	106236	AB040896	Hs.21104	KIAA1463 protein	3.8	83	22	7.5
5	106286	AI765107	Hs.274422	hypothetical protein FLJ20550	3.3	97	30	6.4
	106290	AW961393	Hs.16364	hypothetical protein FLJ10955	4.5	116	26	4.5
		R98185	Hs.17240	ESTs	7	70	3	1.3
		AB007866		KIAA0406 gene product	3.2	37	12	2.6
		AW977397		ESTs	3.8	38	1	1.9
10						255	16	6.6
10		AA447453		Homo sapiens mRNA; cDNA DKFZp586M0723 (
		AW748420		Homo sapiens cDNA: FLJ21487 fis, clone C	4.9	337	70	2.7
	106394	Z42993	Hs.25320	Homo sapiens clone 25142 mRNA sequence	3.1	72	23	5
	106432	AK000310	Hs.17138	hypothetical protein FLJ20303	3.1	165	54	1.6
	106459	AA789081	Hs.4029	glioma-amplified sequence-41	3.1	31	1	2.6
15		AB033042		cofactor required for Sp1 transcriptiona	5.5	147	27	4.4
		Al205785	Hs.30348	ESTs	4.4	222	51	1.8
		NM_014892		KIAA1116 protein	7.4	74	3	1.7
					15.2	152	1	12.6
		AA243837		ESTS				
20		AK000933		Homo sapiens cDNA FLJ10071 fis, clone HE	3.8	263	69	3.9
20		AA452379		ESTs, Moderately similar to ALU7_HUMAN A	4.9	49	1	4.1
	106611	R49131	Hs.26267	ATP-dependant interferon response protei	5.8	58	5	3.1
	106628	AW188205	Hs.12311	Homo sapiens clone 23570 mRNA sequence	5.3	166	32	14.9
	106650	AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp564O0122 (i	5.4	75	14	8.0
	106683	BE296396		DIPB protein	3.6	210	58	4.7
25		N28524	Hs.29403	hypothetical protein FLJ22060	5.7	57	10	4.8
23		N38902	Hs.334437	hypothetical protein MGC4248	4.4	371	84	3.2
					4.3	101	24	1.6
		AA600357		TIA1 cytotoxic granule-associated RNA-bi				
		NM_007118		triple functional domain (PTPRF interact	4.6	46	1	4.
20		AL044182		KIAA0753 gene product	3.5	58	17	1.6
30	106846	AB037744	Hs.34892	KIAA1323 protein	5.4	192	36	4.4
	106868	BE185536	Hs.301183	molecule possessing ankyrin repeats indu	3.3	696	214	1.8
	106882	AA149537	Hs.26994	hypothetical protein FLJ20477	3.8	38	1	1.6
		AA835868		mannosidase, alpha, class 1A, member 1	4.3	43	10	2.2
		AK001826		hypothetical protein FLJ11269	3.6	36	1	1.2
35		AF039023		RAN binding protein 6	4.5	45	i	3.8
33				Homo sapiens, clone IMAGE:3685398, mRNA,	5.7	94	17	7.3
		AA134329						2.3
		AI868648	Hs.22315	ESTs	3.5	180	52	
		AF216751		CDA14	5.5	130	24	12.5
	106990	AA280722	Hs.24758	ESTs, Weakly similar to I38022 hypotheti	3.2	266	83	1.8
40	107008	AL157479	Hs.23740	KIAA1598 protein	5.1	298	59	4.4
	107014	AA598820		gb:ae36h12.s1 Gessler Wilms tumor Homo s	3.3	228	69	2.8
		AV650537	Hs.247309	succinate-CoA ligase, GDP-forming, beta	3.1	55	18	3.8
		AW401864		programmed cell death 8 (apoptosis-induc	3.1	75	24	2.2
		AW385224		ectonucleotide pyrophosphatase/phosphodi	3.1	367	119	2.3
45					3.9	98	25	8.6
45		AL122043		hypothetical protein DKFZp566G1424		63	1	5.4
		AB037765		KIAA1344 protein	6.3			
		AA249096		ESTs	4.6	71	16	3.6
		AV661958		GK001 protein	2.5	392	155	4.3
	107151	AW378065	Hs.8687	ESTs	15.6	156	7	10.8
50	107217	AL080235	Hs.35861	DKFZP586E1621 protein	4.8	48	8	3.1
	107222	BE172058	Hs.82689	tumor rejection antigen (gp96) 1	3.4	251	74	23.7
	107240	Al290284	Hs.159872	ESTs	3.6	36	6	0.5
		AW263124		nuclear receptor co-repressor/HDAC3 comp	5.4	483	90	4
		AA186629		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	199	44	19.2
55				hypothetical protein MGC4606	12.5	156	13	2.9
55		BE277457					35	9.6
		T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586I0324 (f	3.2	110		2.6
		T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.5	35	1	
	107485	AL042613	Hs.262476	S-adenosylmethionine decarboxylase 1	5.8	151	26	11.4
	107612	A1498986	Hs.60090	Homo sapiens cDNA FLJ13595 fis, clone PL	3.2	32	5	2.1
60	107638	A1580492	Hs.42743	hypothetical protein	4.4	73	17	6.2
		AA149707		ubiquitin-like 3	3.5	282	80	3.7
		AW732573		potassium voltage-gated channel, delayed	5.7	85	15	7.8
		AW372451		CGI-79 protein	3.5	35	1	1
		AA054949		ESTs	4.3	43	10	2.7
65		AA025782		ESTs	3.1	31	9	2.2
05				ESTs	4.7	47	4	4.3
			Hs.42826	lg superfamily receptor LNIR		90	1	5.5
	10/922	BE153855	HS.0 140U	ig aupenamily receptor LNIK	9	30	1	0.0

	107994	AA036811	Hs.48469	LIM domains containing 1	4.5	45	1	3.8
		AL121031		SWI/SNF related, matrix associated, acti	6.5	65	2	6
		AJ404672		hypothetical protein FLJ23571	7.4	74	8	6
		BE548479		hypothetical protein FLJ10773	3.4	34	1	2.3
5	108339	AW151340	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7	187	1	17
	108467	A1478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	3.8	38	1	3.2
	108539	AA084677	Hs.54558	hypothetical protein FLJ22222	5.7	57	1	4.9
		AW022410		ESTs	3.2	32	5	1.7
1.0		BE546947		homeo box C10	8.7	247	29	5.7
10		AB029000		KIAA1077 protein	3.7	625	168	3.8
		AF133123		general transcription factor IIIC, polyp	3.7	37	1	3.2
		AF070578		Homo sapiens clone 24674 mRNA sequence	3.4	34	1	2.8
			Hs.49376	hypothetical protein FLJ20644	3.5	35	1	3.2
1 5		AW295647		hypothetical protein MGC5350	5.3	53	1	2.8
15		AL117452		DKFZP586G1517 protein	4.8	96	20	6.5
		AK001468		anillin (Drosophila Scraps homolog), act	5.4	54	1	4
		BE276891		retinoic acid induced 3	3.1	529	170	4.1
			Hs.173648	ESTs, Weakly similar to Zinc-finger prot	3.3	33 34	5 1	1.7 2.6
20		NM_007240		dual specificity phosphatase 12	3.4	31	8	2.0
20		BE062109		chloride channel, calcium activated, fam	3.1 3.4	71	21	2.4
		AW608930 AW419196		hypothetical protein FLJ20618	4.1	334	82	3.4
		AK000684		hypothetical protein FLJ13782 hypothetical protein FLJ22104	3.3	33	1	2.9
		H89083	Hs.181915	ESTs	4	40	7	1.1
25		BE220601		hypothetical protein FLJ13033	3.8	233	, 62	3.8
23		AA219691		RAB6 interacting, kinesin-like (rabkines	8.8	199	23	16.1
		AA179962		EST	3.2	32	1	2.2
		AW976516		Homo sapiens cDNA: FLJ21354 fis, clone C	3.2	32	10	2.9
		Al381800	Hs.300684	calcitonin gene-related peptide-receptor	4.9	121	25	10.4
30		AA375752		Homo sapiens mRNA; cDNA DKFZp586F1822 (f		114	39	9.9
		AW975746		KIAA1702 protein	7.1	71	1	6.5
		AL096858		KIAA0929 protein Msx2 interacting nuclea	6.9	69	5	6.2
		R98881	Hs.109655	sex comb on midleg (Drosophila)-like 1	3.3	39	12	1.5
		BE543313		hypothetical protein FLJ10520	4.2	56	14	2.2
35		U80736	Hs.110826	trinucleotide repeat containing 9	12.3	123	1	11.3
	109481	AA878923	Hs.289069	hypothetical protein FLJ21016	3.2	286	91	5.7
	109517	Al631874	Hs.155140	casein kinase 2, alpha 1 polypeptide	8.3	83	8	1.9
	109597	AA989362	Hs.293780	ESTs	5.9	59	10	4.2
		F10024	Hs.268740	ESTs	3.2	41	13	3.3
40		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (i		208	36	1.8
		AW965076		hypothetical protein 669	5	50	5	4.1
		R68827	Hs.95011	syntrophin, beta 1 (dystrophin-associate	3.7	37	4	2
		AW390822		L-kynurenine/alpha-aminoadipate aminotra	14.2	142	1	9.5
15		Al084066	Hs.20072	myosin regulatory light chain interactin	4.1	41	7	1.7
45		AA001266		ESTs	4.2	58	14	0.8
		Al796320	Hs.10299	Homo sapiens cDNA FLJ13545 fis, clone PL	3.2	136	43	3.6
		BE075297 Al668594		ESTs, Weakly similar to A43932 mucin 2 p ESTs, Weakly similar to CP4Y_HUMAN CYTOC	6.3	693 913	110 199	7.2 2.9
		AK000768	Hs.176588	hypothetical protein FLJ20761	3.8	38	7	2.8
50		Al610702	Hs.28212	ESTs, Weakly similar to TRHY_HUMAN TRICH		78	12	3
50		H11236	Hs.31034	peroxisomal biogenesis factor 11A	3.7	37	1	2.1
			Hs.36823	ESTs	3.6	36	10	2.5
		H61560	110.00020	gb:yr22g03.s1 Soares fetal liver spleen	3.3	33	1	1.8
		AA071276	Hs.19469	KIAA0859 protein	3.5	35	8	1.9
55		AB007902		KIAA0442 protein	3.6	282	79	1.7
		H97678	Hs.31319	ESTs	4.4	103	24	3.8
		NM_014899		KIAA0878 protein	3.3	138	42	3.6
		BE000831		Homo sapiens cDNA FLJ11812 fis, clone HE	13.5	135	1	5.1
		N22414		gb:yw39a07.s1 Weizmann Olfactory Epithel	5.4	54	1	3.7
60			Hs.12244	hypothetical protein FLJ20097	4.7	47	4	4.2
	110799	AI089660	Hs.323401	dpy-30-like protein	5	50	1	4.3
		AL157503	Hs.27552	Homo sapiens mRNA; cDNA DKFZp586N2424 (i		31	1	2.7
				solute carrier family 19 (thiamine trans	8.4	84	1	5.3
~~		AI740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	10.5	105	4	7.1
65		BE612992		hypothetical protein FLJ10607 similar to	7.9	79	1	6.2
		AW963705		molecule possessing ankyrin repeats indu	3.9	353	90	1.2
	110908	Al433165	Hs.9856	ESTs	3.1	31	1	1.3

		BE092285		hypothetical protein FLJ13187	20.9	209	1	19.5
		BE242691		ESTS	3.4	115	34	2.4
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.5	35	9	3.2
5		H44186	Hs.15456	PDZ domain containing 1	4.3	43	1	2
3		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	5.4 7.2	54 72	1 10	4.3 6.1
		AB037807		hypothetical protein	7.7	77	1	5
		N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	25.1	288	12	6.7
		AK000136		asporin (LRR class 1)	3.9	146	37	9.8
10		AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.3	63	1	5.8
10		AK002055		hypothetical protein FLJ11193	3.7	119	33	6.7
		AB037782		KIAA1361 protein	3.6	402	112	4.9
		AA852773 AW389845		KIAA1866 protein ESTs	4.3	43	1	1
		AA902656		NIF3 (Ngg1 interacting factor 3, S.pombe	3.3	33	1	1.1
15		AA345644		PAN2 protein	4.8	61	13	5.6
13		AW263155		hypothetical protein FLJ10540	4.3	43	5	2.2
		W20090	Hs.6616	ESTs	4.1	41	1	2.6
		BE314949		hypothetical protein FLJ23309	3.8	425	111	4
		AW160993		hypothetical gene DKFZp434A1114	4.3	65	15	5.7
20		AK000987		oxidation resistance 1	3.4	314	91	2.4
		U82670	Hs.9786	zinc finger protein 275	3.5	35	1	2.1
		BE071382		hypothetical protein FLJ20170	3.5	105	30	9.6
		AW502285		hypothetical protein FLJ12879	3.2	37	12	3.5
		BE383234		Homo sapiens, clone MGC:15393, mRNA, com		62	2	5.9
25		AF027208		prominin (mouse)-like 1	8.1	328	41	1.7
		R40576	Hs.21590	hypothetical protein DKFZp564O0523	4.2	125	30	7.4
		NM_015310		KIAA0942 protein	6.5	65	10	1.5
•		R44538		gb:yg29c02.s1 Soares infant brain 1NiB H	3.3	33	10	2.3
		R41823	Hs.7413	ESTs; calsyntenin-2	6.1	185	31	6.6
30	112197	NM_003655	5Hs.5637	ESTs	3.5	507	145	3.3
	112198	Al432672	Hs.288539	hypothetical protein FLJ22191	3.5	40	12	2.5
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	112253	R51818		gb:yg77h12.s1 Soares infant brain 1NIB H	4	70	18	6.8
	112269	R53734	Hs.25978	ESTs, Weakly similar to 2109260A B cell	3.7	37	1	3
35	112275	AW972635	Hs.301904	hypothetical protein FLJ12671	4.3	45	11	4.4
	112280	AA863360	Hs.26040	ESTs, Weakly similar to fatty acid omega	2.8	751	270	1.3
	112305	AK000914	Hs.26244	hypothetical protein FLJ10052	3.5	41	12	3.7
	112483	AW969785	Hs.285885	Homo sapiens cDNA FLJ11321 fis, clone PL	4.2	42	6	3.6
40		R68425	Hs.13809	hypothetical protein FLJ10648	4.7	54	12	4.5
40		AA412205		ESTs	4.8	48	2	3.4
		Z42387	Hs.83883	transmembrane, prostate androgen induced	4.5	390	87	5.3
		AL134324		ESTs	3.2	99	31	3.1
		Al571940	Hs.7549	ESTs	9.6	124	13	9
15		N39342	Hs.103042	microtubule-associated protein 1B	9.1	91 65	6	8.3
45		AA283057		hypothetical protein FLJ14281	6.5	65 35	6	4.8
		T66847	Hs.194040	ESTs, Weakly similar to 138022 hypotheti	3.5	35 35	1	1.4 3.3
		AW449560		inner mitochondrial membrane peptidase 2	3.5 7.6	76	4	3.3 4.2
		AI791905	Hs.95549	hypothetical protein	3.1	453	148	7
50		A1075407	Hs.296083 Hs.17207	ESTs, Moderately similar to 154374 gene Homo sapiens cDNA FLJ11922 fis, clone HE	3.6	36	4	2.6
50		AI869372 T97307	113.17207	gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		AL359588	He 70/1	hypothetical protein DKFZp762B226	4.6	46	4	4.3
		A1269096	Hs.135578	chitobiase, di-N-acetyl-	3.6	36	1	1.2
		T62849	Hs.11090	membrane-spanning 4-domains, subfamily A	3.3	744	227	2.5
55		BE247683	Hs.14611	dual specificity phosphatase 11 (RNA/RNP	3.3	180	54	2.1
55		W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C	5.1	51	5	4.5
		NM_005032		plastin 3 (T isoform)	3.2	238	75	2.1
		AA457211		bromodomain adjacent to zinc finger doma	4.3	43	8	3.6
		AW002834		ESTs	6.1	110	18	10.2
60		W76027	Hs.23920	hypothetical protein FLJ11105	4	48	12	4
	113923	AW953484		hypothetical protein FLJ22041 similar to	3.7	239	65	3.6
		W17056	Hs.83623	nuclear receptor subfamily 1, group I, m	4.3	819	191	1.2
		AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082 (fr		123	12	7
		A1825386	Hs.164478	hypothetical protein FLJ21939 similar to	4.4	44	6	2.3
65		AB026436		dual specificity phosphatase 10	4.5	45	4	2.6
	114057	AF116653	Hs.34192	Homo sapiens PRO0823 mRNA, complete cds	3.5	35	6	3.2
	114082	AK001612	Hs.26962	Homo sapiens cDNA FLJ10750 fis, clone NT	3.1	31	5	1.5

	114124	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
		AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr	6.7	67	1	6.3
	114162	AF155661		pyruvate dehydrogenase phosphatase	3.8	73	19	1.8
_	114196	AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	4.4	104	24	5.1
5	114208	AL049466	Hs.7859	ESTs	5.7	57	1	4.9
	114239	AL137667	Hs.267445	Homo sapiens mRNA; cDNA DKFZp434B231 (fr	3.3	33	1	2.4
	114251		Hs.21948	ESTs	4.2	46	11	1.4
	114306	AF100143		fibroblast growth factor 13	4.5	45	2	3
1.0		AF183810		trichorhinophalangeal syndrome l	4.4	44	1	3
10		AW970128		anterior gradient 2 (Xenepus laevis) hom	4.7	770	166	5.8
		Al521936	Hs.107149	novel protein similar to archaeal, yeast	5.2	52	3	2.3
		Al859865	Hs.154443	minichromosome maintenance deficient (S.	4.6	196	43	10
		AF212848		ets homologous factor	13.7	137	1	8.9
1.5		AV656017		CGI-76 protein	3.3	168	51	7.3
15		AA159181		serologically defined colon cancer antig	7.4	137	19	1.8
		AI648602		ESTs	4.7	57	12	4.7
		AL157545		bromodomain and PHD finger containing, 3	9.1	91	1	7.6
		BE165762		hypothetical protein from BCRA2 region	10.1	111	11 11	10.2 5
20		BE092696		ESTS PAR DAD	6.4 35.9	67 359	10	29.7
20		A1733881	Hs.72472	BMP-R1B	9.4	94	8	7.3
		AW162998	⊓S.∠4004	KIAA1376 protein gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens		115	1	6.9
		AA251089 AA329340	He 4867	mannosyl (alpha-1,3-)-glycoprotein beta-	4.2	42	9	1.1
		AW265668		hypothetical protein FLJ12428	5.1	51	1	4.2
25		AI751438	Hs.41271	Homo sapiens mRNA full length insert cDN	4.5	290	65	3.7
23		NM_014158		HSPC067 protein	4.8	48	1	4.4
			Hs.191533	ESTs	3.2	49	16	4.2
		AK000219		hypothetical protein FLJ20212	3.3	33	1	3
		AW183695		ESTs	5.8	58	1	5
30		AW365434		hypothetical protein FLJ10116	5.5	343	62	2.5
		AI422867	Hs.88594	ESTs	11.2	112	1	10.3
		BE545072		hypothetical protein FLJ10461	4.5	96	21	7.8
	115536	AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act	5.9	59	1	4.2
	115583	NM_012317	7Hs.45231	leucine zipper, down-regulated in cancer	9.8	98	1	8.8
35	115600	AA081395		Homo sapiens cDNA FLJ10366 fis, clone NT	4.6	46	2	1.8
	115622	Al088691	Hs.208414	Homo sapiens mRNA; cDNA DKFZp564D0472 (f		44	7	1.1
	115646	N36110	Hs.305971	solute carrier family 2 (facilitated glu	3.2	372	115	2.1
		AW992356		Homo sapiens pyruvate dehydrogenase kina	10.2	506	50	2.8
40		W87707	Hs.82065	interleukin 6 signal transducer (gp130,	5.2	405	78	10.1
40		AW992405		Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
		AW899053		F-box only protein 8	3.1	58	19	2.5 28.5
		AW582256		anterior gradient 2 (Xenepus laevis) hom	5.7	368	65	2.2
		AW338063		zinc-finger protein ZBRK1	3.9 4.2	39 79	8 19	1.9
45		R50956 BE300266	Hs.159993	gycosyltransferase transducin-like enhancer of split 1, hom	5.8	58	1	4.4
43			Hs.332938	hypothetical protein MGC5370	6.2	62	1	5.4
		AA291377		ESTs	3.2	40	13	0.7
			Hs.42911	ESTs	8.4	101	12	8.7
		AW673312		hypothetical protein FLJ20331	3.6	36	1	2
50		Al198719	Hs.176376	ESTs	5.1	51	1	2
•		AL133916		hypothetical protein FLJ20093	3.4	34	8	1
		AF126743		DNAJ domain-containing	3.5	35	8	3.3
		AF189011		putative ribonuclease III	4.5	45	9	3.4
		AW861622		Homo sapiens cDNA FLJ14934 fis, clone PL	5.2	52	4	3.9
55	116226	AW976438	Hs.17428	RBP1-like protein	3.8	38	7	2.1
	116238	AV660717	Hs.47144	DKFZP586N0819 protein	5.1	198	39	17.9
	116250	N76712	Hs.44829	ESTs, Weakly similar to I38022 hypotheti	13.3	133	8	3.2
	116256	AA328153	Hs.88201	ESTs, Weakly similar to A Chain A, Cryst	3.3	106	33	9.8
	116298	Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	4.8	179	38	2.8
60		AL133033	Hs.4084	KIAA1025 protein	3.2	173	55	3
		AL133623	Hs.82501	similar to mouse Xm1 / Dhm2 protein	3.7	37	1	1.8
		N50174	Hs.46765	ESTs	3.9	39	10	0.6
			Hs.71252	hypothetical protein DKFZp761C169	5.6	106	19	9
CF		AF191018		putative nucleotide binding protein, est	3.6	256	72	3.7
65		A1654450	Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr		119	39	2
		AA313607	Hs.58633	Homo sapiens cDNA: FLJ22145 fis, clone H	5.5	315	58	3.1 1.6
	1764/0	AI272141	Hs.83484	SRY (sex determining region Y)-box 4	3.4	496	144	1.6

	116507	AI418366	Hs.68501	ESTs	3.1	31	4	1.9
		AW888411		leukemia-associated phosphoprotein p18 (3.3	931	279	5.6
	116625	F01601	Hs.241567	RNA binding motif, single stranded inter	3.6	36	1	1.9
~		AI768015	Hs.92127	ESTs	4.5	96	22	6.9
5		AW902848		ESTs CT40	4.2	42	1	2.7
		F10577	Hs.306088	v-crk avian sarcoma virus CT10 oncogene	7.1 4.3	71 190	9 44	6.9 5.4
		AA741307 H25836	Hs.301527	hypothetical protein FLJ20073 ESTs, Moderately similar to unknown [H.s	22.8	228	9	12.4
		AW362955		Homo sapiens cDNA FLJ14415 fis, clone HE	4.9	108	22	9
10		AW161357		microtubule-associated protein tau	4.6	163	35	7.3
_ 0		H64938	Hs.337434	ESTs, Weakly similar to A46010 X-linked	6.9	69	10	2.4
		AW085208		ESTs	4.8	48	1	2.5
	117067	H91164	Hs.335797	ESTs	3.3	33	1	2.3
1 ~-		H95785	Hs.167652	ESTs, Highly similar to 1819485A CENP-E	3.1	38	13	1.7
15		AW901347		hypothetical protein FLJ23342	4.8	48	1	0.9
		N25929	Hs.42500	ADP-ribosylation factor-like 5	3.1 3.6	295 41	96 12	27.9 2.8
		W03011 M18217	Hs.306881 Hs.172129	MSTP043 protein Homo sapiens cDNA: FLJ21409 fis, clone C	3.9	322	83	4.4
		Al041793	Hs.42502	ESTs	3.5	72	21	1.3
20		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174	9	6.9
		N30205	Hs.93740	ESTs, Weakly similar to 138022 hypotheti	3.2	35	11	0.7
		AW341639		hypothetical protein FLJ22059	5	50	1	4.7
	117667	U59305	Hs.44708	Ser-Thr protein kinase related to the my	4.5	211 1	47	5
0.5		AW877787		KIAA0853 protein	4.6	46	1	3.8
25		N49967	Hs.46624	HSPC043 protein	3.1	31	1	2.7
		AI521436	Hs.38891	ESTS	4.9	49	1	4.4
		AA374756		Homo sapiens mRNA for KIAA1771 protein,	5 3.6	50 89	2 25	3.1 0.9
		AI813865 AF091434	Hs.164478 Hs.43080	hypothetical protein FLJ21939 similar to platelet derived growth factor C	3.2	378	117	2.8
30		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	14.5	145	1	2.4
50		N66845	113.42110	gb:za46c11.s1 Soares fetal liver spleen	3.1	199	64	1
		N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HE	6	60	5	3.7
		A1949952	Hs.49397	ESTs	3.3	81	25	1.5
2.5		N79496	Hs.50824	EST, Moderately similar to I54374 gene N	3.4	740	217	2.8
35		AW134482		hypothetical protein FLJ13964	4.3	162	38	12.1
		T58283	Hs.10450	Homo sapiens cDNA: FLJ22063 fis, clone H	3.4	118	35	2.3
			Hs.44577	ESTS	3.5 8.4	35 84	1 10	2.9 0.8
		Al191811 AW292577	Hs.54629	ESTs ESTs	7.3	73	3	5.4
40		N29309	Hs.39288	ESTs	5	50	5	4.7
70		NM_01665		KDEL (Lys-Asp-Glu-Leu) endoplasmic retic	3.7	37	6	0.5
		N98488	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:zb82h01.s1 Soares_senescent_fibroblas	3.3	36	11	0.6
		R39261	Hs.90790	Homo sapiens cDNA: FLJ22930 fis, clone K	3.3	167	51	2.6
		R45175	Hs.117183	ESTs	5.3	53	6	2.3
45		H09334	Hs.92482	ESTs	3.7	37	4	3
		AI061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82 40	1	6.4 1.2
		NM_00124		cyclin T2	4 3.3	571	4 171	2
		BE048061 T78324	Hs.250895	ephrin-A3 ribosomal protein L34	3.4	34	3	2.4
50		AW474547		Homo sapiens PIG-M mRNA for mannosyltran	4.6	60	13	4.8
20		AL079310		high-mobility group protein 2-like 1	8.1	94	12	6.5
		AF088033		ESTs	3.3	33	8	0.9
	119638	NM_01612	2Hs.56148	NY-REN-58 antigen	3.3	33	10	0.5
		AA243837		ESTs	5.4	54	1	4.1
55		AA918317		B-cell CLL/lymphoma 11B (zinc finger pro	4.6	46	7	0.8
		Al905687	Hs.2533	EST	3.5	2073	595	2.1
		NM_01662		hypothetical protein	4.4 3.4	44 34	1	3.1 2.5
		AL133396		prion protein 2 (dublet) ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	36	1	2.9
60		AJ223810 AW245741		ESTs, Weakly similar to A35659 krueppel-	5.2	52	6	1.8
00		AI057404	Hs.58698	ESTs	3.7	37	4	1.9
		AL050097		DKFZP586B0319 protein	6.9	162	24	2.6
		BE565849		copine III	3.7	590	159	3.8
		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	6.9	319	47	2.1
65			Hs.153746	hypothetical protein FLJ22490	5.3	53	5	0.9
			Hs.108787	phosphatidylinositol glycan, class N	3.2 3.4	106 34	34 1	3.3
	120260	ANUUUUUT	Hs.101590	hypothetical protein	3.4	JH	1	1.7

	400000	**********	11 000000	1 11 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		404	20	4.0
		AW995911		hypothetical protein FLJ23399	4.2	124	30	1.8
		R06859	Hs.193172	ESTs, Weakly similar to I38022 hypotheti	7.5	112	15	2.5
		AA223249		abl-interactor 12 (SH3-containing protei	3.3	33	10	2.8
_	120418	AW966893	Hs.26613	Homo sapiens mRNA; cDNA DKFZp586F1323 (f	4.8	48	1	0.5
5	120473	AA251973	Hs.269988	ESTs	3.4	34	4	0.1
	120493	AW968080	Hs.152939	Homo sapiens clone 24630 mRNA sequence	3.9	161	42	2
		AA261852		ESTs	6.8	68	1	0.2
		AA284447		ESTs	3.2	32	5	0.6
		BE244580		hypothetical protein FLJ10330	8.5	127	15	1.6
10					3.7	37	1	0.5
10		AB037744		KIAA1323 protein				
		H39599	Hs.294008	ESTs	3.6	36	8	0.2
		AA703226		Homo sapiens mRNA; cDNA DKFZp586B211 (fr		101	18	1.6
	120649	AA687322	Hs.192843	leucine zipper protein FKSG14	5.4	54	10	2.5
	120658	AI952639	Hs.98267	ESTs	3.2	32	8	3
15	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	5.3	58	11	3.3
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.3	33	3	0.2
		AA347422		EST, Weakly similar to B34087 hypothetic	3.8	38	7	0.2
				ESTs	3.5	37	11	0.1
					3.1	31	1	0.4
20		AA481003		ESTs				
20		AA398155		ESTs	7.9	79	1	2.7
		Al972375	Hs.29626	hypothetical brain protein my038	5.1	51	1	2.4
	121125	AL042981	Hs.251278	KIAA1201 protein	3.7	37	10	1
	121176	AL121523	Hs.97774	ESTs	7	70	1	0.9
	121202	AA970946	Hs.97794	ESTs	3.9	39	1	0.2
25		AA406293		ESTs	3.4	34	1	8.0
25		AF044197		B-cell attracting chemokine 1 (CXCL13;	3.5	35	1	2.6
		AK000282		hypothetical protein FLJ20275	10.3	103	i	9.3
				ESTs, Weakly similar to T26525 hypotheti	3.5	143	41	2.6
		A1002968	Hs.235402				3	0.8
20		AA412488		TATA box binding protein (TBP)-associate	4.6	46		
30		AA412494	Hs.98152	EST	4.2	77	19	1.4
	121581	AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sap	3.2	32	1	8.0
	121709	Al338247	Hs.98314	Homo sapiens mRNA; cDNA DKFZp586L0120 (f	3.4	34	10	0.7
	121723	AA243499	Hs.104800	hypothetical protein FLJ10134	2.9	214	74	3.7
		AA449644		Homo sapiens cDNA FLJ14201 fis, clone NT	3.9	39	1	0.2
35		AA425887		hypothetical protein FLJ14303	4.4	48	11	0.9
33		AV650929		- Th	3.6	150	42	3.2
				splicing factor (CC1.3)	2.7	864	321	0.6
		Al249368	Hs.98558	ESTs; protease inhibitor 15 (PI15)				
		AW117207		ESTs	3.5	35	3	2.3
4.0		Al810721	Hs.95424	ESTs	4.9	49	7	3.7
40	122063	AW794215	Hs.301226	KIAA1085 protein	3.2	88	28	1.2
	122223	AF169797	Hs.27413	adaptor protein containing pH domain, PT	12.6	126	7	7.5
	122235	AA436475	Hs.112227	membrane-associated nucleic acid binding	4.1	43	11	1.6
		AI298368	Hs.150926	fucose-1-phosphate guanylyltransferase	3.1	31	1	1
		AA446189		ESTs	3.3	53	16	4
45		BE567620		ESTs	3.2	291	91	4
73				ESTs, Weakly similar to ALU1_HUMAN ALU S	3.1	31	6	8.0
		AA449453				_	1	3
		AW651706		hypothetical protein FLJ14007	3.5	35		
		AA454149		EST	3.2	32	10	3.1
~ 0		AW366286		splicing factor (CC1.3)	3.2	36	11	2.5
50		AA335721		ESTs	5.6	108	20	1.8
	122873	AA749382	Hs.118797	ubiquitin-conjugating enzyme E2D 3 (homo	3.6	36	1	3.4
	122946	A1718702	Hs.308026	major histocompatibility complex, class	3.7	162	44	12.4
	122963	AA478446	Hs.69559	KIAA1096 protein	7.2	72	1	5.7
			Hs.194215	ESTs, Weakly similar to l38022 hypotheti	4.7	59	13	4.7
55		AW338067		Homo sapiens cDNA FLJ11946 fis, clone HE	3.3	207	63	3.5
33				niban protein	3.8	207	55	5.5
		AL135185						
		A1073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
			Hs.105273	ESTs	4.1	72	18	1.5
			Hs.293796	ESTs	3.7	41	11	1.6
60	123442	AA299652	Hs.111496	Homo sapiens cDNA FLJ11643 fis, clone HE	6.7	67	2	2.1
		AL049325		Homo sapiens mRNA; cDNA DKFZp564D036 (fr	3.4	34	1	2.6
			Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA,	9.7	102	11	6
			Hs.112110	mitochondrial ribosomal protein L42	4.2	42	7	2.9
	123502	AW975051	Hs.293156	ESTs, Weakly similar to I78885 serine/th	3.9	39	1	3.2
65			Hs.173933	nuclear factor I/A	4.3	43	i	3.5
05				hypothetical protein	5.8	58	i	4.9
	123518	AL035414	Hs.21068					
	123523	AA608588		gb:ae54e06.s1 Stratagene lung carcinoma	3.1	927	295	2.1

		AF150208		damage-specific DNA binding protein 1 (1	5	121	25	5.9
		AA608955	Hs.109653	ESTs	6.8	68	10	6.1
		AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	8.5	85	1	4.3
~		BE550112		· · · · - · · · · · · · · · · ·		39	5	3.7
5	123709	AA706910	Hs.112742	ESTs	3.9	60	16	4.8
		AA425769		Alg5, S. cerevisiae, homolog of	3.4	80	24	3.8
		AW082862		hypothetical protein FLJ23189	4.5	45	2	3.6
			Hs.270016	ESTs	5.8	321	55	17
10		BE387335		ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
10	124287		Hs.5123	inorganic pyrophosphatase	3.1	41	14	2.7
	124292		Hs.13366	Homo sapiens cDNA: FLJ23567 fis, clone L	3.2	32	1	1.5
		AA249027		ribosomal protein S6	10.5	105	1	9.9
		NM_005402		v-ral simian leukemia viral oncogene hom	12.8	141	11	12.2
15		AF283776		Homo sapiens mRNA; cDNA DKFZp586C1723 (f		31	1	1.8
15			Hs.179864	ESTs	3.3	33	1	1.7
	124677		11- 440007	gb:ye84c03.s1 Soares fetal liver spleen	4.2	42	7	3 3.3
	124777		Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.4	210 162	63 25	3.3 14.7
				heterogeneous nuclear ribonucleoprotein	6.5 3.1	31	6	2.4
20	125079		Hs.271396	ESTS	3.4	985	286	2.8
20	125091		Ha 422720	gb:ye20f05.s1 Stratagene lung (937210) H ESTs, Moderately similar to KIAA1215 pro	3.6	224	63	4
		AA570056			6.3	63	6	5
		AB037742 W38240	118.24330	KIAA1321 protein Empirically selected from AFFX single pr	3.6	38	11	2.6
		W93048	Hs.250723	hypothetical protein MGC2747	3.1	31	1	2.8
25		AA782536		N-myristoyltransferase 2	3.2	37	12	3.6
23		AW401809		KIAA1150 protein	13.1	131	1	5.1
	125299		Hs.102720	ESTs	7.7	81	i 1	7.6
		AA173319		hypothetical protein MGC12217	14.3	143	9	13.1
		W72949	Hs.77495	UBX domain-containing 1	3.3	34	11	3.2
30		AL038165		translocase of outer mitochondrial membr	8.2	124	15	11.5
-		AA421691		UDP-glucose ceramide glucosyltransferase	3.7	224	61	21
		AA287921		ESTs	6.7	67	1	6
	125621		Hs.278544	acetyl-Coenzyme A acetyltransferase 2 (a	5.5	55	10	4.2
		AA418069		natural killer-tumor recognition sequenc	5.5	63	12	1
35		AW292171		scaffold attachment factor B	4.3	68	16	2.8
		AF078847		general transcription factor IIH, polype	4.8	48	5	4.1
			Hs.75722	ribophorin II	6.8	223	33	2.8
	125770	AA143045	Hs.81665	v-kit Hardy-Zuckerman 4 feline sarcoma v	8.3	87	11	0.4
	125827	NM_003403	3Hs.97496	YY1 transcription factor	11.3	124	11	9.7
40	125852	AW630088	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B1264 (f	30.6	306	4	26.5
	126349	T30968	Hs.13531	hypothetical protein FLJ10971	4.9	68	14	1.4
	126384	AW090198	Hs.4779	KIAA1150 protein	6.4	74	12	6.6
	126590	W78968	Hs.181307	H3 histone, family 3A	5	264	53	3.4
4.5		AA316181		six transmembrane epithelial antigen of	3.8	38	1	2.7
45		AW518478		ESTs	3.6	36	6	2.9
		AA643322		a disintegrin and metalloproteinase doma	3.1	31	1	2.5
		AA036755		syntaxin 16	4.4	76	18	1
		AW663887		hypothetical protein FLJ10936	3.8	38	1	3
5 0		AW163483		double ring-finger protein, Dorfin	6.7	155	23	1.4
50		AL043489		mitochondrial carrier homolog 2	8.8	110	13	10.5
		AA129640		ESTs	3.6	36	10	1.9
	1209/1	T26989	Hs.283664	aspartate beta-hydroxylase	5.5 3.1	79 33	15 11	4.4 2.3
		AA625690		ESTS	3.5	35	1	3.1
55		AA936428		ESTs ESTs	4.8	106	22	1
55	127439	AA412108	Hs.14368	SH3 domain binding glutamic acid-rich pr	7.5	75	1	6.5
		A1926047	Hs.162859	ESTs	3.8	38	7	3.4
		AA703684		ESTs, Moderately similar to ALU5_HUMAN A	3.3	33	9	0.9
		AF175265		vacuolar protein sorting 35 (yeast homol	4.3	152	35	12.5
60	127774	AA313639	Hs 119488	cystein-rich hydrophobic domain 2	5.4	73	14	6.8
00	127999	AW978827	Hs 69851	nucleolar protein family A, member 1 (H/	5.2	81	16	1.1
	128218	AA186733	Hs.292154	stromal cell protein	3.9	220	57	2.5
		AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3
			Hs.100261	Homo sapiens mRNA; cDNA DKFZp564B222 (fr	4.6	46	8	3.9
65		A1694143	Hs.296251	programmed cell death 4	7.2	72	1	5.8
	128501	AL133572	Hs.199009	protein containing CXXC domain 2	3.8	38	1	0.9
	128517	AW994403	Hs.100861	hypothetical protein FLJ14600	5.6	73	13	6.1

	128530	Al932995	Hs.183475	Homo sapiens clone 25061 mRNA sequence	4.2	104	25	7.8
		N25956	Hs.101810	Homo sapiens cDNA FLJ14232 fis, clone NT	3.1	172	55	3.1
		U31875	Hs.272499	short-chain alcohol dehydrogenase family	3.3	105	32	3
5		N48373 D87432	Hs.10247	activated leucocyte cell adhesion molecu	7.3 3.1	106 31	15 1	5 2.2
5		AA307211	Hs.10315	solute carrier family 7 (cationic amino proteasome (prosome, macropain) subunit,	3.6	130	36	3.5
		NM_004131		granzyme B (granzyme 2, cytotoxic T-lymp	3.9	43	11	1.8
		AF026692		secreted frizzled-related protein 4	17.4	409	24	7.8
		AB011125		KIAA0553 protein	3.1	34	11	2.7
10		NM_014720		Ste20-related serine/threonine kinase	3.6	36	5	1.5
		AK001731		Homo sapiens mRNA; cDNA DKFZp586H0924 (1		288	87	7.9
		R57988	Hs.10706	epithelial protein lost in neoplasm beta	11.3	113	8	2.5
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
1.5		AA009647		a disintegrin and metalloproteinase doma	4.6	132	29	9.7
15		AA115333		ESTs	8.2	82	1	7.4
		BE250162		dihydrofolate reductase	5 3.2	50 814	1 257	3.3 2.4
		L12350 N23018	Hs.108623 Hs.171391	thrombospondin 2 C-terminal binding protein 2	4.4	44	1	3.8
		Al132988	Hs.109052	chromosome 14 open reading frame 2	14.2	142	6	9.4
20		AF013758		polyadenylate binding protein-interactin	7.1	71	1	6.2
		BE169531		TAK1-binding protein 2; KIAA0733 protein	5	64	13	6.3
		AF220050		uncharacterized hematopoietic stem/proge	5.2	75	15	6.4
	129278	NM_015344	1Hs.11000	leptin receptor overlapping transcript-l	3.7	39	11	3.2
~ -		NM_014918		KIAA0990 protein	9.5	95	1	8.5
25		AL049538		ras association (RalGDS/AF-6) domain con	7.6	92	12	1.4
		BE220806		Homo sapiens clone 23785 mRNA sequence	7.1	150	21	14.5
		BE219987		phosphatidylinositol glycan, class F	3.9 3.6	54	14 1	5.1 2.7
		X61959 NM_005754	Hs.207776	aspartylglucosaminidase Ras-GTPase-activating protein SH3-domain	3.0 4	36 40	4	3.2
30		AW964541		hypothetical protein FLJ21127	4.6	199	44	2.3
20		N30436	Hs.11556	Homo sapiens cDNA FLJ12566 fis, clone NT	4.2	42	1	3.8
		M26939	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	6.4	1111	175	5
		BE242144		ATP-binding cassette, sub-family E (OABP	4.8	48	8	3.8
	129721	NM_001415	5Hs.211539	eukaryotic translation initiation factor	5.8	171	30	2.9
35	129740	BE165866	Hs.83623	nuclear receptor subfamily 1, group I, m	4.5	45	1	2.4
		R42216	Hs.12342	Homo sapiens clone 24538 mRNA sequence	5.3	53	9	3.6
		R39246	Hs.239666	Homo sapiens cDNA FLJ13495 fis, clone PL	3.1	31	2	2.5
		AB028945		cortactin SH3 domain-binding protein	11.4 4.7	114 556	1 119	10 4.5
40		Al222069 T71333	Hs.13015 Hs.13854	hypothetical protein similar to mouse Dn ESTs	3.1	31	3	3
70		NM_000399		early growth response 2 (Krox-20 (Drosop	3.2	32	1	0.2
		BE061916		chromosome 8 open reading frame 2	6.7	67	1	5.7
			Hs.324787	solute carrier family 5 (inositol transp	1	1	1	1
		AK001635		hypothetical protein FLJ10773	14.6	219	15	7.6
45		T47294	Hs.149923	X-box binding protein 1	3.1	1336	434	1.4
		AW977534		calcium/calmodulin-dependent serine prot	5.3	53	9	3.2
		U38847	Hs.151518	TAR (HIV) RNA-binding protein 1	4.2	46	11	1.1
		AB040914		KIAA1481 protein	13.2 3.3	331 354	25 108	12.4 4
50		AF127577 AL135301		nuclear receptor interacting protein 1 hypothetical protein FLJ10849	8.1	81	9	5.5
50		AW067800		stanniocalcin 2	72.2	722	1	1.9
		BE385099		hypothetical protein MGC3017	6.5	65	4	5.3
	130417	AW163518	Hs.155485	huntingtin interacting protein 2	3.5	79	23	2.5
		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
55		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
		W19744	Hs.180059	Homo sapiens cDNA FLJ20653 fis, clone KA	3.9	39	1	1.9
		AW876523		hypothetical protein FLJ12910	3.9	39	1	2.6
		AA383092		replication protein A3 (14kD)	4.4	44	1	4.1
60		AA383256 Al354355	Hs.1657 Hs.16697	estrogen receptor 1 down-regulator of transcription 1, TBP-b	32.2 5.2	322 251	1 48	4.7 21
UU		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	10	100	1	7.6
	130619	Al963376	Hs.12532	chromosome 1 open reading frame 21	3.9	39	ί	3.4
		AF176012	Hs.260720	J domain containing protein 1	10.5	105	i	9
	130677	AL161961	Hs.17767	KIAA1554 protein	6.8	129	19	12.1
65	130681	R62676	Hs.17820	Rho-associated, coiled-coil containing p	4.1	41	1	3.6
		R68537	Hs.17962	ESTs	9.2	234	26	16.8
	130712	AJ271881	Hs.279762	bromodomain-containing 7	17.5	175	2	12.8

	130723	BE247676	Hs.18442	E-1 enzyme	8.1	81	3	2.8
		AF052105		chromosome 12 open reading frame	4.9	49	1	4.3
		AA197226		hypothetical protein MGC11321	3.6	100	28	6.6
<u>-</u>		Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.4	525	154	5.3
5		AF080158		inhibitor of kappa light polypeptide gen	10.5	121	12	1.6
		AL044315		Homo sapiens mRNA for KIAA1750 protein,	6	202	34	3.7
		NM_003528		H2B histone family, member Q	7.1	100	14 27	7.5 1.7
		NM_012446 BE613269		single-stranded-DNA-binding protein hypothetical protein DKFZp761N0624	3.2 3.5	87 124	35	6.5
10		T97401	Hs.21929	ESTs	4.5	45	1	2.5
		AA749230		dolichyl-phosphate (UDP-N-acetylglucosam	3.2	210	66	3.8
		BE207357		KIAA1821 protein	3.8	42	11	0.6
		NM_016156		KIAA1073 protein	6.7	67	6	1.9
		BE541042		Homo sapiens cDNA: FLJ21848 fis, clone H	5.8	115	20	2.5
15		AW953575		p53-induced protein PIGPC1	3.8	585	153	3.7
	131164	AW013807	Hs.182265	keratin 19	5.2	1320	256	3.2
		AA465113		ESTs, Weakly similar to A34615 profilagg	3.8	38	1	3.3
		BE540516		hypothetical protein MGC3195	4.8	48	1	4.1
20		A1815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.1	343	56	16.4
20		AL080080		thioredoxin domain-containing	8	100	13	2.9
		A1038989	Hs.332633	Bardet-Biedl syndrome 2	4	95	24	1.1
		AW206008		Homo sapiens cDNA: FLJ21778 fis, clone H	4.6 3.5	239 402	53 114	3.5 2.1
		NM_003155 Al750575	Hs.173933	stanniocalcin 1 nuclear factor I/A	3.3	775	233	2.4
25		AW293165		ESTs	3.8	38	1	3
23		AK001123		hypothetical protein FLJ10261	3.9	116	30	0.5
		NM_014810		KIAA0480 gene product	7.6	76	1	5
		AA992841		KIAA1458 protein	5.1	113	22	6.1
		Al452601	Hs.288869	nuclear receptor subfamily 2, group F, m	8.4	169	20	4.6
30	131501	AV661958	Hs.8207	GK001 protein	3.1	197	63	18.7
	131535	N22120	Hs.75277	hypothetical protein FLJ13910	5.9	59	1	4.4
	131544	AL355715	Hs.28555	programmed cell death 9 (PDCD9)	5.1	51	1	3.9
		AA093668		muscleblind (Drosophila)-like	3.8	79	21	6.9
25		NM_003512		H2A histone family, member L	4	350	88	3
35		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.7	381	81	6.4
		AA306477		hypothetical protein FLJ10687	4.6	46	7	3.8
		NM_002104		granzyme K (serine protease, granzyme 3;	3.2	82	26 14	6.6
		BE297635 AB012124		heat shock 70kD protein 9B (mortalin-2)	6.7 3.8	93 51	14	8.4 1.7
40		AW963776		transcription factor-like 5 (basic helix SAR1 protein	7.2	72	4	5.7
40		AF017986		secreted frizzled-related protein 2	2.1	1561	757	1.7
		AA961420		ESTs	11.7	117	1	10.1
		AB014548		KIAA0648 protein	4.8	48	i	4.6
		D87077	Hs.196275	KIAA0240 protein	3.2	207	64	5.5
45		X86098	Hs.301449	adenovirus 5 E1A binding protein	3.4	115	34	9.1
	131836	W00712	Hs.32990	DKFZP566F084 protein	5.8	91	16	1.4
	131853	A1681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	4.9	632	129	1.7
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	6.8	68	1	5.6
5 0		AW361018		upstream regulatory element binding prot	4	140	35	1.8
50		BE502341		ESTS	5.7	57	1	4.5
		AF078866		Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	90	17	2.9
	131919	T15803	Hs.272458	protein phosphatase 3 (formerly 2B), cat	5.6 7.4	95 102	17 14	9.1 6.5
		BE252983 NM_002916		ubiquitin specific protease 1 replication factor C (activator 1) 4 (37	3.7	103 37	1	3.4
55		AK000010		hypothetical protein FLJ20003	3.5	35	1	2.5
55		W79283	Hs.35962	ESTs	5.5	168	31	4.4
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	3.7	37	9	2.8
		AA503020		hypothetical protein FLJ22418	40.2	402	1	4
		Al878910	Hs.3688	cisplatin resistance-associated overexpr	7.3	73	1	1.2
60		AA121098	Hs.3838	serum-inducible kinase	22.6	226	10	0.9
	132094	NM_01604	5Hs.3945	CGI-107 protein	3.1	227	73	16.8
		AW190902		cysteine knot superfamily 1, BMP antagon	3.5	73	21	6.3
		AW960474		ESTs	3.6	141	39	12.6
<i>C</i> =	132143	D52059	Hs.7972	KIAA0871 protein	4.9	49	1	4.1
65	132160	W26406	Hs.295923	seven in absentia (Drosophila) homolog 1	4.4	53	12	2.1
	132164	AI752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	5 10.7	225	45	9.1
	132180	NM_004466	UNS.4 10	fibroblast activation protein, alpha	10.7	433	41	7.2

	132197	Al699482	Hs.42151	ESTs	3.4	58	17	4
		AI078645	Hs.431	murine leukemia viral (bmi-1) oncogene h	4.2	42	1	2.2
		NM_01598		cytokine receptor-like molecule 9	3.4	34	2	3
		U28831	Hs.44566	KIAA1641 protein	18.6	186	10	1.5
5		N37065	Hs.44856	hypothetical protein FLJ12116	5.5	323	59	10.5
		NM_00354		H4 histone family, member G	3.3	979	298	2.2
	132384	AA312135	Hs.46967	HSPCO34 protein	3.6	36	1	3.1
		W32624	Hs.278626	Arg/Abl-interacting protein ArgBP2	5.9	186	32	3.7
		AL135094		hypothetical protein FLJ14495	4.2	159	38	7.1
10	132407	BE613126	Hs.47783	B aggressive lymphoma gene	4.6	46	1	4.3
		N87549	Hs.125287	zinc finger protein ZNF140-like protein	3.6	146	41	1.1
		AB020699		KIAA0892 protein	3.3	33	4	2.9
		AW169847		KIAA1634 protein	8.3	145	18	3.7
		AB023164		KIAA0947 protein	4.6	46	1	4.4
15		T78736	Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	1	8.4
~~		AA306105		SEC22, vesicle trafficking protein (S. c	4.9	49	1	4.4
		BE568452		protein regulator of cytokinesis 1	11.8	201	17	19.1
		Al929659		signal recognition particle 72kD	3.8	38	1	3
		AW803564		Homo sapiens cDNA: FLJ22528 fis, clone H	4.8	93	20	3.1
20		AW606927		hypothetical protein DKFZp586F1122 simil	6.1	61	2	5.9
~0		BE262677		hypothetical protein PRO1855	3.4	193	58	12.3
		AF037335		carbonic anhydrase XII	14.2	390	28	22.5
		AL050025		hypothetical protein FLJ20151	3.3	909	274	3.2
		AU076916		guanine monphosphate synthetase	5	50	1	4.1
25		AB018319		KIAA0776 protein	4.2	171	41	12.6
~~		AA025480		ESTs, Weakly similar to T33468 hypotheti	6.5	65	1	5.6
		AW242243		peroxisomal farnesylated protein	3.7	37	<u>i</u>	2.2
		U25435	Hs.57419	CCCTC-binding factor (zinc finger protei	7	115	17	5.4
		AL120050		Homo sapiens cDNA: FLJ23005 fis, clone L	3.3	61	19	5.1
30		NM_00144		glypican 4	4.8	48	1	3.6
50		BE077155		hypothetical protein DKFZp761B1514	12.6	126	8	9.9
		Al936442	Hs.59838	hypothetical protein FLJ10808	11	187	17	10.4
		BE613337		geminin	3.3	106	33	2.6
		AL047045		Homo sapiens clone 122482 unknown mRNA	3.5	110	32	2.1
35		AF234532		myosin X	4.1	62	15	4.9
55		AA093322		RNA binding motif protein 3	22.1	221	9	17.8
		X77343	Hs.334334	transcription factor AP-2 alpha (activat	12.7	311	25	2.4
		AA112748		clone HQ0310 PRO0310p1	3	380	127	5.5
		NM_00637		sema domain, immunoglobulin domain (lg),	7.3	271	37	2.3
40		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4
40		U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.6	36	1	3.1
		AK001628		KIAA0483 protein	5.2	117	23	5
		AA218564		vacuolar protein sorting 26 (yeast homol	3.1	359	118	2.5
		Al275243	Hs.180201	hypothetical protein FLJ20671	5.1	58	12	5.7
45		AF231981		homolog of yeast long chain polyunsatura	3	816	275	3.9
70		W32474	Hs.301746	RAP2A, member of RAS oncogene family	3.1	234	76	8.6
		AK001489		ADP-ribosylation factor-like 1	8.1	81	1	4.6
		Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
		BE297855		NRAS-related gene	3.3	33	1	2.9
50		AJ001388		zinc finger protein 238	7.9	234	30	18.9
50		AI499220	Hs.71573	hypothetical protein FLJ10074	4.6	46	5	3.5
		AK001519		CGI-74 protein	5	110	22	9.7
		AF245505		DKFZP564I1922 protein	3.2	725	227	3.2
		AF017987		secreted frizzled-related protein 1	4.1	374	91	1.1
55		AB033061		KIAA1235 protein	4.3	43	1	3.9
55		Al929357	Hs.323966	Homo sapiens clone H63 unknown mRNA	5.5	186	34	16.5
		W01556	Hs.238797	ESTs, Moderately similar to 138022 hypot	3.5	35	7	2.1
				arginine-glutamic acid dipeptide (RE) re	3.6	39	11	0.4
		AW998046 NM_00441		desmoplakin (DPI, DPII)	4.1	640	158	3
60		NM_00016		gap junction protein, alpha 1, 43kD (con	3.2	351	111	5.2
00						226	71	2.8
		W25797	Hs.177486	amyloid beta (A4) precursor protein (pro	3.2 3.4	178	53	8.8
		AU077050		translin nucleolar and coiled-body phosphprotein	3.4 4.7	47	1	4
		D21262	Hs.75337	ubiquitin-conjugating enzyme E2N (homolo		47 85	1	7.2
65		AW246428		splicing factor, arginine/serine-rich 5	8.5 3.6	36	1	0.4
0.5		NM_00692		tyrosine 3-monooxygenase/tryptophan 5-mo	3.4	234	68	10.7
		Al352558	Hs.75544	MAD (mothers against decapentaplegic, Dr	3.4 9.3	234 93	1	7.8
	133/40	AW410035	⊓S./ 000Z	was (mouters against decapentaplegic, Dr	۵.5	50	1	7.0

		M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	560	174	2.6
		AA557660		decorin	5.4 4.7	144	27 1	13.3 4.1
		BE622743 NM_002463		arfaptin 1 myxovirus (influenza) resistance 1, homo	3.3	47 380	114	4.1
5		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (304	46	7.8
Ū		AA147026		ESTs	6.2	600	97	4.1
•		AU076964		calumenin	3.3	889	267	5
	133968	AA355986	Hs.232068	transcription factor 8 (represses interl	3.7	91	25	2.6
		R48316	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564C1216 (f 3.4	91	27	8.5
10	133999	AA535244	Hs.78305	RAB2, member RAS oncogene family	7.8	78	1	5.6
		NM_00502		serine (or cysteine) proteinase inhibito	5.9	59	1	3.3
		AF091622		KIAA0244 protein	5.8	58	1	4.9
		U51166	Hs.173824	thymine-DNA glycosylase	6.4	100	16	4.4
15		R51273 NM_004354	Hs.79029	ESTs	5.1 5	51 50	9 1	3.8 3.2
15		BE513171		cyclin G2 mitochondrial ribosomal protein L3	4.8	246	51	3.9
		U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
		NM_01478		KIAA0203 gene product	4.6	69	15	5.8
		D28459	Hs.80612	ubiquitin-conjugating enzyme E2A (RAD6 h	7	97	14	7.5
20		C05768	Hs.8078	Homo sapiens clone FBD3 Cri-du-chat crit	3.4	34	5	2.6
		X76040	Hs.278614	protease, serine, 15	3.6	36	1	2.8
	134282	R45621	Hs.81057	hypothetical protein MGC2718	6.7	67	9	5.7
		Al022650	Hs.8117	erbb2-interacting protein ERBIN	4.5	137	31	12
25		BE538082		ESTs, Moderately similar to A46010 X-lin	5.2	52	1	4.9
25		AW903838		chondroitin sulfate proteoglycan 2 (vers	8.6	568	66	22.4
		AW959281		ESTs	4.8	53	11	3.7
		AW291946		interleukin 6 signal transducer (gp130,	7.1	71	4 23	6.4 2.8
		NM_00198: AA339449		v-erb-b2 avian erythroblastic leukemia v phosphoribosylglycinamide formyltransfer	3 4.4	68 44	1	4.1
30		N22687	Hs.8236	ESTs	13.3	445	34	6
50		AU077143		minichromosome maintenance deficient (S.	4.5	45	2	3.4
		AA456539		lysosomal	6	60	5	5.9
		Al916662		kinectin 1 (kinesin receptor)	4.1	301	73	6.1
		AW067903		collagen, type XI, alpha 1	4.6	1216	267	4.4
35	134415	Al750762	Hs.82911	protein tyrosine phosphatase type IVA, m	4.9	163	34	15.1
	134417	NM_006416	5Hs.82921	solute carrier family 35 (CMP-sialic aci	4.9	49	3	3.8
		W95642	Hs.82961	trefoil factor 3 (intestinal)	3.2	1872	592	3.3
		AU077196		collagen, type V, alpha 2	6.3	1075	171	3.8
40		U29344	Hs.83190	fatty acid synthase	3.3	710	217	2
40		X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411 153	12	5.1 4.3
		AF061739 D63477	Hs.83954 Hs.84087	protein associated with PRK1 KIAA0143 protein	4.8 3.1	147	32 48	12.7
		BE091005		activated RNA polymerase II transcriptio	3.3	33	1	2
		M14156	Hs.85112	insulin-like growth factor 1 (somatomedi	4.2	42	5	2.6
45		U66615	Hs.172280	SWI/SNF related, matrix associated, acti	3.9	39	ī	2.5
		AW903849	Hs.173840	HUEL (C4orf1)-interacting protein	3.7	41	11	0.6
	134604	NM_002884	4Hs.865	RAP1A, member of RAS oncogene family	5.2	52	1	3
		AW068223		ubiquitin C-terminal hydrolase UCH37	4.9	49	1	3.7
~ 0		AW299723		bone morphogenetic protein receptor, typ	5.2	52	5	3.5
50		AK001741		hypothetical protein FLJ10879	6.4	64	1	5.1
		A1750878	Hs.87409	thrombospondin 1	12.6	126	1 15	10.8 2.6
		AF271212 AK000606		disrupter of silencing 10 golgi SNAP receptor complex member 1	5.4 3.4	81 179	52	1.5
		X04011	Hs.88974	cytochrome b-245, beta polypeptide (chro	3.4	143	45	13.9
55		AF129536	Hs.284226	F-box only protein 6	7	70	6	6
55		BE281128	Hs.9030	TONDU	3.1	31	1	2.3
		Al879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
	134917	X87241	Hs.166994	FAT tumor suppressor (Drosophila) homolo	3.2	153	48	4.7
	134921	AL137491	Hs.125511	Homo sapiens mRNA; cDNA DKFZp434P1530 (f 4	452	114	2
60		AK002085	Hs.92308	Homo sapiens cDNA FLJ11223 fis, clone PL	5.1	150	30	7.2
		AW968058		nudix (nucleoside diphosphate linked moi	8.2	114	14	9.9
		H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
		AL034344	Hs.284186	forkhead box C1	5.4	259	48 304	1.4
65		A1272141	Hs.83484	SRY (sex determining region Y)-box 4 KIAA1682 protein	3.3 3.8	1296 240	394 64	2.2 3.2
05		AK000967 W55956	Hs.93872 Hs.94030	Homo sapiens mRNA; cDNA DKFZp586E1624 (101	13	7.9
		AW274526		ovarian carcinoma antigen CA125	3.3	33	1	2.6
	100000						-	-

•	135117	W52493	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	5.3	53	1	4.1	
-	`135144	NM_01625	5Hs.95260	Autosomal Highly Conserved Protein	7.4	74	5	2.4	
	135154	AK001835	Hs.267812	sorting nexin 4	6.6	69	11	6.3	
_	135155	Al207958	Hs.166556	Homo sapiens, Similar to TEA domain fami	6.1	61	1	5.1	
5	135172	AB028956	Hs.12144	KIAA1033 protein	3.4	88	26	1.4	
	135242	AI583187	Hs.9700	cyclin E1	3.1	31	1	2.3	
	135243	BE463721	Hs.97101	putative G protein-coupled receptor	3.4	169	50	9.1	
	135269	NM_00340	3Hs.97496	YY1 transcription factor	3.4	475	142	2.5	
	135356	BE312948	Hs.18104	hypothetical protein FLJ11274	3.1	31	10	1.7	
10	135357	A1565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	4.7	710	151	2.5	-
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1	
	135397	L14922	Hs.166563	replication factor C (activator 1) 1 (14	3.2	32	1	2.4	
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	117	37	9.4	
	٠	Al471525	Hs.247486	ESTs	3.8	58	16	5.5	
15		X70683	Hs.93668	ESTs	1.8	1047	596	1.6	
		L14922	Hs.82128	5T4 oncofetal trophoblast glycoprotein	5	285	58	1.2	
		M23263	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotransfera	as	3.1	31	1	2.6
		A1267886	Hs.148027	polymerase (RNA) II (DNA directed) polypeptide		7.8	137	18	11.9
• •		AA044840	Hs.241676	stromal cell-derived factor 1	4.7	114	25	0.9	
20		N90960	Hs.227459	ESTs; Moderately similar to !!!! ALU SUBFAMIL'		4.7	151	32	9.3
		AA873285		ESTs	4.7	47	3	4.4	
		T56679	Hs.865	RAP1A; member of RAS oncogene family	4	40	1	3.4	
		AA305536		"EST176522 Colon carcinoma (Caco-2) cell line		3.6	121	34	11.8
0.5		AI369384		arylsulfatase D	3.5	113	33	1.7	
25		AA219081	Hs.242396	ESTs: Moderately similar to !!!! ALU SUBFAMIL	/1	3.4	107	32	9.9

TABLE 10A

Table 10 A shows the accession numbers for those pkeys lacking unigeneID's for Table 10. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

4	\sim	
1	11	
	17	

5

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number

Genbank accession numbers

15

Accession:

	Pkey	CAT number	Accession
	123619	371681_1	AA602964 AA609200
20	104602	524482_2	H47610 R86920
	121581	283769_1	AA416568 AA442889 AA417233 AA442223
	123523	genbank_AA608588	AA608588
	100821	tigr_HT4306	M26460 U09116
~ ~	125091		
.25		NOT_FOUND_entre	
	118475	J	N66845
	104787	3	
	106055	J	
••		genbank_T97307	T97307
30		entrez_K01160	K01160
		entrez_M21305	M21305
		entrez_M55998	
	124677	O	
2.5	110581	O	H61560
35		genbank_N98488	N98488
		genbank_N22414	N22414
	112092	3	R44538
		genbank_R51818	
40	107014	_	
40	114988	genbank_AA251089	AA251089

TABLE 11: Figure 11 from BRCA 001-3 PCT

Unique Eos probeset identifier number

Pkey:

5 **Table 11** depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	UnigenelD: Unig Unigene Title: Unig		mplar Access jene number jene gene title					
	R2:			normal body tissue entile tumor to normal body				
15	R3:			entile tamor to normal body entile normal body to tumor				
	R4:			normal breast tissue				
		7100	o or tarrior to	normal broade addad				
				,				
•	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20								
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	13.2	244	19	9.9
		D13666		osteoblast specific factor 2 (fasciclin	15.7	1030		5
		X51501	Hs.99949	prolactin-induced protein	22.7	760	34	1.4
25		L05424		CD44 antigen (homing function and Indian	8.5	85	1	3.2
25				neuropeptide Y receptor Y1	15.3	153	1	14.1
		NM_00289		RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
		S70114		TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
20			Hs.95243	transcription elongation factor A (SII)-	7.3	73	1	5.3
30				death associated protein 3	9.3	93	5	8
			Hs.46452	mammaglobin 1	8.5	2058		1.4
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
		NM_00139		dual specificity phosphatase 4	20.2	202	5	1.3
25		U63830		TRAF family member-associated NFKB activ	8.2	82	1	6.8
35		D85390	Hs.5057	carboxypeptidase D	5.6	56	1	5.3
			Hs.297753		7.5	136	18	3.4
		NM_00034		SRY (sex determining region Y)-box 9 (ca	7.3	73	1	5.2
			Hs.26102	opposite strand to trichorhinophalangeal	29	290	1	26.8
40		AJ239923	Hs.30098	ESTs	14.9	149	1	6.4
40		Al858702		ESTs, Weakly similar to N-WASP [H.sapien	7.7 7	77 70	1	5.1
		A1139058		leucine-rich repeat-containing 2 ESTs	7.4	74	1	6.5 6
			Hs.23165	frizzled (Drosophila) homolog 6	16.2	162	ί	4.2
		AW50373		KIAA1488 protein	5.5	55	i	5.2
45			Hs.22862	ESTs	2.8	131	47	3.9
40				CEGP1 protein	25.4	508	20	3
			Hs.30738	hypothetical protein FLJ10407	8.3	83	3	1.8
		AW377314		DKFZP5641052 protein	6.9	69	1	4.4
		Al240665		ESTs	21.2	212	6	17.4
50			Hs.11713	E74-like factor 5 (ets domain transcript	26.3	356	14	1
50			Hs.33287	nuclear factor I/B	9.9	483	49	1.8
			Hs.30652	KIAA1344 protein	6.3	63	1	5.4
		AV661958		GK001 protein	2.5	392	155	4.3
		AW37806		ESTs	15.6	156	7	10.8
55			Hs.61460	lg superfamily receptor LNIR	9	90	1	5.5
			Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7	187	i	17
				hypothetical protein FLJ13782	4.1	334	82	3.4
				KIAA1702 protein	7.1	71	1	6.5
		U80736		trinucleotide repeat containing 9	12.3	123	i	11.3
60				L-kynurenine/alpha-aminoadipate aminotra	14.2	142	i .	9.5
	110000	BE075297	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	6.3	693	110	7.2
			Hs.29724	hypothetical protein FLJ13187	20.9	209	1	19.5
		N46180		Homo sapiens cDNA FLJ13289 fis, clone OV	7.7	77	1	5
				*·····				

	111179	AK000136	Hs 10760	asporin (LRR class 1)	25.1	288	12	6.7
				hypothetical protein FLJ11193	6.3	63	1	5.8
				KIAA1866 protein	3.6	402	112	4.9
			Hs.87128	hypothetical protein FLJ23309	3.8	425	111	4
5		AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
		A1571940	Hs.7549	ESTs	9.6	124	13	9
	113702			gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
	114138	AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr	6.7	67	1	6.3
10	114768	AF212848	Hs.182339	ets homologous factor	13.7	137	1	8.9
	114860	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	9.1	91	1	7.6
	114965	Al733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
	114988	AA251089		gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens	11.5	115	1	6.9
	115206	AW183695	Hs.186572	ESTs	5.8	58	1	5
15	115719	AW992405		Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
	115844			hypothetical protein MGC5370	6.2 ·	62	1	5.4
	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	1.8	1047		1.6
		H25836		ESTs, Moderately similar to unknown [H.s	22.8		9	12.4
20		M18217		Homo sapiens cDNA: FLJ21409 fis, clone C	3.9		83	4.4
20		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4		9	6.9
			Hs.42179	bromodomain and PHD finger containing, 3	14.5	145	1	2.4
		Al061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
-		Al905687	Hs.2533	EST	3.5	2073		2.1
25				hypothetical protein FLJ10330	8.5	127	15	1.6
25				hypothetical protein FLJ20275	10.3	103	1	9.3
				hypothetical protein FLJ10134	2.9		74	3.7
		AA478446	Hs.69559	KIAA1096 protein	7.2	72	1	5.7
		A1073913	MS.100686	ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
30		AA602964 AA706910	LI- 440740	gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	8.5	85 60	1 16	4.3 4.8
30		AI147155	Hs.112742		3.9 5.8		55	4.0 17
			Hs.270016		10.4		85	5.3
				ESTs, Weakly similar to S64054 hypotheti ribosomal protein S6	10.5	105	1	9.9
		AW401809		KIAA1150 protein	13.1	131	1	5.1
35			Hs.164950		6.7	67	1	6
55		D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr	30.6		4	26.5
		AI954968		matrix Gla protein	7.5	75	1	6.5
		Al694143	Hs.296251	programmed cell death 4	7.2	72	1	5.8
				secreted frizzled-related protein 4	17.4	409	24	7.8
40	128925	R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
			Hs.107968		8.2	82	1	7.4
	129229	AF013758	Hs.109643	polyadenylate binding protein-interactin	7.1	71	1	6.2
	129337	NM_014918	3Hs.110488	KIAA0990 protein	9.5	95	1	8.5
				Homo sapiens clone 23785 mRNA sequence	7.1		21	14.5
45		AB028945		cortactin SH3 domain-binding protein	11.4	114	1	10
		BE061916		chromosome 8 open reading frame 2	6.7	67	1	5.7
			Hs.324787		1	1	1	1
		AK001635		hypothetical protein FLJ10773	14.6	219	15	7.6
50				KIAA1481 protein	13.2	331	25	12.4
50				stanniocalcin 2	72.2	722 65	1 4	1.9 5.3
				hypothetical protein MGC3017	6.5			
		U63630		protein kinase, DNA-activated, catalytic	6.1 10.8	61 706	1 66	5.7 9.2
		D90041 AA383256	Hs.1657	N-acetyltransferase 1 (arylamine N-acety estrogen receptor 1	32.2	322	1	4.7
55		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	10		1	7.6
33			Hs.279762	bromodomain-containing 7	17.5		2	12.8
		AW953575		p53-induced protein PIGPC1	3.8		153	3.7
		NM_014810		KIAA0480 gene product	7.6	76	1	5
	131564		Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.7		81	6.4
60			Hs.31433	ESTs	11.7	117	1	10.1
•	131877			topoisomerase (DNA) Il alpha (170kD)	6.8	68	1	5.6
			Hs.36563	hypothetical protein FLJ22418	40.2	402	i	4
		U28831	Hs.44566	KIAA1641 protein	18.6	186	10	1.5
	132528		Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	1	8.4
65	132742	AA025480		ESTs, Weakly similar to T33468 hypotheti	6.5	65	1	5.6
		X77343		transcription factor AP-2 alpha (activat	12.7		25	2.4
			Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4

	133199	AF231981	Hs.250175	homolog of yeast long chain polyunsatura	3	816	275	3.9	
	133240	AK001489	Hs.242894	ADP-ribosylation factor-like 1	8.1	81	1	4.6	
	133271	Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8	
	133640	AW246428	Hs.75355	ubiquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2	
5	133746	AW410035	Hs.75862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8	
	133999	AA535244	Hs.78305	RAB2, member RAS oncogene family	7.8	78	1	5.6	
	134110	U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1	
	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12	5.1	
	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	6.4	64	1	5.1	
10	134880	AI879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5	
	135029	H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10	
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1	
	128305	AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3	

TABLE 11A

Table 11A shows the accession numbers for those pkeys lacking unigeneID's for Table 11. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset identifier number

CAT number: Accession:

Gene cluster number Genbank accession numbers

15

Pkey CAT number Accession

20 123619 371681_1 AA602964 AA609200 113702 genbank_T97307 T97307 114988 genbank_AA251089 AA251089

TABLE 12: Figure 12 from BRCA 001-3 PCT

5 **Table 12** depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10 15	Pkey: ExAccn: UnigenelD: Unigene Title: R1: R2: R3: R4:		Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal body tissue Ratio of 90th percentile tumor to body Ratio of 75th percentile body to tumor Ratio of tumor to normal breast tissue					
	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20		D12485	Hs.11951	phosphodiesterase I (PC-1)	13.2	244	19	9.9
	105500	AW602166	Hs.222399	ESTs	25.4	508	20	3
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	114124	W57554	Hs.125019	ESTs	24.2	242	10	5.6
	119771	AI905687	Hs.2533	ESTs	3.5	2073	595	2.1
25	121723	AA243499	Hs.104800	ESTs	2.9	214	74	3.7
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	17.4	409	24	7.8
	131148	AW953575	Hs.303125	ESTs	3.8	585	153	3.7
	131985	AA503020	Hs.36563	ESTs	40.2	402	1	4
	133100	AF231081	He 250175	Homo saniens clone 23904 mRNA sequence	3	816	275	3.9

TABLE 13: Table 1 from BRCA 001-5 US

5 Table 13 depicts a preferred group of genes upregulated in breast cancer cells.

10	Pkey:	Unique Eos probeset identifier number			
	ExAccn:	Exemplar Accession number, Genbank accession number			

UnigeneID: Unigene Title: R1:

Unigene number
Unigene gene title Ratio of tumor to normal body tissue

	R1: Ratio of tumor to normal body tissue				
15					
13	Pkey	ExAccn	UniGene ID	Unigene Title	R1
		27010011	011100110110	onigono i nio	• • • • • • • • • • • • • • • • • • • •
	100038	M97935		control	16.7
	100039	M97935		control	6.3
20	100040	M97935		control	8.3
		M97935		control	14.8
		AB003103		proteasome (prosome; macropain) 26S sub	7.5
			Hs.111783	Lsm1 protein	4.9
2.5		AF006084		actin related protein 2/3 complex; subunit	4.7
25		AF007875		dolichyl-phosphate mannosyltransferase p	13.4
		D00596	Hs.82962	thymidylate synthetase	15.9
		D10495	Hs.155342	protein kinase C; delta	4.6
		D10523	Hs.168669	oxoglutarate dehydrogenase (lipoamide)	7.5
20		D11094	Hs.61153	proteasome (prosome; macropain) 26S sub	4.4
30		D12485	Hs.11951	phosphodiesterase l/nucleotide pyrophosp	8.7
		D13627	Hs.15071	chaperonin containing TCP1; subunit 8 (t	9.5
		D13643	Hs.75616	Human mRNA for KIAA0018 gene; comp	6
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin I-like	8.5 10.5
35		D14657	Hs.81892	KIAA0101 gene product	4.6
33		D14812 D14878	Hs.173714	MORF-related gene X	7.9
		D14676 D21090	Hs.82043 Hs.178658	D123 gene product RAD23 (S. cerevisiae) homolog B	7.9 5.6
		D21090 D25538	Hs.172199	adenylate cyclase 7	9.9
		D25336 D26308	Hs.76289	biliverdin reductase B (flavin reductase (N	4.9
40		D26598	Hs.82793	proteasome (prosome; macropain) subunit	14.2
40		D26599	Hs.1390	proteasome (prosome; macropain) subunit	11.3
		D28137	Hs.118110	bone marrow stromal cell antigen 2	5.7
		D28915	Hs.82316	interferon-induced; hepatitis C-associated	5.7
		D31888	Hs.78398	KIAA0071 protein	7.4
45		D43950	Hs.1600	chaperonin containing TCP1; subunit 5 (e	5.6
		D49396	Hs.75454	antioxidant protein 1	12.9
		D50525	Hs.699	hypothetical protein	8.4
		D63391	Hs.6793	platelet-activating factor acetylhydrolase;	6.8
	100340	D63487	Hs.82563	KIAA0153 protein	4.4
50	100355	D78129	Hs.71465	Homo sapiens mRNA for squalene epoxid	12.6
	100363	D78514	Hs.78563	ubiquitin-conjugating enzyme E2G 1 (hom	4.6
	100368	D79987	Hs.153479	extra spindle poles; S. cerevisiae; homolo	6.5
	100372	D79997	Hs.184339	KIAA0175 gene product	8.4
	100375	D80004	Hs.75909	KIAA0182 protein	4.5
55		D82060	Hs.278721	Ke4 gene; mouse; human homolog of	8.1
		D83777	Hs.75137	KIAA0193 gene product	10.7
		D84145	Hs.39913	novel RGD-containing protein	7.2
		D84557	Hs.155462	minichromosome maintenance deficient (m	7.2
60		D86425	Hs.82733	nidogen 2	5.4
60		D86479	Hs.118397	AE-binding protein 1	4.3
		D86957	Hs.80712	KIAA0202 protein	11.9
		D86985	Hs.79276	Human mRNA for KIAA0232 gene; comp	9.7
		D87464	Hs.10037	KIAA0274 gene product	6.4
65		D87465	Hs.74583	KIAA0275 gene product	10 6,2
03	100448	D87469	Hs.57652	EGF-like-domain; multiple 2	0.2
				215	

	100467	D89052	Hs.7476	ATPase; H+ transporting; lysosomal (vacu	7.5
		D89289	Hs.118722	fucosyltransferase 8 (alpha (1;6) fucosyltr	5
		HT1112	Hs.10842	Ras-Like Protein Tc4	16.9
5		HT1400	Hs.79137	Carboxyl Methyltransferase, Aspartate, A	5.6
3		HT2710	Hs.114599	Collagen, Type Viii, Alpha 1	7.5 4.4
		HT3018 HT3127	Hs.132748 Hs.169610	Ribosomal Protein L39 Homolog Epican, Alt. Splice 11	4.6
		HT3938	Hs.169610	Epican, Alt. Splice 17 Epican, Alt. Splice 12	4.4
		HT3742	Hs.287820	Fibronectin, Alt. Splice 1	9
10		HT26388	Hs.89603	Mucin 1, Epithelial, Alt. Splice 9	4.7
- 0		HT4018	Hs.191356	Basic Transcription Factor, 44 Kda Subun	13.7
		HT4343	Hs.278544	Cytosolic Acetoacetyl-Coenzyme A Thio	10.6
	100830	HT4344	Hs.4756	Rad2	5.5
	100840	HT4392	Hs.183418	Protein Kinase Pitslre, Alpha, Alt. Splice	4.1
15		HT417	Hs.297939	Cathepsin B	4
		HT4582	Hs.75113	Transcription Factor Ilia	4.9
		HT5158	Hs.5398	Guanosine 5'-Monophosphate Synthase	8.7
	100914		Hs.324178	Ras Inhibitor Inf	7.2
20	100916		Hs.73946	Endothelial Cell Growth Factor 1	5.9 4.6
20	100945	J02923	Hs.180686 Hs.76506	Oncogene E6-Ap, Papillomavirus lymphocyte cytosolic protein 1 (L-plastin	30.1
		J02525 J03589	Hs.76480	ubiquitin-like 4	8.3
		J03909	Hs.14623	interferon; gamma-inducible protein 30	6.9
		J03934	Hs.80706	diaphorase (NADH/NADPH) (cytochrom	4.3
25		J04430	Hs.1211	acid phosphatase 5; tartrate resistant	5.9
	101017	J04599	Hs.821	biglycan	5.1
	101031	J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B;	37.2
		J05249	Hs.79411	replication protein A2 (32kD)	6.1
20		K02405	Hs.73931	Human MHC class II HLA-DQ-beta mRN	4.3
30		K03515	Hs.180532	glucose phosphate isomerase	4.3
		L06132	Hs.149155	voltage-dependent anion channel 1	7.4
		L06797	Hs.89414	chemokine (C-X-C motif); receptor 4 (fus	4.6 18.3
		L07615 L12723	Hs.169266	Human neuropeptide Y receptor Y1 (NPY heat shock 70kD protein 4	17.4
35		L12723	Hs.90093 Hs.9884	Homo sapiens liver expressed protein gen	7.6
55		L19779	Hs.795	H2A histone family; member O	10.9
		L25876	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	7.4
		L29008	Hs.878	sorbitol dehydrogenase	14.6
	101247	L33801	Hs.78802	glycogen synthase kinase 3 beta	7.5
40	101282	L38810	Hs.79387	proteasome (prosome; macropain) 26S sub	4.4
		L42572	Hs.78504	inner membrane protein; mitochondrial (m	5.8
		L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topo	18.9
		L77213	Hs.30954	phosphomevalonate kinase	7.5
45		L77701	Hs.16297	COX17 (yeast) homolog; cytochrome c ox	9.3 18.1
43		M13755	Hs.833	interferon-stimulated protein; 15 kDa proliferating cell nuclear antigen	8.6
		M15796 M16342	Hs.78996 Hs.182447	heterogeneous nuclear ribonucleoprotein C	4.5
		M20902	Hs.268571	apolipoprotein C-I	6.1
		M22538	Hs.51299	NADH dehydrogenase (ubiquinone) flavo	8.7
50		M22877	Hs.169248	Human somatic cytochrome c (HCS) gene	4.2
		M22960	Hs.118126 '	protective protein for beta-galactosidase (6.5
		M23379	Hs.758	RAS p21 protein activator (GTPase activa	14
		M24594	Hs.20315	interferon-induced protein 56	9.2
<i></i>		M30818	Hs.926	myxovirus (influenza) resistance 2; homol	5.1
55		M30938	Hs.84981	X-ray repair complementing defective rep	4.7
		M31169	11- 00044	Human propionyl-CoA carboxylase beta-s	5.5 8.5
		M31642 M34677	Hs.82314 Hs.83363	hypoxanthine phosphoribosyltransferase 1 DNA segment on chromosome X (unique)	4.5
		M37583	пs.оззоз Hs.119192	H2A histone family; member Z	5.7
60		M60750	Hs.2178	H2B histone family; member A	5.8
00		M60752	Hs.121017	H2A histone family; member A	13.5
		M60858	Hs.79110	nucleolin	4
		M63256	Hs.75124	cerebellar degeneration-related protein (62	7.6
	101702	M64929	Hs.179574	protein phosphatase 2 (formerly 2A); regu	4.2
65	101754	M77142	Hs.239489	TIA1 cytotoxic granule-associated RNA-b	4.5
		M77836	Hs.79217	pyrroline-5-carboxylate reductase 1	5.7
	101767	M81057	Hs.180884	carboxypeptidase B1 (tissue)	21.7

	101770 M81601	Hs.78869	transcription elongation factor A (SII); 1	4.6
	101791 M83822	Hs.62354	cell division cycle 4-like	9.7
	101803 M86546	Hs.155691	pre-B-cell leukemia transcription factor 1	5.5
_	101809 M86849	Hs.323733	Homo sapiens connexin 26 (GJB2) mRNA	22.5
5	101839 M93036	Hs.692	membrane component; chromosomal 4; su	4
	101851 M94250	Hs.82045	midkine (neurite growth-promoting factor	7.6
	101888 M99701	Hs.95243	transcription elongation factor A (SII)-like	11.4
	101973 S82597	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	4.6 4.1
10	101991 U00968 102009 U02680	Hs.166 Hs.82643	Human SREBP-1 mRNA; complete cds protein tyrosine kinase 9	4.1
10	102005 002000 102025 U03911	Hs.78934	mutS (E. coli) homolog 2 (colon cancer; n	4
	102027 U07158	Hs.83734	syntaxin 4A (placental)	6.1
	102051 U07550	Hs.1197	heat shock 10kD protein 1 (chaperonin 10	4.4
	102083 U10323	Hs.75117	interleukin enhancer binding factor 2; 45k	10.4
15	102095 U11313	Hs.75760	sterol carrier protein 2	9.5
	102130 U15009	Hs.1575	small nuclear ribonucleoprotein D3 polyp	6.6
	102133 U15173	Hs.155596	BCL2/adenovirus E1B 19kD-interacting p	4.3
	102148 U16954	Hs.75823	ALL1-fused gene from chromosome 1q	6.9
20	102179 U19713	Hs.76364	allograft inflammatory factor 1	4.8
20	102180 U19718	Hs.83551	microfibrillar-associated protein 2	7.2 7.2
	102193 U20758 102198 U21090	Hs.313 Hs.74598	secreted phosphoprotein 1 (osteopontin; b polymerase (DNA directed); delta 2; regu	4.3
	102190 021090 102202 U21931	Hs.574	fructose-bisphosphatase 1	4.5
	102209 U22970	Hs.265827	interferon; alpha-inducible protein (clone	9.9
25	102211 U23070	Hs.78776	putative transmembrane protein	4.9
	102220 U24389	Hs.65436	lysyl oxidase-like 1	8.5
	102224 U24704	Hs.148495	proteasome (prosome; macropain) 26S sub	5.4
	102234 U26312	Hs.278554	chromobox homolog 3 (Drosophila HP1 g	7.7
20	102250 U28014	Hs.74122	caspase 4; apoptosis-related cysteine prot	5.4
30	102260 U28386	Hs.159557	karyopherin alpha 2 (RAG cohort 1; impo	6.3
	102261 U28488	Hs.155935	complement component 3a receptor 1	5.7 6.1
	102273 U30888 102298 U32849	Hs.75981 Hs.54483	ubiquitin specific protease 14 (tRNA-guan N-myc (and STAT) interactor	4.1
	102302 U33052	Hs.69171	protein kinase C-like 2	4.3
35	102305 U33286	Hs.90073	chromosome segregation 1 (yeast homolo	5.4
	102320 U34683	Hs.82327	glutathione synthetase	4.1
	102330 U35451	Hs.77254	chromobox homolog 1 (Drosophila HP1 b	4
	102348 U37519	Hs.87539	aldehyde dehydrogenase 8	9.4
40	102361 U39400	Hs.75859	chromosome 11 open reading frame 4	5.2
40	102362 U39412	Hs.75932	N-ethylmaleimide-sensitive factor attachm	9.3
	102369 U39840	Hs.299867	hepatocyte nuclear factor 3; alpha	7.7 10.4
	102395 U41767 102409 U43286	Hs.92208 Hs.118725	a disintegrin and metalloproteinase domai selenophosphate synthetase 2	6.2
	102409 043200 102418 U43923	Hs.79058	suppressor of Ty (S.cerevisiae) 4 homolog	4.1
45	102416 U44772	Hs.3873	palmitoyl-protein thioesterase (ceroid-lipo	4.8
	102457 U48807	Hs.2359	dual specificity phosphatase 4	6.3
	102465 U49352	Hs.81548	2;4-dienoyl CoA reductase 1; mitochondri	9.4
	102495 U51240	Hs.79356	Lysosomal-associated multispanning mem	6.5
~ 0	102534 U56833	Hs.198307	von Hippel-Lindau binding protein 1	8.6
50	102546 U57877	Hs.3577	succinate dehydrogenase complex; subuni	4.3
	102549 U58046	Hs.198899	eukaryotic translation initiation factor 3; s	6.3 5
	102557 U58766 102562 U59309	Hs.264428 Hs.75653	tissue specific transplantation antigen P35 fumarate hydratase	6
	102562 U59877	Hs.223025	RAB31; member RAS oncogene family	9.1
55	102580 U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatid	7.9
	102581 U61145	Hs.77256	enhancer of zeste (Drosophila) homolog 2	7.6
	102590 U62136	Hs.79300	Homo sapiens enterocyte differentiation a	7
	102591 U62325	Hs,324125	amyloid beta (A4) precursor protein-bindi	4
66	102592 U62389	Hs.11223	Human putative cytosolic NADP-depende	5
60	102617 U65928	Hs.198767	Jun activation domain binding protein	6.1
	102618 U65932	Hs.81071	extracellular matrix protein 1	23.2
	102638 U67319	Hs.9216	caspase 7; apoptosis-related cysteine prot karyopherin (importin) beta 2	8.9 7.1
	102663 U70322 102666 U70660	Hs.168075 Hs.279910	ATX1 (antioxidant protein 1; yeast) homo	4.7
65	102679 U72661	Hs.11342	ninjurin 1; nerve injury-induced protein-1	4.7
00	1026/3 0723379	Hs.93002	ubiquitin carrier protein E2-C	7.7
	102704 U76638	Hs.54089	BRCA1 associated RING domain 1	5.6

	102705 U77180	Hs.50002	small inducible cytokine subfamily A (Cy	11.8
	102721 U79241	Hs.118666	Human clone 23759 mRNA; partial cds	15
	102729 U79254	Hs.181311	asparaginyl-tRNA synthetase	5
5	102739 U79282	Hs.155572	Human clone 23801 mRNA sequence	6 13.1
5	102742 U79293 102761 U82130	Hs.159264 Hs.118910	Human clone 23948 mRNA sequence tumor susceptibility gene 101	7
	102788 U86602	Hs.74407	nucleolar protein p40	4.1
	102790 U87269	Hs.154196	E4F transcription factor 1	7.1
	102801 U89606	Hs.38041	pyridoxal (pyridoxine; vitamin B6) kinase	4.7
10	102808 U90426	Hs.179606	nuclear RNA helicase; DECD variant of D	7.5
	102817 U90904	Hs.83724	Human clone 23773 mRNA sequence	15.2
	102823 U90914	Hs.5057	carboxypeptidase D	6.6
	102827 U91327	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6 6.1
15	102838 U94592 102841 U95006	Hs.80658	Human uncoupling protein homolog (UCP Human D9 splice variant B mRNA; comp	4.2
15	102844 U96113	Hs.37616 Hs.324275	Homo sapiens Nedd-4-like ubiquitin-prot	6.8
	102868 X02419	Hs.77274	plasminogen activator; urokinase	4
	102907 X06985	Hs.202833	heme oxygenase (decycling) 1	22.7
	102919 X12447		aldolase A; fructose-bisphosphate	9.9
20	102929 X13238	Hs.74649	cytochrome c oxidase subunit Vic	5.4
	102973 X16663	Hs.14601	hematopoletic cell-specific Lyn substrate	4.8
	102983 X17620	Hs.118638	non-metastatic cells 1; protein (NM23A)	4.6 20.6
	102985 X17644 103003 X52003	Hs.2707 Hs.1406	G1 to S phase transition 1 trefoil factor 1 (breast cancer; estrogen-ind	10.7
25	103003 X52003 103018 X53296	Hs.81134	interleukin 1 receptor antagonist	5.8
	103023 X53793	Hs.117950	multifunctional polypeptide similar to SA	4
	103036 X54925	Hs.83169	matrix metalloproteinase 1 (interstitial col	7.3
	103060 X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin	17.8
20	103073 X59417	Hs.74077	proteasome (prosome; macropain) subunit	5.6
30	103075 X59543	Hs.2934	ribonucleotide reductase M1 polypeptide cyclin D1 (PRAD1: parathyroid adenomat	4.2 6.7
	103080 X59798 103094 X60787	Hs.82932 Hs.296281	interleukin enhancer binding factor 1	5.7
	103105 X61970	Hs.76913	proteasome (prosome; macropain) subunit	5.8
	103121 X63679	Hs.4147	translocating chain-associating membrane	4.2
35	103149 X66363	Hs.171834	PCTAIRE protein kinase 1	12
	103180 X69433	Hs.5337	isocitrate dehydrogenase 2 (NADP+); mit	18.9
	103182 X69819	Hs.99995	intercellular adhesion molecule 3	10.7 4.1
	103188 X70040 103191 X70218	Hs.2942 Hs.2903	macrophage stimulating 1 receptor (c-met protein phosphatase 4 (formerly X); cataly	10.7
40	103193 X70476	Hs.75724	coatomer protein complex; subunit beta 2	8.2
••	103194 X70649	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box pol	13.7
	103195 X70940	Hs.2642	eukaryotic translation elongation factor 1	13.4
	103206 X72755	Hs.77367	monokine induced by gamma interferon	15.1
15	103207 X72790	11- 24244	Human endogenous retrovirus mRNA for	5.3
45	103208 X72841 103216 X74262	Hs.31314 Hs.16003	retinoblastoma-binding protein 7 retinoblastoma-binding protein 4	12.3 4.1
	103216 X74202 103226 X75042	Hs.44313	v-rel avian reticuloendotheliosis viral onco	6.9
	103230 X75861	Hs.74637	testis enhanced gene transcript	7.9
	103262 X78565	Hs.289114	hexabrachion (tenascin C; cytotactin)	5
50	103278 X79882	Hs.80680	lung resistance-related protein	5.7
	103297 X81788	Hs.9078	immature colon carcinoma transcript 1	4.6 4.5
	103302 X82103 103316 X83301	Hs.3059 Hs.324728	coatomer protein complex; subunit beta	4.5 7.1
	103330 X85373	Hs.77496	SMA5 small nuclear ribonucleoprotein polypepti	4
55	103349 X89059	110.71100	serine/threonine kinase 9	4.7
	103352 X89398	Hs.78853	uracil-DNA glycosylase	5.3
	103364 X90872	Hs.279929	SULT1C sulfotransferase	4
	103374 X91788	Hs.84974	chloride channel; nucleotide-sensitive; 1A	4.2
60	103380 X92396	Hs.24167	synaptobrevin-like 1	13.6 14.2
00	103395 X94754 103402 X95404	Hs.279946 Hs.180370	methionine-tRNA synthetase cofilin 1 (non-muscle)	4.6
	103402 X96506	Hs.295362	DR1-associated protein 1 (negative cofact	8.3
	103420 X97065	Hs.173497	Sec23 (S. cerevisiae) homolog B	4.9
<i></i>	103421 X97074	Hs.119591	adaptor-related protein complex 2; sigma	5
65	103427 X97303	Hs.250655	H.sapiens mRNA for Ptg-12 protein	7 4 =
	103430 X97544 103438 X98263	Hs.20716 Hs.152720	translocase of inner mitochondrial membr M-phase phosphoprotein 6	4.5 4.5
	TODAGO NAUEGO	110.102120	iii pilado piloopilopiotalii o	-1.0

	400404	1/00000	=0.470	the self the self to the first of the self to	4.0
		Y00285	Hs.76473	insulin-like growth factor 2 receptor	4.2
		Y00796	Hs.174103	integrin; alpha L (antigen CD11A (p180);	4.5
		Y08991	Hs.83050	phosphatidylinositol 3-kinase-associated p	4.1
~		Y09912	Hs.33102	transcription factor AP-2 beta (activating	4.5
5		Z14982	Hs.180062	proteasome (prosome; macropain) subunit	4.3
		Z15115	Hs.75248	topoisomerase (DNA) II beta (180kD)	4
		Z22548	Hs.146354	thioredoxin-dependent peroxide reductase	7.6
		Z29083	Hs.82128	5T4 oncofetal trophoblast glycoprotein	14.6
	103621	Z47727	Hs.150675	polymerase (RNA) II (DNA directed) pol	6.3
10	103622	Z48042	Hs.278672	membrane component; chromosome 11; s	4.4
	103658	Z74615	Hs.172928	collagen; type I; alpha 1	5.9
	103680	Z93784		Homo sapiens DNA sequence from PAC	4.4
	103772	AA092473	Hs.278554	chromobox homolog 3 (Drosophila HP1 g	4.9
	103774	AA092898	Hs.92918	ESTs; Weakly similar to R07G3.8 [C.eleg	6.1
15	103821	AA157623	Hs.198793	KIAA0750 gene product	23.3
	103835	AA172215	Hs.93748	ESTs; Moderately similar to TRANSCRIP	4
	103886	AA236384	Hs.105737	ESTs; Weakly similar to gene 9306 protei	4.9
	103890	AA236843	Hs.72085	ESTs; Weakly similar to unknown [S.cere	7.8
			Hs.239189	ESTs	4.8
20		AA393432		hypothetical protein	5.3
		AA428090		ESTs	28.7
			Hs.268371	zv68f6.r1 Soares_total_fetus_Nb2HF8_9w	5.7
			Hs.283037	ESTs; Highly similar to HSPC039 protein	6.9
		AA476564		ESTs; Weakly similar to finger protein HZ	5.2
25			Hs.283740	ESTs	7.8
			Hs.114309	ESTs	5.1
		AA486946		Homo sapiens mRNA; cDNA DKFZp564	4.3
		AB000221		small inducible cytokine subfamily A (Cy	12.3
			Hs.168212	kinesin family member 3B	6.2
30		C01687	Hs.7381	ATP synthase; H+ transporting; mitochon	4.2
-		C02582	Hs.109253	ESTs; Highly similar to N-terminal acetyl	4.5
		D52818	Hs.111680	endosulfine alpha	4.7
		D55869	Hs.284123	Homo sapiens mRNA full length insert cD	4.2
		H19378	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4
35		L44497	Hs.7351	ESTs	4.9
-		M19169	Hs.123114	cystatin SN	11.6
		N33807	Hs.324275	protease; serine; 15	5.6
		R56678	Hs.88959	Human DNA sequence from clone 967N2	6.3
		R81003	Hs.325820	serine protease; umbilical endothelium	13.6
40		AA004274	Hs.19151	ESTs	6.3
			Hs.106106	ESTs	10.1
	104658	AA007145	Hs.27268	Homo sapiens mRNA; cDNA DKFZp564	4.3
		AA007234		ESTs	16.6
	104675	AA009596	Hs.301553	ESTs; Moderately similar to !!!! ALU SU	4.6
45		AA025534		ESTs	4.8
	104785	AA027163	Hs.7942	ESTs	8.1
			Hs.301871	ESTs; Moderately similar to cAMP induc	10.9
	104804	AA031357	Hs.31803	ESTs; Weakly similar to N-WASP [H.sap	5.5
	104807	AA032147	Hs.23296	ESTs	10.4
50	104837	AA039469	Hs.21126	ESTs; Weakly similar to KIAA0299 [H.s	4.6
			Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	4.3
	104867	AA045481	Hs.225979	Human gene from PACs 37M17 and 305B	4.5
	104884	AA053021	Hs.14511	SCO (cytochrome oxidase deficient; yeast	4.7
	104906	AA055809	Hs.26802	ESTs; Weakly similar to phosphoprotein [8.8
55		AA057193		ESTs	5.5
	104921	AA057839	Hs.1508	ESTs	4.2
-	104926	AA058846	Hs.33363	DKFZP434N093 protein	7
	104938	AA064627	Hs.318725	ESTs; Highly similar to CGI-72 protein [H	7.1
			Hs.114218	ESTs	5.7
60	104957	AA074919	Hs.10026	ESTs; Weakly similar to ORF YJL063c [S	4.7
		AA076672		ESTs	5.5
		AA084602		ESTs	4.3
	104975	AA086071	Hs.50758	chromosome-associated polypeptide C	8.3
	104977	AA088228	Hs.18272	ESTs	6.2
65	104978	AA088458	Hs.19322	ESTs	6.7
	104987	AA101723	Hs.11861	ESTs	9.2
	105002	AA113266	Hs.182704	ESTs; Moderately similar to alternatively	6.9

	105012 AA116036	He 0320	chromosome 20 open reading frame 1	10.7
	105012 AA110030		proteasome (prosome; macropain) subunit	5.7
	105029 AA126855		ESTs	4.4
	105033 AA127964		TP53 target gene 1	6.3
5	105035 AA128486		ESTs	6.5
	105039 AA130349		ESTs	4
	105062 AA134968		ESTs	4.3
	105076 AA142858		ESTs	6.4
	105087 AA147884		ESTs	9.2
10	105091 AA148859		ESTs; Weakly similar to !!!! ALU SUBFA	5.7
	105093 AA149051		ESTs	6.3
	105107 AA152302		DKFZP566G223 protein	6.2
	105127 AA158132	Hs.301957	ESTs; Weakly similar to contains similari	5.7
	105132 AA159501	Hs.247280	HBV associated factor	4.2
15	105143 AA165333	Hs.24808	ESTs	4.7
	105154 AA171736	Hs.35947	methyl-CpG binding domain protein 4	9
	105162 AA176690	Hs.4084	KIAA1025 protein	9.1
	105186 AA191512	Hs.28005	Homo sapiens mRNA; cDNA DKFZp564	19.3
	105209 AA205072	Hs.227743	KIAA0980 protein	7.4
20	105223 AA211388	Hs.7750	ESTs	5.1
	105252 AA227428	Hs.9728	ESTs; Weakly similar to KIAA0512 prote	11.1
	105253 AA227448	Hs.5003	KIAA0456 protein	6.4
	105261 AA227871	Hs.6361	MEK partner 1	9.1
~ -	105263 AA227926		ESTs	6.7
25	105274 AA228122		ATPase; H+ transporting; lysosomal (vacu	5.3
	105297 AA233451		transcriptional intermediary factor 1	8.7
	105309 AA233790		ESTs; Weakly similar to cDNA EST yk38	7.4
	105312 AA233854		S-phase kinase-associated protein 2 (p45)	5.8
20	105342 AA235286		ESTs	4.5
30	105376 AA236559		ESTs; Weakly similar to !!!! ALU SUBFA	5.8
	105386 AA236950		ESTs	5.5
	105397 AA242868		ESTs; Weakly similar to house-keeping p	7.7
	105399 AA243007		ESTs; Highly similar to SH3 domain-bind	5.6
25	105400 AA243052		RNA binding motif protein 8	5.8
35	105404 AA243303		ESTs	9.1 4.4
	105409 AA243562		ESTs	5.1
	105436 AA252172		ESTs; Moderately similar to cAMP induc	4.9
	105483 AA255874		ESTs ESTs	6
40	105493 AA256268 105495 AA256317		Homo sapiens mRNA; cDNA DKFZp586	5.2
40	105496 AA256323		DKFZP434N126 protein	8.7
	105490 AA250325		CGI-96 protein	9.5
	105507 AA256678		ESTs; Moderately similar to CCR4-associ	4.1
	105538 AA258860		ring finger protein (C3H2C3 type) 6	4.1
45	105544 AA261954		ESTs	8
-13	105546 AA262032		ESTs; Weakly similar to 62D9.a [D.melan	8.1
	105549 AA262417		ESTs	4.6
	105551 AA262477		ribonuclease HI; large subunit	9.1
	105560 AA262783		ESTs	4.5
50	105565 AA278302		ESTs; Weakly similar to partial CDS [C.e	4.2
•	105566 AA278323		Homo sapiens clone 24606 mRNA sequen	11.9
	105575 AA278717	Hs.12772	ESTs	5.9
	105584 AA279012	Hs.3454	ESTs; Weakly similar to KIAA0665 prote	4.4
	105596 AA279418		ESTs	4
55	105604 AA279787	Hs.15467	ESTs; Moderately similar to putative pho	5.6
	105610 AA279991	Hs.99872	ESTs; Weakly similar to trithorax homolo	5.3
	105621 AA280865	Hs.6375	Homo sapiens mRNA; cDNA DKFZp564	4.8
	105627 AA281245	Hs.23317	ESTs	7.5
	105638 AA281599	Hs.247817	Homo sapiens mRNA for for histone H2B	5.9
60	105645 AA282138	Hs.11325	ESTs	6.4
	105650 AA282347		ESTs; Highly similar to HSPC003 [H.sap	11.3
	105666 AA283930		ESTs	4.7
	105674 AA284755		CDW52 antigen (CAMPATH-1 antigen)	8
	105687 AA286809		ESTs	7.1
65	105700 AA287643		ESTs; Weakly similar to hypothetical pro	4.9
	105705 AA290767		Homo sapiens mRNA; cDNA DKFZp434	8
	105709 AA291268	ms.26/61	DKFZP586L0724 protein	6.8

		AA292711		ESTs	6.4
			Hs.110857	ESTs	7
		AA348014		ESTs	7.1
5		AA350771		ESTs	13.4
5		AA358038		SH3-binding domain glutamic acid-rich p	4.3
		AA393803		ESTs; Moderately similar to COLLAGEN	5.3
			Hs.286131	KIAA0438 gene product	4.1
		AA394126		ESTs; Highly similar to CGI-27 protein [H	14.6
10		AA394140		ESTS	4.9
10		AA397920		Homo sapiens mRNA; cDNA DKFZp564	4.9
			Hs.101067	ESTs	4.8
			Hs.171118	ESTs	4
		AA400999		Human ring zinc-finger protein (ZNF127-	4.8
15		AA404248		ESTs	5.2
15			Hs.263727	ESTs; Weakly similar to bisphosphate 3'-	4
		AA406105		adaptor-related protein complex 1; gamma	8.3
		AA406321		KIAA0895 protein	4.6
		AA410336		ESTs; Weakly similar to PROBABLE AT	4.5
20		AA410510		ESTs	4.9
20		AA410972		ESTs	5.8
		AA411462		ESTs; Weakly similar to veli 1 [H.sapiens	6.9
		AA411819		KIAA0898 protein	5
		AA412473		ESTs	6.6
25		AA412700		ubiquitin-conjugating enzyme E2L 6	4.6
23		AA417067		ESTs	4.5
		AA417558		ESTs	12.3
		AA417761		Homo sapiens clone 24416 mRNA sequen	5
		AA421104		ESTs	15.4
30		AA424006		ESTs; Moderately similar to H5AR [M.m	6.4
30		AA425304		ESTs	5.1
		AA425367		ESTs	11.1
		AA425872		NADH dehydrogenase (ubiquinone) 1 alp	19.3
		AA428024		ESTs	4.7 5.7
35		AA428239 AA428582		ESTs	
33				ESTs; Moderately similar to metargidin p	7.7 8
		AA429951		ESTs ESTs Woodshy similar to VIr218 on IS core	_
		AA430074		ESTs; Weakly similar to Ylr218cp [S.cere	4.4
		AA431462		ESTs ESTs	4.9
40		AA435536			8.8
40		AA435591		signal sequence receptor; gamma (transloc	8.7
		AA436244		ESTs	4.5
		AA436568 AA436705		ESTs	4 4.4
		AA441798		KIAA0766 gene product ESTs; Moderately similar to pIL2 hypoth	23.7
45		AA442253		ESTs, Moderately similar to pilez hypoth	4.7
40		AA442763			6.1
		AA443923		cyclin B2 ESTs	6.8
		AA446949		ESTs	4.7
		AA447223		Homo sapiens clone 25142 mRNA sequen	4.4
50		AA448282		ESTs; Weakly similar to F55C12.5 [C.ele	4.5
50		AA449741		glioma-amplified sequence-41	4.8
		AA449912		ESTs; Highly similar to CGI-77 protein [H	5.2
		AA450047			
		AA450351		ESTs ESTs	6.8 12.4
55		AA450351		transcription factor AP-2 alpha (activating	4.5
55		AA452411		ESTs; Highly similar to mediator [H.sapie	5.1
		AA452584		protein phosphatase 1; regulatory (inhibito	4.9
		AA453786		ESTs	8.3
		AA455970		patched related protein translocated in ren	
60		AA456598		ESTs	7.6 8.2
00		AA456646		ESTS	6.2 4.8
		AA457730		Homo sapiens clone 23851 mRNA sequen	4.0 4.4
		AA457730		ESTs; Weakly similar to torsinA [H.sapie	4.4 7
		AA458934		ESTs weakly similar to torsina [rl.saple	7 4.5
65		AA459657		Homo sapiens clone 23570 mRNA sequen	4.5 6.5
00		AA459961		ESTs	5.5
		AA460239		ESTS	5.5 4.4
	100017		1.0.12000	2013	4.4

		AA460969		mitogen-activated protein kinase kinase ki	8.4 5.3
		AA463745 AA465171		ESTs; Weakly similar to PROBABLE AT ESTs	5.6
		AA465339		ESTs	10.1
5		AA476473		triple functional domain (PTPRF interacti	10.4
•		AA477263		ESTs	4.2
		AA477717		interleukin 13 receptor; alpha 1	6.9
		AA478558		API5-like 1	5.1
10		AA482014		centrin; EF-hand protein; 3 (CDC31 yeast	5.1
10		AA482112		ESTs	4.8
		AA482548		ESTs	10.3
		AA486183		ESTs; Weakly similar to similar to oxyste	6.2
		AA487228 AA488872		ESTs Homo sapiens mRNA; cDNA DKFZp586	4.5 7.9
15		AA489101		oxysterol binding protein	6.4
13		AA489665		ESTs	4.6
		AA490323		SUMO-1 activating enzyme subunit 1	4.2
		AA490885		ESTs	12.3
		AA490899		ESTs	6.2
20	106941	AA496204	Hs.237971	ESTs	4
	106942	AA496347	Hs.31314	retinoblastoma-binding protein 7	4.8
		AA496788		KIAA0532 protein	4
		AA504631		ESTs; Weakly similar to hypothetical 43.2	4.4
25		AA505141		Human DNA sequence from clone 167A1	5.4
25		AA521121		bromodomain adjacent to zinc finger dom ESTs	4.1 5.7
		AA521157 AA598461		insulin-like growth factor binding protein	18.7
		AA598710		ESTs	6.2
		AA599214		ESTs	4.1
30			Hs.247309	succinate-CoA ligase; GDP-forming; beta	5.3
		AA600134		glyceronephosphate O-acyltransferase	4.8
	107053	AA600147	Hs.5741	ESTs; Weakly similar to NADH-cytochro	5.8
		AA600310		programmed cell death 8 (apoptosis-induc	4.9
2.5		AA609210		ESTs	8.4
35		AA609723		ESTs	8
		AA609943		ESTs	9.5 4.9
		AA620553		flap structure-specific endonuclease 1 ESTs	5.3
		AA620598 AA620795		ESTS	4
40			Hs.170088	ESTs	6.7
		AA621169		ESTs	19
		AA621340		ESTs; Weakly similar to ORF YKR081c [8.1
	107174	AA621714	Hs.25338	ESTs	8.5
	107217	D51095	Hs.35861	DKFZP586E1621 protein	7.2
45		D59971	Hs.25925	ESTs	7.9
		T34527	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	5.6
		T40327	Hs.30661	lung resistance-related protein	8.4
		T81665	Hs.278422	DKFZP586G1122 protein	7.5 4.7
50		U85625 U85773	Hs.8297 Hs.154695	ribonuclease 6 precursor phosphomannomutase 2	4.8
30		W58247	Hs.279766	Homo sapiens kinesin superfamily motor	6.3
		Y13936	Hs.17883	protein phosphatase 1G (formerly 2C); ma	8.3
		AA024835		potassium voltage-gated channel; delayed	7.3
		AA026030		ESTs; Weakly similar to CALPAIN 2; LA	7.3
55	107908	AA026894	Hs.42826	ESTs	4.9
		AA041341		ESTs	5.4
		AA041551		ESTs	8.4
		AA046424		ESTs; Weakly similar to HYPOTHETICA	6.6
60		AA058686		ESTS	7.7 1
60		AA003157 AA071514	Hs.172608	ESTs ESTs	4 4
		AA100694		Human DNA sequence from BAC 15E1 o	1 5.5
		AA112396		ESTs: Moderately similar to HOMEOBO	14.3
		AA115562		Homo sapiens mRNA; cDNA DKFZp564	5.2
65		AA120785		ESTs	5.6
		AA121315	Hs.70823	KIAA1077 protein	10.5
	108733	AA126422		zn84f1.s1 Stratagene lung carcinoma 9372	4.4

	400==4		11 774040		4.0
		AA128125		ESTs; Moderately similar to CELL GROW	4.6
			Hs.273344	DKFZP564O0463 protein	5.5
			Hs.111680	ESTs	7.2
-			Hs.293591	ESTs	11.3
5			Hs.194691	retinoic acid induced 3	8.9
	109008	AA156360	Hs.87128	ESTs	14.7
	109010	AA156460	Hs.44229	dual specificity phosphatase 12	4.9
	109011	AA156542	Hs.72127	ESTs	4.6
	109042	AA159525	Hs.71779	Homo sapiens DNA from chromosome 19	7.2
10	109086	AA166695	Hs.270737	tumor necrosis factor (ligand) superfamily	4
	109090	AA167006	Hs.70499	ESTs	5.9
		AA167708		ESTs	4.2
			Hs.257924	ESTs	4
			Hs.301997	DKFZP434N126 protein	4
15		AA179845		RAB6 interacting; kinesin-like (rabkinesin	13.6
			Hs.283707	ESTs	11.8
			Hs.192789	ESTs; Weakly similar to !!!! ALU SUBFA	5.4
		AA195255		ESTs	6.7
		AA195515		ESTs; Weakly similar to alternatively spli	4.9
20				ESTs	5.4
20		AA196332			5.5
		AA206800		ESTs; Moderately similar to zinc finger p	20.1
			Hs.110826	trinucleotide repeat containing 9	
			Hs.295232	ESTs	4.7
25		AA232904		ESTs	6.8
25			Hs.289069	ESTs; Weakly similar to WD40 protein C	10.6
		AA233892		ESTs; Weakly similar to !!!! ALU SUBFA	8
		AA234087		ESTs; Weakly similar to ORF2: function	8.2
		F02027	Hs.171937	ESTs	4.8
• •		F04165	Hs.235873	ESTs; Weakly similar to K11C4.2 [C.eleg	5.2
30	109644	F04477	Hs.291531	ESTs; Moderately similar to GLYCERAL	6.6
	109703	F09684	Hs.24792	ESTs; Weakly similar to ORF YOR283w	7.1
	109726	F10009	Hs.9196	ESTs	5
	109747	F10161	Hs.22969	ESTs	4.7
	109799	F10770	Hs.180378	Homo sapiens clone 669 unknown mRNA	4.5
35	109814	F10979	Hs.153106	Homo sapiens clone 23728 mRNA sequen	8.7
		H20543	Hs.6278	DKFZP586B1621 protein	16.6
		H25577	Hs.176588	ESTs; Weakly similar to CYTOCHROME	6.2
		H29285	Hs.32468	ESTs	4.5
		H56965	Hs.4082	yr09f06.s1 Soares fetal liver spleen 1NFL	5.7
40		H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CO	19.5
		H95079	Hs.15617	ESTs; Weakly similar to !!!! ALU SUBFA	6.2
		H98714	Hs.24131	ESTs	30.2
		N22262	Hs.131705	ESTs	5.8
		N23174	Hs.22891	solute carrier family 7 (cationic amino aci	8.2
45		N24716	Hs.12244	ESTs; Weakly similar to C44B9.1 [C.eleg	6.7
7.7		N25262	Hs.27931	ESTs	5.9
			Hs.323401	Human ring zinc-finger protein (ZNF127-	4
		N26101	Hs.27552	ESTs; Weakly similar to putative p150 [H	4.3
		N29454	Hs.30246	solute carrier family 19 (thiamine transpo	12.8
50		N30856		Homo sapiens mRNA full length insert cD	10.1
50		N31952	Hs.167531		4.7
		N32919	Hs.27931	ESTs	4.2
		N33063	11- 470005	ESTs; Weakly similar to S164 [H.sapiens	
		N33438	Hs.170065	ESTS	12.5
<i></i>		N39148	Hs.6880	DKFZP434D156 protein	4
55		N46252	Hs.29724	ESTs	23.2
		N48787	Hs.305979	protease inhibitor 1 (anti-elastase); alpha-	4.8
		N51374	Hs.96870	Homo saplens mRNA full length insert cD	5.4
		N53375	Hs.166146	Homer; neuronal immediate early gene; 3	4.7
		N53388	Hs.7222	ESTs	13.3
60	111018	N54067	Hs.3628	mitogen-activated protein kinase kinase ki	5.7
		N59543	Hs.15456	PDZ domain containing 1	8.3
	111100	N62522	Hs.20450	ESTs	14.3
		N63823	Hs.269115	ESTs	7.9
		N64378	Hs.83293	ESTs; Highly similar to unknown function	4.4
65		N64683	Hs.290943	ESTs	6
-		N66857	Hs.14808	ESTs; Weakly similar to !!!! ALU CLASS	4.1
		N67102	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	5.5
				•	

	444400	11 04000	F07	p 19
	111178 N67227	Hs.24633	ESTs	5.7
	111179 N67239	Hs.10760	ESTs	37 5.6
	111181 N67278	Hs.171802	ESTs; Weakly similar to hypothetical pro	5.6
5	111184 N67437	Hs.243901	Homo sapiens mRNA; cDNA DKFZp564	8.7 7.3
5	111221 N68869 111223 N68921	Hs.15119 Hs.297939	ESTs ESTs; Weakly similar to neogenin [H.sap	7.3 9
	111229 N69113	Hs.110855	ESTs	8.9
	111241 N69514	Hs.288880	ESTs; Weakly similar to CGI-82 protein [6.9
	111268 N70481	Hs.26118	Homo sapiens clone 24766 mRNA sequen	4.5
10	111295 N73275	Hs.21275	ESTs; Weakly similar to ubiquitin-conjug	5.6
10	111299 N73808	Hs.24936	ESTs	8.5
	111336 N79565	Hs.29894	ESTs	6.7
	111357 N91023	Hs.87128	ESTs	15
	111370 N92915	Hs.94631	brefeldin A-inhibited guanine nucleotide-e	5.2
15	111806 R33468	Hs.279008	ESTs	10
,	111825 R35885	Hs.286148	stromal antigen 1	4.5
	111836 R36228	Hs.25119	ESTs	7.2
	111890 R38678	Hs.12365	ESTs	17.3
	111923 R39995	Hs.25925	Homo sapiens clone 23860 mRNA sequen	7.3
20	111942 R40576	Hs.21590	ESTs	9.2
	111987 R42036	Hs.6763	KIAA0942 protein	10.6
	112101 R44793	Hs.296341	adenylyl cyclase-associated protein 2	5.3
•	112134 R46025	Hs.7413	ESTs	17.4
	112197 R49482	Hs.5637	ESTs	4.4
25	112244 R51309	Hs.70823	KIAA1077 protein	11
	112253 R51818		Homo sapiens mRNA; cDNA DKFZp566	9.3
	112305 R54822	Hs.26244	ESTs	4.4
	112449 R63802	Hs.124186	ring finger protein 2	6.3
• •	112483 R66534	Hs.285885	ESTs	4.9
30	112519 R68631	Hs.11861	ESTs	14.3
	112610 R79392	Hs.23643	ESTs	5.2
	112693 R88741	Hs.91065	ESTs; Moderately similar to proliferation	4.6
	112751 R93507	Hs.8207	ESTs	5.6
25	112801 R97486	Hs.157160	protein kinase; DNA-activated; catalytic p	8.7
35	112869 T03313	Hs.4747	dyskeratosis congenita 1; dyskerin	5.9
	112871 T03352	Hs.12285	ESTs	5.8
	112908 T10065	Hs.3530	TLS-associated serine-arginine protein	4.1
	112966 T17119	Hs.102548	glucocorticoid receptor DNA binding fact	5.7
40	112971 T17185	Hs.83883	ESTs	6.4 9.1
40	112995 T23528	Hs.7155	ESTs; Weakly similar to TYKi protein [M	5.4
	113047 T25867	Hs.7549 Hs.6986	ESTs	5.7
	113075 T34660 113117 T47819	Hs.159153	ESTs; Weakly similar to !!!! ALU SUBFA ESTs	5.8
	113206 T58044	Hs.241471	ESTs; Moderately similar to !!!! ALU SU	6.4
45	113248 T63857	113.241471	yc16e1.s1 Stratagene lung (#93721) Homo	4.6
73	113260 T64896	Hs.287420	ESTs	6.9
	113277 T65797	Hs.11774	protein (peptidyl-prolyl cis/trans isomeras	5.6
	113278 T65802	Hs.11135	yc11h10.s1 Stratagene lung (#937210) Ho	4.5
	113440 T86121	Hs.191445	ESTs	6.4
50	113523 T90037	Hs.95549	ESTs	6.4
•	113604 T92735	Hs.296083	ESTs	8.7
	113702 T97307		ESTs; Moderately similar to !!!! ALU SU	9.5
	113783 W19222	Hs.7041	ESTs; Weakly similar to !!!! ALU SUBFA	5.2
	113794 W37382	Hs.11090	ESTs	11.9
55	113808 W44735	Hs.9286	ESTs	16.7
	113811 W44928	Hs.6994	ESTs	4
	113822 W47350	Hs.17466	retinoic acid receptor responder (tazaroten	4.8
	113823 W47388	Hs.55099	rab6 GTPase activating protein (GAP and	4
	113836 W56792	Hs.12040	ESTs; Weakly similar to KIAA0881 prote	4.1
60	113857 W65477	Hs.5297	Homo sapiens mRNA; cDNA DKFZp564	4.3
	113886 W72471	Hs.23920	ESTs	4.6
	113895 W73738	Hs.12921	ESTs	7.1
	113923 W80763	Hs.3849	ESTs; Weakly similar to FK506-binding p	6.8
~~	113931 W81205	Hs.3496	ESTs	6.1
65	113950 W85765	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434	14
	113970 W86748	Hs.8109	ESTs	15
	114051 W94942	Hs.177534	dual specificity phosphatase 10	5.4

	114057	W96222	Hs.34192	ESTs	4.8
		Z38266	Hs.288649	Homo sapiens PAC clone DJ0777O23 fro	5.1
		Z38347	Hs.118338	ESTs; Weakly similar to similar to S. cere	6.2
	114109	Z38435	Hs.184108	ribosomal protein L21	4.6
5	114124	Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 prote	22
	114138	Z38763	Hs.15740	amyloid beta (A4) precursor protein-bindi	8.8
	114149	Z38814	Hs.27196	ESTs	4
	114162	Z38909	Hs.22265	ESTs	7.2
	114177	Z39062	Hs.23740	ESTs	5.3
10		Z39211	Hs.150926	fucose-1-phosphate guanylyltransferase	4.4
	114208	Z39301	Hs.7859	ESTs	5.1
		Z39897	Hs.13297	ESTs	7.2
		Z39898	Hs.21948	ESTs	14.7
1.5		Z40715	Hs.184641	delta-6 fatty acid desaturase	19.4
15		Z40758	Hs.173091	DKFZP434K151 protein	8.9
		Z41342	Hs.22941	ESTs	13.7
		AA024604		ESTs	10.1
			Hs.104613	ESTs	5.7
20			Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:po	7.3
20			Hs.106469	suppressor of var1 (S.cerevisiae) 3-like 1	4.3 11.7
			Hs.293380	ESTs	7.3
			Hs.292833	ESTs ESTs: Wookly similar to BTB ASSOCIAT	6.1
		AA113303	Hs.107149	ESTs; Weakly similar to PTB-ASSOCIAT transmembrane 4 superfamily member (te	4.3
25			Hs.110857	ESTs; Highly similar to putative DNA-dir	7.1
23			Hs.154443	minichromosome maintenance deficient (S	5.3
			Hs.109929	ESTs	4.2
			Hs.269956	ESTs	4.8
		AA161161		multiple inositol polyphosphate phosphata	7.1
30		AA165313		ESTs	4.4
		AA235035		ESTs; Moderately similar to ubiquitin spe	5
			Hs.196437	ESTs; Weakly similar to R26660_1; parti	16.9
	114902	AA236359	Hs.39504	ESTs	5.1
	114940	AA243012	Hs.75928	ESTs	8.5
35	114965	AA250737	Hs.72472	ESTs	35.1
	115047	AA252627	Hs.82916	homeo box B5	5.7
	115054	AA252863	Hs.87729	ESTs	6.2
	115061	AA253217	Hs.41271	ESTs	13
4.0	115082	AA255557	Hs.198269	NADH dehydrogenase (ubiquinone) 1 alp	28.2
40		AA256486		ESTs	8.8
			Hs.279938	ESTs; Weakly similar to supported by GE	4.1
			Hs.284216	ESTs	8.3
			Hs.186572	ESTs	5.1
15		AA278650		ESTs; Weakly similar to similar to the bet	4.6
45			Hs.283732	ESTs	8.3
		AA278961		ESTs	10.1 9.5
		AA279071	Hs.293736	splicing factor 3b; subunit 1; 155kD ESTs	5.8
			Hs.122579	ESTs	5.1
50		AA281793		ESTs	5
50			Hs.193063	ESTS	6.1
		AA283198		ESTs	4.9
			Hs.193090	ESTs	5.8
		AA287138		ESTs; Weakly similar to ASPARTYL-TR	11.7
55		AA292537		Human DNA sequence from clone 620E1	6.8
		AA331393		ESTs	5.8
		AA398392		ESTs; Weakly similar to F33G12.3 gene p	9.7
			Hs.283037	ESTs; Highly similar to HSPC039 protein	8.7
		AA400247		ESTs	4
60	115612	AA400948	Hs.71243	ESTs; Weakly similar to zinc finger prote	8.4
			Hs.305971	ESTs	5.3
		AA405098		ESTs	16.1
		AA405620		ESTs; Weakly similar to weak similarity t	4.7
c=	115658	AA405625	Hs.183056	Human DNA sequence from clone 34B21	5.1
65	115675	AA406546	HS.82065	Homo sapiens mRNA; cDNA DKFZp564	20.5
		AA417102	HS.90960	ESTs	4.8
	115/63	AA421560		ESTs	7

		AA421562		anterior gradient 2 (Xenepus laevis) homo	41.6
	115835	AA428576	Hs.41371	ESTs	4.2
	115844	AA430124	Hs.7773	ESTs	11.9
	115875	AA433943	Hs.43946	ESTs; Weakly similar to Weak similarity	33.5
5		AA435839		KIAA0887 protein	7.2
•		AA441911		ESTs; Weakly similar to KIAA0926 prote	5.1
		AA443602		ESTs	4.8
		AA443793		ESTs	8.3
10		AA443798		poly(A)-specific ribonuclease (deadenylat	13.5
10			Hs.301048	cofilin 1 (non-muscle)	7.5
	115967	AA446887	Hs.42911	ESTs	8.8
	115984	AA447687	Hs.91109	ESTs	13.1
	116009	AA449448	Hs.44238	ESTs	5.5
		AA451748		Human DNA sequence from clone 718J7	7.5
15		AA452112		thioredoxin-like	12.7
13					
		AA453656		ESTs	7.2
			Hs.176376	ESTs	11.8
	116108	AA457566	Hs.28777	ESTs	4.5
	116121	AA459254	Hs.48855	ESTs	4.5
20	116127	AA459703	Hs.279884	v-myc avian myelocytomatosis viral onco	4.3
		AA459956		ESTs; Highly similar to putative ribonucle	7.6
		AA460649		ESTs	4.8
			Hs.108646	ESTs	6.8
0.5		AA478397		ESTs	4.9
25	116222	AA478415	Hs.89986	ESTs	4
	116238	AA479362	Hs.47144	DKFZP586N0819 protein	4.6
	116246	AA479961	Hs.250646	ESTs; Highly similar to ubiquitin-conjuga	4
	116249	AA480886	Hs 86693	ESTs	18.5
		AA480975		ESTs	10.8
30		AA481146		ESTs; Weakly similar to OXYSTEROL-B	9.1
50					
		AA481256		ESTs; Weakly similar to lysophospholipa	8.4
			Hs.272239	Homo sapiens mRNA; cDNA DKFZp586	7.2
	116265	AA482595	Hs.55189	ESTs; Weakly similar to F25B5.3 [C.eleg	11.1
	116282	AA486550	Hs.204501	ESTs; Weakly similar to Wiskott-Aldrich	6.2
35	116298	AA489046	Hs.94109	ESTs	4.9
		AA489194		ESTs; Weakly similar to snRNP protein B	4.6
		AA490959		Homo sapiens mRNA; cDNA DKFZp564	5.8
		AA491457		ESTs	4.3
40		AA496127		ESTs	8.4
40		AA504116		Homo sapiens mRNA; cDNA DKFZp434	5.3
	116357	AA504806	Hs.90797	Homo sapiens clone 23620 mRNA sequen	5.2
	116415	AA609204	Hs.27973	KIAA0874 protein	6.6
	116443	AA620313	Hs.190488	ESTs; Weakly similar to KERATIN; TYP	4.5
		C13992	Hs.83484	ESTs	4.5
45		C14088	110.00101	glyceraldehyde-3-phosphate dehydrogena	5.6
73			U- 75227		
		D51272	Hs.75337	nucleolar phosphoprotein p130	4.1
		D51276	Hs.81915	leukemia-associated phosphoprotein p18	5.8
		F02028	Hs.81907	ESTs	4.9
	116647	F03069	Hs.15395	ESTs; Weakly similar to ARGINYL-TRN	6.1
50	116674	F04816	Hs.92127	ESTs	10.6
	116680	F08813	Hs.273829	LINE retrotransposable element 1	4.2
		F09983	Hs.317589	ESTs	13
		F13665	Hs.65641		
				ESTs	8.5
e e		F13681	Hs.53913	ESTs	5.6
55		F13779	Hs.165909	ESTs	11.6
	116734	F13789	Hs.93796	DKFZP586D2223 protein	5.4
	116760	H11054	Hs.155342	protein kinase C; delta	4.3
		H22566	Hs.30098	ESTs	5.7
		H25836	Hs.301527	tumor necrosis factor (ligand) superfamily	8.8
60		H28581	Hs.15641	ESTs	8.6
UU					
		H29532	Hs.101174	microtubule-associated protein tau	22.2
		H47357	Hs.109701	ESTs; Moderately similar to weak similar	6.7
		H68116	Hs.168732	ESTs	6.5
		H72948	Hs.821	biglycan	20.7
65	117216	N20083	Hs.42792	ESTs	4.4
	117232	N20579	Hs.61153	ESTs	7.4
	117284	N22162	Hs.183779	ESTs; Weakly similar to cDNA EST yk33	4.1
				,	

	117344	N24046	Hs.210706	ESTs	7.4
		N24954	Hs.42502	ESTs	10.5
		N26175	Hs.93405	ESTs	5.8
		N26257	Hs.39871	KIAA0727 protein	8.4
5		N26722	Hs.42645	ESTs	18.1
		N31726	Hs.44268	ESTs; Highly similar to myelin gene expr	5.8
	117557	N33920	Hs.44532	diubiquitin	12.3
		N36421	Hs.13323	ESTs; Weakly similar to SODIUM- AND	4.4
	117639	N36923	Hs.44833	ESTs	6
10	117754	N47469	Hs.59757	ESTs	7.6
	117852	N49408	Hs.136102	KIAA0853 protein	5.9
		N50050	Hs.303025	ESTs; Weakly similar to keratin; 67K typ	7.9
	117924	N51056	Hs.38891	ESTs	7.9
4.5	117950	N51394	Hs.75478	KIAA0956 protein	5
15		N52000	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586	7
		N57773	Hs.93560	ESTs; Weakly similar to trg [R.norvegicu	4.8
		N62195	Hs.77910	3-hydroxy-3-methylglutaryl-Coenzyme A	13.4
		N62339	Hs.166254	heat shock 90kD protein 1; alpha	5.4
20		N62827	Hs.48645	EST	4.2
20		N63604	Hs.47166	ESTs	7.2
		N64168	Hs.48938	ESTS	6
		N66158	Hs.74649	ESTs	4.1 5.4
		N66769	Hs.291033	ESTs ESTs	10.8
25		N66818 N66845	Hs.42179	ESTs; Weakly similar to !!!! ALU CLASS	4.5
23		N67149	Hs.50115	ESTs	5.3
		N67889	Hs.49397	ESTs	10.4
		N68010	Hs.49427	ESTs	7.9
		N69222	113.70721	ESTs	9.2
30		N71781	Hs.50081	Homo sapiens mRNA full length insert cD	9.8
		N72113	Hs.50187	ESTs	4.3
		N90719	Hs.94445	ESTs	8.1
		N92966		ESTs; Highly similar to CGI-90 protein [H	12.5
		N93629	Hs.93391	ESTs	5
35		N94362	Hs.125830	ESTs	7.3
-		N94439	Hs.45105	ESTs	8.2
		N99256	Hs.114611	ESTs	5
	119042	R05316	Hs.5472	ESTs	4
	119075	R36451	Hs.287820	fibronectin 1	6
40		T15916	Hs.102950	ESTs; Highly similar to coat protein gamm	4.1
		T16387	Hs.65328	ESTs	12.1
		T23820	Hs.155478	cyclin T2	5.6
		T25725		ESTs	14.3
15		T62571	Hs.146388	microtubule-associated protein 7	4
45		W35390	Hs.55533	ESTs	5.3
		W42451	Hs.92260 Hs.233694	high-mobility group protein 2-like 1	5.6 6.5
		W46286	Hs.56009	ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3	8.1
		W47620 W60473	Hs.57787	ESTs	5.5
50		W69134	Hs.57987	ESTs	4.6
50		W69747	Hs.94806	KIAA1062 protein	4
		W73788	Hs.43213	ESTs	4
		W80702	Hs.58461	ESTs	4.8
		W80852	Hs.250696	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4.2
55		W81129	Hs.44865	Homo sapiens mRNA; cDNA DKFZp586	4.8
		W84767	Hs.58698	ESTs	5.9
		W86779	Hs.272531	DKFZP586B0319 protein	9
		W86835	Hs.14158	copine III	4.8
		W87812	Hs.93581	Homo sapiens mRNA; cDNA DKFZp586	4
60	120131	Z38656	Hs.75887	coatomer protein complex; subunit alpha	4.2
	120150	Z39549	Hs.153746	ESTs	11
		Z40805	Hs.91668	ESTs	8.2
		Z41815	Hs.65946	ESTs	15.6
~~		AA169752		ESTs; Weakly similar to Similarity to Yea	4.2
65			Hs.221040	KIAA1038 protein	6.8
			Hs.104106	ESTs .	15.2
	120352	AAZ11400	Hs.193172	ESTs	6.8

	120/120	* * * * * * * * * * * * * * * * * * * *	Un 172604	VIA A 1007 protein	5.6
			Hs.173694 Hs.192905	KIAA1097 protein ESTs	5.6
			Hs.104413	ESTs	4.5
		AA280738		ESTs	4.9
5			Hs.192843	ESTs	4.5
3			Hs.238205	ESTs	6.7
			Hs.292913	ESTs	8.3
			Hs.102506	eukaryotic translation initiation factor 2 al	4.6
		AA292655		ESTs	10.6
10			Hs.100747	ESTs	5.4
- 0		AA358015		EST	7.1
			Hs.301872	ESTs; Moderately similar to !!!! ALU SU	4.6
			Hs.301444	ESTs	8.2
			Hs.104650	ESTs; Highly similar to similar to mago n	8.6
15			Hs.129206	casein kinase 1; gamma 3	10.5
-		AA398155		ESTs	10.9
		AA398936		EST	7.4
	121291	AA401753	Hs.8186	lung cancer candidate	5.3
	121320	AA403008	Hs.301927	T-cell receptor; alpha (V;D;J;C)	13.5
20	121463	AA411745	Hs.239681	ESTs; Weakly similar to KIAA0554 prote	8.9
	121596	AA416740	Hs.174104	ESTs	22.6
	121723	AA419622	Hs.104800	ESTs; Weakly similar to Mouse 19.5 mRN	8
	121748	AA421171	Hs.234545	ESTs	5.6
~ -		AA434411		ESTs	5.3
25	122522	AA449444	Hs.98969	ESTs	4
		AA454756		ESTs	4
		AA456326		ESTs	6.2
		AA459894		ESTs	5.3
20		AA463740		Src-like-adapter	13.1
30			Hs.108812	ESTs; Weakly similar to B0041.5 [C.eleg	5.5
			Hs.101840	ESTs	6.3
			Hs.194215	ESTs	6
			Hs.106290	Kelch motif containing protein	12.5
35			Hs.323231	ESTs; Weakly similar to alternatively spli	4.4
33			Hs.104207	ESTS	8.3
			Hs.191721	ESTs	4.2 5.2
			Hs.129928	ESTs; Moderately similar to KIAA0454 p ESTs	4.2
			Hs.194024 Hs.100686	ESTs; Weakly similar to secreted cement	14.6
40		AA488892	115.100000	ESTs; Weakly similar to Gag-Pol polypro	4.5
70		AA489020	He 60233	ESTs	5,2
			Hs.187585	ESTs	4
			Hs.223014	protease; serine; 15	7.3
			Hs.111496	ESTs	5.9
45			Hs.112493	Homo sapiens mRNA; cDNA DKFZp564	4.1
			Hs.112110	ESTs	4
			Hs.293156	ESTs	12.8
		AA608751		ESTs; Weakly similar to !!!! ALU SUBFA	7.9
		AA609200		ESTs	23.1
50			Hs.158549	ESTs	6.6
	123729	AA609778	Hs.278672	membrane component; chromosome 11; s	4.7
	123819	AA620636	Hs.112264	ESTs	4
	123960	AA621785	Hs.287733	methylmalonate-semialdehyde dehydroge	7.6
	124000	D57317	Hs.74861	activated RNA polymerase II transcription	4.4
55	124006	D60302	Hs.270016	ESTs	20.6
	124012	D80240	Hs.241471	HUM5G11A Human fetal brain (TFujiwa	6.7
	124021		Hs.13974	ESTs	4.7
	124049		Hs.74519	primase; polypeptide 2A (58kD)	4.7
C C	124059		Hs.283713	ESTs	7.7
60	124243		Hs.133525	ESTs	5.5
	124308		Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	11.4
	124314		Hs.215766	GTP-binding protein	13.7
	124315		Hs.288757	v-ral simian leukemia viral oncogene hom	14
65	124350		Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8.6
65	124352		Hs.102406	ESTS	7.2 5.2
	124357		Ua 7525	yw37g07.s1 Morton Fetal Cochlea Homo ESTs; Highly similar to COBW-like place	5.2 7.9
	124390	1429323	Hs.7535	Lors, riighty antinat to oobyy-like place	1.3

	124438	N40188	Hs.11090	ESTs	9.5
		N48000		Homo sapiens mRNA; cDNA DKFZp586	4.8
		N50114	Hs.266175	ESTs	6.1
	124539	N63172	Hs.146409	cell division cycle 42 (GTP-binding prote	5.6
5	124626	N74604	Hs.11090	ESTs	12.8
		N79515	Hs.306117	interleukin 13 receptor; alpha 1	6.4
	124644	N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.3
	124676	R01037	Hs.181013	phosphoglycerate mutase 1 (brain)	12.3
	124677	R01073		ESTs; Weakly similar to !!!! ALU CLASS	5.4
10	124724	R12405	Hs.112423	Homo sapiens mRNA; cDNA DKFZp586	6.6
		R40923	Hs.106604	ESTs	4.9
		R41933		ESTs	7.2
		R44357	Hs.48712	ESTs; Weakly similar to cDNA EST EMB	8.6
1 ~		R63652	Hs.137190	ESTs	4.9 4.7
15		R88992	Hs.180612	ESTs	4.7 4.4
		T10598	Hs.324841	ESTs; Weakly similar to !!!! ALU SUBFA murine leukemia viral (bmi-1) oncogene h	12.6
		T11134	Hs.431	, , , , , , , , , , , , , , , , , , ,	4.1
		T78089 T92544	Hs.270134 Hs.137548	ESTs CD84 antigen (leukocyte antigen)	14.8
20		W15495	Hs.129781	chromosome 21 open reading frame 5	6.7
20		W37999	Hs.24336	ESTs	4.8
		W38419	113.24000	ESTs	5.3
		W86423	Hs.105413	ESTs	6.6
		W93640	Hs.4779	ESTs; Moderately similar to similar to AD	5.8
25		Z39436	Hs.102720	ESTs	12.2
		Z39821	Hs.288193	ESTs	10.2
	125304	Z39833	Hs.124940	GTP-binding protein	6.8
	125474	AA151216	Hs.75103	tyrosine 3-monooxygenase/tryptophan 5-m	8
	125509	AA044232	Hs.288967	ESTs	5.4
30			Hs.267812	sorting nexin 4	4.1
		AA507383		cytochrome c oxidase subunit VIc	11.5
		AI432621	Hs.82685	CD47 antigen (Rh-related antigen; integri	4
			Hs.191356	general transcription factor IIH; polypepti	9.4 6.2
35		Al283493	Hs.75722	ribophorin II	25.9
33		H09290 AA434562	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564 ESTs	4.1
		N90960	Hs.265398	ESTs; Weakly similar to transformation-r	16.4
		N99638	Hs.124084	tumor necrosis factor receptor superfamily	9.5
		A1066486	Hs.40500	similar to S. cerevisiae RER1	5.6
40		U46278	Hs.122489	ESTs	7.5
		W40262	Hs.146310	ESTs; Weakly similar to putative p150 [H	4.1
		W78968	Hs.181307	H3 histone; family 3A	4.5
		AA205862		ESTs	5.2
	126721	T72569	Hs.125359	Thy-1 cell surface antigen	4.4
45	126764	Al334393	Hs.102178	ESTs	4.6
		AI203334	Hs.160628	ESTs	11.7
			Hs.279607	ESTs	4
		A1052047	Hs.26102	ESTs	7 5.6
50		R31652	Hs.821	biglycan	5.6 14.3
50			Hs.179729	collagen; type X; alpha 1 (Schmid metaph	4.5
			Hs.204214	ESTs ESTs; Weakly similar to weak similarity t	5.1
			Hs.10340 Hs.264190	ESTs; Weakly similar to Weak similarity t	17.3
			Hs.136713	ESTs; Weakly similar to V4-1 [H.sapiens	4.1
55		Al281549	Hs.311054	ESTs	5.5
		AA904617		ESTs	5.8
		H02682	Hs.292154	ESTs; Moderately similar to recombinatio	5.8
		D59653	Hs.241471	EST	7.4
		U83908	Hs.296251	programmed cell death 4	5.8
60			Hs.100861	ESTs; Weakly similar to p60 katanin [H.s	8.3
			Hs.183475	Homo sapiens clone 25061 mRNA sequen	6.6
			Hs.101448	metastasis associated 1	5.2
		AA412048		keratin 8	5.1
6F		U31875	Hs.152677	short-chain alcohol dehydrogenase family	27.1
65		L38608	Hs.10247	activated leucocyte cell adhesion molecule	13.2 6.7
			Hs.102708	DKFZP434A043 protein Homo sapiens mRNA for G7b protein (G	6.7 4.5
	128049	AA 142853	Hs.103106	Homo sapiens micrax for Gra protein (G	4.0

	128651	AA446990	Hs.103135	ESTs	6.1
	128653	R48943	Hs.10315	solute carrier family 7 (cationic amino aci	4.4
	128656	AA458542	Hs.10326	coatomer protein complex; subunit epsilon	14.3
_	128717	T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566	24.5
5		M64174	Hs.50651	Janus kinase 1 (a protein tyrosine kinase)	7.3
		N49308	Hs.104938	ESTs; Weakly similar to alpha 1(XVIII) c	9.2
		X85372	Hs.105465	small nuclear ribonucleoprotein polypepti	5.4
		W93562	Hs.105749	KIAA0553 protein	4.6
1.0		W15528	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586	4
10		AA455658		basement membrane-induced gene	6.9
		AA400271		Homo sapiens mRNA for putative Ca2+t	4.5
		AA252023		ESTs; Weakly similar to HRIHFB2157 [H	6.4
		D61676	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4
15		AA410325		ESTs	7 5.2
13		N29353 AA485655	Hs.107318	kynurenine 3-monooxygenase (kynurenin	13.1
				proteasome (prosome; macropain) subunit	5.8
		F10290 AA460049	Hs.185807	Homo sapiens clone 24758 mRNA sequen ESTs; Weakly similar to SODIUM- AND	12.6
		AA131421		ESTs, Weakly Similar to SODIOW-AND	9.8
20		H13108	Hs.107968	ESTs	13.9
20		X62466	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	10.7
		AA129465		ESTs	4.7
		L12350	Hs.108623	thrombospondin 2	4.4
		AA234530		N-ethylmaleimide-sensitive factor	20.7
25		AA131252		ESTs	5.9
	129164	AA282183	Hs.109045	ESTs	5.8
		R40556	Hs.318401	ESTs; Highly similar to HSPC039 protein	7.6
	129224	X89109	Hs.109606	coronin; actin-binding protein; 1A	12
	129229	AA211941	Hs.109643	polyadenylate binding protein-interacting	7.9
30	129240	W24360	Hs.237868	interleukin 7 receptor	5.3
		AA435665	Hs.109706	ESTs; Moderately similar to HN1 [M.mus	8.4
		H88033	Hs.109727	KIAA0733 protein	7.8
		AA151574		pilin-like transcription factor	6.4
25		AA090695		ESTs	6.2
35		Z35227	Hs.109918	ras homolog gene family; member H	5.4
		AA026318		glucose regulated protein; 58kD	4.4
		C20976	Hs.110165	ESTs; Highly similar to ribosomal protein	5.7
		N93155	Hs.285976	calmodulin 1 (phosphorylase kinase; delta	7.7 6
40		AA037467 AA167268		ESTs Human ras inhibitor mRNA; 3' end	9.3
-1 0		H18027	Hs.184697	plexin C1	18.2
		W92984	Hs.288224	ESTs	5.9
		AA151621		ESTs	4.1
		T80814	Hs.11101	discs; large (Drosophila) homolog 3 (neur	10.9
45		AA172056		ESTs	5.3
		N23707	Hs.111138	KIAA0712 gene product	4
		AA412087		EST; Highly similar to protein inhibitor o	8
		AA421213		Lsm3 protein	5.5
	129513	C00225	Hs.306163	ESTs; Weakly similar to fos39554_1 [H.s	5.5
50	129519	AA298786	Hs.112242	ESTs	6.8
		R21443	Hs.166254	heat shock 90kD protein 1; alpha	5
	129622	AA278243	Hs.323949	ESTs	6.8
		AA447410		ESTs; Weakly similar to !!!! ALU SUBFA	5.1
~ ~		AA258308		Homo sapiens mRNA; cDNA DKFZp564	5.3
55		U26727	Hs.1174	cyclin-dependent kinase inhibitor 2A (mel	8.2
		R50008	Hs.11806	7-dehydrocholesterol reductase	4.3
		AA442768		translocase of inner mitochondrial membr	4.4
		M88458	Hs.118778	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4
60		X06700	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danlos associated molecule with the SH3 domain	6
UU		AA454618			6.4 7.7
		AA252436 AA452161		lysophospholipase I YME1 (S.cerevisiae)-like 1	7.7 5
		N20593	Hs.288932	GDP dissociation inhibitor 2	6.9
		AA102520		ESTs; Weakly similar to heat shock prote	5
65		AA043021		UDP-Gal:betaGlcNAc beta 1;4- galactosy	6.6
		M87789		immunoglobulin gamma 3 (Gm marker)	4
			Hs.140452	cargo selection protein (mannose 6 phosp	5.8
		_	•		

	120000	A A DOC 440	Ua 226540	ECTs, Madamtaly similar to BET97 IM m	E C
		M90696	Hs.236510 Hs.181301	ESTs; Moderately similar to PFT27 [M.m cathepsin S	5.6 5.4
			Hs.125849	ESTs; Moderately similar to !!!! ALU SU	7.4
			Hs.146428	collagen; type V; alpha 1	7.6
5		T24055	Hs.91379	ribosomal protein L26	4
-		X14850	Hs.147097	H2A histone family; member X	12.1
			Hs.197955	KIAA0704 protein	5
		AA234717		ESTs	7.8
		M36803	Hs.1504	hemopexin	7.2
10		M61764	Hs.21635	tubulin; gamma 1	5.6
			Hs.151469	calcium/calmodulin-dependent serine pro	7.5
	130189	D43947	Hs.151761	KIAA0100 gene product	6.4
	130208	AA620556	Hs.15250	peroxisomal D3;D2-enoyl-CoA isomerase	6.4
	130211	D50840	Hs.23703	UDP-glucose ceramide glucosyltransferas	4.5
15	130235	X14046	Hs.153053	CD37 antigen	9.1
	130276	S75295	Hs.169149	karyopherin alpha 1 (importin alpha 5)	8.6
		L13738	Hs.153937	activated p21cdc42Hs kinase	5
		AA620323		ubiquitin-activating enzyme E1C (homolo	6.1
20		D86967	Hs.154332	KIAA0212 gene product	10
20		AA135673		KIAA0391 gene product	6.1
		X84373	Hs.155017	nuclear receptor interacting protein 1	10.6
		Z38501	Hs.8768	ESTs; Weakly similar to !!!! ALU SUBFA	8.3
		T47333	Hs.155188	TATA box binding protein (TBP)-associa	7.1
25		X66364	Hs.166071	cyclin-dependent kinase 5	5.6 4.1
23		D13630	Hs.155291	KIAA0005 gene product Homo sapiens mRNA for putative glucosy	4.6
		AA449417 N29888	Hs.155356 Hs.155410	ESTs	7
		M21121	Hs.241392	small inducible cytokine A5 (RANTES)	4.1
		U58522	Hs.155485	huntingtin-interacting protein 2	7.9
30		D21260	Hs.178710	clathrin; heavy polypeptide-like 2	4
50		U35835	Hs.155637	protein kinase; DNA-activated; catalytic p	6.8
		X17059	Hs.155956	N-acetyltransferase 1 (arylamine N-acetyl	26.4
		L38951	Hs.180446	karyopherin (importin) beta 1	4.8
		AA416723		Homo sapiens mRNA for KIAA0446 prot	6.1
35		L32137	Hs.1584	cartilage oligomeric matrix protein (pseud	8.3
			Hs.252587	pituitary tumor-transforming 1	7.5
	130558	H96654	Hs.15984	ESTs; Weakly similar to gene pp21 protei	5.6
	130568	AA232535	Hs.16085	ESTs; Highly similar to CGI-13 protein [H	4
4.0		W24957	Hs.293907	ESTs; Moderately similar to similar to C.e	13.3
40		H66211	Hs.16331	ESTs	10.1
		X03635	Hs.1657	estrogen receptor 1	39.9
		AA132007		ESTs	5.1
		AA477739		ESTs	5.9
45		AA235247		ESTs; Weakly similar to cytochrome P45	4.1
43		F03969	Hs.260720	matrix metalloproteinase 2 (gelatinase A;	8.3 10.3
		L23808	Hs.1695 Hs.1697	matrix metalloproteinase 12 (macrophage ATPase; H+ transporting; lysosomal (vacu	7
		M60346 M87503	Hs.1706	interferon-stimulated transcription factor	5.5
		D59711	Hs.17132	ESTs	7.2
50		H17861	Hs.17767	ESTs	13.5
50		D82808	Hs.17820	Rho-associated; coiled-coil containing pro	6
	130693	AA487202		ESTs	6.1
	130703	N63295	Hs.18103	ESTs	4.3
			Hs.201673	cornichon-like	4
55		AA292066		adenylate cyclase 7	5.1
	130714	X92896	Hs.18212	DNA segment on chromosome X (unique)	8.4
	130715	T98227	Hs.171952	occludin	5.7
		AA203527		POP7 (processing of precursor; S. cerevis	6.2
		AA471293		ESTs	8.2
60		AA435633		Homo sapiens clone 23965 mRNA sequen	8.3
		R39390	Hs.19525	ESTs	4.5
		AA223386		ESTs; Weakly similar to katanin p80 subu	7.7
		AA425439	Hs.143323	putative DNA/chromatin binding motif	4.3
65		AA287327	Hs.20478	ceroid-lipofuscinosis; neuronal 2; late infa	9.8
65		M58028	Hs.2055	ubiquitin-activating enzyme E1 (A1S9T a kinesin-like 2	4.3 4.5
		D14678	Hs.20830 Hs.20991		4.5 4
	12009.1	D31891	115.20391	SET domain; bifurcated; 1	4

	130005	AA056489	Un 120000	ESTs	8.7
		W03592	Hs.21198	translocase of outer mitochondrial membr	20.9
		AA291710		collagen; type IV; alpha 3 (Goodpasture a	9
		AA074596		bromodomain adjacent to zinc finger dom	5.3
5		M97935	Hs.21486	signal transducer and activator of transcrip	18.8
•		X57985	Hs.2178	H2B histone family; member Q	13.4
		R45698	Hs.21893	ESTs; Weakly similar to cAMP inducible	8.5
		N48963	Hs.21992	KIAA0689 protein	7.2
		AA435748		ESTs; Weakly similar to phosphatidic acid	5.2
10		X02530	Hs.2248	small inducible cytokine subfamily B (Cy	10.1
		T35341	Hs.22880	ESTs; Highly similar to dipeptidyl peptid	6.3
	131153	H11760	Hs.23606	ESTs	7.3
	131185	M25753	Hs.23960	cyclin B1	6.2
	131200	AA609427	Hs.293732	ESTs; Moderately similar to !!!! ALU SU	4.3
15	131206	AA044078	Hs.24210	ESTs	5.5
	131210	AA430047	Hs.95549	ESTs	7.1
	131227	AA429472	Hs.236522	DKFZP434P106 protein	5.6
	131244	D38076	Hs.24763	RAN binding protein 1	5.5
••	131245	AA620599	Hs.24766	DKFZP564E1962 protein	6.7
20		AA256042		ESTs	5.8
		U25997	Hs.25590	stanniocalcin	8.9
		AA463450		Nijmegen breakage syndrome 1 (nibrin)	6.5
		R34531	Hs.92200	KIAA0480 gene product	9.2
05		H84658	Hs.279836	ESTs	12.1
25		AA608962		calcyclin binding protein	18.1
		Z39053	Hs.27263	ESTs	7.5
		AA121127		H3 histone; family 3A	5.5
		X02152	Hs.2795	lactate dehydrogenase A	5.1
20		N39152	Hs.301804	ESTs	4.3
30		D60856	Hs.28309	UDP-glucose dehydrogenase	8.4
		N33236	Hs.28555	ESTs; Weakly similar to B0511.8 [C.eleg	5.6
		D30946	Hs.28707	signal sequence receptor; gamma (transloc	8.7 18.8
		U90551 AA491465	Hs.28777	H2A histone family; member L ESTs	11.8
35		AA235385			4.7
55		M15182	Hs.183868	ESTs; Moderately similar to alternatively glucuronidase; beta	5.2
		U52100	Hs.29191	epithelial membrane protein 2	4,4
		D14533	Hs.192803	xeroderma pigmentosum; complementatio	4.6
		AA136126		mitogen-activated protein kinase-activated	4.3
40		AA136660		ESTs	9.4
10		U26174	Hs.3066	granzyme K (serine protease; granzyme 3	9.7
		L11066	Hs.3069	heat shock 70kD protein 9B (mortalin-2)	6.2
		AA599653		transcription factor-like 5 (basic helix-loo	8.3
		W60913	Hs.110796	ESTs; Weakly similar to cDNA EST yk45	9
45		AA233225		MRS1 protein	5.2
		D49738	Hs.31053	cytoskeleton-associated protein 1	6.6
		D31352	Hs.31433	ESTs	11
		H46831	Hs.107767	ESTs; Moderately similar to CaM-KII inh	4.9
	131781	AA460450	Hs.31989	DKFZP586G1722 protein	9.2
50	131795	N32724	Hs.32317	Sox-like transcriptional factor	4.5
		L76517	Hs.3260	presenilin 1 (Alzheimer disease 3)	5.4
		AA437226		interleukin 10 receptor; alpha	4
		AA091932	Hs.180628	dynamin-like protein	6.7
~ ~		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5
55		AA044095		ESTs	11.1
		AA158258		heterogeneous nuclear protein similar to r	5.6
		AA248470		ESTs; Weakly similar to RING finger pro	4.5
		AA205460	Hs.69476	ESTs	14.3
60		D62657	Hs.35086	ubiquitin-specific protease 1	6.2
60		W90146	Hs.35962	ESTs	6.3
		D86960	Hs.3610	KIAA0205 gene product	4.2 4.3
		R70167 AA410424	Hs.154938	ESTs Homo sapiens mRNA; cDNA DKFZp586	4.3 4.6
		F09788	Hs.268122 Hs.3622	procollagen-proline; 2-oxoglutarate 4-diox	6.4
65		AA479515		Human DNA sequence from clone 703H1	12
55		D82399	Hs.136644	Homo sapiens clone 23714 mRNA sequen	10
		W67251	Hs.267659	Homo sapiens vav 3 oncogene (VAV3) m	4.7
	102011		10.201000	Tionio dapiono far o onoogono (Trito) in	

		T68246	Hs.306079	chaperonin containing TCP1; subunit 5 (e	5.2
		D82226	Hs.211594	proteasome (prosome; macropain) 26S sub	8.5
	132085	D44466	Hs.3887	proteasome (prosome; macropain) 26S sub	13.5
_	132089	AA131971	Hs.39122	ESTs	4.8
5	132109	AA599801	Hs.40098	ESTs	6.2
	132143	AA257056	Hs.7972	KIAA0871 protein	14.6
	132149	T10822	Hs.324743	ESTs	5.3
	132153	N90141	Hs.41066	ESTs; Moderately similar to ELONGATI	9.2
	132160	AA281770	Hs.295923	seven in absentia (Drosophila) homolog 1	5.5
10	132164	U84573	Hs.41270	procollagen-lysine; 2-oxoglutarate 5-dioxy	8.1
	132180	AA405569	Hs.418	fibroblast activation protein; alpha; sepras	15.4
	132183	L19183	Hs.199695	hypothetical protein	12.2
	132225	AA128980		ESTs	5.6
	132227	AA412620	Hs.4248	ESTs	6.7
15	132235	F09058	Hs.42656	ESTs	6.2
		AA608856		murine leukemia viral (bmi-1) oncogene h	6
		N41849	Hs.7120	Homo sapiens cytokine receptor related p	5.6
		AA285290		small EDRK-rich factor 2	6.8
		N37065	Hs.44856	ESTs	4.7
20		AA479933		Human DNA sequence from clone 167A1	4.2
		R70914	Hs.281434	heat shock 70kD protein 1	9.1
		W85888	Hs.47334	ESTs; Moderately similar to !!!! ALU SU	4
		F09979	Hs.4774	ESTs	15
		AA431459		ESTs	8
25			Hs.260116	KIAA1104 protein	4
23		AA426218		ESTs	5.3
		AA047896		ESTs	15.4
		AA429478		ESTs; Highly similar to CGI-49 protein [H	9
		T03749	Hs.4990	KIAA1089 protein	8.5
30		AA283006		chromosome-associated polypeptide C	4.3
50					9.8
		AA488987		synaptogyrin 2	10.1
		AA417152		protein regulator of cytokinesis 1	
		L37042	Hs.283738	casein kinase 1; alpha 1	5.9
25		AA412452		DKFZP434N024 protein	4.2
35		AA199588		ARP3 (actin-related protein 3; yeast) hom	4.2
		AA386264		isocitrate dehydrogenase 2 (NADP+); mit	5.2
		AA171913		carbonic anhydrase XII	10.1
		AA253330		adaptor-related protein complex 1; gamma	4.8
40		U33821	Hs.5437	Tax1 (human T-cell leukemia virus type I	5.7
40		AA453614		KIAA0776 protein	4.4
		M60830	Hs.5509	ecotropic viral integration site 2B	15.6
		N47109	Hs.5521	ESTs	7
		AA417962		geranylgeranyl diphosphate synthase 1	5.6
4 =		W42674	Hs.264636	ESTs; Moderately similar to neuronal thre	4.9
45		AA490862		ESTs; Weakly similar to C43H8.1 [C.eleg	7.9
		X54326	Hs.55921	glutamyl-prolyl-tRNA synthetase	4.1
		H99152	Hs.57079	ESTs	8
		AA331777		mutL (E. coli) homolog 1 (colon cancer; n	8
	132811	U25435	Hs.57419	transcriptional repressor	4
50	132817	AB004884	Hs.57553	tousled-like kinase 2	6.5
	132840	N23817	Hs.5807	Homo sapiens clone 23675 mRNA sequen	5.6
	132845	D62588	Hs.5813	ESTs	12.4
	132847	T48195	Hs.58189	eukaryotic translation initiation factor 3; s	7
	132856	W79865	Hs.58367	glypican 4	6.2
55	132869	N26855	Hs.203961	ESTs	6.5
	132874	AA425776	Hs.58609	ESTs	5.6
	132880	AA444369	Hs.177537	ESTs	7.2
	132894	D82422	Hs.5944	ESTs	7.5
	132900	N56451	Hs.5978	LIM domain only 7	4.4
60	132903	AA235404	Hs.5985	Homo sapiens clone 25186 mRNA sequen	9.1
		X83618	Hs.59889	3-hydroxy-3-methylglutaryl-Coenzyme A	10.7
			Hs.234896	ESTs; Highly similar to geminin [H.sapie	10.2
		AA496037		ESTs	4.7
		AA252605		KIAA0616 protein	7.1
65		AB002305		KIAA0307 gene product	8.3
		U04209	Hs.61418	microfibrillar-associated protein 1	4.3
		AA234791	Hs.61469	Human gene from PAC 753P9; chromoso	13.2
				•	

	132959	AA028103	Hs.61472	ESTs; Weakly similar to unknown [S.cere	18.9
		N77151	Hs.61638	myosin X	5.8
	132984	H80409	Hs.62112	zinc finger protein 207	4.3
_	132990	AA458761	Hs.18387	transcription factor AP-2 alpha (activating	4.2
5		AA505133		solute carrier family 2 (facilitated glucose	26.4
		Y00062	Hs.170121	protein tyrosine phosphatase; receptor typ	4.4
		AF006082		ARP2 (actin-related protein 2; yeast) hom	4.7
		C21400	Hs.278605	KIAA0970 protein	6.6
10		AA047036		ESTs	7.9
10		W81298	Hs.6289	growth factor receptor-bound protein 2	5.2
		X62055	Hs.63489	protein tyrosine phosphatase; non-recepto	4
		S67325	Hs.63788	propionyl Coenzyme A carboxylase; beta	5.2
		AA071387		jumping translocation breakpoint	5
1.5		R33663	Hs.64056	ESTs	5.4
15		N70633	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
		AA122147		KIAA0483 protein	5 5.6
			Hs.285996	ESTs	4.1
		AA156049		ESTs ATPaso: H+ transporting: lucocomal (vacu	6.2
20		D16469 R37367	Hs.6551 Hs.6727	ATPase; H+ transporting; lysosomal (vacu Ras-GTPase activating protein SH3 doma	5.1
20		Y10659	Hs.285115	interleukin 13 receptor; alpha 1	6.2
		Z41415	Hs.6823	ESTs; Weakly similar to intrinsic factor-B	8.3
		N90029	Hs.6831	Homo sapiens clone 1400 unknown prote	4.7
			Hs.179882	Homo sapiens clone 24655 mRNA sequen	5.5
25		D31161	Hs.242894	ESTs	9
		AF006086		actin related protein 2/3 complex; subunit	7.7
		W72187	Hs.69192	ESTs; Weakly similar to cDNA EST yk37	6.7
		AA488886		ESTs	4.2
		AA421079		ESTs; Weakly similar to Sox-like transcri	4.9
30		AA410507		ESTs	4.3
	133287	L.15702	Hs.69771	B-factor; properdin	9.3
	133294	R79723	Hs.69997	zinc finger protein 238	30.4
	133297	AA600057	Hs.70266	KIAA0905 protein	10.4
~ =			Hs.152316	ESTs	8.5
35	133362	H06195	Hs.7194	ESTs; Highly similar to CGI-59 protein [H	14
		AA156897		DKFZP564I1922 protein	5
		X57579	Hs.727	inhibin; beta A (activin A; activin AB alp	13.9
		AA491296		ESTs	4.3
40		N79516	Hs.73287	ESTs; Weakly similar to eyelid [D.melano	4.5
40		AA255438		Homo sapiens mRNA; cDNA DKFZp566	8
		T23983	Hs.323966	ESTs	5
		AA094989		voltage-dependent anion channel 3	8.7 5
		X03068 X78710	Hs.73931	major histocompatibility complex; class II metal-regulatory transcription factor 1	5.3
45		AA316868	Hs.211581	ESTs; Weakly similar to 140G11.h [D.me	6.8
73		X52947	Hs.74471	gap junction protein; alpha 1; 43kD (conn	5.7
		D63480	Hs.278634	KIAA0146 protein	4.8
		AA313977		transcription elongation factor B (SIII); po	9.5
		W94333	Hs.279915	translocase of inner mitochondrial membr	5
50		F03717	Hs.75063	human immunodeficiency virus type I enh	7.4
- 0		L37368	Hs.75104	RNA-binding protein S1; serine-rich dom	5
		D13315	Hs.75207	glyoxalase I	4.2
		AA148318		KIAA0069 protein	4.5
	133627	U09587	Hs.75280	glycyl-tRNA synthetase	10
55	133633	D21262	Hs.75337	nucleolar phosphoprotein p130	4.5
		U24166	Hs.234279	microtubule-associated protein; RP/EB fa	15.2
		D83004	Hs.75355	ubiquitin-conjugating enzyme E2N (homo	9.1
		D89077	Hs.75367	Src-like-adapter	6.4
C O		AA479139		acid phosphatase 1; soluble	4.8
60		AA287383		ESTs	4.2
		AA458946		ESTs	4.3
		K01396	Hs.297681	protease inhibitor 1 (anti-elastase); alpha-	8.3
		N21648	Hs.75659	MpV17 transgene; murine homolog; glom	4.6
65		Y00282	Hs.75722 Hs.75737	ribophorin II pericentriolar material 1	7.5 9.4
03		L27841 U49278	Hs.75875	ubiquitin-conjugating enzyme E2 variant	9.4 4.5
		D21255	Hs.75929	cadherin 11 (OB-cadherin; osteoblast)	6.4
	100100	DE 1200	113.1 0323	oddiscin 11 (Obrodutom, obtobiasty	U. 7

		W73693	Hs.76038	isopentenyl-diphosphate delta isomerase	7.9
		Z23090	Hs.76067	heat shock 27kD protein 1	4.1
		J03473	Hs.177766	ADP-ribosyltransferase (NAD+; poly (AD	13
_	133784	AA214305	Hs.301064	ESTs	5.2
5	133814	M33882	Hs.76391	myxovirus (influenza) resistance 1; homol	11.7
	133829	AA453783	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564	9.4
	133834	AA147510	Hs.288660	serine protease; umbilical endothelium	4.8
	133839	M59815	Hs.170250	complement component 4A	6.7
	133842	U73477	Hs.285013	putative human HLA class II associated p	7.1
10	133845	T68510	Hs.76704	ESTs	6.3
		U86782	Hs.178761	26S proteasome-associated pad1 homolog	13.7
	133867	D43948	Hs.76989	KIAA0097 gene product	4.1
	133868	U58090	Hs.183874	cullin 4A	4
	133871	AA454597	Hs.182793	ESTs	4.7
15		X01060	Hs.77356	transferrin receptor (p90; CD71)	8.3
		N32811	Hs.77542	ESTs	5
		W72783	Hs.58382	ESTs; Weakly similar to C13F10.5 [C.ele	4.5
		AA045870		Homo sapiens mRNA; cDNA DKFZp564	6.3
			Hs.173878	4-nitrophenylphosphatase domain and non	6.4
20		L34587	Hs.184693	transcription elongation factor B (SIII); po	6.3
20		D00760	Hs.250811	proteasome (prosome; macropain) subunit	11.9
		C02374	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564	8.2
		M28213	Hs.78305	RAB2; member RAS oncogene family	5.2
		J03077	Hs.78575	prosaposin (variant Gaucher disease and v	4.6
25		Z81326	Hs.78589	protease inhibitor 12 (neuroserpin)	6.5
23		S82470	Hs.78768	BB1	11.9
			Hs.172801		5.2
		D28473 D87685	Hs.78893	isoleucine-tRNA synthetase	7.3
				KIAA0244 protein cullin 3	4.7
20		H98621	Hs.78946		7
30		U51166	Hs.173824	thymine-DNA glycosylase	4.5
		M22382	Hs.79037	heat shock 60kD protein 1 (chaperonin)	9.4
		X06323	Hs.79086	ribosomal protein; mitochondrial; L3	9.4 4.4
		U41060	Hs.79136	LIV-1 protein; estrogen regulated	
25		U32519	Hs.220689	Ras-GTPase-activating protein SH3-doma	6.6
35		AA398908		Human Chromosome 16 BAC clone CIT9	8.6
		M63138	Hs.79572	cathepsin D (lysosomal aspartyl protease)	9.3
		U88871	Hs.79993	peroxisomal biogenesis factor 7	6.3
		L28010	Hs.808	heterogeneous nuclear ribonucleoprotein F	4.3
40		AA430008		ESTs	6.9
40		AA313414		Homo sapiens clone 24856 mRNA sequen	7.4
		U16306	Hs.81800	chondroitin sulfate proteoglycan 2 (versic	6.1
		D38551	Hs.81848	RAD21 (S. pombe) homolog	8.6
			Hs.111222	ESTs; Weakly similar to CGI-128 protein	6.1
45		R82074	Hs.82109	syndecan 1	4.4
45		L43575	Hs.82171	Human clone 191B7 placenta expressed m	6.6
		M37033	Hs.82212	CD53 antigen	5.3
		X54199	Hs.82285	phosphoribosylglycinamide formyltransfe	4.8
		D62633	Hs.8236	ESTs	15.2
~ 0		AA412720		ESTs; Highly similar to CGI-118 protein	7.2
50		X02874	Hs.82396	2';5'-oligoadenylate synthetase 1	6.4
	134381	U56637	Hs.184270	capping protein (actin filament) muscle Z-	4
		M15841	Hs.82575	small nuclear ribonucleoprotein polypepti	5.7
		L09717	Hs.8262	lysosomal-associated membrane protein 2	6.9
		H99801	Hs.82689	tumor rejection antigen (gp96) 1	4.5
55	134401	AA243746		kinectin 1 (kinesin receptor)	11.2
		J04177	Hs.82772	collagen; type XI; alpha 1	15.3
	134415	AA329274		protein tyrosine phosphatase type IVA; m	4.1
	134417	D87969	Hs.82921	solute carrier family 35 (CMP-sialic acid t	4.2
		L08044	Hs.82961	trefoil factor 3 (intestinal)	5.9
60	134421	AA122386	Hs.82985	collagen; type V; alpha 2	5.8
	134423	W96151	Hs.83006	ESTs; Highly similar to CGI-139 protein	4.4
	134438	AA449984	Hs.246857	ESTs; Highly similar to proteine kinase JN	7
	134446	T25732	Hs.83419	KIAA0252 protein	4.6
_	134453	X70683	Hs.83484	SRY (sex determining region Y)-box 4	5.1
65	134470	X54942	Hs.83758	CDC28 protein kinase 2	20.3
		R38185	Hs.83954	Homo sapiens unknown mRNA	5
		D63477	Hs.84087	KIAA0143 protein	16.1

	101100				
		M63180	Hs.84131	threonyl-tRNA synthetase	6.1
		U45328	Hs.84285	ubiquitin-conjugating enzyme E2I (homol	4.6
		H24460	Hs.848	FK506-binding protein 4 (59kD)	6.2
~		U66615	Hs.172280	SWI/SNF related; matrix associated; actin	4.8
5		AA234966		CGG triplet repeat binding protein 1	4.7
		R68884	Hs.86347	ESTs; Weakly similar to predicted using G	5.8
		X74496	Hs.86978	prolyl endopeptidase	4.5
		W23625	Hs.8739	ESTs; Weakly similar to ORF YGR200c [13.7
1.0		AA454070		ESTs	5.8
10		AA250745		protein kinase; cAMP-dependent; catalyti	8.9
	134711	X04011	Hs.88974	cytochrome b-245; beta polypeptide (chro	6.8
	134714	U89922	Hs.890	lymphotoxin beta (TNF superfamily; mem	35.7
	134722	W47183	Hs.284226	ESTs; Weakly similar to neural F box pro	8.1
	134776	J05582	Hs.89603	mucin 1; transmembrane	6.2
15	134806	Z49099	Hs.89718	spermine synthase	4.2
	134810	M27394	Hs.89751	membrane-spanning 4-domains; subfamily	7
	134840	U51477	Hs.89981	diacylglycerol kinase; zeta (104kD)	4.1
	134843	H60595	Hs.90061	progesterone binding protein	4.7
	134853	D82348	Hs.90280	5-aminoimidazole-4-carboxamide ribonuc	10.2
20		U84011	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotr	12.1
		Z39762	Hs.90419	KIAA0882 protein	6
		N27670	Hs.9071	progesterone membrane binding protein	5
		N46086	Hs.92308	ESTs	4.1
		AA236324		Homo sapiens mRNA; chromosome 1 spe	16.8
25		H05625	Hs.5831	ESTs	4
		AA282343		purine-rich element binding protein B	4.4
	-	D59675	Hs.92927	ESTs	7
		U54999	Hs.278338	LGN protein	4.8
		AA224180	710.27 0000	ESTs; Moderately similar to 17-beta-hydr	13.6
30		AA243497	He 173685	Human DNA sequence from clone 30M3	4
50		U77948	Hs.278589	general transcription factor II; i	8
		AA598449		Homo sapiens clone 24483 unknown mRN	5.4
		L08069	Hs.94		9.3
				heat shock protein; DNAJ-like 2	
35		AA495950		ESTs	6.7
55		W52493	Hs.94694	Homo sapiens clone 24837 mRNA sequen	10.2
		AA044842		Homo sapiens mRNA; cDNA DKFZp586	6.6
		AA126433		sorting nexin 4	7.4
		D31157	Hs.324277	ESTs; Weakly similar to growth factor-res	6.2
40		AA454930		ESTs	19.5
40		AA215333		putative G protein-coupled receptor	8.8
		H20989	Hs.198281	pyruvate kinase; muscle	12.4
		D83174	Hs.9930	collagen-binding protein 2 (colligen 2)	5.5
		AA480109		TYRO protein tyrosine kinase binding pro	5.4
15		U05237	Hs.99872	fetal Alzheimer antigen	7.8
45		M23263	Hs.99915	androgen receptor (dihydrotestosterone re	9.1
		L10333	Hs.99947	reticulon 1	5.3
		M97935		AFFX control: STAT1	8.3
		M97935		AFFX control: STAT1	7
50		M97935		AFFX control: STAT1	14
50		AI199738	Hs.208275	ESTs; Weakly similar to !!!! ALU CLASS	9.1
		AI694585	Hs.270464	ESTs; Weakly similar to !!!! ALU CLASS	7.4
		AW079607		ESTs; Weakly similar to ZnT-3 [H.sapien	30.1
		AW015860		ESTs	11.9
		AA699328		ESTs	5.5
55		Al492179	Hs.166244	ESTs; Weakly similar to cDNA EST yk40	11
	300921	AW293224	Hs.232165	ESTs	11
	301124	T79326	Hs.298262	ESTs; Weakly similar to dJ88J8.1 [H.sapi	8.8
	301165	N85789	Hs.150186	ESTs; Weakly similar to PTERIN-4-ALP	6
		Al682905	Hs.270431	ESTs; Weakly similar to !!!! ALU SUBFA	4.7
60		AA373124		ESTs; Weakly similar to C17G10.1 [C.ele	8
		AA526313		ESTs	4.2
		N99399	Hs.143046	EST cluster (not in UniGene) with exon h	18
	301884	AA312082		GDNF family receptor alpha 1	20.7
		NM_004694		EST cluster (not in UniGene) with exon h	11.6
65	302002	AF013956	Hs.5637	chromobox homolog 4 (Drosophila Pc cla	9.2
	302032	NM_001992	2Hs.128087	EST cluster (not in UniGene) with exon h	4.3
	302067		Hs.222399	ESTs; Weakly similar to protein-tyrosine	7.8
				, and annual as processing of the same	-

	302145	NM_00361	3Hs.151407	EST cluster (not in UniGene) with exon h	15.1
	302236	Al128606	Hs.6557	zinc finger protein 161	25.8
	302276	NM_00444	8Hs.323910	EST cluster (not in UniGene) with exon h	21.6
_			Hs.175563	Homo sapiens mRNA; cDNA DKFZp564	41.4
5	302326	NM_00427	1Hs.184018	EST cluster (not in UniGene) with exon h	8.9
			Hs.190386	KIAA0924 protein	5.4
			Hs.200102	Homo sapiens mRNA; cDNA DKFZp434	8.9
		AB021227		matrix metalloproteinase 24 (membrane-in	5.2
10			Hs.226434	EST cluster (not in UniGene) with exon h	5.3
10			Hs.251446	EST cluster (not in UniGene) with exon h	9.9
			Hs.247874	multiple UniGene matches	4.3
		L36149	Hs.248116	chemokine (C motif) XC receptor 1	4.9
			Hs.102696	ESTs; Weakly similar to C11D2.4 [C.eleg	5.3
15		AW293005		ESTs	8.4
13		AA343696		ESTs; Weakly similar to putative [H.sapie	4.5
		X04588	Hs.85844	EST cluster (not in UniGene) with exon h	6.8 8.4
		U66049	Hs.82171	EST cluster (not in UniGene) with exon h	22.8
		N58545	Hs.42346	histone deacetylase 3	6.8
20		N46406	Hs.315111	EST cluster (not in UniGene) with exon h EST cluster (not in UniGene) with exon h	8.9
20			Hs.84700 Hs.317714	pallid (mouse) homolog; pallidin	10.1
			Hs.279926	EST cluster (not in UniGene) with exon h	24.4
			Hs.103180	actin-like 6	6.3
		Al929819	Hs.4055	ESTs	17.7
25		U09759	Hs.246857	mitogen-activated protein kinase 9	11.4
			Hs.180799	ESTs	15.8
		Al815990	Hs.293515	ESTs	7.2
		AA488528		EST cluster (not in UniGene) with exon h	5.3
		T07216	Hs.301226	EST cluster (not in UniGene) with exon h	16.2
30		AA397546		ESTs	8.9
		Al953377	Hs.28444	ESTs; Weakly similar to predicted using G	12
	303642	AW299459	Hs.111977	EST cluster (not in UniGene) with exon h	4.2
	303654	AA436942	Hs.288529	ESTs	8.4
	303733	AW502498	Hs.15220	ESTs; Weakly similar to zinc finger prote	5.2
35	303780	Al424014	Hs.18995	ESTs; Moderately similar to KIAA0456 p	28.4
	303792	C75094	Hs.199839	ESTs; Highly similar to NG22 [H.sapiens	4.4
		Al337304	Hs.126268	ESTs; Weakly similar to similar to PDZ d	8.1
			Hs.172928	collagen; type I; alpha 1	7.5
40		AA421948		EST singleton (not in UniGene) with exon	6.5
40		AA456426		EST	5.4
		AA505702		EST singleton (not in UniGene) with exon	9.8
		AA507875		EST singleton (not in UniGene) with exon	7.5
		AA533185	11- 400470	EST singleton (not in UniGene) with exon	7
45			Hs.169476	glyceraldehyde-3-phosphate dehydrogena	12.4
43		AA653159		EST singleton (not in UniGene) with exon	8.7
	305453	AA725116 AA738110	⊓S./ 0400	EST singleton (not in UniGene) with exon	5.3 4.1
		AA872838		EST singleton (not in UniGene) with exon keratin 8	7.7
		AA876109		EST singleton (not in UniGene) with exon	6.3
50		AA884479		EST singleton (not in UniGene) with exon	5.6
50		AA889992	Hs 2186	EST singleton (not in UniGene) with exon	13.2
			Hs.283370	EST singleton (not in UniGene) with exon	4.4
		AA906161		EST singleton (not in UniGene) with exon	4.6
		AA970548		EST singleton (not in UniGene) with exon	7.6
55		AA987722		EST singleton (not in UniGene) with exon	19.7
		AA995761		EST singleton (not in UniGene) with exon	5.5
	307117	AI184111	Hs.76067	heat shock 27kD protein 1	7.7
	307138	Al185516	Hs.172928	collagen; type I; alpha 1	8.8
	307187	AI190870	Hs.276417	EST singleton (not in UniGene) with exon	4.1
60		A1280859	Hs.62954	EST singleton (not in UniGene) with exon	6
		Al281603	Hs.172928	EST singleton (not in UniGene) with exon	10.8
		Al351739	Hs.276726	EST singleton (not in UniGene) with exon	4.7
		A1472733	Hs.270208	ESTs	4.2
~ =		AI581398	Hs.172928	collagen; type I; alpha 1	5.4
65		AI687580	Hs.169476	EST singleton (not in UniGene) with exon	10.1
		A1738593	Hs.101774	EST singleton (not in UniGene) with exon	15.1
	3086//	Al761173		EST singleton (not in UniGene) with exon	4.6

		AI829848	Hs.182937	peptidylprolyl isomerase A (cyclophilin A	5.9
	308974	A1872290	Hs.300697	immunoglobulin gamma 3 (Gm marker)	4.5
		AI873242		EST singleton (not in UniGene) with exon	7.6
<u>بے</u>		AI880172		EST singleton (not in UniGene) with exon	6.6
5		AI951118		EST singleton (not in UniGene) with exon	24.3
		Al952723	Hs.90207	EST singleton (not in UniGene) with exon	6.1
		AI955915		major histocompatibility complex; class I;	5.6
		AI969897		EST singleton (not in UniGene) with exon	6.2
1.0		Al990102		EST singleton (not in UniGene) with exon	7.9
10		AW170035		EST	64.5
		AW191929		EST	5.3
	309629	AW192764	Hs.172928	collagen; type I; alpha 1	6.9
	309641	AW194230	Hs.253100	EST	11.4
	309698	AW238461	Hs.73742	ribosomal protein; large; P0	4.3
15	309700	AW241170	Hs.179661	Homo sapiens clone 24703 beta-tubulin m	11.9
	310073	Al335004	Hs.148558	ESTs	4.2
	310094	AW450967	Hs.235240	ESTs	5.7
	310373	AW080778	Hs.145582	ESTs	4.8
	310438	AW022192	Hs.200197	ESTs	39.1
20	310470	Al281848	Hs.194691	ESTs	4.9
	310583	AW205632	Hs.211198	ESTs	7
	310877	T47784	Hs.188955	ESTs	4.1
	311067	Al587332	Hs.209115	ESTs	11.2
	311166	Al821294	Hs.118599	ESTs	24.1
25	311199	T57896	Hs.191095	EST cluster (not in UniGene)	5.7
	311465	AI758660	Hs.206132	ESTs	15.7
	311587	Al828254	Hs.271019	ESTs	6.4
	311774	AA700870	Hs.14304	ESTs	6.2
	311785	AI056769	Hs.133512	ESTs	5
30	311923	T60843	Hs.189679	ESTs	5.9
	311935	AA216387		EST cluster (not in UniGene)	5.5
	311972	N51511	Hs.188449	ESTs	5.2
	312014	A1435650	Hs.128778	ESTs	4.3
	312047	AA588275	Hs.180669	ESTs	14.7
35	312147	T89855	Hs.195648	EST cluster (not in UniGene)	9.8
	312153	AA759250	Hs.153028	cytochrome b-561	27.1
	312168	T92251	Hs.198882	ESTs	4.2
	312172	Al222168	Hs.191168	ESTs	6.1
	312226	A!796815	Hs.199993	ESTs; Weakly similar to ubiquitous TPR	5.5
40	312292	AW451893	Hs.151124	ESTs	18.4
	312312	Al080505	Hs.134529	ESTs	11.9
	312369	AA582039	Hs.173884	Homo sapiens mRNA; chromosome 1 spe	4
	312407	R46180	Hs.153485	ESTs	13.6
	312430	AW139117	Hs.117494	ESTs	4.1
45	312470	AW451347	Hs.175862	ESTs	4.6
	312483	Al417526	Hs.7753	ESTs	15.3
	312521	AA033609	Hs.319093	ESTs	12.5
		A1498371	Hs.183526	ESTs	14.6
		AW439195		ESTs	5.3
50		R99834	Hs.250383	ESTs	8.4
		H63791		EST cluster (not in UniGene)	4.3
	312821	AA699325	Hs.269880	ESTs	8.3
		AW292286		ESTs	7.1
~ ~		AA846353		ESTs	5.9
55		AA828713		EST cluster (not in UniGene)	4.1
		AA088446		ESTs	7.3
		AI422367	Hs.163533	ESTs	6.1
		AA732534		ESTs	4.2
C O		AA720887		EST cluster (not in UniGene)	18.1
60		N59284	Hs.288010	ESTs	17
		Al738851		ESTs	12.9
		N74924	Hs.182099	ESTs	7.1
		AW068358		ESTs	13.7
65		AW449211		ESTs	27.9
65		AW292127		ESTs	9.8
		AA741151		ESTs	8.2
	313455	AW081702	HS.985/1	ESTs	6.9

	313590 AA804410 Hs.291677	EST cluster (not in UniGene)	5.3
	313663 Al953261 Hs.169813	EST's	7.6
	313667 U69201 Hs.13684	ESTs; Weakly similar to choline kinase is	12.5
		ESTs, Weakly similar to choline kindse is	5.5
5	313749 AW450376 Hs.119004		4.3
5	313832 AW271022 Hs.133294	ESTs	
	313881 AA535580 Hs.16331	ESTs	7.7
	313915 Al969390 Hs.163443	ESTs	27.1
	313955 Al858884 Hs.270647	ESTs	5.7
	313974 Al310151 Hs.173524	ESTs	4.3
10	314097 AA648744 Hs.269493	ESTs	14.5
	314129 AA228366 Hs.115122	ESTs	9.5
	314359 AA205569 Hs.194193	ESTs	5.4
	314384 AA535840 Hs.162203	ESTs; Weakly similar to alternatively spli	5.3
	314394 Al380563 Hs.130816	ESTs	13.2
15	314462 AA347951 Hs.326413	ESTs	6.2
13	314465 AA602917 Hs.156974	ESTs	18.1
		ESTs :	4.2
	314470 Al934422 Hs.30661		
	314488 AA358265 Hs.182890	ESTs	6.1
20	314506 AA833655 Hs.206868	ESTs	27.8
20	314510 Al204418 Hs.190080	ESTs	9.5
	314558 Al873274 Hs.190721	ESTs	22.5
	314661 AA436432 Hs.324239	EST cluster (not in UniGene)	13.3
	314691 AW207206 Hs.136319	ESTs	21.4
	314754 AW026761 Hs.134374	ESTs	4.4
25	314775 AI149880 Hs.188809	ESTs	4.4
	314943 Al476797 Hs.184572	cell division cycle 2; G1 to S and G2 to M	18.4
	314961 AW008061 Hs.231994	ESTs	10.2
	314963 Al689617 Hs.200934	ESTs	5.3
	315006 Al538613 Hs.298241	ESTs	20.7
30	315010 AA531082 Hs.240049	ESTs	5
50	315010 AA531002 Hs.240049 315019 AA532807 Hs.105822	ESTs	6.1
			12
	315033 Al493046 Hs.146133	ESTs	
	315036 AA534953 Hs.163297	ESTs	8.3
2.5	315037 AW205863 Hs.133988	ESTs; Weakly similar to gene MAC25 pr	6.1
35	315051 AW292425 Hs.163484	EST	12.7
	315054 Al968598 Hs.78768	ESTs	7.6
	315073 AW452948 Hs.257631	ESTs	13.9
	315080 AA744550 Hs.136345	ESTs	4.4
	315083 Al221325 Hs.205442	ESTs	5.1
40	315088 AA557351 Hs.152448	ESTs; Moderately similar to MULTIFUN	4.7
	315175 Al025842 Hs.152530	ESTs	11.9
	315196 AA972756 Hs.44898	ESTs	28.8
	315296 AA876905 Hs.125286	ESTs	16.1
	315303 AW194364 Hs.128022	ESTs; Weakly similar to FIG-1 PROTEIN	25.7
45	315352 AA604799 Hs.136528	ESTs; Moderately similar to !!!! ALU SU	12.3
73	315364 AA643602 Hs.155485	ESTs; Highly similar to serine protease [H	4.6
		ESTs	4.8
	315368 AW291563 Hs.104696		4.4
	315390 Al801565 Hs.200113	ESTs; Weakly similar to alternatively spli	
50	315408 AW273261 Hs.216292	ESTs	5
50	315458 AA872000 Hs.116104	ESTs	7.6
	315472 AA828850 Hs.165469	ESTs	4.9
	315478 AA665612 Hs.120874	ESTs	5.2
	315498 AA628539 Hs.116252	ESTs; Moderately similar to !!!! ALU SU	4.8
	315527 Al791138 Hs.116768	ESTs	4.4
55	315530 Al200852 Hs.127780	ESTs .	22.4
	315562 AA737415 Hs.152826	ESTs	5.9
	315634 AA837085 Hs.220585	ESTs	8.8
	315647 AA648983 Hs.212911	ESTs	15
	315652 Al521489 Hs.3053	ESTs	6.3
60	315676 AW002565 Hs.124660	ESTs	9.2
00	315680 AA814309 Hs.123583	ESTs	8.1
		ESTS	13.4
	315735 Al831760 Hs.155111		
	315741 AA812168 Hs.122559	ESTs	5.4
CF	315769 AA744875 Hs.189413	ESTs	4.4
65	315978 AA830893 Hs.119769	ESTs	10.4
	315984 Al015862 Hs.131793	ESTs	5
	316042 AW297979 Hs.170698	ESTs	14.7

	240400	* * 000000	11- 404000	FOT-	
			Hs.124366	ESTs	4
		Al908272	Hs.293102	EST cluster (not in UniGene)	32.6
			Hs.202599	ESTs	4.8
_			Hs.270823	ESTs	4.8
5	316480	Al749921	Hs.205377	ESTs	12.9
	316564	Al743571	Hs.168799	ESTs; Weakly similar to !!!! ALU SUBFA	8.1
	316714	AA809792	Hs.123307	ESTs	5
	316715	A1440266	Hs.170673	ESTs	4.2
	316828	AA828116	Hs.173076	ESTs	5.2
10			Hs.134604	ESTs	13.3
			Hs.210846	ESTs	6.2
			Hs.137007	ESTs	5.3
			Hs.124620	ESTs	7.2
15			Hs.143707	ESTs	4.1
15			Hs.189144	ESTs; Weakly similar to RENAL SODIU	4.2
		Al805392	Hs.325335	ESTs	4.5
		Al732892	Hs.190489	ESTs	6.4
		AA490718		EST cluster (not in UniGene)	4.4
			Hs.158549	ESTs	5.9
20	317658	AW139077	Hs.202217	ESTs	4.6
	317674	AW294909	Hs.132208	ESTs	5.2
	317685	A1798630	Hs.149997	ESTs	4.3
			Hs.128929	ESTs	12.4
			Hs.224398	ESTs	12.1
25			Hs.211265	ESTs	8.8
45			Hs.159983	ESTs	12.6
			Hs.149991	ESTs	5.6
			Hs.133469	ESTs	4
20			Hs.170939	ESTs	5.2
30			Hs.248942	ESTs	4.7
			Hs.131562	ESTs	15.7
			Hs.150521	ESTs	5.9
	318186	AW016773	Hs.3709	ESTs	5.3
	318481	Al291584	Hs.145921	ESTs; Weakly similar to HYPOTHETICA	7.6
35	318566	Al335361	Hs.226376	ESTs	5.8
		AW247252		nucleoside phosphorylase	11.1
			Hs.294014	ESTs	16.3
			Hs.181307	H3 histone; family 3A	4
		NM_00254		EST cluster (not in UniGene)	21.3
40		_	Hs.144479	ESTs	35
+0					
		AA317274		ESTs	11.7
		F15257	Hs.27	glycine dehydrogenase (decarboxylating;	7
		R06841	Hs.270307	EST cluster (not in UniGene)	8.9
		R83716	Hs.14355	ESTs	8.2
45	319668	NM_00273	1Hs.87773	EST cluster (not in UniGene)	25.4
	319763	AA460775	Hs.6295	ESTs	7
	319913	AA179304	Hs.271586	ESTs; Moderately similar to !!!! ALU SU	8.7
	319936	W22152	Hs.282929	EST cluster (not in UniGene)	5.6
	319951	AA307665	Hs.14559	ESTs	4.9
50		H06350	Hs.135056	ESTs	9.2
• •		AA632632		EST cluster (not in UniGene)	4.6
			Hs.278233	EST cluster (not in UniGene)	16.7
			Hs.113292	calpain 9 (nCL-4)	5.4
				EST cluster (not in UniGene)	5.3
55			Hs,291712		
55		D63271	11 00700	EST cluster (not in UniGene)	5.5
		AA984373		EST cluster (not in UniGene)	15
	320187		Hs.303428	EST cluster (not in UniGene)	6.7
		AL039402	Hs.125783	DEME-6 protein	24.3
	320401	U90449	Hs.152717	nucleoside diphosphate kinase type 6 (inh	10
60		Al884396	Hs.24131	ESTs	5.4
	320488	R31386	Hs.191791	EST cluster (not in UniGene)	4.9
	320521	N31464	Hs.24743	ESTs	9.5
	320661	AA864846	Hs,115175	EST cluster (not in UniGene)	6.6
		R61576	Hs.313951	hypothetical protein	5.9
65		R63161	Hs.118249	EST cluster (not in UniGene)	4
		U96044	Hs.181125	EST cluster (not in UniGene)	15.3
		AL050145	Hs.225986	Homo sapiens mRNA; cDNA DKFZp586	7.2
	0_000			biene un au A : - : - : - : - : - : - : - : - :	

	224040 44727244 11-404224	ECT -luster (-et la libiCana)	6.4
	321012 AA737314 Hs.194324 321050 AW393497	EST cluster (not in UniGene)	6.1 5
	321050 AW393497 321051 AF134149 Hs.240395	EST cluster (not in UniGene) EST cluster (not in UniGene)	11.4
	321031 AF134149 Hs.240393 321171 AI769410 Hs.221461	ESTs	7.7
5	321192 AA295304 Hs.297939	ESTs; Weakly similar to neogenin [H.sap	5.5
3	321354 AA078493	EST cluster (not in UniGene)	16.9
	321387 H68014 Hs.141278	ESTs; Weakly similar to !!!! ALU SUBFA	4.2
	321412 AW366305 Hs.22891	EST cluster (not in UniGene)	6.3
	321489 AW392474 Hs.172759	ESTs; Moderately similar to !!!! ALU SU	9
10	321539 N98619 Hs.42915	ARP2 (actin-related protein 2; yeast) hom	11.3
	321593 H84762 Hs.253197	ESTs	10.4
	321666 D28390 Hs.272897	EST cluster (not in UniGene)	19.9
	321891 AW157424 Hs.165954	ESTs	5.6
1.5	321910 H67065 Hs.271530	ESTs; Weakly similar to !!!! ALU SUBFA	5.4
15	321953 AW068268 Hs.292833	ESTs; Weakly similar to !!!! ALU CLASS	6.5
	321978 N77342 Hs.21851	EST cluster (not in UniGene)	10.2
	322017 AA310039 Hs.9192	ESTs	9.8
	322026 AA233527 Hs.283675	low density lipoprotein receptor (familial	27.8
20	322035 AL137517 Hs.306201	EST cluster (not in UniGene)	40.2 5.7
20	322171 AF085968 Hs.48474	EST cluster (not in UniGene)	3.7 7.7
	322175 AF085975 322236 AL134970 Hs.104222	EST cluster (not in UniGene) follistatin-like 1	14.4
	322303 W07459 Hs.157601	EST cluster (not in UniGene)	13.4
	322735 AA086123 Hs.297856	EST cluster (not in UniGene)	7.6
25	322777 AA679082 Hs.269947	ESTs	4.4
	322818 AW043782 Hs.293616	ESTs	21
	322882 AW248508 Hs.279727	DiGeorge syndrome critical region gene 2	15.3
	322975 C16391	EST cluster (not in UniGene)	21.3
	322991 C18965 Hs.159473	ESTs	11.7
30	323011 AA580288	EST cluster (not in UniGene)	8.9
	323091 AW014094 Hs.210761	ESTs	10.8
	323107 Al301107 Hs.150790	ESTs	6.5
	323136 AL120351 Hs.30177	EST cluster (not in UniGene)	5.5
25	323168 AL120862 Hs.124165	ESTs	17.9
35	323195 Al064982 Hs.117950	multifunctional polypeptide similar to SA Homo sapiens mRNA; cDNA DKFZp586	5.8 11.6
	323201 AL049370 Hs.13350 323203 AA203135 Hs.130186	ESTs	6.4
	323243 W44372 Hs.110771	EST cluster (not in UniGene)	7.3
	323244 T70731 Hs.193620	EST cluster (not in UniGene)	15.8
40	323328 AA228078 Hs.255096	EST cluster (not in UniGene)	4.8
	323332 Al829520 Hs.227513	ESTs	20.2
	323333 AA228883 Hs.208558	EST cluster (not in UniGene)	8.8
	323570 AL038623 Hs.208752	ESTs; Weakly similar to !!!! ALU SUBFA	5
	323604 Al751438 Hs.41271	ESTs; Weakly similar to !!!! ALU SUBFA	6.5
45	323685 AA344205 Hs.289088	EST cluster (not in UniGene)	7.1
	323753 AA327102 Hs.70266	EST cluster (not in UniGene)	6.1
	323817 AA410943	EST cluster (not in UniGene)	16.8
	323845 Al684674 Hs.41127	ESTs; Weakly similar to waclaw [D.melan	10.1
50	323930 AA570698 Hs.8173	ESTs	6.4
30	323997 AA844907 Hs.274454	EST cluster (not in UniGene)	8 6.3
	324047 AA378201 Hs.271340 324261 AL044891 Hs.269350	EST cluster (not in UniGene)	50.1
	324302 AA543008 Hs.292471	EST cluster (not in UniGene) ESTs: Weakly similar to I!!! ALU SUBFA	5.7
	324338 AL138357 Hs.145078	ESTs. Weakly similar to him ALO CODI A	9.5
55	324344 AW502000 Hs.46677	EST cluster (not in UniGene)	4.4
	324432 AA464510 Hs.152812	EST cluster (not in UniGene)	16.7
	324495 AW501411 Hs.122489	ESTs; Weakly similar to !!!! ALU CLASS	5.5
	324497 AW152624 Hs.136340	ESTs	5.4
	324598 AA502659 Hs.163986	ESTs	8.8
60	324603 AW016378 Hs.292934	ESTs	23.1
	324620 AA448021 Hs.94109	EST cluster (not in UniGene)	21.2
	324727 Al610425 Hs.19597	ESTs	5
	324774 Al031771 Hs.132586	ESTs	5
CF	324783 AA640770 Hs.200994	EST cluster (not in UniGene)	4.1
65	324824 Al826999 Hs.224624	ESTs	6.3
	324826 AA704806 Hs.143842 324902 D31323 Hs.271492	ESTs ESTs	11.7 4.8
	324902 D31323 Hs.271492	ESTs	4.0

	324961 AA613792 324987 T06882 Hs.172634 324988 T06997 Hs.121028	EST cluster (not in UniGene) ESTs EST cluster (not in UniGene)	13.3 19.6 24.5
5	325146 Al064690 Hs.171176 325622 326213 326474 326816	ESTs CH.14_hs gi 5867000 CH.17_hs gi 5867224 CH.19_hs gi 5867405 CH.20_hs gi 6552458	4.6 5.2 8.1 12.7 9.4
10	326817 327110 327196 327283 327313 327450	CH.20_hs gi 6552458 CH.21_hs gi 6117842 CH.01_hs gi 5867446 CH.01_hs gi 5867478 CH.01_hs gi 5867501 CH.02_hs gi 5867766	11.7 14.7 5.1 4.3 4.8 4.1
15	328059 328304 328492 328857 329367	CH.02_rs gij6307700 CH.06_hs gij6117819 CH.07_hs gij6004478 CH.07_hs gij6868455 CH.07_hs gij6381927 CH.X_hs gij5868842	6.2 5.4 7 5.2 7.6
20	329373 329655 329899 329960 330084	CH.X_hs gi 6682537 CH.14_p2 gi 648516 CH.15_p2 gi 6563505 CH.16_p2 gi 5091594 CH.19_p2 gi 6015302	12 4 4 7.6 4
25	330384 M23263 330385 AA449749 330387 H14624 330388 X03363 330409 D50692 Hs.78221	androgen receptor (dihydrotestosterone re ESTs; Highly similar to secreted apoptosi ESTs; Highly similar to secreted apoptosi HER2 receptor tyrosine kinase (c-erbB-2; c-myc binding protein	5.8 10.2 4.4 17.7 10.1
30	330460 TIGR:HT544 330486 M13755 Hs.833 330494 M29696 Hs.237868 330500 M34423 Hs.79222 330510 M75099 Hs.227729	Hs.73946 interferon-stimulated protein; 15 kDa interleukin 7 receptor galactosidase; beta 1 FK506-binding protein 2 (13kD)	Endothelial Cell Growth Factor 1 5.5 67 6 13.1 29
35	330513 M81057 Hs.180884 330541 U22970 Hs.265827 330542 U23942 Hs.226213 330547 U32989 Hs.183671 330551 U39840 Hs.299867	carboxypeptidase B1 (tissue) multiple UniGene matches cytochrome P450; 51 (lanosterol 14-alpha tryptophan 2;3-dioxygenase hepatocyte nuclear factor 3; alpha	38.5 7.4 15 11 6.5
40	330562 U49082 Hs.76460 330573 U62800 Hs.83393 330673 D57823 Hs.321403 330711 AA164687 Hs.177576 330814 AA015730 Hs.265398	transporter protein cystatin E/M Sec23 (S. cerevisiae) homolog A mannosyl (alpha-1;3-)-glycoprotein beta-1 ESTs; Weakly similar to transformation-r	7.7 4 10.5 24.3 44.1
45	330850 AA075298 Hs.322710 330874 AA127474 Hs.191157 330884 AA133457 Hs.102548 330912 AA195936 Hs.82719 330924 AA232136 Hs.159737	ESTs ESTs; Weakly similar to !!!! ALU SUBFA ESTs general transcription factor IIA; 1 (37kD a Homo sapiens mRNA; cDNA DKFZp434	4.4 8.1 5.2 5 9.1
50	330997 H55762 Hs.9302 331014 H98597 Hs.30340 331024 N32919 Hs.27931 331046 N66563 Hs.191358 331135 R61398 Hs.4197	ESTS ESTS ESTS ESTS ESTS	7.6 13.5 9.1 10.5 7.4
55	331145 R72427 Hs.129873 331148 R73816 Hs.17385 331222 T98531 Hs.173904 331230 W69807 Hs.16537 331306 AA252079 Hs.63931	ESTs; Weakly similar to CYTOCHROME ESTs ESTs hypothetical protein; similar to (U06944)	41.9 4.7 4.1 4.9 15.1
60	331327 AA281076 Hs.109221 331337 AA287662 Hs.50495 331341 AA303125 Hs.23240 331344 AA357927 Hs.126550	dachshund (Drosophila) homolog ESTs ESTs ESTs; Weakly similar to !!!! ALU SUBFA ESTs ESTs	4.8 7.6 13 12.4
65	331362 AA417956 Hs.40782 331363 AA421562 Hs.91011 331376 AA443802 Hs.41007 331384 AA456001 Hs.93847	anterior gradient 2 (Xenepus laevis) homo ESTs; Weakly similar to cDNA EST yk47 ESTs	6.5 28.2 15.1 7.9

	004470			mow.	
		N26608	Hs.40639	ESTs	7
		N49967	Hs.46624	ESTs	19.8
		N51517	Hs.47282	ESTs	6.5
~		W85712	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danlos	13.8
5		W88502	Hs.182258	ESTs	9.9
		AA284372		ESTs	5.6
		AA284840		ESTs	5.8
		AA292721		ESTs; Weakly similar to unknown [H.sap	7.4
10		AA312861		ESTs	7.8
10		AA411144		ESTs	15.2
		AA432166		succinate dehydrogenase complex; subuni	24.3
		AA454756		ESTs	5
		AA487910		ESTs; Weakly similar to !!!! ALU CLASS	10.5
1.5		AA490831		ESTs	11.4
15		AA504779		ESTs	13.6
		AA598594		ESTs	9.1
	332093	AA608794	Hs.112592	ESTs	8.8
	332139	AA620669	Hs.112879	EST	9
• •		N22508	Hs.139315	ESTs	7.1
20		N33213	Hs.100425	ESTs	12.2
		N57927	Hs.120777	ESTs; Weakly similar to RNA POLYME	15.6
		N58172	Hs.109370	ESTs	16.9
		N70088	Hs.138467	ESTs	4
~ ~		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.2
25		T96130	Hs.137551	ESTs	7.7
		W15495	Hs.129781	chromosome 21 open reading frame 5	14.1
		W60326	Hs.288684	ESTs	4.4
		W93640	Hs.4779	ESTs; Moderately similar to similar to AD	16.9
•		AA489630		KIAA0665 gene product	4.8
30		M12036	Hs.323910	Human tyrosine kinase-type receptor (HE	10.4
		AA018182		deiodinase; iodothyronine; type II	5.8
		AA281753		inositol 1;4;5-triphosphate receptor; type	19
		N63192	Hs.1892	EST; Highly similar to PHENYLETHAN	15.3
2.5		AA234896		E1A binding protein p300	12.3
35		R41791	Hs.36566	LIM domain kinase 1	11.1
		AA417152		protein regulator of cytokinesis 1	18.2
		AA262768		KIAA1067 protein	15.2
		H93968	Hs.75725	transgelin 2	4.7
40		T59161	Hs.76293	thymosin; beta 10	5.5
40		AA479968	Hs.88251	arylsulfatase A	9.8
	332927			CH22_FGENES.38_1	17.7
	332929			CH22_FGENES.38_3	4.7
	332930			CH22_FGENES.38_4	7.4
45	332955			CH22_FGENES.48_12	5.4 17.8
43	332958			CH22_FGENES.48_15	10.6
	332961			CH22_FGENES.48_18	4.3
	332983			CH22_FGENES.54_5	
	333009			CH22_FGENES.61_1	5.2
50	333010			CH22_FGENES.61_2	8.1
50	333013			CH22_FGENES.61_5 CH22_FGENES.79_14	8.5
	333108				5.6 6.3
	333139			CH22_FGENES.83_16	
	333254			CH22_FGENES.118_2	6.8 11.4
55	333305			CH22_FGENES.137_2 CH22_FGENES.139_12	5.1
55	333343			y 51, m = 1, 1, 1, 1, 1, 1, 1, 2	12.7
	333388			CH22_FGENES.144_3	4.2
	333456			CH22_FGENES.157_5 CH22_FGENES.157_8	4.2 7.6
	333459			CH22_FGENES.173_2	8.2
60	333517			CH22_FGENES.173_2 CH22_FGENES.203_4	5
00	333585			CH22_FGENES.245_6	4.3
	333679			CH22_FGENES.264_1	4.3 13.4
	333743			CH22_FGENES.268_1	4
	333758			CH22_FGENES.271_6	5.6
65	333767 333768			CH22_FGENES.271_0 CH22_FGENES.271_7	12.2
0.5	333769			CH22_FGENES.271_8	48.3
	333795			CH22_FGENES.275_1	6.1
	550,50				

	333706	CHOS ECENES 375 3	6.8
	333796 333903	CH22_FGENES.275_3	4.4
	333892 333004	CH22_FGENES.292_14	6.5
	333904	CH22_FGENES.294_2	
5	333905	CH22_FGENES.294_3	9.3
5	333921	CH22_FGENES.296_12	9.6 15.0
	333968	CH22_FGENES.307_4	15.9
	334102	CH22_FGENES.327_60	7.1
	334222	CH22_FGENES.360_3	6.7
10	334223	CH22_FGENES.360_4	33.5
10	334264	CH22_FGENES.367_15	18.5
	334343	CH22_FGENES.375_25	6.1
	334360	CH22_FGENES.378_5	6.1
	334784	CH22_FGENES.432_9	4.8
1.5	334789	CH22_FGENES.432_14	5.1
15	334794	CH22_FGENES.434_2	7
	334889	CH22_FGENES.452_3	12.4
	335004	CH22_FGENES.472_8	7.9
	335115	CH22_FGENES.496_2	18.8
•	335287	CH22_FGENES.526_11	4.5
20	335342	CH22_FGENES.536_1	5.3
	335491	CH22_FGENES.570_23	24
	335495	CH22_FGENES.570_28	7
	335498	CH22_FGENES.571_7	12.2
	335544	CH22_FGENES.576_5	8.4
25	335610	CH22_FGENES.583_4	12.9
	335653	CH22_FGENES.590_4	6.7
	335682	CH22 FGENES.595_2	12.1
	335687	CH22 FGENES,596_2	13.9
	335755	CH22_FGENES.604_4	11.5
30	335782	CH22_FGENES.609_4	17.9
•	335791	CH22_FGENES.611_7	27.3
	335809	CH22_FGENES.617_6	19.2
	335822	CH22_FGENES.619_7	19.1
	335823	CH22_FGENES.619_8	4.5
35	335824	CH22_FGENES.619_11	40.2
55	335825	CH22_FGENES.619_12	34.3
		CH22_FGENES.635_3	10.2
	335895 335917	CH22_FGENES.636_13	6
		CH22_FGENES.636_16	8.8
40	335920 336035		5.9
40	336035	CH22_FGENES.678_6	5.8
•	336042	CH22_FGENES.679_4	
	336093	CH22_FGENES.691_2	11.6
	336096	CH22_FGENES.691_5	7.6
15	336150	CH22_FGENES.706_6	6.3
45	336152	CH22_FGENES.706_9	10.5
	336416	CH22_FGENES.823_38	5
	336444	CH22_FGENES.827_10	4.8
	336449	CH22_FGENES.829_6	13.6
	336471	CH22_FGENES.829_30	6.9
50	336512	CH22_FGENES.834_7	21.4
	336558	CH22_FGENES.842_3	8.2
	336560	CH22_FGENES.842_5	9
	336676	CH22_FGENES.43-4	9.4
	336959	CH22_FGENES.367-13	19
55	337968	CH22_EM:AC005500.GENSCAN.103-2	13.4
	338008	CH22_EM:AC005500.GENSCAN.127-9	15.2
	338057	CH22_EM:AC005500.GENSCAN.160-1	13.9
	338410	CH22_EM:AC005500.GENSCAN.341-6	8
	338451	CH22_EM:AC005500.GENSCAN.359-3	11.6
60	338588	CH22 EM:AC005500.GENSCAN.432-1	10.3
00	338665	CH22_EM:AC005500.GENSCAN.464-2	4.8
	338689	CH22_EM:AC005500.GENSCAN.475-3	6.7
	338832	CH22_DJ246D7.GENSCAN.6-9	4.8
	338980	CH22_DJ240D7.GENSCAN.0-9 CH22_DA59H18.GENSCAN.2-4	5.1
65		CH22_DA39H10.GENSCAN.2-4 CH22_BA354I12.GENSCAN.29-7	6.9
03	339352 220273	CH22_BA334112.GENSCAN.29-7 CH22_BA232E17.GENSCAN.1-29	4.3
	339373	UNZZ_DAZOZE II .GENOUAN. 1-23	4.3

TABLE 13A

Table 13 A shows the accession numbers for those pkeys lacking unigeneID's for Table 13. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Unique Eos probeset identifier number

Pkey: CAT number: Gene cluster number Accession: Genbank accession numbers

15

	Pkey	CAT number	Accession
20	103207 103349 110856 113248	371681_1 30635_4 110522 19346_14 328626_1	AA602964 AA609200 X72790 X89059 AA992380 N33063 N21418 H79958 R21911 H79957 T63857 AW971220 AA493469 T63699
25	123169	44573_2	AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970
30	102522	genbank AA6	BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005 08751 AA608751
35	116480 132225 125154 118475	genbank_AA1 genbank_AA1 genbank_W38 genbank_N66 25180_2	088 C14088 28980 AA128980 419 W38419
40			AA323294 W04965 H38759 AA206622 AA580747 AI541172 AA381075 AA354229 AW402353 AW405575 AW404021 AW406207 AA075752 AW176066 AA287222 AA195818 T20243 R87945 AA295539 AA402533 AA232419 AA224515 AW401583 AA331367 AW402140 AW249079 R31488 AA075757 X05236 AW239490 AA338036 AW239495 AA357262 AA431005 AA306726 R33804 AA216544 AW275288 AA227044 AL038124 AA243300 C03242 AA315615 AD35840 R64336 AA313917 AA0118963 AA001385 AA054395 H30840 AW498825 AA086141 AI557324 AA121576 H39128 R77161 AA019688 AA380987 AA348140 AA348257 AW176086 AA362432 AA171389 AA362416 AA299938 AA319093 AA337972 C04921 AA345696 R89640 AA085425 AA481708
45			AA313637 AL039229 H84490 H86153 F00656 AA326668 AA347304 R65890 H41949 AA339309 AW402002 AW404854 AA3192582 AA112802 H09248 N83165 H38367 AA356339 AA455763 R66853 AA294935 H85911 AA310414 H93436 N87014 AA001186 H83640 AA411328 AA317929 C04192 AW406288 U46335 AA323179 AA427649 AI366131 H14328 AA197161 AA379497 AA311816 AA017206 AA001137 AA017420 AA012990 AW163775 AA021397 AA295513 AA355248 AA374921 AW380419 AA345864 AA318058 AA371711 AA363255 AA057094 R88057 AA394045 AW362741 AA479579 AW362789
50			AW362775 AA223624 AW362809 AW362746 AW362753 AW380412 AA057104 AA295271 X06352 AW362771 X12447 R59553 R87925 AA292864 R83920 F01120 AA496740 AA852551 AL039209 AA093339 AA333961 N86416 C03325 C03831 AA194750 AA359270 AA359460 AW245492 AA339400 AA330784 AI908970 N89223 AW361938 AI940063 AA134323 AA371741 F01267 AW372970 AA341973 AA346098 AW372969 AA337549 AA327342 H93855 AI074079 F29118 AA852940 F35696 AA345963
55			AA079578 AA113785 C02989 AA095945 C03145 C05199 AA346024 AA190506 AW361659 Al909845 AW374374 AW374382 AW374401 AW374373 AW374370 Al909831 AW374367 AA353658 F01041 C02843 AA375948 AW374414 AA213946 Al525039 H13744 R31007 AA112044 AA134404 H47935 AW177018 AA429768 AA336873 AA112875 H46393 AA191267 D59131 AW406037 AA055244 AA341880 AA179024 AA308537 AW406985 AW327311 H30301 AA300705 H43788 AW364149 AA806213 AA481936 C04941 AW375299 M21190 AA410818 AA250940 Al354547 AA317422 AA250903 Al865497 AA890603
60			AA366197 AW498538 M78072 AW406461 C03092 F00308 H56488 AA336320 AW406501 AA354102 AA382942 AA096393 AW376830 AA383446 F01259 AW081388 T94036 AA379643 H43842 AI524063 AA621727 AA379099 AA371417 R66811 H44129 N84794 F01135 AA477852 AA293062 AW361595 H27194 AI831650 H43253 H24797 AI564680 AA380090 W20057 AI921586 AI192549 AW090808 H25967 AA918121 AI626060 H20221 AA812572 H42178 AA887222 H96000 C03180 F00946

C03986 Al318091 Al860172 AA582179 Al633388 AA557193 R68075 F24105 AW518239 W56622 Al625219 Al925243 AW468046 Al921828 AA339164 Al144391 AA643334 AA459631 AA873247 AW373432 AA604384 H27600 Al680458 AA159956 AA610836 AA364298 AW373435 AA604225 W73754 AW087924 AA599776 N89227 Al630871 Al633128 AW514329 AA010455 AA563928 Al571596 Al128394 W73707 Al423575 AA583809 AA657988 Al950837 AA169782 AA600009 Al885540 AA771884 5 AI978829 AA505408 AA533937 AA481469 AA610869 AA775241 AW273870 AW070909 AI905695 AA480115 AA574051 Al889185 AA773167 AA331375 AA001437 AA194324 AA194300 AA558632 Al038538 AA411329 AA781570 Al833176 AA935520 AW074197 AA583063 AW073099 AW001198 AA948025 AA587857 AA191540 AI460085 AA193244 AI538037 AA515572 AA758587 Al149311 AA508610 AA206409 AA534004 AA994600 AA827543 Al916349 AW245129 AW517804 D25663 AA781985 AA284536 Al819422 H16040 H27531 AA456564 AA845555 Al423596 AA012908 AA889439 AA716311 AA968868 10 AA320508 AA725731 AA834202 AA935997 AA724815 AA769353 AA594803 F00827 Al342442 Al003519 Al002503 Al347597 AJ040946 AA197162 AA987883 AA292865 AW001944 AJ640711 AW244044 AA456784 F30588 AA290829 H24754 AJ978683 AA483686 AA583939 AA121382 AA833831 AA477102 AA977322 AA666379 F35456 AA993537 AI749610 AA226934 AA716204 AW513025 AA628543 AA583705 F25702 Al368748 Al124097 Al880086 AA477513 Al758834 Al690753 AA477746 F37761 AA642243 AA159957 AA250844 AA459406 AA427566 F25054 AI569314 AA961665 AI922050 AI759000 AA555236 AA514432 15 AA293474 AA001129 AA826789 AA641390 AA134405 F35585 AA477416 AW193359 Al361315 AA284988 F36340 Al361322 F26969 AA991922 AA021267 F26973 Al361314 F35891 Al918509 AA250964 AA190992 AA577139 AA865535 AA134324 AW192842 Al224046 F18975 AA779626 AA856894 AW269997 AW014614 H95554 F31378 AA374868 F26343 AA654007 AI830942 AA113195 F26432 W56652 AA464690 AA055263 AA340654 AA031448 AA976399 AA972526 AA063476 R83921 T16240 AA533290 N91545 H44053 AA883451 AA513761 AA086477 H09249 F20482 F26737 AA054148 AA857063 AA017259 20 AA179789 AA088908 H43704 AA194320 F35950 Al880127 F20441 F32878 AA962483 H39094 H56489 H44621 F19390 AI302232 F25162 AA826965 AA086052 AA917410 AA454513 R59554 AA196755 AA086369 AA079530 H28106 AA243301 AI025737 AA101239 AA088887 AI214910 AA974886 F16089 F26054 AA515092 F33436 F32829 M78061 AA235645 F19715 F37529 Al811549 AA665180 AA708200 F01124 F32382 AA346220 AA627361 F30741 F30010 F28543 AA211715 F20245 AA331222 F25634 F21996 W28215 F21911 R65793 Al192566 H20130 H84491 AA719223 AA557435 F16967 F26989 F30353 25 AA857159 AA291918 F28234 F20840 F25176 F22437 T27904 AA480355 F19528 R87926 H14286 F27532 AW337864 F28411 H13692 F25651 AA975454 F24229 F29657 F18024 AA464779 F17588 F34954 AA947328 F18063 AA657777 AA459644 N91455 F27850 F29608 F27206 F18418 F31459 F18564 F33496 F16376 F29740 F29843 F29904 F29866 F19135 AW276602 T40337 F24835 F34672 F26474 Al926215 AA464185 F18217 N26193 AL043256 T41197 F33055 F00386 F29500 F34191 F33297 Al937207 F22724 F15909 F26232 F18889 AA318627 F29085 AA872104 F17509 F23373 F15660 F17552 F17412 F16863 30 F34033 F21515 F17364 F18383 F16546 F17561 F17260 AA292000 F15723 T47438 F16798 F18046 F18319 F17978 F17566 F34230 F33258 F20860 F17998 Al695701 118600 genbank_N69222 N69222 118952 genbank_N92966 N92966 120873 genbank_AA358015 113702 genbank_T97307 AA358015 35 T97307 Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165 129982 221_267 AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107 Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 40 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 45 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 50 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068661 AF068664 55 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 Al857980 AW368899 Al905833 AW406586 AA482084 Al872299 AA715266 AW404328 Al831674 Al709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113 60 115763 genbank_AA421560 AA421560 genbank_N22401 124357 N22401 108733 504187 1 AA121022 AA126422 101544 entrez_M31169 M31169 124447 genbank_N48000 N48000 124677 genbank R01073 R01073 65 124777 genbank_R41933 R41933 119302 genbank_T25725 T25725

```
103680 entrez_Z93784Z93784
          135029 H58818_at
          112253 genbank R51818
                                             R51818
         Pkey
                  CAT number Accession
  5
          322175 46877_1
                                  AF085975 H53458 H53459
          323011 139750_1
                                 AA580288 AA315655 AA133031 AA377748
         322975 1510563_1
317210 211994_1
                                 C16391 C16413
                                 AW881145 AA490718 M85637 AA304575 T06067 AA331991
                                  AA410943 AW948953 AA334202 AA332882
          323817 233566_1
10
          309583 1046029 -- 2
                                 AW170035
          324961 376239_1
                                  AA613792 AW182329 T05304 AW858385
          303502 325188_1
                                  BE174240 AA488528 AL042253
          320133 447553_1
                                 BE151746 BE336853 D63271 T94955 AA774994
          311935 174129 1
                                 AA216387 T63548 AA228676
15
          321050 502195_1
                                 C05928 AW393497
         319977 345248_1
                                 AA534222 AA632632 T81234
                                 AW962299 AA310349 AW962294 H63791 H63751
         312772 4380 7
         321354 116028 -2
                                 AA078493
         336512 CH22_3941FG_834_7_LINK_DJ
336558 CH22_3992FG_842_3_LINK_DJ
20
          336560 CH22_3994FG_842_5_LINK_DJ
          329367 c_x_hs
          329373 c_x_hs
         336676 CH22_4154FG_43_4_
         338008 CH22_6490FG__LINK_EM:AC00
338057 CH22_6558FG__LINK_EM:AC00
25
         329655 c14_p2
336959 CH22_4764FG_367_13_
          329899 c15_p2
30
         329960 c16_p2
         338410 CH22_7067FG__LINK_EM:AC00
338451 CH22_7124FG__LINK_EM:AC00
         338588 CH22_7331FG__LINK_EM:AC00
338665 CH22_7438FG__LINK_EM:AC00
338689 CH22_7464FG__LINK_EM:AC00
35
          308677 Al761173
          338832 CH22_7678FG__LINK_DJ246D7
         338980 CH22_7859FG__LINK_DA59H18
          333009 CH22_233FG_61_1_LINK_EM:A
40
          333010 CH22_234FG_61_2_LINK_EM:A
         333013 CH22_237FG_61_5_LINK_EM:A
         308981 Al873242
         308995 Al880172
         333108 CH22_336FG_79_14_LINK_EM:
45
         333139 CH22_368FG_83_16_LINK_EM:
         333254 CH22_495FG_118_2_LINK_EM:
         333305 CH22_550FG_137_2_LINK_EM:
         333343 CH22_589FG_139_12_LINK_EM
333388 CH22_634FG_144_3_LINK_EM:
50
         326213 c17_hs
         333456 CH22_706FG_157_5_LINK_EM:
         333459 CH22_709FG_157_8_LINK_EM:
         333517 CH22_773FG_173_2_LINK_EM:
333585 CH22_846FG_203_4_LINK_EM:
333679 CH22_941FG_247_6_LINK_EM:
55
         326474 c19_hs
         333743 CH22_1009FG_264_1_LINK_EM
333758 CH22_1024FG_268_1_LINK_EM
333767 CH22_1034FG_271_6_LINK_EM
60
         333768 CH22_1035FG_271_7_LINK_EM
         333769 CH22_1036FG_271_8_LINK_EM
333795 CH22_1063FG_275_1_LINK_EM
333796 CH22_1065FG_275_3_LINK_EM
          335004 CH22_2326FG_472_8_LINK_EM
65
          333892 CH22_1163FG_292_14_LINK_E
          335115 CH22_2447FG_496_2_LINK_EM
```

333904 CH22_1176FG_294_2_LINK_EM

	333905 333921 333968	CH22_1177FG_294_3_LINK_EM CH22_1194FG_296_12_LINK_E CH22_1245FG_307_4_LINK_EM
5	328059 335287 326816 326817	c_6_hs CH22_2629FG_526_11_LINK_E c20_hs c20 hs
10	335342 335491 335495 335498	CH22_2689FG_536_1_LINK_EM CH22_2843FG_570_23_LINK_E CH22_2847FG_570_28_LINK_E CH22_2850FG_571_7_LINK_EM
15	328304 305453 335544 335610	c_7_hs AA738110 CH22_2899FG_576_5_LINK_EM CH22_2969FG_583_4_LINK_EM
	335653 335682 335687	CH22_3013FG_590_4_LINK_EM CH22_3043FG_595_2_LINK_EM CH22_3048FG_596_2_LINK_EM
20	328492 335755 335782 335791 335809	c_7_hs CH22_3122FG_604_4_LINK_EM CH22_3151FG_609_4_LINK_EM CH22_3160FG_611_7_LINK_EM CH22_3181FG_617_6_LINK_EM
25	335822 335823 335824 335825	CH22_3195FG_619_7_LINK_EM CH22_3196FG_619_8_LINK_EM CH22_3197FG_619_11_LINK_E CH22_3198FG_619_12_LINK_E
30	335895 335917 335920 305898	CH22_3272FG_635_3_LINK_EM CH22_3294FG_636_13_LINK_E CH22_3297FG_636_16_LINK_E AA872838
35	305913 305950 328857 330084	AA876109 AA884479 c_7_hs c19_p2
	337968 309177 309198 309226	CH22_6419FGLINK_EM:AC00 Al951118 Al955915 Al969897
40	339352 309279 339373 325622	CH22_8317FGLINK_BA354I1 Al990102 CH22_8348FGLINK_BA232E1 c14_hs
45	334102 332927 332929 332930 332955	CH22_1380FG_327_60_LINK_E CH22_148FG_38_1_LINK_C20H CH22_150FG_38_3_LINK_C20H CH22_151FG_38_4_LINK_C20H CH22_179FG_48_12_LINK_EM:
50	332958 332961 332983 334222	CH22_182FG_48_15_LINK_EM: CH22_185FG_48_18_LINK_EM: CH22_207FG_54_5_LINK_EM: CH22_1506FG_360_3_LINK_EM
55		CH22_1507FG_360_4_LINK_EM CH22_1551FG_367_15_LINK_E c21_hs CH22_1636FG_375_25_LINK_E CH22_1654FG_378_5_LINK_EM
60	327196 327283 327313 304465	c_1_hs c_1_hs c_1_hs AA421948
65	304507 327450 304591	AA456426
	304659	AA533185 CH22_2096FG_432_9_LINK_EM

	334789	CH22_2101FG_432_14_LINK_E
	334794	CH22_2106FG_434_2_LINK_EM
	336035	CH22_3420FG_678_6_LINK_DJ
_	336042	CH22_3427FG_679_4_LINK_DJ
5	336093	CH22_3481FG_691_2_LINK_DJ
	336096	CH22_3484FG_691_5_LINK_DJ
	334889	CH22_2206FG_452_3_LINK_EM
	336150	CH22_3540FG_706_6_LINK_DA
	336152	CH22_3543FG_706_9_LINK_DA
10	336416	CH22_3833FG_823_38_LINK_B
	336444	CH22_3864FG_827_10_LINK_D
	336449	CH22_3870FG_829_6_LINK_DJ
	336471	CH22 3894FG 829 30 LINK D

TABLE 13B

Table 13B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 13B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Dkov	Dof	Strand	Alt manifian
	Pkey	Ref	Strand	Nt_position
	332955	Dunham, I. et.al.	Plus	2508896-2508992
	332958	Dunham, I. et.al.	Plus	2516164-2516310
20	332961	Dunham, I. et.al.	Plus	2521424-2521555
	333139	Dunham, I. et.al.	Plus	3369495-3369571
	333254	Dunham, I. et.al.	Plus	2521424-2521555
	333305	Dunham, I. et.al.	Plus	4630388-4630645
	333388	Dunham, I. et.al.	Plus	4913749-4913805
25	333517	Dunham, I. et.al.	Plus	5570729-5570925
	333585	Dunham, I. et.al.	Plus	6234778-6234894
	333679	Dunham, I. et.al.	Plus	7068795-7068896
	333767	Dunham, I. et.al.	Plus	7694407-7694623
• •	333768	Dunham, I. et.al.	Plus	7695440-7695697
30	333769	Dunham, I. et.al.	Plus	7696625-7696707
	333795	Dunham, I. et.al.	Plus	7807688-7807795
	333796	Dunham, I. et.al.	Plus	7808253-7808319
	333892	Dunham, I. et.al.	Plus	8156825-8157001
2.5	333921	Dunham, I. et.al.	Plus	8380325-8380441
35	333968	Dunham, I. et.al.	Plus	8681004-8681241
	334102	Dunham, I. et.al.	Plus	9995140-9996373
	334264	Dunham, I. et.al.	Plus	13234447-13234544
	334343	Dunham, I. et.al.	Plus	13655828-13656307
40	334794	Dunham, I. et.al.	Plus	16374312-16374458
40	334889	Dunham, I. et.al.	Plus	19286024-19286515
	335287	Dunham, I. et.al.	Plus	22299047-22299299
	335491	Dunham, I. et.al.	Plus	24128651-24128827
	335495	Dunham, I. et.al.	Plus	24140688-24140872
15	335498	Dunham, I. et.al.	Plus	24172082-24172161
45	335653	Dunham, I. et.al.	Plus	25329710-25329802
	335687	Dunham, I. et.al.	Plus	25445952-25446064
	335809	Dunham, I. et.al.	Plus	26310772-26310909
	335822	Dunham, I. et.al.	Plus	26364087-26364196
50	335823	Dunham, I. et.al.	Plus	26365925-26366004
30	335824	Dunham, I. et.al.	Plus	26376860-26376942
	335825	Dunham, I. et.al.	Plus	26378175-26378268
	336035	Dunham, I. et.al.	Plus	29016748-29017410
	336093	Dunham, I. et.al.	Plus	29556922-29557002
55	336096	Dunham, I. et.al.	Plus	29578878-29579047
33	336444	Dunham, I. et.al.	Plus	34190585-34190718
	336959	Dunham, I. et.al.	Plus	13233040-13233126
	338008	Dunham, I. et.al.	Plus	7697068-7697236
	338057 338410	Dunham, I. et.al.	Plus Plus	8526397-8526522
60	338588	Dunham, I. et.al.	Plus	19292807-19292916
JU	338665	Dunham, I. et.al.	Plus	22896767-22896920
	338832	Dunham, I. et.al. Dunham, I. et.al.	Plus	24472654-24472853
	338980	Dunham, I. et.al.	Plus	27775128-27775290
	339352	Dunham, I, et.al.	Plus	29896789-29896874 33544784-33545121
	JJJJJJZ	ournain, i, cl.ai,	i ius	00074104-00040121

	332929	Dunham, I. et.al.	Minus	2020758-2020664
	332930	Dunham, I. et.al.	Minus	2022565-2022497
	332983	Dunham, I. et.al.	Minus	2631933-2631797
_	333009	Dunham, I. et.al.	Minus	2766043-2765856
5	333010	Dunham, I. et.al.	Minus	2766207-2766119
	333013	Dunham, I. et.al.	Minus	2772278-2772039
	333108	Dunham, I. et.al.	Minus	3240494-3240389
	333343	Dunham, I. et.al.	Minus	4692886-4692753
10	333456	Dunham, I. et.al.	Minus	2631933-2631797
10	333459	Dunham, I. et.al.	Minus	5144548-5144344
	333743	Dunham, I. et.al.	Minus	7573218-7573060
	333758	Dunham, I. et.al.	Minus Minus	7666413-7666091 8217374-8217261
	333904 333905	Dunham, I. et.al. Dunham, I. et.al.	Minus	8217796-8217670
15	334222	Dunham, I. et.al.	Minus	12732417-12732289
13	334223	Dunham, I. et.al.	Minus	12734365-12734269
	334360	Dunham, I. et.al.	Minus	13728850-13728751
	334784	Dunham, I. et.al.	Minus	16294548-16294360
	334789	Dunham, I. et.al.	Minus	16306095-16305996
20	335004	Dunham, I. et.al.	Minus	20581911-20581794
	335115	Dunham, I. et.al.	Minus	21388250-21388146
	335342	Dunham, I. et.al.	Minus	22597448-22597284
	335544	Dunham, I. et.al.	Minus	24650505-24650403
0.5	335610	Dunham, I. et.al.	Minus	25068943-25068841
25	335682	Dunham, I. et.al.	Minus	25421215-25421093
	335755	Dunham, I. et.al.	Minus	25763806-25763747
	335782	Dunham, I. et.al.	Minus	25908578-25908440
	335791	Dunham, I. et.al.	Minus Minus	25948563-25948411
30	335895	Dunham, I. et.al.	Minus	26975307-26975239 27028481-27028377
50	335917 335920	Dunham, I. et.al. Dunham, I. et.al.	Minus	27034927-27034811
	336042	Dunham, I. et.al.	Minus	29041694-29041500
	336150	Dunham, I. et.al.	Minus	30150423-30150256
	336152	Dunham, I. et.al.	Minus	30156053-30155870
35	336416	Dunham, I. et.al.	Minus	34047408-34047311
	336449	Dunham, I. et.al.	Minus	34204707-34204577
	336471	Dunham, I. et.al.	Minus	34215091-34214978
	336512	Dunham, I. et.al.	Minus	34278373-34278275
4.0	336558	Dunham, I. et.al.	Minus	34375825-34375698
40	336560	Dunham, I. et.al.	Minus	34376814-34376596
	336676	Dunham, I. et.al.	Minus	2022565-2022497
	337968	Dunham, I. et.al.	Minus	7095797-7095680
	338451	Dunham, I. et.al.	Minus	20174286-20174193
45	338689	Dunham, I. et.al.	Minus	24893073-24892972 33860127-33860047
43	339373 325622	Dunham, I. et.al. 5867000	Minus Plus	69994-70075
	329655	6448516	Minus	35565-35843
	329899	6563505	Minus	111058-111783
	329960	5091594	Minus	1031-1162
50	326213	5867224	Minus	60751-60927
- •	326474	5867405	Plus	16995-18101
	330084	6015302	Minus	57019-59337
	326816	6552458	Plus	198354-198436
	326817	6552458	Plus	199909-200001
55	327110	6117842	Plus	94608-94785
	327196	5867446	Plus	180921-181333
	327283	5867478	Minus	567-962
	327313	5867501	Minus	89734-89838
60	327450	5867766	Minus	47928-48076
60	328059	6117819 5868455	Plus	37052-37204
	328492 328304	6004478	Minus Minus	46094-46241 3884-3952
	328857	6381927	Minus	80557-81051
	329367	5868842	Minus	87201-87587
65	329373	6682537	Minus	38950-39301

TABLE 14: Table 2 from BRCA 001-5 US

Table 14, a subset of table 13, depicts a preferred group of genes highly upregulated in breast 5 cancer cells.

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal breast tissue Pkey: ExAccn: UnigeneID: Unigene Title: 10

15	Pkey	ExAccn	UniGene ID	Unigene Title	R1
		M97935	1) 00000	AFFX control: STAT1	16.7
		D00596	Hs.82962	thymidylate synthetase	15.9
20		J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin)	30.1
20		J05070 L07615	Hs.151738	matrix metalloproteinase 9 (gelatinase B; 9	37.2
		L12723	Hs.169266 Hs.90093	Human neuropeptide Y receptor Y1 (NPYY heat shock 70kD protein 4	18.3 17.4
		L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topois	18.9
		M13755	Hs.833	interferon-stimulated protein; 15 kDa	18.1
25		M86849	Hs.323733	Homo sapiens connexin 26 (GJB2) mRNA	22.5
		U65932	Hs.81071	extracellular matrix protein 1	23.2
		U79241	Hs.118666	Human clone 23759 mRNA; partial cds	15
		U90904	Hs.83724	Human clone 23773 mRNA sequence	15.2
	102907	X06985	Hs.202833	heme oxygenase (decycling) 1	22.7
30	102985	X17644	Hs.2707	G1 to S phase transition 1	20.6
	103060	X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin 3	17.8
	103180	X69433	Hs.5337	isocitrate dehydrogenase 2 (NADP+); mito	18.9
		X72755	Hs.77367	monokine induced by gamma interferon	15.1
2.5			Hs.198793	KIAA0750 gene product	23.3
35		AA428090		ESTs	28.7
		AA007234		ESTs	16.6
		AA191512		Homo sapiens mRNA; cDNA DKFZp564G	19.3
		AA421104		ESTs	15.4 10
40		AA621169	Hs.110826	ESTs	19 20.1
40		H20543	Hs.6278	trinucleotide repeat containing 9 DKFZP586B1621 protein	16.6
		H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CON	19.5
		H98714	Hs.24131	ESTs	30.2
		N46252	Hs.29724	ESTs	23.2
45		N67239	Hs.10760	ESTs	37
	111357	N91023	Hs.87128	ESTs	15
	112134	R46025	Hs.7413	ESTs .	17.4
		W86748	Hs.8109	ESTs	15
- 0		Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 protein	22
50		Z40715	Hs.184641	delta-6 fatty acid desaturase	19.4
			Hs.196437	ESTs; Weakly similar to R26660_1; partial	16.9
		AA250737		ESTs	35.1
		AA405098		ESTs	16.1
55		AA433943		ESTs; Weakly similar to Weak similarity t	33.5
33		H29532 H72948	Hs.101174 Hs.821	microtubule-associated protein tau	22.2
		N26722	Hs.42645	biglycan ESTs	20.7 18.1
		Z41815	Hs.65946	ESTs	15.6
			Hs.104106	ESTs	15.2
60		AA416740		ESTs	22.6
50		AA609200		ESTs	23.1
		D60302	Hs.270016	ESTs	20.6
		H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B	25.9
		N90960	Hs.265398	ESTs; Weakly similar to transformation-rel	16.4

	127677	AA916752	Hs.264190	ESTs; Highly similar to MEM3 [M.muscul	17.3
		U31875	Hs.152677	short-chain alcohol dehydrogenase family m	27.1
		T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566L	24.5
_		AA234530		N-ethylmaleimide-sensitive factor	20.7
5		H18027	Hs.184697	plexin C1	18.2
		X17059	Hs.155956	N-acetyltransferase 1 (arylamine N-acetylt	26.4 39.9
		X03635 W03592	Hs.1657 Hs.21198	estrogen receptor 1 translocase of outer mitochondrial membra	20.9
		M97935	Hs.21486	signal transducer and activator of transcript	18.8
10		AA608962		calcyclin binding protein	18.1
		U90551	Hs.28777	H2A histone family; member L	18.8
	132180	AA405569	Hs.418	fibroblast activation protein; alpha; seprase	15.4
	132406	F09979	Hs.4774	ESTs	15
1 =		AA047896		ESTs	15.4
15		AA505133		solute carrier family 2 (facilitated glucose t	26.4
		R79723	Hs.69997	zinc finger protein 238	30.4 15.2
		U24166 D62633	Hs.234279 Hs.8236	microtubule-associated protein; RP/EB fam ESTs	15.2
		J02033 J04177	Hs.82772	collagen; type XI; alpha 1	15.3
20		X54942	Hs.83758	CDC28 protein kinase 2	20.3
		D63477	Hs.84087	KIAA0143 protein	16.1
		U89922	Hs.890	lymphotoxin beta (TNF superfamily; memb	35.7
		AA454930		ESTs	19.5
0.7		AA312082		GDNF family receptor alpha 1	20.7
25		NM_00444		EST cluster (not in UniGene) with exon hit	21.6
		AL117607	Hs.1/5563	Homo sapiens mRNA; cDNA DKFZp564N	41.4 24.3
		Al951118 AW170035		EST singleton (not in UniGene) with exon EST	64.5
		AW022192		ESTs	39.1
30		AI821294		ESTs	24.1
-		AA759250		cytochrome b-561	27.1
		Al969390		ESTs	27.1
	314506	AA833655	Hs.206868	ESTs	27.8
0.5		Al873274		ESTs	22.5
35		AW207206		ESTs	21.4
		A1476797		cell division cycle 2; G1 to S and G2 to M	18.4 28.8
		AA972756 AI908272		ESTs EST cluster (not in UniGene)	32.6
		AW167087		ESTs	15.7
40		Al285898	Hs.294014	ESTs	16.3
••		NM_00254		EST cluster (not in UniGene)	21.3
	318744	AI793124	Hs.144479	ESTs	35
		NM_00273		EST cluster (not in UniGene)	25.4
15		AA321166		EST cluster (not in UniGene)	16.7
45		AL039402		DEME-6 protein	24.3
		U96044 AW043782	Hs.181125	EST cluster (not in UniGene) ESTs	15.3 21
		AW248508		DiGeorge syndrome critical region gene 2	15.3
		AL044891		EST cluster (not in UniGene)	50.1
50		AA464510		EST cluster (not in UniGene)	16.7
		AW016378		ESTs	23.1
	324620	AA448021	Hs.94109	EST cluster (not in UniGene)	21.2
		T06997	Hs.121028	EST cluster (not in UniGene)	24.5
<i>E</i>		X03363		HER2 receptor tyrosine kinase (c-erbB-2; E	17.7
55		M13755	Hs.833	interferon-stimulated protein; 15 kDa ESTs: Weakly similar to transformation-rel	67 44.1
		AA015730 R72427	Hs.265398 Hs.129873	ESTs; Weakly similar to CYTOCHROME	41.9
		AA252079		dachshund (Drosophila) homolog	15.1
		AA432166		succinate dehydrogenase complex; subunit	24.3
60		AA281753		inositol 1;4;5-triphosphate receptor; type 3	19
*		N63192	Hs.1892	EST; Highly similar to PHENYLETHANO	15.3
		AA262768	Hs.243901	KIAA1067 protein	15.2
	332958			CH22_FGENES.48_15	17.8
65	333769			CH22_FGENES.271_8	48.3
65	333968 334223			CH22_FGENES.307_4 CH22_FGENES.360_4	15.9 33.5
	334223			CH22_FGENES.360_4 CH22_FGENES.367_15	18.5
	007207				

 335791
 CH22_FGENES.611_7
 27.3

 336512
 CH22_FGENES.834_7
 21.4

 338008
 CH22_EM:AC005500.GENSCAN.127-9
 15.2

TABLE 14A

Table 14A shows the accession numbers for those pkeys lacking unigeneID's for Table 14. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

	Pkey	CAT number	Accession
20	336512 338008	10460292 CH22_3941FG_ CH22_6490FG_	834_7_LINK_DJ _LINK_EM:AC00
25	333968 335791	CH22_1036FG_ CH22_1245FG_ CH22_3160FG_ Al951118	307_4_LINK_EM
	332958 334223 334264	CH22_182FG_4 CH22_1507FG_ CH22_1551FG_	360_4_LINK_EM

TABLE 14B

336512 Dunham, I. et.al. Minus 34278373-34278275

Table 14B shows the genomic positioning for those pkeys lacking unigene ID's and 5 accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Ref: Sequence source entitled "The			orresponding to an Eos probeset . The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication e DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. and from which exons were predicted.
15	Nt_posit	ion: Indicate	s nucleoti	de positions of predicted exons.
	Pkey	Ref	Strand	Nt_position
20	333769 333968	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al.	Plus Plus	2516164-2516310 7696625-7696707 8681004-8681241 13234447-13234544
25	338008 334223	,	Plus Minus	7697068-7697236 12734365-12734269 25948563-25948411

TABLE 15: Table 3 from BRCA 001-5 US

Table 15 shows genes downregulated in breast cancer cells.

5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number

Pkey: ExAccn: UnigeneID: Unigene Title: R1: 10

Unigene gene title Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UniGene IE	Unigene Title	R1
	100115	D00632	Hs.172153	glutathione peroxidase 3 (plasma)	1.7
	100499	TIGR:HT1428		Globin, Beta	1.5
	100502	TIGR:HT1496	Hs.169228	Adrenal-Specific Protein Pg2	2.3
	100815	TIGR:HT4268	Hs.9739	L-Glycerol-3-Phosphate:Nad+ Oxidoreduct	1.7
20	101125	L10373	Hs.82749	transmembrane 4 superfamily member 2	1.5
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha po	2.9
	101397	M15856	Hs.180878	lipoprotein lipase	1.6
	101883	M98399	Hs.75613	CD36 antigen (collagen type I receptor; thr	1.6
	102227	U25138	Hs.93841	potassium large conductance calcium-activ	1.6
25	102857	X00129	Hs.76461	retinol-binding protein 4; interstitial	3
		X73079	Hs.288579	polymeric immunoglobulin receptor	1.8
		Y09267	Hs.132821	flavin containing monooxygenase 2	1.5
		Z21966	Hs.2815	POU domain; class 6; transcription factor 1	1.8
20		AA007629	11 40704	glycerol-3-phosphate dehydrogenase 1 (sol	2.4
30		AA146619	Hs.18791	ESTs; Weakly similar to CALCIUM-BIND	1.7
		AA164519	Hs.15248	ESTs	1.5 1.5
		AA417915	Hs.25930	ESTs	1.6
		AA487576 AA609645	Hs.26530 Hs.211568	serum deprivation response (phosphatidyls eukaryotic translation initiation factor 4 gam	2.7
35		AA004901	Hs.261164		1.6
55		AA037388	Hs.82223	Human DNA sequence from clone 141H5 o	1.7
		AA099820	Hs.49696	ESTs	2.4
		N64265	Hs.19515	vz44h12.s1 Morton Fetal Cochlea Homo sa	1.7
		R36447	Hs.24453	ESTs	1.6
40		R70255		ESTs	1.9
	112808	R97970	Hs.281022	EST	1.5
	113086	T40652	Hs.209100	DKFZP434C171 protein	1.9
	115740	AA418033	Hs.283559	ESTs	1.6
		AA443800	Hs.43125	ESTs	2
45		AA446661	Hs.173233		2.2
		N20300	Hs.218707		1.7
		N32174	Hs.44317	SRY (sex-determining region Y)-box 10	1.7
		R15436	Hs.77889	Friedreich ataxia region gene X123	1.7
50		R71792		ESTs; Weakly similar to cell death activato	2.8 1.9
30		T71021.	Hs.285681 Hs.249129		3
		W73386 AA365784	Hs.97044	ESTS	1.6
		AA405747	Hs.97984	ESTs; Weakly similar to WASP-family pro	1.8
		AA421184	Hs.97549	ESTs	1.5
55		AA434447	Hs.106771		2.5
55		AA443695	Hs.293410		2.1
		AA448300	Hs.160318		1.5
		AA598841	Hs.167382		1.8
		AA600135		ESTs: Moderately similar to !!!! ALU SUB	1.5
60		W94688	Hs.103253		1.7
	126300	D81972		HUM427D08B Human fetal brain (TFujiw	1.8
		R72515	Hs.160318		1.6
		AA309765	Hs.116017		1.5
	127357	AA452788	Hs.75432	zx39g11.r1 Soares_total_fetus_Nb2HF8_9	1.7

	127638	AA634405	Hs.122608	ESTs	1.5
		AA972780		ESTs; Weakly similar to !!!! ALU SUBFA	1.5
	128351	AI092391	Hs.134886	ESTs	1.5
	128842	N44757	Hs.20340	ESTs	1.6
5	128870	R71403	Hs.75309	eukaryotic translation elongation factor 2	1.7
	129146	AA459944	Hs.108924	DKFZP586P1422 protein	1.5
	129285	T62068	Hs.11006	ESTs	2.1
	129331	N93465		ESTs; Highly similar to CGI-38 protein [H	1.5
	130085	M62402		insulin-like growth factor binding protein 6	1.7
10		M25079		hemoglobin; beta	1.7
		AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
		AA131466	Hs.23767	ESTs	1.9
		M12272	Hs.4	alcohol dehydrogenase 3 (class I); gamma p	2.2
15		AA295848	Hs.25475	aquaporin 7	1.7
13	131810			leptin (murine obesity homolog)	2.5 1.6
	132931	AA045503	Hs.56874 Hs.6090	ESTs; Weakly similar to Homo sapiens p2 deleted in bladder cancer chromosome regi	1.5
	133120		Hs.65424	tetranectin (plasminogen-binding protein)	2
		U95367	Hs.70725	gamma-aminobutyric acid (GABA) A recep	1.5
20	133507		Hs.74369	integrin; alpha 7	1.7
		S95936	Hs.284176		2.3
		N56898	Hs.75652	glutathione S-transferase M5	1.9
		N79674	Hs.8022	TU3A protein	4.6
	134699	U56814	Hs.88646	deoxyribonuclease I-like 3	1.5
25	134749	L10955	Hs.89485	carbonic anhydrase IV	1.6
		M72885	Hs.95910	Human G0S2 protein gene; complete cds	1.9
		AW027556	Hs.156286		1.7
		Al369956	Hs.257891		1.5
20		AA514805	Hs.293055		1.8
30		A1807692	Hs.129129		1.6 2.1
		AA923549	Hs.224121		1.8
	302910	V00505	Hs.36977	hemoglobin; alpha 1 hemoglobin; delta	1.6
		T04868	Hs.46780	EST cluster (not in UniGene) with exon hit	1.7
35		U94362	Hs.58589	glycogenin 2	1.5
		H91086	1.0.0000	EST singleton (not in UniGene) with exon	1.5
		AA516384		EST singleton (not in UniGene) with exon	1.5
		AA550994		EST singleton (not in UniGene) with exon	1.7
	305612	AA782347	Hs.272572	EST singleton (not in UniGene) with exon	1.5
40		AA923457		EST singleton (not in UniGene) with exon	1.5
		Al192534		EST singleton (not in UniGene) with exon	1.6
		AI222691		EST singleton (not in UniGene) with exon	1.5
		A1452732		EST singleton (not in UniGene) with exon	1.9
45		A1612774	Hs.79372 Hs.255504	retinoid X receptor; beta	1.5 1.5
43		AW296073 AI720978		ESTs; Moderately similar to alternatively s	1.8
		AW241947	Hs.232478		1.6
		AW238092	Hs.254759		2.1
		T79860	Hs.118180		1.9
50		H25237	Hs.306814		2.3
		N49684	Hs.143040		1.8
	313283	W32480	Hs.157099	ESTs	2.2
	313374	AW328672	Hs.132760	ESTs	1.9
		A1754634	Hs.131987		1.7
55		AA759098	Hs.192007		1.8
		AA680055	Hs.264885		1.5
		AA948612	Hs.130414		1.6
		A1205077	Hs.294085		1.7
60	316890	AA837079 Al480204	Hs.24647 Hs.177131	ESTs	1.5 1.5
00	317604	A1400204	Hs.300756		1.6
	317604	AI650625 AW206520	Hs.129621		1.5
		W26902	Hs.154085		1.7
		H22654	Hs.6382	EST cluster (not in UniGene)	1.5
65	321594	AA021402	Hs.11067	ESTs	1.7
	322102	H45589		EST cluster (not in UniGene)	1.5
	322814	A1824495	Hs.211038	ESTs	2.2

	322929	Al365585	Hs.146246	ESTs	2.3
	323831	AA335715	Hs.200299	ESTs	1.7
	324044	AL045752	Hs.22350	ESTs	1.8
_	324675	AW014734	Hs.157969	ESTs	2.2
5	325272			CH.11_hs gi 5866902	1.5
	325558	•		CH.12_hs gij6056302	1.6
	325656			CH.14_hs gi 6056305	1.6
	326120			CH.17_hs gi[5867194	1.5
	326139			CH.17_hs gij5867203	1.5
10	326855			CH.20_hs gi 6552460	1.5
	327438			CH.02_hs gi[6004454	1.6
	329733			CH.14_p2 gi 6065783	1.6
	330931	F01443	Hs.284256	ESTs	4.6
	331591	N71677	Hs.42146	ESTs	1.9
15		AA621393	Hs.112984		1.5
	332364		Hs.103253		2.1
		H21819	Hs.14896	Homo sapiens clone 24590 mRNA sequenc	1.5
	334175			CH22_FGENES.349_10	1.5
• •	334347			CH22_FGENES.375_31	1.8
20	334737			CH22_FGENES.424_12	1.8
	335352			CH22_FGENES.539_5	1.5
	335639			CH22_FGENES.584_19	1.6
	336244			CH22_FGENES.746_2	1.5
~ ~	336336			CH22_FGENES.814_8	1.7
25	336865			CH22_FGENES.305-1	1.6
	337494			CH22_FGENES.799-12	1.6
	337764			CH22_EM:AC000097.GENSCAN.119-1	1.8
	337983			CH22_EM:AC005500.GENSCAN.110-1	2
20	338192			CH22_EM:AC005500.GENSCAN.228-1	1.5
30	339366			CH22_BA354I12.GENSCAN.34-2	1.5

TABLE 15A

Table 15A shows the accession numbers for those pkeys lacking unigeneID's for Table 15.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

304682 AA550994

306193 AA923457

336244 CH22_3642FG_746_2_LINK_DA

336336 CH22_3746FG_814_8_LINK_BA

```
Unique Eos probeset identifier number
        Pkey:
        CAT number:
                         Gene cluster number
                         Genbank accession numbers
        Accession:
15
        Pkey
                CAT number Accession
        126300 250375 2
                             D81972 BE003132
20
        112538 504579_1
                              AA908813 R70255
        123505 genbank_AA600135
                                        AA600135
        104672 6735_7
                             AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263
                              Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375
                              H45809 F33447 AA774528 AA007629 H42537 C01077 F32386
25
        322102 46708_1
                             H45589 H19807 AF075038 H19808 H42437
        336865 CH22 4590FG 305 1
        338192 CH22_6755FG__LINK_EM:AC00
        329733 c14_p2
        326120 c17_hs
30
        326139 c17_hs
        326855 c20_hs
        335352 CH22_2699FG_539_5_LINK_EM
        335639 CH22_2999FG_584_19_LINK_E
        307206 Al192534
35
        307377 Al222691
337494 CH22_5727FG_799_12_
        337764 CH22_6115FG_LINK_EM:AC00
337983 CH22_6438FG_LINK_EM:AC00
339366 CH22_8336FG_LINK_BA354I1
40
        325272 c11_hs
        325558 c12_hs
        325656 c14 hs
        334175 CH22_1455FG_349_10_LINK_E
        304182 H91086
45
        334347 CH22_1640FG_375_31_LINK_E
        327438 c_2_hs
        304622 AA516384
        334737 CH22_2049FG_424_12_LINK_E
```

TABLE 15B

Table 15B shows the genomic positioning for those pkeys lacking unigene ID's and
 accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey:	Unique number corresponding to an Eos probeset
10	Ref:	Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:	Indicates DNA strand from which exons were predicted.
	Nt_position:	Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Nt_position
	334347 334737	Dunham, I. et.al. Dunham, I. et.al.	Plus Plus	13663814-13663926 15998517-15998685
20	335639	Dunham, I. et.al.	Plus	25173591-25173696
	337494 334175	Dunham, I. et.al. Dunham, I. et.al.	Plus Minus	33339024-33339148 11668659-11668597
	335352	Dunham, I. et.al.	Minus	22681512-22681384
0.5	336244	Dunham, I. et.al.	Minus	31402729-31402583
25	336336	Dunham, I. et.al.	Minus	33797209-33797076
	336865	Dunham, I. et.al.	Minus	8622405-8622289
	337764	Dunham, I. et.al.	Minus	4035640-4035446
	337983	Dunham, I. et.al.	Minus	7275495-7275271
30	338192 339366	Dunham, I. et.al. Dunham, I. et.al.	Minus Minus	13248453-13248277 33647431-33647293
50	325272	5866902	Minus	13247-13312
	325558	6056302	Plus	70930-71030
	325656	6056305	Minus	78190-78707
	329733	6065783	Plus	163237-163450
35	326120	5867194	Plus	36116-36276
	326139	5867203	Minus	218901-218960
	326855	6552460	Minus	111390-111463
	327438	6004454	Minus	199569-199692

TABLE 16: Table 4 from BRCA 001-5 US

Table 16, a subset of table 15, depicts a preferred group of genes highly downregulated in 5 breast cancer cells.

Pkey: ExAccn: UnigenelD: Unigene Title: R1:

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UniGene (D	Unigene Title	R1
	100502 101367	TIGR:HT1496 M12963	Hs.169228 Hs.4	Adrenal-Specific Protein Pg2 alcohol dehydrogenase 1 (class I); alpha	2.3 2.9
	102857	X00129	Hs.76461	retinol-binding protein 4; interstitial	3
20	104672	AA007629		glycerol-3-phosphate dehydrogenase 1	2.4
	107099	AA609645	Hs.211568	eukaryotic translation initiation factor 4 gam	2.7
	108604	AA099820	Hs.49696	ESTs	2.4
	115949	AA443800	Hs.43125	ESTs	2
25		AA446661	Hs.173233	ESTs	2.2
25	119175	R71792	Hs.301002	ESTs; Weakly similar to cell death activator	2.8
	119798	W73386	Hs.249129	ESTS	3
	122127	AA434447	Hs.106771	ESTs	2.5
	122348 129285	AA443695 T62068	Hs.293410 Hs.11006	ESTs ESTs	2.1 2.1
30	131267	AA211776	Hs.2504		3.8
50	131282	M12272	Hs.4	myomesin 1 (skelemin) (185kD) alcohol dehydrogenase 3 (class I); gamma	2.2
	131810	D49487	Hs.194236	leptin (murine obesity homolog)	2.5
		X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2.3
	133601	S95936	Hs.284176	transferrin	2.3
35	134111	N79674	Hs.8022	TU3A protein	4.6
		AA923549	Hs.224121	ESTs	2.1
	311794	AW238092	Hs.254759	ESTs	2.1
	312575	H25237	Hs.306814	ESTs	2.3
	313283	W32480	Hs.157099	ESTs	2.2
40	322814	A1824495	Hs.211038	ESTs	2.2
	322929	Al365585	Hs.146246	ESTs	2.3
	324675	AW014734	Hs.157969	ESTs	2.2
	330931	F01443	Hs.284256	ESTs	4.6
4	332364	W94688	Hs.103253	perilipin	2.1
45	337983			CH22_EM:AC005500.GENSCAN.110-1	2

TABLE 16A

Table 16A shows the accession numbers for those pkeys lacking unigeneID's for Table 16. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey:

Unique Eos probeset identifier number

CAT number: Accession:

Gene cluster number Genbank accession numbers

15

20

Pkey CAT number Accession

104672 6735_7

AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263 Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375

H45809 F33447 AA774528 AA007629 H42537 C01077 F32386

TABLE 17: Table 1 from BRCA 014 P

Table 17 shows accession numbers representing 759 sequences of breast cancer genes or fragments thereof encoding breast cancer modulating proteins. For each overexpressed gene identified, a ratio of the relative amount of expression in breast tumors versus normal breast tissue.

10		
	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title
15	R1·	Ratio of tumor to normal breast tissue

	Pkey	ExAccn	UnigenelD	Unigene Title	R1
20		AV654694	Hs.82316	interferon-induced, hepatitis C-associat	3
		AW291587	Hs.82733	nidogen 2	3.2
		A1962060		AE-binding protein 1	3.6
		D86983		Melanoma associated gene	3.2
25		X83300	Hs.289103	ATT IT	5.2
25	100960		Hs.117729		4.3
		BE387036	Hs.1211	acid phosphatase 5, tartrate resistant	3
		AA442324	Hs.795	H2A histone family, member O	3.2
	101194	•	Hs.188 Hs.82171	phosphodiesterase 4B, cAMP-specific (dun	3 4.1
30		U66042 BE563085	Hs.833	Homo sapiens clone 191B7 placenta expres	5.3
50		R07566	Hs.73817	interferon-stimulated protein, 15 kDa small inducible cytokine A3 (homologous	3.9
		M25809	Hs.64173	ATPase, H+ transporting, lysosomal (vacu	4.5
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	3.4
35		NM_003528	Hs.2178	H2B histone family, member Q	5.6
		BE019494	Hs.79217	pyrroline-5-carboxylate reductase 1	3.6
		M81057		carboxypeptidase B1 (tissue)	12
		M89907		SWI/SNF related, matrix associated, acti	3.2
	101851	BE260964	Hs.82045	midkine (neurite growth-promoting factor	4.1
40	101878	M97815	Hs.183650	cellular retinoic acid-binding protein 2	6.5
	102209	NM_002038	Hs.265827	interferon, alpha-inducible protein (clo	3
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	3
		NM_001504		G protein-coupled receptor 9	3.7
4 ~		NM_005824		37 kDa leucine-rich repeat (LRR) protein	3.7
45		NM_005651		tryptophan 2,3-dioxygenase	5.2
		AL043202	Hs.90073	chromosome segregation 1 (yeast homolog)	3.5
		U39840		hepatocyte nuclear factor 3, alpha	3.9
		U62325		amyloid beta (A4) precursor protein-bind	4
50		H16646		hypothetical protein PP591	3.5 3.2
50		AA363025 AF080229	HS.100072	Human clone 23801 mRNA sequence gb:Human endogenous retrovirus K clone 1	3.2
		NM_002318	Hs.83354	lysyl oxidase-like 2	3.2
		M73779		retinoic acid receptor, alpha	3.3
		X52509		tyrosine aminotransferase	12.4
55		T81656		ribosomal protein S3	4.5
7,5		X63578		parvalbumin	3
		X72790		gb:Human endogenous retrovirus mRNA for	5.9
		BE390551	Hs.77628	steroidogenic acute regulatory protein r	3.9
		AJ751601	Hs.8375	TNF receptor-associated factor 4	3.3
60		X85134	Hs.72984	retinoblastoma-binding protein 5	3.1
		X90872	Hs.279929	gp25L2 protein	3
		NM_007069	Hs.37189	similar to rat HREV107	3.4
	103456	AA496425	Hs.9629	papillary renal cell carcinoma (transloc	3.2

	103408	Y09306	Hs.30148	homeodomain-interacting protein kinase 3	3.4
		BE616547	Hs.2785	keratin 17	3.7
		L02911		Activin A receptor, type I (ACVR1) (ALK	3.2
		BE336654	Hs.70937	H3 histone family, member A	4.5
5	103825	Al571835	Hs.55468	ESTs	4
	104073	AW779318	Hs.88417	ESTs	3.8
		AW021102	Hs.21509	ESTs	4.3
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
10		AA461618	Hs.31704	ESTs, Weakly similar to KIAA0227 [H.sapi	3.6
10		AA084273 AF173296	Hs.76561	ESTs, Weakly similar to S47072 finger pr DC6 protein	4 3
		AB040927		KIAA1494 protein	3.2
		Al559444	Hs.293960		4.3
		Al929700		endosulfine alpha	3.1
15		H20816		Homo sapiens mRNA; cDNA DKFZp586I1420 (f	3.2
	104556	AV650851	Hs.96900	hypothetical protein; KIAA1830 protein	4.4
	104658	AA360954	Hs.27268	Homo sapiens cDNA: FLJ21933 fis, clone H	3.2
		AA015879	Hs.33536	ESTs	3.2
20		T49951	Hs.9029	DKFZP434G032 protein	4.5
20		AA035613	Hs.141883		6.9
		AW294092	Hs.21594	hypothetical protein MGC15754	11.1 3.5
•		T79340 BE298684	Hs.22575 Hs.26802	B-cell CLL/lymphoma 6, member B (zinc fi protein kinase domains containing protei	6.5
		H78517	Hs.33905	ESTs	3.6
25		AW503733	Hs.9414	KIAA1488 protein	4.5
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	3.8
	105092	AA148982	Hs.29068	ESTs	3
	105093	AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G0321 (f	4.8
20		AW134924	Hs.190325		8.2
30		AA814807	Hs.7395	hypothetical protein FLJ23182	3.1
		AW505076		DiGeorge syndrome critical region gene 8	4.2
		AA252033 AA256750	Hs.28802	hypothetical protein DKFZp434K1421 centaurin-alpha 2 protein	4.4 3.2
		AA279439		hypothetical protein FLJ10504	3.5
35		W16741	Hs.25635	HSPC003 protein	3.7
		Al299139	Hs.17517	ESTs	5.5
		Al133161		CGI-101 protein	3.5
	105809	AW973653	Hs.20104	hypothetical protein FLJ00052	3.3
40		AA195191	Hs.5111	hypothetical protein FLJ20729	3.2
40		AA131657	Hs.23830	ESTs	3.3
		AL117474	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3.2
		W28948	Hs.10762 Hs.301444	ESTs	3.3 4.1
		N39842 BE397649	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	3.1
45		BE383668	Hs.42484	hypothetical protein FLJ10618	3.2
		AA351978	Hs.4943	hepatocellular carcinoma associated prot	7.8
	106533	AL134708	Hs.145998		3
	106614	AA648459	Hs.335951	hypothetical protein AF301222	3.8
5 0		AW958037	Hs.286	ribosomal protein L4	3.3
50		AW499914	Hs.7579	hypothetical protein FLJ10402	3
		BE613328	Hs.21938	hypothetical protein FLJ12492	4.2
		AA485055	HS. 158213	sperm associated antigen 6 gb:qo89h04.x1 NCI_CGAP_Kid5 Homo sapiens	3.4 4.4
		AI311928 AW192535	Hs.19479	ESTs	3.6
55		AW472981		hypothetical protein MGC2771	4.1
33		AA995351	Hs.31314	retinoblastoma-binding protein 7	3.6
		AF216751	Hs.26813	CDA14	5.3
		AW963419		stanniocalcin 2	3.4
60	107158	N32849	Hs.31844	hypothetical protein FLJ12586	3.1
60		AW263124	Hs.315111		5.9
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	3.9
		AW961576	Hs.60178	ESTs Weekly similar to transformation r	4.6
		Al955040 AA025386	Hs.265398 Hs.61311	ESTs, Weakly similar to transformation-r ESTs, Weakly similar to S10590 cysteine	3 3.1
65		T40064	Hs.71968	Homo sapiens mRNA; cDNA DKFZp564F053 (fr	3.1 4.8
55		Al263307		H2B histone family, member L	3.3
		AA058686	Hs.62588	ESTs	3.8

	108435		Hs.194101 Hs.43857	Homo sapiens cDNA: FLJ20869 fis, clone A similar to glucosamine-6-sulfatases	3 3.3
		AB033073 AA121022	HS.43037	gb:zn84f10.r1 Stratagene lung carcinoma	3.9
		AF068290	Hs.79741	hypothetical protein FLJ10116	6.1
5		AA011449	Hs.271627		3.6
		AA136674	Hs.118681		3.9
		AF186114		tumor necrosis factor (ligand) superfami	3.7
		AK000684		hypothetical protein FLJ22104	3.1
10		AI970536	Hs.16603	hypothetical protein FLJ13163	3.7
10		N23235	Hs.30567	ESTs, Weakly similar to B34087 hypotheti	4.5 3.7
		AA196443 AW504732	Hs.86043 Hs.21275	Homo sapiens cDNA FLJ13558 fis, clone PL hypothetical protein FLJ11011	3. <i>1</i> 4.6
		AA232255		ESTs, Moderately similar to A46010 X-lin	6.4
		AA234087		ESTs, Weakly similar to S72482 hypotheti	4.8
15		R45584	Hs.23025	ESTs, Weakly similar to ALU5_HUMAN ALU S	3.3
	109632	AA325138		hypothetical protein FLJ22672	3
	109644	AW973964	Hs.291531	ESTs, Highly similar to 1203217A dehydro	3
		F09609		gb:HSC33H092 normalized infant brain cDN	3.2
20		F06838	Hs.14763	ESTs	3.2
20		R43646 AW818436	Hs.12422 Hs.23590	ESTs solute carrier family 16 (monocarboxylic	3.8 3.3
		AK001680	Hs.30488	DKFZP434F091 protein	3.6
		AW973152	Hs.31050	ESTs	4.2
		AA379597	Hs.5199	HSPC150 protein similar to ubiquitin-con	5.1
25	110675	H89355	Hs.249159	adrenergic, alpha-2A-, receptor	5.3
		Al239832	Hs.15617	ESTs, Weakly similar to ALU4_HUMAN ALU S	3.7
		BE092285	Hs.29724	hypothetical protein FLJ13187	3.7
		N64683 N66563	Hs.290943 Hs.191358		4 3.1
30		AI767435	Hs.29822	ESTs	4.5
50		Al457338	Hs.29894	ESTs	5.4
		R07856	Hs.16355	ESTs	3.2
	111532	R08440		gb:yf19f09.s1 Soares fetal liver spleen	3.1
25		AA602004	Hs.23260	ESTs	3.2
35		R35252	Hs.24944	ESTs, Weakly similar to 2109260A B cell	3.3
		R38239	Hs.12388	ESTs, Weakly similar to putative p150 [H ESTs	3.1 3.4
		AA421081 AF070526	Hs.13429	Homo sapiens clone 24787 mRNA sequence	3.3
		AW379029		ESTs, Weakly similar to unnamed protein	4.4
40		BE246743		hypothetical protein FLJ22635	7.3
		AB033064	Hs.334806	KIAA1238 protein	3.2
		H24334	Hs.26125	ESTs	4.4
		R54797	11- 00004	gb:yg87b07.s1 Soares infant brain 1NIB H	3.4
45		R66067 Al791493	Hs.28664	ESTs ESTs, Weakly similar to A36036 cytochrom	8.2 5.5
40		R82040	Π 5. 1290/ 3	gb:yj06b06.s1 Soares placenta Nb2HP Homo	3.9
		R82331	Hs.164599		5.4
		AW844878	Hs.19769	hypothetical protein MGC4174	3.2
	112678	Al418466	Hs.33665	ESTs	4.7
50		AA082465		choline/ethanolaminephosphotransferase	3.7
		AB032977	Hs.6298	KIAA1151 protein	3.1
		AA828380 AW813731	Hs.126733	ESTs, Moderately similar to S65657 alpha	3.4 3.4
		BE613410	Hs.31575	SEC63, endoplasmic reticulum translocon	3.2
55		T57773	Hs.10263	ESTs	3.5
		BE262470	Hs.241471	RNB6	6.2
		T79925		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
		U54727	Hs.191445		3
60		T91451	Hs.86538	ESTs	3.4
60		AW367788	Hs.323954 Hs.15713	postmelotic segregation increased 2-like hypothetical protein MGC2776	3.1 3.1
		A1702609 NM_004585	Hs.17466	retinoic acid receptor responder (tazaro	3.9
		Al912410	Hs.27475	Homo sapiens cDNA FLJ12749 fis, clone NT	3
		W81598		gb:zd88g02.s1 Soares_fetal_heart_NbHH19W	4.6
65		W84768		gb:zh53d03.s1 Soares_fetal_liver_spleen_	3.1
		W27249	Hs.8109	hypothetical protein FLJ21080	6.9
	114086	AA378776	Hs.288649	hypothetical protein MGC3077	4.3

		AW470411		neurotrimin	4.1
		AW780192	Hs.267596		3.4
		AW163267		suppressor of var1 (S.cerevisiae) 3-like	3.1
_		Al979168	Hs.82226	glycoprotein (transmembrane) nmb	4.8
5		Al733881	Hs.72472		10.1
		AA769266	Hs.193657		3.6
		A1634549	Hs.88155		3.2 4.2
		AW968073		ESTs, Highly similar to A55713 inositol	3
10		AA749209 BE149845	Hs.43728	hypothetical protein hypothetical protein MGC4126	3.6
10		AA814100	Hs.86693	ESTs	3.9
		N46436	Hs.109221		3.4
		AA281636	Hs.334827		4.8
		AA405620	Hs.55158	ESTs, Weakly similar to T29520 hypotheti	3.5
15		AA953006	Hs.88143	ESTs	9.3
		AW293849	Hs.58279	ESTs, Weakly similar to ALU7_HUMAN ALU S	3.4
		AA417812	Hs.38775	ESTs	4
	115787	Al126772	Hs.40479	ESTs	3.1
	115830	AW970529	Hs.86434	hypothetical protein FLJ21816	3.6
20	115835	AA521410	Hs.41371	ESTs	3.1
		NM_014937	Hs.52463	KIAA0966 protein	3
		AK001500		hypothetical protein FLJ13852	3.2
		AA354549	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3
25		AL042465	Hs.43445	poly(A)-specific ribonuclease (deadenyla	3.1
25		AB041035	Hs.93847	NM_016931:Homo sapiens NADPH oxidase 4 (6.7
		AL042355	Hs.70202	WD repeat domain 10 CGI-09 protein	3.6 3.1
		AW450737 AA464976	Hs.62528	ESTs, Moderately similar to A46010 X-lin	3.3
		AI219083	Hs.42532		3.2
30		AF265555		baculoviral IAP repeat-containing 6	3.6
50		AW962196		LBP protein 32	4.1
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	4.1
		AK001114	Hs.53913	hypothetical protein FLJ10252	8.6
	116845	AA649530		gb:ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens	3.2
35	117026	H88256	Hs.50456	ESTs, Moderately similar to ZN75_HUMAN Z	3.5
	117216	AI569804	Hs.42792	ESTs, Weakly similar to I78885 serine/th	3.1
		AL133427	Hs.42506	Homo sapiens mRNA full length insert cDN	3.2
		H84455	Hs.40639	ESTs	4.7
40		AB040959	Hs.93836	DKFZP434N014 protein	3
40		AW968941		hypothetical protein DKFZp566l133	3.3 4.3
		AI183838	Hs.48938 Hs.49105	hypothetical protein FLJ21802 FKBP-associated protein	3.1
		N66028 AW970584	Hs.291033		3.4
		AL157488	Hs.50150	Homo sapiens mRNA; cDNA DKFZp564B182 (fr	5.2
45		AK000465	Hs.50081	KIAA1199 protein	3.4
		N92293		ESTs, Moderately similar to ALU8_HUMAN A	3.3
		BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	19.7
	119036	R95872	Hs.117572	chemokine binding protein 2	3.7
	119063	R16833	Hs.53106	ESTs, Moderately similar to ALU1_HUMAN A	4.1
50		M10905	Hs.287820	fibronectin 1	3.2
		W47620	Hs.56009	2'-5'-oligoadenylate synthetase 3 (100 k	3.3
		AF041853	Hs.43670	kinesin family member 3A	3.1
		Al970797	Hs.64859	ESTs	5
<i>5</i>		AL037824	HS.194695	ras homolog gene family, member l collagen, type III, alpha 1 (Ehlers-Danl	3.8
55		AW449064	Hs.119571 Hs.59529	ESTs, Moderately similar to ALU1_HUMAN A	3.1 8.4
		W94472 AA825686	HS.09029	ESTs, Weakly similar to S65824 reverse t	3.6
		AA196300	Hs.21145	hypothetical protein RG083M05.2	3.2
		AA225084	110.21170	gb:nc21d06.r1 NCI_CGAP_Pr1 Homo sapiens	3.6
60		AA357172	Hs.292581	ESTs, Moderately similar to ALU1_HUMAN A	5.8
00		AA365515		hypothetical protein MGC4840	3
		AA398118	Hs.97579	ESTs, Weakly similar to A46010 X-linked	3.7
		AW976570	Hs.97387	ESTs	5.3
	121095	AA320134	Hs.196029	Homo sapiens mRNA for KIAA1657 protein,	4
65	121103	AA398936	Hs.97697	EST	3.5
		AA399371		similar to SALL1 (sal (Drosophila)-like	6.3
	121337	AW885727	Hs.301570	ESIS	4.7

	121351	AW206227	Hs.287727	hypothetical protein FLJ23132	5
	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	3.6
		AA640987	Hs.193767		5.6
_		NM_015902		progestin induced protein	3.4
5		AK000492	Hs.98806	hypothetical protein	4.1
		AA443311	Hs.98998	ESTs	3 4.7
		AA446965 Al767879	Hs.112092 Hs.99214	ESTs	3.8
		AW973253	Hs.292689		3
10		AA323296	Hs.97837	Homo sapiens mRNA; cDNA DKFZp547J047 (fr	5.6
		AA526911	Hs.82772	collagen, type XI, alpha 1	3.2
	122851	AW205931	Hs.99598	hypothetical protein MGC5338	8.6
	123105	AA487809	Hs.166011	catenin (cadherin-associated protein), d	3
4 ~		AA228776	Hs.191721		6.9
15		AA371307	Hs.125056		3.6
		AA491253		Empirically selected from AFFX single pr	7 3.1
		BE149685 T66087	Hs.17767	KIAA1554 protein Homo sapiens unknown mRNA sequence	3.4
		Al308876		hypothetical protein DKFZp761D112	3.1
20		AI675944		Homo sapiens cDNA FLJ12033 fis, clone HE	3.8
		AA580082	Hs.112264		4.7
		AA352723	Hs.241471	RNB6	3.8
	124243	H69125	Hs.133525		4.1
0.5		N22401		gb:yw37g07.s1 Morton Fetal Cochlea Homo	4.1
25		N22508		Homo sapiens cDNA: FLJ21479 fis, clone C	3.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	3.1 3.5
		N34151 R41396		interferon induced transmembrane protein hypothetical protein FLJ23045	4.3
		BE065136		splicing factor (CC1.3)	6
30		T78906		ESTs, Moderately similar to ALU1_HUMAN A	8.1
		W60326		Homo sapiens cDNA FLJ11750 fis, clone HE	4.7
		AW970536	Hs.105413		3.1
		AF086534	Hs.187561	ESTs, Moderately similar to ALU1_HUMAN A	3.3
25		AL359573		GTP-binding protein	3
35		AW880562	Hs.114574		3
		AI422996	Hs.161378		3.2 3.2
		AI924630 N99638	Hs.4943	hepatocellular carcinoma associated prot gb:za39g11.r1 Soares fetal liver spleen	3.2 4
		AW975814	Hs 326714	Homo sapiens clone IMAGE:713177, mRNA se	4
40		AA648886	Hs.151999		3.8
• •		AW450979		gb:UI-H-BI3-ala-a-12-0-UI.s1 NCI_CGAP_Su	3
	127431	AW771958	Hs.175437	ESTs, Moderately similar to PC4259 ferri	3.6
		AA961459	Hs.125644		4.1
15		AW068311		Homo sapiens mRNA full length insert cDN	3.3
45		AA650274	Hs.41296		4.6
		NM_003616 Y13153		survival of motor neuron protein interac kynurenine 3-monooxygenase (kynurenine 3	3.9 3.1
		AA775076		Homo sapiens, Similar to PRO0478 protein	3.9
		D56365	Hs.63525	poly(rC)-binding protein 2	3.3
50		AA357185		ras homolog gene family, member H	3.1
		AF182277	Hs.330780	cytochrome P450, subfamily IIB (phenobar	3.9
		AA172106	Hs.110950	Rag C protein	6.2
		AA209534		tetraspan NET-6 protein	3.4
55		AK000398	Hs.11747	hypothetical protein FLJ20391	3
55		X56411 Al754813	Hs.1219	alcohol dehydrogenase 4 (class II), pi p collagen, type V, alpha 1	3.2 5.4
		X03363	Hs 323910	v-erb-b2 avian erythroblastic leukemia v	4.4
		Al347487		class I cytokine receptor	4.6
		NM_003450		zinc finger protein 174	5.6
60	130622	A1582291	Hs.16846	ESTs, Weakly similar to O4HUD1 debrisoqu	3
	130703	R77776	Hs.18103	ESTs	3.8
		AA809875	Hs.25933	ESTs	4.2
		AB014544	Hs.21572	KIAA0644 gene product	4.7
65		Al399653	Hs.22917 Hs.23606	ESTs ESTs	4.3 3.8
05		H09048 R71802	Hs.24853	ESTs	3.5
		AW293399		nuclear receptor co-repressor 1	3.6

	131507	A1826268	Hs.27769	ESTs, Weakly similar to MCAT_HUMAN MITOC	3.2
		Al695549		glucuronidase, beta	3.1
		AF017986	Hs.31386	secreted frizzled-related protein 2	3.2
_		BE501849	Hs.32317	high-mobility group 20B	3.2
5		D86960	Hs.3610	KIAA0205 gene product	3.6
		NM_002314	Hs.36566	LIM domain kinase 1	3.2
		AA400091	Hs.39421	ESTs	3.2
		AA426202	Hs.40403	Cbp/p300-interacting transactivator, wit	3
10		D76435 AA192669	Hs.41154 Hs.45032	Zic family member 1 (odd-paired Drosophi ESTs	3.2 3.5
10		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	9.2
		AV660345		CGI-49 protein	8.2
		BE568452	Hs.5101	protein regulator of cytokinesis 1	3.4
		AA326108	Hs.33829	bHLH protein DEC2	3.2
15		AA319233 •		ESTs	4.8
		NM_006276		splicing factor, arginine/serine-rich 7	3.6
		W73311		SAC2 (suppressor of actin mutations 2, y	3.2
	132847	T48195	Hs.58189	eukaryotic translation initiation factor	3.5
• •		Y00272	Hs.184572	cell division cycle 2, G1 to S and G2 to	4.4
20		AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	4.8
		Al128606	Hs.6557	zinc finger protein 161	3.3
		AW952412	Hs.65874	ESTs, Weakly similar to A40348 Elav/Sex-	3.5
		AW162840	Hs.6641	kinesin family member 5C	4.5
25		AW600291	Hs.6823	hypothetical protein FLJ10430	3.3
25		AA085191	Hs.6949	hypothetical protein MGC11275	3 4.5
		Z93241 AW797437	Hs.69771	CGI-96 protein B-factor, properdin	4.1
		BE618768	Hs.7232	acetyl-Coenzyme A carboxylase alpha	5.1
		AW675064	Hs.73875	fumarylacetoacetate hydrolase (fumarylac	3
30		AW162919		RAB2, member RAS oncogene family-like	3.4
50		BE274552	Hs.76578	protein inhibitor of activated STAT3	3.9
		Al908165		GATA-binding protein 3 (T-cell receptor	6.2
		BE391929	Hs.8752	transmembrane protein 4	3.1
	134710	Al433797	Hs.8889	serine hydroxymethyltransferase 1 (solub	3
35	134731	D89377	Hs.89404	msh (Drosophila) homeo box homolog 2	5.8
		J05582	Hs.89603	mucin 1, transmembrane	4
		AF064804	Hs.96757	suppressor of Ty (S.cerevisiae) 3 homolo	3.2
		R61253	Hs.98265	KIAA1877 protein	3.3
40		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	4.8
40		L10333	Hs.99947	reticulon 1	3.8 3.8
		Al199738 AW614220	Hs.189402	ESTs, Weakly similar to ALUA_HUMAN !!!!	4.2
		AW183618	Hs.55610	solute carrier family 30 (zinc transport	9.9
		AW591433		Transmembrane protease, serine 3	4.9
45		Z45270		hypothetical protein FLJ22672	3.4
		AA572949	Hs.207566		3.5
		R10799	Hs.191990		3.8
	301341	AA887801	Hs.208229	G protein-coupled receptor	13.9
	301548	AI091631	Hs.203845	two pore potassium channel KT3.3	4.4
50		AA312082		GDNF family receptor alpha 1	5.7
		U79745	Hs.114924	solute carrier family 16 (monocarboxylic	8.6
		T97905		gb:ye54c10.r1 Soares fetal liver spleen	3.9
		AB020711		KIAA0904 protein	7.7
<i>E E</i>		BE542706		CEGP1 protein	7.3
55		AW749321	Hs.6786	ESTs ribosomal protein L34 pseudogene 1	3.3 4.2
		AL049670		cartilage intermediate layer protein, nu	7.9
	202140	NM_003613 AL049987		Homo sapiens mRNA; cDNA DKFZp564F112 (fr	5.6
		AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	5.4
60		AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (f	34.1
00		AL117406		ATP-binding cassette transporter MRP8	6.7
		AL109712		Homo sapiens mRNA full length insert cDN	4
		AI678059		synaptonemal complex protein 2	4.3
	302385	AJ224172	Hs.204096	lipophilin B (uteroglobin family member)	13.8
65	302680	AW192334	Hs.38218 .		9.6
		A1038997	Hs.132921		5
	302857	AF282265	Hs.44836	inner centromere protein antigens (135kD	3.4

	302892	AW176909	Hs.42346	calcineurin-binding protein calsarcin-1	3.4
	302970	W05608	Hs.312679	ESTs, Weakly similar to A49019 dynein he	5.1
	303271	AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	3.7
					4.1
_	_	AL121460		hypothetical protein FLJ20508	
5		AW006352		ESTs, Weakly similar to T32554 hypotheti	4.2
	303540	AA355607	Hs.309490	ESTs, Weakly similar to putative WHSC1 p	4.3
	303563	AA367699	Hs.10082	potassium intermediate/small conductance	3.3
		AW299459		gb:xs50d08.x1 NCI_CGAP_Kid11 Homo sapien	4.2
			U= 4000E		
10		Al424014	Hs.18995	KIAA1304 protein	3.6
10		AW629759		gb:hh70e05.y1 NCI_CGAP_GU1 Homo sapiens	4.9
	303852	R53434	Hs.90207	hypothetical protein MGC11138	3.7
	304328	AA149951	Hs.62112	zinc finger protein 207	3
		AA582081	110102112	gb:nn32h08.s1 NCI_CGAP_Gas1 Homo sapiens	4.1
1.5		AA876109		gb:nx24h01.s1 NCI_CGAP_GC3 Homo sapiens	3
15	305917	AA876469		gb:oe48b04.s1 NCI_CGAP_Pr25 Homo sapiens	3.1
	307010	Al140014		gb:qa68f09.x1 Soares_fetal_heart_NbHH19W	3.5
		Al144243		gb:gb85b12.x1 Soares_fetal_heart_NbHH19W	3.9
					4.3
		AI476803		gb:tj77e12.x1 Soares_NSF_F8_9W_OT_PA_P_S	
•	308307	Al581398	Hs.172928	collagen, type I, alpha 1	4.6
20	308615	AK000142	Hs.101774	hypothetical protein FLJ23045	4.4
	309177	Al951118		Homo sapiens breast cancer antigen NY-BR	17.3
		AW024348		EST, Weakly similar to A27217 glucose tr	3.2
			115.233131		
		AW168083		gb:xg59g04.x1 NCI_CGAP_Ut4 Homo sapiens	3.1
	309583	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	57.6
25	310064	Al199712	Hs.148486	ESTs, Weakly similar to 1917210A Pro/Arg	4.6
		Al685841	Hs.161354		3.6
					4.6
		AW022192	Hs.200197		-
	310683	Al939456	Hs.160870		3.2
	310727	AK000703	Hs.323822	Homo sapiens mRNA for KIAA1551 protein,	3.6
30	310781	Al380797	Hs.158992	ESTs	10.2
		Al955121		N-acetylgalactosamine-4-O-sulfotransfera	3.4
		AI476732	Hs.263912		10.9
	311117	Al671439	Hs.196029	Homo sapiens mRNA for KIAA1657 protein,	3.1
	311166	AI821005	Hs.118599	ESTs	10.8
35	311237	AA641098	Hs 208809	ESTs, Moderately similar to ALU1_HUMAN A	4.3
50			Hs.206132		4.4
		A1758660			
		Al828254		ESTs, Weakly similar to A47582 B-cell gr	5.1
	311598	AW023595	Hs.232048	ESTs	5.8
	311774	AA700870	Hs.14304	ESTs	3.3
40		A1056769	Hs.133512	FSTs	3.9
••		R12375	Hs.194600		3.3
		AA767342		ESTs, Weakly similar to PSF_HUMAN PTB-AS	3
	311913	Al358522	Hs.270188	ESTs	3
	311923	T60843	Hs.189679	ESTs	5.6
45		AA216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
1.5		AA373630	Un 100750		3
			Hs.188750		
		AA759263	Hs.14041	ESTs	3.4
	312067	T78968	Hs.14411	ESTs	3.5
	312090	T80177	Hs.118064	similar to rat nuclear ubiquitous casein	3.8
50		Al633744		ESTs, Weakly similar to I38022 hypotheti	4.4
50					
		BE261944		hexokinase 1	5.2
	312168	T92251	Hs.198882	ESTs	3.3
	312182	T94344	Hs.326263	ESTs	3.3
		AA700439	Hs.188490	FSTs	3.4
55		AW438602	Hs.191179		3.9
55					
		H73505	Hs.117874		4
	312226	AA315703	Hs.199993	ESTs, Weakly similar to ALUB_HUMAN !!!!	4.9
	312299	AA972712	Hs.269737	ESTs	5.7
		AA516420		ESTs, Weakly similar to l38022 hypotheti	6.3
60			Ha 250000	ECTs Wookly similar to CREGET sinhs 10	
60		AW439195		ESTs, Weakly similar to S65657 alpha-1C-	4.9
		AW291545	Hs.185018		4.9
	312837	AW292286	Hs.255058	ESTs	4.4
		AA497043	Hs.115685		3.1
		AI422023	Hs.161338		4.3
65				proteolipid protein 1 (Pelizaeus-Merzbac	3.3
05	040000	N76497	Hs.1787		
		AF026944	Hs.293797		5.8
	313096	AW073310	Hs.163533	Homo sapiens cDNA FLJ14142 fis, clone MA	4.5

	0.40.400				4.0
	313126	AA746503	Hs.283313	ESTs	10
	313166	Al801098	Hs.151500	ESTs	3.5
	313197	AW979008	Hs.222487	ESTs	3.3
	313280	AW960454	Hs.222830	ESTs	4.7
5		Al420611	Hs.127832		3.4
-		AW449211		GDNF family receptor alpha 1	12.4
		AW150945	Hs.144758		4.1
		A1032087	Hs.269819		3
10		Al674685	Hs.200141		5.2
10	313417	AA741151	Hs.137323	ESTs	3.5
	313434	W92070		gb:zh48g05.r1 Soares_fetal_liver_spleen_	3.7
	313569	Al273419	Hs.135146	hypothetical protein FLJ13984	. 3
		AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	5.6
		AI540978	He 301007	hypothetical protein FLJ13033	3.2
15			Ha 162442	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
13		C18863			
		AW175896	Hs.65114		3
		A1535895	Hs.221024		4.9
		AV657317	Hs.288649	hypothetical protein MGC3077	3.9
	314043	AA827082	Hs.291872	ESTs	3.1
20	314078	AW129357	Hs.329700	ESTs	8.3
		AA648744	Hs.269493		6.6
		Al732083	Hs.187619		6.2
					4
		AA228366	Hs.115122		
0.5		AA740616		gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	5.9
25		AA743396	Hs.189023		3.1
	314244	AL036450	Hs.103238	ESTs	4
	314305	Al280112	Hs.125232	Homo sapiens cDNA FLJ13266 fis, clone OV	8
		Al697901	Hs.192425		3.7
		AA907153	Hs.190060		3.3
30		AW961597		ESTs, Moderately similar to I38022 hypot	4.2
50					3.3
		Al660412	Hs.234557		
		AA602917	Hs.156974		4.7
		AA833655		Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
	314510	A1204418	Hs.190080	ESTs	4
35	314546	AW007211	Hs.16131	hypothetical protein FLJ12876	3.4
	314547	AA399272	Hs.144341		6.7
		Al873274	Hs.190721		27.4
		AA425310		ESTs, Weakly similar to A47582 B-cell gr	4.4
		AW979268	113.100700	gb:EST391378 MAGE resequences, MAGP Homo	
40			11- 400040		
40		AW207206	Hs.136319		20.7
		AA457367	Hs.191638		3.6
	314754	AW026761	Hs.134374		3.6
	314814	BE350122	Hs.157367	ESTs, Weakly similar to I78885 serine/th	4.9
	314864	AW971198	Hs.294068	ESTs	4.3
45	314881	A1095087	Hs.152299	ESTs, Moderately similar to S65657 alpha	3.7
		AA828032	Hs.189076		3.1
		AW972359	Hs.293334		3
		AI538613		Transmembrane protease, serine 3	10.9
50		AA533447	Hs.312989		5.3
50		AW292425	Hs.163484	ESIS	12.9
		AA551104		ESTs, Moderately similar to ALUC_HUMAN!	5.8
	315073	AW452948	Hs.257631	ESTs	4.2
	315080	AA744550	Hs.136345	ESTs	3.7
		A1025842	Hs.152530	ESTs	6
55		AW136134	Hs.220277		3.9
55		Al241331		ESTs, Moderately similar to I38937 DNA/R	4.4
	315190	AI367347		Homo sapiens clone TCCCTA00151 mRNA sequ	8.2
	315198	Al741506		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.6
	315240	R38772		myelin transcription factor 1-like	3.4
60	315263	AW510994	Hs.220740	ESTs	3.4
		Al222165	Hs.144923	ESTs	4.9
		AA876905	Hs.125286		4
		AB037745		KIAA1324 protein	4.7
		AA218940		fidgetin-like 1	3.1
65					
65		AI378817	Hs.191847	EOTo Madamataly similar to ALLIA LILIMAN A	3.1
		AA628539	ПS. 1 10202	ESTs, Moderately similar to ALU1_HUMAN A	3.2
	310520	AI193043	⊓S.128085	ESTs, Weakly similar to T17226 hypotheti	4.1

	315530	AW015415	Hs.127780	ESTs	8.9
		AA737415	Hs.152826		5.5
	315634	AA837085	Hs.220585	ESTs	6.3
_		AA648983	Hs.212911		3.6
5		Al418055	Hs.161160		5.1
		AW515373		Homo sapiens cDNA FLJ13580 fis, clone PL	3.1
		AW270550	Hs.116957		3.8
		AA737345	Hs.294041	— - · -	5
10		AA683336	Hs.189046		3.1 4.7
10		AW865916 AA830893	Hs.151206 Hs.119769		4.1
		Al217477	Hs.194591		4.1
		AA764950	Hs.119898		7
		AI469960	Hs.170698		4.9
15		Al962796	Hs.136754		4.1
	316072	AW517524	Hs.135201	NOD2 protein	3.2
	316074	AW975114	Hs.293273	ESTs	3.8
		AW203986	Hs.213003		3.2
20		AI187742	Hs.125562		3.7
20		A1904982	Hs.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7
		A1433540	Li- 004000	gb:ti69g05.x1 NCI_CGAP_Kid11 Homo sapien	3.1
		Al640761 AA740994	Hs.224988 Hs.209609		3.5 3.8
		AA740994 AA741300		ESTs, Weakly similar to I38022 hypotheti	3.0 4.4
25		AA747807	Hs.149500		3.2
20		AA938198		poly(A) polymerase gamma	9.4
		AW293174	Hs.252627		4.4
		Al440266		ESTs, Weakly similar to T24832 hypotheti	3
	316868	AI660898	Hs.195602		3.2
30	316869	A1954880	Hs.134604	ESTs	3.2
		AA836331	Hs.134981		4.4
		AA838114	Hs.221612		3.7
		AW014875	Hs.137007		4.6
35		A1732892	Hs.190489 Hs.126036		5.9 4.1
33		AW445167 Al125252	Hs.126419		3.5
		A1806867	Hs.126594		5.1
		AA972965	Hs.135568		6.9
		AI822034	Hs.137097		4.6
40	317674	AW294909	Hs.132208	ESTs	4.3
		AW664964	Hs.128899		6.1
		X56348		ret proto-oncogene (multiple endocrine n	3.1
		Al681545		hypothetical protein FLJ13117	3.4
15		A1827248		Homo sapiens cDNA FLJ11469 fis, clone HE	9.6
45		AW102941	Hs.211265		4.1 10.3
		Al565071 AW294522	Hs.159983 Hs.149991		3.1
	-	A1077540	Hs.134090		3.9
		AW294013	Hs.200942		3
50		AI093930		Homo sapiens cDNA: FLJ21000 fis, clone C	4.4
•		AF107493		Homo sapiens LUCA-15 protein mRNA, splic	5.4
		AW402677		RNA binding motif protein, X chromosome	4.4
	318625	AA526235	Hs.193162	Homo sapiens cDNA FLJ11983 fis, clone HE	5.9
		T49598	Hs.156832		4
55		NM_002543	Hs.77729	oxidised low density lipoprotein (lectin	7.3
		AI793124	Hs.144479		17.8
		F11802	Hs.6818	ESTs	3
		NM_012391 Al524124	Hs.79414 Hs.270307	prostate epithelium-specific Ets transcr	3.6 4.6
60		W88532	Hs.254562		3.3
00		AA761668	113.201002	gb:nz24c08.s1 NCI_CGAP_GCB1 Homo sapiens	3.2
		T79366	Hs.108258	actin binding protein; macrophin (microf	3.3
		AA071267		gb:zm61g01.r1 Stratagene fibroblast (937	6.2
		C19035	Hs.164259	ESTs	3.3
65		AA534222		gb:nj21d02.s1 NCI_CGAP_AA1 Homo sapiens	4.3
		AA321166	Hs.278233		3.4
	320167	AA984373	Hs.90790	Homo sapiens cDNA: FLJ22930 fis, clone K	4.1

	320187	T99949	Hs.303428	Homo sapiens cDNA FLJ14832 fis, clone OV	5.3
		AL039402		DEME-6 protein	9.2
		Al026984	Hs.293662		3.1
		U78082		RNA polymerase II transcriptional regula	3.1
5		N50617	Hs.80506	small nuclear ribonucleoprotein polypept	6.1
5		Al160015	Hs.118112		3.5
				=	
		Al601188	Hs.120910		3
		AA214584	Hs.290167		3.7
4.0	320915	Al359144	Hs.143688	Homo sapiens cDNA: FLJ23031 fis, clone L	3.1
10	321016	BE144167	Hs.49994	hypothetical protein similar to RNA-bind	3.3
	321107	Al732643	Hs.144151	ESTs	12.3
	321171	AI769410	Hs.221461	ESTs	3.3
	321253	AA610649	Hs.333239	ESTs	3
		AB033041		vang (van gogh, Drosophila)-like 2	3.9
15		Al432199	Hs.247084		3
13		AW975944	Hs.237396		11.7
			Hs.197531		3.8
		Al471598			
		U29112	Hs.196151		4.4
20		D80630		gb:HUM091D02B Human fetal brain (TFujiwa	3.2
20		R59890	Hs.83623	nuclear receptor subfamily 1, group I, m	3.1
		H67065		ESTs, Weakly similar to ALU7_HUMAN ALU S	4.7
	321937	AL049351	Hs.302058	Homo sapiens mRNA; cDNA DKFZp566C093 (fr	3.5
	321978	N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5
	322035	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	19
25	322136	AF075083		gb:Homo sapiens full length insert cDNA	3.6
	322258	BE265745	Hs.194359	ESTs, Weakly similar to ALUC_HUMAN !!!!	3
		W76326		gb:zd60d04.r1 Soares_fetal_heart_NbHH19W	4.4
		Al357412	Hs.157601		11.5
		AW963372	Hs.46677	PRO2000 protein	3
30		T55958	113.40077	gb:yb35f05.r1 Stratagene fetal spleen (9	3
50		AF147347		gb:Homo sapiens full length insert cDNA	4.2
			Un 256160		4
		AF155108		Homo sapiens, Similar to RIKEN cDNA 2810	5.4
		W92147	Hs.118394		
25		AA017656		gb:ze39h01.r1 Soares retina N2b4HR Homo	3.1
35		AW068805		Homo sapiens cDNA FLJ12280 fis, clone MA	5.2
		AW043782	Hs.293616		7.6
		AW248508	Hs.279727	Homo sapiens cDNA FLJ14035 fis, clone HE	5.9
	322975	C16391		gb:C16391 Clontech human aorta polyA mRN	16.5
	323091	Al902456	Hs.210761	ESTs, Weakly similar to 138022 hypotheti	4
40	323131	AK002088	Hs.270124	Homo sapiens cDNA FLJ11226 fis, clone PL	3.3
	323168	AL120862	Hs.124165	programmed cell death 9 (PDCD9)	6.3
	323244	AW675572	Hs.193620		4.6
		AL133990	Hs.190642	ESTs	10.5
		A1829520		gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2
45		AV651680	Hs.208558		4.3
15		AI655499	Hs.161712		9.2
		AW445014	Hs.197746		3.1
					4
		BE081058	Hs.243023		3
50		AA317962		ESTs, Moderately similar to PC4259 ferri	
50		AW961560	Hs.97600	ESTs	3.2
		AA410943		BMP-R1B	8.4
	323930	AL043683	Hs.8173	hypothetical protein FLJ10803	3.3
	323974	AI825204	Hs.211408		4.5
		AL044949	Hs.116298	ESTs	4.5
55	324036	A1472078	Hs.303662	ESTs	8.4
	324261	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4
		AA431159	Hs.122954	ESTs	3
		Al524039	Hs.192524	ESTs	3
	324305	AA642007	Hs.116369		3.3
60	324432	AA464510	Hs.152812		16.5
50		AI823969	Hs.132678		3.3
					5
	324598	AW972227		Homo sapiens cDNA: FLJ22765 fis, clone K	
	324603	AW993522	Hs.292934		10.4
<i>(</i> =	324631	AA937116		ESTs, Weakly similar to I54374 gene NF2	3.3
65		BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.2
	324748	AW974941		ESTs, Weakly similar to I78885 serine/th	3
	324771	AA631739	Hs.335440	£81	3

	324823 324824	Al031771 AW516704 Al826999 AA704806	Hs.132586 Hs.208726 Hs.224624 Hs.143842	ESTs	4.2 3.4 3.1 4.4	
5	324961 324987	AA613792 AI375572 AI805416	Hs.172634 Hs.213897	gb:no97h03.s1 NCI_CGAP_Pr2 Homo sapiens ESTs	3.9 18.8 3.3	
	325146 325372	A1064690	Hs.171176	ESTs Phase 2 & 3 Exons	4.2 4.4	
10	325544			Phase 2 & 3 Exons	5.7	
	327075			Phase 2 & 3 Exons	3.8	
	332798 334223			C22000007:gi 12314195 emb CAB99338.1 (A NM_005080*:Homo sapiens X-box binding pr	4.3 26.2	
	334447		•	NM_012429*:Homo sapiens SEC14 (S. cerevi	3.9	
15	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1	
	335824 338255			ENSP00000249072*:DJ222E13.1 (N-TERMINAL NM_014323*:Homo sapiens zinc finger prot	20 9	
		R21945		splicing factor, arginine/serine-rich 5	4	
20		AW812795		ESTs, Moderately similar to I38022 hypot	4.6	
20		R97268 AA731602	Hs.177269 Hs.120266		3.2 3.9	
		BE382657	Hs.21486	signal transducer and activator of trans	4.1	
	453542	AW836724	Hs.339660	Homo sapiens mRNA expressed only in plac	3.7	
25		M97935 M97935		AFFX control: STAT1 AFFX control: STAT1	3.2 3	
20		M55150		fumarylacetoacetate	3	
		M13755		interferon stimulated protein; 15 kDa	4.5	
		Al052047 AA252033		ESTs ESTs; Weakly similar to !!!! ALU SUBFAMILY J	6.7 3.2	
30		AA401739		ESTs	3.3	
		H18459		hepatocellular carcinoma associated protein;	3 4.2	
		R48744 M31682		ESTs inhibin; beta B (activin AB beta polypeptide)	3	
		AA416873		ESTs	3	
35		D80240		HUM5G11A Human fetal brain (TFujiwara) Homo	4	
		R49590		ESTs CH22_FGENES.678_5	3.2 16.8	
				CH22_FGENES.619_7	12.9	
40				CH22_FGENES.619_12 CH22_EM:AC005500.GENSCAN.127 9	11.3 9.2	
40				CH22_EM:AC005500.GENSCAN:127 5	8.5	
				CH22_FGENES.271_8	8.4	
				CH22_FGENES.619_13 CH22_FGENES.271_7	8 7.3	
45				CH22_FGENES.271_7 CH22_FGENES.617_7	7.2	
				CH.07_hs gi 6004473	7.1	
		X03363		CH22_FGENES.264_1 HER2 receptor tyrosine kinase (c erbB 2; ERBB2; n	6.8 eu) 6.6	
		700000		CH22_FGENES.617_9	6.5	
50				CH.07_hs gi 5868264	5.8	
				CH.19_hs gi 5867439 CH22_FGENES.6 3	5.7 5.3	
				CH.17_hs gi 5867230	5.1	
<i>5 5</i>				CH.20_hs gi[6552458	5.1	
55				CH22_EM:AC005500.GENSCAN.148 22 CH22_FGENES.669_10	4.7 4.6	
		AA034918		KIAA1028 protein	4.6	
				CH22_FGENES.48_12	4.5	
60		AF049569		CH22_FGENES.118_2 ESTs	4.5 4.4	
00		M13955		multiple UniGene matches	4.3	
				CH22_FGENES.619_8	4.3	
		HG4126 HT43	196	CH22_FGENES.13 7	4.3 Zinc Finger Protein Hzf4	4.3
65				CH22_FGENES.360_3	4.3	
				CH22_FGENES.706_9	4.3	
				CH.21_hs gi 6531965	4.2	

		CH.17_hs gi 5867215	4.1 4.1	
	HG2614 HT2710	CH22_FGENES.669_8	4.1 Collagen, Type Viii, Alpha 1 4.1	
	1102014 11121 IU	CH22_FGENES.48_18	4.1	
5	X83535	matrix metalloproteinase 14 (membrane inserted)	4	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	CH22_FGENES.271_6	3.9	
		CH22_FGENES.617_3	3.9	•
		CH22_FGENES.290_8	3.8	
1.0	HG4716 HT5158		Guanosine 5' Monophosphate Synthase	3.8
10		CH22_FGENES.13 5	3.8	
		CH22_FGENES.13 2	3.8	
		CH.14_hs gi 6682474	3.8 3.8	
		CH.02_hs gi[5867750 CH22_FGENES.617_8	3.7	
15	HG4677 HT5102	01122_1 GENES.017_0	Oncogene Ret/Ptc2, Fusion Activated	3.7
10	1104077 1110102	CH22_DJ32I10.GENSCAN.23 39	3.7	
		CH22_FGENES.543_20	3.7	
		CH22_EM:AC005500.GENSCAN.96 1	3.7	
		CH22_FGENES.204_2	3.5	
20		CH22_FGENES.619_4	3.5	
		CH.16_hs gi 5867087	3.5	
	AA714311	EST cluster (not in UniGene)	3.4	
		CH22_EM:AC005500.GENSCAN.149 9	3.4 3.4	
25		CH22_EM:AC005500.GENSCAN.421 5 CH22_FGENES.13 4	3.3	
23		CH.07_hs gi 6004478	3.3	
		CH22_FGENES.360_1	3.3	
	HG2465 HT4871	0/122 04/120/000	Dna Binding Protein Ap 2, Alt. Splice 3	3.3
		CH22_FGENES.6_2	3.3	
30		CH22_C20H12.GENSCAN.16 2	3.2	
		CH22_C65E1.GENSCAN.8 1	3.2	
	AA707750	ESTs; Weakly similar to cis Golgi matrix	3.1	
		CH22_FGENES.307_4	3.1	
35		CH22_EM:AC005500.GENSCAN.248 14	3.1 3.1	
33		CH.06_hs gi 5902482 CH22_FGENES.669_5	3.1	
		CH22_FGENES.009_5 CH22_DJ32I10.GENSCAN.19 8	3.1	
		CH22_FGENES.527_6	3.1	
		CH22_FGENES.330_10	3.1	
40		CH22_FGENES.14 2	3.1	
	AA976074	ESTs	3	
		CH22_FGENES.226 7	3	
		CH22_FGENES.13 3	3	
15		CH22_EM:AC005500.GENSCAN.209 12	3 3 3	
45	4	CH22_FGENES.271_3	3	

TABLE 17A

Table 17A shows the accession numbers for those pkeys lacking unigeneID's for Table 17. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number

Accession:

Genbank accession numbers

AA046309 AI263500 AA046397

313591 103087_1

```
15
        Pkey
               CAT number Accession
        116845 393481_1
                            AA649530 AA659316 H64973
20
        103207 30635_-4
                            X72790
                            N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815
        126257
               182217 1
                            AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 Al636743 AW614951 BE467547 Al680833
        102791 37186_1
                            AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574
                            N25695 AW665466 Al818326 AA126128 Al480345 AW013827 AA248638 Al214968 AA204735 AA207155 AA206262 AA204833
25
                            AW003247 AW496808 Al080480 Al631703 Al651023 Al867418 AW818140 AA502500 Al206199 Al671282 Al352545 BE501030
                            Al652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048
                            AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 Al624817 BE466611 Al206344 AA574397
                            AA348354 Al493192
                            AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359
        126872 142696_1
30
                            BE011367 BE011368 BE011362 BE011215 BE011365 BE011363
        112631 1746257_1
                            R82040 R70934
        120742 176835_1
                            AA225084 AA302713
        106864 324239_1
                            Al311928 AA936030 T51931 AA609816 AA487195 AA664207
        109700 genbank_F09609
                                      F09609
35
        111532 genbank_R08440
                                      R08440
        113938 genbank_W81598
                                      W81598
               genbank_W84768
        113947
                                      W84768
               genbank_N22401
        124357
                                      N22401
                            AA121022 AA126422
        108733 504187_1
40
        112303 genbank_R54797
                                      R54797
                            AF075083 H52291 H52528
        322136 46802 1
                            W76326 AF086341 W72300
        322296 47334 1
        321811 1527481_1
                            D80630 D80896 D80895
                            AW979268 AA878419 AA431342 AA431628
        314648 293660_1
45
        322520
               38916 1
                            T55958 T57205 AF147346
        322521
               38917 1
                            AF147347 T55426 T55503
                            AA017656 AA017374 AA019761
        322675 86787_1
                            Al829520 Al791832 AA228414 Al791823 AA229211 AA229315
        323332
               179142_1
        316186 425440_1
                            AI433540 AA728984 AA804981
50
        322975 1510563_1
                            C16391 C16413
                            BE069341 AW748403 AL044891 Al908240 AA393080
        324261 273265_1
        323817 233566_1
                            AA410943 AW948953 AA334202 AA332882
        301976 128835 1
                            T97905 AA101672
                            AA613792 AW182329 T05304 AW858385
        324961 376239_1
55
        303642 284260_1
                            AW299459 AA417112
               386364_1
                            AW629759 AW749955 AA633408 Al651005
        303797
        319551 357371 1
                            AA761668 AA573621 R92814 R09670
                            AA216387 T63548 AA228676
        311935 174129 1
                            AA071267 T65940 T64515 AA071334
        319834
               112523_1
60
        319977 345248_1
                            AA534222 AA632632 T81234
        314138 179960_1
                            AA740616 AA654854 AA229923
```

308106 Al476803
338255 CH22_6856FG__LINK_EM:AC00
335809 CH22_3181FG_617_6_LINK_EM
335824 CH22_3197FG_619_11_LINK_E

5 307010 Al140014
307041 Al144243
305913 AA876109
305917 AA876469
309574 AW168083

10 325372 c12_hs
325544 c12_hs
32798 CH22_14FG_6_5_LINK_C4G1.G
334223 CH22_1507FG_360_4_LINK_EM
327075 c21_hs
327075 c21_hs
334447 CH22_1746FG_387_7_LINK_EM
304782 AA582081
313434 441798_1 W92070 AW019952 W92053

TABLE 17B

Table 17B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 17. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Nt_position
20	335809 335824 332798	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al.	Plus	14308764-14308824 26310772-26310909 26376860-26376942 232147-231974 12734365-12734269
25	338255 325372 325544	Dunham, I. et.al. 5866920 6682452 6531965	Minus Minus Plus Plus	15242294-15242231 1117061-1117304 171228-171286 4041318-4041431

TABLE 18: Table 2 from BRCA 014 P

Table 18 shows genes with atleast five times the expression in breast tumor tissue than is expressed in normal body tissues. 5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number

Pkey: ExAccn: UnigeneID: Unigene Title: R1: 10

Unigene number

Unigene gene title Ratio of tumor to normal body tissue

15	Pkey	ExAccn	UnigenelD	Unigene Title	R1
		BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
20		M81057	Hs.180884	carboxypeptidase B1 (tissue)	12
20		M97815 X52509	Hs.183650 Hs.161640	cellular retinoic acid-binding protein 2 tyrosine aminotransferase	6.5 12.4
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
		AA035613	Hs.141883	ESTs	6.9
		AW963419		stanniocalcin 2	5.3
25		AA011449	Hs.271627	ESTs	6.1
		AB033064	Hs.334806	KIAA1238 protein	7.3
		A1791493	Hs.129873	ESTs, Weakly similar to A36036 cytochrom	8.2
		R82331	Hs.164599	ESTs	5.4
	113206	BE262470	Hs.241471	RNB6	6.2
30	113970	W27249	Hs.8109	hypothetical protein FLJ21080	6.9
		Al733881	Hs.72472	BMP-R1B	10.1
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	19.7
		AW449064		collagen, type III, alpha 1 (Ehlers-Dani	8.4
25	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	5.6
35		AF182277	Hs.330780	cytochrome P450, subfamily IIB (phenobar	6.2
		Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	6.2 5.8
		D89377 AW183618	Hs.89404	msh (Drosophila) homeo box homolog 2 solute carrier family 30 (zinc transport	9.9
		AW 103010 AA312082	Hs.105445	GDNF family receptor alpha 1	5.7
40		AB020711	Hs.278346	KIAA0904 protein	7.7
70		BE542706		CEGP1 protein	7.3
		AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	5.4
		AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (
		AL117406	Hs.200102	ATP-binding cassette transporter MRP8	6.7
45		AJ224172	Hs.204096	lipophilin B (uteroglobin family member)	13.8
		AI951118	Hs.326736	Homo sapiens breast cancer antigen NY-BR	17.3
	309583	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	57.6
		A1380797	Hs.158992	ESTs	10.2
- 0	311166	Al821005	Hs.118599	ESTs	10.8
50		AA216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
		BE261944	Hs.118625	hexokinase 1	5.2
			Hs.105445	GDNF family receptor alpha 1	12.4
		C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
<i>- -</i>		AA648744	Hs.269493	ESTS	6.6
55		AA740616	Un nococo	gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	
		AA833655	Hs.206868	Homo sapiens cDNA FLJ14056 fis, clone HE	8.5 27.4
		A1873274	Hs.190721 Hs.136319	ESTs ESTs	20.7
		AV207200 AI538613	Hs.298241	Transmembrane protease, serine 3	10.9
60			Hs.312989	ESTs	5.3
50	315051		Hs.163484	ESTs	12.9

	315196	AI367347	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA sequ	18.2
	315530	AW015415	Hs.127780	ESTs	8.9
	315634	AA837085	Hs.220585	ESTs	6.3
	316012	AA764950	Hs.119898	ESTs	7
5	316177	A1904982	Hs.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7
	316580	AA938198	Hs.146123	poly(A) polymerase gamma	9.4
	317803	AW664964	Hs.128899	ESTs	6.1
	317881	A1827248	Hs.224398	Homo sapiens cDNA FLJ11469 fis, clone HE	9.6
		NM_002543		oxidised low density lipoprotein (lectin	7.3
10		AI793124	Hs.144479	ESTs	17.8
		AL039402		DEME-6 protein	9.2
	321107	AI732643	Hs.144151	ESTs	12.3
	321644	AW975944		ESTs	11.7
	321978	N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5
15		AL137517		hypothetical protein DKFZp564O1278	19
		AW068805		Homo sapiens cDNA FLJ12280 fis, clone MA	5.2
		AW043782		ESTs	7.6
	322975			gb:C16391 Clontech human aorta polyA mRN	16.5
	323262	AL133990	Hs.190642	ESTs	10.5
20		AI829520		gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2
	323817	AA410943		BMP-R1B	8.4
		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4
	324432	AA464510	Hs.152812	ESTs	16.5
	324598	AW972227	Hs.163986	Homo sapiens cDNA: FLJ22765 fis, clone K	5
25	324603	AW993522	Hs.292934	ESTs	10.4
	324987	AI375572	Hs.172634	ESTs	18.8
	325544			Phase 2 & 3 Exons	5.7
	330388		Hs.46	HER2 receptor tyrosine kinase (c-erb-b2,	6.6
	334223			NM_005080*:Homo sapiens X-box binding pr	26.2
30	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1
	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL	20
		AI052047			6.7
		R72427			5.5
					9.2
35					8
					6.5
					7.3
				CH22_FGENES,271_8	12.9
					8.4
40					11.3
		•			8.5
					7.1
					7.2
					16.8

TABLE 18A

Table 18A shows the accession numbers for those pkeys lacking unigeneID's for Table 18. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

Gene cluster number

334223 CH22_1507FG_360_4_LINK_EM

Accession: Genbank accession numbers

	Pkey	CAT number	Accession
	323332	179142_1	Al829520 Al791832 AA228414 Al791823 AA229211 AA229315
20	322975	1510563_1	C16391 C16413
	324261	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	323817	233566_1	AA410943 AW948953 AA334202 AA332882
	311935	174129_1	AA216387 T63548 AA228676
	314138	179960_1	AA740616 AA654854 AA229923
25	335809	CH22_3181FG_	617_6_LINK_EM
	335824	CH22 3197FG	619 11 LINK E
	325544	c12 hs	·

TABLE 18B

Table 18B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 18. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Sequen	ce source.	responding to an Eos probeset The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.		
15	Strand: Nt_posit		Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.			
	Pkey	Ref	Strand	Nt_position		
	335800	Dunham Lotal	Diuc	26340772 26340000		

TABLE 19: 1045 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES

Table 19 shows 1045 genes up-regulated in breast cancer compared to normal adult tissues. These were selected from 59680 probesets on the Affymetrix/Eos-Hu03 GeneChip array such that the ratio of "average" breast cancer to "average" normal adult tissues was greater than or equal to 2.5. The "average" breast cancer level was set to the 90th percentile value. The "average" normal adult tissue level was set to the 90th percentile value amongst 144 non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst the 144 non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated.

15	Pkev:	Unique Eos probeset identifier number
13	rkey.	Offique Eos probeset identifier frumber
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title

R1: Ratio of tumor to normal body tissue

	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	408591	AF015224	Hs.46452	mammaglobin 1	137.6
25	406964			gb:Human alpha satellite and satellite 3	71.0
	400291	AA401369	Hs.190721		68.4
	407277	AW170035		Homo sapiens breast cancer antigen NY-BR	54.2
	449746	Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	
•		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	
30		AA250737	Hs.72472	BMP-R1B	37.4
	427585		Hs.179729		32.9
		AW138959	Hs.245123		31.9
		AA195651	Hs.104106		30.4
~ ~	407377			gb:C16391 Clontech human aorta polyA mRN	27.7
35	450705		Hs.25351	iroquois homeobox protein 5	24.8
	407212	AA412108	Hs.269350		22.0
		NM_000230	Hs.194236		21.9
	404561			trichorhinophalangeal syndrome I (TRPS1)	21.8
4.0		AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
40		Al375572			17.3
		AA009647	Hs.8850	a disintegrin and metalloproteinase doma	16.6
	422109	S73265	Hs.1473	gastrin-releasing peptide	16.5
		AW840171	Hs.265398	ESTs, Weakly similar to transformation-r	16.0
		A1263307			15.8
45	420813	X51501	Hs.99949	prolactin-induced protein	15.8
		Al267700	Hs.317584		15.5
		AL120862	Hs.124165	programmed cell death 9 (PDCD9)	14.8
		Al905687	Hs.2533	aldehyde dehydrogenase 9 family, member	14.5
~ ^	423575		Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	13.7
50		AJ224172	Hs.204096		13.6
		AL133990	Hs.190642		13.5
	448595	AB014544	Hs.21572	KIAA0644 gene product	13.0
	427217	AA399272	Hs.144341		12.8
	402578			C1001134:gi 2117372 pir I65981 fatty ac	12.6
55	422805	AA436989	Hs.121017	H2A histone family, member A	12.2
	424634	NM_003613	Hs.151407		12.0
	456207	AA193450		gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	11.9
	424086	Al351010	Hs.102267	lysyl oxidase	11.9
	459587	AA031956		gb:zk15e04.s1 Soares_pregnant_uterus_NbH	11.5

	416208	AW291168	Hs.41295	ESTs, Weakly similar to MUC2_HUMAN MUCIN	11.5
		NM_001394	Hs.2359	dual specificity phosphatase 4	11.5
	407276	A1951118	Hs.326736		11.4
	434377	AW137148	Hs.306593	Homo sapiens cDNA FLJ11382 fis, clone HE	11.3
5	448390	AL035414	Hs.21068	hypothetical protein	11.1
		NM_007115	Hs.29352	tumor necrosis factor, alpha-induced pro	11.0
		A1684808		programmed cell death 9 (PDCD9)	10.9
		N78223		transcription factor	10.7
		AW873596	Hs.182278		10.6
10		H87879			10.5
10		H01019	Hs.102267		
	402606	A A E 700E0	11- 00070	NM_024626:Homo sapiens hypothetical prot	10.4
		AA576953	Hs.22972	hypothetical protein FLJ13352	10.4
		Al370413	Hs.36563	hypothetical protein FLJ22418	10.3
1 ~		Al357412	Hs.157601		10.2
15		W72838	Hs.2533	aldehyde dehydrogenase 9 family, member	10.1
	424905	NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related k	10.1
	432441	AW292425	Hs.163484	ESTs	9.9
	427365	AI873274	Hs.190721	ESTs	9.9
	438950	H23789	Hs.144530	EST	9.8
20	422835	BE218705	Hs.121378	metallothionein-like 5, testis-specific	9.7
	425692	D90041		N-acetyltransferase 1 (arylamine N-acety	9.7
		W20027	Hs.23439	ESTs	9.6
		AL360204		Homo sapiens mRNA full length insert cDN	9.6
		AI624342	Hs.170042	FSTs	9.5
25		Al907673	710.770072	gb: L-BT152-080399-004 BT152 Homo sapien	9.3
20		Al267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082 (fr	
		AJ224741	Hs.278461		9.1
			Hs.334473		9.1
		AI127076		• • • • • • • • • • • • • • • • • • • •	
30		D60730	Hs.57471	ESTS	9.1
30		AA410943		gb:zt32h03.r1 Soares ovary tumor NbHOT H	9.1
	406348	1104075	11 070400	Target Exon	9.0
		U31875		short-chain alcohol dehydrogenase family	9.0
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	9.0
25		AF026944	Hs.293797		8.8
35	405654			C12001521:gi 7513934 pir T31081 cca3 pr	8.8
	418601	AA279490	Hs.86368	calmegin	8.8
		A1955040	Hs.265398	ESTs, Weakly similar to transformation-r	8.7
	408771	AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.5
	409041	AB033025	Hs.50081	KIAA1199 protein	8.4
40	442353	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	8.3
	451561	N52812	Hs.177403		8.2
	424001	W67883	Hs.137476	paternally expressed 10	8.2
		NM_007050		protein tyrosine phosphatase, receptor t	8.1
		AL080207		DKFZP434G232 protein	8.1
45	405095			Target Exon	8.1
		AA236115	Hs.120785		8.0
		AF026941	Hs.17518	Homo sapiens cig5 mRNA, partial sequence	8.0
		BE242870	Hs.75379	solute carrier family 1 (glial high affi	8.0
		AW876523	Hs.15929	hypothetical protein FLJ12910	8.0
50		R17798	Hs.7535	COBW-like protein	7.9
50		AI811202		Homo sapiens cDNA: FLJ23523 fis, clone L	7.9
		AF044197			7.9
			HS. 100431	small inducible cytokine B subfamily (Cy matrix metalloproteinase 11 (MMP11; stro	
		M31126	⊓S.27 2020		7.8
55	400285		11 45000	Eos Control	7.7
33		T27503	Hs.15929	hypothetical protein FLJ12910	7.6
		AW880562	Hs.114574	ESIS	7.5
		AW976987		ESTs, Weakly similar to 2109260A B cell	7.5
		H69125	Hs.133525		7.5
CO		Al222020		CocoaCrisp	7.4
60	426214	H59846		ESTs, Moderately similar to ALU7_HUMAN A	7.4
	447475	Al380797	Hs.158992	ESTs	7.3
	415263	AA948033	Hs.130853	ESTs	7.2
		AW602166		CEGP1 protein	7.2
		AW368397	Hs.150042	Homo sapiens cDNA FLJ14438 fis, clone HE	7.1
65		AW242243		peroxisomal farnesylated protein	7.0
		AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act	6.9
		AI734009		KIAA1603 protein	6.9
	77000	, 41,04000		···· ········ process	

	400 400	410=00=0			
		AI678059		synaptonemal complex protein 2	6.9
		Al375672	Hs.165028		6.9
		A1732643	Hs.144151	· ·	6.9
_	421373	AA808229	Hs.167771	ESTs	6.8
5	451398	Al793124	Hs.144479	ESTs	6.8
	404253			NM_021058*:Homo sapiens H2B histone fami	6.8
	441098	Al015591	Hs.131004	ESTs, Weakly similar to T17227 hypotheti	6.7
	426215	AW963419	Hs.155223	stanniocalcin 2	6.6
	428227	AA321649	Hs.2248	small inducible cytokine subfamily B (CX	6.6
10		BE545072	Hs.122579	hypothetical protein FLJ10461	6.6
		AW818127		gb:CM1-ST0277-061299-059-b07 ST0277 Homo	
		Al418055	Hs.161160		6.6
		Al733682	Hs.130239		6.6
		Al970394	Hs.197075		6.6
15			Hs.620		
13		L11690		bullous pemphigoid antigen 1 (230/240kD)	6.5
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	6.5
		BE041395		ESTs, Weakly similar to unknown protein	6.5
	400301		Hs.1657	estrogen receptor 1	6.5
20		AW023482	Hs.97849	ESTs	6.5
20	425704	U79293	Hs.159264	Human clone 23948 mRNA sequence	6.4
	441134	W29092	Hs.7678	cellular retinoic acid-binding protein 1	6.4
	424902	NM_003866	Hs.153687	inositol polyphosphate-4-phosphatase, ty	6.4
	448693	AW004854	Hs.228320	hypothetical protein FLJ23537	6.4
		AL137517		hypothetical protein DKFZp564O1278	6.2
25		NM_014398	Hs.10887	similar to lysosome-associated membrane	6.1
		AA586894		S100 calcium-binding protein A7 (psorias	6.1
		Al240665	Hs.8895	ESTs (poorlab	6.1
		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; inters	6.0
					6.0
30		AA972965	Hs.135568		
50	418092		Hs.106604		6.0
		AA464510	Hs.152812		5.9
		AA310693		HSPC072 protein	5.9
		AW975944	Hs.237396		5.9
0.5		H39960		Homo sapiens cDNA FLJ12280 fis, clone MA	5.9
35	425707	AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	5.9
	410785	AW803341		gb:IL2-UM0079-090300-050-D03 UM0079 Homo	5.9
	425398	AL049689	Hs.156369	hypothetical protein similar to tenascin	5.9
	414812	X72755	Hs.77367	monokine induced by gamma interferon	5.8
	459371	R20991		gb:yg06h01.r1 Soares infant brain 1NIB H	5.8
40		N28519	Hs.135191	ESTs, Weakly similar to unnamed protein	5.8
		AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.8
		W52854	Hs.27099	hypothetical protein FLJ23293 similar to	5.7
		AW162916		hypothetical protein PRO2577	5.7
		AI733881			5.6
15			Hs.72472		
45		AW016531	Hs.122147		5.6
		AW067903	Hs.82772		5.5
		AA463893	Hs.220933		5.5
		R41396		. • 1	5.5
		AW299598	Hs.50895	homeo box C4	5.4
50	434539	AW748078	Hs.214410	ESTs, Weakly similar to MUC2_HUMAN MUCIN	5.4
		A1742605	Hs.193696		5.4
	453931	AL121278	Hs.25144	ESTs	5.4
		BE246919	Hs.10290	U5 snRNP-specific 40 kDa protein (hPrp8-	5.4
	447102	BE167434	Hs.98471	ESTs, Weakly similar to T18712 hypotheti	5.4
55		A1879148	Hs.26770	fatty acid binding protein 7, brain	5.4
		AW067800	Hs.155223	stanniocalcin 2	5.3
		AA291553	Hs.190086		5.3
		AW970060	1.01.100000	gb:EST382140 MAGE resequences, MAGK Hom	
		AA421081	Hs.12388	ESTs	5.3
60					5.3
UU		U65011	Hs.30743	preferentially expressed antigen in mela	
		AB028945	Hs.12696	cortactin SH3 domain-binding protein	5.3
	456938			tyrosine aminotransferase	5.3
	422867		Hs.1584	cartilage oligomeric matrix protein (COM	5.2
C =		R28363	Hs.24286	ESTs	5.2
65		AW207084	Hs.132816	hypothetical protein MGC14801	5.2
		N92293		ESTs, Moderately similar to ALU8_HUMAN A	5.2
	416276	U41060	Hs.79136	LIV-1 protein, estrogen regulated	5.2

	400000	V00000		LIEDO es contantementos biseses (e este bo	E 0
		X03363	L)- 07500	HER2 receptor tyrosine kinase (c-erb-b2,	5.2
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	5.2
		AW449211		GDNF family receptor alpha 1	5.2
5		AB028992	HS.193143	KIAA1069 protein	5.2
)		AW852530	11. 000040	gb:PM1-CT0243-071099-001-g06 CT0243 Homo	
		AW851980		ESTs, Weakly similar to S72482 hypotheti	5.2
		AI916269		ESTs, Weakly similar to ALU5_HUMAN ALU S	5.1
		AA032279	Hs.61635	six transmembrane epithelial antigen of	5.1
1.0		Al283133	Hs.297420		5.1
10		Al791495		calmodulin-like skin protein	5.1
		A1798680	Hs.25933	ESTs	5.1
		AA642007	Hs.116369		5.1
		AW207206	Hs.136319		5.1
15	405494		11- 404007	C2001837*:gi[12697903]db][BAB21770.1] (A ESTs, Weakly similar to l38022 hypotheti	5.1 5.1
13		AW195285 Al201849	пs. 19409 <i>1</i>	gb:qs76g04.x1 NCI_CGAP_Pr28 Homo sapiens	
		X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.0
		BE387335		ESTs, Weakly similar to S64054 hypotheti	5.0
		R43646	Hs.12422	ESTs	5.0
20		W02414	Hs.38383	ESTs	5.0
20		AW665281	Hs.224625		5.0
		AA236776	Hs.79078	MAD2 (mitotic arrest deficient, yeast, h	5.0
		AK000713		hypothetical protein FLJ20706	5.0
		AW512260	Hs.87767	ESTs	4.9
25		X82125	Hs.25040	zinc finger protein 239	4.9
		AJ003029	Hs.65792	syntrophin, gamma 2	4.9
		M30703		amphiregulin (schwannoma-derived growth	4.9
		AI655499	Hs.161712		4.8
		AI820662	Hs.129598		4.8
30		AF220050		uncharacterized hematopoletic stem/proge	4.8
	400286			C16000922:gi 7499103 pir T20903 hypothe	4.8
	407506	U71600		gb:Human zinc finger protein zfp31 (zf31	4.8
	420026	Al831190	Hs.166676	ESTs	4.8
	441377	BE218239	Hs.202656	ESTs	4.8
35	457726	Al217477	Hs.194591	ESTs	4.8
	412785	AW997556	Hs.78521	KIAA1717 protein	4.8
	428368	BE440042	Hs.83326	matrix metalloproteinase 3 (stromelysin	4.7
	436026	AI349764	Hs.217081	ESTs	4.7
4.0	409110	AA191493	Hs.48778	niban protein	4.7
40	400284			estrogen receptor 1	4.7
		AW248508		Homo sapiens cDNA FLJ14035 fis, clone HE	4.7
		R42185	Hs.274803		4.7
		BE062109		chloride channel, calcium activated, fam	4.7
15		AW961489	Hs.154116	and the second s	4.7
45		NM_003462	Hs.33846	dynein, axonemal, light intermediate pol	4.7
		AF077345	Hs.177936		4.6 4.6
		AW813731		ESTs, Moderately similar to S65657 alpha	4.6
		R63503	Hs.28419	ESTs C4000700*:~;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;	4.6
50	405718	AW207523	Hs.197628	C4000799*:gi 6330365 dbj BAA86508.1 (AB	4.6
50		Z40313		Homo sapiens clone IMAGE:23371, mRNA seq	4.6
		M81057		carboxypeptidase B1 (tissue)	4.6
		Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	4.6
		AK000282		hypothetical protein FLJ20275	4.6
55		AW855717	110.200001	gb:RC1-CT0279-081299-013-b01 CT0279 Homo	
		AA242758	Hs.79136	LIV-1 protein, estrogen regulated	4.6
		AA808189	Hs.272151		4.6
		AW936273		gb:QV0-DT0020-090200-107-g07 DT0020 Homo	4.6
		AL036877	Hs.282878		4.6
60		AA514660	Hs.128443		4.6
		H15261	Hs.21948	ESTs	4.6
		AW246333	Hs.17901	Homo sapiens, clone IMAGE:3937015, mRNA,	4.6
	445537	AJ245671	Hs.12844	EGF-like-domain, multiple 6 (EGFL6)	4.5
~ =	424590	AW966399	Hs.46821	hypothetical protein FLJ20086	4.5
65	432374	W68815	Hs.301885	Homo sapiens cDNA FLJ11346 fis, clone PL	4.5
		AW503329		gb:UI-HF-BN0-akx-e-02-0-UI.r1 NIH_MGC_50	4.5
	406747	AI925153	Hs.217493	annexin A2	4.5

	412102	H56435		gb:yq98e09.r1 Soares fetal liver spleen	4.5
	431716	D89053	Hs.268012	fatty-acid-Coenzyme A ligase, long-chain	4.5
	411050	AW814902		gb:MR1-ST0206-120400-022-f08 ST0206 Homo	
_	401418			C14000338*:gi 7459502 pir S74665 outer	4.5
5		AK001074		Homo sapiens cDNA FLJ10212 fis, clone HE	4.5
		AK001581		hypothetical protein FLJ10719; KIAA1794	4.4
		AA135257	Hs.47783	B aggressive lymphoma gene	4.4
		AA335497		ESTs, Weakly similar to 138022 hypotheti	4.4
10		AW419196		hypothetical protein FLJ13782	4.4 4.4
10		AW664964 BE463857	Hs.128899	hypothetical protein FLJ21062	4.4
		R31178		fibronectin 1	4.4
		AW905138	113,201020	gb:QV0-NN1071-280400-207-g07 NN1071 Homo	
	405196			C2000662*:gi[7512792]pir] T12482 hypothe	4.4
15		N47863	Hs.336901	ribosomal protein S24	4.4
	401793			C17001545:gì 5360127 gb AAD42882.1 AF155	4.4
		AA381209		gb:EST94257 Activated T-cells I Homo sap	4.4
		AB007975	Hs.131454	KIAA0506 protein	4.4
	400238	NA		C19000274*:gi 12741327 ref XP_008833.2	4.4
20	425627	AF019612	Hs.297007	membrane-bound transcription factor prot	4.4
	400608			C10001899:gi 7508633 pir T25392 hypothe	4.4
		AV657310	Hs.282898		4.3
		AL138272	Hs.62713	ESTs	4.3
25	405906 405925			Target Exon	4.3 4.3
23		BE247684	Hs.103070	Target Exon	4.3
		H57646	Hs.42586	KIAA1560 protein	4.3
		N63855		zinc finger protein	4.3
		AA603305	110.112001	gb:np12d11.s1 NCI_CGAP_Pr3 Homo sapiens	4.3
30		N71277		gb:za36e03.s1 Soares fetal liver spleen	4.3
		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	4.2
	450715	A1266484	Hs.31570	ESTs, Weakly similar to KIAA1324 protein	4.2
	421451	AA291377	Hs.50831	ESTs	4.2
2 ~		AA033714		hypothetical protein FLJ14260	4.2
35		NM_001898	Hs.123114	cystatin SN	4.2
		BE158766		gb:IL2-HT0397-071299-024-F02 HT0397 Homo	
		BE144884	Ua 0470	gb:CM0-HT0182-041099-065-e11 HT0182 Homo	4.2
		BE538082 AF123050	Hs.8172 Hs.44532	ESTs, Moderately similar to A46010 X-lin diubiquitin	4.2
40		S82472	113,44332	gb:beta -pol=DNA polymerase beta {exon a	4.2
40	404285			C6001909:gi 704441 dbi BAA18909.1 (D298	4.2
		NM_005940	Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.2
		AW812795		ESTs, Moderately similar to 138022 hypot	4.2
		AA026880	Hs.25252	prolactin receptor	4.2
45	421147	AW592167	Hs.293299	ESTs	4.2
		Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	4.2
		AW821113	Hs.72402	ESTs	4.2
		AA024538		Human DNA sequence from clone RP1-28H20	4.2
50		AW378065	Hs.8687	ESTS	4.2
50		AI085198	Hs.164226		4.2
		AB007948	MS. 100244	KIAA0479 protein matrix metalloproteinase 9 (gelatinase B	4.1 4.1
	424687	J05070 AA894564	Hs.22242	ESTs	4.1
		AA634806	10.22272	gb:ab28c02.r1 Stratagene lung (937210) H	4.1
55		BE241831	Hs.172330	hypothetical protein MGC2705	4.1
		R18717	Hs.8929	hypothetical protein FLJ11362	4.1
	455700	BE068115		gb:CM1-BT0368-061299-060-g07 BT0368 Homo	4.1
	431924	AK000850	Hs.272203	Homo sapiens cDNA FLJ20843 fis, clone AD	4.1
		AI886558	Hs.184987		4.1
60	401451			NM_004496*:Homo sapiens hepatocyte nucle	4.1
	431676	AI685464	1) 45000	gb:tt88f04.x1 NCI_CGAP_Pr28 Homo sapiens	4.1
		Al735283	Hs.172608		4.1
	429270	W60379	Hs.57773 Hs.135223	ESTs	4.1 4.1
65	443903	AI220547 AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	4.1
05	421 122	U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.1
	432912	BE007371	Hs.200313		4.1

	403585			Target Exon	4.1
		Al394151	Hs.37932	ESTs	4.1
		AA640891	Hs.102406		4.1
_		BE264901		carbonic anhydrase VIII	4.1
5		NM_004354	Hs.79069	cyclin G2	4.1
	400555	AA296520	Hs.89546	selectin E (endothelial adhesion molecul Target Exon	4.1 4.1
	410079	1194362	Hs.58589	glycogenin 2	4.0
		NM_003528	Hs.2178	H2B histone family, member Q	4.0
10		AA448460	Hs.112017	GE36 gene	4.0
		AL359055	Hs.67709		4.0
		AL117406		ATP-binding cassette transporter MRP8	4.0
		NM_002666 AA228776	Hs.103253	·	4.0 4.0
15		AW954552	Hs.191721	zinc finger protein	4.0
10		AW938484	113,172004	gb:CM0-DT0057-290200-253-d06 DT0057 Homo	
	404142			Target Exon	4.0
	441143	Al027604	Hs.159650	ESTs	4.0
20		AI693927	Hs.265165		4.0
20		AA165232	Hs.222069		4.0
	452891		HS.2128/5	ESTs, Weakly similar to DYH9_HUMAN CILIA gb:601283601F1 NIH_MGC_44 Homo sapiens c	4.0 4.0
	452281	BE390440	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.0
		AA417383	Hs.82582	integrin, beta-like 1 (with EGF-like rep	4.0
25		Al281848		retinoic acid induced 3	4.0
	447377		Hs.334334	transcription factor AP-2 alpha (activat	4.0
		AL119723		gb:DKFZp761A2124_r1 761 (synonym: hamy2)	4.0
		AA356170	Hs.26750	hypothetical protein FLJ21908	4.0
30		Al591147 Al741122	Hs.61232	ESTs Homo sapiens cDNA FLJ14232 fis, clone NT	4.0 4.0
50		N99626	113.101010	gb:za39d11.r1 Soares fetal liver spleen	4.0
		Al199738	Hs.208275	ESTs, Weakly similar to ALUA_HUMAN !!!!	4.0
	452166	AI948607	Hs.264680		4.0
0.5		AF153330	Hs.30246	solute carrier family 19 (thiamine trans	3.9
35		AA263143	Hs.24596	RAD51-interacting protein	3.9
	406554		Un 40479	Target Exon	3.9 3.9
	445813	AA573006	Hs.19173	ESTs alanine-glyoxylate aminotransferase 2-li	3.9
		AA442176	113.100370	gb:zw63b08.r1 Soares_total_fetus_Nb2HF8_	3.9
40		M86153	Hs.75618	RAB11A, member RAS oncogene family	3.9
	401781			Target Exon	3.9
	415296		Hs.328142		3.9
		AA026777	11- 000400	gb:ze93c11.r1 Soares_fetal_heart_NbHH19W	3.9
45	442500	AI819068	Hs.209122	actin related protein	3.9 3.9
73		Al472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	3.9
		AF086534		ESTs, Moderately similar to ALU1_HUMAN A	3.9
	428042	AA419529	Hs.76391	myxovirus (influenza) resistance 1, homo	3.9
5 0		AB037791	Hs.29716	hypothetical protein FLJ10980	3.9
50		BE537217	Hs.30343	ESTs	3.9
		BE568414	Hs.14549/ Hs.133916	Homo sapiens cDNA: FLJ22097 fis, clone H	3.9 3.9
		AI073512 BE152428	HS.133910	gb:CM0-HT0323-151299-126-b04 HT0323 Homo	
	401785	DE 132420		NM_002275*:Homo sapiens keratin 15 (KRT1	3.9
55		M86699	Hs.169840	TTK protein kinase	3.9
		AI989885	Hs.231926	ESTS	3.9
	436033		Hs.255748		3.9
		BE172186	00074	gb:MR0-HT0559-110300-005-h11 HT0559 Homo	
60		AA236645 AI184268	Hs.98274 Hs.339665	ESTS	3.8
00		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3.8
	403593		, 10.1 0020	Target Exon	3.8
		AW016669	Hs.29190	ESTs	3.8
	419854	AW664873	Hs.87836	Homo sapiens PAC clone RP5-1087M19 from	3.8
65		W02410	Hs.205555		3.8
		AI217928	Hs.144762	ESIS	3.8
	409542	AA503020	Hs.36563	hypothetical protein FLJ22418	3.8

		T49951	Hs.9029	DKFZP434G032 protein	3.8
	458194	AW383618		ESTs, Moderately similar to ALU2_HUMAN A	3.8
	422475	AL359938	Hs.117313	Meis (mouse) homolog 3	3.8
	440705	AA904244	Hs.153205	ESTs	3.8
5	447290	Al476732	Hs.263912	ESTs	3.8
_	403426			Target Exon	3.8
		AA470158	Hs.98202	ESTs	3.8
		BE222648		ESTs, Highly similar to c380A1.1b [H.sap	3.8
		AW206942	Hs.253594		3.8
10					3.8
10		AW105231	Hs.192035		
		AW794600	11 404040	gb:RC6-UM0014-170300-022-C05 UM0014 Hon	
		NM_005756		G protein-coupled receptor 64	3.8
		BE622641	Hs.38489		3.8
1.5		Al742618	Hs.181733	ESTs, Weakly similar to nitrilase homolo	3.7
15	401747			Homo sapiens keratin 17 (KRT17)	3.7
	420633	NM_014581		odorant-binding protein 2A	3.7
	423545	AP000692	Hs.129781	chromosome 21 open reading frame 5	3.7
,	433138	AB029496	Hs.59729	semaphorin sem2	3.7
	434715	BE005346	Hs.116410	ESTs	3.7
20	428664	AK001666	Hs.189095	similar to SALL1 (sal (Drosophila)-like	3.7
	450951	AA018534	Hs.103334		3.7
	402696	NA		C3002523:gi[6686211 sp]Q27533 YH2M_CAEEI	_3.7
	446868	AV660737	Hs.135100		3.7
	458154	AW816379	Hs.335018	ESTs .	3.7
25	422026	U80736	Hs.110826	trinucleotide repeat containing 9	3.7
		AB020689	Hs.90419		3.7
		AA312082		GDNF family receptor alpha 1	3.7
		N62840	Hs.48648	ESTs	3.7
	401508			NM_024817:Homo sapiens hypothetical prot	3.7
30		AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7
20		U79734	Hs.97206	huntingtin interacting protein 1	3.7
		AI021992	Hs.124244		3.7
		AA629065	Hs.116301		3.7
		R55373	Hs.20864	ESTs	3.7
35			HS.20004	gb:601441282F1 NIH_MGC_72 Homo sapiens of	
33		BE623004	LI= 407070		3.7
		Al347502		hypothetical protein FLJ20761	3.7
		T32982	Hs.102720		
	405232	A) 400704	11- 044550	NM_015832:Homo sapiens methyl-CpG bindin	3.7
40		AL109791	MS.241559	Homo sapiens mRNA full length insert cDN	3.7
40		BE011668		gb:CM3-BN0223-100500-177-a04 BN0223 Hom	
		Al239923	Hs.30098	ESTs	3.7
		A1970797	Hs.64859	ESTs	3.7
		Al248584	Hs.190745	Homo sapiens cDNA: FLJ21326 fis, clone C	3.7
4.5	401049			Target Exon	3.6
45		D31771	Hs.89404	msh (Drosophila) homeo box homolog 2	3.6
	420179	N74530	Hs.21168	ESTs	3.6
		AV658444	Hs.280776	tankyrase, TRF1-interacting ankyrin-rela	3.6
	437259	Al377755	Hs.120695		3.6
	428309	M97815	Hs.183650	cellular retinoic acid-binding protein 2	3.6
50	450522	Al698839		gb:wd31f02.x1 Soares_NFL_T_GBC_S1 Homo s	3.6
	451952	AL120173	Hs.301663	ESTs	3.6
	412209	AW901456		gb:RC0-NN1012-270300-031-c07 NN1012 Home	3.6
		AA352111		gb:EST60061 Activated T-cells XX Homo sa	3.6
	443830	AI142095	Hs.143273	ESTs	3.6
55	439255	BE164500		gb:RC4-HT0469-230300-014-e10 HT0469 Homo	3.6
		AA157291	Hs.21479	ubinuclein 1	3.6
		AA062954	Hs.141883		3.6
		Y12735	Hs.38018	dual-specificity tyrosine-(Y)-phosphoryl	3.6
		AK000054	Hs.12347	hypothetical protein FLJ20047	3.6
60	404091		110112011	Target Exon	3.6
00		AA125985	Hs.56145	thymosin, beta, identified in neuroblast	3.6
	405153	. 3 (120000	. 10.00 140	Target Exon	3.6
		AA380177	He 1259/5	ribulose-5-phosphate-3-epimerase	3.6
	403639		110,120040	ENSP00000233023*:CDNA FLJ12662 fis, clon	3.6
65	404360	II/		C7001385;gil12082809 gb AAG48618.1 AF315	3.6
05		AA766296	Hs.99200	ESTs - 13	3.6
		AB007961		KIAA0492 protein	3.6
	423330	UD01301	113.12/330	Minutes protein	0.0

		BE350295	Hs.15032	RAN binding protein 17	3.6
	431750	AA514986	Hs.283705	ESTs	3.6
	439907	AA853978	Hs.124577		3.6
	453596	AA441838	Hs.62905	hypothetical protein FLJ14834	3.6
5	406446	NA			3.6
_		AA315308	Hs 195870		3.6
		AW015415	Hs.127780		3.6
		W87707	Hs.82065	interleukin 6 signal transducer (gp130,	3.6
10		A1697121		•	3.6
10		AW291095	Hs.21814	interleukin 20 receptor, alpha	3.6
		AW297920	Hs.130054	ESIS	3.5
		AW860158		gb:RC0-CT0379-290100-032-b04 CT0379 Homo	
	459023	AW968226	Hs.60798	ESTs	3.5
	402820			NM_017646*:Homo sapiens tRNA isopentenyl	3.5
15	417009	AA191719	Hs.314714	ESTs	3.5
	447048	AW393080	Hs.228320	hypothetical protein FLJ23537	3.5
		Al806335			3.5
		AA420683	Hs.98321	hypothetical protein FLJ14103	3.5
		NM_015368	Hs.30985	pannexin 1	3.5
20	400610	_	113.00300		3.5
20		W07361	Un 22545		3.5
			Hs.22545	•	
		AW960146		hypothetical protein FLJ12888	3.5
		AI805416	Hs.213897		3.5
0.5		NM_004272		Homer, neuronal immediate early gene, 1B	3.5
25		AW392342		centrosomal P4.1-associated protein; unc	3.5
		AW448937	Hs.197030		3.5
	423841	AW753967		gb:RC2-CT0304-080100-011-h12 CT0304 Homo	
	416806	NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.5
	422060	R20893	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	3.5
30	433104	AL043002	Hs.128246	ESTs, Moderately similar to unnamed prot	3.5
	415778	H84847	Hs.49391	hypothetical protein LOC54149	3.5
	413054	AW316843	Hs.66309	hypothetical protein MGC11061	3.5
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	3.5
		AI917494	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	3.5
35		AI057094	Hs.96867	Homo sapiens cDNA: FLJ23155 fis, clone L	3.5
55		Al370876	Hs.79090	exportin 1 (CRM1, yeast, homolog)	3.5
		AW850178	113.7 3030		3.5
			11- 204547	•	
		AA314337		ribosomal protein S7	3.5
40		AA877124	Hs.172844		3.5
40	431291		Hs.25275	Kruppel-type zinc finger protein	3.5
		Al935016	Hs.216639		3.5
	455838	BE145808		gb:MR0-HT0208-101299-103-f11 HT0208 Homo	3.5
	458771	AW295151	Hs.163612	ESTs	3.5
	442942	AW167087	Hs.131562	ESTs	3.5
45	436550	Z50158	Hs.270235	ESTs, Weakly similar to MMHUB1 laminin b	3.5
	418849	AW474547	Hs.53565	Homo sapiens PIG-M mRNA for mannosyltran	3.5
,		BE614743		prostaglandin E synthase	3.5
		AW505021	Hs.88414	BTB and CNC homology 1, basic leucine zi	3.5
		Al908400	Hs.143789		3.5
50		AF086224	Hs.55238	ESTs	3.5
20	405917		113.00200	C17000675:gij7290703 gb AAF46150.1 (AE0	3.5
			Un 176000		3.5
		AW993582	Hs.176220		
		W47595		transforming growth factor, beta 2	3.4
~ ~		AA283185	Hs.19327	ESTs	3.4
55		AW904466		PDZ domain protein (Drosophila inaD-like	3.4
		BE252383	Hs.184668	SBBI31 protein	3.4
	455651	BE064962		gb:RC1-BT0313-130400-016-c02 BT0313 Homo	
	410555	U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.4
	447754	AW073310	Hs.163533	Homo sapiens cDNA FLJ14142 fis, clone MA	3.4
60	418636	AW749855		gb:QV4-BT0534-281299-053-c05 BT0534 Homo	3.4
	404097			C5000242*:gi 9369379 gb AAF87128.1 AC006	3.4
		AF119861	Hs.283032	hypothetical protein PRO2015	3.4
		Al215069	Hs.89113	ESTs	3.4
	402421			C1001578*:gij6759903 gb AAF28099.1 (AF1	3.4
65	405248				3.4
5 5		AJ404672	He 334483	hypothetical protein FLJ23571	3.4
		BE247275		U5 snRNP-specific protein, 116 kD	3.4
	403000	DECTI AI U	110.101101	Co on the copound protein, I to No	J.7

	433393	AF038564	Hs.98074	itchy (mouse homolog) E3 ubiquitin prote	3.4
	432239	X81334	Hs.2936	matrix metalloproteinase 13 (collagenase	3.4
	458747	BE618395	Hs.257391	hypothetical protein DKFZp761J1523	3.4
~	442082		Hs.7413	ESTs; calsyntenin-2	3.4
5		AA210765		gb:zr90c06.r1 NCI_CGAP_GCB1 Homo sapiens	
		A1346468	Hs.145789		3.4
		A1613276	Hs.5662	guanine nucleotide binding protein (G pr	3.4
		Al247716 AA164366	Hs.232168	hypothetical protein FLJ23511	3.4 3.4
10		AI971313		KIAA0551 protein	3.4
10		AF102546	Hs.63931	dachshund (Drosophila) homolog	3.3
	405460		110.00001	Target Exon	3.3
		AW503603	Hs.129915	phosphotriesterase related	3.3
	453472	AL037925		gb:DKFZp564M037_r1 564 (synonym: hfbr2)	3.3
15	447078	AW885727	Hs.301570	ESTs	3.3
	441690		Hs.33106	ESTs	3.3
		AA814043	Hs.88045	ESTs	3.3
	418478		Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.3
20		BE296227		serine/threonine kinase 15	3.3
20		AI160386	Hs.125087		3.3
		AF055575 NM_000685	Hs.23838 Hs.89472	calcium channel, voltage-dependent, L ty angiotensin receptor 1	3.3
		AA160079		Homo sapiens mRNA for partial 3'UTR, seq	3.3
		AW503857	Hs.4007	Sarcolemmal-associated protein	3.3
25		NM_005982	Hs.54416	sine oculis homeobox (Drosophila) homolo	3.3
		AW138872	Hs.135288		3.3
	420807	AA280627	Hs.57846	EST\$	3.3
	409695	AA296961		gb:EST112514 Adrenal gland tumor Homo sa	3.3
20		AI936450	Hs.147482		3.3
30	402892			Target Exon	3.3
		AA994896	Hs.22514	ESTs	3.3
		AA741545		ESTs, Weakly similar to T24961 hypotheti	3.3 3.3
		R21945 Al954968		splicing factor, arginine/serine-rich 5 matrix Gla protein	3.3
35		AV653771	118.213003	gb:AV653771 GLC Homo sapiens cDNA clone	3.3
55		AA121686	Hs.10592	ESTs	3.3
	406151			Target Exon	3.3
		AW511956	Hs.293261	ESTs	3.3
4.0	411171	AW820260		gb:QV2-ST0296-150200-040-c10 ST0296 Homo	3.3
40	432415			ESTs, Weakly similar to A43932 mucin 2 p	3.3
		AF086120	Hs.102793		3.3
	401575		LI- 44000	Target Exon	3.3
		AL045633	Hs.44269 Hs.155743	ESTs	3.3 3.3
45		Al344166 AW369771	Hs.52620	integrin, beta 8	3.3
73		AW204610	Hs.22270	ESTs	3.3
		AA976718	Hs.202242		3.3
		AA206186	Hs.79889	monocyte to macrophage differentiation-a	3.3
		AW043921	Hs.130526		3.3
50	451474	T70874	Hs.207636	ESTs	3.2
	442559	T10213	Hs.159993	gycosyltransferase	3.2
		A1824009	Hs.44577	ESTs	3.2
	420036		Hs.52792	Homo sapiens mRNA; cDNA DKFZp586l1823 (f	
55		W88774		ESTs	3.2
55		BE336654	Hs.70937	H3 histone family, member A ESTs, Weakly similar to fatty acid omega	3.2 3.2
		AA863360 BE311926	Hs.26040 Hs.15830	hypothetical protein FLJ12691	3.2
	403637		115.15000	C3001106*:gij10047201]dbj]BAB13394.1] (A	3.2
	405547	IN/A		NM_018833*:Homo sapiens transporter 2, A	3.2
60	427878	C05766	Hs.181022	CGI-07 protein	3.2
		AI821005	Hs.118599		3.2
	410313	R10305	Hs.185683		3.2
	416856			ESTs, Weakly similar to I38022 hypotheti	3.2
<i>~</i> =		Al652777	Hs.197069		3.2
65		NM_004460	Hs.418	fibroblast activation protein, alpha	3.2
		AI253123		ESTs, Highly similar to S21424 nestin [H	3.2
	409000	N23235	Hs.30567	ESTs, Weakly similar to B34087 hypotheti	3.2

	452190	H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	3.2
	430965	AA489732	Hs.154918	ESTs	3.2
	405394			Target Exon	3.2
		BE169810	Hs.47557	ESTs	3.2
5		H03556		ESTs, Weakly similar to thyroid hormone	3.2
J					3.2
		AA765917	Hs.122840		
		AK000684	Hs.183887	••	3.2
		AL121282	Hs.257786		3.2
10		AW856552		gb:RC1-CT0294-080100-012-a04 CT0294 Homo	
10		NM_005429	Hs.79141	vascular endothelial growth factor C	3.2
		AA758239	Hs.180330		3.2
		A1249368	Hs.98558	ESTs	3.2
		H38857		Homo sapiens cDNA FLJ20738 fis, clone HE	3.2
		Ai904743	Hs.104650	hypothetical protein FLJ10292	3.2
15	438078	AI016377	Hs.131693		3,2
	448816	AB033052	Hs.22151		3,2
	419519	AI198719	Hs.176376		3.2
	404580			NM_014112*:Homo sapiens trichorhinophala	3.2
	447046	AA326187	Hs.17170	G protein-coupled receptor 4	3.2
20	457473	AW974903	Hs.291231	ESTs	3.1
	429838	AW904907	Hs.30732	hypothetical protein FLJ13409; KIAA1711	3.1
	459702	Al204995		gb:an03c03.x1 Stratagene schizo brain S1	3,1
	400195	NA		NM_007057*:Homo sapiens ZW10 interactor	3.1
		AW408557	Hs.235498	hypothetical protein FLJ14075	3.1
25		AW974175	Hs.188751	ESTs, Weakly similar to MAPB_HUMAN MICRO	
		AA312735	Hs.30512	Homo sapiens mRNA for KIAA0556 protein,	3.1
		AA701327	Hs.17949	ESTs	3.1
		AA906366	Hs.190535		3.1
		D38122	Hs.2007	tumor necrosis factor (ligand) superfami	3.1
30		AW891294		solute carrier family 4, sodium bicarbon	3.1
50	439677		Hs.164599		3.1
		AI638627			3.1
		AA503653			3.1
		AA339449	Hs.82285	-	3.1
35			H5.02200	phosphoribosylglycinamide formyltransfer gb:nc71f10.s1 NCI_CGAP_Pr1 Homo sapiens	3.1
55		AA470519	Un 47466		3.1
		BE327311	Hs.47166	HT021	
		AW806906	Un 100050	gb:QV4-ST0023-160400-172-d12 ST0023 Homo	
		H15302	ns. 100930	Homo sapiens mRNA; cDNA DKFZp566A1046 (f	
40	405336		11- 004550	Target Exon	3.1
40		AI683150			3.1
		Al583052	Hs.270058		3.1
		BE160636	11- 400040	gb:PM1-HT0422-291299-002-c08 HT0422 Homo	
		Al768801	HS.169943	Homo sapiens cDNA FLJ13569 fis, clone PL	3.1
15	405848			Target Exon	3.1
45		BE066976		gb:PM0-BT0340-211299-003-c12 BT0340 Homo	
		M29994		· · · · · · · · · · · · · · · · · · ·	3.1
		W26713	Hs.256972		3.1
	423518			•	3.1
50		AI065104			3.1
50		BE165753		• • •	3.1
		AA706910	Hs.112742		3.1
		AL050027		gb:Homo sapiens mRNA; cDNA DKFZp566C0324	
		AI541305	Hs.48778		3.1
		AW407181	Hs.218377		3.1
55		AF026942			3.1
		AW807227		gb:MR4-ST0062-180200-001-e10 ST0062 Homo	
	424085	NM_002914	Hs.139226		3.1
	416790	R83066	Hs.7043		3.1
	420020	BE295866	Hs.94382	adenosine kinase	3.1
60	426119	W94997	Hs.189917		3.1
	426968	U07616			3.1
	457421	AL117431	Hs.112165		3.1
	453403	BE466639	Hs.61779	Homo sapiens cDNA FLJ13591 fis, clone PL	3.1
		AW138413	Hs.139336	ATP-binding cassette, sub-family C (CFTR	3.1
65	426650	AA382814		gb:EST96097 Testis I Homo sapiens cDNA 5	3.1
		Al248013	Hs.106532		3.1
-		AW135274	Hs.12433		3.1

	116166	H38026	Hs.308	arrantin 2 ratinal (V arrantin)	3.1
		BE219794		arrestin 3, retinal (X-arrestin) ESTs	3.1
		AK001423	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	3.0
		AB033035	Hs.51965	KIAA1209 protein	3.0
5		BE153855	Hs.61460	lg superfamily receptor LNIR	3.0
-		AA232658		UDP-glucose:glycoprotein glucosyltransfe	3.0
	419346	Al830417	Hs.44143	polybromo 1	3.0
		N93266	Hs.40747	ESTs	3.0
4.0		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (
10		NM_005357	Hs.95351	lipase, hormone-sensitive	3.0
	405609	NA		ENSP00000241065*:CDNA	3.0
	404274	11074000	11- 004045	NM_002944*:Homo sapiens v-ros avian UR2	3.0
		Al971362	Hs.231945		3.0
15		H07118 N59650	Hs.6099 Hs.27252	ESTs · ESTs	3.0
13	406291		115.27252	Target Exon	3.0
		BE383592		gb:601297871F1 NIH_MGC_19 Homo sapiens of	
		AW972359	Hs.293334		3.0
	442246	AI791988	Hs.129115	ESTs	3.0
20	451353	N21043	Hs.42932	ESTs	3.0
		AI969716	Hs.13034	ESTs	3.0
		BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	3.0
	401326		11- 40504	C10000447*:gi 1168375 sp P43467 AGA1_PED	
25		BE169746	Hs.12504 Hs.162859	likely ortholog of mouse Arkadia	3.0
23		AI926047 AF245505	Hs.72157	DKFZP564I1922 protein	3.0
	401045	AI 240000	113.72107	C11001883*:gi 6753278 ref NP_033938.1 c	3.0
		AA584062	Hs.272798	hypothetical protein FLJ20413	3.0
		Al221894	Hs.39311	ESTs	3.0
30	442611	BE077155	Hs.177537	hypothetical protein DKFZp761B1514	3.0
		AW958879	Hs.270535		3.0
		H91882		Dvl-binding protein IDAX (inhibition of	3.0
		NM_014711		KIAA0419 gene product	3.0
35		R13474	HS.290263	ESTs, Weakly similar to I38022 hypotheti gb:yg99d09.r1 Soares infant brain 1NIB H	3.0 3.0
55		R52782 AB014528	Hs.43133	KIAA0628 gene product	3.0
		AW004683	Hs.78934	mutS (E. coli) homolog 2 (colon cancer,	3.0
		AI754212	Hs.21951	Homo sapiens Xq pseudoautosomal region;	3.0
		AW021173	Hs.18612	Homo sapiens cDNA: FLJ21909 fis, clone H	3.0
40	411836	AW901879	Hs.314453		3.0
	415030	D31118		hypothetical protein MGC10520	3.0
		AW294795	Hs.198529		3.0
		AA878939	Hs.125406		3.0
45		A1375957		F-box only protein 22	3.0
43		AA281279 NM_014400	Hs.23317 Hs.11950	hypothetical protein FLJ14681 GPI-anchored metastasis-associated prote	3.0
		AA701259	Hs.189299	•	3.0
		AI041793	Hs.42502	ESTs	3.0
		BE175605		gb:RC5-HT0580-100500-022-H07 HT0580 Home	0.80
50	448062	AW295923	Hs.255472	KIAA1843 protein	3.0
		M31659	Hs.180408	solute carrier family 25 (mitochondrial	3.0
		AA397658	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PL	3.0
		W01938	Hs.337243	ESTs, Weakly similar to ALU7_HUMAN ALU S	2.9
55		W57554		lymphoid nuclear protein (LAF-4) mRNA	2.9 2.9
55	445625	U22376 BE246743	Hs.1334	v-myb avian myeloblastosis viral oncogen hypothetical protein FLJ22635	2.9
	403677		113.200323	C4001462:gi 4887715 gb AAA79329.2 (L088	2.9
		BE067650		gb:MR4-BT0358-090300-003-e01 BT0358 Homo	
		W87434	Hs.106015	ESTs, Moderately similar to ALU1_HUMAN A	2.9
60	443127		Hs.180312	mitochondrial ribosomal protein S16	2.9
	448104	Al674818	Hs.316433	Homo sapiens cDNA FLJ11375 fis, clone HE	2.9
		AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (
		AW365665	Hs.120388		2.9
65		A1633559	Hs.310359		2.9 2.9
65	402109	N34128	Hs.145268	Target Exon -	2.9
	429629		Hs.30622	Homo sapiens cDNA FLJ13010 fis, clone NT	2.9
	,20020			Transport and the second secon	

	442295	Al827248	Hs.224398	Homo sapiens cDNA FLJ11469 fis, clone HE	2.9
	419752	AA249573	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN Z	2.9
	404721			NM_005596*:Homo sapiens nuclear factor l	2.9
	445107	AJ208121	Hs.147313	ESTs, Weakly similar to 138022 hypotheti	2.9
5	401987			NM_002737*:Homo sapiens protein kinase C	2.9
	430566	AA481282	Hs.190149	ESTs	2.9
	444517	Al939339	Hs.146883	ESTs	2.9
	445563	AW873606	Hs.149006	ESTs	2.9
	427691	AW194426	Hs.20726	ESTs	2.9
10	456561	AI868634	Hs.246358	ESTs, Weakly similar to T32250 hypotheti	2.9
	401458			Target Exon	2.9
	421039	NM_003478	Hs.101299	cullin 5	2.9
	459504	BE514127		gb:601315974F1 NIH_MGC_8 Homo sapiens cD	2.9
	424962	NM_012288	Hs.153954	TRAM-like protein	2.9
15	409617	BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	2.9
	416931	D45371	Hs.80485	adipose most abundant gene transcript 1	2.9
	413221	BE161151		gb:PM0-HT0425-141299-001-F08 HT0425 Homo	2.9
	409732	NM_016122	Hs.56148	NY-REN-58 antigen	2.9
	433687	AA743991		gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	2.9
20	434340	AI193043	Hs.128685	ESTs, Weakly similar to T17226 hypotheti	2.9
	454529	Z45439	Hs.270425	ESTs	2.9
	421379	Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	2.9
	452291	AF015592	Hs.28853	CDC7 (cell division cycle 7, S. cerevisi	2.9
_	457402	AW452648	Hs,149342	activation-induced cytidine deaminase	2.9
25	449051	AW961400	Hs.333526	HER2 receptor tyrosine kinase (c-erb-b2,	2.9
	408761	AA057264	Hs.238936	ESTs, Weakly similar to (defline not ava	2.9
	401093			C12000586*:gi 6330167 dbj BAA86477.1 (A	2.9
		A1651474	Hs.163944		2.9
• •	447985	Al681475	Hs.200949		2.9
30		AW235786		hypothetical protein MGC10954	2.9
		Al472078	Hs.303662		2.9
		BE265067		gb:601193893F1 NIH_MGC_7 Homo sapiens cD	
	405953			Target Exon	2.8
25		AW296927	11- 400554	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	2.8
35		AA846811		Homo sapiens cDNA: FLJ23089 fis, clone L	2.8
		AA295331		Homo sapiens cDNA FLJ20042 fis, clone CO	2.8 2.8
		AA243837	Hs.57787 Hs.3782	ESTs ESTs	2.8
		AW206453 AW452434	Hs.58006	ESTs, Weakly similar to ALU5_HUMAN ALU S	2.8
40		BE176480	113,30000	gb:RC3-HT0585-160300-022-c02 HT0585 Homo	
40		AL039852	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.8
		A1038997	Hs.132921		2.8
		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.8
		AW806899	,,0,0000	gb:QV4-ST0023-160400-172-c12 ST0023 Homo	
45		Al910896	Hs.132413		2.8
		Y00272	Hs.184572	cell division cycle 2, G1 to S and G2 to	2.8
	424800	AL035588	Hs.153203	MyoD family inhibitor	2.8
	411086	BE070800		gb:RC3-BT0502-251199-011-c07 BT0502 Homo	2.8
	400250	NA		Eos Control	2.8
50	449168	NM_016206	Hs.23142	colon carcinoma related protein	2.8
	456482	AA485224		gb:aa41b12.s1 NCI_CGAP_GCB1 Homo sapiens	32.8
	426044	AA502490	Hs.336695		2.8
		AA383550	Hs.271699	polymerase (DNA directed) iota	2.8
	405873			Target Exon	2.8
55		AA994364		ESTs, Weakly similar to T25472 hypotheti	2.8
		Al075375	Hs.128193	ESTs, Weakly similar to IRX2_HUMAN IROQU	2.8
		BE158791		gb:IL2-HT0397-091299-025-D02 HT0397 Homo	
*		AA398155	Hs.97600	ESTs	2.8
60		A1754813		collagen, type V, alpha 1 ESTs	2.8 2.8
60		AW294631	Hs.11325	ESTs, Moderately similar to CALB_HUMAN C	2.8
		AA298758	115.103/4/	gb:EST22d11 WATM1 Homo sapiens cDNA clon	
	417742	R64719		C1003621*:gi]12407405 gb]AAG53491.1 AF22	2.8
		R41339	Hs.12569	ESTs	2.8
65		AW338625	Hs.22120	ESTs	2.8
00	401497		. 1014-5-160	Target Exon	2.8
	402376			C19000763*:gi[1363912]pir[JC4296 ring f	2.8
				J	

	405041			C3001706*:gi 1345652 sp P15989 CA36_CHIC	2.8
		NM_003686	Hs.47504	exonuclease 1	2.8
	431917		Hs.2868	peripheral myelin protein 2	2.8
5		AA761190 AA744862	Hs.244627	ESTs ESTs, Weakly similar to I54374 gene NF2	2.8 2.8
9		AF086325	113.134233	gb:Homo sapiens full length insert cDNA	2.8
	401283			Target Exon	2.8
		AW803201		gb:IL2-UM0077-070500-080-E06 UM0077 Homo	
	417601	NM_014735	Hs.82292	KIAA0215 gene product	2.8
10	418236	AW994005	Hs.337534		2.8
		AW291488	Hs.117305	Homo sapiens, clone IMAGE:3682908, mRNA	2.8
		AW815098		gb:QV4-ST0212-091199-023-f10 ST0212 Homo	
		BE247550	Hs.86859	growth factor receptor-bound protein 7	2.8
15		Al651930 AK000375	Hs.135684 Hs.88820	HDCMC28P protein	2.8 2.8
13	414661		Hs.21929	ESTs	2.8
		AI650633		Homo sapiens cDNA: FLJ23031 fis, clone L	2.8
		Al916662		kinectin 1 (kinesin receptor)	2.7
• •	428824	W23624	Hs.173059		2.7
20		NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	2.7
		BE386870		gb:601275271F1 NIH_MGC_20 Homo sapiens of	
	440868			ESTs, Moderately similar to 138022 hypothypothetical protein FLJ10525	2.7 2.7
		BE247449 AV646449	Hs.31082 Hs.282872		2.7
25		Al378562	Hs.159585		2.7
		AW371048	Hs.93758	H4 histone family, member H	2.7
	406504	NA		C5000558:gi 4504675 ref NP_002175.1 int	2.7
		AW959861	Hs.290943		2.7
20		NM_004525		low density lipoprotein-related protein	2.7
30		H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, comp	2.7
		D13666 N34524	HS.130340	osteoblast specific factor 2 (fasciclin gb:yy56d10.s1 Soares_multiple_sclerosis_	2.7 2.7
		BE314524	Hs.78776	putative transmembrane protein	2.7
		NM_005014	Hs.94070	osteomodulin	2.7
35	406182			Target Exon	2.7
	416495	X69970	Hs.79350	RYK receptor-like tyrosine kinase	2.7
		AI916512	Hs.198394		2.7
		AA301228	Hs.43299	hypothetical protein FLJ12890	2.7
40		AW968128	Hs.336679		2.7 2.7
40		AA128978 M31158	Hs.154706 Hs.77439	hypothetical protein FLJ14917 protein kinase, cAMP-dependent, regulato	2.7
		BE563085	Hs.833	interferon-stimulated protein, 15 kDa	2.7
		AB026264		hypothetical protein IMPACT	2.7
	437030	AA742577	Hs.303781		2.7
45		AF075079		gb:Homo sapiens full length insert cDNA	2.7
		W74653	Hs.271593	ESTs, Moderately similar to A47582 B-cel	2.7
	406153	V49647	Ua 110507	Target Exon stearoyl-CoA desaturase (delta-9-desatur	2.7 2.7
	406625	AI188139	Hs.147050		2.7
50		Al572739		6-phosphofructo-2-kinase/fructose-2,6-bi	2.7
		H09604	Hs.13268	ESTs	2.7
		AA255920	Hs.88095	ESTs	2.7
		AA495925	Hs.9394	ESTs	2.7
<i></i>		BE379623	Hs.27693	peptidylprolyl isomerase (cyclophilin)-l	2.7
55		A1050073	Hs.135338		2.7
		A1741320 AA054726	Hs.285574	Homo sapiens cDNA: FLJ23228 fis, clone C	2.7 2.7
		N91716		ESTs, Weakly similar to I38022 hypotheti	2.7
	429922	Z97630	Hs.226117	H1 histone family, member 0	2.7
60	418203	X54942	Hs.83758	CDC28 protein kinase 2	2.7
	439509	AF086332	Hs.58314	ESTs	2.7
	402184	NA	11 0=-::	ENSP00000245238*:CDNA FLJ10922 fis, clon	2.7
		AW449251	Hs.257131		2.7 2.7
65	457029	A1825440 A1373638	Hs.224952 Hs.133900		2.7
00	441541	AA938663	Hs.199828		2.7
	441111	AI806867	Hs.126594		2.7
				205	

	423020	AA383092	Hs.1608	replication protein A3 (14kD)	2.7
		AV653485	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	
	427961	AW293165	Hs.143134		2.7
_		X91662	Hs.66744	twist (Drosophila) homolog (acrocephalos	2.7
5		AW137636	Hs.146059		2.7
		AA496493	Hs.23136	ESTs	2.7
	406069	NA Al470235	Un 470600	Target Exon	2.7 2.7
	401256		Hs.172698	NM_024089*:Homo sapiens hypothetical pro	2.7
10		AW975942	Hs.48524	ESTs	2.7
		AW958037	Hs.286	ribosomal protein L4	2.7
	455511	BE144762		gb:CM0-HT0180-041099-065-b04 HT0180 Homo	2.7
		BE327427	Hs.79953	ESTs	2.6
1.5		AA045857	Hs.54943	fracture callus 1 (rat) homolog	2.6
15		AL121053	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT	2.6
		AF160477 AK001122	Hs.61460 Hs.105859	lg superfamily receptor LNIR hypothetical protein FLJ10260	2.6 2.6
		AW893940	Hs.59698	ESTs	2.6
		Z30201	1.0.0000	gb:HHEA22G Atrium cDNA library Human hea	2.6
20		D38299	Hs.170917	prostaglandin E receptor 3 (subtype EP3)	2.6
	433068	NM_006456	Hs.288215	sialyltransferase	2.6
		AA300900	Hs.98849	ESTs, Moderately similar to AF161511 1 H	2.6
,		AA447990	Hs.190478		2.6
25		AW975920 Al346487	Hs.283361 Hs.28739	ESTS	2.6 2.6
43		AI340467 AI123555	Hs.81796	ESTS	2.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	2.6
		AW754311		gb:CM1-CT0337-141299-068-f07 CT0337 Homo	
• •	417061	AI675944	Hs.188691	Homo sapiens cDNA FLJ12033 fis, clone HE	2.6
30		M25809	Hs.64173	ATPase, H transporting, lysosomal (vacuo	2.6
		AK002016		Homo sapiens, clone MGC:16327, mRNA, com	2.6
		NM_013989 AW292286		deiodinase, iodothyronine, type II	2.6 2.6
		AA018311	Hs.255058 Hs.114762		2.6
35	405822	AA010311	113.117102	Target Exon	2.6
		AW976201	Hs.53913	hypothetical protein FLJ10252	2.6
	417315	AI080042		ribosomal protein S24	2.6
		AA643687		Homo sapiens cDNA FLJ11980 fis, clone HE	2.6
40		AW205878	Hs.29643	Homo sapiens cDNA FLJ13103 fis, clone NT	2.6
40	405638	AW812256		Target Exon gb:RC0-ST0174-191099-031-a07 ST0174 Homo	2.6
	403943	AVV0 12230		C5000355:gi 4503225 ref NP_000765.1 cyt	2.6
		Z25884	Hs.121483	chloride channel 1, skeletal muscle (Th	2.6
	402800			Target Exon	2.6
45	449144	A1989503	Hs.233405	ESTs	2.6
		AW846080	Hs.314324		2.6
		H03754		wingless-type MMTV integration site fami	2.6
		AW974476 AA418187	Hs.330515	regulator of G-protein signalling 16	2.6 2.6
50		AK001826	Hs.25245	hypothetical protein FLJ11269	2.6
		BE246010		Homo sapiens mRNA for FLJ00038 protein,	2.6
		AW855802		gb:RC1-CT0279-170200-023-d08 CT0279 Homo	2.6
	427317	AB028955	Hs.175780	KIAA1032 protein	2.6
	408875		Hs.48604	DKFZP434B168 protein	2.6
55	427510			small nuclear RNA activating complex, po	2.6
	423201 406271	NM_000163	HS. 125 180	growth hormone receptor Target Exon	2.6 2.6
		BE566962	Hs.7063	Homo sapiens cDNA: FLJ20913 fis, clone A	2.6
		AW016892	Hs.100855		2.6
60		Al928513	Hs.59203	ESTs	2.6
	434398	AA121098	Hs.3838	serum-inducible kinase	2.6
		BE069326	11 400	gb:QV3-BT0381-170100-060-g03 BT0381 Homo	
		W24320	Hs.102941	Homo sapiens cDNA: FLJ21531 fis, clone C	2.6
65		X64984 AA830431	He 190044	gb:H.sapiens mRNA HTPCRX10 for olfactory	2.6 2.6
05		AA668763	Hs.180811 Hs.291939		2.6
		AI681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	2.6

	455100	BE160198		gb:QV1-HT0413-010200-059-h03 HT0413 Homo	
		BE274552	Hs.76578	P	2.6
		A1732892 AA831267	Hs.190489 Hs.12244		2.6 2.6
5		AA825686			2.6
	404440			NM_021048:Homo sapiens melanoma antigen,	2.6
	403388			01 12 11	2.6
	403775 405037			Target Exon NM_021628*:Homo sapiens arachidonate lip	2.6 2.6
10		AF290544			2.6
10		AA282067	Hs.88972		2.6
		AI872932		J	2.6
		AW516211			2.6
15		AI702885 BE391727	Hs.145568		2.6 2.6
15		N72264		J = 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	2.6
	457411	AW085961	Hs.130093		2.6
		Y08565	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6
20	404443	NM_003512	Hs.28777		2.6 2.6
20		Al073913		ESTs, Weakly similar to JE0350 Anterior	2.6
		Al192105	Hs.147170		2.6
		AW963372	Hs.46677		2.6
25		F13036	Hs.27373	Homo sapiens mRNA; cDNA DKFZp564O1763 (f	2.6 2.6
25		R36075 AW081681	He 269064	gb:yh88b01.s1 Soares placenta Nb2HP Homo ESTs, Weakly similar to T42689 hypotheti	2.6
		NM_000169	Hs.69089		2.6
	406922	S70284		gb:stearoyl-CoA desaturase [human, adipo	2.6
20		H62943	Hs.154188		2.6
30		BE065837 NM_012247	He 12/027	gb:RC2-BT0318-110100-012-g12 BT0318 Homo SELENOPHOSPHATE SYNTHETASE; Human s	
		Al538613		Transmembrane protease, serine 3	2.5
		AF012023		integrin cytoplasmic domain-associated p	2.5
2.5		AK001058	Hs.12680	Homo sapiens cDNA FLJ10196 fis, clone HE	2.5
35		BE245652		zinc finger protein 266	2.5 2.5
		L22524 AB020641	Hs.2256 Hs.57856	matrix metalloproteinase 7 (MMP7; uterin PFTAIRE protein kinase 1	2.5
		NM_000909		neuropeptide Y receptor Y1	2.5
40		AW973708		Homo sapiens cDNA FLJ13446 fis, clone PL	2.5
40		AA767881	Hs.122897		2.5 2.5
		AK001741 AL042306	Hs.8739 Hs.97689	hypothetical protein FLJ10879 VASA protein	2.5
		AW628666	Hs.98440	ESTs, Weakly similar to I38022 hypotheti	2.5
		AK002032	Hs.272245	Homo sapiens cDNA FLJ11170 fis, clone PL	2.5
45		BE080908	11- 070000	gb:QV1-BT0631-280200-084-h07 BT0631 Homo	
		AI362790 BE394723		KIAA1684 protein; likely homolog of mous S100 calcium-binding protein A6 (calcycl	2.5 2.5
		NM_002318	Hs.83354	lysyl oxidase-like 2	2.5
		AW375610		hypothetical protein FLJ13046 similar to	2.5
50		A1424899	Hs.188211		2.5
		BE091089 U64820	Hs.66521	gb:PM4-BT0724-130400-006-c07 BT0724 Homo Machado-Joseph disease (spinocerebellar	2.5
		AW972565	Hs.32399	ESTs, Weakly similar to S51797 vasodilat	2.5
		AW089705		ESTs, Weakly similar to S64329 probable	2.5
55		AI471598	Hs.197531		2.5
		AA065081	Hs.11090	gb:zm13a03.s1 Stratagene pancreas (93720 membrane-spanning 4-domains, subfamily A	2.5 2.5
		BE178536 AF109298	Hs.118258		2.5
		AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.5
60	455935	BE158687		gb:CM0-HT0395-280100-169-b09 HT0395 Homo	
		AW953168	Hs.12407	ESTs Human DNA coguence from clone RP5-1103G7	2.5
	416589 404826	AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7 Target Exon	2.5
		NM_001809	Hs.1594	centromere protein A (17kD)	2.5
65	421991	NM_014918		KIAA0990 protein	2.5
		NM_007350	Hs.82101	pleckstrin homology-like domain, family gb:RC1-NN0073-260400-011-g09 NN0073 Homo	2.5
	448516	AW898595		95470 1-14140013-200400-011-903 14140013 FIOLIIC	JE,U

	403356 404983	NA		ENSP00000251525*:Hypothetical protein Kl ENSP00000252242*:Keratin, type II cytosk	2.5 2.5
		AA215535	Hs.98133	ESTs	2.5
		AW467143		actin related protein	2.5
5		AF186114		tumor necrosis factor (ligand) superfami	2.5
-		AW071349	Hs.215937		2.5
		AW582962		CGI-47 protein	2.5
		AF086041	Hs.42975	ESTs	2.5
	400925	0000		Target Exon	2.5
10	404552	NA		ENSP00000220888*:ZINC FINGER TRANSCRIF	T12.5
		AL133117	Hs.81376	Homo sapiens mRNA; cDNA DKFZp586L1121 (f	
	418841	NM_002332	Hs.89137	low density lipoprotein-related protein	2.5
	426853	U32974	Hs.172777	baculoviral IAP repeat-containing 4	2.5
	427738	NM_000318	Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	2.5
15	457384	AA501760	Hs.15806	Homo sapiens mRNA; cDNA DKFZp434H2019 (f	2.5
	447128	AI271898	Hs.164866		2.5
	454693	AW813428		gb:MR3-ST0192-010200-210-c05 ST0192 Homo	
		AA641876	Hs.191840		2.5
20	402077			Target Exon	2.5
20		X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	2.5
		AW885757	Hs.257862		2.5
		T27308	Hs.16986	hypothetical protein FLJ11046	2.5
		A1807894	Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr	
25		A1024353		hypothetical protein FLJ14298	2.5
25		AA059013	Hs.22607	ESTs	2.5 2.5
		AA122393 AW162919	Hs.70811	hypothetical protein FLJ20516 RAB2, member RAS oncogene family-like	2.5
		AVV 102919 AI126772	Hs.40479	ESTs	2.5
		AI580090	Hs.48295	RNA helicase family	2.5
30		N80077	Hs.24792	chromosome 12 open reading frame 5	2.5
50		AA449644		Homo sapiens cDNA FLJ14201 fis, clone NT	2.5
		AW297921	Hs.255703		2.5
		AA256769	Hs.94949	methylmalonyl-CoA epimerase	2.5
		AW086180	Hs.37636	ESTs, Weakly similar to KIAA1392 protein	2.5
35		U29344	Hs.83190	fatty acid synthase	2.5
	430388	AA356923		nuclear cap binding protein subunit 2, 2	2.5
	423242	AL039402	Hs.125783	DEME-6 protein	2.5
	416241	N52639	Hs.32683	ESTs	2.5
		AI743977	Hs.205144		2.5
40		AA740875	Hs.44307	ESTs, Moderately similar to l38022 hypot	2.5
		AW500507		KIAA1600 protein	2.5
		AI920783	Hs.191435		2.5
		AA479033		ESTs, Weakly similar to A47582 B-cell gr	2.5
45		A1446747		olfactory receptor, family 7, subfamily	2.5
43		AA116021 NM 007069	Hs.38260	ubiquitin specific protease 18 similar to rat HREV107	2.5 2.5
		H00820	Hs.37189 Hs.30977	ESTs, Weakly similar to B34087 hypotheti	2.5
		AA236255	Hs.298419		2.5
		H20669	Hs.35406	ESTs, Highly similar to unnamed protein	2.5
50		AL046412	Hs.202151		2.5
•		Al640355	Hs.312691		2.5
		AW298631	Hs.27721	Wolf-Hirschhorn syndrome candidate 1-lik	2.5
		A1937547		hypothetical protein MGC2601	2.5
	411337	AW837349		gb:QV2-LT0038-270300-108-d12 LT0038 Homo	2.5
55	438290	AA843719	Hs.122341	ESTs	2.5
	406414			C5000506*:gi[124941 sp P18614 ITA1_RAT I	2.5
		AB033043	Hs.149377	hypothetical protein DKFZp761L0424	2.5
		BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	
60		AA347746	Hs.9521	ESTs, Weakly similar to ZN43_HUMAN ZINC	2.5
60		BE159984	Hs.125395		2.5
		AA635062	Hs.50094	Homo sapiens mRNA; cDNA DKFZp434O0515 (i	
		D86983		Melanoma associated gene	2.5
		AL135623		KIAA0575 gene product	2.5 2.5
65		AA442324	Hs.795	H2A histone family, member O cytochrome P450, subfamily XIB (steroid	2.5
UJ		D13752 AA081395	Hs.42173	Homo sapiens cDNA FLJ10366 fis, clone NT	2.5
	403133	WA00 1989	113,742113	Target Exon	2.5
	403133			I diggi wholi	۷.0

413189	BE070231		gb:QV4-BT0407-260100-087-112 B10407 Homo	2.5
400346	AB041269	Hs.272263	Homo sapiens mRNA for keratin 19, partia	2.5
435509	Al458679	Hs.181915	ESTs	2.5
458145	A1239457	Hs.130794	ESTs	2.5

TABLE 19A

Table 19A shows the accession numbers for those pkeys lacking unigeneID's for Table 19. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	Λ	
ı	1,	

5

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number

Genbank accession numbers

15

Accession:

Pkey

CAT number	Accessions

		O/11 Mainbei	7.00030110
20	407647 407980	1007366_1 103087_1	AW860158 AW862385 AW860159 AW862386 AW862341 AW821869 AW821893 AW062660 AW062656 AA046309 Al263500 AA046397
	408254	1049346_1	AW807227 AW807576 AW807137 AW807157 AW807495 AW807494 AW807417 AW807083 AW845786 AW845801 AW807130 AW807335 AW807081 AW807349 AW807339 AW807164 AW807341 AW807224 AW845903 AW177424 AW807159 AW807123 BE141576 AW807340 AW807334 AW807520 AW807205 AW807505 BE141574 AW807390
25			AW807395 AW845789 AW807101 AW807089 AW807519 AW807239 AW807509 AW807356 AW807526 AW807098 AW807307 AW807153 AW807295 AW807313 AW807322 AW807265 AW807513 AW807516 AW807166 AW807501
			AW807120 AW807168 AW807121 AW807527 AW807151 AW807203 AW807489 AW807511 AW807518 AW845800 AW807507 AW845793 AW845796 AW807296 AW845781 AW807444 AW845871 AW807512 AW807242 AW807141
			AW807522 AW807487 AW807514 AW807142 AW807232 AW807379 AW807114 AW807518 AW807199 AW807211 AW807498 AW807492 AW807218 AW807082 AW807525 AW807493 AW807523 AW807687 AW845784
30			AW807037 AW807128 AW807080 AW807118 AW845807 AW807524 AW845803 AW807249 AW845795 AW807160
•			AW807343 AW807515 AW807233 AW807289 AW177102 AW807352 AW807394 AW177105 AW807176 AW177103
			AW845870 AW177099 AW177101 AW807528 AW807336 AW807038 AW177100 AW807411 AW807088 AW845865
			AW807226 AW807517 AW807397 AW807303 AW807177 AW807154 AW807136 AW807146 AW807085 AW807521
			AW807488 AW807385 AW807355 AW807223 AW807155
35	409163	110418_1	AA065081 AA075017 AA084791 AA071015 AA081560 AA071459 AA545727 AA083100 AA085366 AA115845 AA075457
		•	AA064704 AA082878 AA075742 AA069162
	409695	114876_1	AA296961 AA296889 AA076945 AA077528 AA077497
	410534	1207247_1	AW905138 AW753008 R13818 Z43519
40	410672	1214882_1	AW794600 AW794730
40	410784	1221005_1	AW803201 BE079700 BE062940
	410785	1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
	410835	1223785_1	AW806906 AW806915 AW866460 AW866475 AW866462 AW866448 AW866372 AW866604
	411050 411086	1230330_1	AW814902 BE156656 BE156667 BE156590 BE156441 BE156447 BE070800 AW875226 BE149115
45	411093	1231500_1 1231970 1	BE067650 AW817053
73	411111	1232669 1	AW818127 AW818161 R09719
	411171	1234393_1	AW820260 AW820332 R94406
	411337	1239217 1	AW837349 AW837355 AW882717
	411514	1248638_1	AW850178 AW850233 AW850445 AW850446
50	411670	1253680_1	AW856552 AW861101 AW856574 AW861099 AW861100 AW856573 AW856576 AW856562
	411905	1265181 1	BE265067 BE264978 AW875420
	412102	1277395_1	H56435 H56572 AW892929
	412209	1283610_1	AW901456 AW901450 AW901441
	412248	1285000_1	BE176480 AW903298 AW903313
55	413043	1346556_1	BE158766 BE061699 BE147360 BE147362 BE061666 BE061697 BE061647 BE061678
	413111	1349546_1	BE065837 BE065805 BE065799 BE065818 BE065839 BE065831 BE065894 BE065789 BE065792
	413189	1352723_1	BE070231 BE070229 BE070255
	413221	1353887_1	BE161151 BE162495 BE161002 BE072205 BE160989 BE162482
C O	413499	1373910_1	BE144884 H97942
60	413708	1384140_1	BE158791 BE158806 BE158748 BE158744 BE158740 BE158739 BE158811 BE158700 BE158741 BE158683 BE158685
	414210	1426051_1	BE383592 BE261671
	414596	1465004_1	BE386870 Z41986 H08501

	414605	14657901	BE390440
	415747		AA381209 AA381245 AA167683
		155189_1	
	416173	1574973_1	R52782 R17313 H24192 R19876
	417742	1696282_1	R64719 Z44680 R12451
5			
3	417974	171237_1	AA210765 T95700 H94407
	418636	177402_1	AW749855 AA225995 AW750208 AW750206
	419536	185688 1	AA603305 AA244095 AA244183
	420854	197072_1	AW296927 Al684514 Al263168 AA281079
	422156	212379_1	N34524 AA305071 AW954803 AA502335 Al433430 Al203597 AW026670 AW265323 AW850787 AA317554 AW993643
10			
10			AW835572 AW385512 Al334966 W32951 H62656 H53902 R88904 AW835732
	422996	223666_1	BE091089 BE091123 AA319959
	423833	232451_1	AW503329 N46610 AA331571
		000507 4	
	423841	232507_1	AW753967 AA370795 AA331630 AW962550
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
15	425201	247933_1	AA352111 AW962247 AA429695
10			
	426650	270283_1	AA382814 AA402411 AA412355
	426878	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	430264	315008_1	AA470519 BE303010 BE302954 BE384120
•	430785	323486_1	Z30201 AA486132 T72025
20	431676	336411_1	Al685464 AW971336 AA513587 AA525142
	433687	373061_1	AA743991 AA604852 AW272737
		_	
	434338	383982_1	AW754311 AA630185 AW803285
	434469	387447_1	AA634806 C18732 AA729161 AA729860
	435447	406400 1	Al872932 AA682306 BE220163 W88695 T81307 H91447
25			
23	437152	43386_1	AL050027 BE089051
	437854	44418_1	AL119723 AL119874 Al909018 U50537
	439031	46798_1	AF075079 H48601 H48795
		_	
	439255	470321_1	BE164500 AA832198 BE164502
	444910	624951_1	Al201849 BE069007 AW946544
30	445432	63943 1	AV653771 BE089370
50			
	446922	69865_1	BE175605 Z43529 F06610 BE175602 AV661027
	447197	711623_1	R36075 Al366546 R36167
	448420	76273_1	BE623004 AA380669 BE263627 BE246433
25	448516	766241_1	AW898595 AW898588 AW898590 AW898663 AW898592 Al525093
35	450522	837264_1	Al698839 Al909260 Al909259
	450736	844652 1	AW970060 AI732366 AI792313 AW839644
		_	
	451024	85565_1	AA442176 AA259181
	451067	85759_1	BE172186 AA059279 AA020815 AA013437
	451340	86640_1	AW936273 AW340350 AA017208
40			
40	452542	921410_1	AW812256 AW812257 Al906423 Al906422
	452564	92227_1	AA026777 N50065 R09961 N54721
	453472	968371_1	AL037925 AL037931 AL037957
	454307		AW855717 AW362452 AW362443
		1106070_1	
	454359	1130674_1	N71277 AW390764
45	454545	1223779_1	AW806899 AW866451 AW866393 AW866297 AW817869
	454693	1229132_1	AW813428 AW813444 AW813367 AW813368 AW813429 AW813424
	454714	1230493_1	AW815098 BE154843 BE154831
	455047	1250536_1	AW852530 AW852527 AW852526
	455092	1252971_1	BE152428 AW855572 AW855607
50			
50	455097	1253130_1	AW855802 AW855794 AW855797 AW855806 AW855796 AW855808 AW855793 AW855807
	455100	1253334 1	BE160198 AW935898 T11520 AW935930 AW856073 AW861034
	455431	1289854_1	AW938484 BE001245 BE001190
	455511	1321229_1	BE144762 AW979091
	455609	1337548_1	BE011668 BE011689 BE011627 BE011679 BE011699 BE011678 BE011696 BE011675 BE011622 BE011635
55	455651	1348732 1	BE064962 BE064979 BE064853 BE064857 BE064856 BE064977 BE064960 BE064860 BE064815 BE064957 BE064804
55	700001	10 101 02_1	BE064816 BE064850 BE064806 BE064796 BE064818 BE064975 BE064819 BE064810 BE064668 BE065059
	455685	1350393_1	BE066976 BE066928 BE066927
	455700	1351264 1	BE068115 BE068104 BE068102 BE068096 BE068103 BE068154 BE068198
			BE069326 BE069290 BE069352
CO	455708	1352232_1	
60	455732	1353874_1	BE080908 BE072258 BE072190 BE072236
	455838	1374605_1	BE145808 BE145807 BE181883
	455935	1384144_1	BE158687 BE158688
	455945	1385588_1	BE160636 BE160606 BE160703
	456207	1650781	AA193450
65	456482	192289_1	AA485224 AA287308 AA258121
05			
	458094	47311_1	AF086325 W72956 W73221 AA219112
	458673	679507_1	N99626 Al302701

TABLE 19B

Table 19B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 19. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.						
15	Strand: Nt_position:	Indicat	es DNA strand from which exons were predicted. es nucleotide positions of predicted exons.				
	Pkey Ref	Strand	Nt_position				
20	400555 980119° 400608 9887666 400610 988767° 400925 765192° 401045 8117619	Minus Minus Plus	134694-134817 96756-97558 117606-117928,124040-124147 38183-38391,43900-44086 90044-90184,91111-91345				
25	401049 7232177 401093 8516137 401256 9796573 401283 9800093 401326 9212516	Plus Minus Minus Minus	149157-150692 22335-23166 45482-45620 47256-47456 226246-227505				
30	401418 7452889 401451 6634068 401458 9187886 401497 7381770 401508 7534110	Minus Plus Plus	124865-125075 119926-121272 76485-77597 92607-92813 110779-110983				
35	401575 7229804 401747 9789672	Minus Minus	76253-76364 118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097- 131258,131866-131932,132451-132575,133580-134011				
40	401781 7249190 401785 7249190 401793 7263888 401987 4406829 402077 8117414 402109 8131678	Minus Minus Minus Plus Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814 165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942 102945-103083 72893-73021,76938-77049 65014-65195 17722-1771859,173197-173303				
45	402184 857600° 402376 9625329 402421 979634° 402578 9884928 402606 9909429 402696 7328818	Minus Minus Plus Minus	112844-112986,113505-113636 21753-22385 46609-46662,46758-46811,86293-86346,89776-89829,90048-90101,102817-102924 66350-66496 81747-82094 23600-23731				
50	402765 9367757 402800 6010175 402820 6456853 402892 8086844 403133 7331427	Plus Plus Minus Minus	109588-109726 43921-44049,46181-46273 82274-82443 194384-194645 38314-38634				
55	403356 8569930 403388 943833 403426 9719529 403585 8101208 403593 6862650	Plus Plus Minus Minus	92839-93036 112733-113001,114599-114735 157156-158183 131266-131769 62554-62712,69449-69602				
60	403637 8671936 403639 8671946 403677 7331517 403775 7770586 403943 7711864	Minus Plus Minus Minus Minus	142647-142771,145531-145762 113234-113326,115186-115287,119649-119786 55008-55083,62860-63051 102247-102326,103095-103148 100742-100904,101322-101503				

```
404091 7684554
                                     82121-83229
                           Minus
        404097 7770701
                                     55512-55781
                           Plus
        404142 9856692
                                     80316-80459
                           Minus
         404253 9367202
                           Minus
                                     55675-56055
 5
        404274 9885189
                           Plus
                                     104127-104318
        404285 2326514
                                     32282-32416
                           Plus
         404360 9858450
                                     122873-122966,151324-151469,153093-153253
                           Minus
                                     80430-81581
        404440 7528051
                           Plus
         404443 7579073
                                     87198-87441
                           Minus
         404552 7243881
10
                           Plus
                                     19854-20010
         404561 9795980
                                     69039-70100
                           Minus
         404580 6539738
                           Minus
                                     240588-241589
         404721 9856648
                                     173763-174294
                           Minus
         404826 6572184
                                     47726-48046
                           Plus
15
         404983 4432779
                                     51178-51374,52000-52173
                           Minus
         405037 7543748
                           Minus
                                     127374-127578
         405041 7547195
                                     121230-121714
                           Plus
                                     138877-139066
         405095 8072599
                           Plus
                                     175317-175500
         405153 9965565
                           Minus
20
         405196 7230083
                           Minus
                                     135716-135851
         405232 7249042
                           Plus
                                     125904-126063
         405248 7259728
405336 6094635
                                     637-777
                           Plus
                                     33267-33563
                           Plus
         405394 6624123
                           Minus
                                     31900-32373
25
         405460 7684569
                           Minus
                                     52223-52389
         405494 8050952
                                     70284-70518
                           Minus
                                     124361-124520,124914-125050
         405547 1054740
                           Plus
         405609 5757553
                           Minus
                                     42814-43010,43583-43783,44863-45033,46429-46554,47815-48018,49961-50153,51624-51727,51823-51959,52702-
                                     52918,55469-55601,57111-57307,58169-58296,60215-60332,61482-61727
                                     199260-199372,199826-199929
30
         405638 6289229
                           Plus
         405654 4895155
                           Minus
                                     53624-53759
         405718 9795467
                                     113080-113266
                           Plus
                                     154660-154974,155203-155379
         405822 6273498
                           Minus
                                     28135-28244
         405848 7651809
                           Minus
35
         405873 6758747
                           Minus
                                     32129-32764
         405906 7705124
                                     10835-11059
                           Minus
         405917 7712162
                           Minus
                                     106829-107213
         405925 6758795
                                     129935-130282
                           Plus
                                     65101-65574
         405953 7960374
                           Minus
40
         406069 9117732
                                     68880-69374
                           Plus
                                     94087-94285
         406151 7144806
                           Minus
         406153 9929734
                                     12902-13069
                           Minus
         406182 5923650
                           Minus
                                     28256-28935
         406271 7534217
                           Plus
                                     36179-36692
45
         406291 5686274
                                     9562-9867
                           Plus
                                     71754-71944
         406348 9255985
                           Minus
                                     49593-49850
         406414 9256407
                           Plus
         406446 9454509
                                     116424-116527,118721-118859,121187-121364
                           Minus
         406504 7711360
                                     107068-107277
                           Minus
50
                                     106956-107121
         406554 7711566
                           Plus
```

TABLE 20: 544 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EXTRACELLULAR OR CELL-SURFACE PROTEINS

Table 20 shows 544 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst the 73 breast cancer specimens was greater than or equal 100 units, and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains). The predicted protein domains are noted.

15

10

5

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

20 Pred.Prot.Domains: Predicted Protein Domains

Unigene Title: Unigene gene title

R1: Ratio of 93rd percentile of tumor to 85th percentile of normal body tissue

25	Pkey	ExAccn	UnigenelD	Pred.Prot.Domains	UnigeneTitle	R1
		AF015224		SS,Uteroglobin,SS,Uteroglobin	mammaglobin 1	168.6
		AA401369		TM	ESTS	73.2 65.7
20		AI668594		,SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	57.6
30		AW170035 AA250737		TM	Homo sapiens breast cancer antigen NY-BR BMP-R1B	57.6 55.9
		U31875	Hs.272499	death,ZU5,TM,Activin_recp,pkinase,	short-chain alcohol dehydrogenase family	53.8
		BE069341	∏S.272499	,SS,TM TM	qb:QV3-BT0381-270100-073-c08 BT0381 Homo	50.3
		NM_000230	∩⊔e 104236	SS,Leptin,SS,Leptin,	leptin (murine obesity homolog)	40.8
35		AA195651		,SS,Dihydroorotase,	ESTs	39.3
33		L11690	Hs.620	Plectin_repeat,SH3,spectrin,SS,Plectin_r	bullous pemphigoid antigen 1 (230/240kD)	37.3
		D31152	Hs.179729	SS,C1g,Collagen,SS,C1g,Collagen,	collagen, type X, alpha 1 (Schmid metaph	35.2
		AJ224172		,SS,Uteroglobin,	lipophilin B (uteroglobin family member)	30.0
		AA009647		,SS,TM,disintegrin,Pep_M12B_propep,Repro		25.7
40		AF044197		SS,IL8,SS	small inducible cytokine B subfamily (Cy	25.2
. •		S73265	Hs.1473	SS,Bombesin,SS	gastrin-releasing peptide	24.8
		AI624342		,SS,TM,Cation_efflux	ESTs	24.1
	451110	AI955040	Hs.265398	SS	ESTs, Weakly similar to transformation-r	24.0
	400297	Al127076	Hs.334473	TM	hypothetical protein DKFZp564O1278	23.8
45	420813	X51501	Hs.99949	SS,SS	prolactin-induced protein	22.8
	452744	A1267652	Hs.30504	,SS,TM,GNS1_SUR4,cNMP_binding,Rlla	Homo sapiens mRNA; cDNA DKFZp434E082 (fr	22.6
		NM_003613		ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
		X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
= 0		AI905687		SS	aldehyde dehydrogenase 9 family, member	20.3
50		AI375572	Hs.172634	,pkinase,	ESTs	19.2
		AA193450		,SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
				TM	hypothetical protein DKFZp564O1278	18.2
		AA399272		SS	ESTs	18.2
		X52509	Hs.161640	,SS,TM,aminotran_1_2,Cadherin_C_term,cad		18.1
55		AW840171	Hs.265398	SS 450 CO THE 450	ESTs, Weakly similar to transformation-r	17.9
	402578	*1000003	U- 000004	SS,p450,SS,TM,p450	C1001134:gi 2117372 pir 165981 fatty ac	17.8
		A1263307	Hs.239884	SS	H2B histone family, member L	17.8 17.7
		AL120862		SS	programmed cell death 9 (PDCD9)	17.7 17.5
	444342	NM_014398	ons.1000/	Lamp,SS,TM,Lamp,	similar to lysosome-associated membrane	17.5

	449765	N92293	Hs.206832	SS	ESTs, Moderately similar to ALU8_HUMAN A	17.3
		AA321649			small inducible cytokine subfamily B (CX	17.0
			Hs.155956	,SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
			Hs.137476	,pkinase,	paternally expressed 10	16.5
5		AB014544		LRRCT,LRR,SS,LRRCT,serine_carbpept	KIAA0644 gene product	16.3
5					ESTs	16.2
			Hs.57471	SS SS,hemopexin,Peptidase_M10,SS,Peptidase_		15.7
			Hs.83169			15.5
		AA296520		SS,lectin_c,sushi,EGF,SS,EGF,lectin_c,su	selectin E (endothelial adhesion molecul	
10		AA441838		SS	hypothetical protein FLJ14834	15.5
10		NM_007115			tumor necrosis factor, alpha-induced pro	15.0
			Hs.15456	PDZ,SS	PDZ domain containing 1	14.9
		AA236115		SS	ESTs	14.8
			Hs.30743	SS,SS	preferentially expressed antigen in mela	14.7
	422805	AA436989	Hs.121017	histone,SS,histone,histone	H2A histone family, member A	14.3
15	448390	AL035414	Hs.21068		hypothetical protein ·	14.2
	447342	Al199268	Hs.19322	,SS,lipocalin	Homo sapiens, Similar to RIKEN cDNA 2010	14.2
	411869	W20027	Hs.23439	,SS,Peptidase_M1,	ESTs	13.9
		AI082692		,SS,TM,SNF	ESTs	13.7
		AA031956			gb:zk15e04.s1 Soares_pregnant_uterus_NbH	13.7
20		Al733682	Hs 130239	SS	ESTs	13.5
20			Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1		13.5
		BE336654			H3 histone family, member A	13.3
		AA948033			ESTs	13.2
				,SS,histone,histone,linker_histone	ESTs	13.1
25		AA706910		,SS,Ribosomal_L7Ae,		
25		Al951118		TM	Homo sapiens breast cancer antigen NY-BR	13.1
		AW873596		,SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
		A1684808		SS	programmed cell death 9 (PDCD9)	12.9
		Al351010		,SS,Lysyl_oxidase	lysyl oxidase	12.8
• •	400295	W72838	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
30			Hs.108106	,SS,G9a,PHD,	transcription factor	12.5
	427365	A1873274	Hs.190721	TM	ESTs	12.4
	433365	AF026944	Hs.293797	,SS,TPR	ESTs	12.3
	409269	AA576953	Hs.22972	SS,TM,UPF0016,SS,TM,UPF0016	hypothetical protein FLJ13352	12.0
		AJ224741		SS,EGF,vwa,SS,TM,vwa,	matrilin 3	11.9
35		AW732573		TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
		BE007371		,SS,TM,Folate_carrier	ESTs	11.9
		Al357412		SS SS	ESTs	11.8
			Hs.102267		lysyl oxidase	11.8
		NM_002497		pkinase,SS,TM,pkinase,polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
40		AL049689		SS Twiphinase, polypreny_sym,	hypothetical protein similar to tenascin	11.6
40					ESTs	11.5
			Hs.24286	,SS,TM,7tm_1,p450,rrm		11.5
		Al907673		,pkinase,	gb:IL-BT152-080399-004 BT152 Homo sapien	11.4
		AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	
15		AL360204	Hs.283853	SS	Homo sapiens mRNA full length insert cDN	11.4
45	402606			SS	NM_024626:Homo sapiens hypothetical prot	11.3
		H57646	Hs.42586	,SS,Acyltransferase,	KIAA1560 protein	11.2
			Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S24	le,ribosomal protein S24	11.1
		AF026941		,TM,IBR	Homo sapiens cig5 mRNA, partial sequence	11.1
	431385	BE178536	Hs.11090	,SS,TM	membrane-spanning 4-domains, subfamily A	11.1
50	423887	AL080207	Hs.134585	,SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
	415385	R17798	Hs.7535	,SS,Fork_head,	COBW-like protein	10.9
		U79293	Hs.159264	SS	Human clone 23948 mRNA sequence	10.7
		NM_007050		,SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
		AB007948		,SS,laminin_B,laminin_EGF,laminin_Nterm	KIAA0479 protein	10.3
55		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase		10.3
33		NM_000685		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
		U80736	Hs.110826	SS	trinucleotide repeat containing 9	10.3
			Hs.301663	,SS,pkinase,	ESTs	10.3
					ESTs	10.2
60		AW016531	ΠS. 122 147	,SS,ArfGap,		
60	400608			SS,TM,SS,TM	C10001899:gi 7508633 pir T25392 hypothe	10.1
		BE242870		SS	solute carrier family 1 (glial high affi	10.0
		W68815	Hs.301885	SS	Homo sapiens cDNA FLJ11346 fis, clone PL	9.9
	402408			,SS,carb_anhydrase	NM_030920*:Homo sapiens hypothetical pro	9.8
			Hs.12844	,SS,TM,ras	EGF-like-domain, multiple 6 (EGFL6)	9.7
65			Hs.26770	SS,lipocalin,lipocalin,	fatty acid binding protein 7, brain	9.6
	405654	NA		BTB,SS	C12001521:gi 7513934 pir T31081 cca3 pr	9.6
			Hs.161160	SS	ESTs	9.6

	416220	N49776	Hs.170994	,SS,TM	hypothetical protein MGC10946	9.5
		M30703	Hs.270833	SS,TM,EGF,SS	amphiregulin (schwannoma-derived growth	9.5
		AW368397		,SS,UDPGT	Homo sapiens cDNA FLJ14438 fis, clone HE	9.4
		AA032279		TM	six transmembrane epithelial antigen of	9.4
5		AA279490		SS,TM,calreticulin,SS,TM,calreticulin,	calmegin	9.4
5					BMP-R1B	9.4
		Al733881		death,ZU5,TM,Activin_recp,pkinase,		
		AA291377		TM	ESTs	9.3
		Al678059	Hs.202676	SS	synaptonemal complex protein 2	9.3
4.0	442441	AI820662	Hs.129598	SS	ESTs	9.1
10		X73114	Hs.169849	,SS,TM,fn3,ig,	myosin-binding protein C, slow-type	9.1
	406687	M31126	Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase_	_matrix metalloproteinase 11 (MMP11; stro	9.1
	448693	AW004854	Hs.228320	SS	hypothetical protein FLJ23537	9.1
		AB041035		Ferric_reduct,TM,Ferric_reduct,	NM_016931:Homo sapiens NADPH oxidase 4 (9.1
		H59846	Hs.128355	SS	ESTs, Moderately similar to ALU7_HUMAN A	9.0
15			Hs.25933	,SS,TM,histone,Sec1,histone,sugar_tr	ESTs	8.9
13		X72755	Hs.77367	SS,IL8,SS,IL8	monokine induced by gamma interferon	8.8
			115.11301		Eos Control	8.8
	400285		U- 445000	,TM,ABC_tran,ABC_membrane,		8.8
		D30783	Hs.115263	SS,TM,EGF,SS,TM	epiregulin	
20		NM_004354		cyclin,SS	cyclin G2	8.8
20		AW512260		SS	ESTs	8.7
	452281		Hs.28792	,SS,TGF-beta,TGFb_propeptide,	Homo sapiens cDNA FLJ11041 fis, clone PL	8.7
		AA642007		SS	ESTs	8.6
	408380	AF123050	Hs.44532	,SS,TM,ubiquitin,7tm_3,ANF_receptor,sush	diubiquitin	8.6
	443788	AI732643	Hs.144151	TM	ESTs	8.6
25		A1222020		SS,SS	CocoaCrisp	8.5
		BE622641		SS.SS.ENTH.I LWEQ.ENTH.I LWEQ.DNA r	mis_reESTs, Weakly similar to I38022 hypotheti	8.5
		H69125	Hs.133525	,SS,TM	ESTs	8.5
		NM_004525		SS,EGF,ldl_recept_a,ldl_recept_b,SS,TM,E	low density lipoprotein-related protein	8.4
		AW963419		SS SS	stanniocalcin 2	8.4
30						8.4
50		AA635062		TM	Homo sapiens mRNA; cDNA DKFZp434O0515 (f	8.3
		A1831297		TM	ESTs	
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_003866		SS,SS	inositol polyphosphate-4-phosphatase, ty	8.3
		X65724	Hs.2839	SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
35	418092	R45154	Hs.106604	,death,ZU5,pkinase,Activin_recp,	ESTs	8.3
	439840	AW449211	Hs.105445	SS	GDNF family receptor alpha 1	8.2
	427811	M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_M	114carboxypeptidase B1 (tissue)	8.2
	420807	AA280627	Hs.57846	SS,cpn10	ESTs	8.2
		W47595	Hs.169300	SS,TGF-beta,TGFb_propeptide,SS	transforming growth factor, beta 2	8.2
40		AW885727		,SS,kazal,	ESTs	8.1
10		AW419196		SS	hypothetical protein FLJ13782	8.1
		AW248508		SS	Homo sapiens cDNA FLJ14035 fis, clone HE	8.0
	404347	AV1240300	113.213121	SS	Target Exon	8.0
		A A 7 4 2 0 0 4		TM	gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	8.0
45		AA743991	11- 407774			8.0
45		AA808229		,SS,IMPDH_C,IMPDH_N,CBS	ESTs	
		NM_016010		SS	CGI-62 protein	7.9
		X70697	Hs.553	TM,SNF,SS,TM,SNF,	solute carrier family 6 (neurotransmitte	7.9
		N39015	Hs.190368	,SS,TM	ESTs	7.8
~ 0		AL138272		,TM,cpn60_TCP1,Sema,	ESTs	7.8
50		Al085198	Hs.164226	,TSPN,vwc,tsp_1,EGF,thiored,	ESTs	7.8
		AI754693	Hs.145968	,TM,cadherin,Cadherin_C_term,	ESTs	7.7
	444649	AW207523	Hs.197628	,SS,rrm,	ESTs	7.6
	435147	AL133731	Hs.4774	,TM,SDF,UPAR_LY6,	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	7.6
		A1742605	Hs.193696	TM	ESTs	7.6
55		AW207206		SS	ESTs	7.6
		AK000713		,SS,UDPGT	hypothetical protein FLJ20706	7.5
		AL031224		SS,SS	transcription factor AP-2 beta (activati	7.5
		R41396			hypothetical protein FLJ23045	7.5
			Hs.101774	SS		
60		AA157291		SS SC TM TM	ubinuclein 1	7.5
60		U41060	Hs.79136	SS,TM,TM	LIV-1 protein, estrogen regulated	7.5
		AW378065		,SS,Pep_M12B_propep,Reprolysin,tsp_1,	ESTs	7.4
		Al742170	Hs.31297	,SS,TM	duodenal cytochrome b	7.4
		Al240665	Hs.8895	,SS,TM,disintegrin,Pep_M12B_propep,Repro		7.3
		U22376	Hs.1334	SS,NA,myb_DNA-binding	v-myb avian myeloblastosis viral oncogen	7.3
65	450603	R43646	Hs.12422	SS	ESTs	7.2
	422867	L32137	Hs.1584	SS,EGF,tsp_3,SS,E2F_TDP,	cartilage oligomeric matrix protein (COM	7.2
		U37519	Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2
					•	

	426451	AI908165	Hs.169946	SS,GATA,	GATA-binding protein 3 (T-cell receptor	7.1
	450701	H39960	Hs.288467	,SS,LRR	Homo sapiens cDNA FLJ12280 fis, clone MA	7.1
	419519	Al198719	Hs.176376	SS	ESTs	7.1
		U92649	Hs.64311	,TM,disintegrin,Reprolysin,	a disintegrin and metalloproteinase doma	7.1
5		AB029496		SS,ig,Sema,SS,Sema,efhand	semaphorin sem2	7.0
9		AA102670		CO TIM CO TIM	gamma-aminobutyric acid (GABA) A recepto	7.0
						7.0
		W87707	Hs.82065	,TM,fn3,	interleukin 6 signal transducer (gp130,	
		X63578	Hs.295449	SS,efhand,SS,efhand,ras	parvalbumin	7.0
10		R31178	Hs.287820	,SS,fn3,fn1,fn2,fn2,fn1	fibronectin 1	6.9
10	442818	AK001741	Hs.8739	WD40,SS	hypothetical protein FLJ10879	6.9
	407366	AF026942		,TM,IBR	gb:Homo sapiens cig33 mRNA, partial sequ	6.8
	427427	AF077345	Hs.177936	SS,lectin_c,SS	ESTs	6.8
		AW803341		SS	gb:IL2-UM0079-090300-050-D03 UM0079 Homo	6.7
	401045			ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_		
15	, , , , , ,	C11001883	*:ail67532781rei	f[NP_033938.1] c	6.7	
10	118086	Al123555		,SS,Reprolysin,tsp_1,	ESTs	6.7
						6.7
		R41823	Hs.7413	,TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	
		AA243837		SS	ESTs	6.6
20		A1655499		,TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
20		R20893	Hs.325823	,SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	6.6
	444381	BE387335	Hs.283713	,SS,mito_carr	ESTs, Weakly similar to S64054 hypotheti	6.6
	404091	NA		,TM,7tm_3,ANF_receptor,	Target Exon	6.6
	417866	AW067903	Hs.82772	SS,Collagen,COLFI,TSPN,SS,TSPN	collagen, type XI, alpha 1	6.6
		AL135623		SS.SS	KIAA0575 gene product	6.5
25		U85658	Hs.61796	,SS,Ribosomal_S4e	transcription factor AP-2 gamma (activat	6.4
		AW067800		SS	stanniocalcin 2	6.2
		NM_005025		,SS,serpin,	serine (or cysteine) proteinase inhibito	6.2
		AI815601		SS,TM,ig,SS,TM	CD83 antigen (activated B lymphocytes, i	6.2
		AA219691			RAB6 interacting, kinesin-like (rabkines	6.2
20				,SS,kinesin,		
30		AW167087		,SS,ig,Sema,pkinase,	ESTs	6.2
		AA026880		,SS,TM,fn3,	prolactin receptor	6.1
			Hs.9029	filament,SS,filament,filament	DKFZP434G032 protein	6.1
		W26713	Hs.256972	,SS,TM,DAGKa,DAGKc,	ESTs	6.1
	428479	Y00272	Hs.184572	,SS,pkinase,pkinase	cell division cycle 2, G1 to S and G2 to	6.1
35	400300	X03363		,SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu	ırHER2 receptor tyrosine kinase (c-erb-b2,	6.1
			Hs.102720	SS	ESTs	6.1
		U94362	Hs.58589		glycogenin 2	6.1
	401781	00.002		,SS,filament,Pribosyltran,filament,Armad	Target Exon	6.1
	117350	NM_012093	RHe 18268	SS,adenylatekinase,	adenylate kinase 5	6.1
40	402230		01 13. 10200	,SS,TM,p450,	Target Exon	6.1
-1 0		NM_003528	Ua 2470	histone,SS,histone,	H2B histone family, member Q	6.1
						6.0
		Al249368		,SS,TM	ESTs :	
		BE550224		SS	metallothionein 1E (functional)	6.0
4 ~			Hs.93913	SS,IL6,IL6,	interleukin 6 (interferon, beta 2)	6.0
45		N32536	Hs.42645		solute carrier family 16 (monocarboxylic	6.0
	419703	Al793257	Hs.128151	,SS,zf-C2H2,	ESTs	5.8
	424687	J05070	Hs.151738	SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe	pmatrix metalloproteinase 9 (gelatinase B	5.8
	449679	AI823951	Hs.129700	SS	tolloid-like 1	5.8
	421296	NM_002666	3Hs.103253	SS	perilipin	5.8
50		AW664964		,SS,TM	ESTs	5.7
- •		AA242758		,SS,TM	LIV-1 protein, estrogen regulated	5.7
		AB020689		SS	KIAA0882 protein	5.7
			Hs.208275	SS	ESTs, Weakly similar to ALUA_HUMAN !!!!	5.7
		X81334		SS.Peptidase M10,hemopexin,SS,Peptidase		5.6
55			Hs.2936		- , , ,	
33		AA904244	HS. 153205	TM	ESTs	5.6
	400286			SS,TM,ABC_tran,ABC_membrane,SS	C16000922:gi]7499103 pir T20903 hypothe	5.6
		H38026	Hs.308	arrestin,SS	arrestin 3, retinal (X-arrestin)	5.5
		NM_000163		SS,TM,fn3,SS	growth hormone receptor	5.5
		W57554	Hs.125019	SS	lymphoid nuclear protein (LAF-4) mRNA	5.5
60	439509	AF086332	Hs.58314	,SS,TM,Syntaxin	ESTs	5.4
		NM_005940		SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
		NM_001898		,SS,cystatin,	cystatin SN	5.4
		NM_005824		SS	37 kDa leucine-rich repeat (LRR) protein	5.4
		AJ297436		,SS,TM	prostate stem cell antigen	5.4
65		AF153330		,SS,TM	solute carrier family 19 (thiamine trans	5.3
00		AL355715		SS	programmed cell death 9	5.3
		AF086120		,SS,TM,UDPGT,casein_kappa	ESTs	5.2
	403010	AI 000 120	113.102/33	,00, mi,00F G I,0006m_nappa	2010	0.2

	111111	*1000007	11 400504	00 774 71	5om	- 0
		A1806867		,SS,TM,Phosphodiest,	ESTs	5.2
		N54926	Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
		M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
_	418636	AW749855		,SS,TM,HECT	gb:QV4-BT0534-281299-053-c05 BT0534 Homo	5.2
5	429353	AL117406	Hs.200102	,SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
		R81733	Hs.33106	,SS,HECT,zf-UBR1,PABP,14-3-3,	ESTs	5.1
		W17064	Hs.332848	SS	SWI/SNF related, matrix associated, acti	5.1
		AI685086	Hs.26339	,SS,ras,	ESTs, Weakly similar to S21348 probable	5.1
		X52730	Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_7		0.1
10	720020					•
10	400000		nolamine N-met		5.1	E 4
		Al633559	Hs.310359	SS	ESTs	5.1
			Hs.125087	SS	ESTs	5.1
	403593			,CIDE-N,pkinase	Target Exon	5.1
	407758	D50915	Hs.38365	SS,SS	KIAA0125 gene product	5.0
15	445234	AW137636	Hs.146059	,SS,TM	ESTs	5.0
	411165	NM_000169	9Hs.69089	SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo	galactosidase, alpha	4.9
		NM_01458		SS,lipocalin,SS,lipocalin	odorant-binding protein 2A	4.9
		W88559	Hs.1787	,TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
		AA206186		SS,TM,TM	monocyte to macrophage differentiation-a	4.9
20	401093	AA200 100	113.7 3003		C12000586*:gij6330167 dbj BAA86477.1 (A	4.9
20		1100004	11- COCOO	TM,LRRCT,TM,LRRCT,		
		U80034	Hs.68583	Peptidase_M3,	mitochondrial intermediate peptidase	4.9
		AW085961		SS	ESTs	4.9
		Al247716		,SS,adh_zinc,	ESTs	4.9
~ ~		NM_004460		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_	_N_fibroblast activation protein, alpha	4.9
25	417975	AA641836	Hs.30085	,SS,trypsin	hypothetical protein FLJ23186	4.9
	421072	AI215069	Hs.89113	SS	ESTs	4.8
	427032	AF012023	Hs.173274	,SS,14-3-3	integrin cytoplasmic domain-associated p	4.8
		M73700	Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
	403199			SS,TM,Folate_carrier,SS,TM,Folate_carrie	NM_025243*:Homo sapiens solute carrier f	4.8
30		AW057736	He 303010	,SS,TM,pkinase,Recep_L_domain,SH2,PH,Fi		4.8
50		AF070526				4.7
				,SS,Ca_channel_B,	Homo sapiens clone 24787 mRNA sequence	
		M93221	Hs.75182	SS,TM,lectin_c,fn2,Ricin_B_lectin,SS,TM	mannose receptor, C type 1	4.7
		AA526235		SS	Homo sapiens cDNA FLJ11983 fis, clone HE	4.7
2.5		BE093589		SS	hypothetical protein FLJ23468	4.6
35		AA447453		,SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
		AW016669		,SS,TM,CBS,voltage_CLC	ESTs	4.6
	450606	AI668605	Hs.60380	,TM,Glyco_hydro_1	ESTs, Moderately similar to ALU6_HUMAN A	4.6
	435542	AA687376	Hs.269533	,SS,pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
	417576	AA339449	Hs.82285	AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	phosphoribosylglycinamide formyltransfer	4.6
40		A1860021		pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
		AA151342		SS,UPF0099,SS,UPF0099,	CGI-147 protein	4.6
		BE614743		,SS,TM,MAPEG,	prostaglandin E synthase	4.5
		Al493046		,SS,TM,UDPGT	ESTs	4.5
15	452190		Hs.91668	,SS,TM,PH,SH2,Furin-like,pkinase,Recep_L	Homo sapiens clone PP1498 unknown mRNA	4.5
45		AA831879		,SS,Hist_deacetyl,	ESTs	4.5
			Hs.78915	pkinase,OPR,	GA-binding protein transcription factor,	4.5
			Hs.1406	SS,trefoil,SS,TM,ldl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
		BE391804	Hs.62661	SS,TM,GBP,TM,GBP	guanylate binding protein 1, interferon-	4.5
	426327	W03242	Hs.44898	SS	Homo sapiens clone TCCCTA00151 mRNA sequ	4.5 °
50	406639	M97711		SS,SS,ig,	gb:Human T-cell receptor (V beta 18.1, J	4.5
	452834	AI638627	Hs.105685	,SS,DEAD,Fork_head	KIAA1688 protein	4.5
		AA179949		SS	Homo sapiens mRNA; cDNA DKFZp564N0763 (f	4.4
		AA863360		,SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
		AA976718		,ig,Sema,	ESTs	4.4
55		AA312082		SS	GDNF family receptor alpha 1	4.4
55					hypothetical protein MGC15754	
		AW294092		,SS,ras,Y_phosphatase,ras		4.4
		BE466639		,SS,HMG_box,filament,	Homo sapiens cDNA FLJ13591 fis, clone PL	4.4
		AK000136		SS,LRR,SS	asporin (LRR class 1)	4.4
60	453619		Hs.33922	SS	Homo sapiens, clone MGC:9084, mRNA, comp	4.3
60		NM_000246		SS,LRR,	MHC class II transactivator	4.3
		Al472078		,SS,ArfGap,	ESTs	4.3
	431701	AW935490	Hs.14658	,SS,BIR	Human chromosome 5q13.1 clone 5G8 mRNA	4.3
	416931	D45371	Hs.80485	SS,C1q,Collagen,SS,C1q,	adipose most abundant gene transcript 1	4.3
		AW296927		,SS,TM,Peptidase_M1,	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3
65	418867		Hs.89404	SS,homeobox,homeobox,	msh (Drosophila) homeo box homolog 2	4.3
		BE464288		,SS,TM,MIP,	ESTs	4.3
	447490	AW262580	Hs.147674	,SS,TM,cadherin,cadherin	protocadherin beta 16	4.3
	TT1 TUU	, ., , , , , , , , , , , , , , , , , ,		,,	protogramonii bota 19	

				*	
	441560	F13386 Hs.7888	,pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
	409064	AA062954 Hs.141883	,SS,CUB,	ESTs	4.3
	422667	H25642 Hs.133471	,SS,TM,FMO-like	ESTs	4.3
_	454032	W31790 Hs.194293	,SS,TM	ESTs, Weakly similar to I54374 gene NF2	4.3
5	432663	Al984317 Hs.122589	TM	ESTs	4.3
	401747		,SS,filament,filament	Homo sapiens keratin 17 (KRT17)	4.3
		NM_013257Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2
		Al571514 Hs.133022	,SS,TM	ESTs	4.2
1.0		AW073310 Hs.163533	,pkinase,	Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
10		Al954968 Hs.279009	,SS,TM	matrix Gla protein	4.2
		Al821005 Hs.118599	,SS,GDNF,	ESTs	4.2
		AW972565 Hs.32399	WH1,WH1	ESTs, Weakly similar to S51797 vasodilat	4.2
		NM_000399Hs.1395	zf-C2H2,SS	early growth response 2 (Krox-20 (Drosop	4.2
15		Al345227 Hs.105448	,SS,TM,pkinase	ESTs, Weakly similar to B34087 hypotheti	4.1
15		AA829286 Hs.332053	,SS,SAA_proteins,ABC_membrane,ABC_tran		4.1 4.1
		AI192105 Hs.147170	SS COLTILIDAD Calleger	ESTS	4.1
		AI827248 Hs.224398	,COLFI,vwc,Collagen,	Homo sapiens cDNA FLJ11469 fis, clone HE wingless-type MMTV integration site fami	4.1
		AI683487 Hs.152213	,wnt,		4.1
20		Al150491 Hs.90756	,TM,Glyco_hydro_1	ESTs centromere protein A (17kD)	4.1
20	406922	NM_001809Hs.1594	,SS,TM,thiolase, SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
		AL133916 Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
		AL035588 Hs.153203	HLH,SS	MyoD family inhibitor	4.1
	429922		,SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
25		AW594641 Hs.192417	,SS,TM	ESTs	4.0
20	409038		SS,IL8,SS,IL8	small inducible cytokine subfamily A (Cy	4.0
		BE153855 Hs.61460	,SS,HLH	Ig superfamily receptor LNIR	4.0
		NM_005357Hs.95351	,SS,TM,p450,	lipase, hormone-sensitive	4.0
		AA479033 Hs.130315	,SS,TM	ESTs, Weakly similar to A47582 B-cell gr	4.0
30	403329		SS,SS	Target Exon	4.0
		AW014875 Hs.137007	SS	ESTs	4.0
		Al073913 Hs.100686	SS	ESTs, Weakly similar to JE0350 Anterior	4.0
		AW451645 Hs.151504	,SS,Collagen,COLF1,TSPN,	Homo sapiens cDNA FLJ11973 fis, clone HE	4.0
	452410	AL133619 Hs.29383	,SS,TM,ras	Homo sapiens mRNA; cDNA DKFZp434E2321 (f	4.0
35	418661	NM_001949Hs.1189	SS	E2F transcription factor 3	4.0
	431958		SS,TM,Cadherin_C_term,cadherin,SS,TM,cad	dcadherin 3, type 1, P-cadherin (placenta	4.0
	425071	NM_013989Hs.154424	SS,T4_deiodinase,T4_deiodinase,	deiodinase, iodothyronine, type II	4.0
		R36075	,TM,SDF,	gb:yh88b01.s1 Soares placenta Nb2HP Homo	4.0
40	428722		,SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
40	428330		SS,Peptidase_M10,SS,Peptidase_M10,hemo		3.9
		AL039402 Hs.125783	SS	DEME-6 protein	3.9
•	449048		SS,SS,TM	similar to S68401 (cattle) glucose induc	3.9
		M31158 Hs.77439	,SS,cNMP_binding,RIIa,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
15		AW452631 Hs.313803	,SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8 3.8
45		NM_015434Hs.48604	SS	DKFZP434B168 protein	3.8
		BE247550 Hs.86859	SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8
		AB006190 Hs.25475	SS,TM,MIP,SS,TM,MIP, SS	aquaporin 7 KIAA1204 protein	3.8
	414870	N72264 Hs.300670 Al935962 Hs.26289	SS	ESTs	3.8
50		NM_007069Hs.37189	TM,TM	similar to rat HREV107	3.8
50		AA371307 Hs.125056	,SS,DENN	ESTs	3.8
		BE170651 Hs.8700	,SS,START,	deleted in liver cancer 1	3.8
		AW293165 Hs.143134	SS	ESTs	3.8
		AW873606 Hs.149006	,SS,WH1,WH1	ESTs	3.8
55	403943	,	p450,SS,p450	C5000355:gi 4503225 ref NP_000765.1 cyt	3.8
~~		AA057264 Hs.238936	,SS,TM,7tm_1,	ESTs, Weakly similar to (defline not ava	3.8
		AW959861 Hs.290943	SS	ESTs	. 3.8
		NM_002407Hs.97644	,SS,SRCR,Uteroglobin	mammaglobin 2 (MGB2; mammaglobin B; lip	3.8
		Al208121 Hs.147313	,SS,TM	ESTs, Weakly similar to l38022 hypotheti	3.7
60		AW974476 Hs.183601	SS,RGS,RGS,RGS	regulator of G-protein signalling 16	3.7
		BE160198	TM	gb:QV1-HT0413-010200-059-h03 HT0413 Homo	3.7
		M26380 Hs.180878	,SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7
	418203	X54942 Hs.83758	CKS,SS,CKS,	CDC28 protein kinase 2	3.7
<i>-</i> -	430376	AW292053 Hs.12532	SS	chromosome 1 open reading frame 21	3.7
65		Al878918 Hs.10526	SS	cysteine and glycine-rich protein 2	3.7
		AW373784 Hs.71	SS,ig,MHC_I,connexin,SCAN,SS,TM	alpha-2-glycoprotein 1, zinc	3.7
	429638	Al916662 Hs.211577	SS,TM,SS	kinectin 1 (kinesin receptor)	3.7

			_			
		Al041793 Hs		,TM,7tm_1,	ESTs	3.7
	451859	H44491 Hs	.252938	,SS,TM,EGF,ldl_recept_a,ldl_recept_b,EGF	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
	420281	Al623693 Hs		,SS,AAA,	ESTs	3.7
	427691	AW194426 Hs	.20726	,SS,Glycos_transf_2,	ESTs	3.7
5				SS	ESTs	3.7
•				Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
		BE379727 Hs		lipocalin,SS,lipocalin,lipocalin,ferriti	fatty acid binding protein 4, adipocyte	3.7
						3.7
		AW301344 Hs		,SS,Pribosyltran,Sulfatase	DNA replication factor	
10		NM_014735Hs			KIAA0215 gene product	3.7
10		Al126271 Hs.		SS	ESTs, Weakly similar to YZ28_HUMAN HYPOT	3.7
	425548	AA890023 Hs	.1906	SS,TM,fn3,SS,TM,fn3,	prolactin receptor	3.7
	446619	AU076643 Hs	.313	,SS,TM,efhand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	411213	AA676939 Hs.	.69285	SS,TM,CUB,F5_F8_type_C,MAM,SS,TM,CUE		3.6
				SS,TM,Desaturase,SS	stearoyi-CoA desaturase (delta-9-desatur	3.6
15		AL049176 Hs.		SS	chordin-like	3.6
10		AW207175 Hs.		,SS,7tm_1,SPRY,	ESTs	3.6
						3.6
		T97307		,SS,TM,GDA1_CD39	gb:ye53h05.s1 Soares fetal liver spleen	
	401866			,SS,filament,	Target Exon	3.6
20				SS,homeobox,Ets,SS,homeobox,	mesenchyme homeo box 1	3.6
20		AA502490 Hs.		SS	ESTs	3.6
	426310	NM_000909Hs.	.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
	440029	AW089705 Hs.		SS	ESTs, Weakly similar to S64329 probable	3.6
	408573	AA284775 Hs.	.43148	,SS,TM,PMP22_Claudin,	ESTs	3.6
			.271387	,SS,TM,IL8	small inducible cytokine subfamily A (Cy	3.6
25		NM_014400Hs		,SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
20		Al791493 Hs.			ESTs, Weakly similar to A36036 cytochrom	3.6
		Al308876 Hs.		,TM,hemopexin,Peptidase_M10,hemopexin,P		3.6
			70457			3.6
		AF245505 Hs.		ig,LRRCT,	DKFZP564l1922 protein	
20		Al417828 Hs.		,SS,TM	ESTs	3.5
30		AA847843 Hs.		,SS,HMG_box,	Homo sapiens, clone IMAGE:3351295, mRNA	3.5
			.323910	,SS,TM,SH2,PH,pkinase,Recep_L_domain,Fu		3.5
	449051	AW961400 Hs.	.333526	SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
	434398	AA121098 Hs.	.3838	pkinase,POLO_box,SS,pkinase,POLO_box,	serum-inducible kinase	3.5
					hypothetical protein FLJ20093	3.5
35	459496	AA808940 Hs.		,SS,TM,KRAB,SCAN,zf-C2H2,ig	EST	3.5
-		NM_002543Hs.		SS,TM	oxidised low density lipoprotein (lectin	3.5
		AA116021 Hs.		SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
						3.5
		Al651930 Hs.		SS	ESTs	
40		BE280074 Hs.			cyclin B1	3.5
40		AW452434 Hs.			ESTs, Weakly similar to ALU5_HUMAN ALU S	3.5
	421991	NM_014918Hs.	.110488	SS	KIAA0990 protein	3.4
	420058	AK001423 Hs.	.94694	SS	Homo sapiens cDNA FLJ10561 fis, clone NT	3.4
	425776	U25128 Hs.	159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4
	407846	AA426202 Hs.	.40403	,TM,ABC_membrane,ABC_tran,Ribosomal_S	4eCbp/p300-interacting transactivator, wit	3.4
45	406925		9739	COTILIAN I LOWID DI CAD DAG E	5 T. 1 10	3.4
		AA250970 Hs.	251946	SS,rrm,PABP,pkinase,14-3-3,rrm	poly(A)-binding protein, cytoplasmic 1-I	3.4
		NM_002318Hs.		SS,TM,mito_carr,Lysyl_oxidase	reglyceror-3-phosphate denydrogenase 1 (so poly(A)-binding protein, cytoplasmic 1-l lysyl oxidase-like 2	3.4
		BE390551 Hs.		SS,START,SS,START,NNMT_PNMT_TEMT,		3.4
		NM_003512Hs.	20777	SS,histone,Calc_CGRP_IAPP,ig,MHC_I,SPR	V H2A histone family member I	3.4
50						3.4
50	420002	NM_000346Hs.	2010	SS,HMG_box,	SRY (sex determining region Y)-box 9 (ca	3.4
		AA442324 Hs.	./95	histone,SS,histone,BolA	H2A histone family, member O	
		M25809 Hs.	.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
	401780			filament,SS,filament,filament	NM_005557*:Homo sapiens keratin 16 (foca	3.4
	447131	NM_004585Hs.		TM	retinoic acid receptor responder (tazaro	3.4
55	418334	AA319233 Hs.	.5521	,SS,TM,Ribosomal_L27e,	ESTs	3.4
	415138	C18356 Hs.	.295944	Kunitz_BPTI,	tissue factor pathway inhibitor 2	3.4
		AF182277 Hs.		SS,p450,SS	cytochrome P450, subfamily IIB (phenobar	3.4
		AA825686 Hs.		SS	ESTs. Weakly similar to S65824 reverse t	3.4
				SS,IL8,	small inducible cytokine subfamily B (Cy	3.4
60		NM_005419Hs.		SH2,STAT,SS,STAT	signal transducer and activator of trans	3.4
00					CDC2-related protein kinase 7	3.4
		AW968504 Hs.		,pkinase,		
	405366	DE0745-0 11		RhoGEF,PH,SS,RhoGEF,PH,	NM_003371*:Homo sapiens vav 2 oncogene (3.4
		BE274552 Hs.		SAP,SS,FG-GAP,vwa	protein inhibitor of activated STAT3	3.4
~ ~		AW797437 Hs.		SS,sushi,trypsin,vwa,rrm,fibrinogen_C,fn	B-factor, properdin	3.3
65				,SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
	416406	D86961 Hs.		,SS,TM	lipoma HMGIC fusion partner-like 2	_. 3.3
	433068	NM_006456Hs.	288215	,SS,Pribosyltran,	sialyltransferase	3.3
	·					

	445462 AA378776 Hs.288649	SS,SS	hypothetical protein MGC3077	3.3
	439452 AA918317 Hs.57987	SS,SS	B-cell CLL/lymphoma 11B (zinc finger pro	3.3
	452017 AF109302 Hs.27495	SS	prostate cancer associated protein 7	3.3
	409099 AK000725 Hs.50579	SS	hypothetical protein FLJ20718	3.3
5	452106 Al141031 Hs.21342	SS	ESTs	3.3
	447519 U46258 Hs.339665	SS	ESTs	3.3
	426928 AF037062 Hs.172914	,SS,adh_short,TGF-beta,TGFb_propeptide	retinol dehydrogenase 5 (11-cis and 9-ci	3.3
	438825 BE327427 Hs.79953	,SS,TM,histone,ANF_receptor,guanylate_cy	ESTs	3.3
	414575 H11257 Hs.22968	,SS,pkinase,ig,	Homo sapiens clone IMAGE:451939, mRNA se	3.3
10	417837 AL079905 Hs.1103	SS,TGFb_propeptide,TGF-beta,SS	transforming growth factor, beta 1	3.3
	422128 AW881145	SS	gb:QV0-OT0033-010400-182-a07 OT0033 Homo	3.3
	445941 Al267371 Hs.172636	SS,SS,lipoxygenase,PLAT	ESTs	3.3
	429973 Al423317 Hs.164680	.SS.T-box.UDPGT	ESTs	3.3
	444542 Al161293 Hs.280380	SS,SS,Peptidase_M1,EGF,ig,lectin_c,sushi	aminopeptidase	3.3
15	459561 Al547306 Hs.134981	SS	ESTs	3.3
	425741 AF052152 Hs.159412	,pkinase,	Homo sapiens clone 24628 mRNA sequence	3.3
	426501 AW043782 Hs.293616	SS	ESTs	3.3
	456508 AA502764 Hs.123469	SS	ESTs, Weakly similar to AF208855 1 BM-01	3.3
	434228 Z42047 Hs.283978	,SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
20	415752 BE314524 Hs.78776	TM	putative transmembrane protein	3.3
	400419 AF084545	,SS,Peptidase_M1,	Target	3.3
	439750 AL359053 Hs.57664	,TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
	423858 AL137326 Hs.133483	,SS,TM	Homo sapiens mRNA; cDNA DKFZp434B0650 (f	3.3
	428514 AW236861 Hs.193139	,SS,START,NNMT_PNMT_TEMT,	ESTs	3.3
25	428698 AA852773 Hs.334838	SS THE TAXABLE PROPERTY.	KIAA1866 protein	3.3
	448988 Y09763 Hs.22785	SS,TM,TM	gamma-aminobutyric acid (GABA) A recepto	3.3
	432072 N62937 Hs.269109	,Sema,ig,	ESTs	3.3
	417433 BE270266 Hs.82128	SS,TM,LRRCT,LRRNT,LRR,TM,LRRCT,	5T4 oncofetal trophoblast glycoprotein	3.3
	452194 Al694413 Hs.332649	,SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
30	444051 N48373 Hs.10247	,SS,ig,	activated leucocyte cell adhesion molecu	3.2
50	420042 AW015140 Hs.161723	,SS,CUB,	ESTs	3.2
	457292 Al921270 Hs.334882	SS,TM,SS,TM,G-patch	hypothetical protein FLJ14251	3.2
	421458 NM_003654Hs.104576	SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
	431104 AW970859 Hs.313503	,Sema,ig,	ESTs	3.2
35	443767 BE562136 Hs.9736	,SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
55	419589 AW973708 Hs.201925	,FGF,	Homo sapiens cDNA FLJ13446 fis, clone PL	3.2
	415447 Z97171 Hs.78454	SS,OLF,OLF,OLF,Ribosomal_L4	myocilin, trabecular meshwork inducible	3.2
	443464 BE548446 Hs.5167	SS,TM,SSF,SS,TM	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	3.2
	423431 AA326062	,SS,p450,p450	gb:EST29171 Cerebellum II Homo sapiens c	3.2
40	413278 BE563085 Hs.833	,SS,TM,ubiquitin,laminin_G,laminin_EGF,k	interferon-stimulated protein, 15 kDa	3.2
	458451 AW297181 Hs.195922	,SS,Ribosomal_L14	ESTs	3.2
	440449 AA885430 Hs.201925	,FGF,	Homo sapiens cDNA FLJ13446 fis, clone PL	3.2
	413753 U17760 Hs.75517	SS,laminin_EGF,laminin_Nterm,adh_short,S	laminin, beta 3 (nicein (125kD), kalinin	3.2
	434876 AF160477 Hs.61460	,SS,HLH	lg superfamily receptor LNIR	3.2
45	435575 AF213457 Hs.44234	SS,ig,SS,TM	triggering receptor expressed on myeloid	3.2
	415773 R21651 Hs.324725	,SS,TM,Ribosomal_S3Ae,G-gamma	ESTs, Moderately similar to A47582 B-cel	3.2
	446440 AV658411 Hs.42656	SS	KIAA1681 protein	3.2
	450847 NM_003155Hs.25590	,SS,homeobox,	stanniocalcin 1	3.2
	426075 AW513691 Hs.270149	,SS,fn3,	ESTs, Weakly similar to 2109260A B cell	3.2
50	452110 T47667 Hs.28005	,SS,TM,Activin_recp,pkinase	Homo sapiens cDNA FLJ11309 fis, clone PL	3.2
	439963 AW247529 Hs.6793	,TM,p450,Ets	platelet-activating factor acetylhydrola	3.2
	402837 NA	SS	ENSP00000241312*:DJ947L8.1.8 (novel Sush	3.2
	439451 AF086270 Hs.278554	,SS,Chromo_shadow,chromo,	heterochromatin-like protein 1	3.1
	406664 L34041 Hs.9739		PEglycerol-3-phosphate dehydrogenase 1 (so	3.1
55	417315 Al080042 Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S24	4e.ríbosomal protein S24	3.1
	413011 AW068115 Hs.821	SS,LRR,LRRNT,SS,LRRNT,LRR,	biglycan	3.1
	414987 AA524394 Hs.294022	,SS,connexin,hormone_rec,zf-C4,connexin	hypothetical protein FLJ14950	3.1
	429197 H24471 Hs.26930	,SS,Gelsolin,	ESTs, Weakly similar to T20272 hypotheti	3.1
	448030 N30714 Hs.325960	,SS,TM	membrane-spanning 4-domains, subfamily A	3.1
60	407604 AW191962 Hs.249239	,SS,TM,C1q,	collagen, type VIII, alpha 2	3.1
	419092 J05581 Hs.89603	SS,TM,SEA,	mucin 1, transmembrane	3.1
	456672 AK002016 Hs.114727	,SS,PK,PK	Homo sapiens, clone MGC:16327, mRNA, com	3.1
	443171 BE281128 Hs.9030	SS,TM,7tm_1,rrm,SS	TONDU	3.1
	452256 AK000933 Hs.28661	,TM,GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
65	432201 Al538613 Hs.298241	SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protease, serine 3	3.1
	406642 AJ245210	SS	gb:Homo sapiens mRNA for immunoglobulin	3.1
	400903 NA	SS	Target Exon	3.1

	434408	Al031771	Hs.132586	,SS,Glyco_hydro_2	ESTs	3.1
	452994	AW962597	Hs.31305	SS,WD40,SS,WD40,	KIAA1547 protein	3.1
	445903	A1347487	Hs.132781	fn3,SS,TM,EF1BD	class I cytokine receptor	3.1
_	424364	AW383226	Hs.201189	SS	ESTs, Weakly similar to G01763 atrophin-	3.1
5	410196	A1936442	Hs.59838	UBACT_repeat,SS,UBACT_repeat,ThiF_fami	lyhypothetical protein FLJ10808	3.1
	419150	T29618	Hs.89640	,TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
	433417	AA587773	Hs.8859	,SS,SRCR,	Homo sapiens, Similar to RIKEN cDNA 5830	3.1
	418624	A1734080	Hs.104211	,Sema,ig,	ESTs	3.1
	436291	BE568452	Hs.5101	,SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
10	411000	N40449	Hs.201619	SS	ESTs, Weakly similar to S38383 SEB4B pro	3.1
	412519	AA196241	Hs.73980	SS,Troponin,Hemagglutinin,SS,TM,C2,Tropo		3.1
	450223	AA418204	Hs.241493	,SS,pro_isomerase,	natural killer-tumor recognition sequenc	3.1
	422790	AA809875	Hs.25933	,TM,histone,Sec1,histone,sugar_tr	ESTs	3.1
			Hs.199754	,SS,TM,7tm_2,GPS	ESTs	3.1
15	435854	AJ278120	Hs.4996	.SS,WD40	putative ankyrin-repeat containing prote	3.1
	447388	AW630534	Hs.76277	,SS,TM,rrm,oxidored_q6,oxidored_q6	Homo sapiens, clone MGC:9381, mRNA, comp	3.1
		R00866		SS	gb:ye79c02.s1 Soares fetal liver spleen	3.0
			Hs.298241	,SS,TM,trefoil,trypsin,trefoil	Transmembrane protease, serine 3	3.0
			Hs.126730	,TM,PH,	ESTs, Weakly similar to KIAA1214 protein	3.0
20			Hs.325823	.SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	3.0
		R91600		,SS,Ran_BP1,LIM,Ran_BP1,GRIP,TPR,LIM	gb:yq10c02.r1 Soares fetal liver spleen	3.0
			Hs.162209	SS,TM,SS,TM,PMP22_Claudin,PMP22_Claudin	dinclaudin 8	3.0
		H58373	Hs.332938	,SS,TM	hypothetical protein MGC5370	3.0
	401197			arf, arf,	ENSP00000229263*:HSPC213.	3.0
25		AW204256	Hs.291887	,wnt,	ESTs	3.0
			Hs.336432	,SS,rrm,zf-RanBP,pkinase,C2,pkinase_C,DA		3.0
	410274	AA381807	Hs.61762	SS,SS	hypoxia-inducible protein 2	3.0
		W27249	Hs.8109	SS	hypothetical protein FLJ21080	3.0
	404826			,SS,TM	Target Exon	3.0
30	458389	H70284	Hs.160152	,SS,RA	ESTs, Weakly similar to FPHU alpha-fetop	3.0
		AL034548		HMG_box,pkinase,zf-CCHC,SS,TM,HMG_box		3.0
		AW977653		.SS,ribonuc_red_sm,	ribonucleotide reductase M2 polypeptide	3.0
			Hs.193465	,death,ZU5,pkinase,Activin_recp,	ESTs	3.0
			Hs.282804	SS,Cu-oxidase,SS,Cu-oxidase,Cu-oxidase	hypothetical protein FLJ22704	3.0
35		C05837	Hs.145807	,SS,TM	hypothetical protein FLJ13593	3.0
			Hs.179808	SS	ESTs	3.0
		AW103364		SS,TGF-beta,TGFb_propeptide,SS,TGF-beta		3.0
		AU077005		SS,disintegrin,Reprolysin,Pep_M12B_prope	a disintegrin and metalloproteinase doma	3.0
			Hs.127698	SS	ESTs, Moderately similar to 2109260A B c	3.0
40		AB032417		Frizzled,Fz,SS,TM,Frizzled,Fz,	frizzled (Drosophila) homolog 4	3.0
. •		U20325	Hs.1707	SS.SS	cocaine- and amphetamine-regulated trans	3.0
		AW385224		,SS,TM,Phosphodiest,	ectonucleotide pyrophosphatase/phosphodi	3.0
			Hs.131257	,SS,TM,G-gamma	ESTs	3.0
			Hs.105822	,SS,TM,pkinase,	ESTs	3.0
	.02207	002001		1001[p		

TABLE 20A

Table 20A shows the accession numbers for those pkeys lacking unigeneID's for Table 20. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	0	

5

Pkey:	Unique Eos probeset identifier number
CAT number	Gene cluster number

Accession: Genbank accession numbers

15

	Pkey	CAT number	Accessions
20	410785 411667 418636 420854	1221055_1 1253334_1 177402_1 197072 1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 BE160198 AW935898 T11520 AW935930 AW856073 AW861034 AW749855 AA225995 AW750208 AW750206 AW296927 AI684514 AI263168 AA281079
25	422128	211994_1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	426878	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	433687	373061_1	AA743991 AA604852 AW272737
30	447197	711623_1	R36075 Al366546 R36167
	451631	878098_1	R00866 R01523 Al806815
	456207	1650781	AA193450
	456592	202684_1	R91600 T87079 AA291455

TABLE 20B

Table 20B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 20. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref;	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15				
1.5	Pkey	Ref	Strand	Nt_position
	400608	9887666	Minus	96756-97558
	400903	2911732	Plus	59112-59228
20	401045	8117619	Plus	90044-90184,91111-91345
	401093	8516137	Minus	22335-23166
	401197	9719705	Plus	176341-176452
		9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-131258,131866-
				131932.132451-132575.133580-134011
25	401780	7249190	Minus	28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573
	401781	7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
	401866	8018106	Plus	73126-73623
		9966312	Minus	29782-29932
		9796239	Minus	110326-110491
30	402578	9884928	Plus	66350-66496
	402606	9909429	Minus	81747-82094
		9369121	Minus	2013-2186,9570-9758,11136-11309,19429-19677,21210-21455,23368-23562,24342-24527,29132-29320
	403199	9958183	Minus	58895-59036,66618-66789
	403329	8516120	Plus	96450-96598
35	403593	6862650	Minus	62554-62712,69449-69602
		7711864	Plus	100742-100904,101322-101503
	404091		Minus	82121-83229
		9838195	Plus	74493-74829
		6572184	Plus	47726-48046
40	405366		Plus	22478-22632
-		4895155	Minus	53624-53759

TABLE 21: 210 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EITHER ENZYMES OR PROTEINS AMENABLE TO MODULATION BY SMALL MOLECULES

Table 21 shows 210 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small molecules. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst 73 breast cancers was greater than or equal 80 units, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulatable by small molecules (e.g. pkinase, peptidase, phosphatase, ATPase, or ion_transporter domains). The predicted protein domains are noted.

20	Pkey: ExAccn:

5

Unique Eos probeset identifier number

Exemplar Accession number, Genbank accession number

UnigeneID: Unigene Title: Unigene number Unigene gene title

R1

Ratio of 93rd percentile tumor to 85th percentile of normal body tissue

2	25	Pkey	ExAcen	UnigenelD	Predicted Protein Domains	UnigeneTitle	R1
		•		Ū		· ·	
				Hs.176588	SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
	• •				death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	55.9
	30		U31875	Hs.272499	SS,TM	short-chain alcohol dehydrogenase family	53.8
					SS,Dihydroorotase,	ESTs	39.3
			AW138959		Phosphodiest,Somatomedin_B,	ESTs	34.9
			AA009647		SS,TM,disintegrin,Pep_M12B_propep,Reprol	a disintegrin and metalloproteinase doma	25.7
		429170	NM_001394	4Hs.2359	DSPc,Rhodanese,	dual specificity phosphatase 4	24.9
-	35	445730	A1624342	Hs.170042	SS,TM,Cation_efflux	ESTs	24.1
		424634	NM_003613	3Hs.151407	ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
		420757	X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
		424399	Al905687	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	20.3
	• •	447350	Al375572	Hs.172634	pkinase,	ESTs	19.2
4	40	456207	AA193450		SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
		456938	X52509	Hs.161640	SS,TM,aminotran_1_2,Cadherin_C_term,cadl		18.1
		402578			SS,p450,SS,TM,p450	C1001134:gi 2117372 pir 165981 fatty ac	17.8
		425692		Hs.155956	SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
			W67883	Hs.137476	pkinase,	paternally expressed 10	16.5
4	45	418007	M13509	Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase_	_matrix metalloproteinase 1 (MMP1; inters	15.7
		421727	Y13153	Hs.107318		kynurenine 3-monooxygenase (kynurenine 3	15.3
		411869	W20027	Hs.23439	SS,Peptidase_M1,	ESTs	13.9
		400289	X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1	Omatrix metalloproteinase 10 (MMP10; str	13.5
		443348	AW873596	Hs.182278	SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
-	50	424086	Al351010	Hs.102267	SS,Lysyl_oxidase	lysyl oxidase	12.8
		400295	W72838	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
		408771	AW732573	Hs.47584	TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
		421155	H87879	Hs.102267		lysyl oxidase	11.8
		424905	NM_002497	7Hs.153704	pkinase,SS,TM,pkinase,polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
- 5	55	438167	R28363	Hs.24286	SS,TM,7tm_1,p450,rrm	ESTs	11.5
		459583	Al907673		pkinase,	gb:IL-BT152-080399-004 BT152 Homo sapien	11.5
			AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
		445263	H57646	Hs.42586	SS,Acyltransferase,	KIAA1560 protein	11.2

	423887	AL080207	Hs.134585	SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
	•	NM_007050		SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase_		10.3
_		NM_000685		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
5		AL120173		SS,pkinase,	ESTs	10.3
	402408			SS,carb_anhydrase death,ZU5,TM,Activin_recp,pkinase,	NM_030920*:Homo sapiens hypothetical pro BMP-R1B	9.8 9.4
				SS,Peptidase_M10,hemopexin,SS,Peptidase_		9.1
		AB041035		Ferric_reduct, TM, Ferric_reduct,	NM_016931:Homo sapiens NADPH oxidase 4 (9.1
10	400285			TM,ABC_tran,ABC_membrane,	Eos Control	8.8
	408380	AF123050			diubiquitin	8.6
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_003866		SS,SS	inositol polyphosphate-4-phosphatase, ty	8.3
15	431725			SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
15	418092			death,ZU5,pkinase,Activin_recp,	ESTs	8.3 8.2
				SS,Zn_carbOpept,Propep_M14,SS,Propep_M GATase_2,SIS,	glutamine-fructose-6-phosphate transamin	8.1
		AW242243	Hs 168670	SS,TM,WD40,ubiquitin,E1-E2_ATPase,Cation		7.8
		NM_001034		SS SS	ribonucleotide reductase M2 polypeptide	7.6
20		NM_004482		SS,TM,Glycos_transf_2,Ricin_B_lectin,DPP	UDP-N-acetyl-alpha-D-galactosamine:polyp	7.6
	456986			SS,TM,7tm_1,	prostaglandin E receptor 3 (subtype EP3)	7.5
				SS,TM,disintegrin,Pep_M12B_propep,Reprol		7.3
	407721			pkinase,	dual-specificity tyrosine-(Y)-phosphoryl	7.2
25	418004			SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member a disintegrin and metalloproteinase doma	7.2 7.1
25		AW204099		TM,disintegrin,Reprolysin,	ESTs, Weakly similar to AF126780 1 retin	6.9
		AP000692		GAF,PDEase	chromosome 21 open reading frame 5	6.8
	401045	711 000002		ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_		
		C11001883		NP_033938.1 c	6.7	
30	442082	R41823	Hs.7413	TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
				TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
	404091			TM,7tm_3,ANF_receptor,	Target Exon	6.6
		Al248013		zf-C2H2	ESTs, Weakly similar to I38588 reverse t replication factor C (activator 1) 2 (40	6.5 6.5
35		NM_002914 AF055575		SS,AAA,Viral_helicase1,rrm, TM,ion_trans,SS,TM,ion_trans,	calcium channel, voltage-dependent, L ty	6.4
55		AA932186		TM,7tm_1,	ESTs	6.2
		NM_005025			serine (or cysteine) proteinase inhibito	6.2
		AW167087		SS,ig,Sema,pkinase,	ESTs	6.2
40	428795				ESTs, Highly similar to A39769 N-acetyll	6.1
40	428479				cell division cycle 2, G1 to S and G2 to	6.1
	400300			SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		6.1
		NM_012093		SS,adenylatekinase,	adenylate kinase 5 Target Exon	6.1 6.1
	402230 424687			SS,TM,p450, SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe		5.8
45				6PF2K,PGAM,	6-phosphofructo-2-kinase/fructose-2,6-bi	5.8
	432239			SS,Peptidase_M10,hemopexin,SS,Peptidase_		5.6
	400286				C16000922:gi 7499103 pir T20903 hypothe	5.6
		NM_005940			matrix metalloproteinase 11 (MMP11; stro	5.4
50		AA828246		UCH-1,pkinase,OPR,Rhodanese,AMP-binding		5.4
50		AF086120			ESTS	5.2
		AI806867 N54926			ESTs G protein-coupled receptor 34	5.2 5.2
	427711			SS	solute carrier family 25 (mitochondrial	5.2
		AL117406			ATP-binding cassette transporter MRP8	5.1
55	425325			SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_T		
			olamine N-meth		5.1	
		AW291095			interleukin 20 receptor, alpha	5.1
	403593			CIDE-N,pkinase	Target Exon	5.1
60		AA564991		alpha-amylase,	ESTs	5.0
60		Al281848		SS,TM,7tm_3,Ribosomal_L13 SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo	retinoic acid induced 3	4.9 4.9
		NM_000169 W88559			proteolipid protein 1 (Pelizaeus-Merzbac	4.9
	411096				mitochondrial intermediate peptidase	4.9
		NM_004460		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_		4.9
65	417975	AA641836	Hs.30085	SS,trypsin	hypothetical protein FLJ23186	4.9
	447752		Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
	427122	AW057736	Hs.323910	SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu	riHER2 receptor tyrosine kinase (c-erb-b2,	4.8
				316		
				510		

	400181		•	SS,TM,3Beta_HSD,	ENSP00000171555:CDNA FLJ10727 fis, clone	4.6
	452093	AA447453		SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
	435542	AA687376	Hs.269533	SS,pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
	417576	AA339449	Hs.82285	AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	phosphoribosylglycinamide formyltransfer	4.6
5			Hs.270651	pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
_			Hs.146688	SS,TM,MAPEG,	prostaglandin E synthase	4.5
	452190				Homo sapiens clone PP1498 unknown mRNA	4.5
	440000	Al345455		· · · · · · · · · · · · · · · · · ·	GA-binding protein transcription factor,	4.5
				pkinase,OPR,		4.5
10		AI910275		SS,trefoil,SS,TM,ldl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	
10		AA863360		SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
		AW294092	Hs.21594	SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
	400205				NM_006265*:Homo sapiens RAD21 (S. pombe)	4.4
		AW296927		SS,TM,Peptidase_M1,	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3
	432690	AF181490	Hs.278627	SS,pyr_redox,SS,Ribosomal_L39	prenylcysteine lyase	4.3
15	441560		Hs.7888	pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
		AL043004		SS,pkinase,	KIAA0135 protein	4.3
	439024		Hs.35598	SS,TM,trypsin,vwd,ig	ESTs	4.3
			7Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2
			Hs.163533	pkinase,	Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
20						4.2
20		NM_00291		SS,AAA,PI3_PI4_kinase,PI3Ka,PI3K_rbd,PI3		
			Hs.105448	SS,TM,pkinase	ESTs, Weakly similar to B34087 hypotheti	4.1
				SS,SAA_proteins,ABC_membrane,ABC_tran,		4.1
		NM_00180		SS,TM,thiolase,	centromere protein A (17kD)	4.1
~ -	418478		Hs.1174	ank,ank	cyclin-dependent kinase inhibitor 2A (me	4.1
25	406922	S70284		SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
	439285	AL133916	Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
	429922	Z97630	Hs.226117	SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
		NM 00535		SS,TM,p450,	lipase, hormone-sensitive	4.0
				SS,T4_deiodinase,T4_deiodinase,	deiodinase, iodothyronine, type II	4.0
30				SS,Y_phosphatase,Band_41	ESTs, Moderately similar to ALU7_HUMAN A	4.0
20		U76456	Hs.190787	SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
	428330		Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemo		3.9
						3.9
		M31158		SS,cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	
25			Hs.313803	SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8
35		BE247550		SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8
		AA129640	Hs.128065	SS,Peptidase_C1,gpdh	ESTs	3.8
	403943			p450,SS,p450	C5000355:gi 4503225 ref NP_000765.1 cyt	3.8
	444618	AV653785	Hs.173334		ELL-RELATED RNA POLYMERASE II, ELONGATIO	3.8
	408761	AA057264	Hs.238936	SS,TM,7tm_1,	ESTs, Weakly similar to (defline not ava	3.8
40	427809	M26380	Hs.180878	SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7
	418203	X54942	Hs.83758	CKS,SS,CKS,	CDC28 protein kinase 2	3.7
		AI041793		TM,7tm_1,	ESTs	3.7
	424676			Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
			Hs.122908	SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
45		NM_01473		PHD,pkinase,SS	KIAA0215 gene product	3.7
73					secreted phosphoprotein 1 (osteopontin,	3.7
		AU076643		SS,TM,efnand,ion_trans	stearoyl-CoA desaturase (delta-9-desatur	3.6
	406625			SS,TM,Desaturase,SS		3.6
				SS,7tm_1,SPRY,	ESTs	
~^			9Hs.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
50		NM_00315		SS,pkinase,vwa,vwa,Glyco_transf_8	serine/threonine kinase 2	3.6
		NM_014400		SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
	431493	Al791493	Hs.129873	SS,p450,p450	ESTs, Weakly similar to A36036 cytochrom	3.6
			Hs.194687		cholesterol 25-hydroxylase	3.6
	414175	Al308876	Hs.103849	TM,hemopexin,Peptidase_M10,hemopexin,Pe	ephypothetical protein DKFZp761D112	3.6
55		AW895719		TM,ion_trans,K_tetra,	gb:QV4-NN0039-290300-154-f06 NN0039 Homo	3.6
		NM_00381		,	a disintegrin and metalloproteinase doma	3.6
	425320		Hs.83190	Acyl_transf,adh_zinc,ketoacyl-synt,pp-bi	fatty acid synthase	3.5
			Hs.271699	IMS,SS	polymerase (DNA directed) iota	3.5
	407104		Hs.323910	SS,TM,SH2,PH,pkinase,Recep_L_domain,Fu		3.5
60					HER2 receptor tyrosine kinase (c-erb-b2,	3.5
60			Hs.333526	SS		
		AA121098		pkinase,POLO_box,SS,pkinase,POLO_box,	serum-inducible kinase	3.5
	454042		Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
		AA116021		SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
		AF039241		Peptidase_M24,	histone deacetylase 5	3.5
65			Hs.177534	DSPc,Myosin_tail,	dual specificity phosphatase 10	3.5
	412049	N53437	Hs.18268	SS,adenylatekinase,	adenylate kinase 5	3.5
	425776		Hs.159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4
					•	

	407846	AA426202 Hs.40403	TM,ABC_membrane,ABC_tran,Ribosomal_S	AcChn/n300-interacting transactivator, wit	3.4
		L34041 Hs.9739		PE-glycerol-3-phosphate dehydrogenase 1 (so	3.4
		AA250970 Hs.251946	SS,rrm,PABP,pkinase,14-3-3,rrm	poly(A)-binding protein, cytoplasmic 1-l	3.4
		NM_002318Hs.83354	SS,TM,mito_carr,Lysyl_oxidase	lysyl oxidase-like 2	3.4
5					3.4
3		AA833930 Hs.288036	SS,IPPT,	tRNA isopentenylpyrophosphate transferas	
		M25809 Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
		U52077		gb:Human mariner1 transposase gene, comp	3.4
		AF182277 Hs.330780	SS,p450,SS	cytochrome P450, subfamily IIB (phenobar	3.4
		AA825686 Hs.321176	SS	ESTs, Weakly similar to S65824 reverse t	3.4
10	408101	AW968504 Hs.123073	pkinase,	CDC2-related protein kinase 7	3.4
	422083	NM_001141Hs.111256	lipoxygenase,PLAT,	arachidonate 15-lipoxygenase, second typ	3.3
	411393	AW797437 Hs.69771	SS,sushi,trypsin,vwa,rrm,fibrinogen_C,fn	B-factor, properdin	3.3
	435767	H73505 Hs.117874	SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
		NM_006456Hs.288215	SS,Pribosyltran,	sialyltransferase	3.3
15		AF037062 Hs.172914	SS,adh_short,TGF-beta,TGFb_propeptide	retinol dehydrogenase 5 (11-cis and 9-ci	3.3
10		H11257 Hs.22968	SS,pkinase,ig,	Homo sapiens clone IMAGE:451939, mRNA se	3.3
		Al267371 Hs.172636	SS,SS,lipoxygenase,PLAT	ESTs	3.3
		Al161293 Hs.280380	SS,SS,Peptidase_M1,EGF,ig,lectin_c,sushi	aminopeptidase	3.3
		AF052152 Hs.159412		Homo sapiens clone 24628 mRNA sequence	3.3
20			pkinase,		3.3 3.3
20		Z42047 Hs.283978	SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	
		D85782 Hs.3229	00 B (I) 144	cysteine dioxygenase, type l	3.3
		AF084545	SS,Peptidase_M1,	Target	3.3
		AL359053 Hs.57664	TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
~ ~		R19897 Hs.106604	death,ZU5,pkinase,Activin_recp,	ESTs	3.3
25		Al694413 Hs.332649	SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
		NM_003654Hs.104576	SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
	443767	BE562136 Hs.9736	SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
	422648	D86983 Hs.118893	peroxidase,LRRCT,	Melanoma associated gene	3.2
	423431	AA326062	SS,p450,p450	gb:EST29171 Cerebellum II Homo sapiens c	3.2
30	451264	AI768235	SS.Trehalase	gb:wg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S	3.2
		T47667 Hs.28005	SS,TM,Activin_recp,pkinase	Homo sapiens cDNA FLJ11309 fis, clone PL	3.2
		AW247529 Hs.6793	TM,p450,Ets	platelet-activating factor acetylhydrola	3.2
		U39817 Hs.36820	SS,DEAD,HRDC,helicase_C,	Bloom syndrome	3.1
	406664		SS,TM,transport_prot,SWIB,RhoGAP,DAG_F		glycerol-3-
35		ite dehydrogenase 1 (so	3.1	<u>.</u>	giyocioi-o-
55		R31770 Hs.23540	TM,7tm_1,	ESTs	3.1
		U77413 Hs.100293	1301,7 011_1,	O-linked N-acetylglucosamine (GlcNAc) tr	3.1
			CC TM 74 4 CC		3.1
		BE281128 Hs.9030	SS,TM,7tm_1,rrm,SS	TONDU	
40		AK000933 Hs.28661	TM,GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
40		Al538613 Hs.298241	SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protease, serine 3	3.1
		T29618 Hs.89640	TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
		Al149286 Hs.55099	SS	rab6 GTPase activating protein (GAP and	3.1
		NM_003937Hs.169139		kynureninase (L-kynurenine hydrolase)	3.1
	436291	BE568452 Hs.5101	SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
45	450223	AA418204 Hs.241493	SS,pro_isomerase,	natural killer-tumor recognition sequenc	3.1
	424269	AW137691 Hs.199754	SS,TM,7tm_2,GPS	ESTs	3.1
		AW591433 Hs.298241	SS,TM,trefoil,trypsin,trefoil	Transmembrane protease, serine 3	3.0
		BE077084 Hs.336432	SS,rrm,zf-RanBP,pkinase,C2,pkinase_C,DAC		3.0
			''-: !b	•	

TABLE 21A

Table 21 A shows the accession numbers for those pkeys lacking unigeneID's for Table 21. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	11
ı	v

5

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number

Accession:

Genbank accession numbers

15

	Pkey	CAT number	Accessions
20	420854	197072_1	AW296927 Al684514 Al263168 AA281079
	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	451264	863988_1	Al768235 R31400 H29082 H23107
	455325	1279475_1	AW895719 N31451 N41451
	456207	1650781	AA193450

TABLE 21B

Table 21B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 21. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15				
	Pkey	Ref	Strand	Nt_position
	401045	8117619	Plus	90044-90184,91111-91345
	402230	9966312	Minus	29782-29932
20	402408	9796239	Minus	110326-110491
	402578	9884928	Plus	66350-66496
	403593	6862650	Minus	62554-62712,69449-69602
	403943	7711864	Plus	100742-100904,101322-101503
	404091	7684554	Minus	82121-83229

TABLE 22: 739 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 22 shows 739 genes up-regulated in breast cancer compared to normal adult breast. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the denominator was the 85th percentile value for 12 non-malignant breast specimens, and the 96th percentile value amongst the 73 breast cancers was greater than or equal 100 units.

10

15

5

Pkey:	Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigeneID: Unigene number
Unigene Title: Unigene gene title

R1: Ratio of 90th percentile tumor to 85th percentile normal breast tissue

20	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
20	400292	AA250737	Hs.72472	BMP-R1B	51.5
	424735		Hs.272499	short-chain alcohol dehydrogenase family	38.3
		Al127076	Hs.334473	hypothetical protein DKFZp564O1278	29.9
		AL137517	Hs.334473	hypothetical protein DKFZp564O1278	26.9
25		Al955040	Hs.265398	ESTs, Weakly similar to transformation-r	25.8
23	431211		Hs.323733	gap junction protein, beta 2, 26kD (conn	23.2
		X54942	Hs.83758	CDC28 protein kinase 2	22.6
		AA046309	113.007.00	gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	18.9
30		AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	18.0
50		AB033025	Hs.50081	KIAA1199 protein	17.6
		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	17.6
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	17.1
		Al263307	Hs.239884		17.0
35		T97307		gb:ye53h05.s1 Soares fetal liver spleen	16.1
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	16.1
		Al440266	Hs.170673		16.0
		AA321649	Hs.2248	small inducible cytokine subfamily B (CX	15.5
	444342	NM_014398	BHs.10887	similar to lysosome-associated membrane	15.1
40	422505	AL120862	Hs.124165	programmed cell death 9 (PDCD9)	14.9
	430515	AA746503	Hs.283313	ESTs	14.7
	417308	H60720	Hs.81892	KIAA0101 gene product	14.4
	452744	AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082	(fr14.4
	412446	Al768015	Hs.92127	ESTs	14.2
45	415539	A1733881	Hs.72472	BMP-R1B	14.1
		AW840171	Hs.265398		13.8
		AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	13.8
	400205			NM_006265*:Homo sapiens RAD21 (S. pomb	
~ ^		AA489732	Hs.154918		13.4
50	415263		Hs.130853		13.3
		AL120173	Hs.301663		13.2
	449722		Hs.23960	cyclin B1	13.2
	406685			gb:Human nonspecific crossreacting antig	13.0
	406690		Hs.220529	carcinoembryonic antigen-related cell ad	12.8
55	429925		5Hs.226213		12.8
	416498		Hs.79351	potassium channel, subfamily K, member 1	12.7
		Al493046	Hs.146133	ESTs	12.5
	441377	BE218239	Hs.202656	ESTS	12.5
C O	456207			gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sa	pr12.4
60		AA436989		H2A histone family, member A	12.2
	407811	AW190902		cysteine knot superfamily 1, BMP antagon	12.2
	4071/8	AA195651	Hs.104106	ESIS	12.2

	420931	AF044197	Hs.100431	small inducible cytokine B subfamily (Cy	12.1
		Y13153		kynurenine 3-monooxygenase (kynurenine 3	12.0
		Al031771	Hs.132586		12.0
~		H44186	Hs.15456	PDZ domain containing 1	11.9
5		BE178536		membrane-spanning 4-domains, subfamily A	11.8 11.7
		AW873596 NM_006159		calmodulin 2 (phosphorylase kinase, delt nel (chicken)-like 2	11.7
		AF026944		ESTs	11.6
		AA156781		metallothionein 1E (functional)	11.5
10	412472	AW975398	Hs.293836		11.4
	416030		Hs.21948	ESTs	11.3
		AW600291		hypothetical protein FLJ10430	11.3
	420757	X78592 BE336654	Hs.99915	androgen receptor (dihydrotestosterone r H3 histone family, member A	11.3 11.2
15		AI633559	Hs.310359		11.2
10		AA765694			11.0
		Al684808		programmed cell death 9 (PDCD9)	10.9
		N78223		transcription factor	10.7
20		AA576953		hypothetical protein FLJ13352	10.6
20		AW965339			10.6
		Al370413 W67883	Hs.36563	hypothetical protein FLJ22418 paternally expressed 10	10.4 10.4
		Al199268	Hs.19322		10.4
				NIMA (never in mitosis gene a)-related k	10.1
25		H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, com	p10.1
		AW167087			10.1
				Homo sapiens cDNA FLJ11382 fis, clone HE	
		AA399272 Al624342	Hs.144341 Hs.170042		10.1 10.0
30		A1926047	Hs.162859		10.0
50		AL355715		programmed cell death 9	9.9
		AW966399		hypothetical protein FLJ20086	9.9
	432169		Hs.2910	phosphoribosyl pyrophosphate synthetase	9.9
25		H23789	Hs.144530		9.9
35		A1655499	Hs.161712		9.8
		BE613126	Hs.47783	CGI-49 protein B aggressive lymphoma gene	9.8 9.7
	407377		110.77700	gb:C16391 Clontech human aorta polyA mRN	
		AA151342	Hs.12677	CGI-147 protein	9.7
40	443462	AI064690	Hs.171176		9.7
		AI022650	Hs.8117	erbb2-interacting protein ERBIN	9.7
				uncharacterized bone marrow protein BM04	9.7
		AL360204 AF059214		Homo sapiens mRNA full length insert cDN cholesterol 25-hydroxylase	9.6 9.6
45	449448		Hs.57471	ESTs	9.6
		Al375499	Hs.27379	ESTs	9.5
		R31178		fibronectin 1	9.3
				leucine-rich repeat-containing 2	9.3
50		R17798	Hs.7535	COBW-like protein	9.3
50		U80736 AJ224741	Hs.278461	trinucleotide repeat containing 9	9.2 9.2
				heterochromatin-like protein 1	9.2
		AA410943		gb:zt32h03.r1 Soares ovary tumor NbHOT H	
	442432	BE093589	Hs.38178	hypothetical protein FLJ23468	9.1
55		Al337735	Hs.173919		
		AW732573		potassium voltage-gated channel, delayed ESTs	9.0 9.0
	428479	AI076089	Hs.292239 Hs.184572		8.9
		AI767756	Hs.82302	Homo sapiens cDNA FLJ14814 fis, clone NT	8.9
60	402408			NM 030920*:Homo sapiens hypothetical pro	8.9
_	418601	AA279490	Hs.86368	calmegin	8.8
		W03242	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA s	
		A1198719	Hs.176376		8.8 8.8
65		AW296024 Al754693	Hs.150434 Hs.145968		8.8 8.8
33		A1745649	Hs.26549	KIAA1708 protein	8.7
		AW594641		•	8.7

	427585	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	8.6
				Homo sapiens cDNA FLJ11381 fis, clone HE	
		Al651474	Hs.163944	ESTs	8.6
_				CTP synthase	8.4
5		AW067903		collagen, type XI, alpha 1	8.4
		AA382207 AA767373	Hs.35669	ecotropic viral integration site 2B ESTs, Moderately similar to ALU1_HUMAN A	8.3 8.3
		AL080207		DKFZP434G232 protein	8.2
		BE268362		COBW-like protein	8.2
10				protein tyrosine phosphatase, receptor t	8.2
		AJ132592	Hs.59757	zinc finger protein 281	8.2
		X65724	Hs.2839	Norrie disease (pseudoglioma)	8.1
		AI283476	Hs.263478		8.1
15		AW876523 Al811202		hypothetical protein FLJ12910 Homo sapiens cDNA: FLJ23523 fis, clone L	8.1 8.1
13		AA781795			8.0
				ESTs, Weakly similar to 2109260A B cell	8.0
				DNA replication factor	8.0
	427961	AW293165	Hs.143134	ESTs	8.0
20		AA379597	Hs.5199	HSPC150 protein similar to ubiquitin-con	8.0
		AA662240		AF15q14 protein	8.0
		U29926	Hs.83918	adenosine monophosphate deaminase (isofo	
	400285	NA AF039241	Hs.9028	Eos Control histone deacetylase 5	7.9 7.9
25		M18728	113.3020	gb:Human nonspecific crossreacting antig	7.8
		D43945	Hs.113274	transcription factor EC	7.8
	454024	AA993527		hypothetical protein FLJ23403	7.8
	444542	Al161293		aminopeptidase	7.8
20		A1683487		wingless-type MMTV integration site fami	7.7
30		AL110216	Hs.12285	ESTs, Weakly similar to 155214 salivary	7.6
		H69912 T27503	Hs.48269 Hs.15929	vaccinia related kinase 1 hypothetical protein FLJ12910	7.6 7.6
		AK001741		hypothetical protein FLJ10879	7.6
		NM_003937			7.5
35	424687		Hs.151738	matrix metalloproteinase 9 (gelatinase B	7.5
	446315	NM_016293	3Hs.14770	bridging integrator 2	7.5
		H69125	Hs.133525		7.5
		M97711		gb:Human T-cell receptor (V beta 18.1, J	7.5
40		AW512260 AA961694		ESTs	7.4 7.4
40		NM_001809		kinesin protein 9 gene centromere protein A (17kD)	7. 4 7.4
		Al391662	Hs.160963		
		AV653785		ELL-RELATED RNA POLYMERASE II, ELON	
	410361	BE391804	Hs.62661	guanylate binding protein 1, interferon-	7.3
45	400268			NM_003292:Homo sapiens translocated prom	
		AF086332	Hs.58314	ESTs	7.3
		AL138272	Hs.62713	ESTs	7.3 7.3
		N58172	Hs.109370	carboxylesterase 2 (intestine, liver)	7.3 7.2
50				F-box only protein 5	7.1
		AI073913		ESTs, Weakly similar to JE0350 Anterior	7.1
	430287	AW182459	Hs.125759	ESTs, Weakly similar to LEU5_HUMAN LEUK	E7.0
		AA398155	Hs.97600	ESTs	7.0
<i>E E</i>		A1475858		gb:tc87d07.x1 NCI_CGAP_CLL1 Homo sapier	
55					7.0 7.0
		BE062906 AK001468	Hs.28338 Hs.62180	KIAA1546 protein anillin (Drosophila Scraps homolog), act	7.0
		AA808229	Hs.167771		6.9
		AW241821			6.9
60		Al263293	Hs.152096	cytochrome P450, subfamily IIJ (arachido	6.8
		AW500106	Hs.23643	serine/threonine protein kinase MASK	6.8
				GDNF family receptor alpha 1	6.8
	414080	AA135257	Hs.47783	B aggressive lymphoma gene	6.8
65		AI767056 AF123050	Hs.193002 Hs.44532	ES1S diubiquitin	6.7 6.7
05		BE545072		hypothetical protein FLJ10461	6.7
	446651	AA393907	Hs.97179	ESTs	6.7
	170001				**

	419839	U24577	Hs.93304	phospholipase A2, group VII (platelet-ac	6.7
		AA810265	Hs.122915		6.7
		AI910275 AW023482	Hs.1406	trefoil factor 1 (pS2) ESTs	6.7 6.6
5		NM_003816		a disintegrin and metalloproteinase doma	6.6
_		NM_016010		CGI-62 protein	6.6
		Al215069	Hs.89113	ESTs	6.5
		A1798680	Hs.25933	ESTS	6.5
10		N40449 Al151418		ESTs, Weakly similar to S38383 SEB4B pro protein phosphatase 3 (formerly 2B), cat	6.5 6.4
10	409757		3Hs.123114		6.4
		AF026941		Homo sapiens cig5 mRNA, partial sequence	6.4
	456938			tyrosine aminotransferase	6.4
15		Al820961	Hs.193465		6.4 6.4
13	452838	NM_003866 U65011	Hs.30743	preferentially expressed antigen in mela	6.4
		AA918317	Hs.57987	B-cell CLL/lymphoma 11B (zinc finger pro	6.4
		AJ235664		gb:Homo sapiens mRNA for immunoglobulin	6.3
20		AI222020		CocoaCrisp	6.3 6.3
20		AF217513 Al193043		clone HQ0310 PRO0310p1 ESTs, Weakly similar to T17226 hypotheti	6.2
		AA394183	Hs.26873	ESTs	6.2
	402578			C1001134:gi 2117372 pir 165981 fatty ac	6.2
25		AW161391		deoxycytidine kinase	6.1
25	430447 432415	W17064 T16971		SWI/SNF related, matrix associated, acti ESTs, Weakly similar to A43932 mucin 2 p	6.1 6.1
		A1082692	Hs.134662		6.1
		Al694143		programmed cell death 4	6.1
20		BE440042	Hs.83326	matrix metalloproteinase 3 (stromelysin	6.1
30		Al126772	Hs.40479	ESTs	6.0 6.0
	420344	BE463721	Hs.97101 Hs.32964	putative G protein-coupled receptor SRY (sex determining region Y)-box 11	6.0
	425397			topoisomerase (DNA) II alpha (170kD)	6.0
0.5	418007		Hs.83169	matrix metalloproteinase 1 (MMP1; inters	6.0
35	428585		Hs.185140	KIAA0403 protein	6.0
		AA761605 AA583206		ESTs, Weakly similar to ALU1_HUMAN ALU3 RAR-related orphan receptor A	6.0
		M31126		matrix metalloproteinase 11 (MMP11; stro	6.0
		R45154	Hs.106604		6.0
40	447051			ESTs, Weakly similar to Con1 [H.sapiens]	6.0
	441233 432239	AA972965 X81334	Hs.135568 Hs.2936	matrix metalloproteinase 13 (collagenase	6.0 6.0
		AA100847		ESTs, Highly similar to AF174600 1 F-box	5.9
		Al831297	Hs.123310		5.9
45		AW972512	Hs.20985	sin3-associated polypeptide, 30kD	5.9
		AW803341	Un 140554	gb:lL2-UM0079-090300-050-D03 UM0079 Ho	
		Al793124	Hs.144479	CGI-83 protein	5.9 5.9
				hypothetical protein FLJ22624	5.8
50	412022	AI005043	Hs.24143	Wiskott-Aldrich syndrome protein interac	5.8
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	5.8
		Al375572 AA305599	Hs.172634	hypothetical protein PRO2013	5.8 5.8
	409151	AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. c	5.8
55		AI571940	Hs.7549	ESTs	5.8
	452281	T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	5.8
		AI299139	Hs.17517	ESTs sterol-C4-methyl oxidase-like	5.8 5.8
	430361	Al033965 X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	5.7
60		AV657117		ESTs, Moderately similar to S65657 alpha	5.7
		AA831879	Hs.136985	ESTs	5.7
		W47595		transforming growth factor, beta 2	5.7 5.7
	452401 448663	NM_007119 BE614599		tumor necrosis factor, alpha-induced pro hypothetical protein MGC14797	5.7 5.7
65		AW016531			5.7
	446203	Z47553	Hs.14286	flavin containing monooxygenase 5	5.7
	428336	AA503115	Hs.183752	microseminoprotein, beta-	5.6

	430379	AF134149	Hs.240395	potassium channel, subfamily K, member 6	5.6
	422835	BE218705	Hs.121378	metallothionein-like 5, testis-specific	5.6
		AL044878		3-hydroxy-3-methylglutaryl-Coenzyme A re	5.6
~		AF098158		chromosome 20 open reading frame 1	5.6
5	400301	X03635	Hs.1657	estrogen receptor 1	5.6
		AW885727			5.6
		AL157504		Homo sapiens mRNA; cDNA DKFZp586O072	
		AA906288			5.5
10		R41396	HS.1017/4	hypothetical protein FLJ23045 hypothetical protein FLJ13782	5.5
10		BE247706		membrane-spanning 4-domains, subfamily A	5.5
	401645		115.05751	C16001440*:gi 12330704 gb AAG52890.1 AF	
	437967	BE277414	Hs.5947	mel transforming oncogene (derived from	5.5
		AI734009		KIAA1603 protein	5.4
15		AJ742605	Hs.193696		5.4
	440270	NM_01598	6Hs.7120	cytokine receptor-like molecule 9	5.4
	437536	X91221	Hs.144465		5.4
		R28363	Hs.24286	ESTs	5.4
20		BE392914		Homo sapiens cDNA FLJ11344 fis, clone PL	5.4
20		H59846		ESTs, Moderately similar to ALU7_HUMAN A	5.4
		AA319146		secretogranin II (chromogranin C)	5.4
		L32137	Hs.1584	cartilage oligomeric matrix protein (COM	5.4
		N34895	Hs.44648	ESTs	5.4
25		AW205168 AF025441		Opa-interacting protein 5	5.4
23		AA576635	Hs.6153	CGI-48 protein	5.3 5.3
		AA814100		ESTs	5.3
		U91616	Hs.91640	nuclear factor of kappa light polypeptid	5.3
		H39960		Homo sapiens cDNA FLJ12280 fis, clone MA	
30		AF070526		Homo sapiens clone 24787 mRNA sequence	
	449051	AW961400	Hs.333526	HER2 receptor tyrosine kinase (c-erb-b2,	5.2
	418758	AW959311	Hs.172012	hypothetical protein DKFZp434J037	5.2
				transcription factor 19 (SC1)	5.2
25		U65590	Hs.81134	interleukin 1 receptor antagonist	5.2
35		AF013758			5.2
		AK000713		hypothetical protein FLJ20706	5.2
	403485	AF077345	Hs.177936	C3001813*:gi 12737279 ref XP_012163.1] k	5.2
		AA586894	He 112/08	S100 calcium-binding protein A7 (psorias	5.2 5.1
40		A1878857	Hs 109706	hematological and neurological expressed	5.1
, ,		X69490	Hs.172004		5.1
		X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.1
		M81933	Hs.1634	cell division cycle 25A	5.1
	412281	Al810054	Hs.14119		5.1
45		AW955776		ESTs, Moderately similar to ALU7_HUMAN A	5.1
		AL121278	Hs.25144		5.1
	404347				5.1
		M30703	Hs.270833		5.1
50		D28235			5.1
50		BE568452 R43646	Hs.5101 Hs.12422	·	5.1
	434725	AK000796	Hs.4104		5.1 5.0
	435981	H74319	Hs.188620		5.0
	407376				5.0
55		AA305688	Hs.267695		5.0
	405348	NA		C7001664:gi 12698061 dbj BAB21849.1 (AB	
	436196	AK001084	Hs.333498	Homo sapiens cDNA FLJ10222 fis, clone HE	
	437065	AL036450	Hs.103238		5.0
<i>c</i> 0		A1936442	Hs.59838		5.0
60		NM_006235	Hs.2407		5.0
		AU076643	Hs.313		4.9
	403329		11- 02005	Target Exon	4.9
		BE623003 Al820662		Homo sapiens clone TCCCTA00142 mRNA se	
65		AW371048	Hs.129598		4.9 4.0
05		AW966163	1 13,557 50	gb:EST378236 MAGE resequences, MAGI Ho	4.9 mo/ 9
			Hs.182278		11104.9 4.9
	.550.5				7.0

		AA650274		fibronectin leucine rich transmembrane p	4.9
		NM_002104		granzyme K (serine protease, granzyme 3;	4.9
	453204	R10799	Hs.191990	ESTs	4.8
_			Hs.255757	ESTs, Weakly similar to AT2A_HUMAN POTE	N4.8
5		Z45051	Hs.22920	similar to S68401 (cattle) glucose induc	4.8
	408369	R38438		solute carrier family 15 (H??? transport	4.8
	431645	AF078849		dynein light chain-A	4.8
	423575	C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	4.8
	444246	H93281	Hs.10710	hypothetical protein FLJ20417	4.8
10	421524	AA312082	Hs.105445	GDNF family receptor alpha 1	4.8
	452827	Al571835	Hs.55468	ESTs	4.8
	414222	AL135173	Hs.878	sorbitol dehydrogenase	4.8
	456086	AL161999	Hs.77324	eukaryotic translation termination facto	4.8
		M93119	Hs.89584	insulinoma-associated 1	4.8
15			Hs.191518		4.8
		Al357412	Hs.157601		4.8
		AI879148	Hs.26770	fatty acid binding protein 7, brain	4.7
	419968		Hs.93913	interleukin 6 (interferon, beta 2)	4.7
•			9Hs.145296		4.7
20	431585	BE242803	Hs.262823		4.7
			Hs.198793		4.7
		AW192307		dolichyl-P-Glc:Man9GlcNAc2-PP-dolichylgl	4.7
		NM_015310		KIAA0942 protein	4.7
~ ~		A1675749	Hs.211608	nucleoporin 153kD	4.7
25		AF228704	Hs.121524		4.7
	405801			NM_000390:Homo sapiens choroideremia (Ra	
		BE218886			4.6
		W26354	Hs.28891	hypothetical protein FLJ11360; artemis p	4.6
20		U62027		complement component 3a receptor 1	4.6
30		Al864053	Hs.39972	ESTs, Weakly similar to l38588 reverse t	4.6
			Hs.337404		4.6
	403366	NA		Target Exon Target Exon	4.6 4.6
	402542	A1046074	Hs.15607	Homo sapiens Fanconì anemia complementat	
35		Al916071 Al907114	Hs.71465	squalene epoxidase	4.6
55		Al264155	Hs.152981		4.6
		A1459306	Hs.24908	ESTs	4.5
			Hs.245123		4.5
		Al472209	Hs.323117		4.5
40		AW630534		Homo sapiens, clone MGC:9381, mRNA, com	
		AF146761	Hs.20450	BCM-like membrane protein precursor	4.5
		Al692181	Hs.49169	KIAA1634 protein	4.5
		AW962128		gb:EST374201 MAGE resequences, MAGG H	lomo4.5
	428801	AW277121	Hs.254881	ESTs	4.5
45	428500	A1815395	Hs.184641	fatty acid desaturase 2	4.5
	426075	AW513691	Hs.270149	ESTs, Weakly similar to 2109260A B cell	4.4
	437259	Al377755	Hs.120695		4.4
	400409	AF153341	Hs.283954	Homo sapiens winged helix/forkhead trans	4.4
= 0			Hs.59757	zinc finger protein 281	4.4
50		Al815206	Hs.99395	ESTs	4.4
	401866			Target Exon	4.4
		AA228776	Hs.191721		4.4
	406348			Target Exon	4.4
<i></i>		AW895387		gb:QV4-NN0038-300300-157-c10 NN0038 Ho	
55		AW297880	Hs.98661	ESTs	4.4
		AW862214	11- 000007	gb:QV4-CT0361-301299-074-b05 CT0361 Ho	
			Hs.283037		4.4
				guanylate cyclase 1, soluble, beta 2 DKFZP586D0824 protein	4.4 4.4
60		AL110151		Homo sapiens clone PP1498 unknown mRNA	
00		H26735	Hs.91668	low density lipoprotein-related protein	4.3
		AA706003		ESTs	4.3
		Z97630		H1 histone family, member 0	4.3
	421379			small inducible cytokine subfamily B (Cy	4.3
65	400300			HER2 receptor tyrosine kinase (c-erb-b2,	4.3
		AL041243	Hs.174104		4.3
	446595		Hs.15467	hypothetical protein FLJ20725	4.3
				•	

. .

	403011	NA		ENSP00000215330*:Probable serine/threoni	4.3
		Al365384	Hs.11571	Homo sapiens cDNA FLJ11570 fis, clone HE	
		NM_00194		E2F transcription factor 3	4.3
5		AA687538		tetraspan 1	4.3
5		ABU14604 AW188551		KIAA0704 protein	4.3 4.3
		AI091795	Hs.179246	hypothetical protein FLJ14007	4.3
		Al694413		olfactory receptor, family 2, subfamily	4.3
		M63835	Hs.77424	Fc fragment of IgG, high affinity Ia, re	4.2
10	410102	AW248508	Hs.279727	Homo sapiens cDNA FLJ14035 fis, clone HE	4.2
		T47667	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.2
			Hs.142838		4.2
		AW953937	Hs.12891 Hs.191705	ESTs ESTs, Weakly similar to T47184 hypotheti	4.2 4.2
15		Al085198	Hs.164226		4.2
				ESTs, Weakly similar to S72482 hypotheti	4.2
		BE091926		mitotic spindle coiled-coil related prot	4.2
			Hs.125783		4.2
20			Hs.308538		4.2
20		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	4.2
			Hs.288529 Hs.325820	hypothetical protein FLJ22635 protease, serine, 23	4.2 4.2
		BE247676		E-1 enzyme	4.2
		AK001376		hypothetical protein FLJ10514	4.1
25	437295	AW779318	Hs.88417	ESTs	4.1
			Hs.241551	chloride channel, calcium activated, fam	4.1
			Hs.132208		4.1
		BE244074	Hs.290585	regulator of Fas-induced apoptosis	4.1 4.1
30				matrix metalloproteinase 11 (MMP11; stro	4.1
00		AF041163		Human T-cell receptor active alpha-chain	4.1
		BE562826		gb:601336534F1 NIH_MGC_44 Homo sapien	
		AK000136		asporin (LRR class 1)	4.1
25		AA383471	Hs.180669	conserved gene amplified in osteosarcoma	4.1
35	405850		Un 400400	Target Exon	4.1
		A1732892	Hs.190489 Hs.163484		4.0 4.0
	400284		113.105404	estrogen receptor 1	4.0
		N91453	Hs.102987		4.0
40		U20158	Hs.2488	lymphocyte cytosolic protein 2 (SH2 doma	4.0
		AW797437		B-factor, properdin	4.0
		U79293	Hs.159264	Human clone 23948 mRNA sequence	4.0
	419594	AA013051	Hs.91417 Hs.89603	topoisomerase (DNA) II binding protein mucin 1, transmembrane	4.0 4.0
45		Al034351	Hs.19030	ESTs	4.0
		AW963372		PRO2000 protein	4.0
	433404	T32982	Hs.102720		4.0
				thymidine kinase 1, soluble	4.0
50		BE250127		CDC20 (cell division cycle 20, S. cerevi	3.9
30		AW630088 AW411479		Homo sapiens mRNA; cDNA DKFZp564B126- FK506-binding protein 4 (59kD)	
	404580	A44411413	113.040	NM_014112*:Homo sapiens trichorhinophala	3.9 3.0
		AB018345	Hs.27657	KIAA0802 protein	3.9
	459587	AA031956		gb:zk15e04.s1 Soares_pregnant_uterus_NbH	3.9
55	416658		Hs.79432	fibrillin 2 (congenital contractural ara	3.9
		AA243464		pre-B-cell leukemia transcription factor	3.9
		AL117406		ATP-binding cassette transporter MRP8	3.9
	418918		Hs.190325 Hs.89476		3.9 3.9
60		W94197	Hs.110165	ribosomal protein L26 homolog	3.9
		AI201183			3.9
	421168	AF182277	Hs.330780	cytochrome P450, subfamily IIB (phenobar	3.9
		AW935490		Human chromosome 5q13.1 clone 5G8 mRNA	
65		BE019020			3.9
05		NM_002543 AA809875			3.9
		NM_007019			3.9 3.9
					0.0

		AA263172 Hs.35 Al498957 Hs.17086	protein tyrosine phosphatase, non-recept 1 ESTs, Weakly similar to Z195_HUMAN ZINC	3.9 3.8	
		AW236861 Hs.19313		3.8	
		NM_002267Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.8	
5		U40462 Hs.54452		3.8	
		BE565647 Hs.74899		3.8	
		AF055084 Hs.15369	2 Homo sapiens cDNA FLJ14354 fis, clone Y7	3.8	
	400021		AFFX control - HUMISGF3A/M97935_MA	3.8	
10		BE466639 Hs.61779	•	3.8	
10		Al267371 Hs.17263 AA631739 Hs.33544		3.8 3.8	
		AW207206 Hs.13631		3.8	
			4 ESTs, Weakly similar to B28096 line-1 pr	3.8	
	401045	711-10-17-1 110:10-000	C11001883*:gi[6753278]ref[NP_033938.1] c	3.8	
15		AW449612 Hs.15247		3.8	
	423397	NM_001838Hs.1652	chemokine (C-C motif) receptor 7	3.8	
		Al660149 Hs.44865	lymphoid enhancer-binding factor 1	3.8	
		AJ227892 Hs.14627		3.8	
20		AW068115 Hs.821	biglycan	3.8	
20		Al767949 Hs.17983		3.8	
		NM_003512Hs.28777 M81057 Hs.18088	H2A histone family, member L carboxypeptidase B1 (tissue)	3.8 3.8	
		AA165232 Hs.22206		3.8	
		AL353944 Hs.50118			3.8
25			0 HER2 receptor tyrosine kinase (c-erb-b2,	3.7	
	400286	NA	C16000922:gi 7499103 pir T20903 hypothe	3.7	
		Al623693 Hs.19153		3.7	
		AW900992 Hs.93796		3.7	
30			0 hypothetical protein FLJ22439	3.7	
30		AA371307 Hs.12508 Al916662 Hs.21157	o ESTS 7 kinectin 1 (kinesin receptor)	3.7 3.7	
	457001		vitamin D (1,25- dihydroxyvitamin D3) re	3.7	
		AW406878	gb:UI-HF-BL0-adg-g-06-0-UI.r1 NIH_MGC_3		
		NM_014737Hs.80905			
35	436222	Al208737 Hs.12281	0 Homo sapiens cDNA FLJ11489 fis, clone HE		
		Al633553 Hs.13303		3.7	
			2 hypothetical protein FLJ20285	3.7	
		N49813 Hs.75615	· · · · · · · · · · · · · · · · · · ·	3.7	
40		NM_014141Hs.10655 AW958544 Hs.11224		3.7 3.7	
70			6 ESTs, Weakly similar to (defline not ava	3.7	
	406153	74 (007 201 1 10.2000)	Target Exon	3.7	
		AW873606 Hs.14900		3.7	
		Al884911 Hs.32989		3.7	
45		AB011152 Hs.22572		3.7	
		AF113676 Hs.29768		3.6	
		U76248 Hs.2019 ⁻ BE005771 Hs.1537 ⁻		3.6 3.6	
			9 ESTs, Weakly similar to I38022 hypotheti	3.6	
50		X98654 Hs.93837		3.6	
• •		AF188625 Hs.18950		3.6	
	430378	Z29572 Hs.2556	tumor necrosis factor receptor superfami	3.6	
		Al800470 Hs.17194		3.6	
<i></i>			3 transcription factor 2, hepatic; LF-B3;	3.6	
55			6 ESTs, Weakly similar to I38022 hypotheti	3.6	
		BE069341 AW024973 Hs.28367	gb:QV3-BT0381-270100-073-c08 BT0381 Ho	3.6	1
		AV653264 Hs.13982			
	452101				
60		NM_014788Hs.17970		3.6	
	409047	AW961434 Hs.31539	ESTs	3.6	
		NM_000402Hs.80206		3.6	
		W26187 Hs.3327	Homo sapiens cDNA: FLJ22219 fis, clone H	3.6	
65	440516	S42303 Hs.161 AW015415 Hs.12778	cadherin 2, type 1, N-cadherin (neuronal 0 ESTs	3.6	
05			1 retinoic acid induced 3	3.6 3.6	
		R43179 Hs.2289		3.6	
			. 71	0.0	

		AK001015 AA464510	Hs.55220 Hs.152812	BCL2-associated athanogene 2 ESTs	3.6 3.6	
			Hs.194024		3.6	
		AA380731		interleukin 2 receptor, gamma (severe co	3.6	
5		AF088020		EST	3.6	
		H63010	Hs.5740	ESTs	3.5	
		AA351647 Al418055	Hs.161160	eukaryotic translation elongation factor ESTs	3.5 3.5	
		AF234882		suppression of tumorigenicity 7	3.5	
10		AA284166		cyclin-dependent kinase inhibitor 3 (CDK	3.5	
	439569	AW602166	Hs.222399	CEGP1 protein	3.5	
		Al907673		gb:IL-BT152-080399-004 BT152 Homo sapie		
	403212	4)4000000		NM_019595:Homo sapiens intersectin 2 (IT	3.5	
15		AK000725		hypothetical protein FLJ20718	3.5	
13		AA847843 W92147	Hs.62711 Hs.118394	Homo sapiens, clone IMAGE:3351295, mRNA	3.5	
		Z43784	Hs.75893	ankyrin 3, node of Ranvier (ankyrin G)	3.5	
		Al827248		Homo sapiens cDNA FLJ11469 fis, clone HE	3.5	
		AA641836		hypothetical protein FLJ23186	3.5	
20		AK002135		hypothetical protein FLJ11273	3.5	
			Hs.137007		3.5	
				poly(A)-binding protein, cytoplasmic 1-l	3.4	
		BE311926	Hs.15830	hypothetical protein FLJ12691	3.4	2.4
25		AW881145 BE390551	He 77628	gb:QV0-OT0033-010400-182-a07 OT0033 Ho steroidogenic acute regulatory protein r	3.4	3.4
23		W29092	Hs.7678	cellular retinoic acid-binding protein 1	3.4	
		AI167877	Hs.143716		3.4	
	402470			Target Exon	3.4	
• •	418120	AA213437	Hs.192249		3.4	
30		AW875237		ESTs	3.4	
		Al681545		hypothetical protein FLJ13117	3.4	
		U61412	Hs.51133	PTK6 protein tyrosine kinase 6	3.4 3.4	
		M90516	Hs.1674	fucosyltransferase 8 (alpha (1,6) fucosy glutamine-fructose-6-phosphate transamin	3.4	
35		AA447492		ESTs, Weakly similar to AF164793 1 prote	3.4	
-	402359		110120100	C19001991*:gij12656111 gb AAK00751.1 AF.		
		AA284267	Hs.221504		3.4	
		F01020	Hs.172004		3.4	
40		AA812633		ESTs	3.4	
40		R11141		hypothetical protein	3.4 3.4	
		AJ271216 AK001763		dipeptidylpeptidase III hypothetical protein FLJ10901	3.4	
		Y18418		RuvB (E coli homolog)-like 1	3.4	
			Hs.194698		3.4	
45		U58766	Hs.264428	tissue specific transplantation antigen	3.4	
				Homo sapiens, clone IMAGE:3616574, mRNA		
		AF037335		carbonic anhydrase XII (tumor antigen H	3.4	
		AW392550		proteasome (prosome, macropain) subunit, KIAA0175 gene product	3.4 3.3	
50			Hs.200266		3.3	
50		Al335773	Hs.270123		3.3	
	420542	NM_000508	5Hs.1321	coagulation factor XII (Hageman factor)	3.3	
	412754	AW160375		amyloid beta (A4) precursor-like protein	3.3	
		U70370	Hs.84136	paired-like homeodomain transcription fa	3.3	
55		Al627393	Hs.258998		3.3	
		AA361258	Hs.332981	ESTs, Weakly similar to l38022 hypotheti interleukin 7 receptor	3.3 3.3	
		AA161071		squalene epoxidase	3.3	
		BE262660		glutamic-oxaloacetic transaminase 2, mit	3.3	
60		AI086138	Hs.204044		3.3	
	427080	AW068287		ras-related C3 botulinum toxin substrate	3.3	
	426429	X73114	Hs.169849	myosin-binding protein C, slow-type	3.3	
		AA026880	Hs.25252	prolactin receptor	3.3	
65		U41763		clathrin, heavy polypeptide-like 1 a disintegrin and metalloproteinase doma	3.3	
05		BE243136 Al601188	Hs.120910		3.3 3.3	
		AA628967		ESTs, Highly similar to IHH_HUMAN INDIAN	3.3	

	430253	AK001514	Hs.236844	hypothetical protein FLJ10652	3.3
		A1929659		signal recognition particle 72kD	3.3
		AK001455			3.3
_				, ,	3.3
5		H09048	Hs.23606	· · ·	3.3
		H91882			3.3
				Human DNA sequence from clone RP11-2180 ret finger protein 2	, 13.3 3.3
		AW270655			3.3
10		R43409	Hs.6829	Homo sapiens mRNA for KIAA1644 protein,	3.3
10		AW978484			3.3
		AI015709		Homo sapiens mRNA; cDNA DKFZp586l2022	
	439237	AW408158	Hs.318893	ESTs, Weakly similar to A47582 B-cell gr	3.3
				selenophosphate synthetase 2	3.3
15				, ,	3.3
		U24683			3.3
		AA907734			3.3
					3.3 3.3
20		C01765 AA912183	Hs.38750		3.3
20		U46258	Hs.339665		3.3
	404755		110.000000		3.3
		AI821005	Hs.118599	•	3.2
		AW406289			3.2
25	430580	AA806105	Hs.300697	immunoglobulin heavy constant gamma 3 (G	
	400202			NM_002795*:Homo sapiens proteasome (pros	
	400222			NM_002082*:Homo sapiens G protein-couple	
					3.2 3.2
30		BE550224 AJ002744			3.2
50		A1027643	Hs.120912		3.2
		BE379594		ESTs, Moderately similar to ALU7_HUMAN A	
		U79745		solute carrier family 16 (monocarboxylic	3.2
		Al793257	Hs.128151		3.2
35	420380	AA640891	Hs.102406	ESTs	3.2
		H04588	Hs.30469	ESTs	3.2
		Al244459	Hs.110826		3.2
		AI821926	U- 440057	gb:nt78f05.x5 NCI_CGAP_Pr3 Homo sapiens	
40				,	3.2 3.2
40		NM_015156 Al472078	Hs.303662		3.2
		N30714			3.2
		AA310964			3.2
		R35343	Hs.24968	Human DNA sequence from clone RP1-233G	
45		AA837085		ESTs	3.2
		AW292593		Homo sapiens, clone MGC:17333, mRNA, cor	
		AW503785		complement component (3d/Epstein Barr vi	3.2
		AA025386		ESTs, Weakly similar to S10590 cysteine	3.2
50		AW408337		CD7 antigen (p41)	3.2 3.2
50		D50915 AL047586	Hs.38365	KIAA0125 gene product RNA binding motif protein 8B	3.2
		AW768399			3.2
		W20128	Hs.296039		3.2
		AA319233	Hs.5521		3.2
55	450223	AA418204	Hs.241493		3.2
		AW966728	Hs.54642	methionine adenosyltransferase II, beta	3.2
		AL118668		gb:DKFZp761I0310_r1 761 (synonym: hamy2)	
		AW405434	Hs.82575 Hs.334345	small nuclear ribonucleoprotein polypept	3.2 3.2
60		U22029 BE244638	Hs.166	cytochrome P450, subfamily IIA (phenobar sterol regulatory element binding transc	3.2
JU	44119/ 424634	NM_003613		cartilage intermediate layer protein, nu	3.2
		AI345455	Hs.78915	GA-binding protein transcription factor,	3.2
	416714	AF283770		CD79A antigen (immunoglobulin-associated	3.2
	449465)Hs.23598	CREB binding protein (Rubinstein-Taybi s	3.2
65	422166	W72424		S100 calcium-binding protein A9 (calgran	3.2
	409079	W87707	Hs.82065	interleukin 6 signal transducer (gp130,	3.2
	423551	AA327598	Hs.233785	2018	3.2

		AA036849	Hs.61829	Homo sapiens cDNA FLJ12763 fis, clone NT	
		AI733682	Hs.130239		3.2
		A1796870	Hs.54277	DNA segment on chromosome X (unique) 992	
~		AF076292		forkhead box H1	3.2
5		BE122762	Hs.25338	ESTs	3.2
		S57296		v-erb-b2 avian erythroblastic leukemia v	3.2
		AI703172		ESTs, Weakly similar to 2109260A B cell	3.1
	430271	T06199 AW205118		DnaJ (Hsp40) homolog, subfamily B, membe	3.1 3.1
10		Al278023	Hs.89986	interleukin 21 receptor ESTs	3.1
10		BE388898		hypothetical protein FLJ11307	3.1
		AL137589		hypothetical protein DKFZp434K0410	3.1
		BE379335			3.1
		AA247152			3.1
15		AW572659			3.1
		AI124756	Hs.5337	isocitrate dehydrogenase 2 (NADP), mitoc	3.1
	405017	NA		Target Exon	3.1
	433805	AA706910	Hs.112742	ESTs	3.1
• •	437352	AL353957		hypothetical protein DKFZp434P0531	3.1
20		X70297	Hs.2540	cholinergic receptor, nicotinic, alpha p	3.1
		NM_00114		arachidonate 15-lipoxygenase, second typ	3.1
		BE145360			3.1
		Al267700	Hs.317584		3.1
25		Al879263	Hs.6986 Hs.1906	Human glucose transporter pseudogene	3.1 3.1
23		AA890023 BE387202	Hs.118638	prolactin receptor non-metastatic cells 1, protein (NM23A)	3.1
		AW247529		platelet-activating factor acetylhydrola	3.1
		Al638516	Hs.22630	cofactor required for Sp1 transcriptiona	3.1
		AI885190	Hs.156089		3.1
30		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.1
	400814			Target Exon	3.1
	402327			Target Exon	3.1
	416935	AA190712		gb:zp87f09.r1 Stratagene HeLa cell s3 93	3.1
0.5		AL355722		Homo sapiens EST from clone 35214, full	3.1
35		Al571514	Hs.133022		3.1
	449523	NM_000579	9Hs.54443	chemokine (C-C motif) receptor 5	3.1
		1 10 450 40			0.4
	406642	AJ245210		gb:Homo sapiens mRNA for immunoglobulin	3.1
	406642 406624	AF052762	Un 100606	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo	3.1
<i>4</i> ∩	406642 406624 421924	AF052762 BE514514	Hs.109606	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A	3.1 3.1
40	406642 406624 421924 414523	AF052762 BE514514 AU076633	Hs.76353	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito	3.1 3.1 3.1
40	406642 406624 421924 414523 416379	AF052762 BE514514 AU076633 N38857	Hs.76353 Hs.203933	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs	3.1 3.1 3.1 3.1
40	406642 406624 421924 414523 416379 422823	AF052762 BE514514 AU076633 N38857 D89974	Hs.76353 Hs.203933 Hs.121102	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2	3.1 3.1 3.1
40	406642 406624 421924 414523 416379 422823 433904	AF052762 BE514514 AU076633 N38857	Hs.76353 Hs.203933 Hs.121102 Hs.208956	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs	3.1 3.1 3.1 3.1 3.1
40 45	406642 406624 421924 414523 416379 422823 433904 421904	AF052762 BE514514 AU076633 N38857 D89974 Al399956	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035	3.1 3.1 3.1 3.1 3.1 3.1
	406642 406624 421924 414523 416379 422823 433904 421904 428834	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA	3.1 3.1 3.1 3.1 3.1 3.1 3.1
	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 4562823 405381 428746	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416527 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306	AF052762 BE514514 AU076633 N38857 D89974 AI399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306 419123	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 452823 405381 428746 435147 425782 423306 419123 438581	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AW977766	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs hypothetical protein FLJ20035 ESTs homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs ESTs, Moderately similar to 178885 serin	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 405381 428746 435147 425782 423306 419123 438581 417105	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AAW977766 X60992	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.81226	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306 419123 438581 417105 428361	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W8562 AA234276 AW977766 X60992 NM_015905	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.81226 5Hs.183858	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306 419123 438581 417105 428361 417880	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AAW977766 X60992	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.81226 5Hs.183858	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306 419123 438581 417105 428361	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W8562 AA234276 AW977766 X60992 NM_015905	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.81226 5Hs.183858	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs hypothetical protein FLJ20035 ESTs homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hypothetical prot NM_004496*:Homo sapiens hepatocyte nuclei	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306 419123 438581 417105 428361 428361 42	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W8562 AA234276 AW977766 X60992 NM_015905	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.81226 5Hs.183858	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hepatocyte nuclei NM_004496*:Homo sapiens hepatocyte nuclei	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45 50 55	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 405381 428746 435147 425782 423306 419123 438581 417105 428361 417880 402606 401451 421878 409518	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AW977766 X60992 NM_015905 BE241595 AA299652 BE384836	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.81226 5Hs.183858 Hs.82848	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hypothetical prot NM_004496*:Homo sapiens hepatocyte nucle Homo sapiens cDNA FLJ11643 fis, clone HE KIAA1821 protein	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45 50 55	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 405381 428746 435147 425782 423306 419123 438581 417105 428361 417880 402606 401451 421878 409518 416933	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AW977766 X60992 NM_01590 BE241595 AA299652 BE384836 BE561850	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.292133 Hs.81226 5Hs.183858 Hs.82848 Hs.111496 Hs.3454 Hs.80506	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to 178885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hypothetical prot NM_004496*:Homo sapiens hepatocyte nucle Homo sapiens cDNA FLJ11643 fis, clone HE KIAA1821 protein small nuclear ribonucleoprotein polypept	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45 50 55	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306 419123 438581 417105 428361 417880 402606 401451 421878 409518 416933 414324	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AW977766 X60992 NM_015908 BE241595 AA299652 BE241595 AA299652 D82384836 BE561850 Y14768	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.8292133 Hs.81226 5Hs.183858 Hs.82848 Hs.111496 Hs.3454 Hs.30506 Hs.890	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs Homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hypothetical prot NM_004496*:Homo sapiens hepatocyte nucle Homo sapiens cDNA FLJ11643 fis, clone HE KIAA1821 protein small nuclear ribonucleoprotein polypept lymphotoxin beta (TNF superfamily, membe	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45 50 55 60	406642 406624 421924 414523 416379 422823 433904 421904 428834 436043 452823 405381 428746 435147 425782 423306 419123 438581 417105 428361 417880 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 421878 402606 401451 402606 40	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AW977766 X60992 NM_01590 BE241595 AA299652 BE384836 BE561850	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.292133 Hs.81226 5Hs.183858 Hs.82848 Hs.111496 Hs.3454 Hs.80506	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs hypothetical protein FLJ20035 ESTs homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hypothetical prot NM_004496*:Homo sapiens hepatocyte nucle Homo sapiens cDNA FLJ11643 fis, clone HE KIAA1821 protein small nuclear ribonucleoprotein polypept lymphotoxin beta (TNF superfamily, membe minichromosome maintenance deficient (S.	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45 50 55	406642 406624 421924 414523 416379 422823 433904 421904 428834 43581 428746 435147 425782 423306 419123 438581 417105 428361 417105 417	AF052762 BE514514 AU076633 N38857 D89974 AI399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AW977766 AW977766 AW977766 E241595 AA299652 BE384836 BE561850 Y14768 X74794	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.3039315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.292133 Hs.81226 5Hs.183858 Hs.82848 Hs.111496 Hs.3454 Hs.3454 Hs.80506 Hs.890 Hs.154443	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs hypothetical protein FLJ20035 ESTs homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hypothetical prot NM_004496*:Homo sapiens hepatocyte nucle Homo sapiens cDNA FLJ11643 fis, clone HE KIAA1821 protein small nuclear ribonucleoprotein polypept lymphotoxin beta (TNF superfamily, membe minichromosome maintenance deficient (S. C15000476*:gi 12737279 ref XP_012163.1	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
45 50 55 60	406642 406624 41924 414523 416379 422823 433904 421904 428834 4352823 405381 428746 435147 425782 423306 419123 438581 417105 428361 417880 402606 401451 421878 409518 416933 414324 425019 401519 411704	AF052762 BE514514 AU076633 N38857 D89974 Al399956 BE143533 AW899713 AW963838 AB012124 NA AW503820 AL133731 U66468 W88562 AA234276 AW977766 X60992 NM_015908 BE241595 AA299652 BE241595 AA299652 D82384836 BE561850 Y14768	Hs.76353 Hs.203933 Hs.121102 Hs.208956 Hs.109309 Hs.339315 Hs.168830 Hs.30696 Hs.192861 Hs.4774 Hs.159525 Hs.108198 Hs.88253 Hs.8292133 Hs.81226 5Hs.163858 Hs.82848 Hs.1111496 Hs.3454 Hs.80506 Hs.890 Hs.154443 Hs.71573	gb:Homo sapiens mRNA for immunoglobulin gb:Homo sapiens clone csneg8-1 immunoglo coronin, actin-binding protein, 1A serine (or cysteine) proteinase inhibito ESTs vanin 2 ESTs hypothetical protein FLJ20035 ESTs hypothetical protein FLJ20035 ESTs homo sapiens cDNA FLJ12136 fis, clone MA transcription factor-like 5 (basic helix Target Exon Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171 cell growth regulatory with EF-hand doma ESTs ESTs, Moderately similar to I78885 serin CD6 antigen transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule NM_024626:Homo sapiens hypothetical prot NM_004496*:Homo sapiens hepatocyte nucle Homo sapiens cDNA FLJ11643 fis, clone HE KIAA1821 protein small nuclear ribonucleoprotein polypept lymphotoxin beta (TNF superfamily, membe minichromosome maintenance deficient (S.	3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1

	428423	AU076517	Hs.184276	solute carrier family 9 (sodium/hydrogen	3.0	
	413835	AI272727	Hs.249163	fatty acid hydroxylase	3.0	
	412600	L28824	Hs.74101	spleen tyrosine kinase	3.0	
	410491	AA465131	Hs.64001	Homo sapiens clone 25218 mRNA sequence	3.0	
5	433658	L03678	Hs.156110	immunoglobulin kappa constant	3.0	
	427666	Al791495	Hs.180142	calmodulin-like skin protein	3.0	
	452514	AI904898		gb:RC-BT068-130399-085 BT068 Homo sapid	en3.0	
	429500	X78565	Hs.289114	hexabrachion (tenascin C, cytotactin)	3.0	
	432485	N90866	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	3.0	
10	437400	AB011542	Hs.5599	EGF-like-domain, multiple 5	3.0	
	452234	AW084176	Hs.223296	ESTs, Weakly similar to I38022 hypotheti	3.0	
	413269	BE167526		gb:CM4-HT0509-080300-107-g07 HT0509 Hc	omo	3.0
	453216	AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G032	1 (f	3.0
	400929			ENSP00000252232*:Sterol regulatory eleme	3.0	
15	445145	A1961702	Hs.147434	ESTs	3.0	
	432615	AA557191	Hs.55028	ESTs, Weakly similar to 154374 gene NF2	3.0	
	423279	AW959861	Hs.290943	ESTs	3.0	
	429392	AL109712	Hs.296506	Homo sapiens mRNA full length insert cDN	3.0	
	408548	AA055449	Hs.63187	ESTs, Weakly similar to ALUC_HUMAN !!!!	3.0	
20	451346	NM_006338	3Hs.26312	glioma amplified on chromosome 1 protein	3.0	
	413109	AW389845	Hs.110855		3.0	
	401714	NA		ENSP00000241802*:CDNA FLJ11007 FIS, C	LON	3.0
	421462	AF016495	Hs.104624	aquaporin 9	3.0	
~ -	421750	AK000768	Hs.107872	hypothetical protein FLJ20761	3.0	
25	453293	AA382267	Hs.10653	ESTs	3.0	
	457085	AA412446	Hs.98138	ESTs	3.0	
	438930	AW843633	Hs.306163	hypothetical protein AL110115	3.0	

TABLE 22A

Table 22A shows the accession numbers for those pkeys lacking unigeneID's for Table 22.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	for beque	nees comprising each crac
	Pkey:	Unique Eos probeset identifier number
	CAT number:	Gene cluster number
	Accession:	Genhank accession numbers

15			
	Pkey	CAT number	Accessions
	407980	103087_1	AA046309 Al263500 AA046397
	410785	1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
20	411743	1256098 1	AW862214 AW859811 AW862215
	412138	1279172 1	AW895387 AW895547 AW895564 AW895323 AW895405 AW895539 AW895538
	413269	1356961 1	BE167526 BE167651 BE076401 R24654
	416935	163179 1	AA190712 AA190665 AA252564
	422128	211994 1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
25	423945	233566 1	AA410943 AW948953 AA334202 AA332882
	424109	235506_1	AW406878 AW966560 AW966151 AW966496 AA336174 AA335376 AA335537
	424128	235728 1	AW966163 AA335983 AA336011 AA335668 AA335973
	425331	250199 1	AW962128 AA355353 AA427363
	426878	273265 1	BE069341 AW748403 AL044891 Al908240 AA393080
30	432745	353673_1	AI821926 AA658826 AA564492 AA635129 AI791191
	441153	51084_2	BE562826 BE378727
		755099 1	Al475858 AW969013
	451128	859865 1	AL118668 D78823 Al762176
	452514	920172_1	AJ904898 AJ904849 AJ904899
35	456207	1650781	AA193450

TABLE 22B

Table 22B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 22. For each predicted exon, we have listed the genomic 5 sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
10	, 10,,	entitled "The DNA sequence of human chromosome 22." Dunham I, et al., Nature (1999) 402:489-495.

9) 402:489-495.

Strand: Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons. Nt_position:

15				
	Pkey	Ref	Strand	Nt_position
	400814	8569925	Minus	72840-72924,74761-74849
	400929	7651921	Minus	122033-122241,123483-124028
20	401045	8117619	Plus	90044-90184,91111-91345
	401451	6634068	Minus	119926-121272
	401519	6649315	Plus	157315-157950
		7657839	Minus	34986-35133
~ ~		6715702	Plus	96484-96681
25	401866		Plus	73126-73623
	402327		Minus	108675-108770,109801-109910
	402359		Minus	40403-41961
		9796239	Minus	110326-110491
20		9797107	Plus	195129-195776
30	402542		Minus	67076-67594
	402578		Plus	66350-66496
		9909429	Minus	81747-82094
		6693597	Minus	3468-3623
2.5		7630897	Minus	156037-156210
35	403329		Plus	96450-96598
	403366	8783692	Minus	49323-49652
	403485		Plus	2888-3001,3198-3532,3655-4117
	404347		Plus	74493-74829
40	404580		Minus	240588-241589
40		7706327	Minus	53729-53846
	405017		Plus	35551-35690
		2914717	Minus	43310-43462
	405381		Minus	7636-8054
15	405801		Plus	63469-63694
45	405850	6164995	Plus	13871-14110
	406153		Minus	12902-13069
	406348	9255985	Minus	71754-71944

TABLE 23: 320 GENES DOWN-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 23 shows 320 genes down-regulated in breast cancer compared to normal adult breast. These were selected as for Table 22, except that the numerator was set to the median value for 12 non-malignant breast specimens, the denominator was set to the median value amongst the 73 breast cancers, the 90th percentile value amongst the 12 non-malignant breast specimens was greater than or equal 80 units, and the ratio was greater than or equal to 4.0 (i.e. 4-fold down-regulated in tumor vs. normal breast).

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

15 Unigene ID: Unigene number Unigene Title: Unigene gene title

R1: Ratio of 50th percentile normal body tissue to 75th percentile tumor

20	Pkey	ExAccn	UnigenelD	UnigeneTitle	Ratio
•	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	22.4
	428848	NM_000230	Hs.194236	leptin (murine obesity homolog)	17.4
	445263	H57646	Hs.42586	KIAA1560 protein	15.4
25	418935	T28499	Hs.89485	carbonic anhydrase IV	15.0
	407228	M25079	Hs.155376	hemoglobin, beta	14.6
	417511	AL049176	Hs.82223	chordin-like	14.6
	439285	AL133916	Hs.172572	hypothetical protein FLJ20093	14.3
		A1983730	Hs.26530	serum deprivation response (phosphatidyl	13.6
30	410544	A1446543	Hs.95511	ESTs	12.6
	412047	AA934589	Hs.49696	ESTs	12.2
		H25642	Hs.133471	ESTs	12.0
		L34041	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	12.0
		NM_000163	Hs.125180	growth hormone receptor	11.7
35	422163	AF027208	Hs.112360	prominin (mouse)-like 1	10.8
	428769	AW207175	Hs.106771	ESTs	10.6
	407049	X72632		NM_021724*:Homo sapiens nuclear receptor	10.1
	412295	AW088826	Hs.117176	poly(A)-binding protein, nuclear 1	9.8
	425126	N32759	Hs.172944	chorionic gonadotropin, beta polypeptide	9.8
40		Al220684	Hs.272572	hemoglobin, alpha 2	9.5
	447471	AF039843	Hs.18676	sprouty (Drosophila) homolog 2	9.5
		NM_004657	Hs.26530	serum deprivation response (phosphatidyl	9.4
		AW410377	Hs.41502	hypothetical protein FLJ21276	9.0
	411939	AI365585	Hs.146246	ESTs	9.0
45	410532	T53088	Hs.155376	hemoglobin, beta	8.9
	425707	AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	8.8
	416585	X54162	Hs.79386	leiomodin 1 (smooth muscle)	8.7
	443060	D78874	Hs.8944	procollagen C-endopeptidase enhancer 2	8.6
		AA779958	Hs.185932	ESTs	8.5
50		AU076442	Hs.117938	collagen, type XVII, alpha 1	8.4
	433138	AB029496	Hs.59729	semaphorin sem2	8.3
	402195			NM_004497*:Homo sapiens hepatocyte nucle	8.1
	429350	A1754634	Hs.131987	ESTs	8.1
	445107	Al208121	Hs.147313	ESTs, Weakly similar to I38022 hypotheti	8.1
55		N77976	Hs.272572	hemoglobin, alpha 2	8.0
		AW377424	Hs.205126	Homo sapiens cDNA: FLJ22667 fis, clone H	8.0
	417225	AA815048	Hs.24078	hypothetical protein FLJ12649	7.8
		AA760849	Hs.294052	ESTs	7.5
		AK000027	Hs.98633	ESTs	7.5
60		NM_002599	Hs.154437	phosphodiesterase 2A, cGMP-stimulated	7.5
	430327	AW973636	Hs.55931	ESTs	7.4

	447577	Al393693	Hs.183297	DKFZP566F2124 protein	7.4
		Al150491	Hs.90756	ESTs	7.2
		R20893	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	7.2
5		AA452006 AW956360	Hs.333199 Hs.4748	ESTs adenylate cyclase activating polypeptide	7.1 7.1
9		Al352340	Hs.131194	ESTs	7.0
		Al219304	Hs.283108	hemoglobin, gamma G	6.9
	407571	Al446183	Hs.9572	ESTs, Highly similar to CYA5_HUMAN ADENY	6.8
	429580	AA346839	Hs.209100	DKFZP434C171 protein	6.7
10		Al478427	Hs.43125	esophageal cancer related gene 4 protein	6.7
		AB002058	Hs.113275	purinergic receptor P2X-like 1, orphan r	6.7
	420205	AA256395	Hs.88156	ESTs ENSP00000241075*:TRRAP PROTEIN.	6.6
		NM_006691	Hs.17917	extracellular link domain-containing 1	6.6 6.5
15		AA193282	Hs.85863	ESTs, Weakly similar to B34612 zinc fing	6.5
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	6.5
	427283	AL119796	Hs.174185	ectonucleotide pyrophosphatase/phosphodi	6.5
		AW963085		gb:EST375158 MAGE resequences, MAGH Hor	
20		S72043	Hs.73133	metallothionein 3 (growth inhibitory fac	6.4
20		BE250659 AA701483	Hs.15463 Hs.36341	Homo sapiens, clone IMAGE:2959994, mRNA ESTs	6.4 6.3
	402779		HS.30341	Target Exon	6.3
		AA213626	Hs.136204	EST	6.3
		AA742697	Hs.62492	ESTs, Weakly similar to B39066 proline-r	6.3
25		AA001732	Hs.173233	hypothetical protein FLJ10970	6.2
		BE143068		gb:MR0-HT0158-030200-003-b09 HT0158 Hom	
		BE004783	He 40000	gb:MR2-BN0114-270400-004-e11 BN0114 Hom	
		NM_012093 NM_014759	Hs.18268 Hs.334688	adenylate kinase 5 KIAA0273 gene product	6.1 6.1
30		H15968	Hs.293845	Homo sapiens, clone IMAGE:3502329, mRNA,	6.1
		F08212	Hs.234898	ESTs, Weakly similar to 2109260A B cell	6.0
	400089			Eos Control	6.0
		W07475	Hs.277101	cytochrome c oxidase subunit IV isoform	5.9
35		N92818	Hs.64754	ESTs, Weakly similar to potential CDS [H	5.9
33		BE067414 AA062610	Hs.148050	gb:MR4-BT0355-200100-201-e05 BT0355 Home EST	5.9 5.9
	406563		113.140000	Target Exon	5.9
		AW451023	Hs.65848	hypothetical protein DKFZp761O132	5.9
	419313	AA843387	Hs.87279	ESTs	5.9
40		NM_001874	Hs.334873	carboxypeptidase M	5.8
		AW809163	11- 00040	gb:MR4-ST0118-261099-012-a03 ST0118 Homo	
		AB014533 Al372588	Hs.33010 Hs.8022	KIAA0633 protein TU3A protein	5.8 5.8
		AA372052	Hs.334559	Homo sapiens cDNA FLJ14458 fis, clone HE	5.8
45		BE063555	110.00-1000	gb:CM1-BT0283-081199-033-d09 BT0283 Homo	
		AW876813	Hs.3343	phosphoglycerate dehydrogenase	5.7
	425187	AW014486	Hs.22509	ESTs	5.7
		AW452355	Hs.256037	ESTs	5.7
50		AL036557 Al695473	Hs.95910 Hs.298006	putative lymphocyte G0/G1 switch gene ESTs	5.7
50		AA181641	Hs.184907	G protein-coupled receptor 1	5.7 5.6
	404689		1.0.101001	Target Exon	5.6
		R68857	Hs.265499	ESTs	5.6
	406082	S47833	Hs.82927	adenosine monophosphate deaminase 2 (iso	5.6
55		H23963	Hs.32043	ESTs	5.6
		R50253	Hs.249129	cell death-inducing DFFA-like effector a	5.5
		C15819 AW444613	Hs.288809	gb:C15819 Clontech human aorta polyA mRN hypothetical protein FLJ20159	5.5 5.5
		AB020629	Hs.38095	ATP-binding cassette, sub-family A (ABC1	5.5 5.5
60		AI668605	Hs.60380	ESTs, Moderately similar to ALU6_HUMAN A	5.5
	414629	AA345824	Hs.76688	carboxylesterase 1 (monocyte/macrophage	5.5
	401665	700070	11- 404404	C11000703:gi 10048448 ref NP_065258.1 g	5.5
		T99079	Hs.191194	ESTs	5.5
65		AI161428 BE005346	Hs.75916 Hs.116410	splicing factor 3b, subunit 2, 145kD ESTs	5.5 5.5
0.5		BE617015	Hs.11006	ESTs, Moderately similar to T17372 plasm	5.5
		AI432652	Hs.42824	hypothetical protein FLJ10718	5.5
				22.6	
				336	
				,	

	454016	AW016806	Hs.233108	ESTs	5.5
	414913	R25621		gb:yh45f06.r1 Soares placenta Nb2HP Homo	5.4
	459033	AA017590	Hs.129907	ESTs	5.4
		BE172240	Hs.126379	ESTs, Weakly similar to 138022 hypotheti	5.4
5		N49826	Hs.18602	ESTs	5.4
•		AA994520	110110002	gb:ou42g09.s1 Soares_NFL_T_GBC_S1 Homo s	
	403612			Target Exon	5.3
		AA007629	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	5.3
				multimerin	5.3
10		R66634	Hs.268107		
10		BE272452	Hs.183109	monoamine oxidase A	5.3
		AA620814	Hs.144959	ESTs	5.3
		R99530	Hs.272572	hemoglobin, alpha 2	5.3
	427032	AF012023	Hs.173274	integrin cytoplasmic domain-associated p	5.3
	406305	BE261320	Hs.158196	transcriptional adaptor 3 (ADA3, yeast h	5.3
15	437411	AW613948	Hs.194915	ESTs	5.3
	442800	AI809481	Hs.131227	ESTs	5.3
	402054	NA		Target Exon	5.3
		AF212829	Hs.272406	potassium channel, subfamily K, member 9	5.3
		R59638	Hs.6181	ESTs	5.2
20		AI904646	110.0101	gb:QV-BT065-020399-103 BT065 Homo sapien	5.2
20		AB037721	Hs.173871	KIAA1300 protein	5.2
					5.2
		BE467930	Hs.170381	ESTs	
		Al285901	Hs.181297	ESTS	5.2
0.5	402698			ENSP00000251335*:DJ1003J2.1 (sodium and	5.2
25	401810			Target Exon	5.2
	438879	AA827674	Hs.189073	ESTs	5.2
		AA424074	Hs.76780	protein phosphatase 1, regulatory (inhib	5.2
	427809	M26380	Hs.180878	lipoprotein lipase	5.1
	456063	NM_006744	Hs.76461	retinol-binding protein 4, interstitial	5.1
30	451186	AW023469	Hs.65256	ESTs, Weakly similar to leucine-rich gli	5.1
	451882	AI821324	Hs.100445	ESTs	5.1
	402583		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	NM_021620:Homo sapiens PR domain contain	5.1
		NM_006103	Hs.2719	HE4; WFDC2; putative ovarian carcinoma m	5.1
		Al435179	Hs.126820	ESTs	5.1
35		R53467	Hs.269122	ESTs, Weakly similar to ALU1_HUMAN ALU S	5.1
55		BE143867	113.203122	gb:MR0-HT0164-070100-013-h02 HT0164 Homo	
			Wa A	alcohol dehydrogenase 1B (class I), beta	5.1
		X03350	Hs.4		5.1
		BE244537	Hs.167382	natriuretic peptide receptor A/guanylate	
40		AA486620	Hs.41135	endomucin-2	5.0
40		AW026692	Hs.224829	ESTs	5.0
		D59597	Hs.118821	CGI-62 protein	5.0
	434813	Al524307	Hs.162870	ESTs	5.0
	437526	Al076012	Hs.121388	ESTs, Weakly similar to MDHC_HUMAN MALAT	5.0
	454775	BE160229		gb:QV1-HT0413-090200-062-a12 HT0413 Homo	5.0
45	409451	AF012626	Hs.54472	fragile X mental retardation 2	5.0
	409853	AW502327		gb:UI-HF-BR0p-aka-a-07-0-UI.r1 NIH_MGC_5	5.0
	405062	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Target Exon	5.0
		AK000706	Hs.15125	hypothetical protein FLJ20699	5.0
		AW298163	Hs.82318	WAS protein family, member 3	5.0
50		AJ243662	Hs.110196	NICE-1 protein	5.0
50		R62431	Hs.12758	ESTs	5.0
	415421	R35009	Hs.24903	ESTs	5.0
	41/5/4	R00348	11 70071	gb:ye69e06.r1 Soares fetal liver spleen	5.0
		AJ243191	Hs.56874	heat shock 27kD protein family, member 7	5.0
55		AI768289	Hs.304389	ESTs	4.9
	445613	BE550889	Hs.158491	ESTs	4.9
	443074	AW341470	Hs.144907	ESTs	4.9
	451324	A1783600	Hs.208052	ESTs	4.9
		AW014734	Hs.157969	ESTs	4.9
60	449654	Al989812	Hs.199850	ESTs	4.9
• •		N94587	Hs.55063	ESTs	4.9
		AW973716	Hs.13913	KIAA1577 protein	4.9
		AA682722	Hs.192725	ESTs	4.9
		AF026263	Hs.247920	cholinergic receptor, muscarinic 5	4.8
65		AW137094	Hs.97990	ESTs	4.8
05		AA868510	Hs.112496	ESTs	4.8
			Hs.118944	hypothetical protein FLJ22477	4.8
	420334	AI349351	115.110544	hypothetical protein i cozzari i	-1.0

PCT/US02/02242 WO 02/059377

	421795	X63094	Hs.283822	Rhesus blood group, D antigen	4.8
	427138		Hs.173717	phosphatidic acid phosphatase type 2B	4.8
		BE063965 AW450451	Hs.266355	gb:QV3-BT0296-140200-085-h01 BT0296 Homo ESTs	4.8
5		AW139474	Hs.246862	ESTs	4.8
		AA843716	Hs.177927	ESTs	4.7
		Al025499 Al383475	Hs.132238 Hs.171697	ESTs ESTs, Weakly similar to T13924 sdk prote	4.7 4.7
		BE386764	115.17 1037	gb:601273249F1 NIH_MGC_20 Homo sapiens c	
10		AA398716	Hs.97418	ESTs	4.7
		AW292618	Hs.113011	ESTs	4.7
	401590		Hs.242849	Target Exon ESTs	4.7 4.7
		AW134679 AK000123	Hs.180479	hypothetical protein FLJ20116	4.6
15		AA045290	Hs.25930	ESTs, Weakly similar to 2109260A B cell	4.6
	407737		Hs.6659	ESTs	4.6
		AA972327 AW298235	Hs.142903 Hs.101689	ESTs ESTs	4.6 4.6
		Al382726	Hs.182434	ESTs	4.6
20	403017			Target Exon	4.6
	450580		Hs.15248	ESTs	4.6
	404611 414831		Hs.35156 Hs.77439	Homo sapiens cDNA FLJ11027 fis, clone PL protein kinase, cAMP-dependent, regulato	4.6 4.6
		NM_001546	Hs.34853	inhibitor of DNA binding 4, dominant neg	4.6
25		Al142027	Hs.146650	ESTs	4.6
		AL137698	Hs.46531	Homo sapiens mRNA; cDNA DKFZp434C1915 (f	
		AW204277 AF134707	Hs.250723	hypothetical protein MGC2747	4.6 4.6
		Al375984	Hs.278679 Hs.167216	a disintegrin and metalloproteinase doma ESTs	4.6
30	419583			gb:HSBB0D101 STRATAGENE Human skeletal	
		Al348455	Hs.147492	Homo sapiens cDNA FLJ11777 fis, clone HE	4.6
		Al290653	Hs.124758 Hs.6168	ESTs KIAA0703 gene product	4.6 4.6
		NM_014861 AW015933	Hs.112654	Homo sapiens, clone MGC:9764, mRNA, comp	4.5
35	423301		Hs.1645	cytochrome P450, subfamily IVA, polypept	4.5
	417237		Hs.81737	palmitoyl-protein thioesterase 2	4.5
		AL389981	Hs.149219	Homo sapiens mRNA full length insert cDN ESTs	4.5 4.5
	449338	AA335769 H73444	Hs.16262 Hs.394	adrenomedullin	4.5
40	434744		Hs.283828	Homo sapiens genomic DNA, chromosome 21q	4.5
		AF035303		gb:Homo sapiens clone 23943 mRNA sequenc	4.5
		NM_012190	Hs.9520	formyltetrahydrofolate dehydrogenase	4.5 4.5
	415754	AA169114 743619	Hs.12247	hypothetical protein FLJ11413 gb:HSC1GE121 normalized infant brain cDN	4.5
45		BE142052	Hs.62654	kringle-containing transmembrane protein	4.5
		BE387287	Hs.83384	S100 calcium-binding protein, beta (neur	4.4
		AI356125	Hs.157767	ESTs, Weakly similar to HXA2_HUMAN HOMEO	
	401093	AA156998	Hs.211568	eukaryotic translation initiation factor C12000586*:gi 6330167 dbj BAA86477.1 (A	4.4 4.4
50		AW206494	Hs.253560	ESTs	4.4
		AW842353	Hs.321717	ESTs, Weakly similar to S22765 heterogen	4.4
		AL133112	Hs.183085	Homo sapiens mRNA; cDNA DKFZp434K098 (fr	4.4 4.4
		Al264634 AL359599	Hs.131127 Hs.283850	ESTs Homo sapiens mRNA; cDNA DKFZp547C126 (fr	
55		Al380906	Hs.158436	ESTs	4.4
	410490			gb:yj42d08.r1 Soares placenta Nb2HP Homo	4.4
	416069		Hs.20982	ESTS	4.4
		AA807958 AI499723	Hs.314232 Hs.135089	ESTs ESTs	4.4 4.4
60	438327		Hs.172944	chorionic gonadotropin, beta polypeptide	4.4
		AF147401	Hs.23917	ESTs	4.3
	400870	V VU33EUU	∐a 28027	C11000905:gi 11692565 gb AAG39879.1 AF28 homeobox protein from AL590526	4.3
		AA933590 H45384	Hs.28937	gb:yn99c10.r1 Soares adult brain N2b5HB5	4.3
65		M12873		gb:Human Ig rearranged H-chain mRNA VDJ4	4.3
	444567	AV654020	Hs.184261	ESTs, Weakly similar to T26686 hypotheti	4.3
	403263	NA		Target Exon	4.3
				338	
				200 ;	

	410034	BE067414		gb:MR4-BT0355-200100-201-e05 BT0355 Hom	04.3
	456804	AI421645	Hs.139851	caveolin 2	4.3
	448427	BE395260	Hs.309438	EST	4.3
_	416931	D45371	Hs.80485	adipose most abundant gene transcript 1	4.3
5	421296	NM_002666	Hs.103253	perilipin	4.3
	400973	NA		ENSP00000236667*:Mucin 5B (Fragment).	4.3
	452602	AW366194	Hs.55962	ESTs	4.3
		NM_005100	Hs.788	A kinase (PRKA) anchor protein (gravin)	4.3
	405016	14.1000100	. 10.7 00	CY000171*:gij9280405 gb AAF86402.1 AF245	4.3
10		AI475671	Hs.88607	ESTs, Highly similar to F-box protein FB	4.3
10	406118	A147 307 1	113.00007		
		TOOSEO		ENSP00000246632:CDNA FLJ20261 fis, clone	4.3
		T02850	11 004700	gb:FB12A9 Fetal brain, Stratagene Homo s	4.3
		AA480818	Hs.221736	ESTs	4.3
1 =		AW451206	Hs.115899	ESTs	4.3
15		AA342329	Hs.115920	Homo sapiens cDNA: FLJ22816 fis, clone K	4.3
	453880	AI803166	Hs.28462	ESTs, Weakly similar to I38022 hypotheti	4.3
	447384	Al377221	Hs.40528	ESTs	4.2
	414541	BE293116	Hs.76392	aldehyde dehydrogenase 1 family, member	4.2
	444975	AV652165	Hs.182482	ESTs, Weakly similar to T00362 hypotheti	4.2
20	403921			C5000212*:gi 10047237 db BAB13407.1 (A	4.2
		AI798425	Hs.42710	ESTs	4.2
	406344	, 00 120	110112110	C5001660:gi[11611537 dbj BAB18935.1] (AB	4.2
		AA191201	Hs.35861	DKFZP586E1621 protein	4.2
		BE155866	Hs.25522	KIAA1808 protein	
25		AW070634	Hs.25522 Hs.144794	•	4.2
25			MS. 144794	ESTs	4.2
	404682		11-0050	C9001188*:gi 12738842 ref NP_073725.1 p	4.2
		N69913	Hs.6858	ESTs, Weakly similar to 178885 serine/th	4.2
	403433			NM_001622:Homo sapiens alpha-2-HS-glycop	4.2
•		AW975460	Hs.143563	ESTs	4.2
30	414217	Al309298	Hs.279898	Homo sapiens cDNA: FLJ23165 fis, clone L	4.2
	418425	A1871247	Hs.6262	hypothetical protein MGC8407	4.2
	419589	AW973708	Hs.201925	Homo sapiens cDNA FLJ13446 fis. clone PL	4.2
	457029	AA397789	Hs.161803	ESTs	4.2
	447860	AF193807	Hs.131835	Rhesus blood group, B glycoprotein	4.2
35	448988		Hs.22785	gamma-aminobutyric acid (GABA) A recepto	4.2
-		AI733098	Hs.130800	ESTs	4.2
		AF086410	113.130000		
		AA399975	110 074454	gb:Homo sapiens full length insert cDNA	4.2
			Hs.274151	ligatin	4.2
40		AW594172	Hs.278513	TP53TG3 protein	4.2
+0	436112		Hs.187559	ESTs	4.2
		Al144152	Hs.58246	ESTs	4.2
		AA318060	Hs.135121	hypothetical protein FLJ22415	4.2
	419846	NM_015977	Hs.285681	Williams-Beuren syndrome chromosome regi	4.2
4	410036		Hs.57975	calsequestrin 2 (cardiac muscle)	4.1
45	400545	NA		Target Exon	4.1
	403051	NA		Target Exon	4.1
	420139	NM_005357	Hs.95351	lipase, hormone-sensitive	4.1
		AA007534	Hs.125062	ESTs	4.1
		AA034116	Hs.118494	ESTs	4.1
50	440246		Hs.191379	ESTs	4.1
-		Al307802	Hs.135560	ESTs, Weakly similar to T43458 hypotheti	4.1
		Al150595	Hs.122226		
			113.12220	ESTS	4.1
		AA082947	Ha 60400	gb:zn10g07.s1 Stratagene hNT neuron (937	4.1
5.5		BE270758	Hs.69428	hypothetical protein MGC3020	4.1
55		Al306150	Hs.153450	ESTs, Weakly similar to 1909123A Na gluc	4.1
		AK000708	Hs.169764	hypothetical protein FLJ20701	4.1
		AL110416		gb:DKFZp434K0431_r1 434 (synonym: htes3)	4.1
	448640	AW817177	Hs.102558	Homo sapiens, clone MGC:5352, mRNA, comp	4.1
	417481	AA203281	Hs.21798	ESTs	4.1
0	412912	AW118878	Hs.110835	ESTs	4.1
		AW807116		gb:MR4-ST0062-040100-024-b12 ST0062 Homo	
		AW631296		gb:hh83c09.y1 NCI_CGAP_GU1 Homo sapiens	
	435942		Hs.191215	ESTs	4.1
	417629			gb:yc92c07.r1 Soares infant brain 1NIB H	
55	403593			Target Exon	4.1
,,,	403593	11/1			4.0
		D40E04	Hs.270425	Target Exon	4.0
	418190	K4909 I	1 15.27 0420	ESTs	4.0
				339	

	408641	AW245207	Hs.5555	hypothetical protein MGC5347	4.0
	427899	AA829286	Hs.332053	serum amyloid A1	4.0
	445975	AI811536	Hs.145734	ESTs	4.0
_	438831	BE263273	Hs.6439	synapsin II	4.0
5	455578	BE006350	Hs.14355	Homo sapiens cDNA FLJ13207 fis, clone NT	4.0
	401840	NA		Target Exon	4.0
	413753	U17760	Hs.75517	laminin, beta 3 (nicein (125kD), kalinin	4.0
	445030	Al205925	Hs.147238	ESTs, Highly similar to AAC3_HUMAN ALPHA	4.0
	433873	AW156913	Hs.150478	ESTs, Weakly similar to A Chain A, Cryst	4.0
10	456736	AW248217	Hs.1619	achaete-scute complex (Drosophila) homol	4.0
	450112	BE047734	Hs.5473	ESTs, Moderately similar to ALU5_HUMAN A	4.0
	448906	AI589567	Hs.309719	ESTs	4.0

TABLE 23A

Table 23A shows the accession numbers for those pkeys lacking unigeneID's for Table 23. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number
Accession: Genbank accession numbers

15

Pkey CAT number Accessions

```
AW502327 AW502488 AW501829 AW502625 AW502687
       409853 1156226 1
20
                          BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
       410034 1170594_1
       410233 118656_1
                          AA082947 AA083036
       410490 1205347_1
                          H03589 AW750687 AW750688
                          AW809163 AW809247 AW809177 AW809190 AW809225
       410882 1225686 1
                          BE143068 AW849143 AW848705 AW848569 AW848071 AW848475 AW848092 AW848005
       411478 1247073_1
25
                          BE063555 BE151321 BE151319 BE151657 BE151655 BE063556 BE151322
       413065 1347960_1
       413072 1348163 1
                          BE063965 BE063968 BE064034 BE064028 BE063874 BE063966 BE063869 BE064043 BE064033 BE063884
       414593 1464909_1
                          BE386764 BE387560
                          R25621 C03959 C04010
       414913 1506721_1
       415011 151328_1
                          AW963085 AA159005 AW963073
30
                          Z43619 R61274 H12206 R12883
       415986
              1564410_1
              1583547 1
                          H45384 H49125 H41699
       416267
                          R00348 R09593
       417574 1687770_1
       417629 1690392 1
                          T76945 R20210 R05755
       418556 1767866_-1
                          T02850
35
       419583 186198_1
                          F00312 AA247490 F31427 AA383663 F22045
       426328 264901_1
                          AW631296 AA375484
       439590 47413_1
                          AF086410 W94386 W74609
       442398 541271_1
                          AA994520 AW393574
       452205 90415_1
                          C15819 AA024741 AA024742
40
       452654 925931_1
                          BE004783 BE004947 Al911790
       453692 977825_1
                          AL110416 AW876759
                          AW807116 AW807569 AW807415 AW807338 AW807288 AW807263 AW807316 AW177402 AW807413 AW807068 BE141561
       454183 1049636 1
                          BE141569 AW807401 AW807310 BE141565 AW807318 AW807119 AW807299 AW807241 AW807225 AW807204 AW807345
                          AW807103 BE141615 AW807431 AW807393 AW807337 AW807406 AW807259 AW807375 AW845890 AW807220 AW807399
45
                          AW807064 AW807376 AW807024 BE141595 AW807236 AW807027 AW807112 AW807378 AW807202 BE141593 AW807216
                          AW807138 AW807244 AW807221 AW807297 AW807050 AW807248 AW807404 AW807075 AW807237 AW807212 AW807308
                          AW807110 AW807104 BE140912 AW807301 AW807382 AW807294 AW807026 AW807020 AW807108 AW807025 AW807433
                          AW807124 AW807419 AW807031 AW807264 AW807032 AW807029 AW807052 AW807391 AW807207 AW807215 AW807019
                          AW807238 AW807201 BE141590 AW807302 AW807323 AW807380 AW807109 BE141588 AW845877 AW807418 AW807407
50
                          AW807309 BE141614 AW845861 AW807396 AW807300 AW807348 AW807311 AW807214 AW807132 AW807402 AW807350
                          AW80728 AW807298 AW807291 AW807305 AW807217 AW807312 AW807261 AW807268 AW807260 AW807266 AW807198
                          AW807346 AW807315 BE140940 AW807351 AW807122 AW807235 AW807076 AW807314 AW807213 AW807143 AW807131
                           AW800079 AW807066 AW807077 AW845923 AW807421 BE141619 BE140943 AW807420 AW807381 BE141621 AW845921
                          BE141629 BE141625 BE141624 BE141636 BE141630 AW807405 AW807290 AW807353
55
       454404 1170594_1
                          BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
                          BE160229 AW819879 AW820179 AW819882 AW819876 AW820169 BE153201 AW993736 BE152911
       454775 1234106_1
       455282 1273020_1
                          BE143867 AW935060 AW886684
       459159 919998_1
                          AI904646 BE179494 BE179421
```

TABLE 23B

Table 23B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 23. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

	Pkey:	Unique number corresponding to an Eos probeset
10	Ref:	Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
		entifled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Ctronde	Indicates DNA strand from which evens were predicted

Nt_position: Indicates DNA strand from which exons were predicted exons.

15				
10	Pkey	Ref	Strand	Nt_position
	400545	9800107	Minus	124618-124881
• •	400870	9838306	Minus	34081-35027
20	400973	7960452	Minus	98119-98253
	401093	8516137	Minus	22335-23166
	401590	9966320	Minus	33547-33649
	401665	7145001	Plus	121591-122537
	401810	7342191	Plus	129063-129476
25	401840	7684597	Plus	56283-56439
	402054	8083691	Minus	8288-8806
	402195	7689778	Minus	147901-148884
	402583	7684486	Plus	94883-95003
•	402690	8348058	Plus	13368-13998
30	402698	8570304	Minus	108641-108903
	402779	9588555	Minus	38173-39210
	403017	6693623	Plus	78630-79367
	403051	4827080	Minus	5269-5411
~ ~	403263	7770677	Plus	52431-52737
35	403433	9719611	Minus	72225-72437
	403593	6862650	Minus	62554-62712,69449-69602
	403612	8469060	Minus	94723-94859
	403921	7711590	Minus	3297-3536
	404368	7630956	Minus	102053-102199
40	404682	9797231	Minus	40977-41150
	404689	7534100	Plus	119461-119717
	405016	6524300	Plus	51997-53308
	405062	7657730	Plus	101283-101432
	406118	9143818	Plus	53997-54629
45	406344	9255974	Plus	20254-20374,20526-20659,20835-21097
	406563	7711604	Plus	34401-34538

TABLE 24:

Table 24 depicts Seq ID No., UnigeneID, UnigeneTitle, Pkey, Pred.Cell.Loc., and ExAccn
for all of the sequences in Table 25. The information in Table 24 is linked by Seq ID No. to Table 25.

10	Pkey: ExAccn: Unigene Unigene Pred.Ce Seq.ID.N	elD; Title: II.Loc.:	Exemplar Access Unigene number Unigene gene title Predicted Cellula			
15	Pkey	ExAccn	UnigenelD	Unigene Title	Pred.Cell.Loc.	Seq. ID. No.
20	407276 415539 400297 450375		Hs.326736 Hs.72472 Hs.334473 Hs.8850	ESTs, Weakly similar to CP4Y_HUMAN CYTC Homo sapiens breast cancer antigen NY-BR BMP-R1B hypothetical protein DKFZp564O1278 a disintegrin and metalloproteinase doma		Seq ID 1 & 2 Seq ID 3 & 4 Seq ID 5 & 6 Seq ID 7 & 8 Seq ID 9 & 10
25	429170 424399 422505 449765	NM_0013 Al905687	394Hs.2359 394Hs.2359 Hs.2533 Hs.124165 Hs.206832 Hs.155956	dual specificity phosphatase 4 dual specificity phosphatase 4 aldehyde dehydrogenase 9 family, member ESTs ESTs, Moderately similar to ALU8_HUMAN A N-acetyltransferase 1 (arylamine N-acety	nuclear nuclear cytoplasm	Seq ID 11 & 12 Seq ID 11 & 12 Seq ID 13 & 14 Seq ID 15 & 16 Seq ID 17 & 18 Seq ID 19 & 20
30	439840 410102 429220	AW44921 AW24850	19 Hs.155223 11 Hs.105445 08 Hs.279727 06 Hs.136319 Hs.79136	stanniocalcin 2 GDNF family receptor alpha 1 Homo sapiens cDNA FLJ14035 fis, clone HE ESTs LIV-1 protein, estrogen regulated		Seq ID 21 & 22 Seq ID 23 & 24 Seq ID 25 & 26 Seq ID 27 & 28 Seq ID 29 & 30
35	409079 442818 442082 444381	W87707 AK00174 R41823 BE38733	Hs.82065 1 Hs.8739 Hs.7413 5 Hs.283713 0 Hs.25252	interleukin 6 signal transducer (gp130, hypothetical protein FLJ10879 ESTs ESTs, Weakly similar to S64054 hypotheti Homo sapiens cDNA FLJ13603 fis, clone PL		Seq ID 31 & 32 Seq ID 33 & 34 Seq ID 35 & 36 Seq ID 37 & 38 Seq ID 39 & 40
40	442117 433043 429353 452190	W57554 AL11740 H26735	Hs.42645 64 Hs.128899 Hs.125019 6 Hs.200102 Hs.91668	solute carrier family 16 (monocarboxylic ESTs lymphoid nuclear protein (LAF-4) mRNA ATP-binding cassette transporter MRP8 Homo sapiens clone PP1498 unknown mRNA		Seq ID 41 & 42 Seq ID 43 & 44 Seq ID 45 & 46 Seq ID 47 & 48 Seq ID 49 & 50
45	452747 423242 417433 432201	BE15385 AL03940	0 Hs.26040 5 Hs.61460 2 Hs.125783 6 Hs.82128 6 Hs.298241 Hs.136348	ESTs, Weakly similar to fatty acid omega lg superfamily receptor LNIR DEME-6 protein 5T4 oncofetal trophoblast glycoprotein Transmembrane protease, serine 3 osteoblast specific factor 2 (fasciclin		Seq ID 51 & 52 Seq ID 53 & 54 Seq ID 55 & 56 Seq ID 57 & 58 Seq ID 59 & 60 Seq ID 61 & 62
50	439569 114480 404561 325372	AW60216 BE06677	66 Hs.222399 8 Hs.151678 4 Hs.334806	CEGP1 protein UDP-N-acetyl-alpha-D-galactosamine:polyp NM_014112*:Homo sapiens trichorhinophala Phase 2 & 3 Exons KIAA1238 protein	mitochodria nuclear	Seq ID 63 & 64 Seq ID 65 & 66 Seq ID 67 & 68 Seq ID 69 & 70 Seq ID 71 & 72
55	335824 424735 400289 427585	NA U31875 X07820 D31152	Hs.272499 Hs.2258 Hs.179729 '86Hs.226213	ENSP00000249072*:DJ222E13.1 (N-TERMIN short-chain alcohol dehydrogenase family matrix metalloproteinase 10 (stromelysin collagen, type X, alpha 1 (Schmid metaph	IAL ER	Seq ID 73 & 74 Seq ID 75 & 76 Seq ID 77 & 78 Seq ID 79 & 80 Seq ID 81 & 82
60	429441 421155 420931 420813	AJ224172 H87879 AF04419	2 Hs.204096 Hs.102267 7 Hs.100431 Hs.99949	cytochrome P450, 51 (lanosterol 14-alpha lipophilin B (uteroglobin family member) lysyl oxidase small inducible cytokine B subfamily (Cy prolactin-induced protein Homo sapiens mRNA; cDNA DKFZp434E082	extracellular nuclear	Seq ID 83 & 84 Seq ID 83 & 86 Seq ID 85 & 86 Seq ID 87 & 88 Seq ID 89 & 90 Seq ID 91 & 92

	420757	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	cytoplasm	Seq ID 93 & 94
	424905	NM_00249	7Hs.153704	NIMA (never in mitosis gene a)-related k	nuclear	Seq ID 95 & 96
	429859	NM_007050	OHs.225952	protein tyrosine phosphatase, receptor t		Seq ID 97 & 98
	446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	extracellular	Seq ID 99 & 100
5	445537	AJ245671	Hs.12844	EGF-like-domain, multiple 6		Seg ID 101 & 102
	428227	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	extracellular	Seq ID 103 & 104
	424001	W67883	Hs.137476	paternally expressed 10		Seg ID 105 & 106
	421727	Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3		Seq ID 107 & 108
	452838	U65011	Hs.30743	preferentially expressed antigen in mela	nuclear	Seq ID 109 & 110
10	419667	AU077005	Hs.92208	a disintegrin and metalloproteinase doma		Sea ID 111 & 112
	414812	X72755	Hs.77367	monokine induced by gamma interferon	extracellular	Seg ID 113 & 114
	426320	W47595	Hs.169300	transforming growth factor, beta 2	extracellular	Seq ID 115 & 116
	422867	L32137	Hs.1584	cartilage oligomeric matrix protein (pse	extracellular	Seq ID 117 & 118
	411558	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto		Seq ID 119 & 120
15	417866	AW067903	Hs.82772	collagen, type XI, alpha 1		Seq ID 121 & 122
	428398	AI249368	Hs.98558	ESTs		Seq ID 123 & 124
	431958	X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	plasma membrane	eSeq ID 125 & 126
	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	•	Seq ID 127 & 128
	412970	AB026436	Hs.177534	dual specificity phosphatase 10		Seq ID 129 & 130
20	421379	Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	extracellular	Seq ID 131 & 132
	415752	BE314524	Hs.78776	putative transmembrane protein		Seq ID 133 & 134
	444051	N48373	Hs.10247	activated leucocyte cell adhesion molecu		Seq ID 135 & 136
	451110	AI955040	Hs.265398	ESTs, Weakly similar to transformation-r		Seq ID 137 & 138

TABLE 24A

Table 24A shows the accession numbers for those pkeys lacking unigeneID's for Table 24. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Unique Eos probeset identifier number

CAT number:

Gene cluster number

Accession:

Genbank accession numbers

15 Pkey CAT number

Accession

335824 CH22_3197FG_619_11_LINK_E 325372 c12_hs

TABLE 24B

Table 24B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 24. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Ref: 10

Unique number corresponding to an Eos probeset
Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.

Strand:

Indicates DNA strand from which exons were predicted.

Nt_position:

Indicates nucleotide positions of predicted exons.

15

5

Pkey Ref Strand Nt_position 404561 9795980 Minus 69039-70100

20

Table 25

The 69 gene sequences identified to be overexpressed in breast cancer may be used to identify coding regions from the public DNA databases (nr and htgs in Genbank). The sequences may be used to either identify genes that encode known proteins, or they may be used to predict the coding regions from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev, 2000, Genome Res. 10:516-522)



	AGTGAGCAAA TTGTGGAATT TTTGCTGATA AAAAATGCAA ATGCGAATGC AGTTAATAAG 540
	TATAAATGCA CAGCCCTCAT GCTTGCTGTA TGTCATGGAT CATCAGAGAT AGTTGGCATG 600
	CTTCTTCAGC AAAATGTTGA CGTCTTTGCT GCAGATATAT GTGGAGTAAC TGCAGAACAT 660
	TATGCTGTTA CTTGTGGATT TCATCACATT CATGAACAAA TTATGGAATA TATACGAAAA 720
5	TTATCTAAAA ATCATCAAAA TACCAATCCA GAAGGAACAT CTGCAGGAAC ACCTGATGAG 780
•	GCTGCACCCT TGGCGGAAAG AACACCTGAC ACAGCTGAAA GCTTGGTGGA AAAAACACCT 840
	GATGAGGCTG CACCCTTGGT GGAAAGAACA CCTGACACGG CTGAAAGCTT GGTGGAAAAA 900
	ACACCTGATG AGGCTGCATC CTTGGTGGAG GGAACATCTG ACAAAATTCA ATGTTTGGAG 960
	AAAGCGACAT CTGGAAAGTT CGAACAGTCA GCAGAAGAAA CACCTAGGGA AATTACGAGT 1020
10	
10	CCTGCAAAAG AAACATCTGA GAAATTTACG TGGCCAGCAA AAGGAAGACC TAGGAAGATC 1080
	GCATGGGAGA AAAAAGAAGA CACACCTAGG GAAATTATGA GTCCCGCAAA AGAAACATCT 1140
	GAGAAATTTA CGTGGGCAGC AAAAGGAAGA CCTAGGAAGA TCGCATGGGA GAAAAAAGAA 1200
	ACACCTGTAA AGACTGGATG CGTGGCAAGA GTAACATCTA ATAAAACTAA AGTTTTGGAÅ 1260
15	AAAGGAAGAT CTAAGATGAT TGCATGTCCT ACAAAAGAAT CATCTACAAA AGCAAGTGCC 1320
15	AATGATCAGA GGTTCCCATC AGAATCCAAA CAAGAGGAAG ATGAAGAATA TTCTTGTGAT 1380
	TCTCGGAGTC TCTTTGAGAG TTCTGCAAAG ATTCAAGTGT GTATACCTGA GTCTATATAT 1440
	CAAAAAGTAA TGGAGATAAA TAGAGAAGTA GAAGAGCCTC CTAAGAAGCC ATCTGCCTTC 1500
	AAGCCTGCCA TTGAAATGCA AAACTCTGTT CCAAATAAAG CCTTTGAATT GAAGAATGAA 1560
	CAAACATTGA GAGCAGATCC GATGTTCCCA CCAGAATCCA AACAAAAGGA CTATGAAGAA 1620
20	AATTCTTGGG ATTCTGAGAG TCTCTGTGAG ACTGTTTCAC AGAAGGATGT GTGTTTACCC 1680
	AAGGCTACAC ATCAAAAAGA AATAGATAAA ATAAATGGAA AATTAGAAGA GTCTCCTAAT 1740
	AAAGATGGTC TTCTGAAGGC TACCTGCGGA ATGAAAGTTT CTATTCCAAC TAAAGCCTTA 1800
	GAATTGAAGG ACATGCAAAC TTTCAAAGCG GAGCCTCCGG GGAAGCCATC TGCCTTCGAG 1860
	CCTGCCACTG AAATGCAAAA GTCTGTCCCA AATAAAGCCT TGGAATTGAA AAATGAACAA 1920
25	
23	ACATGGAGAG CAGATGAGAT ACTCCCATCA GAATCCAAAC AAAAGGACTA TGAAGAAAAT 1980
	TCTTGGGATA CTGAGAGTCT CTGTGAGACT GTTTCACAGA AGGATGTGTG TTTACCCAAG 2040
	GCTGCGCATC AAAAAGAAAT AGATAAAATA AATGGAAAAT TAGAAGGGTC TCCTGTTAAA 2100
	GATGGTCTTC TGAAGGCTAA CTGCGGAATG AAAGTTTCTA TTCCAACTAA AGCCTTAGAA 2160
	TTGATGGACA TGCAAACTTT CAAAGCAGAG CCTCCCGAGA AGCCATCTGC CTTCGAGCCT 2220
20	
30	GCCATTGAAA TGCAAAAGTC TGTTCCAAAT AAAGCCTTGG AATTGAAGAA TGAACAAACA 2280
	TTGAGAGCAG ATGAGATACT CCCATCAGAA TCCAAACAAA AGGACTATGA AGAAAGTTCT 2340
	TGGGATTCTG AGAGTCTCTG TGAGACTGTT TCACAGAAGG ATGTGTGTTT ACCCAAGGCT 2400
	ACACATCAAA AAGAAATAGA TAAAATAAAT GGAAAATTAG AAGAGTCTCC TGATAATGAT 2460
	ACACATCAAA AAGAAATAAA TAAAATAAA GOAAAATTAA AAGAATCACC TOTAA AATAAA 2400
2 ~	GGTTTTCTGA AGGCTCCCTG CAGAATGAAA GTTTCTATTC CAACTAAAGC CTTAGAATTG 2520
35	ATGGACATGC AAACTTTCAA AGCAGAGCCT CCCGAGAAGC CATCTGCCTT CGAGCCTGCC 2580
	ATTGAAATGC AAAAGTCTGT TCCAAATAAA GCCTTGGAAT TGAAGAATGA ACAAACATTG 2640
	AGAGCAGATC AGATGTTCCC TTCAGAATCA AAACAAAAGA AGGTTGAAGA AAATTCTTGG 2700
	GATTCTGAGA GTCTCCGTGA GACTGTTTCA CAGAAGGATG TGTGTGTACC CAAGGCTACA 2760
4.0	CATCAAAAAG AAATGGATAA AATAAGTGGA AAATTAGAAG ATTCAACTAG CCTATCAAAA 2820
40	ATCTTGGATA CAGTTCATTC TTGTGAAAGA GCAAGGGAAC TTCAAAAAGA TCACTGTGAA 2880
,	CAACGTACAG GAAAAATGGA ACAAATGAAA AAGAAGTTTT GTGTACTGAA AAAGAAACTG 2940
	TCAGAAGCAA AAGAAATAAA ATCACAGTTA GAGAACCAAA AAGTTAAATG GGAACAAGAG 3000
	CTCTGCAGTG TGAGATTGAC TTTAAACCAA GAAGAAGAA AGAGAAGAAA TGCCGATATA 3060
	TTAAATGAAA AAATTAGGGA AGAATTAGGA AGAATCGAAG AGCAGCATAG GAAAGAGTTA 3120
45	GAAGTGAAAC AACAACTTGA ACAGGCTCTC AGAATACAAG ATATAGAATT GAAGAGTGTA 3180
10	
	GAAAGTAATT TGAATCAGGT TTCTCACACT CATGAAAATG AAAATTATCT CTTACATGAA 3240
	AATTGCATGT TGAAAAAGGA AATTGCCATG CTAAAACTGG AAATAGCCAC ACTGAAACAC 3300
	CAATACCAGG AAAAGGAAAA TAAATACTTT GAGGACATTA AGATTTTAAA AGAAAAGAAT 3360
	GCTGAACTTC AGATGACCCT AAAACTGAAA GAGGAATCAT TAACTAAAAG GGCATCTCAA 3420
50	
50	TATAGTGGGC AGCTTAAAGT TCTGATAGCT GAGAACACAA TGCTCACTTC TAAATTGAAG 3480
	GAAAAACAAG ACAAAGAAAT ACTAGAGGCA GAAATTGAAT CACACCATCC TAGACTGGCT 3540
	TCTGCTGTAC AAGACCATGA TCAAATTGTG ACATCAAGAA AAAGTCAAGA ACCTGCTTTC 3600
	CACATTGCAG GAGATGCTTG TTTGCAAAGA AAAATGAATG TTGATGTGAG TAGTACGATA 3660
<i></i>	TATAACAATG AGGTGCTCCA TCAACCACTT TCTGAAGCTC AAAGGAAATC CAAAAGCCTA 3720
55	AAAATTAATC TCAATTATGC AGGAGATGCT CTAAGAGAAA ATACATTGGT TTCAGAACAT 3780
	GCACAAGAG ACCAACGTGA AACACAGTGT CAAATGAAGG AAGCTGAACA CATGTATCAA 3840
	AACGAACAAG ATAATGTGAA CAAACACACT GAACAGCAGG AGTCTCTAGA TCAGAAATTA 3900
	TOTAL OF THE CALLES AND A COLOR OF THE COURT OF THE CALLES AND A COLOR
	TTTCAACTAC AAAGCAAAAA TATGTGGCTT CAACAGCAAT TAGTTCATGC ACATAAGAAA 3960
	GCTGACAACA AAAGCAAGAT AACAATTGAT ATTCATTTTC TTGAGAGGAA AATGCAACAT 4020
60	CATCTCCTAA AAGAGAAAAA TGAGGAGATA TTTAATTACA ATAACCATTT AAAAAACCGT 4080
	ATATATCAAT ATGAAAAAGA GAAAGCAGAA ACAGAAAACT CATGAGAGAC AAGCAGTAAG 4140
	AAACTTCTTT TGGAGAAACA ACAGACCAGA TCTTTACTCA CAACTCATGC TAGGAGGCCA 4200
	GTCCTAGCAT CACCTTATGT TGAAAATCTT ACCAATAGTC TGTGTCAACA GAATACTTAT 4260
	TTTAGAAGAA AAATTCATGA TTTCTTCCTG AAGCCTACAG ACATAAAATA ACAGTGTGAA 4320
65	GAATTACTTG TTCACGAATT GCATAAAGCT GCACAGGATT CCCATCTACC CTGATGATGC 4380
00	AGCAGACATC ATTCAATCCA ACCAGAATCT CGCTCTGCAC TCCAGCCTAG GTGACAGAGT 4440
	GAGACTCCAC CTCGGAAA
70	S ID NO. A Protein coguence:
70	Seq ID NO: 4 Protein sequence: Protein Accession #: NP 443723.1
	Protein Accession #: NP 443723.1

Seq ID NO: 4 <u>Protein sequence:</u>
Protein Accession #: NP_443723.1

⁷⁵

CGVTAEHYAV TCGFHHIHEQ IMEYIRKLSK NHQNTNPEGT SAGTPDEAAP LAERTPDTAE 240 SLVEKTPDEA APLVERTPDT AESLVEKTPD EAASLVEGTS DKIQCLEKAT SGKFEQSAEE 300 TPREITSPAK ETSEKFTWPA KGRPRKIAWE KKEDTPREIM SPAKETSEKF TWAAKGRPRK 360 IAWEKKETPV KTGCVARVTS NKTKVLEKGR SKMIACPTKE SSTKASANDQ RFPSESKQEE 420 5 DEEYSCDSRS LFESSAKIQV CIPESIYQKV MEINREVEEP PKKPSAFKPA IEMQNSVPNK 480 AFELKNEQTL RADPMFPPES KQKDYEENSW DSESLCETVS QKDVCLPKAT HQKEIDKING 540 KLEESPNKDG LIKATCGMKV SIPTKALELK DMQTFKAEPP GKPSAFEPAT EMQKSVPNKA 600 LELKNEQTWR ADEILPSESK QKDYEENSWD TESLCETVSQ KDVCLPKAAH QKEIDKINGK 660 LEGSPVKDGL LKANCGMKVS IPTKALELMD MQTFKAEPPE KPSAFEPAIE MQKSVPNKAL 720 10 ELKNEOTLRA DEILPSESKO KDYEESSWDS ESLCETVSOK DVCLPKATHO KEIDKINGKL 780 EESPDNDGFL KAPCRMKVSI PTKALELMDM QTFKAEPPEK PSAFEPAIEM QKSVPNKALE 840 LKNEQTLRAD QMFPSESKQK KVEENSWDSE ŠLRETVSQKD VCVPKATHQK EMDKISGKLE 900 DSTSLSKILD TVHSCERARE LQKDHCEQRT GKMEQMKKKF CVLKKKLSEA KEIKSQLENQ 960 KVKWEQELCS VRLTLNQEEE KRRNADILNE KIREELGRIE EQHRKELEVK QQLEQALRIQ 1020 DIELKSVESN LNQVSHTHEN ENYLLHENCM LKKEIAMLKL EIATLKHQYQ EKENKYFEDI 1080 KILKEKNAEL QMTLKLKEES LTKRASQYSG QLKVLIAENT MLTSKLKEKQ DKEILEAEIE 1140 15 SHHPRLASAV QDHDQIVTSR KSQEPAFHIA GDACLQRKMN VDVSSTIYNN EVLHQPLSEA 1200 QRKSKSLKIN LNYAGDALRE NTLVSEHAQR DQRETQCQMK EAEHMYQNEQ DNVNKHTEQQ 1260 ESLDQKLFQL QSKNMWLQQQ LVHAHKKADN KSKITIDIHF LERKMQHHLL KEKNEEIFNY 1320 20 NNHLKNRIYQ YEKEKAETEN S Seq ID NO: 5 DNA sequence none found Nucleic Acid Accession #: 273-1785 (underlined sequences correspond to start and stop codons) Coding sequence: 25 51 CGCGGGGCGC GGAGTCGGCG GGGCCTCGCG GGACGCGGGC AGTGCGGAGA CCGCGGCGCT 60 GAGGACGCGG GAGCCGGGAG CGCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT 120
GTGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 30 CATAACCATT TGGCTCTGAG CTATGACAAG AGAGGAAACA AAAAGTTAAA CTTACAAGCC 240 TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA 300 AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCG TCCAAAGGTC 360 35 TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAACAATAT TTGCAGCACA 420 GACGGATATT GTTTCACGAT GATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTTCT 480
GGTTGCCTAG GACTAGAAGG CTCAGATTTT CAGTGTCGGG ACACTCCCAT TCCTCATCAA 540
AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCCTACA 600 CTGCCTCCAT TGAAAAACAG AGATTTTGTT GATGGACCTA TACACCACAG GGCTTTACTT 660 40 ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTATCA TATTATTTTG TTACTTCCGG 720 TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGT TAGAACAGGA TGAAACTTAC 780 ATTCCTCCTG GAGAAATCCCT GAGAGACTTA ATTGAGCAGT CTCAGAGCTC AGGAAGTGGA 840
TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900
ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTGGCGA AAAGGTAGCT 960
GTGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AATATATCAG 1020 45 ACAGTGTTGA TGAGGCATGA AAACATTTTG GGTTTCATTG CTGCAGATAT CAAAGGGACA 1080 GGGTCCTGGA CCCAGTTGTA CCTAATCACA GACTATCATG AAAATGGTTC CCTTTATGAT 1140 TATCTGAAGT CCACCACCCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC 1200 AGTGGCTTAT GTCATTTACA CACAGAAATC TTTAGTACTC AAGGCAAACC AGCAATTGCC 1260
CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT 1320
GACCTGGGCC TGGCTGTTAA ATTTATTAGT GATACAAATG AAGTTGACAT ACCACCTAAC 1380
ACTCGAGTTG GCACCAAACG CTATATGCCT CCAGAAGTGT TGGACGAGAG CTTGAACAGA 1440 50 AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTGGGAG 1500 GTTGCTAGGA GATGTGTATC AGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTATCATGAC 1560 CTAGTGCCCA GTGACCCCTC TTATGAGGAC ATGAGGAGAT ACCAGCTCC TTATCATGAC 1800
CGCCCCTCAT TCCCAAACCG GTGGAGCAGT GATGAGTGC TAAGGCAGAT GGGAAAACCTC 1680
ATGACAGAAT GCTGGGCTCA CAATCCTGCA TCAAGGCTGA CAGCCCTGCG GGTTAAGAAA 1740
ACACTTGCCA AAATGTCAGA GTCCCAGGAC ATTAAACTCT GATAGGAGAG GAAAAGTAAG 1800 55 CATCTCTGCA GAAAGCCAAC AGGTACTCTT CTGTTTGTGG GCAGAGCAAA AGACATCAAA 1860 60 TAAGCATCCA CAGTACAAGC CTTGAACATC GTCCTGCTTC CCAGTGGGTT CAGACCTCAC 1920 CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAGAGA TTGATCCGTG 1980 TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT

Seq ID NO: 6 Protein sequence:
Protein Accession #: none found


EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS $\,$ 480 RLTALRVKKT LAKMSESQDI KL

none found

Seq ID NO: 7 DNA sequence

Nucleic Acid Accession #:

5



PPQNPRKLIL AGNIIHSLMK SDLVEYFTLE MLHLGNNRIE VLEEGSFMNL TRLQKLYLNG 420
NHLTKLSKGM FLGLHNLEYL YLEYNAIKEI LPGTFNPMPK LKVLYLNNNL LQVLPPHIFS 480
GVPLTKVNLK TNQFTHLPVS NILDDLDLLT QIDLEDNPWD CSCDLVGLQQ WIQKLSKNTV 540
TDDILCTSPG HLDKKELKAL NSEILCPGLV NNPSMPTQTS YLMVTTPATT TNTADTILRS 600
LTDAVPLSVL ILGLLIMFIT IVFCAAGIVV LVLHRRRYK KKQVDEQMRD NSPVHLQYSM 660
YGHKTTHHTT ERPSASLYEQ HMVSPMVHVY RSPSFGPKHL EEEEERNEKE GSDAKHLQRS 720
LLEQENHSPL TGSNMKYKTT NQSTEFLSFQ DASSLYRNIL EKERELQQLG ITEYLRKNIA 780
QLQPDMEAHY PGAHEELKLM ETLMYSRPRK VLVEQTKNEY FELKANLHAE PDYLEVLEQQ 840

Seq ID NO: 9 DNA sequence

5

Nucleic Acid Accession #: NM_003474

Coding sequence: 307-3036 (underlined sequences correspond to start and stop codons)

CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG 60 TCAAGGCTGG CTTGTGCCAG AACGGCGCGC GCGCGACGCA CGCACACAC CGGGGGGAAA 120 20 CTTTTTTAAA AATGAAAGGC TAGAAGAGCT CAGCGGCGGC GCGGGCCGTG CGCGAGGGCT 180 CCGGAGCTGA CTCGCCGAGG CAGGAAATCC CTCCGGTCGC GACGCCCGGC CCCGCTCGGC 240 GCCCGCGTGG GATGGTGCAG CGCTCGCCGC CGGGCCCGAG AGCTGCTGCA CTGAAGGCCG 300 GCGACG<u>ATG</u>G CAGCGCGCC GCTGCCCGTG TCCCCCGCCC GCGCCCTCCT GCTCGCCCCTG 360 GCCGGTGCTC TGCTCGCGCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA 420 GCTGATGAAG TTGTCAGTGC CTCTGTTCGG AGTGGGGACC TCTGGATCCC AGTGAAGAGC 480 25 TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA 540 CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCAGTTTCAC GGAAACCCAC 600 TATCTGCAAG ACGGTACTGA TGTCTCCCTC GCTCGAAATT ACACGGTAAT TCTGGGTCAC 660 TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT 720 30 TCTGGTCTCA GGGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA 780 AGTGCAACCA ACAGATACAA ACTCTTCCCA GCGAAGAAGC TGAAAAAGCGT CCGGGGATCA 840 TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT 900 CAGACATGGG CAAGAAGGCA TAAAAGAGAG ACCCTCAAGG CAACTAAGTA TGTGGAGCTG 960 GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAGATCTGGA AAAAGTTAAG 1020 35 CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG 1080 ATCGTGTTGG TAGGCGTGGA AGTGTGGAAT GACATGGACA AATGCTCTGT AAGTCAGGAC 1140 CCATTCACCA GCCTCCATGA ATTTCTGGAC TGGAGGAAGA TGAAGCTTCT ACCTCGCAAA 1200 TCCCATGACA ATGCGCAGCT TGTCAGTGGG GTTTATTTCC AAGGGACCAC CATCGGCATG 1260 GCCCCAATCA TGAGCATGTG CACGGCAGAC CAGTCTGGGG GAATTGTCAT GGACCATTCA 1320 40 GACAATCCCC TTGGTGCAGC CGTGACCCTG GCACATGAGC TGGGCCACAA TTTCGGGATG 1380 AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CGGTTGAGAA AGGAGGCTGC 1440 ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCAGCAGTTG CAGCAGGAAG 1500 GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT GCCGGAAGTC 1560 AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTG TGGAAGAAGG AGAGGAGTGT 1620 GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG 1680 45 AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA 1740 GGAACAGCGT GCAGGGACTC CAGCAACTCC TGTGACCTCC CAGAGTTCTG CACAGGGGCC 1800 AGCCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC 1860 GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA 1920 50 CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT 1980
TATGGCAACT GTGGCAAAGT CTCGAAGAGT TCCTTTGCCA AATGCGAGAT GAGAGATGCT 2040
AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC 2100
GTTTCCATAG AAACAAACAT CCCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC 2160 CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT 2220 55 GCAGATGGAA AAATCTGCCT GAATCGTCAA TGTCAAAATA TTAGTGTCTT TGGGGTTCAC 2280 GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC 2340 GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC 2400 GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT GACCATCCTG 2460 TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG 2520
TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGTG TGCGCCCTTC CCGGCCACCC 2580 60 CGTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCT GATGAGGAAG 2640 CCGCCAGATT CCTACCCACC GAAGGACAAT CCCAGGAGAT TGCTGCAGTG TCAGAATGTT 2700 GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCCTCAGC CCCAGTCAAC TCAGCGAGTG 2760 CTTCCTCCCC TCCACCGGGC CCCACGTGCA CCTAGCGTCC CTGCCAGACC CCTGCCAGCC 2820 65 AAGCCTGCAC TTAGGCAGGC CCAGGGGACC TGTAAGCCAA ACCCCCCTCA GAAGCCTCTG 2880 CCTGCAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CCTTGGCCAG GACCCCAGGA 2940 CAATGGGAGA CTGGGCTCCG CCTGGCACCC CTCAGACCTG CTCCACAATA TCCACACAA 3000 GTGCCCAGAT CCACCCACAC CGCCTATATT AAGTGAGAAG CCGACACCTT TTTTCAACAG 3060 TGAAGACAGA AGTTTGCACT ATCTTTCAGC TCCAGTTGGA GTTTTTTGTA CCAACTTTTA 3120 GGATTITTT TAATGTTAA AACATCATTA CTATAAGAAC TITGAGCTAC TGCCGTCAGT 3180
GCTGTGCTGT GCTATGGTGC TCTGTCTACT TGCACAGGTA CTTGTAAATT ATTAATTTAT 3240
GCAGAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT 3300
CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAAT ATCCTGCTTG 3360 70 ATGGGATTCT GGACAGGATG TGTTTGCTTT CTGATCAAGG CCTTATTGGA AAGCAGTCCC 3420 75 CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGCT CAAGAGATCC CAAGTAGAAT 3480

CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC 3540
TGTGTTTGGC TTTCAGGGAG GCCCTGTGCC CCTTGACAAC TGGCAGGCAG GCTCCCAGGG 3600


ACACCTGGGA GAAATCTGGC TTCTGGCCAG GAAGCTTTGG TGAGAACCTG GGTTGCAGAC 3660 AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGACTGGA ACACTAGACA AGCCAGAACT 3720 TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGGAAGGGG TCTGTAGTGT CACTCAAGGC 3780 GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA 3840 5 CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TGTTTCTGTA AGAAACCTAC TGCCCAGGCA 3900 CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA 3960 CAATGATCCT GTATTCAGAC AGATGAGGAC TTTCCATGGG ACCACAACTA TTTTCAGATG 4020 TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC 4080 AATTAGGCAG ACTCTTTATG CTTGCAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG 4140 TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG 4200 10 CATCCTCTTT TTCCAACTTG GCTGCAGGAA TCTTTAAAAG ATGCTTTTAA CAGAGTCTGA 4260 ACCTATTTCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT 4320 CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGGC TTGGGCAGCA TCCCCTTGAA 4380 CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT 4440 AATGGCATGA GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT 4500 CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT 4560 15 TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA 4620 TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT 4680 TCCCCACTGT ATCTAGGCAA CATAGTATTC ATGACTATGG ATAAACTAAA CACGTGACAC 4740 20 AAACACACA AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT 4800 TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAGCCAT GCTGGAAAAT AATACTGCTG 4860 AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA 4920 TATATACTAT TAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTTT 4980 AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA 5040 25 ACCAAAAAA AAAAAAAAAA AA Seq ID NO: 10 Protein sequence: NP_003465.2 Protein Accession #: 30 11 21 31 41 51 MAARPLPVSP ARALLLALAG ALLAPCEARG VSLWNEGRAD EVVSASVRSG DLWIPVKSFD 60 SKNHPEVLNI RLQRESKELI INLERNEGLI ASSFTETHYL QDGTDVSLAR NYTVILGHCY 120 YHGHVRGYSD SAVSLSTCSG LRGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG 180 SHHNTPNLAA KNVFPPPSQT WARRHKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR 240 LIEIANHVDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300 35 DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLGAAVTLAH ELGHNFGMNH 360 DTLDRGCSCO MAVEKGGCIM NASTGYPFPM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE 420 40 SFGGQKCGNR FVEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT 480 ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGICQTHE QQCVTLWGPG 540 AKPAPGICFE RVNSAGDPYG NCGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS 600 IETNIPLQQG GRILCRGTHV YLGDDMPDPG LVLAGTKCAD GKICLNRQCQ NISVFGVHEC 660 AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL 720 45 LAAGFVVYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FQPCQAHLGH LGKGLMRKPP 780 DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP 840 ALRQAQGTCK PNPPQKPLPA DPLARTTRLT HALARTPGQW ETGLRLAPLR PAPQYPHQVP 900 RSTHTAYIK 50 Sea ID NO: 11 DNA sequence NM 001394 Nucleic Acid Accession #: 400-1584(underlined sequences correspond to start and stop codons) Coding sequence: 51 41 55 GGAGCCGCGC GACCGGCAAA AATACACGGG AGGCCGTCGC CGAAAAAGAGT CCGCGGTCCT 120
CTCTCGTAAA CACACTCTCC TCCACCGGCG CCTCCCCCTC CGCTCTGCGC GCCGCCCGGC 180 TGGGCGCCG AGGCCGCTCC GACTGCTATG TGACCGCGAG GCTGCGGGAG GAAGGGGACA 240 60 GGGAAGAAGA GGCTCTCCCG CGGGAGCCCT TGAGGACCAA GTTTGCGGCC ACTTCTGCAG 300 GGGTCCCTTC TTAGCTCTCG CCTGCCCCTT TCTGCAGCCT AGGTCGCCCA GGTTCTCTTC 360
TCTTCCTCGC GCGCCAGCC GCCTCGGTTC CCGGCGACCA TGGTGACGAT GGAGGAGCTG 420
CGGGAGATGG ACTGCAGTGT GCTCAAAAGG CTGATGAACC GGGACGAGAA TGGCGGCGGC 480
GCGGCGGCA GCGGCAGCCA CGGCACCCTG GGGCTGCCGA GCGGCGCAA GTGCCTGCTG 540

CTGGACTGCA GACCGTTCCT GGCGCACAGC GCGGGCTACA TCCTAGGTTC GGTCAACGTG 600
CGCTGTAACA CCATCGTGCG GCGGCGGCT AAGGGCTCG TGAGCCTGGA GCAGATCCTG 660
CCCGCCGAGG AGGAGGTACG CGCCCGCTTG CGCTCCGGCC TCTACTCCGC GGTCATCGTC 720
TACGACGAG GCAGCCCGCG CGCCGAGAGC CTCCCGGCAG ACACCGT GTCGCTGGTG 780
GTGCAGGCCG TGCGCCGCAA CGCCGAGAGC CCCGCACATCT GCCTGCTCAA AGGCGGCTAT 840
GAGAGGTTTT CCTCCGAGTA CCCAGAATTC TGTTCTAAAA CCAAGGCCCT GGCAGCCATC 900
CCACCCCCGG TTCCCCCCAG CGCCACAGAG CCCTTGGAC TGGGCTGCAG CTCCTGTTGGG 960
ACCCACTAC ACGACCAGGG GGGTCCTGTG GAAGATCCTTC CCTTCCTCTA CCTCGGCAGT 1020
GCCTACCATG CTGCCCGAA AGAACATGCTG GACGCCCTGG GCATCAGGC TCTGTTGAAT 1080
GTCTCCTCGG ACTGCCCAAA CCACTTTGAA GGACACTATC AGTACAAGTG CATCCCAGTG 1140
GAAGATAACC ACAAGGCCGA CATCAGCTCC TGGTTCATGG AAGCCATAGA GTACATCGAT 1200
GCCGTGAAGG ACTGCCTGG GCGCTGCTG GTGCACTGCC AGGCGGGCAT CTCGGGGTCG 1260
GCCACCACTC GCCTGGCCTA CCTGATGATG AAGAAACGGG TGAGGCTTC 1320

65

70

75



AGAGCGAGGT CATATCTTTG CCCTTCCTGG ATCAGCTGGT GTCAACCCTC GTGGGCCTCC 600 TCAGCCCACA CAACCCGGCC CTGGCCGCTG CCGCCTCGA TTATAGATGC CCAGTTCATT TTTACTGGGT GCGTGGTGAA GAAATTATTC CTCGTGGTCA TCGAAGAGGT CGAATTGATG 720 ACTTGCGATA CCAGATAGAT GATAAACCAA ACAACCAGAT TCGAATATCC AAGCAACTCG 780 5 CAGAGTTTGT GCCATTGGAT TATTCTGTTC CTATAGAAAT CCCCACTATA AAATGTAAAC 840 CAGACAAACT TCCATTATTC AAACGGCAGT ATGAAAACCA CATATTTGTT GGCTCAAAAA 900 CTGCAGATCC TTGCTGTTAC GGTCACACCC AGTTTCATCT GTTACCTGAC AAATTAAGAA 960 GGGAAAGGCT TTTGAGACAA AACTGTGCTG ATCAGATAGA AGTTGTTTTT AGAGCTAATG 1020 CTATTGCAAG CCTTTTTGCT TGGACTGGAG CACAAGCTAT GTATCAAGGA TTCTGGAGTG 1080 10 AAGCAGATGT TACTCGACCT TTTGTCTCCC AGGCTGTGAT CACAGATGGA AAATACTTTT 1140 CCTTTTCTG CTACCAGCTA AATACTTTGG CACTGACTAC ACAAGCTGAT CAAAATAACC 1200 CTCGTAAAAA TATATGTTGG GGTACACAAA GTAAGCCTCT TTATGAAACA ATTGAGGATA 1260 ATGATGTGAA AGGTTTTAAT GATGATGTTC TACTTCAGAT AGTTCACTTT CTACTGAATA 1320 GACCAAAAGA AGAAAAATCA CAGCTGTTGG AAAAC<u>TGA</u>AA AAGCATATTT GATTGAGAAC 1380 TGTGGGAATA TTTAAATTTT ACTGAAGGAA CAATAATGAT GAGATTTGTA ACTGTCAACT 1440 ATTAAATACA TTGATTTTTG AGACAAATAT TTCTTATGTC AACCTGTTAT TAGATCTCTT 1500 15 ACTCTGCTCA AATTCATCAC TGAAAGATTT AATTTTAGTT ACCTTTTGTT GATTTAAAAA 1560 TAATTGCATT TGTATATTGC TAACTGATAA GACAAATTGA GTTATTGAGC TATTAAATGC 1620 ACATTTTAAT ATAAATGCAG AAATCCCAAA TAAAATGCTA ACATACTGAA TTCAGTAATT 1680 20 AAAAGAACCC ACTGC Seq ID NO: 16 Protein sequence: NP 057724.1 Protein Accession #: 25 41 MAAARCWRPL LRGPRLSLHT AANAAATATE TTSQDVAATP VARYPPIVAS MTADSKAARL 60 RRIERWQATV HAAESVDEKL RILTKMQFMK YMVYPQTFAL NADRWYQYFT KTVFLSGLPP 120
PPAEPEPEP PEPEPALDLA ALRAVACDCL LQEHFYLRR RRVHRYEESE VISLPFLDQL 180 30 VSTLVGLLSP HNPALAAAAL DYRCPVHFYW VRGEEIIPRG HRRGRIDDLR YQIDDKPNNQ 240 IRISKQLAEF VPLDYSVPIE IPTIKCKPDK LPLFKRQYEN HIFVGSKTAD PCCYGHTQFH 300 LLPDKLRRER LLRQNCADQI EVVFRANAIA SLFAWTGAQA MYQGFWSEAD VTRPFVSQAV 360 ITDGKYFSFF CYQLNTLALT TQADQNNPRK NICWGTQSKP LYETIEDNDV KGFNDDVLLQ 420 35 IVHFLLNRPK EEKSOLLEN

Seq ID NO: 17 DNA sequence

Nucleic Acid Accession #:

21

31

41

40

NM_025059.1

51

Coding sequence: 3-2150 (underlined sequences correspond to start and stop codons)

45 AAACTTACGA TCATCTTTCG GAAGTCCCGG TCACGCGGGA GCAGTTAAAC CACTATCGGA 120 ATGTGGCTCA AAATGCTCGA AGTGAACTTG CAGCAACTTT GGTCAAATTT GAATGTGCTC 180 AGTCTGAGCT TCAAGACCTC CGATCCAAGA TGCTTTCTAA AGAAGTCTCC TGTCAAGAAC 240 TGAAAGCTGA AATGGAGAGC TACAAGGAAA ACAATGCCAG AAAATCATCT CTCCTTACCT 300 CTTTGAGAGA CAGAGTTCAG GAACTAGAAG AAGAATCAGC AGCACTTTCC ACTTCTAAAA 360 TCAGAACAGA AATCACAGCT CACGCTGCAA TCAAGGAGAA CCAGGAATTA AAGAAGAAAG 420 50 TTGTAGAGTT AAATGAAAAA TTACAAAAGT GTTCAAAAGA AAATGAGGAG AATAAGAAAC 480 AAGTTTCAAA GAATTGCAGG AAACATGAGG AATTTCTGAC TCAACTGCGT GACTGCTTGG 540 ATCCAGATGA GAGGAATGAC AAGGCATCAG ATGAAGATTT AATTTTAAAG CTTAGAGACC 600 TGCGCAAAGA AAATGAATTC GTGAAAGGAC AAATTGTTAT TCTTGAAGAG ACTATAAATG 660 TCCATGAGAT GAAACAAAA GCTAGCAGAG AAACGATCAT GAGGCTGGCT TCAGAAGTCA 720
ACAGAGAGCA GAAAAAAGCT GCCTCCTGTA CTGAAGAGAA AGGAAAGCTG AACCAGGACC 780
TGCTCAGTGC TGTAGAAGCA AAAGAAGCTC TTGAAAGGGA AGTTAAGATC TTCCAAGAAA 840
GGCTGCTTGC TGGCCAGCAG GTCTGGGATG CCTCAAAGCA GGAAGTGAGC CTCCTGAAGA 900 55 780 AAAGCTCTTC TGAGTTGGAG AAGAGTTTGA AGGCCAGTCA GGATGCAGTC ACAACCTCAC 960 AAAGCCAGTA CTCCTCATTT AGGGAGAAAA TCGCAGCCCT CCTTAGGGGC AGATTGAGCA 1020 60 TGACTGGGTC CACTGAGGAC ACCATTTTGG AGAAGATTCG AGAAATGGAC AGCCGGGAAG 1080 AAAGCAGGGA CCGGATGGTC TCCCAGCTTG AAGCCCAAAT ATCTGAGCTT GTTGAACAGT 1140 TGGGAAAGGA GTCTGGGTTT CACCAGAAAG CTCTCCAGAG GGCCCAGAAA GCAGAGAATA 1200 TGTTGGAGAC TCTTCAGGGT CAGCTGACAC ACCTGGAGGC AGAGCTGGTT TCTGGAGGTG 1260 65 TTTTGCGAGA CAACTTGAAT TTTGAGAAAC AAAAATATCT TAAATTTCTG GATCAGCTTT 1320 CTCAGAAAAT GAAGTTGGAC CAGATGGCTG CCGAACTTGG CTTTGACACG CGGCTGGACG 1380 TIGGTTTTAGC TCGAACAGAG CAGCTGGTTC GTCTTGAGAG CAATGCAGTC ATTGAGAACA 1440
AGACCATTGC CCACACATTTG CAGAGAAAGC TAAAGACACA GAAAGAAGAAGA CTGAAGAGCA 1500
AAGAATTACA CATGAGCCTC CTCCGGCAGA AAATAGCCCA GCTGGAGGAG GAGAAGCAGG 1560
CACGCACGGC CTTGGTGGTT GAGAGGACA ACGCGCATCT TACCATCAGG AACTTGCAGA 1620 70 AGAAGGTGGA GAGGCTGCAG AAAGAGCTGA ACACGTGTCG AGACTTGCAC ACCGAGCTCA 1680 AAGCCAAACT GGCCGACACC AATGAACTGA AGATTAAAAC TTTGGAACAG ACTAAAGCCA 1740 TTGAAGATCT AAACAAATCC AGAGACCAAC TGGAGAAGAT GAAGGAGAAA GCTGAGAAAA 1800 AGCTCATGTC TGTCAAGTCA GAACTGGATA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860 75 AAAGGGCCAG AAACATGATA GAAGTGGTAA CCAGTGAAAT GAAGACACTA AAAAAATCTC 1920 TGGAAGAAGC AGAAAAGAGA GAAAAGCAGC TGGCAGACTT CAGGGAGGTG GTGTCGCAGA 1980 TGCTAGGCTT GAACGTGACC AGCCTTGCTC TTCCTGATTA TGAAATCATC AAGTGTCTTG 2040

GCATGAGCCT GGACTGCACC AGCCATATCG CGCTGGGTGC CGCTTCGCCA GCGCCCGAGG 60

AAAGATTGGT CCATTCACAT CAGCATCACT TTGTTACCTG TGCCTGCCTC AAAGATGTGA 2100 CTACTGGGCA AGAGAGGCAC CCACAAGGCC ATTTACAGCT TCTTCAT<u>TGA</u> ACACTGTATC 2160 TCTTGAGAGA GGTGGCCATA AGACATGGCA CACAATTCCC AATTTCACAA ATTCCTCATG 2220 TCTTTGAGAT TTGATCAGTT TGTGAATATT TTATGCTTTG ATGATATAGT GAGAATGCAT 2280 5 CACTTGCAAA AACGATCTCA AAAGTGTCAG CCTTAGATAA ACGTCAGCAT TAAAAAACGC 2340 CAAAAAAAA AAAAAAAGC ATTTTAGGAT CCAGAAGAAT TCCACCAGAT TGCATGAGTT 2400 AGATTGGGAA ATGGGAGTGG GAGATAATAT TGGGAGGTAT CTATTTTAAG TCAGGGGCTT 2460 TACTAGCCGA TTTAGTTCTC ACAATAACCA TGTGGAGAAG CTGTGACATT TTTAATTTAC 2520 AACCTTTCTG GGGCTCAGAC ATAAAGTTAC CTATCCAAGG TTGCAGTTGG GTAGTGGTGG 2580 GACCAGGATG GACAACTCAT TGGCCCTGCC TCAAAAGCCA TACCTCTTCT CCTGCTATGC 2640 10 AGAATCTGTT TCTCCTGAAT CTCTGTGATG CTGGTGGGAA TTGTTTGCAT AGAGGAAGGA 2700 CAATAACCCT GCCATCGTGA GTTAATGTCC GGGCTGGTCA CAGTGGTTCA TGCCTGTAAT 2760 CCCAGCACTT TGGGAGTCCA AGGCAGGCAT ATCATTTGAG GTCAGGAGTT TAAGACCAGC 2820 CTGGCTAACA TAGTGAGACC CTGTTTCTAC TAAAAATACA AAAATAAGCC AGGTGTGGTG 2880 GTGCATGACT GTAATCCCAA CTACTCAGCA GGAGAAGCAC TTGAACCCAG GAGACGAGG 2940
CGGCAGTGAG CCAAGATTGT GCCACTGCAC TCCAGCCTGG GCGACAGAGT GAAACTACAT 3000
CTCAGAAAAA AAAAAAAAAA AAAAAAAAAA AAGTTAATGT CCAAAAATGA CAGATTTACA 3060
AGTGTAAGCT ATATGATTTC TTCAAAAAGC AAAAGCAATA TACCTAATTC ATTTGGATCA 3120
AACTTACATA GGTCTCAGGT CCTGTAAGAA ACTTGCCTGT TCTAACTGTT GCTACCAGAT 3180 15 20 TATATCTGGT GGTAATTGTT AATGTTTCAG CAGGGCTGGT CTCAGTCCTT TAAAATGGAA 3240 AGCTTTATTT GGAGCCCAAC CCTATAAGAT GAAGAAATCC TATATAGTCT TATTCACCAA 3300 TATATCCAAT ACACCCACAG CAATGGTACC TTTTTAAGAT CAGGATTTTA TTATGAATTC 3360 CTGTCACTTT CTGTTTTCCA TTTAAATTTC TATTTTACAA ATTTTTCAGG GAATCATATT 3420 CTTAACTTCA CTGAGAAAAA TGTGTTACTC TTTTGGACAA TTTATCTTAT TTCTATCATA 3480 TAAGATGTAT TTTTTTATTG TCCTTAAAAG AAGCTCTAGC ATGAAATTAA AGGAAAGGGA 3540 25 AAGAAATAGA TCTGGTGCAC CCGAACATTA GGAGAAAATG AAAAATATAC AACCAACCGT 3600 TCGTGAGTCA TCAAAAAGTC AAAGTCAGCC TGGCCAACAT GGCAAAACTC CGTCTCTGCA 3660 AAAAATACAA AAATGAGCCC GGTATGTTGG CATATGCCTG TAATCCCAGC TACTCGAGAG 3720 GCTGAGACAC GAAAATTGCT TGAACCTGGG AGGCGGAGGT TGCAATGAGC CGAGATCGCG 3780 CTACTGCACT CCAGCCTGGG CAACAGAGAG AGACCTTGTC TCAAAAAACA ACAACAACAA AAAGTCAAAAG TCATAATAAG CAAATTATTG GCTTCTTTCT TCTAGACYAA AAGAAAATTAA 3900 AGAGATGAAA CAATCAATTG CAAGGGTCAA AACTAGATTG GATCTTGGTT TGAATGAAAA 3960 AAAGCATAAA ATATTCTTGC AATAATTGTA AAAATTTGAA TGTGGACTAA GTCCTAGATT 4020 30 ATATTAAAAT ATTTTTAATT TTTTAAGCTT GACAAATGCA CTGATTGTTA TACTTTAAAT 4080 35 AACTAAAAAT CTGAGAATCC ACAGTGCTAC AGACAATAAA TGATAAAATG GGAAAAAAA 4140 AAAAAAAAA A Seq ID NO: 18 Protein sequence: 40 NP 079335.1 Protein Accession #: MSLDCTSHIA LGAASPAPEE TYDHLSEVPV TREQLNHYRN VAQNARSELA ATLVKFECAQ 60 SELQDLRSKM LSKEVSCQEL KAEMESYKEN NARKSSLLTS LRDRVQELEE ESAALSTSKI 120 RTEITAHAAI KENQELKKKV VELNEKLQKC SKENEENKKQ VSKNCRKHEE FLTQLRDCLD 180 45 PDERNDKASD EDLILKLRDL RKENEFVKGQ IVILEETINV HEMEAKASRE TIMRLASEVN 240 REQKKAASCT EEKEKLNQDL LSAVEAKEAL EREVKIFQER LLAGQQVWDA SKQEVSLLKK 300 SSSELEKSLK ASQDAVTTSQ SQYSSFREKI AALLRGRLSM TGSTEDTILE KIREMDSREE 360 SSDELEASLA ASQUAY 115Q SQ1 55FREAL AALLKORLSM 1031ED ILLE AIREMINED 500
SRDRMVSQLE AQISELVEQL GKESGFHQKA LQRAQKAENM LETLQGQLTH LEAELVSGGV 420
LRDNLNFEKQ KYLKFLDQLS QKMKLDQMAA ELGFDTRLDV VLARTEQLVR LESNAVIENK 480
TIAHNLQRKL KTQKERLESK ELHMSLLRQK IAQLEEEKQA RTALVVERDN AHLTIRNLQK 540
KVERLQKELN TCRDLHTELK AKLADTNELK IKTLEQTKAI EDLNKSRDQL EKMKEKAEKK 600 50 LMSVKSELDT TEHEAKENKE RARNMIEVVT SEMKTLKKSL EEAEKREKQL ADFREVVSQM 660 55 LGLNVTSLAL PDYEIIKCLE RLVHSHQHHF VTCACLKDVT TGQERHPQGH LQLLH Seq ID NO: 19 DNA sequence AF071552, NM 000662 Nucleic Acid Accession #: 60 Coding sequence: 441-1313 (underlined sequences correspond to start and stop codons) 21 31 CTTTGTATAA GGCTCAGCTA AAAGGGAAAT TGAGTGGGTC AGGTACCACG GATACTATAC 60
ACTCTATTGC ATGATTCTCC TGCCTACATC AGAAGACGTT TATAAGCCTA TTTTAAAGGA 120
TACCAGTTGG AATCTCTCT TTATTAATCA CCAAGAGAAC CATGAACAAG CTGTTTATCA 180 65

TTTGACTCAT CATTTAATCT TGATTTCCAG CTTCTCACAC TTGAAAGAAG ACATAATACA 240 TTTCTCACAG GATTCTGGGA CTATTAACTG AACTTATGTG TGTAAAAGGA ATTCATACAA 300

TGAAAGCACT AGAAATAATT ATTATACTTA TAACCATTGT ATTTTTACAT GTTTAAAATA 360
TAGCCATAAT TAGCCTACTC AAATCCAAGT GTAAAAGTAA AATGATTTGC TTTCGTTTTG 420
TTTTCCTTGC TTAGGGGATC ATGGACATTG AAGCATATCT TGAAAAGATT GGCTATAAGA 480
AGTCTAGGAA CAAATTGGAC TTGGAAAACAT TAACTGACAT TCTTCAACAC CAGATCCGAG 540
CTGTTCCCTT TGAGAACCTT AACATCCATT GTGGGGATGC CATGGACTTA GGCTTAGAGG 600

70

75

CCATTTTTGA TCAAGTTGTG AGAAGAAATC GGGGTGGATG GTGTCTCCAG GTCAATCATC 660 TTCTGTACTG GGCTCTGACC ACTATTGGTT TTGAGACCAC GATGTTGGGA GGGTATGTTT 720 ACAGCACTCC AGCCAAAAAA TACAGCACTG GCATGATTCA CCTTCCTCTG CAGGTGACCA 780

TTGATGGCAG GAACTACATT GTCGATGCTG GGTTTGGACG CTCATACCAG ATGTGGCAGC 840 CTCTGGAGTT AATTTCTGGG AAGGATCAGC CTCAGGTGCC TTGTGTCTTC CGTTTGACGG 900
AAGAGAATGG ATTCTGGTAT CTAGACCAAA TCAGAAGGGA ACAGTACATT CCAAATGAAG 960
AATTTCTTCA TTCTGATCTC CTAGAAGACA GCAAATACCG AAAAATCTAC TCCTTTACTC 1020
TTAAGCCTCG AACAATTGAA GATTTTGAGT CTATGAATAC ATACCTGCAG ACATCTCCAT 1080 5 CATCTGTGTT TACTAGTAAA TCATTTTGTT CCTTGCAGAC CCCAGATGGG GTTCACTGTT 1140 TGGTGGGCTT CACCCTCACC CATAGGAGAT TCAATTATA'A GGACAATACA GATCTAATAG 1200 AGTTCAAGAC TCTGAGTGAG GAAGAAATAG AAAAAGTGCT GAAAAATATA TTTAATATTT 1260 CCTTGCAGAG AAAGCTTGTG CCCAAACATG GTGATAGATT TTTACTATT <u>TAG</u>AATAAGG 1320
AGTAAAACAA TCTTGTCTAT TTGTCATCCA GCTCACCAGT TATCAACTGA CGACCTATCA 1380
TGTATCTTCT GTACCCTTAC CTTATTTTGA AGAAAATCCT AGACATCAAA TCATTTCACC 1440
TATAAAAATG TCATCATATA TAATTAAACA GCTTTTTAAA GAAACATAAC CACAAACCTT 1500
TTCAAATAAT AATAATAATA ATAATAATAA ATGTATTTTA AAGATGGCCT GTGGTTATCT 1560 10 TGGAAATTGG TGATTTATGC TAGAAAGCTT TTAATGTTGG TTTATTGTTG AATTC 15 Seq ID NO: 20 <u>Protein sequence:</u> Protein Accession #: NP_000653.1 20 11 31 41 21 MDIEAYLERI GYKKSRNKLD LETLTDILQH QIRAVPFENL NIHCGDAMDL GLEAIFDQVV 60 VEDSKYRKIY SFTLKPRTIE DESMNTYLQ TSPSSVFTSK SFCSLQTPDG VHCLVGFTLT 240

HRRFNYKDNT DLIEFKTLSE EBIEKVLKNI FNISLQRKLV PKHGDRFFTI 25 Seq ID NO: 21 DNA sequence Nucleic Acid Accession #: NM_003714 Coding sequence: 123-1031(underlined sequences correspond to start and stop codons) 30 35 CGGCACGAGC AAAAAGGAAG AGTGGGAGGA GGAGGGGAAG CGGCGAAGGA GGAAGAGGAG 60 CACACACA AAAAAGAAA AGTGGAAGA GAAGAAAA CAGCAAAAA CAGCAAAAA 120
CCATGTGTGC CGAGCGGCTG GGCCAGTTCA TGACCCTGGC TTTGGTGTTG GCCACCTTTG 180
ACCCGGCGCG GGGGACCGAC GCCACCAACC CACCCGAGGG TCCCCAAGAC AGGAGCTCCC 240
AGCAGAAAGG CCGCCTGTCC CTGCAGAATA CAGCGGAGAT CCAGCACTGT TTGGTCAACG 300 40 CTGGCGATGT GGGGTGTGGC GTGTTTGAAT GTTTCGAGAA CAACTCTTGT GAGATTCGGG 360 GCTTACATGG GATTTGCATG ACTTTTCTGC ACAACGCTGG AAAATTTGAT GCCCAGGGCA 420 AGTCATTCAT CAAAGACGCC TTGAAATGTA AGGCCCACGC TCTGCGGCAC AGGTTCGGCT 480 GCATAAGCCG GAAGTGCCCG GCCATCAGGG AAATGGTGTC CCAGTTGCAG CGGGAATGCT 540 ACCTCAAGCA CGACCTGTGC GCGGCTGCCC AGGAGAACAC CCGGGTGATA GTGGAGATGA 600 TCCATTTCAA GGACTTGCTG CTGCACGAAC CCTACGTGGA CCTCGTGAAC TTGCTGCTGA 660 CCTGTGGGGA GGAGGTGAAG GAGGCCATCA CCCACAGCGT GCAGGTTCAG TGTGAGCAGA 720 45 ACTGGGGAAG CCTGTGCTCC ATCTTGAGCT TCTGCACCTC GGCCATCCAG AAGCCTCCCA 780 CGGCGCCCC CGAGCGCCAG CCCCAGGTGG ACAGAACCAA GCTCTCCAGG GCCCACCACG 840 GGGAAGCAGG ACATCACCTC CCAGAGCCCA GCAGTAGGGA GACTGGCCGA GGTGCCAAGG 900 50 GTGAGCGAGG TAGCAAGAGC CACCCAAACG CCCATGCCCG AGGCAGAGTC GGGGGCCTTG 960 GGGCTCAGGG ACCTTCCGG AGCAGCAGCG CCCATGCCG AGGCAGATG GGGGCTCAGGG ACCTTCCGGA AGCAGCGAGT GGGAAGACG ACAGTCTGAG TATTCTGATA 1020 TCCGGAGG<u>TG</u> AAATGAAAGG CCTGGCCACG AAATCTTTCC TCCACGCCGT CCATTTTCTT 1080 ATCTATGGAC ATTCCAAAAC ATTTACCATT AGAGAGGGGG GATGTCACAC GCAGGATTCT 1140 GTGGGGACTG TGGACTTCAT CGAGGTGTGT GTTCGCGGAA CGGACAGGTG AGATGGAGAC 1200 55 CCCTGGGGCC GTGGGGTCTC AGGGGTGCCT GGTGAATTCT GCACTTACAC GTACTCAAGG 1260 GAGCGCCC GCGTTATCCT CGTACCTTTG TCTTCTTTCC ATCTGTGGAG TCAGTGGGTG 1320 TCGGCCGCTC TGTTGTGGGG GAGGTGAACC AGGGAGGGC AGGGCAAGGC AGGGCCCCCA 1380 GAGCTGGGCC ACACAGTGGG TGCTGGGCCT CGCCCCGAAG CTTCTGGTGC AGCAGCCTCT 1440 GGTGCTGTCT CCGCGGAAGT CAGGGCGGCT GGATTCCAGG ACAGGAGTGA ATGTAAAAAT 1500 AAATATCGCT TAGAATGCAG GAGAAGGGTG GAGAGGAGGC AGGGGCCGAG GGGGTGCTTG 1560 60 GTGCCAAACT GAAATTCAGT TTCTTGTGTG GGGCCTTGCG GTTCAGAGCT CTTGGCGAGG 1620 GTGGAGGGAG GAGTGTCATT TCTATGTGTA ATTTCTGAGC CATTGTACTG TCTGGGCTGG 1680 GGGGGACACT GTCCAAGGGA GTGGCCCCTA TGAGTTTATA TTTTAACCAC TGCTTCAAAT 1740 CTCGATTTCA CTTTTTTAT TTATCCAGTT ATATCTACAT ATCTGTCATC TAAATAAATG 1800 65 GCTTTCAAAC AAAAAAAAAA AAAAAAAAAA AAAAAAA Seq ID NO: 22 Protein sequence: Protein Accession #: NP 003705 70 21 31 41 51 11 MCAERLGQFM TLALVLATFD PARGTDATNP PEGPQDRSSQ QKGRLSLQNT AEIQHCLVNA 60

GDVGCGVFEC FENNSCEIRG LHGICMTFLH NAGKFDAQGK SFIKDALKCK AHALRHRFGC 120 ISRKCPAIRE MVSQLQRECY LKHDLCAAAQ ENTRVIVEMI HFKDLLLHEP YVDLVNLLLT 180

CGEEVKEAIT HSVQVQCEQN WGSLCSILSF CTSAIQKPPT APPERQPQVD RTKLSRAHHG 240 EAGHHLPEPS SRETGRGAKG ERGSKSHPNA HARGRVGGLG AQGPSGSSEW EDEQSEYSDI 300

75

RR

5

Seq ID NO: 23 DNA sequence

Nucleic Acid Accession #:



NM_005264.1

CAGGGCGGC GAGGACGGGG GAGGTGGGGG GGGCGCCC CCCGCGCAGC CGACAGCCCC 240 CGCTCTCTAC AAAGAGGCCG AGCTGCGCCT GAAGGGCAGC AGCAACACCA CGGAGTGTGT 420 5 TCCCGTGCCC ACCTCCGAGC ACGTGGCCGA GATCGTGGGC AGGCAAGGCT GCAAGATTAA 480 GGCCTTGAGG GCCAAGACCA ACACCTACAT CAAGACACCG GTGAGGGGCG AGGAACCAGT 540 GTTCATGGTG ACAGGGCGAC GGGAGGACGT GGCCACAGCC CGGCGGGAAA TCATCTCAGC 600 AGCGGAGCAC TTCTCCATGA TCCGTGCCTC CCGCAACAAG TCAGGCGCCG CCTTTGGTGT 660 GGCTCCTGCT CTGCCCGGCC AGGTGACCAT CCGTGTGCGG GTGCCCTACC GCGTGGTGGG 720 GCTGGTGGTG GGCCCCAAAG GGGCAACCAT CAAGCGCATC CAGCAGCAAA CCAACACAT 780 10 CATTATCACA CCAAGCCGTG ACCGCGACCC CGTGTTCGAG ATCACGGGTG CCCCAGGCAA 840 CGTGGAGCGT GCGCGCGAGG AGATCGAGAC GCACATCGCG GTGCGCACTG GCAAGATCCT 900 CGAGTACAAC AATGAAAACG ACTTCCTGGC GGGGAGCCCC GACGCAGCAA TCGATAGCCG 960 CTACTCCGAC GCCTGGCGGG TGCACCAGCC CGGCTGCAAG CCCCTCTCCA CCTTCCGGCA 1020 GAACAGCCTG GGCTGCATCG GCGAGTGCGG AGTGGACTCT GGCTTTGAGG CCCCACGCCT 1080 GGGTGAGCAG GGCGGGGACT TTGGCTACGG CGGGTACCTC TTTCCGGGCT ATGGCGTGGG 1140 CAAGCAGGAT GTGTACTACG GCGTGGCCGA GACTAGCCCC CCGCTGTGGG CGGGCCAGGA 1200 15 GAACGCCACG CCCACCTCCG TGCTCTTCTC CTCTGCCTCC TCCTCCTCCT CCTCTTCCGC 1260 CAAGGCCGC GCTGGGCCCC CGGGCGCACA CCGCTCCCCT GCCACTTCCG CGGGACCGA 1320 20 GCTGGCCGGA CTCCCGAGGC GCCCCCGGG AGAGCCGCTC CAGGGCTTCT CTAAACTTGG 1380 TGGGGGCGGC CTGCGGAGCC CCGGCGGCGG GCGGGATTGC ATGGTCTGCT TTGAGAGCGA 1440 AGTGACTGCC GCCCTTGTGC CCTGCGGACA CAACCTGTTC TGCATGGAGT GTGCAGTACG 1500 CATCTGCGAG AGGACGGACC CAGAGTGTCC CGTCTGCCAC ATCACAGCCA CGCAAGCCAT 1560 CCGAATATTC TCCTAA 25 Seq ID NO: 26 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted 30 51 11 21 31 41 FCFAMPSLVV SGIMERNGGF GELGCFGGSA KDRGLLEDER ALQLALDQLC LLGLGEPPAP 60 RAGEDGGGG GGAPAQPTAP PQPAPPPPPA APPAAPTTAP AAQTPQPPTA PKGASDAKLC ALYKEAELRL KGSSNTTECV PVPTSEHVAE IVGRQGCKIK ALRAKTNTYI KTPVRGEEPV 180 FMVTGRREDV ATARREIISA AEHFSMIRAS RNKSGAAFGV APALPGQVTI RVRVPYRVVG 240 LVVGPKGATI KRIQQQTNTY IITPSRDRDP VFEITGAPGN VERAREEIET HIAVRTGKIL 300 EYNNENDFLA GSPDAAIDSR YSDAWRVHQP GCKPLSTFRQ NSLGCIGECG VDSGFEAPRL 360 GEQGGDFGYG GYLFPGYGVG KQDVYYGVAE TSPPLWAGQE NATPTSVLFS SASSSSSSS 420 35 KARAGPPGAH RSPATSAGPE LAGLPRRPPG EPLOGFSKLG GGGLRSPGGG RDCMVCFESE 480 40 VTAALVPCGH NLFCMECAVR ICERTDPECP VCHITATQAI RIFS Sea ID NO: 27 DNA sequence FGENESH predicted Nucleic Acid Accession #: 1-2070 (underlined sequences correspond to start and stop codons) Coding sequence: 45 ATG AGCGGTG CGGGGGTGGC GGCTGGGACG CGGCCCCCA GCTCGCCGAC CCCGGGCTCT 60 CGGCGCCGGC GCCAGCGCC CTCTGTGGGC GTCCAGTCCT TGAGGCCGCA GAGCCCGCAG 120
CTCAGGCAGA GCACCCGCA GAAACGGAAC CTGGACCTGG AGAAAAGCCT GCAGTTCCTT 180
CAGCAGCAGC ACTCGGAGAT GCTGGCCAAG CTCCATGAGG AGATCGAGCA TCTGAAGCGG 240
GAAAACAAGG GTGAGCCGGC GCGGGGCCCT AGGCCGCCC TGCCTCCCCA GGCACACTCA 300 50 ACACTGCCGC TCCCGCAGCA CAGAAACACA GCCATCAACT CCAGCACACG CCTGGGCTCA 360 GGGGGAACAC AGGACGGGA GCCCTCCAG ACTGTCCTTG CCCACCTGGC TGCACTGGCC 420 55 CCTGTATGCC AACCCAGTGG GTACAGGTTC TGGGGGACCT GGACAGATGC CGCTACCTCT 480 60 GCAGCAACCA TGGGGACAAA GGGAGGAAGC AGAGTCCTGT TTCCTTGCCA CTTGTCCAAG 840
GCACTTCCCC ATCCTGACAG CGGCCCCAC CCAGCCCAGG ATCCTGGGCT GTGGTCTCAA 900
GCTCACTTCC CATTATCTTT GGGGCTGGGG CTGACATCAG GAGGACATCT GACTGGTGA 960
TGGAGCCAGC CTGGGAACAT CGCAGCTGGG GCAGTGCCTA GGGCTCTCCC TTCCCAGGGA 1020
GACATGGAGA AGGGGGTTGA GGGAGGGCC TTCCCTAGCC GCTGTGGCAA CTCCAGTGAG 1080 65 CTGTTCTGGG CAAAGTGTGG CCCAAGTCGG CAGCCCCAGC CCTGCAGTGC TGGGGACGCT 1140 GACAGGACAC GGGAAGAGGC CATGCTTTCC CTCGGGACCT GCTGTTCCAT GTGTCCCAAG 1200 70 TCCTTCAACA AGCAAGATTC AAAAGCTGAC GTCTCCCAGA AGGCGGACCT GGAAGAGGAG 1560
CCCCTACTTC ACAACAGCAA GCTGGACAAA GTTCCTGGGG TACAAGGGCA GGCCAGAAAG 1620 75 GAGAAAGCAG AGGCCTCTAA TGCAGGAGCT GCCTGTATGG GGAACAGCCA GCACCAGGGC 1680 AGGCAGATGG GGGCGGGGC ACACCCCCCA ATGATCCTGC CCCTTCCCCT GCGAAAGCCC 1740 ACCACACTTA GGCAGTGCGA AGTGCTCATC CGCGAGCTGT GGAATACCAA CCTCCTGCAG 1800

ACCCAAGAGC TGCGGCACCT CAAGTCCCTC CTGGAAGGGA GCCAGAGGCC CCAGGCAGCC 1860 CCGGAGGAAG CTAGCTTTCC CAGGGACCAA GAAGCCACGC ATTTCCCCAA GGTCTCCACC 1920 AAGAGCCTCT CCAAGAAATG CCTGAGCCCA CCTGTGGCGG AGCGTGCCAT CCTGCCGCA 1980 CTGAAGCAGA CCCCGAAGAA CAACTTTGCC GAGAGGCAGA AGAGGCTGCA GGCAATGCAG 2040 AAACGGCGCC TGCATCGCTC AGTGCTT<u>TGA</u>

Seq ID NO: 28 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted

LKOTPKNNFA EROKRLQAMQ KRRLHRSVL

10

5

25

30

Seq ID NO: 29 DNA sequence
Nucleic Acid Accession #: NM_012319.2
Coding sequence: 138-2405 (underlined sequences correspond to start and stop codons)

41 11 21 31 CTCGTGCCGA ATTCGGCACG AGACCGCGTG TTCGCGCCTG GTAGAGATTT CTCGAAGACA CCAGTGGGCC CGTGTGGAAC CAAACCTGCG CGCGTGGCCG GGCCGTGGGA CAACGAGGCC 120
GCGGAGACGA AGGCGCAATG GCGAGGAAGT TATCTGTAAT CTTGATCCTG ACCTTTGCCC 180
TCTCTGTCAC AAATCCCCTT CATGAACTAA AAGCAGCTGC TTTCCCCCAG ACCACTGAGA 240 35 AAATTAGTCC GAATTGGGAA TCTGGCATTA ATGTTGACTT GGCAATTTCC ACACGGCAAT 300 ATCATCTACA ACAGCTTTTC TACCGCTATG GAGAAAATAA TTCTTTGTCA GTTGAAGGGT 360 TCAGAAAATT ACTTCAAAAT ATAGGCATAG ATAAGATTAA AAGAATCCAT ATACACCATG 420 40 ACCACGACCA TCACTCAGAC CACGAGCATC ACTCAGACCA TGAGCGTCAC TCAGACCATG 480 AGCATCACTC AGACCACGAG CATCACTCTG ACCATGATCA TCACTCTCAC CATAATCATG 540 CTGCTTCTGG TAAAAATAAG CGAAAAGCTC TTTGCCCAGA CCATGACTCA GATAGTTCAG 600 GTAAAGATCC TAGAAACAGC CAGGGGAAAG GAGCTCACCG ACCAGAACAT GCCAGTGGTA 660 GAAGGAATGT CAAGGACAGT GTTAGTGCTA GTGAAGTGAC CTCAACTGTG TACAACACTG 720 45 TCTCTGAAGG AACTCACTTT CTAGAGACAA TAGAGACTCC AAGACCTGGA AAACTCTTCC 780 CCAAAGATGT AAGCAGCTCC ACTCCACCCA GTGTCACATC AAAGAGCCGG GTGAGCCGGC 840 TGGCTGGTAG GAAAACAAAT GAATCTGTGA GTGAGCCCCG AAAAGGCTTT ATGTATTCCA 900 GAAACACAAA TGAAAATCCT CAGGAGTGTT TCAATGCATC AAAGCTACTG ACATCTCATG 960 GCATGGGCAT CCAGGTTCCG CTGAATGCAA CAGAGTTCAA CTATCTCTGT CCAGCCATCA 1020 TCAACCAAAT TGATGCTAGA TCTTGTCTGA TTCATACAAG TGAAAAGAAG GCTGAAATCC 1080 CTCCAAAGAC CTATTCATTA CAAATAGCCT GGGTTGGTGG TTTTATAGCC ATTTCCATCA 1140 50 TCAGTTTCCT GTCTCTGCTG GGGGTTATCT TAGTGCCTCT CATGAATCGG GTGTTTTTCA 1200 AATTTCTCCT GAGTTTCCTT GTGGCACTGG CCGTTGGGAC TTTGAGTGGT GATGCTTTTT 1260 TACACCTTCT TCCACATTCT CATGCAAGTC ACCACCATAG TCATAGCCAT GAAGAACCAG 1320
CAATGGAAAT GAAAAGAGGA CCACTTTTCA GTCATCTGTC TTCTCAAAAC ATAGAAGAAA 1380
GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGCCTG TATTTCATGT 1440
TTCTTGTTGA ACATGTCCTC ACATTGATCA AACAATTTAA AGATAAGAAG AAAAAGAATC 1500 55 AGAAGAAACC TGAAAATGAT GATGATGTGG AGATTAAGAA GCAGTTGTCC AAGTATGAAT 1560 CTCAACTTTC AACAAATGAG GAGAAAGTAG ATACAGATGA TCGAACTGAA GGCTATTTAC 1620 60 GAGCAGACTC ACAAGAGCCC TCCCACTTTG ATTCTCAGCA GCCTGCAGTC TTGGAAGAAG 1680 GAGCAGACTC ACAAGAGCCC TCCACTTIG ATTCTCAGCA GCCTGCAGTC TIOGAGGAAG 1060
AAGAGGTCAT GATAGCTCAT GCTCATCCAC AGGAAGTCTA CAATGAATAT GTACCCAGAG 1740
GGTGCAAGAA TAAATGCCAT TCACATTTCC ACGATACACT CGGCCAGTCA GACGATCTCA 1860
TTCACCACCA TCATGACTAC CATCATATTC TCCATCATCA CCACCACCAA AACCACCATC 1860
CTCACAGTCA CAGCCAGCGC TACTCTCGGG AGGAGCTGAA AGATGCCGGC GTCGCCACTT 1920
TGGCCTGGAT GGTGATAATG GGTGATGGCC TGCACAATTT CAGCGATGGC CTAGCAATTG 1980 65 GTGCTGCTTT TACTGAAGGC TTATCAAGTG GTTTAAGTAC TTCTGTTGCT GTGTTCTGTC 2040 ATGAGTTGCC TCATGAATTA GGTGACTTTG CTGTTCTACT AAAGGCTGGC ATGACCGTTA 2100 AGCAGGCTGT CCTTTATAAT GCATTGTCAG CCATGCTGGC GTATCTTGGA ATGCCAACAG 2160
GAATTTTCAT TGGTCATTAT GCTGAAAATG TTTCTATGTG GATATTTGCA CTTACTGCTG 2220
GCTTATTCAT GTATGTTGCT CTGGTTGATA TGGTACCTGA AATGCTGCAC AATGATGCTA 2280 70 GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTGG 2340 GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTGG 2340 GTTTTGGAAT TATGTTACTT ATTTCCATAT TTGAACATAA AATCGTGTTT CGTATAAATT 2400 TCTAGTTAAG GTTTAAATGC TAGAGTAGCT TAAAAAGTTG TCATAGTTTC AGTAGGTCAT 2460 AGGGAGATGA GTTTGTATGC TGTACTATGC AGCGTTTAAAA GTTAGTGGGT TTTGTGATTT 2520 TTGTATTGAA TATTGCTGTC TGTTACAAAG TCAGTTAAAG GTACGTTTA ATATTTAAGT 2580 TATTCTATCT TGGAGATAAA ATCTGTATGT GCAATTCACC GGTATTACCA GTTTATTATG 2640 TAAACAAGAG ATTTGGCATG ACATGTTCTG TATGTTTCAG GGAAAAAATGT CTTTAATGCT 2700 75

TGTTTAGGAA TAAGAATGTG CATGAAGCCT AAAATACCAA GAAAGCTTAT ACTGAATTTA 2820 AGCAAAGAAA TAAAGGAGAA AAGAGAAGAA TCTGAGAATT GGGGAGGCAT AGATTCTTAT 2880 AAAAATCACA AAATTTGTTG TAAATTAGAG GGGAGAAATT TAGAATTAAG TATAAAAAGG 2940 5 CAGAATTAGT ATAGAGTACA TTCATTAAAC ATTTTTGTCA GGATTATTTC CCGTAAAAAC 3000 GTAGTGAGCA CTCTCATATA CTAATTAGTG TACATTTAAC TTTGTATAAT ACAGAAATCT 3060 AAATATATT AATGAATTCA AGCAATATAC ACTTGACCAA GAAATTGGAA TTTCAAAATG 3120
TTCGTGCGGG TTATATACCA GATGAGTACA GTGAGTAGTT TATGTATCAC CAGACTGGGT 3180 TATTGCCAAG TTATATATCA CCAAAAGCTG TATGACTGGA TGTTCTGGTT ACCTGGTTTA 3240 10 CAAAATTATC AGAGTAGTAA AACTTTGATA TATATGAGGA TATTAAAACT ACACTAAGTA 3300 TCATTTGATT CGATTCAGAA AGTACTTTGA TATCTCTCAG TGCTTCAGTG CTATCATTGT 3360 GAGCAATTGT CTTTATATAC GGTACTGTAG CCATACTAGG CCTGTCTGTG GCATTCTCTA 3420 GATGTTTCTT TTTTACACAA TAAATTCCTT ATATCAGCTT G Seq ID NO: 30 <u>Protein sequence:</u>
Protein Accession #: NP_036451.2 15 41 51 20 MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL 60 FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSDH 120 EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD 180 SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT 240 NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA 300 25 RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF 360 LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS 420 TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN 480 EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC 540 HSHFHDTLGQ SDDLIHHHHD YHHLLHHHHH QNHHPHSHSQ RYSRELKDA GVATLAWMVI 600 MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY 660 30 NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS 720 RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF Sea ID NO: 31 DNA sequence 35 Nucleic Acid Accession #: NM 002184.1 Coding sequence: 256-3012(underlined sequences correspond to start and stop codons) 40 GAGCAGCCAA AAGGCCCGCG GAGTCGCGCT GGGCCGCCCC GGCGCAGCTG AACCGGGGGC 60 CGCGCCTGCC AGGCCGACGG GTCTGGCCCA GCCTGGCGC AAGGGGTTCG TGCGCTGTGG 120 AGACGCGGAG GGTCGAGGCG GCGCGGCCTG AGTGAAACCC AATGGAAAAA GCATGACATT 180 TAGAAGTAGA AGACTTAGCT TCAAATCCCT ACTCCTTCAC TTACTAATTT TGTGATTTGG 240 AAATATCCGC GCAAGATGTT GACGTTGCAG ACTTGGGTAG TGCAAGCCTT GTTTATTTTC 300 45 CTCACCACTG AATCTACAGG TGAACTTCTA GATCCATGTG GTTATATCAG TCCTGAATCT 360 CCAGTTGTAC AACTTCATTC TAATTTCACT GCAGTTTGTG TGCTAAAGGA AAAATGTATG 420
GATTATTTC ATGTAAATGC TAATTACATT GTCTGGAAAA CAAACCATTT TACTATTCCT 480
AAGGAGCAAT ATACTATCAT AAACAGAACA GCATCCAGTG TCACCTTTAC AGATATAGCT 540
TCATTAAATA TTCAGCTCAC TTGCAACATT CTTACATTCG GACAGCTTGA ACAGAATGTT 600 50 TATGGAATCA CAATAATTTC AGGCTTGCCT CCAGAAAAAC CTAAAAATTT GAGTTGCATT 660 GTGAACGAGG GGAAGAAAT GAGGTGTGAG TGGGATGGTG GAAGGGAAAC ACACTTGGAG 720 ACAAACTTCA CTTTAAAATC TGAATGGGCA ACACACAAGT TTGCTGATTG CAAAGCAAAA 780 CGTGACACCC CCACCTCATG CACTGTTGAT TATTCTACTG TGTATTTTGT CAACATTGAA 840 GTCTGGGTAG AAGCAGAGAA TGCCCTTGGG AAGGTTACAT CAGATCATAT CAATTTTGAT 900 CCTGTATATA AAGTGAAGCC CAATCCGCCA CATAATTTAT CAGTGATCAA CTCAGAGGAA 960 CTGTCTAGTA TCTTAAAATT GACATGGACC AACCCAAGTA TTAAGAGTGT TATAATACTA 1020 55 AAATATAACA TTCAATATAG GACCAAAGAT GCCTCAACTT GGAGCCAGAT TCCTCCTGAA 1080 GACACAGCAT CCACCGATC TTCATTCACT GTCCAAGACC TTAAACCTTT TACAGAATAT 1140 GTGTTTAGGA TTCGCTGTAT GAAGGAAGAT GGTAAGGGAT ACTGGAGTGA CTGGAGTGAA 1200 60 GAAGCAAGTG GGATCACCTA TGAAGATAGA CCATCTAAAG CACCAAGTTT CTGGTATAAA 1260 ATAGATCCAT CCCATACTCA AGGCTACAGA ACTGTACAAC TCGTGTGGAA GACATTGCCT 1320 CCTTTTGAAG CCAATGGAAA AATCTTGGAT TATGAAGTGA CTCTCACAAG ATGGAAATCA 1380 CATTTACAAA ATTACACAGT TAATGCCACA AAACTGACAG TAAATCTCAC AAATGATCGC 1440 TATCTAGCAA CCCTAACAGT AAGAAATCTT GTTGGCAAAT CAGATGCAGC TGTTTTAACT 1500 65 ATCCCTGCCT GTGACTTTCA AGCTACTCAC CCTGTAATGG ATCTTAAAGC ATTCCCCAAA 1560 GATAACATGC TTTGGGTGGA ATGGACTACT CCAAGGGAAT CTGTAAAGAA ATATATACTT 1620 GAGTGGTGTG TGTTATCAGA TAAAGCACCC TGTATCACAG ACTGGCAACA AGAAGATGGT 1680
ACCGTGCATC GCACCTATTT AAGAGGGAAC TTAGCAGAGA GCAAATGCTA TTTGATAACA 1740
GTTACTCCAG TATATGCTGA TGGACCAGGA AGCCCTGAAT CCATAAAGGC ATACCTTAAA 1800
CAAGCTCCAC CTTCCAAAGG ACCTACTGTT CGGACAAAAA AAGTAGGGAA AAACGAAGCT 1860 70 GTCTTAGAGT GGGACCAACT TCCTGTTGAT GTTCAGAATG GATTTATCAG AAATTATACT 1920 ATATTTTATA GAACCATCAT TGGAAATGAA ACTGCTGTGA ATGTGGATTC TTCCCACACA 1980 GAATATACAT TGTCCTCTTT GACTAGTGAC ACATTGTACA TGGTACGAAT GGCAGCATAC 2040 ACAGATGAAG GTGGGAAGGA TGGTCCAGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 2100
GGAGAAATTG AAGCCATAGT CGTGCCTGTT TGCTTAGCAT TCCTATTGAC AACTCTTCTG 2160
GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA AACACATCTG GCCTAATGTT 2220
CCAGATCCTT CAAAGAGTCA TATTGCCCAG TGGTCACCTC ACACTCCTC AAGGCACAAT 2280

75

TTTTCAAGAA CTAACACAGT TATTCCTATA CTGGATTTTA GGTCTCTGAA GAACTGCTGG 2760

ATAGAAGCAA ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATCATTGGA CCTGTTCAAA 2400 AAGGAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC ATGCATGTCA 2460 TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT CTTCACAAAA CACTTCGAGC 2520 ACTGTCCAGT ATTCTACCGT GGTACACAGT GGCTACAGAC ACCAAGTTCC GTCAGTCCAA 2580 5 GTCTTCTCAA GATCCGAGTC TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT 2640 CTACAATTAG TAGATCATGT AGATGGCGGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 2700 AAACAGAACT GCAGTCAGCA TGAATCCAGT CCAGATATTT CACATTTTGA AAGGTCAAAG 2760 CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA AACAGCAGAT TTCAGATCAT 2820 10 ATTTCACAAT CCTGTGGATC TGGGCAAATG AAAATGTTTC AGGAAGTTTC TGCAGCAGAT 2880 GCTTTTGGTC CAGGTACTGA GGGACAAGTA GAAAGATTTG AAACAGTTGG CATGGAGGCT 2940 GCGACTGATG AAGGCATGCC TAAAAGTTAC TTACCACAGA CTGTACGGCA AGGCGGCTAC 3000 CTAAAATGAT TTTATCTGTG AATTC 15 Seq ID NO: 32 <u>Protein sequence:</u> Protein Accession #: NP_002175.1 21 31 20 MLTLQTWVVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDYFHV NANYIVWKTN HFTIPKEQYT IINRTASSVT FTDIASLNIQ LTCNILTFGQ LEQNVYGITI 120 ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT 180 SCTVDYSTVY FVNIEVWVEA ENALGKVTSD HINFDPVYKV KPNPPHNLSV INSEELSSIL 240 25 KLTWTNPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTVQDLK PFTEYVFRIR 300 CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360 GKILDYEVTL TRWKSHLQNY TVNATKLTVN LTNDRYLATL TVRNLVGKSD AAVLTIPACD 420 FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT 480 YLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD 540 30 QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG 600 KDGPEFTFTT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNVPDPSK 660 SHIAQWSPHT PPRHNFNSKD QMYSDGNFTD VSVVEIEAND KKPFPEDLKS LDLFKKEKIN 720 TEGHSSGIGG SSCMSSSRPS ISSSDENESS QNTSSTVQYS TVVHSGYRHQ VPSVQVFSRS 780 ESTQPLLDSE ERPEDLQLVD HVDGGDGILP RQQYFKQNCS QHESSPDISH FERSKQVSSV 840 35 NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG 900 MPKSYLPQTV RQGGYMPQ Seq ID NO: 33 DNA sequence Nucleic Acid Accession #: NM 018255.1 40 Coding sequence: 11-2491 (underlined sequences correspond to start and stop codons) AGTTGGCGAC ATGGTGGCAC CCGTGCTGGA GACTTCTCAC GTGTTTTGCT GCCCAAACCG 45 GGTGCGGGGA GTCCTGAACT GGAGCTCTGG GCCCAGAGGA CTTCTGGCCT TTGGCACGTC 120 CTGCTCCGTG GTGCTCTATG ACCCCCTGAA AAGGGTTGTT GTTACCAACT TGAATGGTCA 180 CACCGCCCGA GTCAATTGCA TACAGTGGAT TTGTAAACAG GATGGCTCCC CTTCTACTGA 240 ATTAGTTTCT GGAGGATCTG ATAATCAAGT GATTCACTGG GAAATAGAGG ATAATCAGCT 300 TTTAAAAGCA GTGCATCTTC AAGGCCATGA AGGACCTGTT TATGCGGTGC ATGCTGTTTA 360 50 CCAGAGGAGG ACATCAGATC CTGCATTATG TACACTGATC GTTTCTGCAG CTGCAGATTC 420 55 CTTTGGTAGA GATCTTTTCC TAGCAAGCTG TTCACAAGAT TGCCTGATAA GAATATGGAA 720 GCTGTATATA AAGTCAACAT CTTTAGAAAC TCAGGATGAC GATAACATAA GACTGAAAGA 780 AAATACTTTT ACCATAGAAA ATGAAAGTGT TAAAATAGCA TTTGCTGTTA CTCTGGAGAC 840 AGTGCTAGCC GGTCATGAAA ACTGGGTAAA TGCAGTTCAC TGGCAACCTG TGTTTTACAA 900 AGATGGTGTC CTACAGCAGC CAGTGAGATT ATTATCTGCT TCCATGGATA AAACCATGAT 960 TCTCTGGGCT CCAGATGAAG AGTCAGGAGT TTGGCTAGAA CAGGTTCGAG TAGGTGAAGT 1020 60 AGGTGGGAAT ACTTTGGGAT TTTATGATTG CCAGTTCAAT GAAGATGGCT CCATGATCAT 1080 TGCTCATGCT TTCCACGGAG CGTTGCACCT TTGGAAACAG AATACAGTTA ACCCAAGAGA 1140 GTGGACTCCA GAGATTGTCA TTTCAGGACA CTTTGATGGT GTCCAAGACC TAGTCTGGGA 1200 TCCAGAAGGA GAATTTATTA TCACTGTTGG TACTGATCAG ACAACTAGAC TTTTTGCTCC 1260 65 ATGGAAGAGA AAAGACCAAT CACAGGTGAC TTGGCATGAA ATTGCAAGGC CTCAGATACA 1320
TGGGTATGAC CTGAAATGTT TGGCAATGAT TAATCGGTTT CAGTTTGTAT CTGGAGCAGA 1380
TGAAAAAGTT CTTCGGGTTT TTTCTGCACC TCGGAATTTT GTGGAAAATT TTTGTGCCAT 1440
TACAGGACAA TCACTGAATC ATGTGCTCTG TAATCAAGAT AGTGATCTTC CAGAAGGAGC 1500 CACTGTCCCT GCATTGGGAT TATCAAATAA AGCTGTCTTT CAGGGAGATA TAGCTTCTCA 1560 70 GCCTTCTGAT GAAGAGGAGC TGTTAACTAG TACTGGTTTT GAGTATCAGC AGGTGGCCTT 1620 TCAGCCCTCC ATACTTACTG AGCCTCCCAC TGAGGATCAT CTTCTGCAGA ATACTTTGTG 1680 TCAGCCTCC ATACTTACTG AGCCTCCAC TGAGGATCAT CTTCTGCAGA ATACTTTGTG 1880 GCCTGAAGTT CAAAAACTAT ATGGGCACGG TTATGAAAAA TATTTGTGTTA CTTGTAACAG 1740 TTCAAAGACT CTGCTTGCCT CAGCTTGTAA GGCAGCTAAG AAAGAGCATG CAGCTATCAT 1800 TCTTTGGAAC ACTACATCTT GGAAACAGGT GCAGAATTTA GTTTTCCACA GTTTTGACAGT 1860 CACGCAGATG GCCTTCTCAC CTAATGAGAA GTTCTTACTA GCTGTTTCCA GAGATCGAAC 1920 75 CTGGTCATTG TGGAAAAAGC AGGATACAAT CTCACCTGAG TTCGAGCCAG TTTTTAGTCT 1980 TTTTGCCTTC ACCAACAAA TTACTTCTGT GCACAGTAGA ATTATTTGGT CTTGTGATTG 2040

TTTAATTCAA AAGATCAAAT GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA 2340

GAGTCCTGAC AGCAAGTATT TCTTCACTGG GAGTCGAGAC AAAAAGGTGG TTGTCTGGGG 2100
TGAGTGCGAC TCCACTGATG ACTGTATTGA GCAACAATT GGCCCCTGCT CCTCAGTCCT 2160
GGACGTGGGT GGGGCTGTGA CAGCTGTCAG CGTCTGCCA GTGCTCACC CTTCTCAACG 2220
ATACGTGGTT GCAGTAGGAT TGGAGTGTGG AAAGATTTGC TTATATACCT GGAAAAAGAC 2280
TGATCAAGTT CCAGAAATAA ATGACTGGAC CCACTGTGTA GAAACAAGTC AAAGCCAAAG 2340
TCATACACTG GCTATCAGAA AATTATGCTG GAAGAATTGC AGTGGAAAAA CTGAACAGAA 2400
GGAAGCAGAA GGTGCTGAGT GGTTACACTT TGCAAGCTGT GGTGAAGATC ACACTGTGAA 2460
GATACACAGA GTCAATAAAT GTGCACTG<u>TA</u>ATGG

Seq ID NO: 34 <u>Protein sequence:</u>
Protein Accession #: NP_060725.1

11

65

70

21

31

1 11 21 31 41 51

MVAPVLETSH VFCCPNRVRG VLNWSSGPRG LLAFGTSCSV VLYDPLKRVV VTNLNGHTAR 60 VNCIQWICKQ DGSPSTELVS GGSDNQVIHW EIEDNQLLKA VHLQGHEGPV YAVHAVYQRR 120 TSDPALCTLI VSAAADSAVR LWSKKGPEVM CLQTLNFGNG FALALCLSFL PNTDVPILAC 180 GNDDCRIHIF AQQNDQFQKV LSLCGHEDWI RGVEWAAFGR DLFLASCSQD CLIRIWKLYI 240 KSTSLETODD DNIRLKENTF TIENESVKIA FAVTLETVILA GHENWVNAVH WOPVFYKDGV 300

GNDDCRIHIF AQQNDQFQKV LSLCGHEDWI RGVEWAAFGR DLFLASCSQD CLIRIWKLYI 240

KSTSLETQDD DNIRLKENTF TIENESVKIA FAVTLETVLA GHENWVNAVH WQPVFYKDGV 300

LQQPVRLLSA SMDKTMILWA PDEESGVWLE QVRVGEVGGN TLGFYDCQFN EDGSMIIAHA 360
FHGALHLWKQ NTVNPREWTP EIVISGHFDG VQDLVWDPEG EFIITVGTDQ TTRLFAPWKR 420

KDQSQVTWHE IARPQIHGYD LKCLAMINRF QFVSGADEKV LRVFSAPRNF VENFCAITGQ 480
SLNHVLCNQD SDLPEGATVP ALGLSNKAVF QGDIASQPSD EEELLTSTGF EYQQVAFQPS 540

ILTEPPTEDH LLQNTLWPEV QKLYGHGYEI FCVTCNSSKT LLASACKAAK KEHAAIILWN 600

25 TTSWKQVQNL VFHSLTVTQM AFSPNEKFLL AVSRDRTWSL WKKQDTISPE FEPVFSLFAF 660
TNKITSVHSR IIWSCDWSPD SKYFFTGSRD KKVVVWGECD STDDCIEHNI GPCSSVLDVG 720
GAVTAVSVCP VLHPSQRYVV AVGLECGKIC LYTWKKTDQV PEINDWTHCV ETSQSQSHTL 780
AIRKLCWKNC SGKTEQKEAE GAEWLHFASC GEDHTVKIHR VNKCAL

Seq ID NO: 35 DNA sequence
Nucleic Acid Accession #: NM_022131

41

Coding sequence: 11-2878 (underlined sequences correspond to start and stop codons)

51

45

GAACAAGA ICAGAGAGAG GCGGCTCG TGCCAAGAGC CCCATGACT GAGTTGACT ACGAGTTACA ACGAGTTTGC 480

TCCCACCTTC AAAGAGCCAG CCTACAAGGC TGTTGTGACG GAGGGCAAGA TCTATGACAG 540

CATTCTGCAG GTGGAGGCCA TTGACCAGGACAC CTGCTCCCCA CAGTACAGCC AGATCTGCAA 660

CACTGAGAATC GTCACCACAG ATGTGCCTTT TGCCATCGAC AGAAATGGCA ACATCAGGAA 660

CACTGAGAAG CTGAGCTATG ACAAACAACA CCAGTATGAG ATCCTGGTGA CCGCCTACCGA 720

CTGTGGACAG AAGCCCGCTG CTCAGGACAC CCTGGTGCAG GTGGATGTGA AGCCAGTTTT 780

CAAGCCTGGC TGGCAAGACT GGACCAAGAG GATTGAGTAC CAGCCTGGCT CCGGGAGCAT 840
GCCCTGTTC CCCAGCATCC ACCTGGAGAC GTGCGATGGA GCCGTGTCTT CCCTCCAGAT 900
CGTCACAGAG CTGCAGACTA ATTACATTGG GAAGGGTTGT GACCGGGAGA CCTACTCTGA 960
GAAATCCCTT CAGAAGTTAT GTGGAGCCTC CTCTGGCATC ATTGACCTCT TGCCATCCCC 1020
TAGCGCTGCC ACCAACTGGA CTGCAGGAACT GCTGGTGGAC AGCAGTGAGA TGATCTTCAA 1840
GTTTGACGGC ACGCAAGGTG CCAAAATCCC CGATGGGATT GTGCCCAAGA ACCTGACCGA 1180

55
GTTTGACGGC AGGCAGGGTG CCAAAATCCC CGATGGGATT GTGCCCAAGA ACCTGACCGA 1140
TCAGTTCACC ATCACCATGT GGATGAAACA CGGCCCCAGC CCTGGTGTGA GAGCCGAGAA 1200
GGAAACCATC CTCTGCAACT CAGACAAAAC CGAAATGAAC CGGCATCACT ATGCCCTGTA 1260
TGTGCACAAC TGCCGCCTCG TCTTTCTCTT GCGGAAGGAC TTCGACCAGG CTGACACCTT 1320
TCGCCCCGCG GAGTTCCACT GGAAGCTGGA TCAGATTTGT GACAAAGAGT GGCACTACTA 1380
TGTCATCAAT GTGGAGTTTC CTGTGGTAAC CTTATACATG GATGGAGCAA CATATGAACC 1440
ATACCTGGTG ACCAACGACT GGCCCATTCA TCCATCTCAC ATAGCCATGC AACTCACAGT 1500

ATACCTGGTG ACCAACGACT GGCCCATTCA TCCATCTCAC ATAGCATGC AACTCACACGT 1500
CGGCGCTTGT TGGCAAGGAG GAGAAGTCAC CAAACCACAG TTTGCTCAGT TCTTTCATGG 1560
AAGCCTGGC AGTCTCACCA TCCGCCCTGG CAAAATGGAA AGCCAGAAGG TGATCTCCTG 1620
CCTGCAGGCC TGCAAGGAAG GGCTGGACAA TAATTCCTTG GAAAGCCTTG CCCAAGGAAT 1680

AAAGTATCAC TTCAACCCCT CGCAGTCCAT CCTGGTGATG GAAGGTGACG ACATTGGGAA 1740 CATTAACCGT GCTCTCCAGA AAGTCTCCTA CATCAACTCC AGGCAGTTCC CAACGGCGGG 1800 TGTGCGGCGC CTCAAAGTAT CCTCCAAAGT CCAGTGCTTT GGGAAGACG TATGCATCAG 1860 TATCCCTGAG GTAGATGCCT ATGTGATGGT CCTCCAGGCC ATCGAGCCCC GGATCACCCT 1920 CCGGGGCACA GACCACTTCT GGAGACCTC TGCCCAGTTT GAAAGTGCCA GGGGAGTGAC 1980

CCTCTTCCCT GATATCAAGA TTGTGAGCAC CTTCGCCAAA ACCGAAGCCC CCGGGGACGT 2040
GAAAACCACA GACCCCAAAT CAGAAGTCTT AGAGGAAATG CTTCATAACT TAGATTTCTG 2100
TGACATTTTG GTGATCGGAG GGGACTTGGA CCCAAGGCAG GAGTGCTTGG AGCTCAACCA 2160
CAGTGAGCTC CACCAACGAC ACCTGGATGC CACTAATTCT ACTGCAGGCT ACTCCATCTA 2220
CGGTGTGGGC TCCATGAGCC GCTATGAGCA GGTGCTACAT CACATCCGCT ACCGCAACTG 2280
GCGTCCGGCT TCCCTTGAGG CCCGGCGTTT CCGGATTAAG TGCTCAGAAC TCAATGGGCG 2340

75 CTACACTAGC AATGAGTTCA ACTTGGAGGT CAGCATCCTT CATGAAGACC AAGTCTCAGA 2400 TAAGGAGCAT GTCAATCATC TGATTGTGCA GCCTCCCTTC CTCCAGTCTG TCCATCATCC 2460 TGAGTCCCGG AGTAGCATCC AGCACAGTTC AGTGGTCCCA AGCATTGCCA CAGTGGTCAT 2520



CTGGGTTGGC ACTTGTTCAG ATTACCCAAA AGGAGATGCT TCTACTGGAT GGAATTCAGT 840 TTCTCGCATC ATTATTGAAG AACTACCAAA A<u>TAA</u>ATGCTT TAATTTTCAT TTGCTACCTC 900 TTTTTTTATT ATGCCTTGGA ATGGTTCACT TAAATGACAT TTTAAATAAG TTTATGTATA 960
CATCTGAATG AAAAGCAAAG CTAAATATGT TTACAGACCA AAGTGTGATT TCACACTGTT 1020
TTTAAATCTA GCATTATTCA TTTTGCTTCA ATCAAAAGTG GTTTCAATAT TTTTTTTAGT 1080
TGGTTAGAAT ACTTTCTTCA TAGTCACATT CTCTCAACCT ATAATTTGGA ATATTGTTGT 1140 5 GGTCTTTTGT TTTTTCTCTT AGTATAGCAT TTTTAAAAAA ATATAAAAGC TACCAATCTT 1200 10 TGTACAATTT GTAAATGTTA AGAATTTTTT TTATATCTGT TAAATAAAAA TTATTTCCAA 1260 CAACCTTAAA AAAAAAAAAA AAAA Seq ID NO: 38 Protein sequence: Protein Accession #: none found 15 MRPQGPAASP QRLRGLLLLL LLQLPAPSSA SEIPKGKQKA QLRQREVVDL YNGMCLQGPA 60 GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFEE SWTPNYKQCS WSSLNYGIDL 120 GKIAECTFTK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ 180 GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE 240 20 Seg ID NO: 39 DNA sequence 25 Nucleic Acid Accession #: NM_000949 285-2153(underlined sequences correspond to start and stop codons) Coding sequence: 31 30 CTCCCTCTTT CTGGATTTTA CCGACCGTTC GCGAAACAGC TTTCCACACA ATGGAGCTTC 120 ATGTCCTCGT GCAGGAAGTA CTCATCGACT GATGTGGCAG ACTTTGCTCC CTGACAAAAC 180 TAAAGAACTC TCCTATTCAT GGAGGCGAAC ACTGAGGATG CTTTCCACAT GAACCCTGAA 240
GTGAACTTCT GATACATTTC CTGCAGCAAG AGAAGGCAGC CACACATGAAG GAAAATGTGG 300
CATCTGCAAC CGTTTTCACT CTGCTACTTT TCTCAACAC CTGCCTTCTG AATGGACAGT 360
TACCTCCTGG AAAACCTGAG ATCTTTAAAT GTCGTTCTCC CAATAAGGAA ACATTCACCT 420 35 GCTGGTGGAG GCCTGGGACA GATGGAGGAC TTCCTACCAA TTATTCACTG ACTTACCACA 480 GGGAAGGAGA GACACTCATG CATGAATGTC CAGACTACAT AACCGGTGGC CCCAACTCCT 540 GCCACTTTGG CAAGCAGTAC ACCTCCATGT GGAGGACATA CATCATGATG GTCAATGCCA 600 40 CTAACCAGAT GGGAAGCAGT TTCTCGGATG AACTTTATGT GGACGTGACT TACATAGTTC 660 AGCCAGACCC TCCTTTGGAG CTGGCTGTGG AAGTAAAACA GCCAGAAGAC AGAAAACCCT 720
ACCTGTGGAT TAAATGGTCT CCACCTACCC TGATTGACTT AAAAACTGGT TGGTTCACGC 780
TCCTGTATGA AATTCGATTA AAACCCGAGA AAGCAGCTGA GTGGGAGATC CATTTTGCTG 840 GGCAGCAAAC AGAGTTTAAG ATTCTCAGCC TACATCCAGG ACAGAAATAC CTTGTCCAGG 900 45 TTCGCTGCAA ACCAGACCAT GGATACTGGA GTGCATGGAG TCCAGCGACC TTCATTCAGA 960 TACCTAGTGA CTTCACCATG AATGATACAA CCGTGTGGAT CTCTGTGGCT GTCCTTTCTG 1020 CTGTCATCTG TTTGATTATT GTCTGGGCAG TGGCTTTGAA GGGCTATAGC ATGGTGACCT 1080 GCATCTTTCC GCCAGTTCCT GGGCCAAAAA TAAAAGGATT TGATGCTCAT CTGTTGGAGA 1140 AGGGCAAGTC TGAAGAACTA CTGAGTGCCT TGGGATGCCA AGACTTTCCT CCCACTTCTG 1200 50 ACTATGAGGA CTTGCTGGTG GAGTATTTAG AAGTAGATGA TAGTGAGGAC CAGCATCTAA 1260 TGTCAGTCCA TTCAAAAGAA CACCCAAGTC AAGGTATGAA ACCCACATAC CTGGATCCTG 1320 ACACTGACTC AGGCCGGGGG AGCTGTGACA GCCCTTCCCT TTTGTCTGAA AAGTGTGAGG 1380 AACCCCAGGC CAATCCCTCC ACATTCTATG ATCCTGAGGT CATTGAGAAG CCAGAGAATC 1440 CTGAAACAAC CCACACCTGG GACCCCCAGT GCATAAGCAT GGAAGGCAAA ATCCCCTATT 1500
TTCATGCTGG TGGATCCAAA TGTTCAACAT GGCCCTTACC ACAGCCCAGC CAGCACAACC 1560
CCAGATCCTC TTACCACAAT ATTACTGATG TGTGTGAGCT GGCTGTGGGC CCTGCAGGTG 1620
CACCGGCCAC TCTGTTGAAT GAAGCAGGTA AAGATGCTTT AAAATCCTCT CAAACCATTA 1680 55

AGTCTAGAGA AGAGGGAAAG GCAACCCAGC AGAGGGAGGT AGAAAGCTTC CATTCTGAGA 1740 CTGACCAGGA TACGCCCTGG CTGCTGCCCC AGGAGAAAAC CCCCTTTGGC TCCGCTAAAC 1800

CCTTGGATTA TGTGGAGATT CACAAGGTCA ACAAAGATGG TGCATTATCA TTGCTACCAA 1860 AACAGAGAGA GAACAGCGGC AAGCCCAAGA AGCCCGGGAC TCCTGAGAAC AATAAGGAGT 1920 ATGCCAAGGT GTCCGGGGTC ATGGATAACA ACATCCTGGT GTTGGTGCCA GATCCACATG 1980 CTAAAAACGT GGCTTGCTTT GAAGAATCAG CCAAAGAGGC CCCACCATCA CTTGAACAGA 2040 ATCAAGCTGA GAAAGCCCTG GCCAACTTCA CTGCAACATC AAGCAAGTGC AGGCTCCAGC 2100

TGGGTGGTTT GGATTACCTG GATCCCGCAT GTTTTACACA CTCCTTTCAC <u>TGA</u>TAGCTTG 2160 ACTAATGGAA TGATTGGTTA AAATGTGATT TTTCTTCAGG TAACACTACA GAGTACGTGA 2220 AATGCTCAAG AATGTAGTCA GACTGACACT ACTAAAGCTC CCAGCTCCTT TCATGCTCCA 2280 TTTTTAACCA CTTGCCTCTT TCTCCAGCAG CTGATTCCAG AACAATCAT TATGTTTCCT 2340 AACTGTGATT TGTAGATTTA CTTTTTGCTG TTAGTTATAA AACTATGTGT TCAATGAAAT 2400 AAAAGCACAC TGCTTAGTAT TCTTGAGGGA CAATGCCAAT AGGTATATCC TCTGGAAAAG 2460

GCTTTCATGA TTTGGCATGG GACAGACGGA AATGAAATTG TCAAAATTGT TTACCATAGA 2520 AAGATGACAA AAGAAAATTT TCCACATAGG AAAATGCCAT GAAAATTGCT TTTGAAAAAC 2580 AACTGCATAA CCTTTACACT CCTCGTCCAT TTTATTAGGA TTACCCAAAT ATAACCATTT 2640 AAAGAAAGAA TGCATTCCAG AACAAATTGT TTACATAAGT TCCTATACCT TACTGACACA 2700

AGCTATAATT TATTTGGACC AAGGAAGCCC TGAAATGAAT TCAACAATTA ATATTCATCG 720 CACTTCTTCT GTGGAAGGAC TTTGTGAAGG AATTGGTGCT GGATTAGTGG ATGTTGCTAT 780


75 TTGCTGATAT GCAAGTAAGA AAT


Seq ID NO: 40 Protein sequence:

60

65

70







QDQAPDESPK LKSSSETSVH CTSYRGVPAS KPEPARAKAK LSKFSIPKQG EESRSGETNS 300
CVEEJIREMT WLPPLSAIQA PGKVEPTKFF FPNKDSQLVS SGHNNPKKGD AEPESPDNGT 360
SNTSMLEDDL KLSSDEENE QQAAQRTALR ALSDSAVVQQ PNCRTSVPSS KGSSSSSSG 420
TSSSSSDSES SSGSDSETES SSSESEGSKP PHFSSPEAEP ASSNKWQLDK WLNKVNPHKP 480
PILIQNESHG SESNQYYNPV KEDVQDCGKV PDVCQPSLRE KEIKSTCKEE QRPRTANKAP 540
GSKGVKQKSP PAAVAVAVSA AAPPPAVPCA PAENAPAPAR RSAGKKPTRR TERTSAGDGA 600
NCHRPEEPAA ADALGTSVVV PPEPTKTRPC GNNRASHRKE LRSSVTCEKR RTRGLSRIVP 660
KSKEFIETES SSSSSSSDSD LESEQEEYPL SKAQTVAASA SSGNDQRLKE AAANGGSGPR 720
APVGSINART TSDIAKELEE QFYTLVPFGR NELLSPLKDS DEIRSLWVKI DLTLLSRIPE 780
HLPQEPGYLS APATKDSESA PPSHTSDTPA EKALPKSKRK RKCDNEDDYR EIKKSQGEKD 840
SSSRLATSTS NTLSANHCNM NINSVAIPIN KNEKMLRSPI SPLSDASKHK YTSEDLTSSS 900
RPNGNSLFTS ASSSKKPKAD SQLQPHGGDL TKAAHNNSEN IPLHKSRPQT KPWSPGSNGH 960
RDCKRQKLVF DDMPRSADYF MQEAKRMKHK ADAMVEKFGK ALNYAEAALS FIECGNAMEQ 1020
GPMESKSPYY LMYSETVELI RYAMRLKTHS GPNATPEDKQ LAALCYRCLA LLYWRMFRLK 1080
RDHAVKYSKA LIDYFKNSSK AAQAPSPWGA SGKSTGTPSP ISPNPFPGSS VGSQGSLSNA 1140
SALSPSTIVS IPQRIHQMAA NHVSITNSIL HSYDYWEMAD NLAKENREFF NDLDLLMGPV 1200
TLHSSMEHLV QYSQQGLHWL RNSAHLS

ACTGGGATAA AGCAAGAAGA CTGATTTTAT GAGCAGGGGT TTGATACATC AAAGGAGATT

Seq ID NO: 47 DNA sequence
Nucleic Acid Accession #: NM_033151
Coding sequence: 351-4499(underlined sequences correspond to start and stop codons)

21


25

51

GCCCAGGATC AAGGGTGCGG TGTTGGGGGT GGGTTGGGGA GGGTGGTTAG AGAAGGTTTC ACTAAGTGAT TTGGGCCTGA GGCCTGAGAA GATGTTTAAA AAGAGGGATC AAGCACAGGC 180 TAAGGAGAG AAAGAGCAGG CACCCAAACC TCTGCATGGC CCCAATATGC TCCCTGCAGG 240 30 GTAGTGCCCC CTCTTCTGGC TGCTCAAGGC GAGATCTAAG CTTCTTCTAA CTCCTGCTGT 300 CTTTTCATAT TCTCTGATTC TGGGAAACGA AGAATTGGCA GGAACTGAAA <u>ATG</u>ACTAGGA 360 AGAGGACATA CTGGGTGCCC AACTCTTCTG GTGGCCTCGT GAATCGTGGC ATCGACATAG 420 GCGATGACAT GGTTTCAGGA CTTATTTATA AAACCTATAC TCTCCAAGAT GGCCCCTGGA 480 GTCAGCAAGA GAGAAATCCT GAGGCTCCAG GGAGGGCAGC TGTCCCACCG TGGGGGAAGT 540 35 ATGATGCTGC CTTGAGAACC ATGATTCCCT TCCGTCCCAA GCCGAGGTTT CCTGCCCCCC 600 AGCCCTGGA CAATGCTGGC CTGTTCTCCT ACCTCACCGT GTCATGGCTC ACCCCGCTCA 660 TGATCCAAAG CTTACGGAGT CGCTTAGATG AGAACACCAT CCCTCCACTG TCAGTCCATG 720 ATGCCTCAGA CAAAAATGTC CAAAGGCTTC ACCGCCTTTG GGAAGAAGAA GTCTCAAGGC 780 GAGGGATTGA AAAAGCTTCA GTGCTTCTGG TGATGCTGAG GTTCCAGAGA ACAAGGTTGA 840 40 TTTTCGATGC ACTTCTGGGC ATCTGCTTCT GCATTGCCAG TGTACTCGGG CCAATATTGA 900 TTATACCAAA GATCCTGGAA TATTCAGAAG AGCAGTTGGG GAATGTTGTC CATGGAGTGG 960 GACTCTGCTT TGCCCTTTTT CTCTCCGAAT GTGTGAAGTC TCTGAGTTTC TCCTCCAGTT 1020 GGATCATCAA CCAACGCACA GCCATCAGGT TCCGAGCAGC TGTTTCCTCC TTTGCCTTTG 1080 AGAAGCTCAT CCAACTTAAG TCTGTAATAC ACATCACCTC AGGAGAGGCC ATCAGCTTCT 1140
TCACCGGTGA TGTAAACTAC CTGTTTGAAG GGGTGTGCTA TGGACCCCTA GTACTGATCA 1200
CCTGCGCATC GCTGGTCATC TGCAGCATTT CTTCCTACTT CATTATTGGA TACACTGCAT 1260
TTATTGCCAT CTTATGCTAT CTCCTGGTTT TCCCACTGGC GGTATTCATG ACAAGAATGG 1320 45 CTGTGAAGGC TCAGCATCAC ACATCTGAGG TCAGCGACCA GCGCATCCGT GTGACCAGTG 1380 AAGTTCTCAC TTGCATTAAG CTGATTAAAA TGTACACATG GGAGAAACCA TTTGCAAAAA 1440 50 TCATTGAAGA CCTAAGAAGG AAGGAAAGGA AACTATTGGA GAAGTGCGGG CTTGTCCAGA 1500 GCCTGACAAG TATAACCTTG TTCATCATCC CCACAGTGGC CACAGCGGTC TGGGTTCTCAA 1560
TCCACACATC CTTAAAGCTG AAACTCACAG CGTCAATGGC CTTCACGCATG CTGGCCTCCT 1620
TGAATCTCCT TCGGCTGTCA GTGTTCTTTG TGCCTATTGC AGTCAAAGGT CTCACGAATT 1680
CCAAGTCTGC AGTGATGAGG TTCAAGAAGT TTTTCCTCCA GGAGAGCCCT GTTTTCTATG 1740
TCCAGACATT ACAAGACCCC AGCAAAGCTC TGGTCTTTGA GGAGGCCACC TTGTCATGGC 1800 55 AACAGACCTG TCCCGGGATC GTCAATGGGG CACTGGAGCT GGAGAGGAAC GGGCATGCTT 1860 CTGAGGGAT GACCAGGCT AGAGATGCCC TCGGGCCAGA GGAAGAAGGGG AACAGCCTGG 1920
GCCAGAGTT GCACAAGATC AACCTGGTGG TGTCCAAGGG GATGATGTTA GGGGTCTGCG 1980
GCAACACGGG GAGTGGTAAG AGCAGCCTGT TGTCAGCCAT CCTGGAGGAG ATGCACTTGC 2040
TCGAGGGCTC GGTGGGGGTG CAGGGAAGCC TGGCCTATGT CCCCCAGCAG GCCTGGATCG 2100
TCAGCGGGAA CATCAGGGAG AACATCCTCA TGGGAGGCGC ATATGACAAG GCCCGATACC 2160 60 TCCAGGTGCT CCACTGCTGC TCCCTGAATC GGGACCTGGA ACTTCTGCCC TTTGGAGACA 2220 TGACAGAGAT TGGAGAGCGG GGCCTCAACC TCTCTGGGGG GCAGAAACAG AGGATCAGCC 2280 TGGCCGCGC CGTCTATTCC GACCGTCAGA TCTACCTGCT GGACGACCCC CTGTCTGCTG 2340
TGGACGCCCA CGTGGGGAAG CACATTTTTG AGGAGTGCAT TAAGAAGACA CTCAGGGGGA 2400
AGACGGTCGT CCTGGTGACC CACCAGCTGC AGTACTTAGA ATTTTGTGGC CAGATCATTT 2460
TGTTGGAAAA TGGGAAAATC TGTGAAAATG GAACTCACAG TGAGTTAATG CAGAAAAAGG 2520 65 GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTTCGGAC ATGTTGCAGG 2580 GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTICGGAC ATGTIGCAGG 2580
ACACAGCAAA GATAGCAGAG AAGCCAAAGG TAGAAAGTCA GGCTCCTGGCC ACCTCCCTGG 2640
AAGAGGTCTCT CAACGGAAAT GCTGTGCCGG AGCATCAGCT CACACAGGAG GAGGAGATGG 2700
AAGAAGGCTC CTTGAGTTGG AGGGTCTACC ACCACTACAT CCAGGCAGCT GGAGGTTACA 2760
TGGTCTCTTG CATAATTTTC TTCTTCGTGG TGCTGATCGT CTTCTTAACG ATCTTCAGCT 2820
TCTGGTGGCT GAGCTACTGG TTGGAGCAGG GCTCGGGGAC CAATAGCAGC CGAGAGAGCA 2880
ATGGAACCAT GGCAGACCTG GGCAACATTG CAGACAATCC TCAACTGTCC TCTTACCAGC 2940 70 75 TGGTGTACGG GCTCAACGCC CTGCTCCTCA TCTGTGTGGG GGTCTGCTCC TCAGGGATTT 3000 TCACCAAAGT CACGAGGAAG GCATCCACGG CCCTGCACAA CAAGCTCTTC AACAAGGTTT 3060


TCCGCTGCCC CATGAGTTTC TTTGACACCA TCCCAATAGG CCGGCTTTTG AACTGCTTCG 3120

CAGGGGACTT GGAACAGCTG GACCAGCTCT TGCCCATCTT TTCAGAGCAG TTCCTGGTCC 3180 TGTCCTTAAT GGTGATCGCC GTCCTGTTGA TTGTCAGTGT GCTGTCTCCA TATATCCTGT 3240 TAATGGGAGC CATAATCATG GTTATTTGCT TCATTTATTA TATGATGTTC AAGAAGGCCA 3300 TCGGTGTGTT CAAGAGACTG GAGAACTATA GCCGGTCTCC TTTATTCTCC CACATCCTCA 3360 5 ATTCTCTGCA AGGCCTGAGC TCCATCCATG TCTATGGAAA AACTGAAGAC TTCATCAGCC 3420 AGTTTAAGAG GCTGACTGAT GCGCAGAATA ACTACCTGCT GTTGTTTCTA TCTTCCACAC 3480 GATGGATGGC ATTGAGGCTG GAGATCATGA CCAACCTTGT GACCTTGGCT GTTGCCCTGT 3540 TCGTGGCTTT TGGCATTTCC TCCACCCCCT ACTCCTTTAA AGTCATGGCT GTCAACATCG 3600 TGCTGCAGCT GGCGTCCAGC TTCCAGGCCA CTGCCCGGAT TGGCTTGGAG ACAGAGGCAC 3660 AGTTCACGGC TGTAGAGAGG ATACTGCAGT ACATGAAGAT GTGTGTCTCG GAAGCTCCTT 3720 10 TACACATGGA AGGCACAAGT TGTCCCCAGG GGTGGCCACA GCATGGGGAA ATCATATTTC 3780 AGGATTATCA CATGAAATAC AGAGACAACA CACCCACCGT GCTTCACGGC ATCAACCTGA 3840 CCATCCGCGG CCACGAAGTG GTGGGCATCG TGGGAAGGAC GGGCTCTGGG AAGTCCTCCT 3900 TGGGCATGGC TCTCTTCCGC CTGGTGGAGC CCATGGCAGG CCGGATTCTC ATTGACGGCG 3960 TGGACATTTG CAGCATCGGC CTGGAGGACT TGCGGTCCAA GCTCTCAGTG ATCCCTCAAG 4020 ATCCAGTGCT GCTCTCAGGA ACCATCAGAT TCAACCTAGA TCCCTTTGAC CGTCACACTG 4080 15 ACCAGCAGAT CTGGGATGCC TTGGAGAGGA CATTCCTGAC CAAGGCCATC TCAAAGTTCC 4140 CCAAAAAGCT GCATACAGAT GTGGTGGAAA ACGGTGGAAA CTTCTCTGTG GGGGAGAGGC 4200 AGCTGCTCTG CATTGCCAGG GCTGTGCTTC GCAACTCCAA GATCATCCTT ATCGATGAAG 4260 20 CCACAGCCTC CATTGACATG GAGACAGACA CCCTGATCCA GCGCACAATC CGTGAAGCCT 4320 TCCAGGGCTG CACCGTGCTC GTCATTGCCC ACCGTGTCAC CACTGTGCTG AACTGTGACC 4380 ACATCCTGGT TATGGGCAAT GGGAAGGTGG TAGAATTTGA TCGGCCGGAG GTACTGCGGA 4440 AGAAGCCTGG GTCATTGTTC GCAGCCCTCA TGGCCACAGC CACTTCTTCA CTGAGA<u>TAA</u>G 4500 GAGATGTGGA GACTTCATGG AGGCTGGCAG CTGAGCTCAG AGGTTCACAC AGGTGCAGCT 4560 25 TCGAGGCCCA CAGTCTGCGA CCTTCTTGTT TGGAGATGAG AACTTCTCCT GGAAGCAGGG 4620 GTAAATGTAG GGGGGGTGGG GATTGCTGGA TGGAAACCCT GGAATAGGCT ACTTGATGGC 4680 TCTCAAGACC TTAGAACCCC AGAACCATCT AAGACATGGG ATTCAGTGAT CATGTGGTTC 4740 TCCTTTTAAC TTACATGCTG AATAATTTTA TAATAAGGTA AAAGCTTATA GTTTTCTGAT 4800 CTGTGTTAGA AGTGTTGCAA ATGCTGTACT GACTTTGTAA AATATAAAAC TAAGGAAAAC 4860 30 Seq ID NO: 48 <u>Protein sequence:</u> Protein Accession #: NP_149163.2 35 $MTRKRTYWVPNSSGGLVNRGIDIGDDMVSGLIYKTYTLQDGPWSQQERNPEAPGRAAVPPWGKYDAALRT\\ MIPFRPKPRFPAPQPLDNAGLFSYLTVSWLTPLMIQSLRSRLDENTIPPLSVHDASDKNVQRLHRLWEEE\\ VSRRGIEKASVLLVMLRFQRTRLIFDALLGICFCIASVLGPILIIPKILEYSEEQLGNVVHGVGLCFALF$ LSECVKSLSFSSSWIINORTAIRFRAAVSSFAFEKLIOFKSVIHITSGEAISFFTGDVNYLFEGVCYGPL VLITCASLVICSISSYFIIGYTAFIAILCYLLVFPLAVFMTRMAVKAQHHTSEVSDQRIRVTSEVLTCIK 40 LIKMYTWEKPFAKIIEDLRRKERKLLEKCGLVQSLTSITLFIIPTVATAVWVLIHTSLKLKLTASMAFSM LASINLLRLSVFFVPIAVKGLTNSKSAVMRFKKFFLQESPVFYVQTLQDPSKALVFEEATLSWQQTCPGI VNGALELERNGHASEGMTRPRDALGPEEGNSLGPELHKINLVVSKGMMLGVCGNTGSGKSSLLSAILEE MHLLEGSVGVQGSLAYVPQQAWIVSGNIRENILMGGAYDKARYLQVLHCCSLNRDLELLPFGDMTEIGER GLNLSGGQKQRISLARAVYSDRQIYLLDDPLSAVDAHVGKHIFEECIKKTLRGKTVVLVTHQLQYLEFCG 45 OIILLENGKICENGTHSELMOKKGKYAQLIOKMHKEATSDMLQDTAKIAEKPKVESQALATSLEESLNGN AVPEHOLTOEEEMEEGSLSWRVYHHYIQAAGGYMVSCIIFFFVVLIVFLTIFSFWWLSYWLEQGSGTNSS RESNGTMADLGNIADNPQLSFYQLVYGLNALLLICVGVCSSGIFTKVTRKASTALHNKLFNKVFRCPMSF FDTIPIGRLLNCFAGDLEQLDQLLPIFSEQFLVLSLMVIAVLLIVSVLSPYILLMGAIIMVICFIYYMMF KKAIGVFKRLENYSRSPLFSHILNSLQGLSSHVYGKTEDFISQFKRLTDAQNNYLLLFLSSTRWMALRL EIMTNLVTLAVALFVAFGISSTPYSFKVMAVNIVLQLASSFQATARIGLETEAQFFAVERILQYMKMCVS EAPLHMEGTSCPQGWPQHGEIIFQDYHMKYRDNTPTVLHGINLTIRGHEVVGIVGRTGSGKSSLGMALFR LVEPMAGRILIDGVDICSIGLEDLRSKLSVIPQDPVLLSGTIRFNLDPFDRHTDQQIWDALERTFLTKAI 50 SKFPKKLHTDVVENGGNFSVGERQLLCIARAVLRNSKIILIDEATASIDMETDTLIQRTIREAFQGCTVL VIAHRVTTVLNCDHILVMGNGKVVEFDRPEVLRKKPGSLFAALMATATSSLR 55 Seq ID NO: 49 DNA sequence Nucleic Acid Accession #: NM 033419 18-980 (underlined sequences correspond to start and stop codons) Coding sequence: 60 41 11 31 CGAGCCAGGG AGAAAGG<u>ATG</u> GCCGGCCTGG CGGCGCGGTT GGTCCTGCTA GCTGGGGCAG 60 CGGCGCTGGC GAGCGGCTCC CAGGGCGACC GTGAGCCGGT GTACCGCGAC TGCGTACTGC 120
AGTGCGAAGA GCAGAACTGC TCTGGGGGCG CTCTGAATCA CTTCCGCTCC CGCCAGCCAA 180
TCTACATGAG TCTAGCAGGC TGGACCTGTC GGGACGACTG TAAGTATGAG TGTATGTGGG 240
TCACCGTTGG GCTCTACCTC CAGGAAGGTC ACAAAGTGCC TCAGTTCCAT GGCAAGTGGC 300 65 CCTTCTCCCG GTTCCTGTTC TTTCAAGAGC CGGCATCGGC CGTGGCCTCG TTTCTCAATG 360 GCCTGGCCAG CCTGGTGATG CTCTGCCGCT ACCGCACCTT CGTGCCAGCC TCCTCCCCCA TGTACCACAC CTGTGTGGCC TCGCCTGGG TGTCCCTCAA TGCATGGTTC TGGTCCACAG 480
TTTTCCACAC CAGGGACACT GACCTCACAG AGAAAATGGA CTACTTCTGT GCCTCACTG 540
TCATCCTACA CTCAATCTAC CTGTGCTGCG TCAGGACCGT GGGGCTGCAG CACCCAGCTG 600
TGGTCAGTGC CTTCCGGGCT CTCCTGCTGC TCATGCTGAC CGTGCACGTC TCCTACCTGA 660 70 GCCTCATCCG CTTCGACTAT GGCTACAACC TGGTGGCCAA CGTGGCTATT GGCCTGGTCA 720 ACGTGGTGTG GTGGCTGGCC TGGTGCCTGT GGAACCAGCG GCGGCTGCCT CACGTGCGCA 75 AGTGCGTGGT GGTGGTCTTG CTGCTGCAGG GGCTGTCCCT GCTCGAGCTG CTTGACTTCC 840 CACCGCTCTT CTGGGTCCTG GATGCCCATG CCATCTGGCA CATCAGCACC ATCCCTGTCC 900 ACGTCCTCTT TTTCAGCTTT CTGGAAGATG ACAGCCTGTA CCTGCTGAAG GAATCAGAGG 960






Seq ID NO: 53 DNA sequence




Coding sequence: 1-1362(underlined sequences correspond to start and stop codons) 51


31



AAAATCTTTC TGAAAGAAGT AAATGATACA CTTCTGGTGA ATGAATTGAA ATCAAAAGAA 1860 TCTGACATCA TGACAACAAA TGGTGTAATT CATGTTGTAG ATAAACTCCT CTATCCAGCA 1920 GACACACCTG TTGGAAATGA TCAACTGCTG GAAATACTTA ATAAATTAAT CAAATACATC 1980 5 CAAATTAAGT TTGTTCGTGG TAGCACCTTC AAAGAAATCC CCGTGACTGT CTATACAACT 2040 AAAATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TTGAAGGCAG TCTTCAGCCT 2100 ATTATCAAAA CTGAAGGACC CACACTAACA AAAGTCAAAA TTGAAGGTGA ACCTGAATTC 2160 AGACTGATTA AAGAAGGTGA AACAATAACT GAAGTGATCC ATGGAGAGCC AATTATTAAA 2220 AAATACACCA AAATCATTGA TGGAGTGCCT GTGGAAATAA CTGAAAAAGA GACACGAGAA 2280 10 GAACGAATCA TTACAGGTCC TGAAATAAAA TACACTAGGA TTTCTACTGG AGGTGGAGAA 2340 ACAGAAGAAA CTCTGAAGAA ATTGTTACAA GAAGAGGTCA CCAAGGTCAC CAAATTCATT 2400 GAAGGTGGTG ATGGTCATTT ATTTGAAGAT GAAGAAATTA AAAGACTGCT TCAGGGAGAC 2460 ACACCCGTGA GGAAGTTGCA AGCCAACAAA AAAGTTCAAG GTTCTAGAAG ACGATTAAGG 2520 GAAGGTCGTT CTCAG<u>TGA</u>AA ATCCAAAAAC CAGAAAAAAA TGTTTATACA ACCCTAAGTC 2580 AATAACCTGA CCTTAGAAAA TTGTGAGAGC CAAGTTGACT TCAGGAACTG AAACATCAGC 2640 15 ACAAAGAAGC AATCATCAAA TAATTCTGAA CACAAATTTA ATATTTTTTT TTCTGAATGA 2700 GAAACATGAG GGAAATTGTG GAGTTAGCCT CCTGTGGTAA AGGAATTGAA GAAAATATAA 2760 CACCTTACAC CCTTTTTCAT CTTGACATTA AAAGTTCTGG CTAACTTTGG AATCCATTAG 2820 AGAAAAATCC TTGTCACCAG ATTCATTACA ATTCAAATCG AAGAGTTGTG AACTGTTATC 2880 20 CCATTGAAAA GACCGAGCCT TGTATGTATG TTATGGATAC ATAAAATGCA CGCAAGCCAT 2940 TATCTCTCCA TGGGAAGCTA AGTTATAAAA ATAGGTGCTT GGTGTACAAA ACTTTTTATA 3000 TCAAAAGGCT TTGCACATTT CTATATGAGT GGGTTTACTG GTAAATTATG TTATTTTTTA 3060 CAACTAATTT TGTACTCTCA GAATGTTTGT CATATGCTTC TTGCAATGCA TATTTTTTAA 3120 TCTCAAACGT TTCAATAAAA CCATTTTTCA GATATAAAGA GAATTACTTC AAATTGAGTA 3180 25 ATTCAGAAAA ACTCAAGATT TAAGTTAAAA AGTGGTTTGG ACTTGGGAA Seq ID NO: 62 <u>Protein sequence:</u>
Protein Accession #: NP_006466 30 MIPFLPMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL GTKKKYFSTC 60 KNWYKKSICG QKTTVLYECC PGYMRMEGMK GCPAVLPIDH VYGTLGIVGA TTTQRYSDAS 120 KLREEIEGKG SFTYFAPSNE AWDNLDSDIR RGLESNVNVE LLNALHSHMI NKRMLTKDLK 180 NGMIIPSMYN NLGLFINHYP NGVVTVNCAR IIHGNQIATN GVVHVIDRVL TQIGTSIQDF 240 IEAEDDLSSF RAAAITSDIL EALGRDGHFT LFAPTNEAFE KLPRGVLERF MGDKVASEAL 300 35 MKYHILNTLQ CSESIMGGAV FETLEGNTIE IGCDGDSITV NGIKMVNKKD IVTNNGVIHL 360 IDQVLIPDSA KQVIELAGKQ QTTFTDLVAQ LGLASALRPD GEYTLLAPVN NAFSDDTLSM 420 VQRLLKLILQ NHILKVKVGL NELYNGQILE TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG 480 40 RNGAIHIFRE IIKPAEKSLH EKLKQDKRFS TFLSLLEAAD LKELLTQPGD WTLFVPTNDA 540 FKGMTSEEKE ILIRDKNALQ NIILYHLTPG VFIGKGFEPG VTNILKTTQG SKIFLKEVND 600 TLLVNELKSK ESDIMTTNGV IHVVDKLLYP ADTPVGNDQL LEILNKLIKY IQIKFVRGST 660 FKEIPVTVYT TKIITKVVEP KIKVIEGSLQ PIIKTEGPTL TKVKIEGEPE FRLIKEGETI 720 TEVIHGEPII KKYTKIIDGV PVEITEKETR EERIITGPEI KYTRISTGGG ETEETLKKLL 780 45 QEEVTKVTKF IEGGDGHLFE DEEIKRLLQG DTPVRKLQAN KKVQGSRRRL REGRSQ Seq ID NO: 63 DNA sequence Nucleic Acid Accession #: NM 020974 Coding sequence: 81-3080 (underlined sequences correspond to start and stop codons) 50 11 31 41 GGCGTCCGCG CACACCTCCC CGCGCCGCCG CCGCCACCGC CCGCACTCCG CCGCCTCTGC 60 CCGCAACCGC TGAGCCATCC ATGGGGGTCG CGGGCCGCAA CCGTCCCGGG GCGCCCTGGG 120 CGGTGCTGCT GCTGCTGCTG CTGCTGCCGC CACTGCTGCT GCTGCGGGG GCGCCTCCCGC 180 CGGGTCGGGG CCGTGCCGC GGGCCGCAGG AGGATGTAGA TGAGTGTGCC CAAGGGCTAG 240 ATGACTGCCA TGCCGACGCC CTGTGTCAGA ACACACCCAC CTCCTACAAG TGCTCCTGCA 300 55 AGCCTGGCTA CCAAGGGGAA GGCAGGCAGT GTGAGGACAT CGATGAATGT GGAAATGAGC 360 TCAATGGAGG CTGTGTCCAT GACTGTTTGA ATATTCCAGG CAATTATCGT TGCACTTGTT 420 60 TTGATGGCTT CATGTTGGCT CATGACGGTC ATAATTGTCT TGATGTGGAC GAGTGCCTGG 480 AGAACAATGG CGGCTGCCAG CATACCTGTG TCAACGTCAT GGGGAGCTAT GAGTGCTGCT 540 GCAAGGAGGG GTTTTTCCTG AGTGACAATC AGCACACCTG CATTCACCGC TCGGAAGAGG 600 GCCTGAGCTG CATGAATAAG GATCACGGCT GTAGTCACAT CTGCAAGGAG GCCCCAAGGG 660 GCAGCGTCGC CTGTGAGTGC AGGCCTGGTT TTGAGCTGGC CAAGAACCAG AGAGACTGCA 65 TCTTGACCTG TAACCATGGG AACGGTGGGT GCCAGCACTC CTGTGACGAT ACAGCCGATG 780 GCCCAGAGTG CAGCTGCCAT CCACAGTACA AGATGCACAC AGATGGGAGG AGCTGCCTTG 840 AGCGAGAGGA CACTGTCCTG GAGGTGACAG AGAGCAACAC CACATCAGTG GTGGATGGGG 900 ATAAACGGGT GAAACGCCGC CTGCTCATGG AAACGTGTGC TGTCAACAAT GGAGGCTGTG 960 ACCGCACCTG TAAGGATACT TCGACAGGTG TCCACTGCAG TTGTCCTGTT GGATTCACTC 1020 TCCAGTTGGA TGGGAAGACA TGTAAAGATA TTGATGAGTG CCAGACCCGC AATGGAGGTT 1080 70 GTGATCATTT CTGCAAAAAC ATCGTGGGCA GTTTTGACTG CGGCTGCAAG AAAGGATTTA 1140 AATTATTAAC AGATGAGAAG TCTTGCCAAG ATGTGGATGA GTGCTCTTTG GATAGGACCT 1200 GTGACCACAG CTGCATCAAC CACCCTGGCA CATTTGCTTG TGCTTGCAAC CGAGGGTACA 1260
CCCTGTATGG CTTCACCCAC TGTGGAGACA CCAATGAGTG CAGCATCAAC AACGGAGGCT 1320
GTCAGCAGGT CTGTGTGAAC ACAGTGGGCA GCTATGAATG CCAGTGCCAC CCTGGGTACA 1380 75 AGCTCCACTG GAATAAAAAA GACTGTGTGG AAGTGAAGGG GCTCCTGCCC ACAAGTGTGT 1440 CACCCGTGT GTCCCTGCAC TGCGGTAAGA GTGGTGGAGG AGACGGGTGC TTCCTCAGAT 1500

TTCATTGGAA AAGGATTTGA ACCTGGTGTT ACTAACATTT TAAAGACCAC ACAAGGAAGC 1800






AGAGTGATGC TGCAGAACTA AATCATAAGG AGGAACATAG CTTGCATGTT CAAGATCCAT 840 CTTCTAGCAG TAAGAAGGAC TTGAAAAGCG CAGTTCTGAG TGAGAAGGCT GGCTTCAATT ATGAAAGCCC CAGTAAGGGA GGAAACTTTC CCTCCTTTCC GCATGATGAG GTGACAGACA GAAATATGTT GGCTTTCTCA TTTCCAGCTG CTGGGGGAGT CTGTGAGCCC TTGAAGTCTC 1020 5 CGCAAAGAGC AGAGGCAGAT GACCCTCAAG ATATGGCCTG CACCCCCTCA GGGGACTCAC 1080 TGGAGACAAA GGAAGATCAG AAGATGTCAC CAAAGGCTAC AGAGGAAACA GGGCAAGCAC 1140
AGAGTGGTCA AGCCAATTGT CAAGGTTTGA GCCCAGTTTC AGTGGCCTCA AAAAACCCAC 1200
AAGTGCCTTC AGATGGGGGT GTAAGACTGA ATAAATCCAA AACTGACTTA CTGGTGAATG 1260
ACAACCCAGA CCCGGCACCT CTGTCTCCAG AGCTTCAGGA CTTTAAATGC AATATCTGTG 1320 10 GATATGGTTA CTACGGCAAC GACCCCACAG ATCTGATTAA GCACTTCCGA AAGTATCACT 1380 TAGGACTGCA TAACCGCACC AGGCAAGATG CTGAGCTGGA CAGCAAAATC TTGGCCCTTC 1440 ATAACATGGT GCAGTTCAGC CATTCCAAAG ACTTCCAGAA GGTCAACCGT TCTGTGTTTT 1500 CTGGTGTGCT GCAGGACATC AATTCTTCAA GGCCTGTTTT ACTAAATGGG ACCTATGATG 1560 TGCAGGTGAC TTCAGGTGGA ACATTCATTG GCATTGGACG GAAAACACCA GATTGCCAAG 1620 GGAACACCAA GTATTTCCGC TGTAAATTCT GCAATTTCAC TTATATGGGC AACTCATCCA 1680 CCGAATTAGA ACAACATTTT CTTCAGACTC ACCCAAACAA AATAAAAGCT TCTCTCCCCT 1740 15 CCTCTGAGGT TGCAAAACCT TCAGAGAAAA ACTCTAACAA GTCCATCCCT GCACTTCAAT 1800 CCAGTGATTC TGGAGACTTG GGAAAATGGC AGGACAAGAT AACAGTCAAA GCAGGAGATG 1860 ACACTCCTGT TGGGTACTCA GTGCCCATAA AGCCCCTCGA TTCCTCTAGA CAAAATGGTA 1920 20 CAGAGGCCAC CAGTTACTAC TGGTGTAAAT TTTGTAGTTT CAGCTGTGAG TCATCTAGCT 1980 CACTTAAACT GCTAGAACAT TATGGCAAGC AGCACGGAGC AGTGCAGTCA GGCGGCCTTA 2040 ATCCAGAGTT AAATGATAAG CTTTCCAGGG GCTCTGTCAT TAATCAGAAT GATCTAGCCA 2100 AAAGTTCAGA AGGAGAGACA ATGACCAAGA CAGACAAGAG CTCGAGTGGG GCTAAAAAGA 2160 AGGACTTCTC CAGCAAGGGA GCCGAGGATA ATATGGTAAC GAGCTATAAT TGTCAGTTCT 2220 25 GTGACTTCCG ATATTCCAAA AGCCATGGCC CTGATGTAAT TGTAGTGGGG CCACTTCTCC 2280 GTCATTATCA ACAGCTCCAT AACATTCACA AGTGTACCAT TAAACACTGT CCATTCTGTC 2340 CCAGAGGACT TTGCAGCCCA GAAAAGCACC TTGGAGAAAT TACTTATCCG TTTGCTTGTA 2400 GAAAAAGTAA TTGTTCCCAC TGTGCACTCT TGCTTCTGCA CTTGTCTCCT GGGGCGGCTG 2460 GAAGCTCGCG AGTCAAACAT CAGTGCCATC AGTGTTCATT CACCACCCCT GACGTAGATG 2520 TACTCCTCTT TCACTATGAA AGTGTGCATG AGTCCCAAGC ATCGGATGTC AAACAAGAAG 2580 30 CAAATCACCT GCAAGGATCG GATGGGCAGC AGTCTGTCAA GGAAAGCAAA GAACACTCAT 2640 GTACCAAATG TGATTTTATT ACCCAAGTGG AAGAAGAGAT TTCCCGACAC TACAGGAGAG 2700 CACACAGCTG CTACAAATGC CGTCAGTGCA GTTTTACAGC TGCCGATACT CAGTCACTAC 2760 TGGAGCACTT CAACACTGTT CACTGCCAGG AACAGGACAT CACTACAGCC AACGGCGAAG 2820 35 AGGACGGTCA TGCCATATCC ACCATCAAAG AGGAGCCCAA AATTGACTTC AGGGTCTACA 2880 ATCTGCTAAC TCCAGACTCT AAAATGGGAG AGCCAGTTTC TGAGAGTGTG GTGAAGAGAG 2940 AGAAGCTGGA AGAGAAGGAC GGGCTCAAAG AGAAAGTTTG GACCGAGAGT TCCAGTGATG 3000 ACCTTCGCAA TGTGACTTGG AGAGGGGCAG ACATCCTGCG GGGGAGTCCG TCATACACCC 3060 AAGCAAGCCT GGGGCTGCTG ACGCCTGTGT CTGGCACCCA AGAGCAGACA AAGACTCTAA 3120 40 GGGATAGTCC CAATGTGGAG GCCGCCCATC TGGCGCGACC TATTTATGGC TTGGCTGTGG 3180 AAACCAAGGG ATTCCTGCAG GGGGCGCCAG CTGGCGGAGA GAAGTCTGGG GCCCTCCCCC 3240 AGCAGTATCC TGCATCGGGA GAAAACAAGT CCAAGGATGA ATCCCAGTCC CTGTTACGGA 3300 GGCGTAGAGG CTCCGGTGTT TTTTGTGCCA ATTGCCTGAC CACAAAGACC TCTCTCTGGC 3360 GAAAGAATGC AAATGGCGGA TATGTATGCA ACGCGTGTGG CCTCTACCAG AAGCTTCACT 3420 45 CGACTCCCAG GCCTTTAAAC ATCATTAAAC AAAACAACGG TGAGCAGATT ATTAGGAGGA 3480 GAACAAGAAA GCGCCTTAAC CCAGAGGCAC TTCAGGCTGA GCAGCTCAAC AAACAGCAGA 3540 GGGGCAGCAA TGAGGAGCAA GTCAATGGAA GCCCGTTAGA GAGGAGGTCA GAAGATCATC 3600 TAACTGAAAG TCACCAGAGA GAAATTCCAC TCCCCAGCCT AAGTAAATAC GAAGCCCAGG 3660
GTTCATTGAC TAAAAGCCAT TCTGCTCAGC AGCCAGTCCT GGTCAGCCAA ACTCTGGATA 3720
TTCACAAAAG GATGCAACCT TTGCACATTC AGATAAAAAG TCCTCAGGAA AGTACTGGAG 3780
ATCCAGGAAA TAGTTCATCC GTATCTGAAG GGAAAGGAAG TTCTGAGAGA GGCAGTCCTA 3840 50 TAGAAAAGTA CATGAGACCT GCGAAACACC CAAATTATTC ACCACCAGGC AGCCCTATTG 3900 AAAAGTACCA GTACCCACTT TTTGGACTTC CCTTTGTACA TAATGACTTC CAGAGTGAAG 3960 CTGATTGGCT GCGGTTCTGG AGTAAATATA AGCTCTCCGT TCCTGGGAAT CCGCACTACT 4020 55 TGAGTCACGT GCCTGGCCTA CCAAATCCTT GCCAAAACTA TGTGCCTTAT CCCACCTTCA 4080 ATCTGCCTCC TCATTTTTCA GCTGTTGGAT CAGACAATGA CATTCCTCTA GATTTGGCGA 4140 TCAAGCATTC CAGACCTGGG CCAACTGCAA ACGGTGCCTC CAAGGAGAAA ACGAAGGCAC 4200 CACCAAATGT AAAAAATGAA GGTCCCTTGA ATGTAGTAAA AACAGAGAAA GTTGATAGAA 4260 GTACTCAAGA TGAACTTTCA ACAAAATGTG TGCACTGTGG CATTGTCTTT CTGGATGAAG 4320 60 TGATGTATGC TTTGCATATG AGTTGCCATG GTGACAGTGG ACCTTTCCAG TGCAGCATAT 4380 GCCAGCATCT TTGCACGGAC AAATATGACT TCACAACACA TATCCAGAGG GGCCTGCATA 4440 GGAACAATGC ACAAGTGGAA AAAAATGGAA AACC<u>TAA</u>AGA GTAAAAACCTT AGCACTTAGC 4500
ACAATTAAAT AGAAATAGGT TTTCTTGATG GGAATTCAAT AGCTTGTAAT GTCTTATGAA 4560
GACCTATTAA AAAAATACTT CATAGAGCCT GCCTTATCCA ACATGAAATT CCCTTCTTTT 4620
GTTATTCTTT CTTTTGATGA GTAGGTTACC AAGATTAAAA AGTGAGATAA ATGGTCAATG 4680 65 AGAAAGAATG GAAGATGGTA AACAATCACT TTTTAAAACC TGTTAAGTCA AAACCATCTT 4740 GGCTAATATG TACTGGGGAA ATAATCCATA AGAGATATCA CCAGACTAGA ATTAATATAT 4800 TTATAAAGAA AGAGACCAAA ACTGTCTAGA ATTTGAAAGG GTTTACATAT TATTATACTA 4860 AAGCAGTACT GGACTGGCCA TTGGACCATT TGTTCCAAAA CCCATAAATT GTTGCCTAAA 4920 TTTATAATGA TCATGAAACC CTAGGCAGAG GAGGAGAAAT TGAAGGTCCA GGGCAATGAA 4980 70 AGAAAAATGG CGCCCTCTCA ATTTAGTCTT CTCTCATTGG CCATGTTTCA GATTTTGACC 5040 TAGAAATGCG AGCTGTGGTT AGGCTTGGTT AGAGTGCAGC AAGCAACATG ACAGATGGTG 5100 GCACGCTGTT TTTACCCAGC CCTGCCTGTA CATACACATG CACACCCTCT CTGATATTTT 5160 TGTCCTTTAG ATGTTCAAAT ACTCAGTAGT CCTTTTGTTT GCGGTTTAGA TTCATTTGT 5220
CCACACATGT ACCCATTTTA AAAAACAATG TCCTCGATGC TTCTGTAGTG ATTTCATTTT 5280
AGCCAGGTAT TTCTTTCTTG TGTGTGATGA ACCAGTATGG ATTTGCTTTT CTAAGCCTCC 5340
TGTTGGTTAC TAATCTCACT TGGCACATTA TAACTAAAGG AATCCCCTCA ATTCAAAAGC 5400 75

CACAAGGTAA CCTGCTGTAT TTATTTATTT TCTTTTGGTT AAATATAATT TCCAAACTTT 5520 GTGGTCAGGC AGCGTCTAAG GTTACGTTAC CACAGACTGA CAGTTGGTAT ATGTACCAGC 5580 CAATCCCTTC ATTAAATGTA TACAGATTTA GTTAAGTAGC ATTAAATAGG ATTCTTAGAA 5640 5 GTATGTCCTC ATAGAACTTT TAATACTTAA GGCTTTGTAA AAACTATCCA TGAAGGGAAA 5700 GCTCCTCAGC ATAACTGCTC AGGGAAATAG GGCTAAATAA CTGAACATTA AATAATTGGT 5760 TAAAGGTGCT GTTAGTCGAG CCTCAATGCT TGCTACAAGG ATGTATGTAC AAGGACTGAC 5820 TTTAATAATT TGCATTATAT TGTCCCAACC AGTAGTTTAT TTTTTGCCAC GGAGATGTAG 5880 AAGATATTAC AAGCTACTGG ATGCACTGTC AGATTAACTT ATTTCATTAA AGAAGTTGGG 5940 10 AGAACAAATA GGAAAAAAA AACTTATTTT TCTAGTAAAT ATTAATGTAT TACATTTCAA 6000 ATAATGGTGC CTGACATATT GAATAATTAT TTTCTACAGT GTACGTATGC AACAAAGATA 6060 TTCCATCATG CATTAGAGTC AGTTCTGGCT CTGCCTAGCT GTTTACATT GCAAAAGATA 8000
CAAACAAGGT AATGAAGCAA CTATTTCTAT TGCAGTAGTA ATCCTTTTGT GTGTGTGTGT 6180
GTGCATTAAA GTTGTAAACG GTAACATGAA ACAAATGAAA GTTCTTGCTA TAATGGTATG 6240
GAAAACAAGA AGGAAATGAA AATATTTTTA TGCCTACTTA GGAAAAAAAG GGTAGCACTT 6300 15 ATTCATTCCA AGTACTTTTT TTTTTTTAAT TTTTAAGCTC TTAACTCACA TTGTTATGCT 6360 TAAGATGATA AACATATATC CTCTTTTTAT TGCTTTGTCT ATGTTTCATA TGAAACATTT 6420 CAGAAATTAT TTTGATAAGT GTTGCTGGAA TCTGCAACGC TGATTTTTTT TTGCATTCTG 6480 TAGTCGCATT TGCACTCCAT TTTTACATTA ATTCGCAGTT GCTTTGTATC ATTGTTTTGT 6540 TTGGGTTTTG TTTCTTTTTC ACAGTGCCGG GTCTTCGTTT CTTAAAGTTG GATGGCAGGT 6600 AGAGTTCAAC CAGTTCGTGA CTGTTGTAGC GAATGAAGTT AAAAAAATGT CTTTCTGATG 6660 20 TTGTGTTGTC ATTTTCATTT TTGCATTTTT TTGTTTGCAT ATTAAAAAAA GAGAAAAGAG 6720 AAAGCAAGAG ACAGAAATCA GGACTAAGTC CTCTGCTTCA GTTTCATTGT TAACGGGCCT 6780 TATTCTGATC TCACCTGTCG CGTAGCTCTA ATATTCACAT AAACTGAAAT AAAGAAGTGG 6840 25 AATGAGGAGC TTTGACATTC AAATTATGTG ATGTAATTTA TCTTCCTTAG GAATTTTGAT 6900 GGATGCATCT CAAAATGTAT AGCCAGACTT GAGAGGTGAC AATTAAAGAT CTAAAAAAAGA 6960 GAGGAGATTC CCCCAAACAA CAATATTTAA TTTTCTTAGT AAAAAGAATA ACAGAATGCA 7020 TCGTGGCAAT CCTTAAGCAA CATTATCTAT GTGGACTGCT TAAATCAGCA AAACACCAGA 7080 AGTTTGGTTA ACTTGGGCAA TATGACAAGT ATTACTTTTT GGGCAAAACT ACTCATTAAG 7140 30 CAATTTCTCT AGTGTGTCGG ACACAAATAG GTTCTTTATT TTTGGCATGT ATGCCTTTTT 7200 ATTTTCATTC AATTTTTTT TTTTCTCAGA CAGACATAGT AGTATCAACT AGCATTGGAA 7260 AATACATATC ACTATTCTTG GAATATTTAT GGTCAGTCTA CTTTTTAGTA AAATATTTTT 7320 CATTTTTTGC TTTCATTATT ATACATATTT TGGTGGAGAA GAGGTTGGGC TTTTTTGAAA 7440 GAGACAAAA TTTATTATAA CACTAAACAC TCCTTTTTTG ACATATTAAA GCCTTTATTC 7500 CATCTCTCAA GATATATTAT AAAATTTATT TTTTTAATTT AAGATTTCTG AATTATTTA 7560 TCTTAAATTG TGATTTTAAA CGAGCTATTA TGGTACGGAA CTTTTTTTAA TGAGGAATTT 7620 35 CATGATGATT TAGGAATTTT CTCTCTTGGA AAAGGCTTCC CCTGTGATGA AAATGATGTG 7680 CCAGCTAAAA TTGTGTGCCA TTTAAAAACT GAAAATATTT TAAAATTATT TGTCTATATT 7740 CTAAATTGAG CTTTGGATCA AACTTTAGGC CAGGACCAGC TCATGCGTTC TCATTCTTCC 7800
TTTTCTCACT CTTTCTCTCA TCACTCACCT CTGTATTCAT TCTGTTGTTT GGGATAGAAA 7860
AATCATAAAG AGCCAACCCA TCTCAGAACG TTGTGGATTG AGAGAGACAC TACATGACTC 7920
CAAGTATATG AGAAAAGGAC AGAGCTCTAA TTGATAACTC TGTAGTTCAA AAGGAAAAAGA 7880 40 GTATGCCCAA TTCTCTCTAC ATGACATATT GAGATTTTTT TTAATCAACT TTTAAGATAG 8040 45 TGATGTTCTG TTCTAAACTG TTCTGTTTTA GTGAAGGTAG ATTTTTATAA AACAAGCATG 8100 GGGATTCTTT TCTAAGGTAA TATTAATGAG AAGGGAAAAA AGTATCTTTA ACAGCTCTTT 8160 GTTGAAGCCT GTGGTAGCAC ATTATGTTTA TAATTGCACA TGTGCACATA ATCTATTATG 8220 ATCCAATGCA AATACAGCTC CAAAAATATT AAATGTATAT ATATTTTAAA ATGCCTGAGG 8280 AAATACATTT TTCTTAATAA ACTGAAGAGT CTCAGTATGG CTATTAAAAT AATTATTAGC 8340 50 CTCCTGTTGT GTGGCTGCAA AACATCACAA AGTGACCGGT CTTGAGACCT GTGAACTGCT 8400 GCCCTGTTTA GTAAATAAAA TTAATGCATT TCTAGAGGGG GAATATCTGC CATCCAGTGG 8460 TGGAAATGTG GAGTAAAGAA GCTGGTGGTC TGCTTCTGTG CTGTATGCCA GCCTTTTGCC 8520 TTAAGTTGAG AGGAGGTCAA CTTTAGCTAC TGTCTTTGGT TTGAGAGCCA TGGCAAAAAA 8580 AAAAAAGAA AAAAGATCA AGTCGTCTTT GGTGAGCCAG TAAGGTGAAA GCTTGCTGAC 8640 TGTCCAAGGC ACAAGAGAAA ATTGAGGAAT TGAAATGCAA CCTGAGTATC AAACTAAATA 8700 TTCTAATCAA AGGTAGGTAC TGTTAGGTGG AATTCTATCA GCAGGCAACT GCAAATGAGA 8760 55 AGAAGATAGA AGGACGCCCG TCGGGACTTT GGAGGGCATT GTTATTTTCC CAAAGAAAGA 8820 CGGCCAAGGG CAGAGCATG GATTCTTTGC AGAGCACTTC CTTTTGGTTT TTCAGTACTG 8880 TTTCATAGAC AGTGGGCTCA CATGTTCCTG ATAGTGCTGC AGTTGCTTAG AAAGCATCCC 8940 60 AGTTAATTGC AGTAATTAGA ACTTCTGGAA TATGCTAGGG CAGAAGTATG TCAAGTATGT 9000 65 TTTTTCCCAA CATATGAACT GCAGCATATC ACTTTTTCTT TTTGTGCCTC AGGTTCCTCA 9300 CCTGTAAAAT TGAAAAATAT ATGTATTAAT AATATTATTA ATAATAATAA TGGTAATGTA 9360 GTACTTGTTT GTAAAGCACT TTGAGATCCT TGGTTGAAAG GCACCATAGG AGTGCCAAGT 9420
ATTATTATGT GGCCAAGGGG GTTATTTAAA CTGTCAGTTC CCAAAGGCCA GGAAAGGTTG 9480
GGGTCATTTT TCTTAAAGAC GAGCTGTAAA TATCAACTAG GCAGCCAATA GTGTTGACTA 9540
TGAAGATGCA AAACTATTAC TAGGCTGATA AAATCATAGT TTCTTAATGG CTACCAATAA 9600 70 GGCAAATATC ACAATAATAA ACGCCAAATT CCTTAGGGCG GACTATTTGA CAACCACATG 9660 GAAAACTTTG GGGGAGGCAT GAGGGGGGAA CATCTCAAAA TGCCAATGTA AAATTTAACT 9720 TACAGCAATA TTCACCAGCA GAAAATGTCT TTCATATGGA ATGATTTCAT GTTGCTAAGA 9780 AAAAGAATTC AATTTGTAGT CCTGATTTGA ATACTAGAAT GTTGGCTATA ATAGTTCTGT 9840
TCTTACAACA CATGAAATTT TTTCGTTTTA TTTTATTTTG TTTTCATAGT GCATGTTCAT 9900
TTCTACTCAC AAACATGTTC TTGGTGTATT TCTTATGCAA ACAATCTTCA GGCAGCAAAG 9960 75 ATGTCTGTTA CATCTAAACT TGAATAATAA AGTTTTACCA CCAGTTACAC A

ATAGATGGAT ACAAATGTCA GACCGTGGGT TTAATTTGTT TAGAACACAT GGCATTTCTT 5460



	COTO A COCA TRANSPORTA A CITA CONTRA A CITATO A CALCULAR COCA COCA COCA COCA COCA COCA COCA CO
	CCTCAAGCCA TCCTGAACTG CGTTAATAAG TTCTGGACAT TTCAAGAGTT GGCTGGCCAT 1200
	GGTGTTCCTC TGCCGGATAC TTTCTCTTAT GGTGGCCACG AAAATTTTTGC TAAAATGATT 1260 GATGAGGCTG AAGTTCTGGA GTTCCCAATG GTAGTAAAGA ATACGCGGGG TCACAGAGGT 1320
	AAAGCTGTTT TCTTGGCTCG AGATAAGCAC CATTTGGCTG ATCTAAGCCA TCTTATTCGC 1380
5	CATGAAGCGC CATACCTGTT CCAGAAGTAT GTTAAAGAGT CTCATGGACG GGATGTACGT 1440
-	GTCATTGTCG TGGGAGGCCG TGTGGTTGGC ACCATGTTAC GTTGTTCAAC AGATGGGAGA 1500
	ATGCAAAGCA ACTGCTCATT AGGTGGTGTG GGGATGATGT GCTCATTGAG TGAACAAGGG 1560
	AAGCAGCTAG CTATCCAGGT GTCTAATATC CTGGGGATGG ATGTGTGTGG CATTGACCTG 1620
	CTGATGAAAG ATGACGGCTC CTTCTGCGTC TGTGAGGCCA ATGCAAATGT AGGTTTCATC 1680
10	GCCTTTGATA AGGCTTGTAA TCTAGATGTA GCTGGTATCA TAGCAGACTA TGCCGCCTCC 1740
	CTTCTACCCT CTGGCCGGCT CACCCGGCGT ATGTCCCTGC TCTCCGTGGT GTCCACTGCC 1800
	AGTGAGACTA GTGAGCCGGA GCTGGGTCCC CCAGCCAGCA CTGCTGTTGA CAACATGAGT 1860
	GCAAGTTCCA GCTCTGTTGA CAGCGACCCT GAAAGCACGG AGCGAGAGCT GCTCACCAAG 1920
	CTCCCAGGGG GCCTGTTCAA CATGAACCAG CTGCTAGCCA ATGAAATCAA ACTACTGGTG 1980
15	GAC <u>TGA</u> CTCC ACTGGTAATT AACCAACAAA ACCCTTGTAA AACTTTCTTT CTTCTTTTCT 2040
	ATTTTTAAAA CCAACTTGCA ATGCTGTTCA TGGAGGATGC TCAGGAAGAT GAGAGAAAAT 2100
	TAGTAGGATT AGTTGGAGAG AGTGGGAGAT AGATGAGACC TCTGCTAGTA AGATGTTACT 2160
	TTCATTTACA AATCCTACAA ATAGAGAGGC AGAATAGGTG GGGTATAGAA AAATGTCAGG 2220
00	CTCTCATAGT TACCCTTTTA AATTGCTAAA AAATGTGTAT GCTCATAGGC CATGAGGAAC 2280
20	AAATACTTTT TTTTTTCAT GGTCCCTTGC TTTTGTTTTT GTACAAAAAA AAATGGTTTT 2340
	GCTACAAATA TCCAAGTAGC ATAACTTCAC ATTGTGTTGG AAGATTTGTC ATCAGTGAGG 2400
	AAAACATCTG CTTAAATTAC AGGAATTTTT GTATTATACA GCTCTGAAAA TTCTGCCATT 2460
	TCCTTATTAA CTAGCAGCTT TAGTTTGTAG TTTATGAAAT CTTGAGGGGC TCTTTTACTG 2520
25	GGATTICTTA TTTTTTGTT TTTTCCCGCT TAATTTGGTG GGAGGTCAAA TTGAATATAA 2580
25	CCCAATAAAG GCTTCTTAAT GACAAAATTG GCATGTTTGC ATGATGAAAT GGAAATGAAC 2640
	AGTATTGCAA TGTCCGGTAT ACAAAATAAC ATTAATTCAA TGTAGATAAA ATTACACTAG 2700
	TTTAAAATAT GTGCATTCAC TTGTATTTGT TAGTGTTTTA GTCTTTTTTG AAAGATGTGC 2760
	TCTGTTAATG TTGCTTTTTT TTTTTTTTT TAATACATGC TAGTCTAACA TTTCCTGCTC 2820
30	TATGCCTGCA TCTTTAACAA TGGCCAAAGT GAAGAAAATG CTACCTTTTT TGTTAACAAG 2880
30	ACACTGACTT GAAACATGTA CATTTAAAGC CTTTTATTTT TTCCCTTTTT GTTTTGGTAG 2940
	TTGGGCATTT AAATAAGGAC AAGGAAAAAT ATTTTTGGGG GCAAATCAAG AGCCTATGAG 3000
	TTCTAAGTAT AAAGCTGAAG TGATTTCGAA TGCCAGCGTT ATATATTTGC ATTTTTCACA 3060 TTTTACGAGG GAGTATATGT GTATGTGTGT GCACGCATGC ATGTGTATGT GTTTTGCTTT 3120
	TTGTTTCCAT CAACTAATCA AAAAGGATAA TTTAGAAAAT GGAGCATGAT GGGAAACAGA 3180
35	GTTTTTGACT TTAAAAAACA GATGAGTTGT TTTCATAAGT AGACTCCACT GGGGTAGAGG 3240
55	TATTCACCTT AAAACATAGG GTGAGTAGAT GCTTTTTTAG GCCTTTTTGT GTATATGTAC 3300
	GTTGTTTGTT TTTTTCCTTT TGTTTCTAGC CTGTTCAGTG TACAGTTTAT TCAAGGCTAC 3360
	ATGCTTTTCT TTAATGCTTC TGGCTATGCA TTTTCTCTTT TTACATATAG GATTTGGGAT 3420
	TGGGGGTGGG TTGGATGTTT TTGTTTGGGG ACTTATTTAG TAGTATTGAG TCTCTTATAG 3480
40	CCCTACTCTT AAGCCTTCAA TACTGTCCAC TCTTTATATT CCTTTACTTG CAGAATTTAT 3540
	AAAAGCCCCC AAACTGCATA TAATATGAGC CTTTAAAACA TGGGTAAAAC TAATCCCATT 3600
	GATGGGTTTG GATGGTATGT TAAGAAATGG AGATGCTGCA GAGCCCAACG TAATTTTTTA 3660
	AACAGCAAGT TTTCCATCTC CCTACGAATC CTCTGAAGCT TTTACCCAAG CCCTTTCTTG 3720
15	CCTCTCCAGT GCTATTTTCC TTCAGATGGA CCTTAAACAT AATTTCTTGG ACACTACTAG 3780
45	AGAGACTTCG AGGCAATAAT AAAAGATCAG TATTAACCAG CTATAACAGA GGTTTGATCA 3840
	TGCTTACTTG TACAGTTTTT CCCCCGTTTT AAAAAGGAAT GTAATAAAAT TTGTTTTTTC 3900
	CATAGAATTA AATAATATTA AAATTGAGTG AAAGGTTGAT TGTTGATGAA TAGAATAGTA 3960
	CCTCTCATCT GTGCAGTGTC TCATTTCACC TCAGAGAAAA GGATACATAA GAGGAGTTTG 4020
50	TAATTTATCT TAGGATATTC TAATTGCATT TAAAAGAACT TATCTTGCGC AGGGTAAATG 4080
50	GGGGACTCAC ATACATATAT TAATACCTCT GACTCATTAA CAGAAAGAAA TACTTGGTAC 4140
	TTCTTTCGCT GAATGACCAT ACTGTGGAGG ATGCATACTA TTTGGTATAG AGAAATAAAT 4200
	GAGGAAGAAA GAACTGCTTA ATTAAATTAT CATTCATATG TTCATATAGA GACCATCTGG 4260 TTGCCATGTG TATTATGACA CATACACTTT GAATAGTTAC ATATCACAAG TATGTAGTTC 4320
	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380
55	ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440
55	TATTATGCAT TCACATGATA TTAAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500
	GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560
	AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620
	TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680
60	AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAATT TTTGTATATT 4740
00	GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800
	TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	TAAAATTTTT AATAGTTTTT TTCTTTTTTG GTGCCTATAA TTGATTGGTC ATTTCTGCTG 4920
	GCTTTTCTCC AATGAACATT GAAATCTTCC TGTATATGTT ACCAATAAGA AAACTACCCT 4980
65	GGAACAGTAG AAAAACCCAA CAAGAGACTT GGCATTCATC AAGCACATTA TCAGACTTTG 5040
	AGAACATATT GAAGGCATTG ACTTTGAAAA TCATCTCTTT TTCTCAAGAA GAAAGCAATG 5100
	GAGAAGCAAA TTTGTTTCAT TCAGTGAATC CCCAGTTTGG GGCTTGTGGG GCTTAGAGAC 5160
	ATTGTGAAAT CAAATCTTGT GTTATACTTT TCTCCTGGCT CACTTTTTTT GAGAAGGTTT 5220
=0	ATGGGCTATT TGGCTGGTGA GACACGATCC CCTCCTAAGA AAATGTAGGT GCTCAGACAG 5280
70	GTAACCACTG CTGCTACTGT TTTTATTTGT TTGTTTGTTC AATTTTATTT AAGATTTGTT 5340
	TTTGTTGTAC TAGGATTTTA AAAAATGTAA TATATTGCAG GATTTATAAC CAG
	Seq ID NO: 72 Protein sequence:
75	Protein Accession #: BAA86552
75	

75

1 11 21 31 41 51 | | | | | | |

380

ELAGHGVPLP DTFSYGGHEN FAKMIDEAEV LEFPMVVKNT RGHRGKAVFL ARDKHHLADL 180 SHLIRHEAPY LFQKYVKESH GRDVRVIVVG GRVVGTMLRC STDGRMQSNC SLGGVGMMCS 240 5 LSEQGKQLAI QVSNILGMDV CGIDLLMKDD GSFCVCEANA NVGFIAFDKA CNLDVAGIIA 300 DYAASLLPSG RLTRRMSLLS VVSTASETSE PELGPPASTA VDNMSASSSS VDSDPESTER 360 ELLTKLPGGL FNMNQLLANE IKLLVD Seq ID NO: 73 DNA sequence 10 XM_040080.2 Nucleic Acid Accession #: Coding sequence: 159-1104 (underlined sequences correspond to start and stop codons) 21 31 51 15 CTGAGTGGGG GCGGGGACTG CTGGAGTTGC GGGGCCTGCC TGGGGTAGGG CGGGGCAGGA 60 CAGCTTGGAG ATAGGGCCCG GAATTGCGGG CGTCACTCTG CTCCTGCGAC CTAGCCAGGC 120 GTGAGGGAGT GACAGCAGCG CATTCGCGGG ACGAGAGCGA TGAGTGAGAA CGCCGCACCA 180 GGTCTGATCT CAGAGCTGAA GCTGGCTGTG CCCTGGGGCC ACATCGCAGC CAAAGCCTGG 240 GGCTCCCTGC AGGGCCCTCC AGTTCTCTGC CTGCACGGCT GGCTGGACAA TGCCAGGTCC 300
TTCGACAGAC TCATCCCTCT TCTCCCGCAA GACTTTTATT ACGTTGCCAT GGATTTCGGA 360
GGTCATGGGC TCTCGTCCCA TTACAGCCCA GGTGTCCCAT ATTACCTCCA GACTTTTGTG 420 20 AGTGAGATCC GAAGAGTTGT GGCAGCCTTG AAATGGAATC GATTCTCCAT TCTGGGCCAC 480 AGCTTCGGTG GCGTCGTGGG CGGAATGTTT TTCTGTACCT TCCCCGAGAT GGTGGATAAA 540 CTTATCTTGC TGGACACGCC GCTCTTTCTC CTGGAATCAG ATGAAATGGA GAACTTGCTG 600 25 ACCTACAAGC GGAGAGCCAT AGAGCACGTG CTGCAGGTAG AGGCCTCCCA GGAGCCCTCG 660 CACGTGTTCA GCCTGAAGCA GCTGCTGCAG AGGTTACTGA AGAGCAATAG CCACTTGAGT 720 GAGGAGTGCG GGGAGCTTCT CCTGCAAAGA GGAACCACGA AGGTGGCCAC AGGTCTGGTT 780 CTGAACAGAG ACCAGAGGCT CGCCTGGGCA GAGAACAGCA TTGACTTCAT CAGCAGGGAG 840 CTGTGTGCGC ATTCCATCAG GAAGCTGCAG GCCCATGTCC TGTTGATCAA AGCAGTCCAC 900 30 GGATATTTTG ATTCAAGACA GAATTACTCT GAGAAGGAGT CCCTGTCGTT CATGATAGAC 960 ACGATGAAAT CCACCCTCAA AGAGCAGTTC CAGTTTGTGG AAGTCCCAGG CAATCACTGT 1020 GTCCACATGA GCGAACCCCA GCACGTGGCC AGTATCATCA GCTCCTTCTT ACAGTGCACA 1080 CACATGCTCC CAGCCCAGCT GTAGCTCTGG GCCTGGAACT ATGAAGACCT AGTGCTCCCA $\,$ 1140 GACTCAACAC TGGGACTCTG AGTTCCTGAG CCCCACAACA AGGCCAGGGA TGGTGGGGAC 1200 AGGCCTCACT AGTCTTGAGG CCCAGCCTAG GATGGTAGTC AGGGGAAGGA GCGAGATTCC 1260 AACTTCAACA TCTGTGACCT CAAGGGGGAG ACAGAGTCTG GGTTCCAGGG CTGCTTTCTC 1320 35 CTGGCTAATA ATAAATATCC AGCCAGCTGG AGGAAGGAAG GGCAGGCTGG GCCCACCTAG 1380 CCTTTCCCTG CTGCCCAACT GGATGGAAAA TAAAAGGTTC TTGTATTCTC A Seq ID NO: 74 <u>Protein sequence:</u> Protein Accession #: XP_040080.1 40 41 11 31 45 MSENAAPGLI SELKLAVPWG HIAAKAWGSL QGPPVLCLHG WLDNASSFDR LIPLLPQDFY 60 YVAMDFGGHG LSSHYSPGVP YYLQTFVSEI RRVVAALKWN RFSILGHSFG GVVGGMFFCT 120 FPEMVDKLIL LDTPLFLLES DEMENLLTYK RRAIEHVLQV EASQEPSHVF SLKQLLQRLL 180 KSNSHLSEEC GELLLQRGTT KVATGLVLNR DQRLAWAENS IDFISRELCA HSIRKLQAHV 240 LLIKAVHGYF DSRQNYSEKE SLSFMIDTMK STLKEQFQFV EVPGNHCVHM SEPQHVASII 300 50 SSFLQCTHML PAQL Seq ID NO: 75 DNA sequence Nucleic Acid Accession #: NM 005794 Coding sequence: 434-1276 (underlined sequences correspond to start and stop codons) 55 21 31 GGTTCCCTTC CACGCTGTGA AGCTTTGTTC TTTTGGTCTT CATGATAAAT CTTGCTGCTG 60 CTCACTCGTT GGGTCCGTGC CACCTTTAAG AGCTGTAACA CTCACCGCGA AGGTCTGCAA 120 60 CTTCACTCCT GGGGCCAGCA AGACCACGAA TGCACCGAGA GGAATGAACA ACTCTGGACA 180 CACCATCTTT AAGAACCGTA ATACTCACCG CAAGGGTCTG CAACTTCATT CTTGAAGTCA 240
GTGAGGCCAA GAACCCATCA ATTCCGTACA CATTTTGGTG ACTTTGAAGA GACTGTCACC 300
TATCACCAAG TGGTGAGACT ATTGCCAAGC AGTGAGACTA TTGCCAAGTG GTGAGACCAT 360
CACCAAGCGG TGAGACTATC ACCTATCGCC AAGTGGCCTG ATTCAGCAGG AAGCATCTCA 420
GACACCAACC ACTATGCTGT CAGCAGTTGC CCGGGGCTAC CAGGGCTGGT TTCATCCCTG 480 65 TGCTAGGCTT TCTGTGAGGA TGAGCAGCAC CGGGATAGAC AGGAAGGGCG TCCTGGCTAA 540 CCGGGTAGCC GTGGTCACGG GGTCCACCAG TGGGATCGGC TTTGCCATCG CCCGACGTCT 600 GGCCGGGAC GGGGCCACG TGGTCATCAG CAGCCGAAG CAGCAGAACG TGGACCGGGC 660
CATGGCCAAG CTGCAGGGG AGGGGCTGAG TGTGCGGGC ATTGTTGTCC ACGTGGGAA 720
GGCTGAGGAC CGGGAGCAGC TGGTGGCCAA GGCCCTGGAG CACTGTGGG GCGTCGACTT 780
CCTGGTGTGC AGCGCAGGGG TCAACCCTCT GGTAGGAGC ACTCTGGGGA CCAGTGAGCA 840 70 GATCTGGGAC AAGATCCTAA GTGTGAACGT GAAGTCCCCA GCCCTGCTGC TGAGCCAGTT 900 GCTGCCCTAC ATGGAGAACA GGAGGGGTGC TGTCATCCTG GTCTCTTCCA TTGCAGCTTA 960 TAATCCAGTA GTGGCGCTGG GTGTCTACAA TGTCAGCAAG ACAGCGCTGC TGGGTCTCAC 1020 75 TAGAACACTG GCATTGGAGC TGGCCCCCAA GGACATCCGG GTAAACTGCG TGGTTCCAGG 1080
AATTATAAAA ACTGACTTCA GCAAAGTGTT TCATGGGAAT GAGTCTCTCT GGAAGAACTT 1140 CAAGGAACAT CATCAGCTGC AGAGGATTGG GGAGTCAGAG GACTGTGCAG GAATCGTGTC 1200

MCSSVAAKLW FLTDRRIRED YPQKEILRAL KAKCCEEELD FRAVVMDEVV LTIEQGNLGL 60 RINGELITAY PQVVVVRVPT PWVQSDSDIT VLRHLEKMGC RLMNRPQAIL NCVNKFWTFQ 120

CTCCACTCGG CTCTGAGAGG AGTGGGGGGC GCTGCGTAGC TGTGGTCCCA GCCCAGGAGC 1320 CTGAGGGGGT GTCTAGGTGA TCATTTGGAT CTGGAGCAGA GTCTGCCATT CTGCCAGACT 1380 AGCAATTTGG GGGCTTACTC ATGCTAGGCT TGAGGAAGAA GAAAAACGCT TCGGCATTCT 1440 5 Seq ID NO: 76 Protein sequence: Protein Accession #: NP_005785 10 21 31 MLSAVARGYQ GWFHPCARLS VRMSSTGIDR KGVLANRVAV VTGSTSGIGF AIARRLARDG 60 AHVVISSRKQ QNVDRAMAKL QGEGLSVAGI VCHVGKAEDR EQLVAKALEH CGGVDFLVCS 120 AGVNPLVGST LGTSEQIWDK ILSVNVKSPA LLLSQLLPYM ENRRGAVILV SSIAAYNPVV 180 15 ALGVYNVSKT ALLGLTRTLA LELAPKDIRV NCVVPGIIKT DFSKVFHGNE SLWKNFKEHH 240 QLQRIGESED CAGIVSFLCS PDASYVNGEN IAVAGYSTRL Seq ID NO: 77 DNA sequence 20 Nucleic Acid Accession #: NM_002425 Coding sequence: 26-1453 (underlined sequences correspond to start and stop codons) 31 21 25 AAAGAAGGTA AGGGCAGTGA GAATGATGCA TCTTGCATTC CTTGTGCTGT TGTGTCTGCC 60 AGTCTGCTCT GCCTATCCTC TGAGTGGGGC AGCAAAAGAG GAGGACTCCA ACAAGGATCT 120 TGCCCAGCAA TACCTAGAAA AGTACTACAA CCTCGAAAAG GATGTGAAAC AGTTTAGAAG 180 AAAGGACAGT AATCTCATTG TTAAAAAAAT CCAAGGAATG CAGAAGTTCC TTGGGTTGGA 240 GGTGACAGGG AAGCTAGACA CTGACACTCT GGAGGTGATG CGCAAGCCCA GGTGTGGAGT 300 TCCTGACGTT GGTCACTTCA GCTCCTTTCC TGGCATGCCG AAGTGGAGGA AAACCCACCT 360 TACATACAGG ATTGTGAATT ATACACCAGA TTTGCCAAGA GATGCTGTTG ATTCTGCCAT 420 30 TGAGAAAGCT CTGAAAGTCT GGGAAGAGGT GACTCCACTC ACATTCTCCA GGCTGTATGA 480 AGGAGAGGCT GATATAATGA TCTCTTTCGC AGTTAAAGAA CATGGAGACT TTTACTCTTT 540 TGATGGCCCA GGACACAGTT TGGCTCATGC CTACCCACCT GGACCTGGGC TTTATGGAGA 600 35 TATTCACTTT GATGATGATG AAAAATGGAC AGAAGATGCA TCAGGCACCA ATTTATTCCT CGTTGCTGCT CATGAACTTG GCCACTCCCT GGGGCTCTTT CACTCAGCCA ACACTGAAGC 720
TTTGATGTAC CCACTCTACA ACTCATTCAC AGAGCTCGCC CAGTTCCGCC TTTCGCAAGA 780
TGATGTGAAT GGCATTCAGT CTCTCTACGG ACCTCCCCCT GCCTCTACTG AGGAACCCCT 840
GGTGCCCACA AAATCTGTTC CTTCGGGATC TGAGATGCCA GCCAAGTGTG ATCCTGCTTT 900 40 GTCCTTCGAT GCCATCAGCA CTCTGAGGGG AGAATATCTG TTCTTTAAAG ACAGATATTT 960 TTGGCGAAGA TCCCACTGGA ACCCTGAACC TGAATTTCAT TTGATTTCTG CATTTTGGCC 1020 CTCTCTTCCA TCATATTTGG ATGCTGCATA TGAAGTTAAC AGCAGGGACA CCGTTTTTAT 1080 TTTTAAAGGA AATGAGTTCT GGGCCATCAG AGGAAATGAG GTACAAGCAG GTTATCCAAG 1140
AGGCATCCAT ACCCTGGGTT TTCCTCCAAC CATAAGGAAA ATTGATGCAG CTGTTTCTGA 1200
CAAGGAAAAG AAGAAAACAT ACTTCTTTGC AGCGGACAAA TACTGGAGAT TTGATGAAAA 1260
TAGCCAGTCC ATGGAGCAAG GCTTCCCTAG ACTAATAGCT GATGACTTTC CAGGAGTTGA 1320 45 GCCTAAGGTT GATGCTGTAT TACAGGCATT TGGATTTTTC TACTTCTTCA GTGGATCATC 1380 ACAGTTTGAG TTTGACCCCA ATGCCAGGAT GGTGACACAC ATATTAAAGA GTAACAGCTG 1440 GTTACATTGC TAGGCGAGAT AGGGGGAAGA CAGATATGGG TGTTTTTAAT AAATCTAATA 1500 50 ATTATTCATC TAATGTATTA TGAGCCAAAA TGGTTAATTT TTCCTGCATG TTCTGTGACT 1560 GAAGAAGATG AGCCTTGCAG ATATCTGCAT GTGTCATGAA GAATGTTTCT GGAATTCTTC 1620 ACTTGCTTTT GAATTGCACT GAACAGAATT AAGAAATACT CATGTGCAAT AGGTGAGAGA 1680 ATGTATTTTC ATAGATGTGT TATTACTTCC TCAATAAAAA GTTTTATTTT GGGCCTGTTC 1740 55 Seq ID NO: 78 Protein sequence: Protein Accession #: NP_002416 31 60 MHLAFLVLLC LPVCSAYPLS GAAKEEDSNK DLAQQYLEKY YNLEKDVKQF RRKDSNLIVK 60 KIQGMQKFLG LEVTGKLDTD TLEVMRKPRC GVPDVGHFSS FPGMPKWRKT HLTYRIVNYT POLPRDAVDS AIEKALKVWE EVTPLTFSRL YEGEADIMIS FAVKEHGDFY SFDGPGHSLA 180
HAYPPGPGLY GDIHFDDDEK WTEDASGTNL FLVAAHELGH SLGLFHSANT EALMYPLYNS 240
FTELAQFRLS QDDVNGIQSL YGPPPASTEE PLVPTKSVPS GSEMPAKCDP ALSFDAISTL 300
RGEYLFFKDR YFWRRSHWNP EPEFHLISAF WPSLPSYLDA AYEVNSRDTV FIFKGNEFWA 360 65 IRGNEVQAGY PRGIHTLGFP PTIRKIDAAV SDKEKKKTYF FAADKYWRFD ENSQSMEQGF 420 PRLIADDFPG VEPKVDAVLQ AFGFFYFFSG SSQFEFDPNA RMVTHILKSN SWLHC 70 Seq ID NO: 79 DNA sequence Nucleic Acid Accession #: NM_000493.1 Coding sequence: 1-2043 (underlined sequences correspond to start and stop codons) 75 ATGCTGCCAC AAATACCCTT TTTGCTGCTA GTATCCTTGA ACTTGGTTCA TGGAGTGTTT 60 TACGCTGAAC GATACCAAAC GCCCACAGGC ATAAAAGGCC CACTACCCAA CACCAAGACA 120

CTTCCTGTGC TCTCCAGATG CCAGCTACGT CAACGGGGAG AACATTGCGG TGGCAGGCTA 1260

5	CAGTTCTTCA TTCCCTACAC CATAAAGAGT AAAGGTATAG CAGTAAGAGG AGAGCAAGGT 180 ACTCCTGGTC CACCAGGCCC TGCTGGACCT CGAGGGCACC CAGGTCCTTC TGGACCACCA 240 GGAAAACCAG GCTACGGAAG TCCTGGACTC CAAGGAGAGC CAGGGTTGCC AGGACCACCG 300 GGACCATCAG CTGTAGGGAA ACCAGGTGTG CCAGGACTCC CAGGAAAACC AGGAGAGAG 360 GGACCATCAG GACCAAAAGG AGATGTTGGA CCAGCTGGCC TACCAGGACC CCGGGGCCCA 420
	CCAGGACCAC CTGGAATCCC TGGACCGGCT GGAATTTCTG TGCCAGGAAA ACCTGGACCA 480 CAGGGACCAC CAGGAGCCCC AGGACCCAGG GGCTTTCCTG GAGAAAAAGGG TGCACCAGGA 540 GTCCCTGGTA TGAATGGACA GAAAGGGGAA ATGGGATATG GTGCTCCTGG TCGTCCAGGT 600 GAGAGGGGTC TTCCAGGCCC TCAGGGTCCC ACAGGACCAT CTGGCCCTCC TGGAGTGGGA 660
10	AAAAGAGGTG AAAATGGGGT TCCAGGACAG CCAGGCATCA AAGGTGATAG AGGTTTTCCG 720 GGAGAAATGG GACCAATTGG CCCACCAGGT CCCCAAGGCC CTCCTGGGGA ACGAGGGCCA 780 GAAGGCATTG GAAAGCCAGG AGCTGGA GCCCCAGGGC AGCCAGGGAT TCCAGGAACA 840 AAAGGTCTCC CTGGGGCTCC AGGAATAGCT GGGCCCCCAG GGCCTCCTGG CTTTGGGAAA 900 CCAGGCTTGC CAGGCCTGAA GGGAGAAAGA GGACCTGCTG GCCTTCCTGG GGGTCCAGGT 960
15	GCCAAAGGGG AACAAGGGCC AGCAGGTCTT CCTGGGAAGC CAGGTCTGAC TGGACCCCCT 1020 GGGAATATGG GACCCCAAGG ACCAAAAGGC ATCCCGGGTA GCCATGGTCT CCCAGGCCCT 1080 AAAGGTGAGA CAGGGCCAGC TGGGCCTGCA GGATACCCTG GGGCTAAGGG TGAAAGGGGT 1140 TCCCCTGGGT CAGATGGAAA ACCAGGGTAC CCAGGAAAAC CAGGTCTCGA TGGTCCTAAG 1200
20	GGTAACCCAG GGTTACCAGG TCCAAAAGGT GATCCTGGAG TTGGAGGACC TCCTGGTCTC 1260 CCAGGCCCTG TGGGCCCAGC AGGAGCAAAG GGAATGCCCG GACACAATGG AGAGGCTGGC 1320 CCAAGAGGTG CCCCTGGAAT ACCAGGTACT AGAGGCCCTA TTGGGCCACC AGGCATTCCA 1380 GGATTCCCTG GGTCTAAAGG GGATCCAGGA AGTCCCGGTC CTCCTGGCCC AGCTGCATA 1440 GCAACTAAGG GCCTCAATGG ACCCACCGGG CCACCAGGGC CTCCAGGTCC AGAGGGCCC 1500
25	TCTGGAGAGC CTGGTCTTCC AGGGCCCCCT GGGCCTCCAG GCCCACCAGG TCAAGCAGTC 1560 ATGCCTGAGG GTTTTATAAA GGCAGGCCAA AGGCCCAGTC TTTCTGGGAC CCCTCTTGTT 1620 AGTGCCAACC AGGGGTAAC AGGAATGCCT GTGTCTGCTT TTACTGTTAT TCTCTCCAAA 1680 GCTTACCCAG CAATAGGAAC TCCCATACCA TTTGATAAAAA TTTTGTATAA CAGGCAACAG 1740 CATTATGACC CAAGGACTGG AATCTTTACT TGTCAGATAC CAGGAATATA CTATTTTTCA 1800 TACCACGTGC ATGTGAAAGG GACTCATGTT TGGGTAGGCC TGTATAAGAA TGGCACCCCT 1860
30	GTAATGTACA CCTATGATGA ATACACCAAA GGCTACCTGG ATCAGGCTTC AGGGAGTGCC 1920 ATCATCGATC TCACAGAAAA TGACCAGGTG TGGCTCCAGC TTCCCAAATGC CGAGTCAAAT 1980 GGCCTATACT CCTCTGAGTA TGTCCACTCC TCTTTCTCAG GATTCCTAGT GGCTCCAATG 2040 TGAGTACCC CCACAGAGCT AATCTAAATC TTGTGCTAGA AAAAGCATTC TCTAACTCTA 2100
35	CCCCACCCTA CAAAATGCAT ATGGAGGTAG GCTGAAAAGA ATGTAATTTT TATTTTCTGA 2160 AATACAGATT TGAGCTATCA GACCAACAAA CCTTCCCCCT GAAAAGTGAG CAGCAACGTA 2220 AAAACGTATG TGAAGCCTCT CTTGAATTTC TAGTTAGCAA TCTTAAGGCT CTTTAAGGTT 2280 TTCTCCAATA TTAAAAAAATA TCACCAAAGA AGTCCTGCTA TGTTAAAAAC AAACAACAAA 2340 AAACAAAGCA ACAAAAAAAA AAATTAAAAA AAAAAACAGA AATAGAGCTC TAAGTTATGT 2400
40	GAAATTTGAT TTGAGAAACT CGGCATTTCC TTTTTAAAAA AGCCTGTTTC TAACTATGAA 2460 TATGAGAACT TCTAGGAAAC ATCCAGGAGG TATCATATAA CTTTAGAAA CTTAAATACT 2520 TGAATATTCA AATTTAAAAAG ACACTGTATC CCCTAAAATA TTTCTGATGG TGCACTACTC 2580 TGAGGCCTGT ATGGCCCCTT TCATCAATAT CTATTCAAAT ATACAGGTGC ATATATACTT 2640 GTTAAAGCTC TTATATAAAA AAGCCCCAAA ATATTGAAGT TCATCTGAAA TGCAAGGTGC 2700
45	TTTCATCAAT GAACCTTTTC AAAACTTTTC TATGATIGCA GAGAAGCTTT TTATATACCC 2760 AGCATAACTT GGAAACAGGT ATCTGACCTA TTCTTATTTA GTTAACACACAG GTGTGATTAA 2820 TTTGATTTCT TTAATTCCTT ATTGAATCTT ATGTGATATG ATTTTCTTGGA TTTACAGAAC 2880 ATTAGCACAT GTACCTTGTG CCTCCCATTC AAGTGAAGTT ATAATTTACA CTGAGGGTTT 2940 CAAAATTCGA CTAGAAGTGG AGATATATTA TTTATTTATTA CACTGTACTG TATTTTTATA 3000
50	TTGCTGTTTA AAACTTTAA GCTGTGCCTC ACTTATTAAA GCACAAAATG TTTTACCTAC 3060 TCCTTATTTA CGACACAATA AAATAACATC AATAGATTTT TAGGCTGAAT TAATTTGAAA 3120 GCAGCAATTT GCTGTTCTCA ACCATTCTTT CAAGGCTTTT CATTCGACAC AATAAAATAA
55	Seq ID NO: 80 Protein sequence: Protein Accession #: NP_000484.1
60	1 11 21 31 41 51
65	GEMGPIGPPG PQGPPGERGP EGIGKPGAAG APGQPGIPGT KGLPGAPGIA GPPGPPGFGK 300 PGLPGLKGER GPAGLPGGPG AKGEQGPAGL PGKPGLTGPP GNMGPQGPKG PGSHGLPGP 360 KGETGPAGPA GYPGAKGERG SPGSDGKPGY PGKPGLDGPK GNPGLPGPKG DPGVGGPPGL 420 PGPVGPAGAK GMPGHNGEAG PRGAPGIPGT RGPIGPPGIP GFPGSKGDPG SPGPPGPAGI 480 ATKGLNGPTG PPGPPGPRGP SCEPGLPGPP GPPGPPGQAV MPEGFIKAGQ RPSLSGTPLV 540 ATKGLNGPTG PROPPGRAGE SCEPGLPGPP GPPGPPGQAV MPEGFIKAGQ RPSLSGTPLV 540 ATKGLNGPTG PROPPGRAGE SCEPGLPGPP GPPGPPGQAV MPEGFIKAGG RPSLSGTPLV 540 ATKGLNGPTG PROPPGRAGE SCEPGLPGPP GPPGPPGQAV MPEGFIKAGG RPSLSGTPLV 540 ATKGLNGPTG PROPPGRAGE SCEPGLPGPP GPPGPPGQAV MPEGFIKAGG RPSLSGTPLV 540 ATKGLNGPTG PGPGPTG SCEPGLPGPP GPPGPPGQAV MPEGFIKAGG RPSLSGTPLV 540 ATKGLNGPTG PGGPTG SCEPGLPGPP GPPGPPGQAV MPEGFIKAGG RPSLSGTPLV 540 ATKGLNGPTG PGGPTG SCEPGLPGPP GPPGPPGQAV MPEGFIKAGG RPSLSGTPLV 540 ATKGLNGPTG PGGPTG PGG
70	SANQGVTGMP VSAFTVILSK AYPAIGTPIP FDKILYNRQQ HYDPRTGIFT CQIPGIYYFS 600 YHVHVKGTHV WYGLYKNGTP VMYTYDEYTK GYLDQASGSA IIDLTENDQV WLQLPNAESN 660 GLYSSEYVHS SFSGFLVAPM


Seq ID NO: 81 DNA sequence
Nucleic Acid Accession #: NM_000786
Coding sequence: 332-1861 (underlined sequences correspond to start and stop codons)

51

11 21 31 41

75

	CGCGATTCTC AGGGATTGAT CCGCCTCTTC AGGTAAGTTA TCTTCCGGCC CCGTACCACT 60
	GTGCCACAGG CGCAGCCCGC TTCCTCAGGT GCCCTATCCC GCGCAGAAGA CCACGGCTTC 120
_	ACAGAGTGTT ATTTAAGGGC GTGGCCAGCG GAACATCCCG CCCCATTCTG TGACGCACGG 180
5	GGTGGCGCG GTGGGACCCG AGGGGTGGGG CTGGGTTTAG TAGGAGACCT GGGGCAAGGC 240
	CCCCTGTGGA CGACCATCTG CCAGCTTCTC TCGTTCCGTC GATTGGGAGG AGCGGTGGCG 300
	ACCTCGGCCT TCAGTGTTTC CGACGGAGTG AATGGCGGCG GCGGCTGGGA TGCTGCTGCT 360
	GGGCTTGCTG CAGGCGGGTG GGTCGGTGCT GGGCCAGGCG ATGGAGAAGG TGACAGGCGG 420
10	CAACCTCTTG TCCATGCTGC TGATCGCCTG CGCCTTCACC CTCAGCCTGG TCTACCTGAT 480 CCGTCTGGCC GCCGGCCACC TGGTCCAGCT GCCCGCAGGG GTGAAAAGTC CTCCATACAT 540
10	TTTCTCCCCA ATTCCATTCC TTGGGCATGC CATAGCATTT GGGAAAAGTC CAATTGAATT 600
	TCTAGAAAAT GCATATGAGA AGTATGGACC TGTATTTAGT TTTACCATGG TAGGCAAGAC 660
	ATTTACTTAC CTTCTGGGGA GTGATGCTGC TGCACTGCTT TTTAATAGTA AAAATGAAGA 720
1 ~	CCTGAATGCA GAAGATGTCT ACAGTCGCCT GACAACACCT GTGTTTGGGA AGGGAGTTGC 780
15	ATACGATGTG CCTAATCCAG TTTTCTTGGA GCAGAAGAAA ATGTTAAAAA GTGGCCTTAA 840
	CATAGCCCAC TTTAAACAGC ATGTTTCTAT AATTGAAAAA GAAACAAAGG AATACTTTGA 900
	GAGTTGGGGA GAAAGTGGAG AAAAAAATGT GTTTGAAGCT CTTTCTGAGC TCATAATTTT 960
	AACAGCTAGC CATTGTTTGC ATGGAAAGGA AATCAGAAGT CAACTCAATG AAAAGGTAGC 1020 ACAGCTGTAT GCAGATTTGG ATGGAGGTTT CAGCCATGCA GCCTGGCTCT TACCAGGTTG 1080
20	GCTGCCTTTG CCTAGTTTCA GACGCAGGGA CAGAGCTCAT CGGGAAATCA AGGATATTTT 1140
	CTATAAGGCA ATCCAGAAAC GCAGACAGTC TCAAGAAAAA ATTGATGACA TTCTCCAAAC 1200
	TTTACTAGAT GCTACATACA AGGATGGGCG TCCTTTGACT GATGATGAAG TAGCAGGGAT 1260
	GCTTATTGGA TTACTCTTGG CAGGGCAGCA TACATCCTCA ACTACTAGTG CTTGGATGGG 1320
25	CTTCTTTTTG GCCAGAGACA AAACACTTCA AAAAAATGT TATTTAGAAC AGAAAACAGT 1380
25	CTGTGGAGAG AATCTGCCTC CTTTAACTTA TGACCAGCTC AAGGATCTAA ATTTACTTGA 1440
	TCGCTGTATA AAAGAAACAT TAAGACTTAG ACCTCCTATA ATGATCATGA TGAGAATGGC 1500
	CAGAACTCCT CAGACTGTGG CAGGGTATAC CATTCCTCCA GGACATCAGG TGTGTGTTTC 1560 TCCCACTGTC AATCAAAGAC TTAAAGACTC ATGGGTAGAA CGCCTGGACT TTAATCCTGA 1620
	TCGCTACTTA CAGGATAACC CAGCATCAGG GGAAAAGTTT GCCTATGTGC CATTTGGAGC 1680
30	TGGGCGTCAT CGTTGTATTG GGGAAAATTT TGCCTATGTT CAAATTAAGA CAATTTGGTC 1740
	CACTATGCTT CGTTTATATG AATTTGATCT CATTGATGGA TACTTTCCCA CTGTGAATTA 1800
	TACAACTATG ATTCACACCC CTGAGAACCC AGTTATCCGT TACAAACGAA GATCAAAA <u>TG</u> 1860
	AAAAAGGTTG CAAGGAACGA ATATATGTGA TTATCACTGT AAGCCACAAA GGCATTCGAA 1920
25	GAGAATGAAG TGTACAAAAC AACTCTTGTA GTTTACTGTT TTTTTAAGTG TGTAATTCTA 1980
35	AAAGCCAGTT TATGATTTAG GATTTTGTTA ACTGAATGGT TCTATCAAAT ATAATAGCAT 2040
	TTGACACATT TTCTAATAGT TATGATACTT ATACATGTGC TTTCAGGAAG TTCCTTGGTG 2100 AAACAATTGT TGAGGGGGGA TCTAGGTAAT TGGCAGATTC TAAATAATAT AATTTCCAGA 2160
	TAGTAATTTT AAGAGTACTC ATCGCTCTTG CCAAATAAGT TCAGGGTATT CAAATCTTGG 2220
	ACTAGTCCTG CAAGGTATAA AGAATAAAAA TCCCAGTGAG ATACTTGGAA ACCACAGTTT 2280
40	ATTATTATTT ATCTGGGCAA TTATTGTGTG TGTGAGGATG GAAGGGTAGG GAATAATCGA 2340
	ACATCTAAAG CCTTGAATAA GAGAATACTA ATTGTTTTGG TATGATGATA CTCAGAAATG 2400
	GAGATATTAT AGGAAAAAGA AATCCTTTGG AATTTTAACT AAAATCACTG CATATGGGAA 2460
	ATTAAGAGAT CCAGGACCAT ATTTGATAAG AGTTCCTAAA AATAATGTAA TTATTAATGC 2520
45	TAAAGACTGC TCATGTATCT TGATCTAATT ACTAAATAAA TTACATATTT ATTTACCTGA 2580 TAAATATGTA TCTAGTTCTA CAAGGTCACA TTTATGTGGA AGTCCAAAGT CAAGTCCTTA 2640
	GGGGATAATT TTGTTTTGGG CTCAGTTGTT CCCTGCTTCC TTTTTTTTTT
	TTGAGATGGA GTCTCGCTCT GTTGCCCAGG CTGGAGTGCA GTGGTGCGAT CTCAGCTCAC 2760
	TGCATCCTCT GCCTCCGGG TTCAAGCAAT TCTCTGCCTC AGCCTCCCAA GTAGTTGGGA 2820
50	TTACAGGCAC CTGCCACCAT GCCTGGCTAA TTTTTTGTAT TTTTAGTAGA GACGGGGGTT 2880
50	TCACTATGTT GGCTAGGCTG GTCTTGAACT CCTGAGCCTC GTGAGTCCAC CCGCCTTGGC 2940
	CTCCCAAAGT GCTGGGATTA CAGGCATGAG CCACCGCACC TGGCCTTCCC TGCTTCCTCT 3000
	CTAGAATCCA ATTAGGGATG TTTGTTACTA CTCATATTGA TTAAAACAGT TAACAAACTT 3060 TTTTCTTTTT AAAATGTGAG ATCAGTGAAC TCTGGTTTTA AGATAATCTG AAACAAGGTC 3120
	CTTGGGAGTA ATAAAATTGG TCACATTCTG TAAAGCACAT TCTGTTTAGG AATCAACTTA 3180
55	TCTCAAATTG TAACTCGGGG CCTAACTATA TGAGATGGCT GAAAAAATAC CACATCGTCT 3240
	GTTTTCACTA GGTGATGCCA AAATATTTTG CTTTATGTAT ATTACAGTTC TTTTTAAAAC 3300
	ACTGGAAGAC TCATGTTAAA CTCTAATTGT GAAGGCAGAA TCTCTGCTAA TTTTTCAGAT 3360
	TAAAATTCTC TTTGAAAAAA T
60	Seq ID NO: 82 Protein sequence:
00	Protein Accession #: NP_000777
	Total Necessian Transcription
	1 11 21 31 41 51
65	MAAAAGMLLL GLLQAGGSVL GQAMEKVTGG NLLSMLLIAC AFTLSLVYLI RLAAGHLVQL 60
	PAGVKSPPYI FSPIPFLGHA IAFGKSPIEF LENAYEKYGP VFSFTMVGKT FTYLLGSDAA 120
	ALLFNSKNED LNAEDVYSRL TTPVFGKGVA YDVPNPVFLE QKKMLKSGLN IAHFKQHVSI 180
	IEKETKEYFE SWGESGEKNV FEALSELIIL TASHCLHGKE IRSQLNEKVA QLYADLDGGF 240 SHAAWLLPGW LPLPSFRRRD RAHREIKDIF YKAIQKRROS QEKIDDILOT LLDATYKDGR 300
70	PLTDDEVAGM LIGLLLAGQH TSSTTSAWMG FFLARDKTLQ KKCYLEQKTV CGENLPPLTY 360
	DQLKDLNLLD RCIKETLRLR PPIMIMMRMA RTPQTVAGYT IPPGHQVCVS PTVNQRLKDS 420
	WVERLDFNPD RYLQDNPASG EKFAYVPFGA GRHRCIGENF AYVQIKTIWS TMLRLYEFDL 480
	IDGYFPTVNY TTMIHTPENP VIRYKRRSK
75	C. VD VO OR DVVA
75	Seq ID NO: 83 DNA sequence Nucleic Acid Accession #: NM 006551.2
	Coding sequence: 64-336 (underlined sequences correspond to start and stop codons)
	38/



GCTCAAGTCT GAACTCTACC TCCAGACAGA <u>ATG</u>AAGTTCA TCTCGACATC TCTGCTTCTC 120 ATGCTGCTGG TCAGCAGCCT CTCTCCAGTC CAAGGTGTTC TGGAGGTCTA TTACACAAGC 180 TTGAGGTGTA GATGTGTCCA AGAGAGCTCA GTCTTTATCC CTAGACGCTT CATTGATCGA 240 ATTCAAATCT TGCCCCGTGG GAATGGTTGT CCAAGAAAAG AAATCATAGT CTGGAAGAAG 300 5 AACAAGTCAA TTGTGTGTGT GGACCCTCAA GCTGAATGGA TACAAAGAAT GATGGAAGTA 360 TTGAGAAAAA GAAGTTCTTC AACTCTACCA GTTCCAGTGT TTAAGAGAAA GATTCCC<u>TGA</u> 420 TGCTGATATT TCCACTAAGA ACACCTGCAT TCTTCCCTTA TCCCTGCTCT GGATTTTAGT 480 TTTGTGCTTA GTTAAATCTT TTCCAGGGAG AAAGAACTTC CCCATACAAA TAAGGCATGA 540 GGACTATGTG AAAAATAACC TTGCAGGAGC TGATGGGGCA AACTCAAGCT TCTTCACTCA 600 10 CAGCACCCTA TATACACTTG GAGTTTGCAT TCTTATTCAT CAGGGAGGAA AGTTTCTTTG 660 AAAATAGTTA TICAGTTATA AGTAATACAG GATTATTTTG ATTATATACT TGTTGTTTAA 720
TGTTTAAAAT TTCTTAGAAA ACAATGGAAT GAGAATTTAA GCCTCAAATT TGAACATGTG 780
GCTTGAATTA AGAAGAAAAT TATGGCATAT ATTAAAAGCA GGCTTCTATG AAAGACTCAA 840
AAAGCTGCCT GGGAGGCAGA TGGAACTTGA GCCTGTCAAG AGGCAAAGGA ATCCATGTAG 900 15 TAGATATCCT CTGCTTAAAA ACTCACTACG GAGGAGAATT AAGTCCTACT TTTAAAGAAT 960 TTCTTTATAA AATTTACTGT CTAAGATTAA TAGCATTCGA AGATCCCCAG ACTTCATAGA 1020 ATACTCAGGG AAAGCATTTA AAGGGTGATG TACACATGTA TCCTTTCACA CATTTGCCTT 1080 GACAAACTTC TTTCACTCAC ATCTTTTTCA CTGACTTTTT TTGTGGGGGC GGGGCCGGGG 1140 GGACTCTGGT ATCTAATTCT TTAATGATTC CTATAAATCT AATGACATTC AATAAAGTTG 1200 20 AGCAAACATT TTACTT Seq ID NO: 88 Protein sequence: NP_006410.1 Protein Accession #: 25 MKFISTSLLL MLLVSSLSPV QGVLEVYYTS LRCRCVQESS VFIPRRFIDR IQILPRGNGC 60 PRKEIIVWKK NKSIVCVDPQ AEWIQRMMEV LRKRSSSTLP VPVFKRKIP 30 Sea ID NO: 89 DNA sequence Nucleic Acid Accession #: NM_002652 Coding sequence: 37-477 (underlined sequences correspond to start and stop codons) 21 31 41 35 CTTCTCTGGG ACACATTGCC TTCTGTTTTC TCCAGC<u>ATG</u>C GCTTGCTCCA GCTCCTGTTC 60 AGGGCCAGCC CTGCCACCCT GCTCCTGGTT CTCTGCCTGC AGTTGGGGGC CAACAAAGCT 120 CAGGACAACA CTCGGAAGAT CATAATAAAG AATTTTGACA TTCCCAAGTC AGTACGTCCA 180 AATGACGAAG TCACTGCAGT GCTTGCAGTT CAAACAGAAT TGAAAGAATG CATGGTGGTT 240

AAAACTTACC TCATTAGCAG CATCCCTCTA CAAAGGTGCAT TTAACTATAA GTATACTGCC 300

TGCCTATGTG ACGACAATCC AAAAACCTTC TACTGGGACT TTTACACCAA CAGAACTGTG 360

CAAATTGCAG CCGTCGTTGA TGTTATTCGG GAATTAGGCA TCTGCCCTGA TGATGCTGCT 420 40 GTAATCCCCA TCAAAAACAA CCGGTTTTAT ACTATTGAAA TCCTAAAGGT AGAATAATGG 480 AAGCCCTGTC TGTTTGCCAC ACCCAGGTGA TTTCCTCTAA AGAAACTTGG CTGGAATTTC 540 45 TGCTGTGGTC TATAAAATAA ACTTCTTAAC ATGCTT Seq ID NO: 90 Protein sequence:
Protein Accession #: NP_002643.1 50 31 MRLLQLLFRA SPATLLLVLC LQLGANKAQD NTRKIIIKNF DIPKSVRPND EVTAVLAVQT 60 ELKECMVVKT YLISSIPLQG AFNYKYTACL CDDNPKTFYW DFYTNRTVQI AAVVDVIREL 120 GICPDDAAVI PIKNNRFYTI EILKV 55 Seq ID NO: 91 DNA sequence AK000341 Nucleic Acid Accession #: Coding sequence: 85-975 (underlined sequences correspond to start and stop codons) 60 GATAGCGCCG GGCAGAGGGA CCCGGCTACC CTGGACAGCG CATCGCCGCC CGCCCGGGTC 60
GCCGCGCCAC AGCCGCTGCG GATC<u>ATG</u>GAA CATCTAAAGG CCTTTGATGA TGAAATCAAT 120 GCTTTTTTGG ACAATATGTT TGGACCGCGA GATTCTCGAG TCAGAGGGTG GTTCACGTTG 180 65 GACTCTTACC TTCCTACCTT TTTTCTTACT GTCATGTATC TGCTCTCAAT ATGGCTGGGT 240 AACAAGTATA TGAAGAACAG ACCTGCTCTT TCTCTCAGGG GTATCCTCAC CTTGTATAAT 300 GCAAGGTGC TTTGGTGGTA CTATTTCTCC AAATCAGTAG AGTTCTCTC CACTTGGGAA 360
GCCAAGGTGC TTTGGTGGTA CTATTTCTCC AAATCAGTAG AGTTCTCTC CACTTGGGAA 420
GCCAAGGTGC TTTGGTGGTA CTATTTCTCC AAATCAGTAG AGTTCCTGGA CACAATTTTC 480
TTCGTTTTGC GGAAAAAAAC GAGTCAGATT ACTTTTCTTC ATGTATATCA TCATGCTTCT 540 70 ATGTTTAACA TCTGGTGGTG TGTCTTGAAC TGGATACCTT GTGGACAAAG TTTCTTTGGA 600 CCAACACTGA ACAGTTTTGT CCACATTCTT ATGTACTCCT ACTATGGACT TTCTGTGTTT 660 CCATCTATGC ACAAGTATCT TTGGTGGAAG AAATATCTCA CACAGGCTCA GCTGGTGCAG 720
TTCGTGCTCA CCATCACGCA CACCATGAGC GCCGTCGTGA AACCGTGTGG CTTCCCCTTC 780
GGTTGTCTCA TCTTCCAGTC ATCTTATATG CTAACGTTAG TCATCCTCTT CTTAAATTTT 840 75 TATGTTCAGA CATACCGAAA AAAGCCAATG AAGAAAGATA TGCAAGAGCC ACCTGCAGGG 900
AAAGAAGTGA AGAATGGTTT TTCCAAAGCC TACTTCACTG CAGCAAATGG AGTGATGAAC 960





TTGTTGGCAC ACCTTATTAC ATGTCTCCTG AACAAATGAA TCGCATGTCC TACAATGAGA 720 THOUGH ACCITATIAC ARTICLE IN AARTHUR TO THOUGHT A ATTOCTIC TO THE ATTOCTIC ATTOCTIC TO THOUGHT A TOCCTIC AT T80

TTACAGCTTT TAGCCAGAAA GAACTCGCTG GGAAAATCAG AGAAGCCAAA TTCAGGCGAA 840

TTCCATACCG TTACTCTGAT GAATTGAATG AAATTATTAC GAGGATGTTA AACTTAAAGG 900

ATTACCATCG ACCTTCTGTT GAAGAAATTC TTGAGAACCC TTTAATAGCA GATTTGGTTG 960 5 CAGACGAGCA AAGAAGAAAT CTTGAGAGAA GAGGGCGACA ATTAGGAGAG CCAGAAAAAT 1020 CGCAGGATTC CAGCCCTGTA TTGAGTGAGC TGAAACTGAA GGAAATTCAG TTACAGGAGC 1080 GAGAGCGAGC TCTCAAAGCA AGAGAAGAAA GATTGGAGCA GAAAGAACAG GAGCTTTGTG 1140 TTCGTGAGAG ACTAGCAGAG GACAAACTGG CTAGAGCAGA AAATCTGTTG AAGAACTACA 1200 10 GCTTGCTAAA GGAACGGAAG TTCCTGTCTC TGGCAAGTAA TCCAGAACTT CTTAATCTTC 1260 CATCCTCAGT AATTAAGAAG AAAGTTCATT TCAGTGGGGA AAGTAAAGAG AACATCATGA 1320 GGAGTGAGAA TTCTGAGAGT CAGCTCACAT CTAAGTCCAA GTGCAAGGAC CTGAAGAAAA 1380 GGCTTCACGC TGCCCAGCTG CGGGCTCAAG CCCTGTCAGA TATTGAGAAA AATTACCAAC 1440 TGAAAAGCAG ACAGATCCTG GGCATGCGC<u>T AG</u>CCAGGTAG AGAGACACAG AGCTGTGTAC 1500 15 AGGATGTAAT ATTACCAACC TTTAAAGACT GATATTCAAA TGCTGTAGTG TTGAATACTT 1560 GGCCCCATGA GCCATGCCTT TCTGTATAGT ACACATGATA TTTCGGAATT GGTTTTACTG 1620 TTCTTCAGCA ACTATTGTAC AAAATGTTCA CATTTAATTT TTCTTTCTTC TTTTAAGAAC 1680 ATATTATAAA AAGAATACTT TCTTGGTTGG GCTTTTAATC CTGTGTGTGA TTACTAGTAG 1740 GAACATGAGA TGTGACATTC TAAATCTTGG GAGAAAAAAT AATATTAGGA AAAAAAATATT 1800 20 TATGCAGGAA GAGTAGCACT CACTGAATAG TTTTAAATGA CTGAGTGGTA TGCTTACAAT 1860 TGTCATGTCT AGATTTAAAT TTTAAGTCTG AGATTTTAAA TGTTTTTGAG CTTAGAAAAC 1920 CCAGTTAGAT GCAATTTGGT CATTAATACC ATGACATCTT GCTTATAAAT ATTCCATTGC 1980 TCTGTAGTTC AAATCTGTTA GCTTTGTGAA AATTCATCAC TGTGATGTTT GTATTCTTTT 2040 TTTTTTTCTG TTTAACAGAA TATGAGCTGT CTGTCATTTA CCTACTTCTT TCCCACTAAA 2100 25 TAAAAGAATT CTTCAGTTA Seq ID NO: 96 <u>Protein sequence:</u>
Protein Accession #: NP_002488 30 51 GIREFNPNIM ANEVERINMI TOSISGENEA RELATEDKIN ASEHOMOSAP IENSMPSRAE 60 DYEVLYTIGT GSYGRCOKIR RKSDGKILVW KELDYGSMTE AEKOMLVSEV NLLRELKHPN 120 IVRYYDRIID RTNTTLYIVM EYCEGGDLAS VITKGTKERQ YLDEEFVLRV MTQLTLALKE 180 35 CHRRSDGGHT VLHRDLKPAN VFLDGKQNVK LGDFGLARIL NHDTSFAKTF VGTPYYMSPE 240 QMNRMSYNEK SDIWSLGCLL YELCALMPPF TAFSQKELAG KIREGKFRRI PYRYSDELNE 300 IITRMLNIKD YHRPSVEEIL ENPLIADLVA DEQRRNLERR GRQLGEPEKS QDSSPVLSEL 360 KLKEIQLQER ERALKAREER LEQKEQELCV RERLAEDKLA RAENLLKNYS LLKERKFLSL 420 ASNPELLNLP SSVIKKKVHF SGESKENIMR SENSESQLTS KSKCKDLKKR LHAAQLRAQA 480 40 LSDIEKNYQL KSRQILGMR Seq ID NO: 97 DNA sequence Nucleic Acid Accession #: NM_007050.2 Coding sequence: 185-4576 (underlined sequences correspond to start and stop codons) 45 41 CCTCCCGCCT CAGTTCGCGC CGCGCCTCGG CTTGGAACGC AGGAGCGCCG GCTCCGGGAG 60 CCCGAGCGGA GCCAGCCGC CGCACAGCCA GCGGCCGCC CGGCGATGCG GGGCCACCCC 120 50 GCGCCCGCCC CAGTCCCGGC CCCGGCCCCC GCGGGAAGGG GCTGAGCTGC CCGCCGCCGC 180 CCGGATGCCG AGCCTCGCCG CGCTCGCCCT CAGCCTGCTC CTGAGGCTGC AGCTGCCGCC 240
ACTGCCCGGC GCCCGGGCTC AGAGCGCCCC AGGTGGCTGT TCCTTTGATG AGCACTACAG 300
CAACTGTGGT TATAGTGTGG CTCTAGGGAC CAATGGGTTC ACCTGGGAGC AGATTAACAC 360 AACGGAGAAA CCAATGCTGG ACCAGGCAGT GCCCACAGGA TCTTTCATGA TGGTGAACAG 420 55 CTCTGGGAGA GCCTCTGGCC AGAAGGCCCA CCTTCTCCTG CCAACCCTGA AGGAGAATGA 480 CACCCACTGC ATCGACTTCC ATTACTACTT CTCCAGCCGT GACAGGTCCA GCCCAGGGGC 540 CTTGAACGTC TACGTGAAGG TGAATGGTGG CCCCCAAGGG AACCCTGTGT GGAATGTGTC 600 CTIGAACGIC FACGIGAAGG IGAATGGIGG CCCCCAAGGG AACCCIGIGI GGAATGIGIC 600
CGGGGGTCGTC ACTGAGGCT GGGTGAAGGC AGAGCTCGCC ATCAGCACTT TCTGGCCACA 660
TTTCTATCAG GTGATATTTG AATCCGTCTC ATTGAAGGT CATCCTGGCT ACATCGCCGT 720
GGACGAGGTC CGGGTCCTTG CTCATCCATG CAGAAAAGCA CCTCATTTTC TGCGACTCCA 780
AAACGTGGAG GTGAATGTGG GGCAGAATGC CACATTTCAG TGCATTGCTG GTGGGAAGTG 840 60 GTCTCAGCAT GACAAGCTTT GGCTCCAGCA ATGGAATGGC AGGGACACGG CCCTGATGGT 900 CACCCGTGTG GTCAACCACA GGCGCTTCTC AGCCACAGTC AGGGGCACAG ACACTGCCCA 960
GCGGAGCGTC AGCAAGTACC GCTGTGTGAT CCGCTCTGAT GGTGGGTCTG GTGTGTCCAA 1020
CTACGCGGAG CTGATCGTGA AAGAGCCTCC CACGCCCATT GCTCCCCCAG AGCTGCTGGC 1080
TGTGGGGGCC ACATACCTGT GGATCAAGCC AAATGCCAAC TCCATCATCG GGGATGGCCC 1140
CATCATCCTG AAGGAAGTGG AATATCGCAC CACCACAGGC ACGTGGGCAG AGACCCACAT 1200 65 AGTCGACTCT CCCAACTATA AGCTGTGGCA TCTGGACCCC GATGTTGAGT ATGAGATCCG 1260 AGTGCTCCTC ACACGACCAG GTGAGGGGGG TACGGGACCG CCAGGGGCTC CCCTCACCAC 1320 70 CAGGACCAAG TGTGCAGATC CGGTACATGG CCCACAGAAC GTGGAAATCG TAGACATCAG 1380 AGCCCGGCAG CTGACCCTGC AGTGGGAGCC CTTCGGCTAC GCGGTGACCC GCTGCCATAG 1440
CTACAACCTC ACCGTGCAGT ACCAGTATG GTTCAACCAG CAGCAGTACG AGGCCGAGGA 1500
GGTCATCCAG ACCTCCTCCC ACTACACCCT GCGAGGCCTG CGCCCCTTCA TGACCATCCG 1560
GCTGCGACTC TTGCTGTCTA ACCCCGAGGG CCGAATGGAG AGCGAGGAGC TGGTGGTGCA 1620 75 GACTGAGGAA GACGTTCCAG GAGCTGTTCC TCTAGAATCC ATCCAAGGGG GGCCCTTTGA 1680


GGAGAAGATC TACATCCAGT GGAAACCTCC CAATGAGACC AATGGGGTCA TCACGCTCTA 1740 CGAGATCAAC TACAAGGCTG TCGGCTCGCT GGACCCAAGT GCTGACCTCT CGAGCCAGAG 1800


GACCACCTAT TCCTTCACCA TCAAGGCCAG CACAGCAAAG GGCTTTGGGC CCCCTGTCAC 1920
CACTCGGATT GCCACCAAAA TTTCAGCTCC ATCCATGCCT GAGTACGACA CAGACACCCC 1980 ATTGAATGAG ACAGACACGA CCATCACAGT GATGCTGAAA CCCGCTCAGT CCCGGGGAGC 2040 5 TCCTGTCAGT GTTTATCAGC TGGTTGTCAA GGAGGAGCGA CTTCAGAAGT CACGGAGGGC 2100 AGCTGACATT ATTGAGTGCT TTTCGGTGCC CGTGAGCTAT CGGAATGCCT CCAGCCTCGA 2160 TTCTCTACAC TACTTTGCTG CTGAGTTGAA GCCTGCCAAC CTGCCTGTCA CCCAGCCATT 2220 TACAGTGGGT GACAATAAGA CATACAATGG CTACTGGAAC CCTCCTCTC CTCCCCTGAA 2280 AAGCTACAGC ATCTACTTCC AGGCACTCAG CAAAGCCAAT GGAGAGACCA AAATCAACTG 2340 TGTTCGTCTG GCTACAAAAG CACCAATGGG CAGCGCCCAG GTGACCCCGG GGACTCCACT 2400 10 CTGCCTCCTC ACCACAGGTG CCTCCACCCA GAATTCTAAC ACTGTGGAGC CAGAGAAGCA 2460 GGTGGACAAC ACCGTGAAGA TGGCTGGCGT GATCGCTGGC CTCCTCATGT TCATCATCAT 2520 TCTCCTGGGC GTGATGCTCA CCATCAAAAG GAGAAGAAAT GCTTATTCCT ACTCCTATTA 2580 CTTGTCCCAA AGGAAGCTGG CCAAGAAGCA GAAGGAGACC CAGAGTGGAG CCCAGAGGGA 2640
GATGGGGCCT GTGGCCTCTG CCGACAAACC CACCACCAAG CTCAGCGCCA GCCGCAATGA 2700
TGAAGGCTTC TCTTCTAGTT CTCAGGACGT CAACGGATTC ACAGATGGCA GCCGCGGGGA 2760
GCTTTCCCAG CCCACCCTCA CGATCCAGAC TCATCCCTAC CGCACCTGTG ACCCTGTGGA 2820 15 GATGAGCTAC CCCCGGGACC AGTTCCAACT CGCCATCCGG GTGGCTGACT TGCTGCAGCA 2880 CATCACGCAG ATGAAGAGAG GCCAGGGCTA CGGGTTCAAG GAGGAATACG AGGCCTTACC 2940 20 AGAGGGGCAG ACAGCTTCGT GGGACACAGC CAAGGAGGAT GAAAACCGCA ATAAGAATCG 3000 ATATGGGAC ATCATATCCT AGGACCAGC CAAGGAGGAT GAAACCGCA ATAAGAATCC 3000
ATATGGGACA ATCATATCCT ACGACCATTC CCGGGTGAGG CTGCTGGTGC TGGATGAGAGA 3060
CCCGCACTCT GACTACATCA ATGCCAACTA CATTGACGGA TACCATCGAC CTCGGCACTA 3120
CATTGCGACT CAAGGTCCGA TGCAGGAGAC TGTAAAGGAC TTTTGGAGAA TGATCTGGCA 3180
GGAGAACTCC GCCAGCATCG TCATGGTCAC AAACCTGGTG GAAGTGGGCA GGGTGAAATG 3240 25 TGTGCGATAC TGGCCAGATG ACACGGAGGT CTACGGAGAC ATTAAAGTCA CCCTGATTGA 3300 AACAGAGCCC CTGGCAGAAT ACGTCATACG CACCTTCACA GTCCAGAAGA AAGGCTACCA 3360 TGAGATCCGG GAGCTCCGCC TCTTCCACTT CACCAGCTGG CCTGACCACG GCGTTCCCTG 3420 CTATGCCACT GGCCTTCTGG GCTTCGTCCG CCAGGTCAAG TTCCTCAACC CCCCGGAAGC 3480 TGGGCCCATA GTGGTCCACT GCAGTGCTGG GGCTGGCGG ACTGGCTGCT TCATTGCCAT 3540 TGACACCATG CTTGACATGG CCGAGAATGA AGGGGTGGTG GACATCTTCA ACTGCGTGCG 3600 30 TGAGCTCCGG GCCCAAAGGG TCAACCTGGT ACAGACAGAG GAGCAATATG TGTTTGTGCA 3660 CGATGCCATC CTGGAAGCGT GCCTCTGTGG CAACACTGCC ATCCCTGTGT GTGAGTTCCG 3720 TTCTCTCTAC TACAATATCA GCAGGCTGGA CCCCCAGACA AACTCCAGCC AAATCAAAGA 3780 TGAATTTCAG ACCCTCAACA TTGTGACACC CCGTGTGCGG CCCGAGGACT GCAGCATTGG 3840 35 GCTCCTGCCC CGGAACCATG ATAAGAATCG AAGTATGGAC GTGCTGCCTC TGGACCGCTG 3900 CCTGCCCTTC CTTATCTCAG TGGACGGAGA ATCCAGCAAT TACATCAACG CAGCACTGAT 3960 GGATAGCCAC AAGCAGCCTG CCGCCTTCGT GGTCACCCAG CACCCTCTAC CCAACACCGT 4020 GGCAGACTTC TGGAGGCTGG TGTTCGATTA CAACTGCTCC TCTGTGGTGA TGCTGAATGA 4080 GATGGACACT GCCCAGTTCT GTATGCAGTA CTGGCCTGAG AAGACCTCCG GGTGCTATGG 4140 40 GCCCATCCAG GTGGAGTTCG TCTCCGCAGA CATCGACGAG GACATCATCC ACAGAATATT 4200 CCGCATCTGT AACATGGCCC GGCCACAGGA TGGTTATCGT ATAGTCCAGC ACCTCCAGTA 4260 CCGACTOT AACATOGCCC GGCACAGGA TGGTTATCGT ATAGTICAGC ACTCCAGTA 4260 CATTGGCTGG CCTGCCTACC GGGACACGCC CCCCTCCAAG CGCTCTCTGC TCAAAGTGGT 4320 CCGACGACTG GAGAAGTGGC AGGACAGTA TGACGGGAGG GAGGGACGTA CTGTGGTCCA 4380 CTGCCTAAAT GGGGGAGGCC GTAGTGGAAC CTTCTGTGCC ATCTGCAGTG TGTGTGAGAT 4440 GATCCAGCAG CAAAACATCA TTGACGTGTT CCACATCGTG AAAACACTGC GTAACAACAA 4500 45 ATCCAACATG GTGGAGACCC TGGAACAGTA TAAATTTGTA TACGAGGTGG CACTGGAATA 4560 TTTAAGCTCC TTT<u>TAG</u>CTCA ATGGGATGGG GAACTGCCGG AGTCCAGAGG CTGCTGTGAC 4620 CAAGCCCCCT TTTGTGTGAA TGGCAGTAAC TGGGCTCAGG AGCTCTGAGG TGGCACCCTG 4680 CCTGACTCCA AGGAGAAGAC TGGTGGCCCT GTGTTCCACG GGGGGCTCTG CACCTTCTGA 4740 50 GGGTCTCCT GTTGCCGTGG GAGATGCTGC TCCAAAAGGC CCAGGCTTCC TTTTCAACCT 4800 AACCAGCCAC AGCCAAGGGC CCAAGCAGAA GTACACCCAC AAGCAAGGCC TTGGATTTCT 4860 GGCTCCCAGA CCACCTGCTT TTGTTCTGAG TTTGTGGATC TCTTGGCAAG CCAACTGTGC 4920 AGGTGCTGGG GAGTGGGAGG CTCCCTGCC CTCCTTCTCC TTAGGAGTGG AGGAGATGTG 4980 TGTTCTGCTC CTCTACGTCA TGGAAAAGAT TGAGGCTCTT GGGGGTCACT GCTCTGCTGC 5040 55 CCCCTGCAAC CTCCTTCAGG GGCCTCTGGC ACCAGACATT TGCAGTCTGG ACCAGTGTGA 5100 CCTTACGATG TTCCCTAGGC CACAAGAGAG GCCCCCCATC CTCACACCTA ACCTGCATGG 5160 GGCTTCGCCC ACAACCATTC TGTACCCCTT CCCCAGCCTG GGCCTTGACC GTCCAGCATT 5220 CACTGGCCGG CCAGCTGTGT CCACAGCAGT TTTTGATAAA GGTGTTCTTT GCTTTTTTGT 5280 GTGGTCAGTG GGAGGGGGTG GAACTGCAGG GAACTTCTCT GCTCCTCCTT GTCTTTGTAA 5340 60 AAAGGGACCA CCTCCCTGGG GCAGGGCTTG GGCTGACCTG TAGGATGTAA CCCCTGTGTT 5400 TCTTTGGTGG TAGCTTTCTT TGGAAGAGAC AAACAAGATA AGATTTGATT ATTTTCCAAA 5460 GTGTATGTGA AAAGAAACTT TCTTTTGGAG GGTGTAAAAT CTTAGTCTCT TATGTCAAAA 5520 AGAAGGGGGC GGGGGAGTTT GAGTATGTAC CTCTAAGACA AATCTCTCGG GCCTTTTATT 5580 TTTTCCTGGC AATGTCCTTA AAAGCTCCCA CCCTGGGACA GCATGCCACT GAGCAAGGAG 5640 AGATGGGTGA GCCTGAAGAT GGTCCCTTTG GTTTCTGGGG CAAATAGAGC ACCAGCTTTG 5700 65 TGCATAATTT GGATGTCCAA ATTTGAACTC CTTCCTAAAG AAACCCAGCA GCCACCTTGA 5760 AAAAGGCCAT TGTGGAGCCC ATTATACTTT GATTTAAAAT AGGCCAAGAG AATCAGGCCT 5820 GGAGATCTAG GGTCTTGTCC AAAGTGTGAG TGAGTCAATG AGAGGGAACC AACATTTGCT 5880 AAGTCTCTAC TGTATGCCAG GGATCATGCT TGGCACTTTC CATAGGACAT TTCACACAGT 5940
CCTTAGAACC CCCAGGAGAG AGCTACTGAC TTGTTATCAT CTCCATTTGA TCATCTCCTC 6000
CAATGAGGAA ACCCACGCAC CTTCCTTAGT AATGAAATCC TGGGTTCCAA AGGGGCAGGT 6060
AATGGCAATG AGACTTCTCC GTGCTGTTTT CTTCATCTTC TCTAAGCCAA GCAATTATTT 6120 70 TATGGAGGGA AAATAAGGCC AGAAACTTCT GAGCAGATAA CTCCACAAAT GGAAATTTAG 6180 TACTTTCTTC CTGATGCCAG TTCTTCTGGG AAGCGCAGAA TTTCAGATAT ATTTTAGTAA 6240 75 CACATTCCCA GCTCCCCAGG AAAGCCAGTC TCATCTAATT TCTTAGTCAG TAAAAACAAT 6300 TCCCTGTTCC TTCAGGCTAT GAATGGACCA GCCAGGGAAA CTCTCGACCT TGATCTCTAG 6360 CCAGTGCTTA GGCCCAATAT CTGACAGCCT CAGGTGGGCT GGGACCTAGG AAGCTCCATC 6420

GGGGAAAGTG TTCAAGCTCC GGAATGAAAC CCACCACCTC TTTGTGGGTC TGTACCCAGG 1860

TTGAAGGCTG GTCTAGCCCC AGACAGGGCA TGAGGGGCAG AGAATTCAAG AAGGTACAGC 6480 TTTGGCCCTC AAGAGCCCAC TGTATGCTGG GGAAATGGAA CCATGGTGCA GTAGTGTGGA 6540 GTGGATGAGT GTTCCATGAG CCTAGGAGCA AGAAAGTCTC TTCGGCCTCG GGCTTCCTGG 6600 AGAAGGGGAC GTCCATTCCT GCTGGGTCTT AACAAGCATA AAAAGGAAAA AAAGGAAACT 6660 5 CAGGCAAAGG GATCCATATG TGCAATGGCA AAGAAATGTG AAAAGGCATT GGGAGAAGCA 6720 GTCTGGGGGA GGCCAGCCCA GTGCGGGCAC AGCACAACAC GGGGAGCAGC AAGAGATGAG 6780 CCAGGGTCCA GGAGACAGAT GCCCATCGCG AGTACAGACT TTGTCCTATT GGCAACAAGG 6840 AGTCCATGGA GCTTTAGAGA GATGCACTCA GCTTCGTGTT GGCCAAGACT CCTTCTGGGC 6900 CAATGGGGCT GCCTCTTTTC CTTTCATCAG ACACTGTGAA AACATTCCCT TAAGCGTGCA 6960 10 CTTTTTAATA TCACATCTAT TTGTCTGTCT GCTCATTGTT TTGTTGCTGG AACTAAATAT 7020 GCAATGGATC ATGAGACTCA GATTCTATGA GAAACCCAGG GTCTCTGCTT TACCACGGAG 7080 CAGGGTCACC AACCCAGATC TCCAGGCCCA TGAGGATGGA ACATGAAAGG AGCCGACAAA 7140 AGTTGCTTCC ATTGGCATGG GCTCTGGAGC TGTCCAGAAG TCCAGGGACA CCAGACTTGA 7200 TCAAGGAAGG GCTGTCACTT TAGAGGTTCA AAAGGAAGTG CCTCAAAGCA AAGGCAAGCA 7260 15 AAGGAACCCC ACGATGAACT TGCTCTTTTC CTTTGATGAG CCTCTCCCCA GGTGTATTTC 7320 AGCAGACCCC GGGGACCCAC CCCCACTGGG CCTGCTGGCC TCCCTCGGCT CCAGCCCAAT 7380 GCCCCAGCTG GCCTTCCCCA GCCTGCAAGG AGCCTGTAGC ATGGCAAATC TGCCTGCTGT 7440 ATGCTATTTT CTTAGATCTT GGTACATCCA GACAGGATGA GGGTGGAGGG AGAGCTATTT 7500 AACACAAATC CTAAGATTTT TTTCTGCTCA GGAAGGGGTG AAATAGCTGG CAGATACAAA 7560 20 AGACAGTGGC TTTTATCATT TTAAATGGTA GGAATTTAAG GTGTGACTTC AGGGAGAAAC 7620 AAACTTGCAA AAAAAAAAA TCTCAGGCCA TGTTGGGGTA ACCCAGCAAG GGCCAGTGAT 7680 GATTTCCCCC AGCTCATCCC CTTATTTTCC CACAACCCAA CCATTCTCTA AAGCAGGACA 7740 GTGAATAGGT CTTAGGCCAG TGCACACAGG AAGAAATTGA GGCTTATGGA TGGGGATGAC 7800 TTCCCTAAGA TCCCATGGGA CAAGGATGTG GCAAGGCTTG GATGAGATGG GGCACCAGTG 7860 CCCAGGAATT TGAACATTTT CCTTTACCCA GGAAATCTCC GGAGCCAACA CCACCACCC 7920 25 CAGGGGGTCT CCCCACCCA CCCCATTTAC AGGGTGAGCT CAGCCTGTCA TGAGCAGAGG 7980 AAAATATTAT TAATGCTCTC TGAGTCTTTA CAACAGGAGC TCTTACCTCA TAGATGTGGG 8040 CTCTGTTTGG GGAAGATGCA AGGAAGTAAT GAGAAGCCCA GGAAATTTCT CCACCTGTGT 8100 TTATGGCCTA AATAGCTTCA GGATGTATCT TAGCTGCACT CCAACATTGC ATCCTTTCTG 8160 GGTGAAGAA TCTGGGCCAA CCAGGGGTCC TTGGGCCTCT AGAAGGCCAC AGTAGGCCTC 8220 TCTTTGTGGG AATGGAAGGG GACAGTTTGC TTTTAGTGCT GGCCCTCTCT GTGGGTGTGG 8280 CCTGCAAAGG AACCAACAGA CCCTATGCTG GGGACTCTAA CATGTGAGCT CATTAAATTC 8340 30 TTCCAGCATT CTAAAGGAGG GTTTGTGATT GTCACCATTT ACTGATGAGG AAACTAAGGC 8400 TCCTAGGGGA GAAATCACTT GCCCACAGTT CCACAGCTAG TGAGTGAATG AACCAGGATT 8460 35 TAAACCGGTT TTTTCTCACT ACAGAGACAA TATTTTTCCA CCATTGTATC TCACATTTTT 8520 CCCAGGAGGT TACCCATAAC AGAAGAGACT AGAGTGGAAC AGATACGTCA GTGGATAAAG 8580 CTCAAAGCAA ACAACAGTAA GCTTAAAATT CCTTCATAGT CTCATGTTTT ACGTTCACAA 8640 TTCATGCAAA ATTTGCATTC CACTTTCTGA TTTAGCCTTG TTGGTTTTAA TATGACTCTA 8700 40 TATGACGGAC CCTAGGTCAG CTGGTCTTCA GCTTGACCCT AGAATTGACT CTAGGAGCAG 8820 TGACCCTGCT GCCTCCCAGA GCCAGTTATA GGCTCAAGAT CAAGACCAAC TGACCTTCTC 8880 CTAGGCAGCT CCTTTGGTGT GTGGGTGCTC TGACCTCACT GTTCATGAGG GGACCTCAAC 8940 TAAGGCATCT TCCAGTTGGG TGCTGGAAGG AACCCATTAA CTCACACTAG AATGATGAGG 9000
ATTTGCTCAT CTGGCGTGGA GAAGGATGAG CCCACAAAAC CCTAAAGGGA AAAGAAGC 9060
TGGACACAGC TGTACTCAGC AGATTCCTGA ATGCTAGGCT GGAAAGTGGT GCCTGTTGTC 9120
CAAGTGGAGT CACATGGTTG CTAATGTGGG CAAGTCTGAG GACACACTTC ATGAGCAGCT 9180 45 GGGGTCTGGA AGGCTCCTCA CTTTACCCTA GCCACACATA ATTACTGGGT GCCTACAGCA 9240 CCTAGCACCT TGGAGGGGGC ACTATTAGGA AATCGAGATT ACTATGGCAC AATTAATTCC 9300 TGGGTAAGGC ATGGGGTTGT GGTGGACAGA GCTCAGTCTT TAGTTTGAAC GAAAACATAC 9360 50 ATACATGAAA AACATACATG AAAAAAGGAC CCTCATCAAC ATTAGAAGGG GTAGATTTGG 9420 AGCACTTTAG GCAGGAAAAC AGGAACGCAA GGCCAGGAAA CTGGAACCCA GTGAATACTC 9480 AGAACCGAGG ATGCAGATGA CTTATTTAGC AAAATGGTCA CTTCTGTGAC ATAGCTGGAG 9540 AAAGGATGGG TAACAGCTTG CCAGAGCCAC TTGGAACAAG GGCAAATCTC AGTGTCTGGG 9600 GCAAAAGATG ATGCATTTCC CTCTGACCCA TCATGTTTAT TCATCCTCCA CTCCCCATTG 9660 55 CCACACTAGC TCTTGCTGTA AGTCCTCACC AGGATCTACA TTTCCTCGTC GCTGGTGGGA 9720 ACCCCTTAGA GTACATAGAG GTATCAGTCC AGTAAGACTG CTCTACACAA CAGAAGTGAG 9780 GCCCAGGGAG TAGCAGCCAG GCCCTTATCC TGTTACCTCT GCAGGAGTGA CTGCCCAACC 9840 CAGATCCAGA GACATTGAAG GAAATGATAA TTCCTTGGTA CCTCACTGCC TTGGGACAAA 9900 ATGAAGAAAG CCACCCTTCC TTAGGCTGCA GCTTGCCACT CCTGGGCTGG GTAAACAGGT 9960 CATCAGCACC AGGCTCAACC AGGAGTAACA TTCTGGAAGA CATGGGTGAG CCCAAGAGGA 10020 60 AGCATGAACA GGACGCTGTT CCTAAGTCAT GTCAACAGGT TGTGCTGGGC CAGGATCCCC 10080 AGGGAAAAA ATGGTCAACC CAACTGGAGG GTAGGTTAGA AGAAAAAAA CATAAACGTG 10140 GATAGTCATG TCATCTCAAA TCCCTGACTT GGCTTCCCCA TTACTTGACA GTCTGAGCTC 10200 CTTCTTAGCC TGTGACCAGC TTCAAATCAC AGCCAAGTAA AACAAGGAAA TAGGAAAAGT 10260
AAATCCAACT AGAAGGACA AGCTGAGATT CAGATTTGTT TACTCCTCCC ATGCAAAGTT 10320
TCCCTGTTGG AGGTTTTCCA TGTATACATG TCTAGAAGTG ATAGAATGCA AGGCCTTGGC 10380
TTTGTCTTGC AGGGATCTGC CTTTGAGGTC ATAGACTGAA CAGCAGGGAG AGAGGTTAGT 10440 65 GGTGGAGTGT GGGGGGAGCT GTTCTAGCTC CAGTTTCTTC TGACACATTT TTCAGGATCA 10500 GGIGAGIGI GGGGGAGCI GTICTAGCIC CAGTITETTE IGACACATTI TICAGGATCA 10500
TGGATCTGAT CCTCCGAAGC ACAGCAGAGA TATCTAAGCC ATATTTTGTGC ACATGAGCAG 10560
ACTCTTCTAG TTTTTTAGTA ACCAGGGATG GGCTTTTGCA TGGCACTGAC TATAGAGATG 10620
TCTTGTAGAG ATCAAGCCAG TCTTTTGCAT CCCACCTGCC CACCTCCAGA AGAGATGGGA 10680
AAAGGTCATC AAAGGGCATT CACCAACTGA AATCCACTCA TGAATGTTAG GTCTCTAAAA 10740
GGAGGCATCA ACACTCACAA TGGTAGCCTC CAAACCTAGC ATCCCACCTA TCTAAGAGCT 10800 70 CAGGGGTGGT CCACTGGGGC AGATACAAGG GAAGTGCAAG GGCTCAGGAT GAAAGAAAAT 10860 75 CTATTGGGAA GAGTTTTAGG GGCTTGATCA TTATGGGGCT TCCTTCTATA TCTGAGAACT 10920 GCTCTGGGTG GTGAGATGTG GACTCTGATC CTTAATTGGA ATGTTCGGAG AATGAGTGTC 10980 TGGTGGCCTT GAAGTGTTGG ACAGAAAAGT ATCAGTATAA AAGCCTGGAG CTCAGGGTAA 11040

TTAATGTAGT TCATGGTTCC TTAGTGAGCA GGACTCTTGG ATGTGGAGGA GAAAGGGTCA 11100 TAGGAAGTAA ACCACCAAAA TTACAAAATT GAGTCTCTGT ACAATTACTT CAGTGCCTTT 11160 GGGCTTATGA ATACAAATCA GTGGGCCTTC TCTATGATGG TCCAACAAAC TCTCAGTGTC 11220 CACCCTGTCC CTGTATCTCC CATGGAAGAT GAATAATGTC AGGTGTTCTT TGGGTCAAAG 11280 GCCCCAGGGC AGTCTGGAGG CTTAGAGGGC AGAGTGGTGT CATTCCATGT AAAGTTAGGC 11340
TTCTGAGGGG TCAGGCAGAA TATGGTGTCC ATATCTTCCA TAGCTCTGCA GATTCTTGGA 11400
TGAAGTCAAG CACAGTTTGC TAGACCCAGG TCACTCCTCT GAGTATAACT AGGACCCATG 11460
AGTGAAACTT AATAGCTGTA AGGAAGAACC TGCTGCTCGC CAGAGAGGAT AAGCTGCCCA 11520 5 TCTCAGCAGC TGTCTAAAAG AAGGCAGGTG TCTCTTTAAA GGGAAGAGAA GCATTGGTGA 11580 10 AATGGATTTC AGGTCACTTC CATTCCAGAT GGGTGAGATC TTGTGGAGCT GGGATCATGT 11640 TTGAACTCAT TCATACCTGT AGAGCACGAA TCCAAGTAGA TTGTGTTTGG TCTGTACAGG 11700 CTGAAGCCC CTGCTCTCCC ACCCAAGTGC CCCACTGAG CAGGCCAACA TGCTGTTGTG 11760 GCCACATATA CTGGGCTGAT CCAGGCTGGT TATCACCAAA CAGCAAACCA TAGGGAACAG 11820 CTGCTTTGCC ATAGACCCAA TACCCATGTA GATCTCTCAT GAGAGCAGCC ATAACTCAGA 11880 15 CCCACTGACC AACAGGGCCA TGAGTGACAG CCAGAACCAG TGAAGGTCCA AGTAGGACAC 11940 AGAGCAGGGC TTTTCTTACC ATACACATTA TCTCCAGAGG TTATTTCTAC CCCACTCCCT 12000 ATTCAAGGCC TGTTGGAGCA CACTGCAAAA GCAAAAGCAC AGTAACTCAA TTTACACATG 12060 ATTATAATCA TTTCCAGTGC ACACATTTCA TCACCAGGTG GATCCTGAGC TAGCCCATGT 12120
AAATCCGGGT TAACCCATAT TGGTAATCAT ACTCAAAAGC ACTTTTCACC CTACATTCTA 12180 20 CTAGCCAATC AAAGACAAAG AGTTGTGGCC TCTACCATTG CCTTGGCTTC TGGACACCCT 12240 CACAAGCTAT CCCAAGGTTC CCGCTCAACT CCAGGGAGGC TGACATCTTC ACATCCACTG 12300 GGCATATAAT ATTGCATGAG ACCAAAGTCT CCACACTCTT TGCAGCCTCC TCCATGAATC 12360 CCAATGGCCT GCACTTGTAC AGTTTGGGTG TTTGATAGAT AAAGCACGTA TGAGAAGAGA 12420 AAACAAAATA AATCAACTTT TTAAAAAAGC CAGCACTGTG CTGTCAATGT TTTTTTTTC 12480 25 TTTTCAATTC TAGCTCAGAA AAGCAGAAGG TAAATAATGT CAGGTCAATG AATATCAGAT 12540 ATATTTTTTG ACTGTACATT ACAGTGAAGT GTAATCTTTT TACACCTGCA AGTCCATCTT 12600 ATTTATTCTT GTAAATGTTC CCTGACAATG TTTGTAATAT GGCTGTGTTA AAAAATCTAT 12660 ACAATAAAGC TGTGACCCTG 30 Seq ID NO: 98 Protein sequence: NP_008981.1 Protein Accession #: 35 GIREFNPPRO TEINTYROSI NEPHOSPHAT ASERECEPTO RTYPETHOMO SAPIENSMAS 60 LAALALSLLL RLOLPPLPGA RAOSAPGGCS FDEHYSNCGY SVALGTNGFT WEOINTTEKP 120 MLDQAVPTGS FMMVNSSGRA SGQKAHLLLP TLKENDTHCI DFHYYFSSRD RSSPGALNVY 180 VKVNGGPQGN PVWNVSGVVT EGWVKAELAI STFWPHFYQV IFESVSLKGH PGYIAVDEVR 240 VLAHPCRKAP HFLRLQNVEV NVGQNATFQC IAGGKWSQHD KLWLQQWNGR DTALMVTRVV
NHRRFSATVS VADTAQRSVS KYRCVIRSDG GSGVSNYAEL IVKEPPTPIA PPELLAVGAT 360
YLWIKPNANS IIGDGPIILK EVEYRTTTGT WAETHIVDSP NYKLWHLDPD VEYEIRVLLT 420
RPGEGGTGPP GAPLTTRTKC ADPVHGPQNV EIVDIRARQL TLQWEPFGYA VTRCHSYNLT 480 40 VQYQYVFNQQ QYEAEEVIQT SSHYTLRGLR PFMTIRLRLL LSNPEGRMES EELVVQTEED 540 VPGAVPLESI QGGPFEEKIY IQWKPPNETN GVITLYEINY KAVGSLDPSA DLSSQRGKVF 600 45 KLRNETHHLF VGLYPGTTYS FTIKASTAKG FGPPVTTRIA TKISAPSMPE YDTDTPLNET 660 DTTITVMLKP AQSRGAPVSV YQLVVKEERL QKSRRAADII ECFSVPVSYR NASSLDSLHY 720 FAAELKPANL PVTQPFTVGD NKTYNGYWNP PLSPLKSYSI YFQALSKANG ETKINCVRLA 780 TKAPMGSAQV TPGTPLCLLT TGASTQNSNT VEPEKQVDNT VKMAGVIAGL LMFIIILLGV 840 MLTIKRRRNA YSYSYYLSQR KLAKKQKETQ SGAQREMGPV ASADKPTTKL SASRNDEGFS 900 50 SSSQDVNGFT DGSRGELSOP TLTIOTHPYR TCDPVEMSYP RDQFQLAIRV ADLLQHITQM 960 KRGQGYGFKE EYEALPEGQT ASWDTAKEDE NRNKNRYGNI ISYDHSRVRL LVLDGDPHSD 1020 YINANYIDGY HRPRHYIATQ GPMQETVKDF WRMIWQENSA SIVMVTNLVE VGRVKCVRYW 1080 PDDTEVYGDI KVTLIETEPL AEYVIRTFTV QKKGYHEIRE LRLFHFTSWP DHGVPCYATG 1140 LLGFVRQVKF LNPPEAGPIV VHCSAGAGRT GCFIAIDTML DMAENEGVVD IFNCVRELRA 1200 QRVNLVQTEE QYVFVHDAIL EACLCGNTAI PVCEFRSLYY NISRLDPQTN SSQIKDEFQT 1260 LNIVTPRVRP EDCSIGLLPR NHDKNRSMDV LPLDRCLPFL ISVDGESSNY INAALMDSHK 1320 55 OPAAFVVTOH PLPNTVADFW RLVFDYNCSS VVMLNEMDTA QFCMQYWPEK TSGCYGPIQV 1380 EFVSADIDED IIHRIFRICN MARPQDGYRI VQHLQYIGWP AYRDTPPSKR SLLKVVRRLE 1440 KWQEQYDGRE GRTVVHCLNG GGRSGTFCAI CSVCEMIQQQ NIIDVFHIVK TLRNNKSNMV 1500 60 ETLEQYKFVY EVALEYLSSF Seq ID NO: 99 DNA sequence Nucleic Acid Accession #: NM 002988.1 Coding sequence: 71-340 (underlined sequences correspond to start and stop codons) 65 CCGGCACGAG AGGAGTTGTG AGTTTCCAAG CCCCAGCTCA CTCTGACCAC TTCTCTGCCT 60
GCCCAGCATC ATGAAGGGCC TTGCAGCTGC CCTCCTTGTC CTCGTCTGCA CCATGGCCCT 120
CTGCTCCTGT GCACAAGTTG GTACCAACAA AGAGCTCTGC TGCCTCGTCT ATACCTCCTG 180 70 GCAGATTCCA CAAAAGTTCA TAGTTGACTA TTCTGAAACC AGCCCCCAGT GCCCCAAGCC 240 AGGTGTCATC CTCCTAACCA AGAGAGGCCG GCAGATCTGT GCTGACCCCA ATAAGAAGTG 300 AGGITCATC CICCIAACCA AGAGAGGCCG GCAGAICIGI GCIGACCCA ATAAGAAGIG 300
GGTCCAGAAA TACATCAGCG ACCTGAAGCT GAATGCCTGA GGGGCCTGGA AGCTGCGAGG 360
GCCCAGTGAA CTTGGTGGGC CCAGGAGGG ACAGGAGCCT GAGCCAGGGC AATGGCCCTG 420
CCACCCTGGA GGCCACCTCT TCTAAGAGTC CCATCTGCTA TGCCCAGCCA CATTAACTAA 480
CTTTAATCTT AGTTTATGCA TCATATTTCA TTTTGAAATT GATTTCTATT GTTGAGCTGC 540
ATTATGAAAT TAGTATTTTC TCTGACATCT CATGACATTG TCTTTATCAT CCTTTCCCCT 600 75





NM_001565.1

Nucleic Acid Accession #:

5	TTTATTCCTG TTCAGCTTCT CAATCAGTGA CTGTGTGCTA AATTTTAGGC TACTGTATCT 2340 TCAGGCCACC TGAGGCACAT CCTCTCTGAA ACGGCTATGG AAGGTTAGGG CCACTCTGGA 2400 CTGGCACACA TCCTAAAGCA CCAAAAGACC TTCAACATTT TCTGAGGCA ACAGAGTATT 2460 TGCCAATAAA TGATCTCTCA TTTTTCCACC TTGACTGCCA ATCTAACTAA AATAATTAAT 2520 AAGTTTACTT TCCAGCCAGT CCTGGAAGTC TGGGTTTTAC CTGCCAAAAC CTCCATCACC 2580 ATCTAAATTA TAGGCTGCCA AATTTGCTGT TTAACATTTA CAGAGAAGCT GATACAAACG 2640 CAGGAAATGC TGATTTCTTT ATGGAGGGGGG AGACGAGGAG GAGGAGGACA TGACTTTTCT 2700
10	TGCGGTTTCG GTACCCTCTT TTTAAATCAC TGGAGGACTG AGGCCTTATT AAGGAAGCCA 2760 AAATTATCGG TGCAGTGTGG AAAGGCTTCC GTGATCCTCT CGCTGCACCC TTAGAAACTT 2820 CACCGTCTTC AAACTCCATT TCCATGGTTC TGTTAATTCT CAAGGAGCAG CAACTCGACT 2880 GGTTCTCCCA GGAGCAGGAA AAACCCTTGT GACATGAAAC ATCTAGGCC TGAAAAGAAA 2940 GTGCTCTCTC AGATGGACTC TTGCATGTTA AGACTATGTC TTCACATCAT GGTGCAAATC 3000 ACATGTACCC AATGACTCCG GCTTTGACAC AACACCTTAC CATCATCATG CCATGATGGC 3060
15	TTCCACAAAG CATTAAACCT GGTAACCAGA GATTACTGGT GGCTCCAGCG TTGTTAGATG 3120 TTCATGAAAT GTGACCACCT CTCAATCACC TTTGAGGGCT AAAGAGTAGC ACATCAAAAG 3180 GACTCCAAAA TCCCATACCC AACTCTTAAG AGGATTTGTCC TGGTACTTCA GAAGAATTT 3240 TCATGAGTGT TCTTAATTGG CTGGAAAAGC ACCAGCTGAC GTTTTGGAAG AATCTATCCA 3300 TGTGTCTGCC TCCATATGCA TCTGGGCATT TCATCTTCAG TCCCCTCATT AGACTGTAGC 3360
20	ATTAGGATGT GTGGAGAGAG GAGAAATGAT TTAGCACCCA GATTCACACT CCTATGCCTG 3420 GAAGGGGGAC ATCTTTGAAG AAGAGGAATT AGGGCTGTGG ACACTGTCTT GAGGATGTGG 3480 ACTTCCTTAG TGAGCTCCAC ATTACTTGAT GGTAACCACT TCAAAAGGAT CAGAATCCAC 3540 GTAATGAAAA AGGTCCCTCT AGAGGATGGA GCTGATGTA AGCTGCCAAT GGATGAAAAG 3600 CCTCAGAAAAG CAACTCAAAG GACTCAAAGC AACGGACAAC ACAAGAGTTG TCTTCAGCCC 3660
25	AGTGACACCT CTGATGTCCC CTGGAAGCTT TGTGCTAACC TGGGACTGCC TGACTTCCTT 3720 TAGCCTGGTC CCTTGCTACT ACCTTGAACT GTTTTATCTA ACCTCTCTT TTCTGTTTAA 3780 TTCTTTGCTA CTGCCATTGA CCCTGCTGCA GGATTTGTGT CATTTTCCTG CCTGGTTGCT 3840 GAGACTCCAT TTTGCTGCCA CACACAGAA TGTAAGAGGC AGGCTTTAAT TGCCAAAGCA 3900 CAGTTTGAGC AGTAGAAAAC AACATGGTGT ATATCTCAAA TTGCCTGACA TGAAGAGGAG 3960
30	TCTAACGGTG AAGTTTCACT TTTCATCAGC ATCATCTTTC ACATGTTCAT TATCATCCGC 4020 TCTTATTCTT GCATGTTTAA ACACTTAAAA TTTTTAGTAT AATTTTTAGT GTGTTTTGAA 4080 GTGGTGACTA GGCTTTCAAA AACTTCCACTT GAATTACAAA GCACTACCA GTTCTTATTG 4140 TTAAACTAAG TAAAAATGAT AAGTAACATA GTGTAAAAATA TTCCTTTACT GTGAACTTCT 4200 TACAATGCTG TGAATGAGAG GCTCCTCAGA ACTGGAGCAT TTGTATAATA ATTCATCCTG 4260
35	TTCATCTTCA ATTTTAACAT CATATATAT TTCAATTCTA TCAATTGGGC CTTTAAAAAT 4320 CATATAAAAG GATATAAAAT TTGAAAAAGAG AAACCTAATT GGCTATTTAA TCCAAAACAA 4380 CTTTTTTTTT TCCTTCAATG GAATCAGAAA GCTTGTCAAT CACTCATGTG TTTTAGAGTA 4440 ATTACTTTTA AAATGGTGCA TTTGTGCTTC TGAACTATTT TGAAGAGTCA CTTCTGTTTA 4500 CCTCAAGTAT CAATTCATC TCCATACATT TGAATTCAAG TTGTTTTTTG TCAAATTTAC 4560
40	AGTTGTCAAT TGATCTTCAA GCTGCAGGGT GCCTAGAAAT GGGCCGTTGT CTGTAGCCCT 4620 GGCATGTGCA CACGGACATT TGCCACCACT GCAAGCAAAA GTCTGGAGAA GTTCACCAAC 4680 GACAAGAACG ATTAGGGAAA ATATGCTGCT GTGGGTTAAC AACTCAGAAA GTCCCTGATC. 4740 CACATTTGGC TGTTTACTAA AGCTTGTGAT TAACTTTTTG GCAGTGTGTA CTATGCTCTA 4800 TTGCTATATA TGCTATCTAT AAATGTAGAT GTTAAGGATA AGTAATTCTA AATTTATTAT 4860
45	TCTATAGTTT TGAAGTTTGG TTAAGTTTCC TTTCACTCAA TTGATTTATT TTGTTGTTAA 4920 TCAAATTTAT GTTAATTGGA TCCTTTAAAT TTTTTTTGGC ATTTTCCAAC AAAAATGGCT 4980 TTATTCATAA GAAAGGAAAA AAATCAATGG AATTTGATAT CTAAAGAAGT TAGAAAGGGA 5040 GCAAAATAAA AAACATAAAG GAGATAGATG AATTAGTAAG CAAATCAGTA GTCGAGTTTT 5100 TCAAACTGGC AAAATTAATT AATTGACTTT TAGCCCAAAT TTACATTGTT AATTAAATCA 5160
50	AGAAGGAAGA AGATCTAAGA GCTCCCATTG ATAGGCAAGC CTAGAGAGAA CTAGCTAAAT 5220 TTATCATGCT AGGATATTGA AACACAGAAA GTTTACATAC ATTTATGAAG GGTCAATTTA 5280 GTTTGGACAG TGAGGTATTT GTCTTAGTGG AAAAAAGGAG AATTAGTCTG ATCAAATCGT 5340 GAAGTAATAC AGTGAACTTG CAGGTGCACA AAATAAGAGG GCCACATCTA TATGGTGCAG 5400 TCTGGAATTC TGTTTAAGTT TGTAGGTACC TCTTGGACTT CTGAATTGAT CCAGTTGTCA 5460
55	TCCACCACAG ACATCTCACA TCAGATACAG ACAGTTCCAA GATTGACAAC AGAGAACAAC 5520 CTGCTGGAAA GACCTGGGCA GAAATGGAGA GCCCTGCGGG AACCATGCTA CATTTTCATC 5580 TAAAGAGAGA ATGCACATCT GATGAGACTG AAAGTTCTTT GTTGTTTTAG ATTGTAGAAT 5640 GGTATTGAAT TGGTCTGTGG AAAATTGCAT TGCTTTTATT TCTTTGTGTA ATCAAGTTTA 5700 AGTAATAGGG GATATATAAT CATAAGCATT TTAGGGTGGG AGGGACTATT AAGTAATTTT 5760
60	AAGTGGGTGG GGTTATTTAG AATGTTAGAA TAATATTATG TATTAGATAT CGCTATAAGT 5820 GGACATGCGT ACTTACTTGT AACCCTTTAC CCTATAATTG CTATCCTTAA AGATTTCAAA 5880 TAAACTCGGA GGGAACTGCA GGGAGACCAA CTTATTTAGA GCGAATTGGA CATGGATAAA 5940 AACCCCAGTG GGAGAAAGTT CAAAGGTGAT TAGATTAATA ATTTAATAGA GGATGAGTGA 6000 CCTCTGATAA ATTACTGCTA GAATGAACTT GTCAATGATG GATGGTAAAT TTTCATGGAA 6060
65	GTTATAAAAG TGATAAATAA AAACCCTTGC TTTTACCCCT GTCAGTAGCC CTCCTCCTAC 6120 CACTGAACCC CATTGCCCCT ACCCCTCCTT CTAACTTTAT TGCTGTATTC TCTTCACTCT 6180 ATATTTCTCT CTATTTGCTA ATATTGCATT GCTGTTACAA TAAAAATTCA ATAAAGATTT 6240 AGTGGTTAAG TGC
70	Seq ID NO: 106 Protein sequence: Protein Accession #: NP_055883.1
75	1 11 21 31 41 51 MTERRRDELS EEINNLREKV MKQSEENNNL QSQVQKLTEE NTTLREQVEP TPEDEDDDIE 60 LRGAAAAAP PPPIEEECPE DLPEKFDGNP DMLAPFMAQC QIFMEKSTRD FSVDRVRVCF 120 VTSMMTGRAA RWASAKLERS HYLMHNYPAF MMEMKHVFED PQRREVAKRK IRRLRQGMGS 180 VIDYSNAFQM IAQDLDWNEP ALIDQYHEGL SDHIQEELSH LEVAKSLSAL IGQCIHIERR 240

LARAAAARKP RSPPRALVLP HIASHHQVDP TEPVGGARMR LTQEEKERRR KLNLCLYCGT 300 GGHYADNCPA KASKSSPAGN SPAPL

NM 003679.1

Seq ID NO: 107 DNA sequence


Nucleic Acid Accession #:

5

Coding sequence: 47-1507(underlined sequences correspond to start and stop codons) 10 GGCACGAGCA GAAGCAACAA TAATTGTGAA AAATACTTCA GCAGTTATGG ACTCATCTGT 60 CATTCAAAGG AAAAAGTAG CTGTCATTGG TGGTGGCTTG GTTGGCTCAT TACAAGCATG CTTTCTTGCA AAGAGGAATT TCCAGATTGA TGTATATGAA GCTAGGGAAG ATACTCGAGT GGCTACCTTC ACACGTGGAA GAAGCATTAA CTTAGCCCTT TCTCATAGAG GACGACAAGC 240 CTTGAAAGCT GTTGGCCTGG AAGATCAGAT TGTATCCCAA GGTATTCCCA TGAGAGCAAG 300 15 AATGATCCAC TCTCTTTCAG GAAAAAAGTC TGCAATTCCC TATGGGACAA AGTCTCAGTA 360 TATTCTTTCT GTAAGCAGAG AAAATCTAAA CAAGGATCTA TTGACTGCTG CTGAGAAATA 420 CCCCAATGTG AAAATGCACT TTAACCACAG GCTGTTGAAA TGTAATCCAG AGGAAGGAAT 480 GATCACAGTG CTTGGATCTG ACAAAGTTCC CAAAGATGTC ACTTGTGACC TCATTGTAGG 540 ATGTGATGGA GCCTATTCAA CTGTCAGATC TCACCTGATG AAGAAACCTC GCTTTGATTA 600
CAGTCAGCAG TACATTCCTC ATGGGTACAT GGAGTTGACT ATTCCACCTA AGAACGGAGA 660
TTATGCCATG GAACCTAATT ATCTGCATAT TTGGCCTAGA AATACCTTTA TGATGATTGC 720
ACTTCCTAAC ATGAACAAAT CATTCACATG TACTTTGTTC ATGCCCTTTG AAGAGTTTGA 780 20 AAAACTTCTA ACCAGTAATG ATGTGGTAGA TTTCTTCCAG AAATACTTTC CGGATGCCAT CCCTCTAATT GGAGAGAAAC TCCTAGTGCA AGATTTCTTC CTGTTGCCTG CCCAGCCCAT 900 25 GATATCTGTA AAGTGCTCTT CATTTCACTT TAAATCTCAC TGTGTACTGC TGGGAGATGC 960 AGCTCATGCT ATAGTGCCGT TTTTTGGGCA AGGAATGAAT GCGGGCTTTG AAGACTGCTT 1020 GGTATTTGAT GAGTTAATGG ATAAATTCAG TAACGACCTT AGTTTGTGTC TTCCTGTGTT 1080 CTCAAGATTG AGAATCCCAG ATGATCACGC GATTTCAGAC CTATCCATGT ACAATTACAT 1140 AGAGATGCGA GCACATGTCA ACTCAAGCTG GTTCATTTTT CAGAAGAACA TGGAGAGATT 1200 30 TCTTCATGCG ATTATGCCAT CGACCTTTAT CCCTCTCTAT ACAATGGTCA CTTTTTCCAG 1260 AATAAGATAC CATGAGGCTG TGCAGCGTTG GCATTGGCAA AAAAAGGTGA TAAACAAAGG 1320 ACTOTTTTTC TTGGGATCAC TGATAGCCAT CAGCAGTACC TACCTACTTA TACACTACAT 1380
GTCACCACGA TCTTCCTCT GCTTGAGAAG ACCATGGAAC TGGATAGCTC ACTTCCGGAA 1440
TACAACATGT TTCCCCGCAA AGGCCGTGGA CTCCCTAGAA CAAATTTCCA ATCTCATTAG 1500
CAGGTGATAG AAAGGTTTTG TGGTAGCAAA TGCATGATTT CTCTGTGACC AAAATTAAGC 1560 35 ATGAAAAAA TGTTTCCATT GCCATATTTG ATTCACTAGT GGAAGATAGT GTTCTGCTTA 1620 TAATTAAACT GAATGTAGAG TATCTCTGTA TGTTAATTGC AATTACTGGT TGGGGGGTGC 1680 ATTTTAAAAG ATGAAACATG CAGCTTCCCT ACATTACACA CACTCAGGTT GAGTCATTCT 1740 AACTATAAAA GTGCAATGAC TAAGATCCTT CACTTCTCTG AAAGTAAGGC CCTAGATGCC 1800 40 TCAGGGAAGA CAGTAATCAT GCCTTTTCTT TAAAAGACAC AATAGGACTC GCAACAGCAT 1860 TGACTCAACA CCTAGGACTA AAAATCACAA CTTAACTAGC ATGTTAACTG CACTTTTCAT 1920 TACGTGAATG GAACTTACCT AACCACAGGG CTCAGACTTA CTAGATAAAA CCAGAAATGG 1980 AAATAAGGAA TTCAGGGGAG TTCCAGAGAC TTACAAAATG AACTCATTTT ATTTTCCCAC 2040 CTTCAAATAT AAGTATTATC ATCTATCTGT TTATCGTCTA TCTATCTATC ATCTATCTAT 2100 45 TCTATTTATT TATGTATTTA GAGATCAGGT CTCACTCTGT TGACCAGGCT GGAGTGCAGT 2220 GGTGAGATCT GGGTTCACTG CAACCTCTGC CTCCTGGGCT CAAGCAATCC TCCCACTTCA 2280 GCCTCCCAAA TAGCTGGGGC TACCATGGTA TTTTTCAGTA GAGACCGGGT CTTGCCATGC 2340 TGCCCAGGCC AGTCTCAAAC TCCTGGCCTC ATGTGATCTG CCCACCTCAG CCTCCCAAAG 2400 50 TACAGGGATT AGAGTTGTGA GCCACCGCTG CCAGCCCAGA GTTACCCTCT AAAGATAAGA 2460 AAAAGGCTAT TAATATCATA CTAAGTGAAG GACAGGAAAG GGTTTTATTC ATAAATTAAA 2520 TGTCTACATG TGCCAGAATG GAAAGGAAAC AAGGGGAGAC AACTTTTATA GAAATACAAA 2580 GCCATTACTT TATTCAATTT CAGACCCTCA GAAGCAATTT ACTAATTTAT TCTTCGACTA 2640 CATACTGCAG CAGAACCAGC AATACACTTG ATTTTTAAAA GCACATTTAG TGAAATGTTT 2700 TCTTTGGTTC ATCCTTCTTT AACAGGCTGC TGAGTCACTC AGAAATCCTT CAAACATGAT 2760 55 ATGATTCAGT GTTTCTTTC TATATTGTCA ATGAAAACCT TGAGTTCTAA TAATCCATGT 2880 TCAGTTTGTA GGGAAAGAAA AAATAATTTT TCCTTCTACC CACTTTAGGT TCCTTGGCTG 2940 GGGCCCCTAT AACAAAAGAC AGATTGACAA GAGAAAAACA AACATAAATT TATTAGCGGG 3000 TATATGTAAT ATATATGTGG GAAATACAG GGAATGAGCA AATCTCAAAG AGCTGGCGTC 3060
TTAGAACCCC CTGGCTTATA TAGCATCGAC AAAGAACAGT AAATTTTTAG AGAAACAACA 3120
AAACAAAGAA AAAGAGCTTT GAGTCTGTAG GGGCAGCAAT TTGGGGGAAG CAAATATATG 3180
GGAGTTTGCC TTGTAGATTC CTCTGGTGGT GGTCTCCAGG CTGACAAGGA TTCAAAGTTG 3240 60 TCTCTGAAAC TCCTCTTTGT CATACTGCAC ATATAAAACG TCTTTTGTTT CCAACAAGAG 3300 65 GATTTCTTTT TCATTCTAGA ATTATCTCCT TGATAACTTG ATCAGATATA GGACATGACA 3360 CTGAATAGAG TCCAACAGTA CAAAAAAAT TCAGTATGTT CTAGCTACTT CACACATGTG 3420 TACGCGACAG TTATTTTTAC AGTAAGGTAT TTTCGAGAAA AATGCATTAC GTGTTTTGGA 3480 AAATAGAGTA ATTTAAAAAA TATATTTGAA ATGAAAATCT CCAACACATT AGAAGATGAT 3540 GATGTTAGAT GCCCATCGTG TGCCACAAGT GGTTTTTTCA TTATGTAAAG CACCCGTTGA 3600 70 ATTAAAAGAA TTTGTTTTTG TTCAACCTCT TCCTGAGGCC CAAGAGCATA TGGGCAATTC 3660 GGATTTCCTG CTGGACCACA AGGTTCTGTT GATATTACAT AGAAACGGGT ATTCCAGACA 3720 CTTCTTATGA TGAAAGTCCA AAAGTGGCAT CCAATTTAAG GCCCCATCTT TCGTTGCCAT 3780 TCTTCATTCC TACAAAGGAC GAACTTGGAT TACATCAACT TTGGACCCAT TGGTTTTGTC 3840 GCTGTCGTCA ACTGACAGTG ATTCACCACT GGTGATGATA AAAATGATGG AAGAAGAGTT 3900 GAAAGTCACT TTTTTCTTTG GCCTGTCCCC ATCTTTCTGT GACATCACAA TGGGTCTGAT 3960 CTGCATTTCA CTTCCAGCTG CTGGTAGGTC TTTAGCAGGC CTCTGGCACC TCAGCAGTCG 4020 75 GAGGCACAGA AGCTGCAAAA GGGATCTTCG AAACTGGGCA GAGAAAAAAT AAAGTGGAAT 4080

ATTAAGTAAA AGTTGGGCAC TAATCTGGAT TAACATTCGA GGAAATCAGT TGAGCTGATT 4140 TAAGTTGTTT TTTGTTTGTT AGCAGGTGTG GATGTGGGGT TATGTGGTCA TGCTCAGATC 4200 TACCTAAATC ACCCCAGAGC TTTATGTCTT TTATTCATTC TAAATCTTAT TAACCGGAAT 4260 ATGTAGGACC ATTTCAATAC CTTGTAATCC TCCAAGCTTC AATCTGCACA CACTTTCTAT 4320 5 GAGGCAGGT ACAACTATTA AGAGATTTTG AACATTAAGT TAGTCACAA ATATTCAGTG 4380
GGCATCTACT AGGTGACAGC CACTGTGCTA TAATTAGAGA CTTTTTACTA TAAGCATCAA 4440 AAACAGATAA GGCTCTTCCT GGCAGAGTTT ACAGCCTGGT GTACTTGCTA ATGTCTCTTT 4500 AATTAGGTGA AGAATTTTTT TTTTCTATCG AAATTACTAA TCAGTTGGGG AAAAAAATAC 4560 TATAGCAGAC AGCACTAATG TCATCAACAA ACATTGTTCT TCTCCGTGTC CTGGGTACAA 4620 10 CATCGAATAA TATTTCTTGG CCTCCTTTCC GCTTCTCCTC TCTGCTGTTC CTCTCTACAA 4680 GAACCTGGGA GGCCAACGCC TAAAGATCAT AATATCACAA TGGAAGGAAC CTAGATTCCT 4740 AAATGACTGC ATAGGACAGA TCCCATCTCC TCCACCCAAT ACATTATTAG ACTGAACTGT 4800 GACCTGAAAT GAGCAATAAA CTCTGTATTA ATTCACTGAA ATGTTGGGGT TGCTTGTTAT 4860 AGTAGTCGGT CCATCATGAC CAGTAAAACA TAAATCAAAA GTTAATGTAA TTGTTATCCC 4920 15 ATTATTTAGA GCGAAATAAA TGTTGAATAT ATGGACTTTC TCAGATTAGG AAATACCAAT 4980 TAAAAATATA ATAAATAGCT Seq ID NO: 108 <u>Protein sequence:</u> Protein Accession #: NP_003670.1 20 31 MDSSVIQRKK VAVIGGGLVG SLQACFLAKR NFQIDVYEAR EDTRVATFTR GRSINLALSH 60 RGRQALKAVG LEDQIVSQGI PMRARMIHSL SGKKSAIPYG TKSQYILSVS RENLNKDLLT 120 AAEKYPNVKM HFNHRLLKCN PEEGMITVLG SDKVPKDVTC DLIVGCDGAY STVRSHLMKK 180 25 PRFDYSQQYI PHGYMELTIP PKNGDYAMEP NYLHIWPRNT FMMIALPNMN KSFTCTLFMP 240 FEEFEKLLTS NDVVDFFQKY FPDAIPLIGE KLLVQDFFLL PAQPMISVKC SSFHFKSHCV 300 LLGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFSNDLSL CLPVFSRLRI PDDHAISDLS 360 MYNYIEMRAH VNSSWFIFQK NMERFLHAIM PSTFIPLYTM VTFSRIRYHE AVQRWHWQKK 420 30 VINKGLFFLG SLIAISSTYL LIHYMSPRSF LCLRRPWNWI AHFRNTTCFP AKAVDSLEQI 480 SNLISR Seq ID NO: 109 DNA sequence Nucleic Acid Accession #: NM_006115.1 35 Coding sequence: 236-1765 (underlined sequences correspond to start and stop codons) 41 21 31 51 GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCCCCTC AGCACCGCTC 60 40 CGGGACACCC CACCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAAATGGA 240 ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 360 TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420 CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 45 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540 TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600 GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660 50 TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA 720 TGGTTTGAGC ACAGAGGCAG AGCAGCCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGTT 780 CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840
GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900
TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTTGG AAGTGACTTG 960
TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020 55 GCGTAGACTC CTCCTCCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080 GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA 1140 TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200 CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT 1260 GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC 1320 60 CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA 1380 CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440 GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC 1500 CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGCACACG TGCTGTATCC 1560
TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620
TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGCCT 1680
TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT 1740 65 GTGCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800 TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860 70 ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920 GTTCAGTGAG GAAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1980 GTGATCTTTG GGGAGATACA TCTTATAGAG TTAGAAATAG AATCTGAATT TCTAAAGGGA 2040 GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGAAAC 2100 TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAA AAAAAAA 75

Seq ID NO: 110 Protein sequence:
Protein Accession #: NP_006106.1



AAFCGNMFVE PGEQCDCGFL DDCVDPCCDS LTCQLRPGAQ CASDGPCCQN CQLRPSGWQC 480 RPTRGDCDLP EFCPGDSSQC PPDVSLGDGE PCAGGQAVCM HGRCASYAQQ CQSLWGPGAQ 540 PAAPLCLQTA NTRGNAFGSC GRNPSGSYVS CTPRDAICGQ LQCQTGRTQP LLGSIRDLLW 600
ETIDVNGTEL NCSWVHLDLG SDVAQPLLTL PGTACGPGLV CIDHRCQRVD LLGAQECRSK 660
CHGHGVCDSN RHCYCEEGWA PPDCTTQLKA TSSLTTGLLL SLLVLLVLVM LGAGYWYRAR 720
LHQRLCQLKG PTCQYRAAQS GPSERPGPPQ RALLARGTKS QGPAKPPPPR KPLPADPQGR 780
CPSGDLPGPG AGIPPLVVPS RPAPPPPTVS SLYL 5 10 Seq ID NO: 113 DNA sequence Nucleic Acid Accession #: NM_002416 Coding sequence: 40-417 (underlined sequences correspond to start and stop codons) 15 41 51 ATCCAATACA GGAGTGACTT GGAACTCCAT TCTATCACTA TGAAGAAAAG TGGTGTTCTT 60 TTCCTCTTGG GCATCATCTT GCTGGTTCTG ATTGGAGTGC AAGGAACCCC AGTAGTGAGA 120 AAGGGTCGCT GTTCCTGCAT CAGCACCAAC CAAGGGACTA TCCACCTACA ATCCTTGAAA 180 20 GACCTTAAAC AATTTGCCCC AAGCCCTTCC TGCGAGAAAA TTGAAATCAT TGCTACACTG 240
AAGAATGGAG TTCAAACATG TCTAAACCCA GATTCAGCAG ATGTGAAGGA ACTGATTAAA 300
AAGTGGGAGA AACAGGTCAG CCAAAAGAAA AAGCAAAAGA ATGGGAAAAA ACATCAAAAA 360
AAGAAAGTTC TGAAAGTTCG AAAATCTCAA CGTTCTCGTC AAAAGAAGA TACA<u>TAA</u>GAG 420 ACCACTTCAC CAATAAGTAT TCTGTGTTAA AAATGTTCTA TTTTAATTAT ACCGCTATCA 480 25 TTCCAAAGGA GGATGGCATA TAATACAAAG GCTTATTAAT TTGACTAGAA AATTTAAAAC 540 ATTACTCTGA AATTGTAACT AAAGTTAGAA AGTTGATTTT AAGATCCAA ACGTTAAGAA 600
TTGTTAAAGG CTATGATTGT CTTTGTTCTT CTACCACCCA CCAGTTGAAT TTCATCATGC 660
TTAAGGCCAT GATTTTAGCA ATACCCATGT CTACACAGAT GTTCACCCAA CCACATCCCA 720
CTCACAACAG CTGCCTGGAA GAGCAGCCCT AGGCTTCCAC GTACTGCAGC CTCCAGAGAG 780 30 TATCTGAGGC ACATGTCAGC AAGTCCTAAG CCTGTTAGCA TGCTGGTGAG CCAAGCAGTT 840 TGAAATTGAG CTGGACCTCA CCAAGCTGCT GTGGCCATCA ACCTCTGTAT TTGAATCAGC 900 CTACAGGCCT CACACACAAT GTGTCTGAGA GATTCATGCT GATTGTTATT GGGTATCACC 960 ACTGGAGATC ACCAGTGTGT GGCTTTCAGA GCCTCCTTTC TGGCTTTGGA AGCCATGTGA 1020 TTCCATCTTG CCCGCTCAGG CTGACCACTT TATTTCTTTT TGTTCCCCTT TGCTTCATTC 1080 AAGTCAGCTC TTCTCCATCC TACCACAATG CAGTGCCTTT CTTCTCCCA GTGCACCTGT 1140 CATATGCTCT GATTTATCTG AGTCAACTCC TTTCTCATCT TGTCCCCAAC ACCCCACAGA 1200 AGTGCTTTCT TCTCCCAATT CATCCTCACT CAGTCCAGCT TAGTTCAAGT CCTGCCTCTT 1260 35 AAATAAACCT TTTTGGACAC ACAAATTATC TTAAAACTCC TGTTTCACTT GGTTCAGTAC 1320 CACATGGGTG AACACTCAAT GGTTAACTAA TTCTTGGGTG TTTATCCTAT CTCTCCAACC 1380 40 AGATTGTCAG CTCCTTGAGG GCAAGAGCCA CAGTATATTT CCCTGTTTCT TCCACAGTGC 1440 CTAATAATAC TGTGGAACTA GGTTTTAATA ATTTTTTAAT TGATGTTGTT ATGGGCAGGA 1500 TGGCAACCAG ACCATTGTCT CAGAGCAGGT GCTGGCTCTT TCCTGGCTAC TCCATGTTGG 1560 CTAGCCTCTG GTAACCTCTT ACTTATTATC TTCAGGACAC TCACTACAGG GACCAGGGAT 1620 GATGCAACAT CCTTGTCTTT TTATGACAGG ATGTTTGCTC AGCTTCTCCA ACAATAAGAA 1680 45 GCACGTGGTA AAACACTTGC GGATATTCTG GACTGTTTTT AAAAAATATA CAGTTTACCG 1740 AAAATCATAT AATCTTACAA TGAAAAGGAC TTTATAGATC AGCCAGTGAC CAACCTTTTC 1800 CCAACCATAC AAAAATTCCT TTTCCCGAAG GAAAAGGGCT TTCTCAATAA GCCTCAGCTT 1860 TCTAAGATCT AACAAGATAG CCACCGAGAT CCTTATCGAA ACTCATTTTA GGCAAATATG 1920
AGTTTTATTG TCCGTTTACT TGTTTCAGAG TTTGTATTGT GATTATCAAT TACCACACCA 1980
TCTCCCATGA AGAAAGGGAA CGGTGAAGTA CTAAGCGCTA GAGGAAGCAG CCAAGTCGGT 2040
TAGTGGAAGC ATGATTGGTG CCCAGTTAGC CTCTGCAGGA TGTGGAAACC TCCTTCCAGG 2100 50 GGAGGTTCAG TGAATTGTGT AGGAGAGGTT GTCTGTGGCC AGAATTTAAA CCTATACTCA 2160 CTTTCCCAAA TTGAATCACT GCTCACACTG CTGATGATTT AGAGTGCTGT CCGGTGGAGA 2220 TCCCACCCGA ACGTCTTATC TAATCATGAA ACTCCCTAGT TCCTTCATGT AACTTCCCTG 2280 55. AAAAATCTAA GTGTTTCATA AATTTGAGAG TCTGTGACCC ACTTACCTTG CATCTCACAG 2340 GTAGACAGTA TATAACTAAC AACCAAAGAC TACATATTGT CACTGACACA CACGTTATAA 2400 TCATTTATCA TATATATACA TACATGCATA CACTCTCAAA GCAAATAATT TTTCACTTCA 2460 AAACAGTATT GACTTGTATA CCTTGTAATT TGAAATATTT TCTTTGTTAA AATAGAATGG 2520 TATCAATAAA TAGACCATTA ATCAG 60 Seq ID NO: 114 Protein sequence: Protein Accession #: 51 31 65 MKKSGVLFLL GIILLVLIGV QGTPVVRKGR CSCISTNQGT IHLQSLKDLK QFAPSPSCEK 60 IEIIATLKNG VQTCLNPDSA DVKELIKKWE KQVSQKKKQK NGKKHQKKKV LKVRKSQRSR 120 70 Seq ID NO: 115 DNA sequence NM 003238.1 Nucleic Acid Accession #: Coding sequence: 182-1426 (underlined sequences correspond to start and stop codons) 75 CAAGCAGGAT ACGTTTTTCT GTTGGGCATT GACTAGATTG TTTGCAAAAG TTTCGCATCA 60 AAAACAAACA ACAACAACAA AAAACCAAAC AACTCTCCTT GATCTATACT TTGAGAATTG 120 399

AQLVTGTSFS GPTVGMAIQN SICSPDFSGG VNMDHSTSIL GVASSIAHEL GHSLGLDHDL 360 PGNSCPCPGP APAKTCIMEA STDFLPGLNF SNCSRRALEK ALLDGMGSCL FERLPSLPPM 420

	AATGCACTAC TGTGTGCTGA GCGCTTTTCT GATCCTGCAT CTGGTCACGG TCGCGCTCAG 240 CCTGTCTACC TGCAGCACAC TCGATATGGA CCAGTTCATG CGCAAGAGGA TCGAGGCGAT 300
5	CCGCGGGCAG ATCCTGAGCA AGCTGAAGCT CACCAGTCCC CCAGAAGACT ATCCTGAGCC 360 CGAGGAAGTC CCCCCGGAGG TGATTTCCAT CTACAACAGC ACCAGGGACT TGCTCCAGGA 420 GAAGGCGAGC CGGAGGGCGG CCGCCTGCGA GCGCGAGAGG AGCGACGAAG AGTACTACGC 480
10	CAAGGAGGTT TACAAAATAG ACATGCCGCC CTTCTTCCCC TCCGAAAATG CCATCCCGCC 540 CACTTTCTAC AGACCCTACT TCAGAATTGT TCGATTTGAC GTCTCAGCAA TGGAGAAGAA 600 TGCTTCCAAT TTGGTGAAAG CAGAGTTCAG AGTCTTTCGT TTGCAGAACC CAAAAGCCAG 660
10	AGTGCCTGAA CAACGGATTG AGCTATATCA GATTCTCAAG TCCAAAGATT TAACATCTCC 720 AACCCAGCGC TACATCGACA GCAAAGTTGT GAAAACAAGA GCAGAAGGCG AATGGCTCTC 780 CTTCGATGTA ACTGATGCTG TTCATGAATG GCTTCACCAT AAAGACAGGA ACCTGGGATT 840
15	TAAAATAAGC TTACACTGTC CCTGCTGCAC TTTTGTACCA TCTAATAATT ACATCATCCC 900 AAATAAAAGT GAAGAACTAG AAGCAAGATT TGCAGGTATT GATGGCAACCT CCACATATAC 960 CAGTGGTGAT CAGAAAACTA TAAAGTCCAC TAGGAAAAA AACAGTGGGA AGACCCACA 1020 TCTCCTGCTA ATGTTATTGC CCTCCTACAG ACTTGAGTCA CAACAGACCA ACCGGCGGAA 1080
20	GAAGCGTGCT TTGGATGCGG CCTATTGCTT TAGAAATGTG CAGGATAATT GCTGCCTACG 1140 TCCACTTTAC ATTGATTTCA AGAGGGATCT AGGGTGGAAA TGGATACACG AACCCAAAGG 1200 GTACAATGCC AACTTCTGTG CTGGAGCATG CCCGTATTTA TGGAGTTCAG ACACTCAGCA 1260
20	CAGCAGGGTC CTGAGCTTAT ATAATACCAT AAATCCAGAA GCATCTGCTT CTCCTTGCTG 1320 CGTGTCCCAA GATTTAGAAC CTCTAACCAT TCTCTACTAC ATTGGCAAAA CACCCAAGAT 1380 TGAACAGCTT TCTAATATGA TTGTAAAGTC TTGCAAATGC AGC <u>TAA</u> AATT CTTGGAAAAG 1440 TGGCAAGACC AAAATGACAA TGATGATGAT AATGATGATG AGCGACGACAA CGATGATGCT 1500
25	TGTAACAAGA AAACATAAGA GAGCCTTGGT TCATCAGTGT TAAAAAATTT TTGAAAAGGC 1560 GGTACTAGTT CAGACACTTT GGAAGTTTGT GTTCTTTTG TTAAAACTTG CATCTGACAC 1620 AAAAAAAGTT GAAGGCCTTA TTCTACATTT CACCTACTTT GTAAGTGAGA GAGACAAGAA 1680 GCAAATTTTT TTAAA
30	Seq ID NO: 116 Protein sequence: Protein Accession #: NP_003229.1
	1 11 21 31 41 51
35	MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP 60 EEVPPEVISI YNSTRDLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP 120 TFYRPYFRIV RFDVSAMEKN ASNLVKAEFR VFRLQNPKAR VPEQRIELYQ ILKSKDLTSP 180 TQRYIDSKVV KTRAEGEWLS FDVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP 240
40	NKSEELEARF AGIDGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK 300 KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH 360 SRVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGKTPKI EQLSNMIVKS CKCS
45	Seq ID NO: 117 DNA sequence Nucleic Acid Accession #: NM_000095.1 Coding sequence: 26-2299 (underlined sequences correspond to start and stop codons)
-15	1 11 21 31 41 51
50	CAGCACCAG CTCCCCGCCA CCGCCATGGT CCCCGACACC GCCTGCGTTC TTCTGCTCAC 60 CCTGGCTGCC CTCGGCGCGT CCGGACAGGG CCAGAGCCCG TTGGGCTCAG ACCTGGGCCC 120 GCAGATGCTT CGGGAACTGC AGGAAACCAA CGCGGCGTG CAGGACTGC GGGACTGGCT 180 GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG 240 CGGGATGCAG CAGTCAGTAC GCACCGGCCT ACCCAGCGTG CGGCCCCTGC TCCACTGCGC 300
55	GCCCGGCTTC TGCTTCCCCG GCGTGGCCTG CATCCAGACG GAGAGCGGCG GCCGCTGCGG 360 CCCCTGCCCC GCGGGCTTCA CGGGCAACGG CTCGCACTGC ACCGACGTCA ACGAGTGCAA 420 CGCCCACCCC TGCTTCCCCC GAGTCCGCTG TATCAACACC AGCCCGGGGT TCCGCTGCGA 480 GGCTTGCCCG CCGGGGTACA GCGGCCCCAC CCACCAGGGC GTGGGGCTGC CTTTCGCCAA 540 GGCCAACAAG CAGGTTTGCA CGGACATCAA CGAGTGTGAG ACCGGGCAAC ATAACTGCGT 600
60	CCCCAACTCC GTGTGCATCA ACACCCGGGG CTCCTTCCAG TGCGGCCCGT GCCAGCCCGG 660 CTTCGTGGGC GACCAGGCGT CCGGCTGCCA GCGCGCGCA CAGCGCTTCT GCCCCGACG 720 CTCGCCCAGC GAGTGCCACG AGCATGCAGA CTGCGTCCTA GAGCGCGATG GCTCGCGGTC 780 GTGCGTGTGT CGCGTTGGCT GGGCCGGCAA CGGGATCCTC TGTGGTCGCG ACACTGACCT 840
~ =	AGACGGCTTC CCGGACGAGA AGCTGCGCTG CCCGGAGCCG CAGTGCCGTA AGGACAACTG 900 CGTGACTGTG CCCAACTCAG GGCAGGAGGA TGTGGACCGC GATGGCATCG GAGACGCCTG 960 CGATCCGGAT GCCGACGGGG ACGGGGTCCC CAATGAAAAG GACAACTGCC CGCTGGTGCG 1020
65	GAACCCAGAC CAGCGCAACA CGGACGAGGA CAAGTGGGGC GATGCGTGCG ACAACTGCCG 1080 GTCCCAGAAG AACGACGACC AAAAGGACAC AGACCAGGAC GGCCGGGGCG ATGCGTGCGA 1140 CGACGACATC GACGGCGACC GGATCCGCAA CCAGGCCGAC AACTGCCCTA GGGTACCCAA 1200 CTCAGACCAG AAGGACAGTG ATGGCGATGG TATAGGGGAT GCCTGTGACA ACTGTCCCCA 1260
70	GAAGAGCAAC CCGGATCAGG CGGATGTGGA CCACGACTTT GTGGGAGATG CTTGTGACAG 1320 CGATCAAGAC CAGGATGGAG ACGGACATCA GGACTCTCGG GACAACTGTC CCACGGTGCC 1380 TAACAGTGCC CAGGAGACT CAGACCACGA TGGCCAGGGT GATGCCTGCG ACGACGACGA 1440 CGACAATGAC GGAGTCCCTG ACAGTCGGGA CAACTGCCGC CTGGTGCCTA ACCCCGGCCA 1500
75	GGAGGACGCG GACAGGGACG GCGTGGGCGA CGTGTGCCAG GACGACTTTG ATGCAGACAA 1560 GGTGGTAGAC AAGATCGACG TGTGTCCGGA GAACGCTGAA GTCACGCTCA CCGACTTCAG 1620 GGCCTTCCAG ACAGTCGTGC TGGACCCGGA GGGTGACGCG CAGATTGACC CCAACTGGGT 1680 GGTGCTCAAC CAGGGAAGGG AGATCGTGCA GACAATGAAC AGCGACCCAG GCCTGGCTGT 1740 GGGTTACACT GCCTTCAATG GCGTGGACTT CGAGGGCACG TTCCATGTGA ACACGGTCAC 1800

TTGATTTCTT TTTTTTATT CTGACTTTTA AAAACAACTT TTTTTTCCAC TTTTTTAAAA 180

GGATGACGAC TATGCGGGCT TCATCTTTGG CTACCAGGAC AGCTCCAGCT TCTACGTGGT 1860 CATGTGGAAG CAGATGGAGC AAACGTATTG GCAGGCGAAC CCCTTCCGTG CTGTGGCCGA 1920 GCCTGGCATC CAACTCAAGG CTGTGAAGTC TTCCACAGGC CCCGGGGAAC AGCTGCGGAA 1980 CGCTCTGTGG CATACAGGAG ACACAGAGTC CCAGGTGCGG CTGCTGTGGA AGGACCCGCG 2040 5 AAACGTGGGT TGGAAGGACA AGAAGTCCTA TCGTTGGTTC CTGCAGCACC GGCCCCAAGT 2100 GGGCTACATC AGGGTGCGAT TCTATGAGGG CCCTGAGCTG GTGGCCGACA GCAACGTGGT 2160 CTTGGACACA ACCATGCGGG GTGGCCGCCT GGGGGTCTTC TGCTTCTCCC AGGAGAACAT 2220 CATCTGGGCC AACCTGCGTT ACCGCTGCAA TGACACCATC CCAGAGGACT ATGAGACCCA 2280 TCAGCTGCGG CAAGCCTAGG GACCAGGGTG AGGACCCGCC GGATGACAGC CACCCTCACC 2340
GCGGCTGGAT GGGGGCTCTG CACCCAGCC AAGGGGTGGC CGTCCTGAGG GGGAAGTGAG 2400 10 AAGGGCTCAG AGAGGACAAA ATAAAGTGTG TGTGCAGGG Seq ID NO: 118 Protein sequence: Protein Accession #: NP_000086.1 15 31 MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRD WLRQQVREIT 60 FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGGR CGPCPAGFTG 120 NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD 180

20 INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRGAQRFCP DGSPSECHEH 240
ADCVLERDGS RSCVCRVGWA GNGILCGRDT DLDGFPDEKL RCPEPQCRKD NCVTVPNSGQ 300
EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK 360
DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD 420 25 VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS 480 RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD 540 PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI 600 FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT 660 ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG 720 30 RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA

Seq ID NO: 119 DNA sequence Nucleic Acid Accession #:

35

NM_014211

Coding sequence: 157-1479 (underlined sequences correspond to start and stop codons)

51

GGGACAGGGC TGAGGATGAG GAGAACCCTG GGGACCCAGA AGACCGTGCC TTGCCCGGAA 60 GTCCTGCCTG TAGGCCTGAA GGACTTGCCC TAACAGAGCC TCAACAACTA CCTGGTGATT 120 40 CCTACTTCAG CCCCTTGGTG TGAGCAGCTT CTCAACATGA ACTACAGCCT CCACTTGGCC 180 TTCGTGTGTC TGAGTCTCTT CACTGAGAGG ATGTGCATCC AGGGGAGTCA GTTCAACGTC 240 GAGGTCGGCA GAAGTGACAA GCTTTCCCTG CCTGGCTTTG AGAACCTCAC AGCAGGATAT 300 AACAAATTTC TCAGGCCCAA TTTTGGTGGA GAACCCGTAC AGATAGCGCT GACTCTGGAC 360 ATTGCAAGTA TCTCTAGCAT TTCAGAGAGT AACATGGACT ACACAGCCAC CATATACCTC 420 CGACAGCGCT GGATGGACCA GCGGCTGGTG TTTGAAGGCA ACAAGAGCTT CACTCTGGAT 480 45 GCCCGCCTCG TGGAGTTCCT CTGGGTGCCA GATACTTACA TTGTGGAGTC CAAGAAGTCC 540 TTCCTCCATG AAGTCACTGT GGGAAACAGG CTCATCCGCC TCTTCTCCAA TGGCACGGTC CTGTATGCCC TCAGAATCAC GACAACTGTT GCATGTAACA TGGATCTGTC TAAATACCCC 660 ATGGACACA AGACATGCAA GTTGCAGCTG GAAAGCTGGG GCTATGATGG AAATGATGTG 720 50 GAGTTCACCT GGCTGAGAGG GAACGACTCT GTGCGTGGAC TGGAACACCT GCGGCTTGCT 780 CAGTACACCA TAGAGCGGTA TITCACCTTA GTCACCAGAT CGCAGCAGGA GACAGGAAAT 840 TACACTAGAT TGGTCTTACA GTTTGAGCTT CGGAGGAATG TTCTGTATTT CATTTTGGAA 900 ACCTACGTTC CTTCCACTTT CCTGGTGGTG TTGTCCTGGG TTTCATTTTG GATCTCTCTC 960 GATTCAGTCC CTGCAAGAAC CTGCATTGGA GTGACGACCG TGTTATCAAT GACCACACTG 1020 55 ATGATCGGGT CCCGCACTTC TCTTCCCAAC ACCAACTGCT TCATCAAGGC CATCGATGTG 1080 TACCTGGGGA TCTGCTTTAG CTTTGTGTTT GGGGCCTTGC TAGAATATGC AGTTGCTCAC 1140 TACAGTTCCT TACAGCAGAT GGCAGCCAAA GATAGGGGGA CAACAAAGGA AGTAGAAGAA 1200 GTCAGTATTA CTAATATCAT CAACAGCTCC ATCTCCAGCT TTAAACGGAA GATCAGCTTT 1260 GCCAGCATTG AAATTTCCAG CGACAACGTT GACTACAGTG ACTTGACAAT GAAAACCAGC 1320 60 GACAAGTTCA AGTTTGTCTT CCGAGAAAAG ATGGGCAGGA TTGTTGATTA TTTCACAATT 1380 CAAAACCCCA GTAATGTTGA TCACTATTCC AAACTACTGT TTCCTTTGAT TTTTATGCTA 1440 GCCAATGTAT TTTACTGGGC ATACTACATG TATTTT<u>TGA</u>G TCAATGTTAA ATTTCTTGCA 1500 TGCCATAGGT CTTCAACAGG ACAAGATAAT GATGTAAATG GTATTTTAGG CCAAGTGTGC 1560
ACCCACATCC AATGGTGCTA CAAGTGACTG AAATAATATT TGAGTCTTTC TGCTCAAAGA 1620
ATGAAGCTCC AACCATTGTT CTAAGCTGTG TAGAAGTCCT AGCATTATAG GATCTTGTAA 1680
TAGAAACATC AGTCCATTCC TCTTTCATCT TAATCAAGGA CATTCCCATG GAGCCCAAGA 1740 65 TTACAAATGT ACTCAGGGCT GTTTATTCGG TGGCTCCCTG GTTTGCATTT ACCTCATATA 1800 AAGAATGGGA AGGAGACCAT TGGGTAACCC TCAAGTGTCA GAAGTTGTTT CTAAAGTAAC 1860 TATACATGTT TTTTACTAAA TCTCTGCAGT GCTTATAAAA TACATTGTTG CCTATTTAGG 1920 GAGTAACATT TTCTAGTTTT TGTTTCTGGT TAAAATGAAA TACATTGT CCTATTAGG 1920
TTGGAAGTCA ATGCACTAAC TCAATACCAA GATGAGTTTT TAAAATAATGA ATATTATTTA 2040
ATACCACAAC AGAATTATCC CCAATTCCA ATAAGTCCTA TCATTGAAAA TTCAAATAATA 2100
AGTGAAGAAA AAATTAGTAG ATCAACAATC TAAACAAATC CCTCGGTTCT AAGATACAAT 2160
GGATTCCCCA TACTGGAAGG ACTCTGAGGC TTTATTCCCC CACCATTGCAT ATCCTTATCAT 2220 70 75 TTTATTATTA TACACACATC CATCCTAAAC TATACTAAAG CCCTTTTCCC ATGCATGGAT 2280 GGAAATGGAA GATTTTTTTG TAACTTGTTC TAGAAGTCTT AATATGGGCT GTTGCCATGA 2340 AGGCTTGCAG AATTGAGTCC ATTTTCTAGC TGCCTTTATT CACATAGTGA TGGGGTACTA 2400


TGCTCTAATG ATCAGGAATG ATGCTTATTA GAAAACAAAC TGCTTGACCC AGGAACAAGT 2580 GGCTTAGCTT AAGTAAACTT GGCTTTGCTC AGATCCCTGA TCCTTCCAGC TGGTCTGCTC 2640 5 TGAGTGGCTT ATCCCGCATG AGCAGGAGCG TGCTGGCCCT GAGTACTGAA CTTTCTGAGT 2700 AACAATGAGA CACGTTACAG AACCTATGTT CAGGTTGCGG GTGAGCTGCC CTCTCCAAAT 2760 CCAGCCAGAG ATGCACATTC CTCGGCCAGT CTCAGCCAAC AGTACCAAAA GTGATTTTTG 2820 AGTGTGCCAG GGTAAAGGCT TCCAGTTCAG CCTCAGTTAT TTTAGACAAT CTCGCCATCT 2880 TTAATTTCTT AGCTTCCTGT TCTAATAAAT GCACGGCTTT ACCTTTCCTG TCAGAAATAA 2940 10 ACCAAGGCTC TAAAAGATGA TTTCCCTTCT GTAACTCCCT AGAGCCACAG GTTCTCATTC 3000 CTTTTCCCAT TATACTTCTC ACAATTCAGT TTCTATGAGT TTGATCACCT GATTTTTTA 3060 ACAAAATATT TCTAACGGGA ATGGGTGGGA GTGCTGGTGA AAAGAGATGA AATGTGGTTG 3120 TATGAGCCAA TCATATTTGT GATTTTTAA AAAAAGTTTA AAAGGAAATA TCTGTTCTGA 3180 AACCCCACTT AAGCATTGTT TTTATATAAA AACAATGATA AAGATGTGAAA CTGTGAAATA 3240 15 AATATACCAT ATTAGCTACC CACC Seq ID NO: 120 Protein sequence: Protein Accession #: NP 055026.1 20 41 21 MNYSLHLAFV CLSLFTERMC IQGSQFNVEV GRSDKLSLPG FENLTAGYNK FLRPNFGGEP 60 VQIALTLDIA SISSISESNM DYTATIYLRQ RWMDQRLVFE GNKSFTLDAR LVEFLWVPDT 120 YIVESKKSFL HEVTVGNRLI RLFSNGTVLY ALRITTTVAC NMDLSKYPMD TQTCKLQLES 180 25 WGYDGNDVEF TWLRGNDSVR GLEHLRLAQY TIERYFTLVT RSQQETGNYT RLVLQFELRR 240 NVLYFILETY VPSTFLVVLS WVSFWISLDS VPARTCIGVT TVLSMTTLMI GSRTSLPNTN 300 CFIKAIDVYL GICFSFVFGA LLEYAVAHYS SLQQMAAKDR GTTKEVEEVS ITNIINSSIS 360 SFKRKISFAS IEISSDNVDY SDLTMKTSDK FKFVFREKMG RIVDYFTIQN PSNVDHYSKL 420 LFPLIFMLAN VFYWAYYMYF 30 Sea ID NO: 121 DNA sequence Nucleic Acid Accession #: NM_001854 Coding sequence: 163-5582 (underlined sequences correspond to start and stop codons) 35 AACCATCAAA TTTAGAAGAA AAAGCCCTTT GACTTTTTCC CCCTCTCCCT CCCCAATGGC 60 TGTGTAGCAA ACATCCCTGG CGATACCTTG GAAAGGACGA AGTTGGTCTG CAGTCGCAAT 120 TTCGTGGGTT GAGTTCACAG TTGTGAGTGC GGGGCTCGGA GATGGAGCCG TGGTCCTCTA 180 40 GGTGGAAAAC GAAACGGTGG CTCTGGGATT TCACCGTAAC AACCCTCGCA TTGACCTTCC TCTTCCAAGC TAGAGAGGTC AGAGGAGCTG CTCCAGTTGA TGTACTAAAA GCACTAGATT TTCACAATTC TCCAGAGGGA ATATCAAAAA CAACGGGATT TTGCACAAAC AGAAAGAATT 360 CTAAAGGCTC AGATACTGCT TACAGAGTTT CAAAGCAAGC ACAACTCAGT GCCCCAACAA 420 AACAGTTATT TCCAGGTGGA ACTTTCCCAG AAGACTTTTC AATACTATTT ACAGTAAAAC 480 45 CAAAAAAAGG AATTCAGTCT TTCCTTTTAT CTATATATAA TGAGCATGGT ATTCAGCAAA 540 TTGGTGTTGA GGTTGGGAGA TCACCTGTTT TTCTGTTTGA AGACCACACT GGAAAACCTG 600 CCCCAGAAGA CTATCCCCTC TTCAGAACTG TTAACATCGC TGACGGGAAG TGGCATCGGG 660 TAGCAATCAG CGTGGAGAAG AAAACTGTGA CAATGATTGT TGATTGTAAG AAGAAAACCA 720 GGAACAC CGIGGAGAAG AAAACIGIGA CAATGATIGI IGATIGAAG AAGAAACCA 720 CGAAACCACT TGATAGAAGT GAGAGGAG ATTGTTGATAC CAATGGAATC ACGGTTTTTG 780 GAACAAGGAT TTTGGATGAA GAAGTTTTTG AGGGGGACAT TCAGCAGTTT TTGATCACAG 840 GTGATCCCAA GGCAGCATAT GACTACTGTG AGCATTATAG TCCAGACTGT GACTCTTCAG 900 CACCCAAGGC TGCTCAAGCT CAGGAACCTC AGATAGATGA GTATGCACCA GAGGATATAA 960 50 TCGAATATGA CTATGAGTAT GGGGAAGCAG AGTATAAAGA GGCTGAAAGT GTAACAGAGG 1020 GACCCACTGT AACTGAGGAG ACAATAGCAC AGACGGAGGC AAACATCGTT GATGATTTTC 1080 55 AAGAATACAA CTATGGAACA ATGGAAAGTT ACCAGACAGA AGCTCCTAGG CATGTTTCTG 1140 GGACAAATGA GCCAAATCCA GTTGAAGAAA TATTTACTGA AGAATATCTA ACGGGAGAGG 1200 ATTATGATTC CCAGAGGAAA AATTCTGAGG ATACACTATA TGAAAACAAA GAAATAGACG 1260 GCAGGGATTC TGATCTTCTG GTAGATGGAG ATTTAGGCGA ATATGATTTT TATGAATATA 1320 AAGAATATGA AGATAAACCA ACAAGCCCCC CTAATGAAGA ATTTGGTCCA GGTGTACCAG 1380 60 CAGAAACTGA TATTACAGAA ACAAGCATAA ATGGCCATGG TGCATATGGA GAGAAAGGAC 1440 AGAAAGGAGA ACCAGCAGTG GTTGAGCCTG GTATGCTTGT CGAAGGACCA CCAGGACCAG 1500 CAGGACCTGC AGGTATTATG GGTCCTCCAG GTCTACAAGG CCCCACTGGA CCCCCTGGTG 1560
ACCCTGGCGA TAGGGGCCCC CCAGGACGTC CTGGCTTACCA AGGGCTGAT GGTCTACCTG 1620
GTCCTCCTGG TACTATGTTG ATGTTACCGT TCCGTTATGG TGGTGATGGT TCCAAAAGGAC 1680
CAACCATCTC TGCTCAGGAA GCTCAGGCTC AAGCTATTCT TCAGCAGGCT CGGATTGCTC 1740 65 TGAGAGGCCC ACCTGGCCCA ATGGGTCTAA CTGGAAGACC AGGTCCTGTG GGGGGGCCTG 1800 GTTCATCTGG GGCCAAAGGT GAGAGTGGTG ATCCAGGTCC TCAGGGCCCT CGAGGCGTCC 1860 AGGGTCCCCC TGGTCCAACG GGAAAACCTG GAAAAAGGGG TCGTCCAGGT GCAGATGGAG 1920 GAAGAGGAAT GCCAGGAGAA CCTGGGGCAA AGGGAGATCG AGGGTTTGAT GGACTTCCGG 1980 GTCTGCCAGG TGACAAAGGT CACAGGGGTG AACGAGGTCC TCAAGGTCCT CCAGGTCCTC 2040 70 CTGGTGATGA TGGAATGAGG GGAGAAGATG GAGAAATTGG ACCAAGAGGT CTTCCAGGTG 2100 AAGCTGGCCC ACGAGGTTTG CTGGGTCCAA GGGGAACTCC AGGAGCTCCA GGGCAGCCTG 2160 GTATGGCAGG TGTAGATGGC CCCCCAGGAC CAAAAGGGAA CATGGGTCCC CAAGGGGAGC 2220 CTGGGCCTCC AGGTCAACAA GGGAATCCAG GACCTCAGGG TCTTCCTGGT CCACAAGGTC 2280 CAATTGGTCC TCCTGGTGAA AAAGGACCAC AAGGAAAACC AGGACTTGCT GGACTTCCTG 2340 GTGCTGATGG GCCTCCTGGT CATCCTGGGA AAGAAGGCCA GTCTGGAGAA AAGGGGGCTC 2400 75 TGGGTCCCCC TGGTCCACAA GGTCCTATTG GATNNCCGGG CCCCCGGGGA GTAAAGGGAG 2460


AAAGTACTGG GTTGACTCAG AGAGTCGCTG TCATTCTGTC ATTGCTGCTA CTCTAACACT 2460 GAGCAACACT CTCCCAGTGG CAGATCCCCT GTATCATTCC AAGAGGAGCA TTCATCCCTT 2520

	CAGATGGTGT CAGAGGTCTC AAGGGATCTA AAGGTGAAAA GGGTGAAGAT GGTTTTCCAG 2520 GATTCAAAGG TGACATGGGT CTAAAAGGTG ACAGAGGAGA AGTTGGTCAA ATTGGCCCAA 2580 GAGGGNAAGA TGGCCCTGAA GGACCCAAAG GTCGAGCAGG CCCAACTGGA GACCCAGGTC 2640
5	CTTCAGGTCA AGCAGGAGAA AAGGGAAAAC TTGGAGTTCC AGGATTACCA GGATATCCAG 2700 GAAGACAAGG TCCAAAGGGT TCCACTGGAT TCCCTGGGTT TCCAGGTGCC AATGGAGAG 2760 AAGGTGCACG GGGAGTAGCT GGCAAACCAG GCCCTCGGGG TCAGCGTGGT CCAACGGGTC 2820
10	CTCGAGGTTC AAGAGGTGCA AGAGGTCCCA CTGGGAAACC TGGGCCAAAG GGCACTTCAG 2880 GTGGCGATGG CCCTCCTGGC CCTCCAGGTG AAAGAGGTCC TCAAGGACCT CAGGGTCCAG 2940 TTGGATTCCC TGGACCAAAA GGCCCTCCTG GACCACCAGG AAGGATGGC TGCCCAGGAC 3000 ACCCTGGGCA ACGTGGGAG ACTGGATTTC AAGGCAAGAC CGGCCCTCCT GGGCCAGGGG 3060
10	GAGTGGTTGG ACCACAGGGA CCAACCGGTG AGACTGGTCC AATAGGGGAA CGTGGGTATC 3120 CTGGTCCTCC TGGCCCTCCT GGTGAGCAAG GTCTTCCTGG TGCTGCAGGA AAAGAAGGTG 3180 CAAAGGGTGA TCCAGGTCCT CAAGGTATCT CAGGGAAAGA TGGACCAGCA GGATTACGTG 3240
15	GTTTCCCAGG GGAAAGAGT CTTCCTGGAG CTCAGGGTGC ACCTGGACTG AAAGGAGGGG 3300 AAGGTCCCCA GGGCCCACCA GGTCCAGTTG GCTCACCAGG AGAACGTGGG TCAGCAGGTA 3360 CAGCTGGCCC AATTGGTTTA CGAGGGCGC CGGGACCTCA GGGTCCTCCT GGTCCAGCTG 3420 GAGAGAAAGG TGCTCCTGGA GAAAAAGGTC CCCAAGGGCC TGCAGGGAGA GATGGAGTTC 3480
20	AAGGTCCTGT TGGTCTCCCA GGGCCAGCTG GTCCTGCCGG CTCCCCTGGG GAAGACGGAG 3540 ACAAGGGTGA AATTGGTGAG CCGGGACAAA AAGGCAGCAA GGGTGGCAAG GGAGAAAATG 3600 GCCCTCCCGG TCCCCCAGGT CTTCAAGGAC CAGTTGGTGC CCCTGGAATT GCTGGAGGTG 3660
25	ATGGTGAACC AGGTCCTAGA GGACAGCAGG GGATGTTTGG GCAAAAAGGT GATGAGGTG 3720 CCAGAGGCTT CCCTGGACCT CCTGGTCCAA TAGGTCTTCA GGGTCGCA GGCCCACCTG 3780 GTGAAAAAGG TGAAAATGGG GATGTTGGTC CATGGGGGCC ACCTGGTCCT CCAGGCCCAA 3840 GAGGCCTCA AGGTCCCAAT GGAGCTGATG GACCACAAGG ACCCCCAGGT TCTGTTGGTT 3900
25	CAGTTGGTGG TGTTGGAGAA AAGGGTGAAC CTGGAGAAGC AGGAAACCCA GGGCCTCCTG 3960 GGAAGCAGG TGTAGGCGGT CCCAAAGGAG AAAGAGGA GAAAGGGGAAA GCTGGTCCAC 4020 CTGGAGCTGC TGGACCTCCA GGTGCCAAGG GGCCGCCAGG TGATGATGTGC CCTAAGGGTA 4080 ACCCGGGTCC TGTTGGTTTT CCTGGAGATC CTGGTCCTCC TGGGGAACTT GGCCCTGCAG 4140
30	GTCAAGATGG TGTTGGTGGT GACAAGGGTG AAGATGGAGA TCCTGGTCAA CCGGGTCCTC 4200 CTGGCCCATC TGGTGAGGCT GGCCCACCAG GTCCTCCTGG AAAACCGAGGT CCTCCTGGAG 4260 CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 GTCCTCCTGG AAAAACCGGC CCAGTCGGTC CTCAGGGACC TGCAGGAAAG CCTGGTCCAG 4380
35	AAGGTCTTCG GGGCATCCCT GGTCCTGTGG GAGAACAAGG TCTCCCTGGA GCTGCAGGCC 4440 AAGATGGACC ACCTGGTCCT ATGGGACCTC CTGGCTTACC TGGTCTCAAA GGTGACCCTG 4500 GCTCCAAGGG TGAAAAAGGGA CATCCTGGTT TAATTGGCCT GATTGGTCCT CCAGGAGAAC 4560
	AAGGGGAAAA AGGTGACCGA GGGCTCCCTG GAACTCAAGG ATCTCCAGGA GCAAAAGGGG 4620 ATGGGGGAAT TCCTGGTCCT GCTGGTCCCT TAGGTCCACC TGGTCCTCCA GGCTTACCAG 4680 GTCCTCAAGG CCCAAAGGGT AACAAAGGCT CTACTGGACC CGCTGGCCAG AAAGGTGACA 4740 GTGGTCTTCC AGGGCCTCCT GGGCCTCCAG GTCCACCTGG TGAAGTCATT CAGCCTTTAC 4800
40	CAATCTTGTC CTCCAAAAAA ACGAGAAGAC ATACTGAAGG CATGCAAGCA GATGCAGATG 4860 ATAATATTCT TGATTACTCG GATGGAATGG AAGAAATATT TGGTTCCCTC AATTCCCTGA 4920 AACAAGACAT CGAGCATATG AAATTTCCAA TGGGTACTCA GACCAATCCA GCCCGAACTT 4980 GTAAAGACCT GCAACTCAGC CATCCTGACT TCCCAGATGG TGAATATTGG ATTGATCCTA 5040
45	ACCAAGGTTG CTCAGGAGAT TCCTTCAAAG TTTACTGTAA TTTCACATCT GGTGGTGAGA 5100 CTTGCATTTA TCCAGACAAA AAATCTGAGG GAGTAAGAAT TTCATCATGG CCAAAGGAGA 5160 AACCAGGAAG TTGGTTTAGT GAATTTAAGA GGGGAAAACT GCTTTCATAC TTAGATGTTG 5220
50	AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280 GGCAAAATTT CACCTACCAC TGTCATCAGT CAGCAGCCTG GTATGTGTG TCATCAGGAA 5340 GTTATGACAA AGCACTTCGC TTCCTGGGAT CAAATGATGA GGAGATGTCC TATGACAATA 5400 ATCCTTTTAT CAAAACACTG TATGATGGTT GTACGTCCAG AAAAGGCTAT GAAAAAACTG 5460
	TCATTGAAAT CAATACACCA AAAATTGATC AAGTACCTAT TGTTGATGTC ATGATCAGTG 5520 ACTTTGGTGA TCAGAATCAG AAGTTCGGAT TTGAAGTTGG TCCTGTTTGT TTTCTTGGCT_5580 AAGATTAAGA CAAAGAACAT ATCAAATCAA CAGAAAATGT ACCTTGGTGC CACCAACCCA 5640 TTTTGTGCCA CATGCAAGTT TTGAATAAGG ATGTATGGAA AACAACGCTG CATATACAGG 5700
55	TACCATTTAG GAAATACCGA TGCCTTTGTG GGGGCAGAAT CACAGACAAA AGCTTTGAAA 5760 ATCATAAAGA TATAAGTTGG TGTGGCTAAG ATGGAAACAG GGCTGATTCT TGATTCCCAA 5820 TTCTCAACTC TCCTTTTCCT ATTTGAATTT CTTTGGTGCT GTAGAAAACA AAAAAAGAAA 5880 AATATATATT CATAAAAAAT ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAACAG 5940
60	TGTGTTTAAT AAATTGTAAT TATTTTGTGT ACAGTTCTAT ACTGTTATCT GTGTCCATTT 6000 CCAAAACTTG CACGTGTCCC TGAATTCCGC TGACTCTAAT TTATGAGGAT GCCGAACTCT 6060 GATGGCAATA ATATATGTAT TATGAAAATG AAGTTATGAT TTCCGATGAC CCTAAGTCCC 6120 TTTCTTTGGT TAATGATGAA ATTCCTTTGT GTGTGTTT
65	Seq ID NO: 122 Protein sequence: Protein Accession #: NP_001845

GPVGGPGSSG AKGESGDPGP QGPRGVQGPP GPTGKPGKRG RPGADGGRGM PGEPGAKGDR 660
GFDGLPGLPG DKGHRGERGP QGPPGPPGDD GMRGEDGEIG PRGLPGEAGP RGLLGPRGTP 660
GAPGQPGMAG VDGPPGPKGN MGPQGEPGPP GQQGNPGPQG LPGPQGPIGP PGEKGPQGKP 720
GLAGLPGADG PPGHPGKEGQ SGEKGALGPP GPQGPIGXPG PRGVKGADGV RGLKGSKGEK 780 5 GEDGFPGFKG DMGLKGDRGE VGQIGPRGXD GPEGPKGRAG PTGDPGPSGQ AGEKGKLGVP 840 GLPGYPGRQG PKGSTGFPGF PGANGEKGAR GVAGKPGPRG QRGPTGPRGS RGARGPTGKP 900 GPKGTSGGDG PPGPPGERGP QGPQGPVGFP GPKGPPGPPG RMGCPGHPGQ RGETGFQGKT 960 GPPGPGGVVG PQGPTGETGP IGERGYPGPP GPPGEQGLPG AAGKEGAKGD PGPQGISGKD 1020 10 GPAGLRGFPG ERGLPGAQGA PGLKGGEGPQ GPPGPVGSPG ERGSAGTAGP IGLRGRPGPQ 1080 GPPGPAGEKG APGEKGPQGP AGRDGVQGPV GLPGPAGPAG SPGEDGDKGE IGEPGQKGSK 1140 GGKGENGPPG PPGLQGPVGA PGIAGGDGEP GPRGQQGMFG QKGDEGARGF PGPPGPIGLQ 1200 GLPGPPGEKG ENGDVGPWGP PGPPGPRGPQ GPNGADGPQG PPGSVGSVGG VGEKGEPGEA 1260 GNPGPPGEAG VGGPKGERGE KGEAGPPGAA GPPGAKGPPG DDGPKGNPGP VGFPGDPGPP 1320 15 GELGPAGQDG VGGDKGEDGD PGQPGPPGPS GEAGPPGPPG KRGPPGAAGA EGRQGEKGAK 1380 GEAGAEGPPG KTGPVGPQGP AGKPGPEGLR GIPGPVGEQG LPGAAGQDGP PGPMGPPGLP 1440 GLKGDPGSKG EKGHPGLIGL IGPPGEQGEK GDRGLPGTQG SPGAKGDGGI PGPAGPLGPP 1500 GPPGLPGPQG PKGNKGSTGP AGQKGDSGLP GPPGPPGPPG EVIQPLPILS SKKTRRHTEG 1560 MQADADDNIL DYSDGMEEIF GSLNSLKQDI EHMKFPMGTQ TNPARTCKDL QLSHPDFPDG 1620 20 EYWIDPNOGC SGDSFK-VYCN FTSGGETCIY PDKKSEGVRI SSWPKEKPGS WFSEFKRGKL 1680 LSYLDVEGNS INMVQMTFLK LLTASARQNF TYHCHQSAAW YDVSSGSYDK ALRFLGSNDE 1740 EMSYDNNPFI KTLYDGCTSR KGYEKTVIEI NTPKIDQVPI VDVMISDFGD QNQKFGFEVG 1800 **PVCFLG** 25 Seq ID NO: 123 DNA sequence NM 015886 Nucleic Acid Accession #: Coding sequence: 485-1261 (underlined sequences correspond to start and stop codons) 30 GAATTCCCCC CCCCCCCCC TCACTTGGTG TGTCTATATG TCTGGCAGAC ATTATCAGCA 60 CATTCTCTGT TGTTACCTGT GATTCATTTT TTCTTCACTC TCCAGGTGAA TTTCAATTGC 120 TGAAAATTTC CCACTGAAAA TATGCAGTAA TATATTTTGT GGTTCAGACA TTTGGGGCAA 180 ATGGTTCACA TTCATTTTAG GGTTAGTGGT CATGCTGTTT ATTTTTCTCT GCTATACAAA 240 35 GTTCCTCTTA GGGGTCTGCC TCATGACACT AAAAAATGAA TAGAGATTCT ACTGTAGGTT 300 ATCTCCTAGG CTTGAGTTCA ACATTTGTTT GGATTTTTGA AGAAAGTCAA ATCAAGCAAT 360 GCTCCCAAAT GATGTCTTTG TAAATTCATA CCCTCTGGCC CTATTTTTTT TCATAGACCC 420 TAACTCTACC TTTCTGCTTT AAAGCAAAGT AAACTCGGTG GCCTCTTCTT CTCCACCCCT 480
CAAAATGATA GCAATCTCTG CCGTCAGCAG TGCACTCCTG TTCTCCCTTC TCTGTGAAGC 540
AAGTACCGTC GTCCTACTCA ATTCCACTGA CTCATCCCCG CCAACCAATA ATTTCACTGA 600
TATTGAAGCA GCTCTGAAAG CACAATTAGA TTCAGCGGAT ATCCCCAAAG CCAGGCGGAA 660 40 GCGCTACATT TCGCAGAATG ACATGATCGC CATTCTTGAT TATCATAATC AAGTTCGGGG 720 CAAAGTGTTC CCACCGGCAG CAAATATGGA ATATATGGTT TGGGATGAAA ATCTTGCAAA 780 ATCGGCAGAG GCTTGGGCGG CTACTTGCAT TTGGGACCAT GGACCTTCTT ACTTACTGAG 840 ATTTTTGGGC CAAAATCTAT CTGTACGCAC TGGAAGATAT CGCTCTATTC TCCAGTTGGT 900 CAAGCCATGG TATGATGAAG TGAAAGATTA TGCTTTTCCA TATCCCCAGG ATTGCAACCC 960 CAGATGTCCT ATGAGATGTT TTGGTCCCAT GTGCACACAT TATACGCAGA TGGTTTGGGC 1020 45 CACTTCCAAT CGGATAGGAT GCGCAATTCA TGCTTGCCAA AACATGAATG TTTGGGGATC 1080 50 AGAAGCACCA TATAAAGTAG GGGTACCATG TTCATCTTGT CCTCCAAGTT ATGGGGGATC 1200 AGAAGCACA TATAAGTAG GOGTACCATG TEACHTOTT CETECHAGAGT TACGAGAGA TACTAGAGAGT TACTAGAGAGAT TACGAGAGAT TACGAGAGAT TACGAGAGAT TACGAGAGAT TACGAGAGAT TACGAGAGAT TACAGAGAGAT TACAGAGAGAT TACAGAGAGA TACATATATAT 1320
ATATGGAGAG AGAATTTTGC ACATATTATA CATATTTTGT GCTAATCTTG TTTTCCTCTT 1380
AGTATCCTT TGTATAAATT AGTGTTTGTC TAGCATGTTT GTTTAATCCT TTGGGAATTC 55 Seq ID NO: 124 Protein sequence: Protein Accession #: NP_056970.1 11 21 31 41 51 60 MIAISAVSSA LLFSLLCEAS TVVLLNSTDS SPPTNNFTDI EAALKAQLDS ADIPKARRKR 60 YISQNDMIAI LDYHNQVRGK VFPPAANMEY MVWDENLAKS AEAWAATCIW DHGPSYLLRF 120 LGONLSVRTG RYRSILQLVK PWYDEVKDYA FPYPQDCNPR CPMRCFGPMC THYTQMVWAT 180 SNRIGCAIHA CQNMNVWGSV WRRAVYLVCN YAPKGNWIGE APYKVGVPCS SCPPSYGGSC 240 65 TDNLCFPGVT SNYLYWFK Seq ID NO: 125 DNA sequence Nucleic Acid Accession #: NM 001793 70 Coding sequence: 54-2543 (underlined sequences correspond to start and stop codons) 11 31 GCGGAACACC GGCCGCCGT CGCGGCAGCT GCTTCACCCC TCTCTCTGCA GCCATGGGGC 60 75 TCCCTCGTGG ACCTCTCGCG TCTCTCCTCC TTCTCCAGGT TTGCTGGCTG CAGTGCGCGG 120 CCTCCGAGCC GTGCCGGGCG GTCTTCAGGG AGGCTGAAGT GACCTTGGAG GCGGGAGGCG 180 CGGAGCAGGA GCCCGGCCAG GCGCTGGGGA AAGTATTCAT GGGCTGCCCT GGGCAAGAGC 240

GADGLPGPPG TMLMLPFRYG GDGSKGPTIS AQEAQAQAIL QQARIALRGP PGPMGLTGRP 540





 $\underline{\mathbf{TG}}\mathbf{CCTGGGAG}\ \mathbf{CCTCGGCCC}\ \mathbf{GCGCCAAGCT}\ \mathbf{GGGTGCTGTT}\ \mathbf{GCTGCGGCTG}\ \mathbf{CTGGCGTTGC} \quad \mathbf{120}$

NEPSRVMPSO PLHIVLESLK REGKEPLVLK GGLSSFKONH ENLCDNSLQL QECREVGGGA 300 SAASSLLPQP IPTTPDIENA ELTPILPFLF LGNEQDAQDL DTMQRLNIGY VINVTTHLPL 360 YHYEKGLFNY KRLPATDSNK QNLRQYFEEA FEFIEEAHQC GKGLLIHCQA GVSRSATIVI 420 5 AYLMKHTRMT MTDAYKFVKG KRPIISPNLN FMGQLLEFEE DLNNGVTPRI LTPKLMGVET 480 Seq ID NO: 131 DNA sequence Nucleic Acid Accession #: NM_005409.3 10 Coding sequence: 94-378 (underlined sequences correspond to start and stop codons) TTCCTTTCAT GTTCAGCATT TCTACTCCTT CCAAGAAGAG CAGCAAAGCT GAAGTAGCAG 60 CAACAGCACC AGCAGCAACA GCAAAAAACA AAC<u>ATG</u>AGTG TGAAGGGCAT GGCTATAGCC 120
TTGGCTGTGA TATTGTGTGC TACAGTTGTT CAAGGCTTCC CCATGTTCAA AAGAGGACGC 180 15 TGTCTTTGCA TAGGCCCTGG GGTAAAAGCA GTGAAAGTGG CAGATATTGA GAAAGCCTCC 240 ATAATGTACC CAAGTAACAA CTGTGACAAA ATAGAAGTGA TTATTACCCT GAAAGAAAAT 300 AAAGGACAAC GATGCCTAAA TCCCAAATCG AAGCAAGCAA GGCTTATAAT CAAAAAAGTT 360 20 GAAAGAAAGA ATTTT<u>TAA</u>AA ATATCAAAAC ATÄTGAAGTC CTGGAAAAGG GCATCTGAAA 420 AACCTAGAAC AAGTTTAACT GTGACTACTG AAATGACAAG AATTCTACAG TAGGAAACTG 480 AGACTTTTCT ATGGTTTTGT GACTTTCAAC TTTTGTACAG TTATGTGAAG GATGAAAGGT 540 GGGTGAAAGG ACCAAAAACA GAAATACAGT CTTCCTGAAT GAATGACAAT CAGAATTCCA 600 CTGCCCAAAG GAGTCCAGCA ATTAAATGGA TTTCTAGGAA AAGCTACCTT AAGAAAGGCT 660 25 GGTTACCATC GGAGTTTACA AAGTGCTTTC ACGTTCTTAC TTGTTGTATT ATACATTCAT 720 GCATTTCTAG GCTAGAGAAC CTTCTAGATT TGATGCTTAC AACTATTCTG TTGTGACTAT 780 GAGAACATTT CTGTCTCTAG AAGTTATCTG TCTGTATTGA TCTTTATGCT ATATTACTAT 840 CTGTGGTTAC AGTGGAGACA TTGACATTAT TACTGGAGTC AAGCCCTTAT AAGTCAAAAG 900 CATCTATGTG TCGTAAAGCA TTCCTCAAAC ATTTTTTCAT GCAAATACAC ACTTCTTTCC 960 30 CCAAATATCA TGTAGCACAT CAATATGTAG GGAAACATTC TTATGCATCA TTTGGTTTGT 1020 TTTATAACCA ATTCATTAAA TGTAATTCAT AAAATGTACT ATGAAAAAA TTATACGCTA 1080 TGGGATACTG GCAACAGTGC ACATATTTCA TAACCAAATT AGCAGCACCG GTCTTAATTT 1140 GATGTTTTC AACTTTATT CATTGAGATG TTTTGAAGCA ATTAGGATAT GTGTGTTTAC 1200 TGTACTTTTT GTTTTGATCC GTTTGTATAA ATGATAGCAA TATCTTGGAC ACATTTGAAA 1260 TACAAAATGT TTTTGTCTAC CAAAGAAAA TGTTGAAAAA TAAGCAAATG TATACCTAGC 1320 AATCACTTTT ACTTTTTGTA ATTCTGTCTC TTAGAAAAAT ACATAATCTA ATCAATTTCT 1380 35 TTGTTCATGC CTATATACTG TAAAATTTAG GTATACTCAA GACTAGTTTA AAGAATCAAA 1440 40 Seq ID NO: 132 Protein sequence: NP_005400.1 Protein Accession #: 51 41 11 21 31 45 MSVKGMAIAL AVILCATVVQ GFPMFKRGRC LCIGPGVKAV KVADIEKASI MYPSNNCDKI 60 EVIITLKENK GQRCLNPKSK QARLIIKKVE RKNF Sea ID NO: 133 DNA sequence NM_012342 Nucleic Acid Accession #: 50 Coding sequence: 373-1155 (underlined sequences correspond to start and stop codons) CTGGGGGGG CGGGAGCTGC GGCGGATACC CTTGCGTGCT GTGGAGACCC TACTCTCTTC 60 GCTGAGAACG GCCGCTAGCG GGGACTGAAG GCCGGGAGCC CACTCCCGAC CCGGGGCTAG 120 CGTGCGTCCC TAGAGTCGAG CGGGGCAAGG GAGCCAGTGG CCGCCGACGG GGGACCGGGA 180 55 AACTTTTCTG GGCTCCTGGA GAGCCCTGTA GCCGCGCTCC ATGCTCCGGC AGCGGCCCGA 240 AACCAGCCC CGCCGCTGAC GGAGCCCGCC GCTCCGGGCA GGGCCCATGC CCTGCGCGCT 300 CCGGGGGTCG TAGCTGCCGC CGAGCCGGGG CTCCGGAAGC CGGCGGGGGC GCCGCGGCCG 360 TGCGGGGGT CAATGGATCG CCACTCCAGC TACATCTTCA TCTGGCTGCA GCTGGAGGTC 420
TGCGCCATGG CCGTGCTGCT CACCAAAGGT GAAATTCGAT GCTACTGTGA TGCTGCCCAC 480
TGTGTAGCCA CTGGTTATAT GTGTAAATCT GAGCTCAGC CCTGCTTCTC TAGACTTCTT 540
GATCCTCAGA ACTCAAATTC CCCACTCACC CATGGCTGCC TGGACTCTCT TGCAAGCACG 600 60 ACAGACATCT GCCAAGCCAA ACAGGCCCGA AACCACTCTG GCACCACCAT ACCCACATTG 660 65 GAATGCTGTC ATGAAGACAT GTGCAATTAC AGAGGGCTGC ACGATGTTCT CTCTCCTCCC 720 AGGGGTGAGG CCTCAGGACA AGGAAACAGG TATCAGCATG ATGGTAGCAG AAACCTTATC 780 ACCAAGGTGC AGGAGCTGAC TTCTTCCAAA GAGTTGTGGT TCCGGGCAGC GGTCATTGCC 840 GTGCCCATTG CTGGAGGGCT GATTTTAGTG TTGCTTATTA TGTTGGCCCT GAGGATGCTT 900 CGAAGTGAAA ATAAGAGGCT GCAGGATCAG CGGCAACAGA TGCTCTCCCG TTTGCACTAC 960 AGCTTTCACG GACACCATTC CAAAAAGGGG CAGGTTGCAA AGTTAGACTT GGAATGCATG 1020 70 GTGCCGGTCA GTGGGCACGA GAACTGCTGT CTGACCTGTG ATAAAATGAG ACAAGCAGAC 1080 CTCAGCAACG ATAAGATCCT CTCGCTTGTT CACTGGGGCA TGTACAGTGG GCACGGGAAG 1140 CTGGAATTCG TATGACGGAG TCTTATCTGA ACTACACTTA CTGAACAGCT TGAAGGCCTT 1200
TTGAGTTCTG CTGGACAGGA GCACTTTATC TGAAGACAAA CTCATTTAAT CATCTTTGAG 1260
AGACAAAATG ACCTCTGCAA ACAGAATCTT GGATATTTCT TCTGAAGGAT TATTTGCACA 1320
GACTTAAATA CAGTTAAATG TGTTATTTGC TTTTAAAATT ATAAAAAGCA AAGAGAAGAC 1380
TTTGTACACA CTGTCACCAG GGTTATTTGC ATCCAAGGGA GCTGGAATTG AGTACCTAAA 1440

75

MEYNKSHIQG AVHINCADKI SRRRLQQGKI TVLDLISCRE GKDSFKRIFS KEIIVYDENT 240

AAATATATAT ATTTTGTCTG A Seq ID NO: 134 Protein sequence: NP_036474.1 Protein Accession #: 41 21 31 MDRHSSYIFI WLQLELCAMA VLLTKGEIRC YCDAAHCVAT GYMCKSELSA CFSRLLDPQN 60 SNSPLTHGCL DSLASTTDIC QAKQARNHSG TTIPTLECCH EDMCNYRGLH DVLSPPRGEA 120 SGQGNRYQHD GSRNLITKVQ ELTSSKELWF RAAVIAVPIA GGLILVLLIM LALRMLRSEN 180 KRLQDQRQQM LSRLHYSFHG HHSKKGQVAK LDLECMVPVS GHENCCLTCD KMRQADLSND 240 KILSLVHWGM YSGHGKLEFV Seq ID NO: 135 DNA sequence NM_001627.1 Nucleic Acid Accession # Coding sequence: 64-1815 (underlined sequences correspond to start and stop codons) CGGGACGACG CCCCTCCTG CGGCGTGGAC TCCGTCAGTG GCCCACCAAG AAGGAGGAGG 60 AAT<u>ATG</u>GAAT CCAAGGGGGC CAGTTCCTGC CGTCTGCTCT TCTGCCTCTT GATCTCCGCC 120 ACCGTCTTCA GGCCAGGCCT TGGATGGTAT ACTGTAAATT CAGCATATGG AGATACCATT 180 ATCATACCTT GCCGACTTGA CGTACCTCAG AATCTCATGT TTGGCAAATG GAAATATGAA AAGCCCGATG GCTCCCCAGT ATTTATTGCC TTCAGATCCT CTACAAAGAA AAGTGTGCAG

TACGACGATG TACCAGAATA CAAAGACAGA TTGAACCTCT CAGAAAACTA CACTTTGTCT

360
ATCAGTAATG CAAGGATCAG TGATGAAAAG AGATTTGTGT GCATGCTAGT AACTGAGGAC

420 AACGTGTTTG AGGCACCTAC AATAGTCAAG GTGTTCAAGC AACCATCTAA ACCTGAAATT 480 GTAAGCAAAG CACTGTTTCT CGAAACAGAG CAGCTAAAAA AGTTGGGTGA CTGCATTTCA 540 GAAGACAGTT ATCCAGATGG CAATATCACA TGGTACAGGA ATGGAAAAGT GCTACATCCC 600 CTTGAAGGAG CGGTGGTCAT AATTTTTAAA AAGGAAATGG ACCCAGTGAC TCAGCTCTAT 660 ACCATGACTT CCACCCTGGA GTACAAGACA ACCAAGGCTG ACATACAAAT GCCATTCACC 720
TGCTCGGTGA CATATTATGG ACCATCTGGC CAGAAAACAA TTCATTCTGA ACAGGCAGTA 780 TTTGATATTT ACTATCCTAC AGAGCAGGTG ACAATACAAG TGCTGCCACC AAAAAATGCC

ATCAAAGAAG GGGATAACAT CACTCTTAAA TGCTTAGGGA ATGGCAACCC TCCCCCAGAG 900 GAATTTTTGT TTTACTTACC AGGACAGCCC GAAGGAATAA GAAGCTCAAA TACTTACACA 960 CTGATGGATG TGAGGCGCAA TGCAACAGGA GACTACAAGT GTTCCCTGAT AGACAAAAAA 1020

TAAACAAAAA TGTGCCCTAT GTAAGCTTCT ACATCTTGAT TTATTGTAAA GATTTAAAAG 1500

TCTCATAAGC ACCTAAAACC CAAAGGTGGC AGCTTGTGAA GATTGGGGAC ACTCATATTG 2340
CCCTAATTAA AAACTGTGAT TTTTATCACA AGGGAGGGGA GGCCGAGAGT CAGACTGATA 2400
GACACCATAG GAGCCGACTC TTTGATATGC CACCAGCGAA CTCTCAGAAA TAAATCACAG 2460
ATGCATATAG ACACATAC ATAATGGTAC TCCCAAACTG ACAATTTTAC CTATTCTGAA 2520
AAAGACATAA AACAGAATT

Seq ID NO: 136 <u>Protein sequence:</u>
Protein Accession #: NP_001618.1

5

10

15

20

25

30

35


NATVVWMKDN IRLRSSPSFS SLHYQDAGNY VCETALQEVE GLKKRESLTL IVEGKPQIKM 420 TKKTDPSGLS KTIICHVEGF PKPAIQWTIT GSGSVINQTE ESPYINGRYY SKIIISPEEN 480

41

51

408

VTLTCTAENQ LERTVNSLNV SAISIPEHDE ADEISDENRE KVNDQAKLIV GIVVGLLLAA 540 LVAGVVYWLY MKKSKTASKH VNKDLGNMEE NKKLEENNHK TEA



It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

WHAT IS CLAIMED IS:

1	1. A method of detecting a breast cancer-associated transcript in a cell
2	from a patient, the method comprising contacting a biological sample from the patient with a
3	polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence
4	as shown in Tables 1-25.

- 1 2. The method of claim 1, wherein the biological sample comprises 2 isolated nucleic acids.
- 1 3. The method of claim 2, wherein the nucleic acids are mRNA.
- 1 4. The method of claim 2, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.
- 1 5. The method of claim 1, wherein the polynucleotide comprises a sequence as shown in Tables 1-25.
- 1 6. The method of claim 1, wherein the polynucleotide is immobilized on 2 a solid surface.
- The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat breast cancer.
- 1 8. The method of claim 1, wherein the patient is suspected of having 2 breast cancer.
- 1 9. An isolated nucleic acid molecule consisting of a polynucleotide 2 sequence as shown in Tables 1-25.
- 1 10. The nucleic acid molecule of claim 9, which is labeled.
- 1 11. An expression vector comprising the nucleic acid of claim 9.
- 1 12. A host cell comprising the expression vector of claim 11.

1		13.	An isolated polypeptide which is encoded by a nucleic acid molecule		
2	having polynucleotide sequence as shown in Tables 1-25.				
1		14.	An antibody that specifically binds a polypeptide of claim 13.		
1		15.	The antibody of claim 14, further conjugated to an effector component.		
1 2	fluorescent lab	16. pel.	The antibody of claim 15, wherein the effector component is a		
1 2	radioisotope o	17. r a cyto	The antibody of claim 15, wherein the effector component is a toxic chemical.		
1		18.	The antibody of claim 15, which is an antibody fragment.		
1		19.	The antibody of claim 15, which is a humanized antibody		
1		20.	A method of detecting a breast cancer cell in a biological sample from		
2	a patient, the r	nethod	comprising contacting the biological sample with an antibody of claim		
3	14.				
1 2	an effector con	21.	The method of claim 20, wherein the antibody is further conjugated to		
2	an enector con	пропол			
1		22.	The method of claim 21, wherein the effector component is a		
2	fluorescent lab	oel.			
1		23.	A method for identifying a compound that modulates a breast cancer-		
2	associated pol	ypeptid	e, the method comprising the steps of:		
3		(i) con	tacting the compound with a breast cancer-associated polypeptide, the		
4	polypeptide en	ncoded 1	by a polynucleotide that selectively hybridizes to a sequence at least		
5	80% identical		quence as shown in Tables 1-25; and		
6		(ii) det	termining the functional effect of the compound upon the polypeptide.		
1		24	A drug screening assay comprising the steps of		

2 (i) administering a test compound to a mammal having breast cancer or a cell isolated therefrom;
4 (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.